EP1053319A2 - Human genes and gene expression products ii - Google Patents

Abstract

This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostic and therapeutic agents employing such novel human polynucleotides, their corresponding genes or gene products, e.g., these genes and proteins, including probes, antisense constructs, and antibodies.

Description

HUMAN GENES AND GENE EXPRESSION PRODUCTS II

Field of the Invention

The present invention relates to novel polynucleotides, particularly to novel polynucleotides of human origin that are expressed in a selected cell type, are differentially expressed in one cell type relative to another cell type (e.g., in cancerous cells, or in cells of a specific tissue origin) and/or share homology to polynucleotides encoding a gene product having an identified functional domain and/or activity.

Background of the Invention

Identification of novel polynucleotides, particularly those that encode an expressed gene product, is important in the advancement of drug discovery, diagnostic technologies, and the understanding of the progression and nature of complex diseases such as cancer.

Identification of genes expressed in different cell types isolated from sources that differ in disease state or stage, developmental stage, exposure to various environmental factors, the tissue of origin, the species from which the tissue was isolated, and the like is key to identifying the genetic factors that are responsible for the phenotypes associated with these various differences

This invention provides novel human polynucleotides, the polypeptides encoded by these polynucleotides, and the genes and proteins corresponding to these novel polynucleotides.

Summary of the Invention

This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostic and therapeutic agents employing such novel human polynucleotides, their corresponding genes or gene products, e.g., these genes and proteins, including probes, antisense constructs, and antibodies. The polynucleotides of the invention correspond to a polynucleotide comprising the sequence information of at least one of SEQ ID NOS: 1-3544, 3546-4510, 4512-4725, 4727-4748, and 4750-5252, which for convenience sake is referred to herein as "SEQ ID NOS: 1-5252." Accordingly, in one embodiment, the present invention features a library of polynucleotides, the library comprising the sequence information of at least one of "SEQ ID NOS: 1-5252". In related aspects, the invention features a library provided on a nucleic acid array, or in a computer-readable format. In one embodiment, the library is comprises a differentially expressed polynucleotide comprising a sequence selected from one of the differentially expressed polynucleotides disclosed herein. In specific related embodiments, the library comprises: 1) a polynucleotide that is differentially expressed in a human breast cancer cell, where the polynucleotide comprises a sequence selected from the group consisting of SEQ ID NOS:15, 36, 44, 45, 89, 146, 154, 159, 165, 172, 174, 183, 203, 261, 364, 366, 387, 419, 420, 496, 503, 510, 512, 529, 552, 560, 564, 570, 590, 606, 644, 646, 693, 707, 711, 726, 746, 754, 756, 875, 902, 921, 942, 990, 1095, 1104, 1122, 1131, 1142, 1170, 1184, 1205, 1286, 1289, 1354, 1387, 1435, 1535, 1751, 1764, 1777, 1795, 1860, 1869, 1882, 1890, 1915, 1933, 1934, 1979, 1980, 2007, 2023, 2040, 2059, 2223, 2245, 2300, 2325, 2409, 2462, 2488, 2486, and 2492; 2) a polynucleotide differentially expressed in a human colon cancer cell, where the polynucleotide comprises a sequence selected from the group consisting of SEQ ID NOS: , 33, 65, 228, 250, 252, 253, 280, 282, 355, 370, 387, 443, 460, 491, 545, 560, 581, 603, 680, 693, 703, 704, 716, 726, 746, 752, 753, 1095, 1104, 1205, 1241, 1264, 1354, 1387, 1401, 1442, 1514, 1734, 1742, 1780, 1851, 1899, 1915, 1954, 2024, 2066, 2262, and 2325; 3) a polynucleotide differentially expressed in a human lung cancer cell, where the polynucleotide comprises a sequence selected from the group consisting of SEQ ID NOS: 10, 54, 65, 171, 174, , 203, 252, 253, 254, , 285, 419, 420, 466, 491, 525, 526, 552, 571, 574, 590, 693, 700, 726, 742, 746, 861, 922, 990, 1088, 1288, 1355, 1417, 1422, 1444, 1454, 1570, 1597, 1979, 2007, 2024, 2034, 2038, 2126, and 2245; 4) a polynucleotide differentially expressed in growth factor-treated human microvascular endothelial cells (HMEC) relative to untreated HMEC, where the polynucleotide comprises a sequence selected from the group consisting of SEQ ID NOS:648, 1899, and 648; or 5) polynucleotides that are differentially expressed across multiple libraries, where the polynucleotide comprises a sequence selected from the group consisting of SEQ ID NOS: 65, 174, 203, 252, 253, 387, 419, 420, 491, 552, 560, 581, 590, 648, 693, 726, 746, 990, 1095, 1124, 1205, 1354, 1387, 1780, 1899, 1915, 1979, 2007, 2024, 2245, and 2325, In another aspect, the invention features an isolated polynucleotide comprising a nucleotide sequence having at least 90% sequence identity to an identifying sequence of "SEQ ID NOS: 1-5252" or a degenerate variant thereof. In related aspects, the invention features recombinant host cells and vectors comprising the polynucleotides of the invention, as well as isolated polypeptides encoded by the polynucleotides of the invention and antibodies that specifically bind such polypeptides.

In one embodiment, the invention features an isolated polynucleotide comprising a sequence encoding a polypeptide of a protein family or having a functional domain selected from the group consisting of: 4 transmembrane segments integral membrane proteins, 7 transmembrane receptors (rhodopsin family or secretin family), eukaryotic aspartyl proteases, ATPases associated with various cellular activities (AAA), Bcl-2, cyclins, DEAD box protein family, DEAD/H helicase protein family, MAP kinase kinase protein family, novel 3'5'-cyclic nucleotide phosphodiesterases, protein kinases, ras protein family, G-protein alpha subunit, phorbol esters/diacylglycerol binding proteins, protein kinase, trypsin, protein tyrosine phosphatase, wnt family of developmental signaling proteins,

WW/rsp5/WWP domain containing proteins, Ank repeat, basic region plus leucine zipper domain, bromodomain, eukaryotic thiol (cysteine) protease active site, EF-hand, ETS domain, type II fibronectin collagen binding domain, thioredoxin, homeobox domain, TNFR/NGFR family cysteine-rich region, WD domain/G-beta repeats, zinc finger (C2H2 type), zinc finger (CCHC class), and zinc finger (C3HC4 type). In a specific related embodiment, the invention features a polynucleotide comprising a sequence of one of the SEQ ID NOS: listed in Table 3 or Table 20.

In another aspect, the invention features a method of detecting differentially expressed genes correlated with a cancerous state of a mammalian cell, where the method comprises the step of detecting at least one differentially expressed gene product in a test sample derived from a cell suspected of being cancerous, where the gene product is encoded by a gene corresponding to a sequence of at least one of the differentially expressed polynucleotides disclosed herein. Detection of the differentially expressed gene product is correlated with a cancerous state of the cell from which the test sample was derived. In one embodiment, the detecting is by hybridization of the test sample to a reference array, wherein the reference array comprises an identifying sequence of at least one of the differentially expressed polynucleotides disclosed herein.

In one embodiment of the method of the invention, the cell is a breast tissue derived cell, and the differentially expressed gene product is encoded by a gene corresponding to a sequence of at least one of SEQ ID NOS:15, 36, 44, 45, 89, 146, 154, 159, 165, 172, 174, 183, 203, 261, 364, 366, 387, 419, 420, 496, 503, 510, 512, 529, 552, 560, 564, 570, 590, 606, 644, 646, 693, 707, 711, 726, 746, 754, 756, 875, 902, 921, 942, 990, 1095, 1104, 1122, 1131, 1142, 1170, 1184, 1205, 1286, 1289, 1354, 1387, 1435, 1535, 1751, 1764, 1777, 1795, 1860, 1869, 1882, 1890, 1915, 1933, 1934, 1979, 1980, 2007, 2023, 2040, 2059, 2223, 2245, 2300, 2325, 2409, 2462, 2486 2488, and 2492.

In another embodiment of the method of the invention, the cell is a colon tissue derived cell, and differentially expressed gene product is encoded by a gene corresponding to a sequence ofat least one of SEQ ID NOS: 65, 228, 252, 253, 280, 355, 491, 581, 603, 680, 693, 716, 726, 746, 752, 753, 1241, 1264, 1401, 1442, 1514, 1851, 1915, 2024, 2066, 33, 250, 282, 370, 387, 443, 460, 545, 560, 703, 704, 1095, 1104, 1205, 1354, 1387, 1734, 1742, 1780, 1899, 1954, 2262, and 2325.

In yet another embodiment of the method of the invention, the cell is a lung tissue derived cell, and differentially expressed gene product is encoded by a gene corresponding to a sequence ofat least one of SEQ ID NOS:10, 54, 65, 171, 174, 203, 252, 253, 254, 285, 419, 420, 466, 491, 525, 526, 552, 571, 574, 590, 693, 700, 726, 742, 746, 861, 922, 990, 1088, 1288, 1355, 1417, 1422, 1444, 1454, 1570, 1597, 1979, 2007, 2024, 2034, 2038, 2126, and 2245.

In another embodiment, the cell is any of a lung, breast, or colon cell and the differentially expressed gene product is encoded by a gene corresponding to a sequence of at least one of SEQ ID NOS:648 and 1899.

In still another embodiment, the cell is any of a breast, colon, or lung cell and the differentially expressed gene product is encoded by a gene corresponding to a sequence of at least one of SEQ ID NOS: 65, 174, 203, 252, 253, 387, 419, 420, 491, 552, 560, 581, 590, 648, 693, 726, 746, 990, 1095, 1124, 1205, 1354, 1387, , 1780, 1899, 1915, 1979, 2007, 2024, 2245, and 2325. Other aspects and embodiments of the invention will be readily apparent to the ordinarily skilled artisan upon reading the description provided herein.

Detailed Description of the Invention The invention relates to polynucleotides comprising the disclosed nucleotide sequences, to full length cDNA, mRNA and genes corresponding to these sequences, and to polypeptides and proteins encoded by these polynucleotides and genes.

Also included are polynucleotides that encode polypeptides and proteins encoded by the polynucleotides of the Sequence Listing. The various polynucleotides that can encode these polypeptides and proteins differ because of the degeneracy of the genetic code, in that most amino acids are encoded by more than one triplet codon. The identity of such codons is well-known in this art, and this information can be used for the construction of the polynucleotides within the scope of the invention.

Polynucleotides encoding polypeptides and proteins that are variants of the polypeptides and proteins encoded by the polynucleotides and related cDNA and genes are also within the scope of the invention. The variants differ from wild type protein in having one or more amino acid substitutions that either enhance, add, or diminish a biological activity of the wild type protein. Once the amino acid change is selected, a polynucleotide encoding that variant is constructed according to the invention. The following detailed description describes the polynucleotide compositions encompassed by the invention, methods for obtaining cDNA or genomic DNA encoding a full-length gene product, expression of these polynucleotides and genes, identification of structural motifs of the polynucleotides and genes, identification of the function of a gene product encoded by a gene corresponding to a polynucleotide of the invention, use of the provided polynucleotides as probes and in mapping and in tissue profiling, use of the corresponding polypeptides and other gene products to raise antibodies, and use of the polynucleotides and their encoded gene products for therapeutic and diagnostic purposes.

I. Polynucleotide Compositions The scope of the invention with respect to polynucleotide compositions includes, but is not necessarily limited to, polynucleotides having a sequence set forth in any one of "SEQ ID NOS: 1-5252"; polynucleotides obtained from the biological materials described herein or other biological sources (particularly human sources) by hybridization under stringent conditions (particularly conditions of high stringency); genes corresponding to the provided polynucleotides; variants of the provided polynucleotides and their corresponding genes, particularly those variants that retain a biological activity of the encoded gene product (e.g., a biological activity ascribed to a gene product corresponding to the provided polynucleotides as a result of the assignment of the gene product to a protein family(ies) and/or identification of a functional domain present in the gene product). Other nucleic acid compositions contemplated by and within the scope of the present invention will be readily apparent to one of ordinary skill in the art when provided with the disclosure here. The invention features polynucleotides that are expressed in cells of human tissue, specifically human colon, breast, and/or lung tissue. Novel nucleic acid compositions of the invention of particular interest comprise a sequence set forth in any one of "SEQ ID NOS: 1-5252" or an identifying sequence thereof. An "identifying sequence" is a contiguous sequence of residues at least about 10 nt to about 20 nt in length, usually at least about 50 nt to about 100 nt in length, that uniquely identifies a polynucleotide sequence, e.g., exhibits less than 90%, usually less than about 80% to about 85% sequence identity to any contiguous nucleotide sequence of more than about 20 nt. Thus, the subject novel nucleic acid compositions include full length cDNAs or mRNAs that encompass an identifying sequence of contiguous nucleotides from any one of "SEQ ID NOS: 1-5252." The polynucleotides of the invention also include polynucleotides having sequence similarity or sequence identity. Nucleic acids having sequence similarity are detected by hybridization under low stringency conditions, for example, at 50°C and 10XSSC (0.9 M saline/0.09 M sodium citrate) and remain bound when subjected to washing at 55°C in IXSSC. Sequence identity can be determined by hybridization under stringent conditions, for example, at 50°C or higher and 0. IXSSC (9 mM saline/0.9 mM sodium citrate). Hybridization methods and conditions are well known in the art, see, e.g., U.S. Patent No. 5,707,829. Nucleic acids that are substantially identical to the provided polynucleotide sequences, e.g. allelic variants, genetically altered versions of the gene, etc., bind to the provided polynucleotide sequences ("SEQ ID NOS: 1-5252") under stringent hybridization conditions. By using probes, particularly labeled probes of DNA sequences, one can isolate homologous or related genes. The source of homologous genes can be any species, e.g. primate species, particularly human; rodents, such as rats and mice; canines, felines, bovines, ovines, equines, yeast, nematodes, etc.

Preferably, hybridization is performed using at least 15 contiguous nucleotides ofat least one of "SEQ ID NOS:l-5252." That is, when at least 15 contiguous nucleotides of one of the disclosed SEQ ID NOs. is used as a probe, the probe will preferentially hybridize with a gene or mRNA (of the biological material) comprising the complementary sequence, allowing the identification and retrieval of the nucleic acids of the biological material that uniquely hybridize to the selected probe. Probes from more than one SEQ ID NO. will hybridize with the same gene or mRNA if the cDNA from which they were derived corresponds to one mRNA. Probes of more than 15 nucleotides can be used, but 15 nucleotides represents enough sequence for unique identification.

The polynucleotides of the invention also include naturally occurring variants of the nucleotide sequences (e.g., degenerate variants, allelic variants, etc.). Variants of the polynucleotides of the invention are identified by hybridization of putative variants with nucleotide sequences disclosed herein, preferably by hybridization under stringent conditions For example, by using appropriate wash conditions, variants of the polynucleotides of the invention can be identified where the allelic variant exhibits at most about 25-30%) base pair mismatches relative to the selected polynucleotide probe. In general, allelic variants contain 15-25% base pair mismatches, and can contain as little as even 5-15%, or 2-5%, or 1-2% base pair mismatches, as well as a single base-pair mismatch.

The invention also encompasses homologs corresponding to the polynucleotides of "SEQ ID NOS: 1-5252", where the source of homologous genes can be any mammalian species, e.g., primate species, particularly human; rodents, such as rats; canines, felines, bovines, ovines, equines, yeast, nematodes, etc. Between mammalian species, e.g., human and mouse, homologs have substantial sequence similarity, e.g., at least 75% sequence identity, usually at least 90%, more usually at least 95% between nucleotide sequences. Sequence similarity is calculated based on a reference sequence, which may be a subset of a larger sequence, such as a conserved motif, coding region, flanking region, etc. A reference sequence will usually be at least about 18 contiguous nt long, more usually at least about 30 nt long, and may extend to the complete sequence that is being compared. Algorithms for sequence analysis are known in the art, such as BLAST, described in Altschul et al, J. Mol. Biol. (1990) 275:403-10.

In general, variants of the invention have a sequence identity greater than at least about 65%, preferably at least about 75%, more preferably at least about 85%, and can be greater than at least about 90% or more as determined by the Smith- Waterman homology search algorithm as implemented in MPSRCH program (Oxford Molecular). For the purposes of this invention, a preferred method of calculating percent identity is the Smith- Waterman algorithm, using the following. Global DNA sequence identity must be greater than 65% as determined by the Smith- Waterman homology search algorithm as implemented in MPSRCH program (Oxford Molecular) using an affine gap search with the following search parameters: gap open penalty, 12; and gap extension penalty, 1.

The subject nucleic acids can be cDNAs or genomic DNAs, as well as fragments thereof, particularly fragments that encode a biologically active gene product and/or are useful in the methods disclosed herein (e.g., in diagnosis, as a unique identifier of a differentially expressed gene of interest, etc.). The term "cDNA" as used herein is intended to include all nucleic acids that share the arrangement of sequence elements found in native mature mRNA species, where sequence elements are exons and 3' and 5' non-coding regions. Normally mRNA species have contiguous exons, with the intervening introns, when present, being removed by nuclear RNA splicing, to create a continuous open reading frame encoding a polypeptide of the invention.

A genomic sequence of interest comprises the nucleic acid present between the initiation codon and the stop codon, as defined in the listed sequences, including all of the introns that are normally present in a native chromosome. It can further include the 3' and 5' untranslated regions found in the mature mRNA. It can further include specific transcriptional and translational regulatory sequences, such as promoters, enhancers, etc., including about 1 kb, but possibly more, of flanking genomic DNA at either the 5' and 3' end of the transcribed region. The genomic DNA can be isolated as a fragment of 100 kbp or smaller; and substantially free of flanking chromosomal sequence. The genomic DNA flanking the coding region, either 3' and 5', or internal regulatory sequences as sometimes found in introns, contains sequences required for proper tissue, stage-specific, or disease- state specific expression.

The nucleic acid compositions of the subject invention can encode all or a part of the subject polypeptides. Double or single stranded fragments can be obtained from the DNA sequence by chemically synthesizing oligonucleotides in accordance with conventional methods, by restriction enzyme digestion, by PCR amplification, etc. Isolated polynucleotides and polynucleotide fragments of the invention comprise at least about 10, about 15, about 20, about 35, about 50, about 100, about 150 to about 200, about 250 to about 300, or about 350 contiguous nucleotides selected from the polynucleotide sequences as shown in "SEQ ID NOS: 1-5252." For the most part, fragments will be ofat least 15 nt, usually at least 18 nt or 25 nt, and up to at least about 50 contiguous nt in length or more. In a preferred embodiment, the polynucleotide molecules comprise a contiguous sequence of at least twelve nucleotides selected from the group consisting of the polynucleotides shown in "SEQ ID NOS: 1-5252." Probes specific to the polynucleotides of the invention can be generated using the polynucleotide sequences disclosed in "SEQ ID NOS: 1-5252." The probes are preferably at least about 12, 15, 16, 18, 20, 22, 24, or 25 nucleotide fragment of a corresponding contiguous sequence of "SEQ ID NOS:l-5252", and can be less than 2, 1, 0.5, 0.1, or 0.05 kb in length. The probes can be synthesized chemically or can be generated from longer polynucleotides using restriction enzymes. The probes can be labeled, for example, with a radioactive, biotinylated, or fluorescent tag. Preferably, probes are designed based upon an identifying sequence of a polynucleotide of one of "SEQ ID NOS: 1-5252." More preferably, probes are designed based on a contiguous sequence of one of the subject polynucleotides that remain unmasked following application of a masking program for masking low complexity (e.g., XBLAST) to the sequence., i.e., one would select an unmasked region, as indicated by the polynucleotides outside the poly-n stretches of the masked sequence produced by the masking program.

The polynucleotides of the subject invention are isolated and obtained in substantial purity, generally as other than an intact chromosome. Usually, the polynucleotides, either as DNA or RNA, will be obtained substantially free of other naturally-occurring nucleic acid sequences, generally being at least about 50%, usually at least about 90% pure and are typically "recombinant", e.g., flanked by one or more nucleotides with which it is not normally associated on a naturally occurring chromosome.

The polynucleotides of the invention can be provided as a linear molecule or within a circular molecule. They can be provided within autonomously replicating molecules (vectors) or within molecules without replication sequences. They can be regulated by their own or by other regulatory sequences, as is known in the art. The polynucleotides of the invention can be introduced into suitable host cells using a variety of techniques which are available in the art, such as transferrin polycation-mediated DNA transfer, transfection with naked or encapsulated nucleic acids, liposome-mediated DNA transfer, intracellular transportation of DNA-coated latex beads, protoplast fusion, viral infection, electroporation, gene gun, calcium phosphate-mediated transfection, and the like.

The subject nucleic acid compositions can be used to, for example, produce polypeptides, as probes for the detection of mRNA of the invention in biological samples (e.g., extracts of human cells) to generate additional copies of the polynucleotides, to generate ribozymes or antisense oligonucleotides, and as single stranded DNA probes or as triple-strand forming oligonucleotides. The probes described herein can be used to, for example, determine the presence or absence of the polynucleotide sequences as shown in "SEQ ID NOS: 1-5252" or variants thereof in a sample. These and other uses are described in more detail below.

Use of Polynucleotides to Obtain Full-Length cDNA and Full-Length Human Gene and Promoter Region

Full-length cDNA molecules comprising the disclosed polynucleotides are obtained as follows. A polynucleotide having a sequence of one of "SEQ ID NOS: 1-5252", or a portion thereof comprising at least 12, 15, 18, or 20 nucleotides, is used as a hybridization probe to detect hybridizing members of a cDNA library using probe design methods, cloning methods, and clone selection techniques such as those described in U.S. Patent No. 5,654,173. Libraries of cDNA are made from selected tissues, such as normal or tumor tissue, or from tissues of a mammal treated with, for example, a pharmaceutical agent. Preferably, the tissue is the same as the tissue from which the polynucleotides of the invention were isolated, as both the polynucleotides described herein and the cDNA represent expressed genes. Most preferably, the cDNA library is made from the biological material described herein in the Examples. Alternatively, many cDNA libraries are available commercially. (Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., (1989) Cold Spring Harbor Press, Cold Spring Harbor, NY). The choice of cell type for library construction can be made after the identity of the protein encoded by the gene corresponding to the polynucleotide of the invention is known. This will indicate which tissue and cell types are likely to express the related gene, and thus represent a suitable source for the mRNA for generating the cDNA. Where the provided polynucleotides are isolated from cDNA libraries, the libraries are prepared from mRNA of human colon cells, more preferably, human colon cancer cells, even more preferably, from a highly metastatic colon cell, Kml2L4-A.

Techniques for producing and probing nucleic acid sequence libraries are described, for example, in Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., (1989) Cold Spring Harbor Press, Cold Spring Harbor, NY. The cDNA can be prepared by using primers based on sequence from "SEQ ID NOS: 1-5252." In one embodiment, the cDNA library can be made from only poly-adenylated mRNA. Thus, poly-T primers can be used to prepare cDNA from the mRNA.

Members of the library that are larger than the provided polynucleotides, and preferably that encompass the complete coding sequence of the native message, are obtained. In order to confirm that the entire cDNA has been obtained, RNA protection experiments are performed as follows. Hybridization of a full-length cDNA to an mRNA will protect the RNA from RNase degradation. If the cDNA is not full length, then the portions of the mRNA that are not hybridized will be subject to RNase degradation. This is assayed, as is known in the art, by changes in electrophoretic mobility on polyacrylamide gels, or by detection of released monoribonucleotides. Sambrook et al., Molecular

Cloning: A Laboratory Manual, 2nd Ed., (1989) Cold Spring Harbor Press, Cold Spring Harbor, NY. In order to obtain additional sequences 5' to the end of a partial cDNA, 5' RACE (PCR Protocols: A Guide to Methods and Applications, (1990) Academic Press, Inc.) is performed. Genomic DNA is isolated using the provided polynucleotides in a manner similar to the isolation of full-length cDNAs. Briefly, the provided polynucleotides, or portions thereof, are used as probes to libraries of genomic DNA. Preferably, the library is obtained from the cell type that was used to generate the polynucleotides of the invention, but this is not essential. Most preferably, the genomic DNA is obtained from the biological material described herein in the Examples. Such libraries can be in vectors suitable for carrying large segments of a genome, such as PI or YAC, as described in detail in Sambrook et al, 9.4-9.30. In addition, genomic sequences can be isolated from human BAC libraries, which are commercially available from Research Genetics, Inc., Huntville, Alabama, USA, for example. In order to obtain additional 5 ' or 3' sequences, chromosome walking is performed, as described in Sambrook et al., such that adjacent and overlapping fragments of genomic DNA are isolated. These are mapped and pieced together, as is known in the art, using restriction digestion enzymes and DNA ligase.

Using the polynucleotide sequences of the invention, corresponding full-length genes can be isolated using both classical and PCR methods to construct and probe cDNA libraries. Using either method, Northern blots, preferably, are performed on a number of cell types to determine which cell lines express the gene of interest at the highest level. Classical methods of constructing cDNA libraries are taught in Sambrook et al, supra. With these methods, cDNA can be produced from mRNA and inserted into viral or expression vectors. Typically, libraries of mRNA comprising poly(A) tails can be produced with poly(T) primers. Similarly, cDNA libraries can be produced using the instant sequences as primers.

PCR methods are used to amplify the members of a cDNA library that comprise the desired insert. In this case, the desired insert will contain sequence from the full length cDNA that corresponds to the instant polynucleotides. Such PCR methods include gene trapping and RACE methods. Gene trapping entails inserting a member of a cDNA library into a vector. The vector then is denatured to produce single stranded molecules. Next, a substrate-bound probe, such a biotinylated oligo, is used to trap cDNA inserts of interest. Biotinylated probes can be linked to an avidin-bound solid substrate. PCR methods can be used to amplify the trapped cDNA. To trap sequences corresponding to the full length genes, the labeled probe sequence is based on the polynucleotide sequences of the invention. Random primers or primers specific to the library vector can be used to amplify the trapped cDNA. Such gene trapping techniques are described in Gruber et al, WO 95/04745 and Gruber et al., U.S. Pat. No. 5,500,356. Kits are commercially available to perform gene trapping experiments from, for example, Life Technologies, Gaithersburg, Maryland, USA.

"Rapid amplification of cDNA ends," or RACE, is a PCR method of amplifying cDNAs from a number of different RNAs. The cDNAs are ligated to an oligonucleotide linker, and amplified by PCR using two primers. One primer is based on sequence from the instant polynucleotides, for which full length sequence is desired, and a second primer comprises sequence that hybridizes to the oligonucleotide linker to amplify the cDNA. A description of this methods is reported in WO 97/19110. In preferred embodiments of RACE, a common primer is designed to anneal to an arbitrary adaptor sequence ligated to cDNA ends (Apte and Siebert, Biotechniques (1993) 75:890-893; Edwards et al, Nuc. Acids Res. (1991) 79:5227-5232). When a single gene-specific RACE primer is paired with the common primer, preferential amplification of sequences between the single gene specific primer and the common primer occurs. Commercial cDNA pools modified for use in RACE are available.

Another PCR-based method generates full-length cDNA library with anchored ends without needing specific knowledge of the cDNA sequence. This method is described in WO 96/40998.

The promoter region of a gene generally is located 5' to the initiation site for RNA polymerase II. Hundreds of promoter regions contain the "TATA" box, a sequence such as TATTA or TATAA, which is sensitive to mutations. The promoter region can be obtained by performing 5' RACE using a primer from the coding region of the gene. Alternatively, the cDNA can be used as a probe for the genomic sequence, and the region 5' to the coding region is identified by "walking up." If the gene is highly expressed or differentially expressed, the promoter from the gene can be of use in a regulatory construct for a heterologous gene.

Once the full-length cDNA or gene is obtained, DNA encoding variants can be prepared by site-directed mutagenesis, described in detail in Sambrook et al., 15.3-15.63. The choice of codon or nucleotide to be replaced can be based on disclosure herein on optional changes in amino acids to achieve altered protein structure and/or function. As an alternative method to obtaining DNA or RNA from a biological material, nucleic acid comprising nucleotides having the sequence of one or more polynucleotides of the invention can be synthesized. Thus, the invention encompasses nucleic acid molecules ranging in length from 15 nucleotides (corresponding to at least 15 contiguous nucleotides of one of "SEQ ID NOS: 1-5252") up to a maximum length suitable for one or more biological manipulations, including replication and expression, of the nucleic acid molecule. The invention includes but is not limited to (a) nucleic acid having the size of a full gene, and comprising at least one of "SEQ ID NOS: 1-5252;"; (b) the nucleic acid of (a) also comprising at least one additional gene, operably linked to permit expression of a fusion protein; (c) an expression vector comprising (a) or (b); (d) a plasmid comprising (a) or (b) ; and (e) a recombinant viral particle comprising (a) or (b). Once provided with the polynucleotides disclosed herein, construction or preparation of (a) - (e) are well within the skill in the art.

The sequence of a nucleic acid comprising at least 15 contiguous nucleotides ofat least any one of "SEQ ID NOS : 1 -5252,", preferably the entire sequence of at least any one of "SEQ ID NOS: 1-5252," is not limited and can be any sequence of A, T, G, and/or C (for DNA) and A, U, G, and/or C (for RNA) or modified bases thereof, including inosine and pseudouridine. The choice of sequence will depend on the desired function and can be dictated by coding regions desired, the intron-like regions desired, and the regulatory regions desired. Where the entire sequence of any one of "SEQ ID NOS: 1-5252" is within the nucleic acid, the nucleic acid obtained is referred to herein as a polynucleotide comprising the sequence of any one of "SEQ ID NOS: 1-5252."

II. Expression of Polypeptide Encoded by Full-Length cDNA or Full-Length Gene The provided polynucleotide (e.g. , a polynucleotide having a sequence of one of

"SEQ ID NOS: 1-5252"), the corresponding cDNA, or the full-length gene is used to express a partial or complete gene product. Constructs of polynucleotides having sequences of "SEQ ID NOS: 1-5252" can be generated synthetically. Alternatively, single- step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides is described by, e.g., Stemmer et al, Gene (Amsterdam) (1995) 164(l):49-52>. In this method, assembly PCR (the synthesis of long DNA sequences from large numbers of oligodeoxyribonucleotides (oligos)) is described. The method is derived from DNA shuffling (Stemmer, Nature (1994) 370:389-391), and does not rely on DNA ligase, but instead relies on DNA polymerase to build increasingly longer DNA fragments during the assembly process. Appropriate polynucleotide constructs are purified using standard recombinant

DNA techniques as described in, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., (1989) Cold Spring Harbor Press, Cold Spring Harbor, NY, and under current regulations described in United States Dept. of HHS, National Institute of Health (NIH) Guidelines for Recombinant DNA Research. The gene product encoded by a polynucleotide of the invention is expressed in any expression system, including, for example, bacterial, yeast, insect, amphibian and mammalian systems. Suitable vectors and host cells are described in U.S. Patent No. 5,654,173.

Bacteria. Expression systems in bacteria include those described in Chang et al, Nature (1978) 275:615; Goeddel et al, Nature (1979) 237:544; Goeddel et al, Nucleic Acids Res. (1980) S:4057; EP 0 036,776; U.S. Patent No. 4,551,433; DeBoer et al, Proc. Natl Acad. Sci. (USA) (1983) £0:21-25; and Siebenlist et al, Cell (1980) 20:269.

Yeast. Expression systems in yeast include those described in Hinnen et al, Proc. Natl. Acad. Sci. (USA) (1978) 75:1929; Ito et α/., J Bacteriol (1983) 755:163; Kurtz et al., Mol Cell. Biol. (1986) 5:142; Kunze et al, J. Basic Microbiol. (1985) 25:141; Gleeson et al, J. Gen. Microbiol. (1986) 732:3459; Roggenkamp et al, Mol. Gen. Genet. (1986) 202:302; Das et al, J Bacteriol. (1984) 75S:1165; De Louvencourt et al, J. Bacteriol. (1983) 154:131; Van den Berg et al, Bio/Technology (1990) 5:135; Kunze et al, J. Basic Microbiol. (1985) 25:141; Cregg et al, Mol. Cell. Biol. (1985) 5:3376; U.S. Patent Nos. 4,837,148 and 4,929,555; Beach and Nurse, Nature (1981) 300:706; Davidow et al, Curr. Genet. (1985) 70:380; Gaillardin et al, Curr. Genet. (1985) 70:49; Ballance et al, Biochem. Biophys. Res. Commun. (1983) 772:284-289; Tilburn et al, Gene (1983) 2(5:205-221; Yelton et al, Proc. Natl Acad. Sci. (USA) (1984) 37:1470-1474; Kelly and Hynes, EMBOJ. (1985) 4:475479; EP 0 244,234; and WO 91/00357.

Insect Cells. Expression of heterologous genes in insects is accomplished as described in U.S. Patent No. 4,745,051 ; Friesen et al, "The Regulation of Baculovirus

Gene Expression", in: The Molecular Biology Of Baculoviruses (1986) (W. Doerfler, ed.); EP 0 127,839; EP 0 155,476; and Vlak et al, J. Gen. Virol. (1988) 69:165-116; Miller et al, Ann. Rev. Microbiol. (1988) 42:111; Carbonell et al, Gene (1988) 73:409; Maeda et al, Nature (1985) 375:592-594; Lebacq-Verheyden et al, Mol Cell. Biol. (1988) 3:3129; Smith et al, Proc. Natl. Acad. Sci. (USA) (1985) 32:8844; Miyajima et al, Gene (1987) 53:273; and Martin et al, DNA (1988) 7:99. Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts are described in Luckow et al, Bio/Technology (1988) 6:47-55, Miller et al, Generic Engineering (1986) 3:277-279, and Maeda et al, Nature (1985) 375:592-594.

Mammalian Cells. Mammalian expression is accomplished as described in Dijkema et al, EMBO J. (1985) 4:761, Gorman et al, Proc. Natl Acad. Sci. (USA) (1982) 79:6777, Boshart et al, Cell (1985) 47:521 and U.S. Patent No. 4,399,216. Other features of mammalian expression are facilitated as described in Ham and Wallace, Meth. Enz. (1979) 53:44, Barnes and Sato, Anal Biochem. (1980) 702:255, U.S. Patent Nos. 4,767,704, 4,657,866, 4,927,762, 4,560,655, WO 90/103430, WO 87/00195, and U.S. RE 30,985.

Polynucleotide molecules comprising a polynucleotide sequence provided herein propagated by placing the molecule in a vector. Viral and non- viral vectors are used, including plasmids. The choice of plasmid will depend on the type of cell in which propagation is desired and the purpose of propagation. Certain vectors are useful for amplifying and making large amounts of the desired DNA sequence. Other vectors are suitable for expression in cells in culture. Still other vectors are suitable for transfer and expression in cells in a whole animal or person. The choice of appropriate vector is well within the skill of the art. Many such vectors are available commercially. The partial or full-length polynucleotide is inserted into a vector typically by means of DNA ligase attachment to a cleaved restriction enzyme site in the vector. Alternatively, the desired nucleotide sequence can be inserted by homologous recombination in vivo. Typically this is accomplished by attaching regions of homology to the vector on the flanks of the desired nucleotide sequence. Regions of homology are added by ligation of oligonucleotides, or by polymerase chain reaction using primers comprising both the region of homology and a portion of the desired nucleotide sequence, for example. The polynucleotides set forth in "SEQ ID NOS: 1-5252" or their corresponding full- length polynucleotides are linked to regulatory sequences as appropriate to obtain the desired expression properties. These can include promoters (attached either at the 5' end of the sense strand or at the 3' end of the antisense strand), enhancers, terminators, operators, repressors, and inducers. The promoters can be regulated or constitutive. In some situations it may be desirable to use conditionally active promoters, such as tissue-specific or developmental stage-specific promoters. These are linked to the desired nucleotide sequence using the techniques described above for linkage to vectors. Any techniques known in the art can be used. When any of the above host cells, or other appropriate host cells or organisms, are used to replicate and/or express the polynucleotides or nucleic acids of the invention, the resulting replicated nucleic acid, RNA, expressed protein or polypeptide, is within the scope of the invention as a product of the host cell or organism. The product is recovered by any appropriate means known in the art. Once the gene corresponding to a selected polynucleotide is identified, its expression can be regulated in the cell to which the gene is native. For example, an endogenous gene of a cell can be regulated by an exogenous regulatory sequence as disclosed in U.S. Patent No. 5,641,670.

III. Identification of Functional and Structural Motifs of Novel Genes

A. Screening Polynucleotide Sequences and Amino Acid Sequences Against Publicly Available Databases

Translations of the nucleotide sequence of the provided polynucleotides, cDNAs or full genes can be aligned with individual known sequences. Similarity with individual sequences can be used to determine the activity of the polypeptides encoded by the polynucleotides of the invention. For example, sequences that show similarity with a chemokine sequence can exhibit chemokine activities. Also, sequences exhibiting similarity with more than one individual sequence can exhibit activities that are characteristic of either or both individual sequences. The full length sequences and fragments of the polynucleotide sequences of the nearest neighbors can be used as probes and primers to identify and isolate the full length sequence corresponding to provided polynucleotides. The nearest neighbors can indicate a tissue or cell type to be used to construct a library for the full-length sequences corresponding to the provided polynucleotides..

Typically, a selected polynucleotide is translated in all six frames to determine the best alignment with the individual sequences. The sequences disclosed herein in the Sequence Listing are in a 5' to 3' orientation and translation in three frames can be sufficient (with a few specific exceptions as described in the Examples). These amino acid sequences are referred to, generally, as query sequences, which will be aligned with the individual sequences. Databases with individual sequences are described in "Computer Methods for Macromolecular Sequence Analysis" Methods in Enzymology (1996) 266^',

Doolittle, Academic Press, Inc., a division of Harcourt Brace & Co., San Diego, California, USA. Databases include Genbank, EMBL, and DNA Database of Japan (DDBJ).

Query and individual sequences can be aligned using the methods and computer programs described above, and include BLAST, available over the world wide web at http://ww.ncbi.nlm.nih.gov/BLAST/. Another alignment algorithm is Fasta, available in the Genetics Computing Group (GCG) package, Madison, Wisconsin, USA, a wholly owned subsidiary of Oxford Molecular Group, Inc. Other techniques for alignment are described in Doolittle, supra. Preferably, an alignment program that permits gaps in the sequence is utilized to align the sequences. The Smith- Waterman is one type of algorithm that permits gaps in sequence alignments. See Meth. Mol Biol. (1997) 70: 173-187. Also, the GAP program using the Needleman and Wunsch alignment method can be utilized to align sequences. An alternative search strategy uses MPSRCH software, which runs on a MASPAR computer. MPSRCH uses a Smith- Waterman algorithm to score sequences on a massively parallel computer. This approach improves ability to identify sequences that are distantly related matches, and is especially tolerant of small gaps and nucleotide sequence errors. Amino acid sequences encoded by the provided polynucleotides can be used to search both protein and DNA databases.

Results of individual and query sequence alignments can be divided into three categories, high similarity, weak similarity, and no similarity. Individual alignment results ranging from high similarity to weak similarity provide a basis for determining polypeptide activity and/or structure. Parameters for categorizing individual results include: percentage of the alignment region length where the strongest alignment is found, percent sequence identity, and p value.

The percentage of the alignment region length is calculated by counting the number of residues of the individual sequence found in the region of strongest alignment, e.g., contiguous region of the individual sequence that contains the greatest number of residues that are identical to the residues of the corresponding region of the aligned query sequence. This number is divided by the total residue length of the query sequence to calculate a percentage. For example, a query sequence of 20 amino acid residues might be aligned with a 20 amino acid region of an individual sequence. The individual sequence might be identical to amino acid residues 5, 9-15, and 17-19 of the query sequence. The region of strongest alignment is thus the region stretching from residue 9-19, an 11 amino acid stretch. The percentage of the alignment region length is: 11 (length of the region of strongest alignment) divided by (query sequence length) 20 or 55%).

Percent sequence identity is calculated by counting the number of amino acid matches between the query and individual sequence and dividing total number of matches by the number of residues of the individual sequences found in the region of strongest alignment. Thus, the percent identity in the example above would be 10 matches divided by 11 amino acids, or approximately, 90.9%

P value is the probability that the alignment was produced by chance. For a single alignment, the p value can be calculated according to Karlin et al, Proc. Natl. Acad. Sci. (1990) 37:2264 and Karlin et al., Proc. Natl. Acad. Sci. (1993) 90. The p value of multiple alignments using the same query sequence can be calculated using an heuristic approach described in Altschul et al., Nat. Genet. (1994) 6: 19. Alignment programs such as BLAST program can calculate the p value. Another factor to consider for determining identity or similarity is the location of the similarity or identity. Strong local alignment can indicate similarity even if the length of alignment is short. Sequence identity scattered throughout the length of the query sequence also can indicate a similarity between the query and profile sequences. The boundaries of the region where the sequences align can be determined according to Doolittle, supra; BLAST or FAST programs; or by determining the area where sequence identity is highest. High Similarity. In general, in alignment results considered to be of high similarity, the percent of the alignment region length is typically at least about 55% of total length query sequence; more typically, at least about 58%; even more typically; at least about 60% of the total residue length of the query sequence. Usually, percent length of the alignment region can be as much as about 62%; more usually, as much as about 64%; even more usually, as much as about 66%). Further, for high similarity, the region of alignment, typically, exhibits at least about 75% of sequence identity; more typically, at least about 78%; even more typically; at least about 80% sequence identity. Usually, percent sequence identity can be as much as about 82%; more usually, as much as about 84%; even more usually, as much as about 86%.

The p value is used in conjunction with these methods. If high similarity is found, the query sequence is considered to have high similarity with a profile sequence when the p value is less than or equal to about IO^"2; more usually; less than or equal to about IO^"3; even more usually; less than or equal to about IO^"4. More typically, the p value is no more than about 10^"5; more typically; no more than or equal to about 10^"10; even more typically; no more than or equal to about IO^"15 for the query sequence to be considered high similarity.

Weak Similarity. In general, where alignment results considered to be of weak similarity, there is no minimum percent length of the alignment region nor minimum length of alignment. A better showing of weak similarity is considered when the region of alignment is, typically, at least about 15 amino acid residues in length; more typically, at least about 20; even more typically; at least about 25 amino acid residues in length. Usually, length of the alignment region can be as much as about 30 amino acid residues; more usually, as much as about 40; even more usually, as much as about 60 amino acid residues. Further, for weak similarity, the region of alignment, typically, exhibits at least about 35% of sequence identity; more typically, at least about 40%; even more typically; at least about 45% sequence identity. Usually, percent sequence identity can be as much as about 50%; more usually, as much as about 55%; even more usually, as much as about 60%. If low similarity is found, the query sequence is considered to have weak similarity with a profile sequence when the p value is usually less than or equal to about IO^"2; more usually; less than or equal to about IO^"3; even more usually; less than or equal to about 10^"4. More typically, the p value is no more than about IO^"5; more usually; no more than or equal to about IO^"10; even more usually; no more than or equal to about IO^"15 for the query sequence to be considered weak similarity.

Similarity Determined by Sequence Identity Alone. Sequence identity alone can be used to determine similarity of a query sequence to an individual sequence and can indicate the activity of the sequence. Such an alignment, preferably, permits gaps to align sequences. Typically, the query sequence is related to the profile sequence if the sequence identity over the entire query sequence is at least about 15%; more typically, at least about 20%; even more typically, at least about 25%; even more typically, at least about 50%. Sequence identity alone as a measure of similarity is most useful when the query sequence is usually, at least 80 residues in length; more usually, 90 residues; even more usually, at least 95 amino acid residues in length. More typically, similarity can be concluded based on sequence identity alone when the query sequence is preferably 100 residues in length; more preferably, 120 residues in length; even more preferably, 150 amino acid residues in length.

Determining Activity from Alignments with Profile and Multiple Aligned Sequences. Translations of the provided polynucleotides can be aligned with amino acid profiles that define either protein families or common motifs. Also, translations of the provided polynucleotides can be aligned to multiple sequence alignments (MSA) comprising the polypeptide sequences of members of protein families or motifs. Similarity or identity with profile sequences or MS As can be used to determine the activity of the gene products (e.g., polypeptides) encoded by the provided polynucleotides or corresponding cDNA or genes. For example, sequences that show an identity or similarity with a chemokine profile or MSA can exhibit chemokine activities. Profiles can designed manually by (1) creating an MSA, which is an alignment of the amino acid sequence of members that belong to the family and (2) constructing a statistical representation of the alignment. Such methods are described, for example, in Birney et al, Nucl Acid Res. (1996) 24(14): 2730-2739. MSAs of some protein families and motifs are publicly available. For example, http://genome.wustl.edu Pfam/ includes MSAs of 547 different families and motifs. These MSAs are described also in

Sonnhammer et al., Proteins (1997) 28: 405-420. Other sources over the world wide web include the site at http://www.embl-heidelberg.de/argos/ali/ali.html; alternatively, a message can be sent to ALf@EMBL-HEIDELBERG.DE for the information. A brief description of these MSAs is reported in Pascarella et al, Prot. Eng. (1996) 9(3) :249-25l. Techniques for building profiles from MSAs are described in Sonnhammer et al, supra; Birney et al, supra; and "Computer Methods for Macromolecular Sequence Analysis," Methods in Enzymology (1996) 266, Doolittle, Academic Press, Inc., a division of Harcourt Brace & Co., San Diego, California, USA.

Similarity between a query sequence and a protein family or motif can be determined by (a) comparing the query sequence against the profile and/or (b) aligning the query sequence with the members of the family or motif. Typically, a program such as Searchwise is used to compare the query sequence to the statistical representation of the multiple alignment, also known as a profile. The program is described in Birney et al, supra. Other techniques to compare the sequence and profile are described in Sonnhammer et al, supra and Doolittle, supra. Next, methods described by Feng et al, J. Mol Evol (1987) 25:351 and Higgins et al, CABIOS (1989) 5:151 can be used align the query sequence with the members of a family or motif, also known as a MSA. Computer programs, such as PILEUP, can be used. See Feng et al, infra. In general, the following factors are used to determine if a similarity between a query sequence and a profile or MSA exists: (1) number of conserved residues found in the query sequence, (2) percentage of conserved residues found in the query sequence, (3) number of frameshifts, and (4) spacing between conserved residues.

Some alignment programs that both translate and align sequences can make any number of frameshifts when translating the nucleotide sequence to produce the best alignment. The fewer frameshifts needed to produce an alignment, the stronger the similarity or identity between the query and profile or MSAs. For example, a weak similarity resulting from no frameshifts can be a better indication of activity or structure of a query sequence, than a strong similarity resulting from two frameshifts. Preferably, three or fewer frameshifts are found in an alignment; more preferably two or fewer frameshifts; even more preferably, one or fewer frameshifts; even more preferably, no frameshifts are found in an alignment of query and profile or MSAs. Conserved residues are those amino acids found at a particular position in all or some of the family or motif members. For example, most chemokines contain four conserved cysteines. Alternatively, a position is considered conserved if only a certain class of amino acids is found in a particular position in all or some of the family members. For example, the N-terminal position can contain a positively charged amino acid, such as lysine, arginine, or histidine.

Typically, a residue of a polypeptide is conserved when a class of amino acids or a single amino acid is found at a particular position in at least about 40% of all class members; more typically, at least about 50%; even more typically, at least about 60% of the members. Usually, a residue is conserved when a class or single amino acid is found in at least about 70% of the members of a family or motif; more usually, at least about 80%; even more usually, at least about 90%; even more usually, at least about 95%.

A residue is considered conserved when three unrelated amino acids are found at a particular position in the some or all of the members; more usually, two unrelated amino acids. These residues are conserved when the unrelated amino acids are found at particular positions in at least about 40% of all class member; more typically, at least about 50%; even more typically, at least about 60% of the members. Usually, a residue is conserved when a class or single amino acid is found in at least about 70% of the members of a family or motif; more usually, at least about 80%; even more usually, at least about 90%; even more usually, at least about 95%.

A query sequence has similarity to a profile or MSA when the query sequence comprises at least about 25% of the conserved residues of the profile or MSA; more usually, at least about 30%; even more usually; at least about 40%. Typically, the query sequence has a stronger similarity to a profile sequence or MSA when the query sequence comprises at least about 45% of the conserved residues of the profile or MSA; more typically, at least about 50%; even more typically; at least about 55%.

B. Screening Polynucleotide and Amino Acid Sequences Against Protein

Profiles The identify and function of the gene that correlates to a polynucleotide described herein can be determined by screening the polynucleotides or their corresponding amino acid sequences against profiles of protein families. Such profiles focus on common structural motifs among proteins of each family. Publicly available profiles are described above in Section IVA. Additional or alternative profiles are described below.

In comparing a novel polynucleotide with known sequences, several alignment tools are available. Examples include PileUp, which creates a multiple sequence alignment, and is described in Feng et al., J. Mol. Evol. (1987) 25:351. Another method, GAP, uses the alignment method of Needleman et al., J. Mol. Biol. (1970) 43:443. GAP is best suited for global alignment of sequences. A third method, BestFit, functions by inserting gaps to maximize the number of matches using the local homology algorithm of Smith et al, Adv. Appl Math. (1981) 2:482.

C. Identification of Secreted & Membrane-Bound Polypeptides Both secreted and membrane-bound polypeptides of the present invention are of particular interest. For example, levels of secreted polypeptides can be assayed in body fluids that are convenient, such as blood, urine, prostatic fluid and semen. Membrane- bound polypeptides are useful for constructing vaccine antigens or inducing an immune response. Such antigens would comprise all or part of the extracellular region of the membrane-bound polypeptides. Because both secreted and membrane-bound polypeptides comprise a fragment of contiguous hydrophobic amino acids, hydrophobicity predicting algorithms can be used to identify such polypeptides. A signal sequence is usually encoded by both secreted and membrane-bound polypeptide genes to direct a polypeptide to the surface of the cell. The signal sequence usually comprises a stretch of hydrophobic residues. Such signal sequences can fold into helical structures. Membrane-bound polypeptides typically comprise at least one transmembrane region that possesses a stretch of hydrophobic amino acids that can transverse the membrane. Some transmembrane regions also exhibit a helical structure. Hydrophobic fragments within a polypeptide can be identified by using computer algorithms. Such algorithms include Hopp & WoodSi Proc. Natl. Acad. Sci. USA (1981) 73:3824-3828; Kyte & Doolittle, J. Mol Biol (1982) 757: 105-132; and RAOAR algorithm, Degli Esposti et al, Eur. J. Biochem. (1990) 790: 207-219. Another method of identifying secreted and membrane-bound polypeptides is to translate the polynucleotides of the invention in all six frames and determine if at least 8 contiguous hydrophobic amino acids are present. Those translated polypeptides with at least 8; more typically, 10; even more typically, 12 contiguous hydrophobic amino acids are considered to be either a putative secreted or membrane bound polypeptide. Hydrophobic amino acids include alanine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, threonine, tryptophan, tyrosine, and valine.

IV. Identification of the Function of an Expression Product of a Full-Length Gene Corresponding to a Polynucleotide Ribozymes, antisense constructs, and dominant negative mutants can be used to determine function of the expression product of a gene corresponding to a polynucleotide provided herein. These methods and compositions are particularly useful where the provided novel polynucleotide exhibits no significant or substantial homology to a sequence encoding a gene of known function. Antisense molecules and ribozymes can be constructed from synthetic polynucleotides. Typically, the phosphoramidite method of oligonucleotide synthesis is used. See Beaucage et al, Tet. Lett. (1981) 22:1859 and U.S. Patent No. 4,668,777. Automated devices for synthesis are available to create oligonucleotides using this chemistry. Examples of such devices include Biosearch 8600, Models 392 and 394 by Applied Biosystems, a division of Perkin-Elmer Corp., Foster City, California, USA; and Expedite by Perceptive Biosystems, Framingham, Massachusetts, USA. Synthetic RNA, phosphate analog oligonucleotides, and chemically derivatized oligonucleotides can also be produced, and can be covalently attached to other molecules. RNA oligonucleotides can be synthesized, for example, using RNA phosphoramidites. This method can be performed on an automated synthesizer, such as Applied Biosystems, Models 392 and 394, Foster City, California, USA. See Applied Biosystems User Bulletin 53 and Ogilvie et al, Pure & Applied Chem. (1987) 59:325.

Phosphorothioate oligonucleotides can also be synthesized for antisense construction. A sulfurizing reagent, such as tetraethylthiruam disulfide (TETD) in acetonitrile can be used to convert the internucleotide cyanoethyl phosphite to the phosphorothioate triester within 15 minutes at room temperature. TETD replaces the iodine reagent, while all other reagents used for standard phosphoramidite chemistry remain the same. Such a synthesis method can be automated using Models 392 and 394 by Applied Biosystems, for example.

Oligonucleotides of up to 200 nucleotides can be synthesized, more typically, 100 nucleotides, more typically 50 nucleotides; even more typically 30 to 40 nucleotides. These synthetic fragments can be annealed and ligated together to construct larger fragments. See, for example, Sambrook et al, supra. A. Ribozymes

Trans-cleaving catalytic RNAs (ribozymes) are RNA molecules possessing endoribonuclease activity. Ribozymes are specifically designed for a particular target, and the target message must contain a specific nucleotide sequence. They are engineered to cleave any RNA species site-specifically in the background of cellular RNA. The cleavage event renders the mRNA unstable and prevents protein expression. Importantly, ribozymes can be used to inhibit expression of a gene of unknown function for the purpose of determining its function in an in vitro or in vivo context, by detecting the phenotypic effect.

One commonly used ribozyme motif is the hammerhead, for which the substrate sequence requirements are minimal. Design of the hammerhead ribozyme is disclosed in Usman et al, Current Opin. Struct. Biol. (1996) 6:527. Ribozymes can also be prepared and used as described in Long et al, FASEBJ. (1993) 7:25; Symons, Ann. Rev. Biochem. (1992) 67:641; Perrotta et al, Biochem. (1992) 37:16; Ojwang et al, Proc. Natl Acad.

Sci. (USA) (1992) 39:10802; and U.S. Patent No. 5,254,678. Ribozyme cleavage of HIV-I RNA is described in U.S. Patent No. 5,144,019; methods of cleaving RNA using ribozymes is described in U.S. Patent No. 5,116,742; and methods for increasing the specificity of ribozymes are described in U.S. Patent No. 5,225,337 and Koizumi et al, Nucleic Acid Res. (1989) 77:7059. Preparation and use of ribozyme fragments in a hammerhead structure are also described by Koizumi et al, Nucleic Acids Res. (1989) 77:7059. Preparation and use of ribozyme fragments in a hairpin structure are described by Chowrira and Burke, Nucleic Acids Res. (1992) 20:2835. Ribozymes can also be made by rolling transcription as described in Daubendiek and Kool, Nat. Biotechnol (1997) 15(3):213. The hybridizing region of the ribozyme can be modified or can be prepared as a branched structure as described in Horn and Urdea, Nucleic Acids Res. (1989) 77:6959. The basic structure of the ribozymes can also be chemically altered in ways familiar to those skilled in the art, and chemically synthesized ribozymes can be administered as synthetic oligonucleotide derivatives modified by monomeric units. In a therapeutic context, liposome mediated delivery of ribozymes improves cellular uptake, as described in Birikh et al, Eur. J. Biochem. (1997) 245:1.

Using the polynucleotide sequences of the invention and methods known in the art, ribozymes are designed to specifically bind and cut the corresponding mRNA species. Ribozymes thus provide a means to inhibit the expression of any of the proteins encoded by the disclosed polynucleotides or their full-length genes. The full-length gene need not be known in order to design and use specific inhibitory ribozymes. In the case of a polynucleotide or full-length cDNA of unknown function, ribozymes corresponding to that nucleotide sequence can be tested in vitro for efficacy in cleaving the target transcript. Those ribozymes that effect cleavage in vitro are further tested in vivo. The ribozyme can also be used to generate an animal model for a disease, as described in Birikh et al, supra. An effective ribozyme is used to determine the function of the gene of interest by blocking its transcription and detecting a change in the cell. Where the gene is found to be a mediator in a disease, an effective ribozyme is designed and delivered in a gene therapy for blocking transcription and expression of the gene.

Therapeutic and functional genomic applications of ribozymes proceed beginning with knowledge of a portion of the coding sequence of the gene to be inhibited. Thus, for many genes, a partial polynucleotide sequence provides adequate sequence for constructing an effective ribozyme. A target cleavage site is selected in the target sequence, and a ribozyme is constructed based on the 5' and 3' nucleotide sequences that flank the cleavage site. Retroviral vectors are engineered to express monomeric and multimeric hammerhead ribozymes targeting the mRNA of the target coding sequence. These monomeric and multimeric ribozymes are tested in vitro for an ability to cleave the target mRNA. A cell line is stably transduced with the retroviral vectors expressing the ribozymes, and the transduction is confirmed by Northern blot analysis and reverse-transcription polymerase chain reaction (RT-PCR). The cells are screened for inactivation of the target mRNA by such indicators as reduction of expression of disease markers or reduction of the gene product of the target mRNA.

B. Antisense

Antisense nucleic acids are designed to specifically bind to RNA, resulting in the formation of RNA-DNA or RNA-RNA hybrids, with an arrest of DNA replication, reverse transcription or messenger RNA translation. Antisense polynucleotides based on a selected polynucleotide sequence can interfere with expression of the corresponding gene. Antisense polynucleotides are typically generated within the cell by expression from antisense constructs that contain the antisense strand as the transcribed strand. Antisense polynucleotides based on the disclosed polynucleotides will bind and/or interfere with the translation of mRNA comprising a sequence complementary to the antisense polynucleotide. The expression products of control cells and cells treated with the antisense construct are compared to detect the protein product of the gene corresponding to the polynucleotide upon which the antisense construct is based. The protein is isolated and identified using routine biochemical methods.

Given the extensive background literature and clinical experience in antisense therapy, one skilled in the art can use selected polynucleotides of the invention as additional potential therapeutics. The choice of polynucleotide can be narrowed by first testing them for binding to "hot spot" regions of the genome of cancerous cells. If a polynucleotide is identified as binding to a "hot spot", testing the polynucleotide as an antisense compound in the corresponding cancer cells clearly is warranted.

C. Dominant Negative Mutations

As an alternative method for identifying function of the gene corresponding to a polynucleotide disclosed herein, dominant negative mutations are readily generated for corresponding proteins that are active as homomultimers. A mutant polypeptide will interact with wild-type polypeptides (made from the other allele) and form a non-functional multimer. Thus, a mutation is in a substrate-binding domain, a catalytic domain, or a cellular localization domain. Preferably, the mutant polypeptide will be overproduced. Point mutations are made that have such an effect. In addition, fusion of different polypeptides of various lengths to the terminus of a protein can yield dominant negative mutants. General strategies are available for making dominant negative mutants (see, e.g., Herskowitz, Nature (1987) 329:219). Such techniques can be used to create loss of function mutations, which are useful for determining protein function.

V. Construction of Polypeptides of the Invention and Variants Thereof The polypeptides of the invention include those encoded by the disclosed polynucleotides. These polypeptides can also be encoded by nucleic acids that, by virtue of the degeneracy of the genetic code, are not identical in sequence to the disclosed polynucleotides. Thus, the invention includes within its scope a polypeptide encoded by a polynucleotide having the sequence of any one of "SEQ ID NOS: 1-5252" or a variant thereof.

In general, the term "polypeptide" as used herein refers to both the full length polypeptide encoded by the recited polynucleotide, the polypeptide encoded by the gene represented by the recited polynucleotide, as well as portions or fragments thereof. "Polypeptides" also includes variants of the naturally occurring proteins, where such variants are homologous or substantially similar to the naturally occurring protein, and can be of an origin of the same or different species as the naturally occurring protein (e.g., human, murine, or some other species that naturally expresses the recited polypeptide, usually a mammalian species). In general, variant polypeptides have a sequence that has at least about 80%, usually at least about 90%, and more usually at least about 98% sequence identity with a differentially expressed polypeptide of the invention, as measured by

BLAST using the parameters described above. The variant polypeptides can be naturally or non-naturally glycosylated, i.e., the polypeptide has a glycosylation pattern that differs from the glycosylation pattern found in the corresponding naturally occurring protein. The invention also encompasses homologs of the disclosed polypeptides (or fragments thereof) where the homologs are isolated from other species, i.e. other animal or plant species, where such homologs, usually mammalian species, e.g. rodents, such as mice, rats; domestic animals, e.g., horse, cow, dog, cat; and humans. By homolog is meant a polypeptide having at least about 35%, usually at least about 40% and more usually at least about 60% amino acid sequence identity a particular differentially expressed protein as identified above, where sequence identity is determined using the BLAST algorithm, with the parameters described supra. In general, the polypeptides of the subject invention are provided in a non-naturally occurring environment, e.g. are separated from their naturally occurring environment. In certain embodiments, the subject protein is present in a composition that is enriched for the protein as compared to a control. As such, purified polypeptide is provided, where by purified is meant that the protein is present in a composition that is substantially free of non-differentially expressed polypeptides, where by substantially free is meant that less than 90%), usually less than 60% and more usually less than 50%) of the composition is made up of non-differentially expressed polypeptides.

Also within the scope of the invention are variants; variants of polypeptides include mutants, fragments, and fusions. Mutants can include amino acid substitutions, additions or deletions. The amino acid substitutions can be conservative amino acid substitutions or substitutions to eliminate non-essential amino acids, such as to alter a glycosylation site, a phosphorylation site or an acetylation site, or to minimize misfolding by substitution or deletion of one or more cysteine residues that are not necessary for function. Conservative amino acid substitutions are those that preserve the general charge, hydrophobicity/hydrophilicity, and/or steric bulk of the amino acid substituted. For example, substitutions between the following groups are conservative: Gly/Ala, Val/Ile/Leu, Asp/Glu, Lys/Arg, Asn/Gln, Ser/Cys, Thr, and Phe/Trp/Tyr.

Variants can be designed so as to retain biological activity of a particular region of the protein (e.g., a functional domain and/or, where the polypeptide is a member of a protein family, a region associated with a consensus sequence). In a non-limiting example, Osawa et al, Biochem. Mol Int. (1994) 34:1003, discusses the actin binding region of a protein from several different species. The actin binding regions of the these species are considered homologous based on the fact that they have amino acids that fall within "homologous residue groups." Homologous residues are judged according to the following groups (using single letter amino acid designations): STAG; ILVMF; HRK; DEQN; and FYW. For example, and S, a T, an A or a G can be in a position and the function (in this case actin binding) is retained.

Additional guidance on amino acid substitution is available from studies of protein evolution. Go et al, Int. J. Peptide Protein Res. (1980) 75:211, classified amino acid residue sites as interior or exterior depending on their accessibility. More frequent substitution on exterior sites was confirmed to be general in eight sets of homologous protein families regardless of their biological functions and the presence or absence of a prosthetic group. Virtually all types of amino acid residues had higher mutabilities on the exterior than in the interior. No correlation between mutability and polarity was observed of amino acid residues in the interior and exterior, respectively. Amino acid residues were classified into one of three groups depending on their polarity: polar (Arg, Lys, His, Gin, Asn, Asp, and Glu); weak polar (Ala, Pro, Gly, Thr, and Ser), and nonpolar (Cys, Val, Met, He, Leu, Phe, Tyr, and Tip). Amino acid replacements during protein evolution were very conservative: 88% and 76% of them in the interior or exterior, respectively, were within the same group of the three. Inter-group replacements are such that weak polar residues are replaced more often by nonpolar residues in the interior and more often by polar residues on the exterior.

Additional guidance for production of polypeptide variants is provided in Querol et al., Prot. Eng. (1996) 9:265, which provides general rules for amino acid substitutions to enhance protein thermostability. New glycosylation sites can be introduced as discussed in Olsen and Thomsen, J. Gen. Microbiol. (1991) 737:579. An additional disulfide bridge can be introduced, as discussed by Perry and Wetzel, Science (1984) 226:555; Pantoliano et al, Biochemistry (1987) 26:2011; Matsumura et al, Nature (1989) 342:291; Nishikawa et al, Protein Eng. (1990) 3:443; Takagi et al, J. Biol. Chem. (1990) 265:6874; Clarke et al., Biochemistry (1993) 32:4322; and Wakarchuk et al, Protein Eng. (1994) 7:1379. Metal binding sites can be introduced, according to Toma et al, Biochemistry (1991) 30:97, and Haezerbrouck et al, Protein Eng. (1993) 6:643. Substitutions with prolines in loops can be made according to Masul et al, Appl Env. Microbiol (1994) 60:3579; and Hardy et al, FEBS Lett. 317:89. Cysteine-depleted muteins are considered variants within the scope of the invention.

These variants can be constructed according to methods disclosed in U.S. Patent No. 4,959,314, which discloses substitution of cysteines with other amino acids, and methods for assaying biological activity and effect of the substitution. Such methods are suitable for proteins according to this invention that have cysteine residues suitable for such substitutions, for example to eliminate disulfide bond formation. Variants also include fragments of the polypeptides disclosed herein, particularly biologically active fragments and/or fragments corresponding to functional domains. Fragments of interest will typically be at least about 10 aa to at least about 15 aa in length, usually at least about 50 aa in length, and can be as long as 300 aa in length or longer, but will usually not exceed about 1000 aa in length, where the fragment will have a stretch of amino acids that is identical to a polypeptide encoded by a polynucleotide having a sequence of any "SEQ ID NOS: 1-5252", or a homolog thereof.

The protein variants described herein are encoded by polynucleotides that are within the scope of the invention. The genetic code can be used to select the appropriate codons to construct the corresponding variants.

VI. Computer-Related Embodiments

In general, a library of polynucleotides is a collection of sequence information, which information is provided in either biochemical form (e.g., as a collection of polynucleotide molecules), or in electronic form (e.g., as a collection of polynucleotide sequences stored in a computer-readable form, as in a computer system and/or as part of a computer program). The sequence information of the polynucleotides can be used in a variety of ways, e.g., as a resource for gene discovery, as a representation of sequences expressed in a selected cell type (e.g., cell type markers), and/or as markers of a given disease or disease state. In general, a disease marker is a representation of a gene product that is present in all cells affected by disease either at an increased or decreased level relative to a normal cell (e.g., a cell of the same or similar type that is not substantially affected by disease). For example, a polynucleotide sequence in a library can be a polynucleotide that represents an mRNA, polypeptide, or other gene product encoded by the polynucleotide, that is either overexpressed or underexpressed in a breast ductal cell affected by cancer relative to a normal (i.e., substantially disease-free) breast cell.

The nucleotide sequence information of the library can be embodied in any suitable form, e.g., electronic or biochemical forms. For example, a library of sequence information embodied in electronic form includes an accessible computer data file (or, in biochemical form, a collection of nucleic acid molecules) that contains the representative nucleotide sequences of genes that are differentially expressed (e.g., overexpressed or underexpressed) as between, for example, i) a cancerous cell and a normal cell; ii) a cancerous cell and a dysplastic cell; iii) a cancerous cell and a cell affected by a disease or condition other than cancer; iv) a metastatic cancerous cell and a normal cell and/or non-metastatic cancerous cell; v) a malignant cancerous cell and a non-malignant cancerous cell (or a normal cell) and/or vi) a dysplastic cell relative to a normal cell. Other combinations and comparisons of cells affected by various diseases or stages of disease will be readily apparent to the ordinarily skilled artisan. Biochemical embodiments of the library include a collection of nucleic acids that have the sequences of the genes in the library, where the nucleic acids can correspond to the entire gene in the library or to a fragment thereof, as described in greater detail below.

The polynucleotide libraries of the subject invention include sequence information of a plurality of polynucleotide sequences, where at least one of the polynucleotides has a sequence of any of "SEQ ID NOS:l-5252." By plurality is meant at least 2, usually at least 3 and can include up to all of "SEQ ID NOS: 1-5252." The length and number of polynucleotides in the library will vary with the nature of the library, e.g., if the library is an oligonucleotide array, a cDNA array, a computer database of the sequence information, etc.

Where the library is an electronic library, the nucleic acid sequence information can be present in a variety of media. "Media" refers to a manufacture, other than an isolated nucleic acid molecule, that contains the sequence information of the present invention.

Such a manufacture provides the genome sequence or a subset thereof in a form that can be examined by means not directly applicable to the sequence as it exists in a nucleic acid. For example, the nucleotide sequence of the present invention, e.g. the nucleic acid sequences of any of the polynucleotides of "SEQ ID NOS: 1-5252," can be recorded on computer readable media, e.g. any medium that can be read and accessed directly by a computer. Such media include, but are not limited to: magnetic storage media, such as a floppy disc, a hard disc storage medium, and a magnetic tape; optical storage media such as CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media. One of skill in the art can readily appreciate how any of the presently known computer readable mediums can be used to create a manufacture comprising a recording of the present sequence information. "Recorded" refers to a process for storing information on computer readable medium, using any such methods as known in the art. Any convenient data storage structure can be chosen, based on the means used to access the stored information. A variety of data processor programs and formats can be used for storage, e.g. word processing text file, database format, etc. In addition to the sequence information, electronic versions of the libraries of the invention can be provided in conjunction or connection with other computer-readable information and/or other types of computer-readable files (e.g., searchable files, executable files, etc, including, but not limited to, for example, search program software, etc.). By providing the nucleotide sequence in computer readable form, the information can be accessed for a variety of purposes. Computer software to access sequence information is publicly available. For example, the BLAST (Altschul et al., supra.) and BLAZE (Brutlag et al. Comp. Chem. (1993) 17:203) search algorithms on a Sybase system can be used to identify open reading frames (ORFs) within the genome that contain homology to ORFs from other organisms.

As used herein, "a computer-based system" refers to the hardware means, software means, and data storage means used to analyze the nucleotide sequence information of the present invention. The minimum hardware of the computer-based systems of the present invention comprises a central processing unit (CPU), input means, output means, and data storage means. A skilled artisan can readily appreciate that any one of the currently available computer-based system are suitable for use in the present invention. The data storage means can comprise any manufacture comprising a recording of the present sequence information as described above, or a memory access means that can access such a manufacture. "Search means" refers to one or more programs implemented on the computer-based system, to compare a target sequence or target structural motif with the stored sequence information. Search means are used to identify fragments or regions of the genome that match a particular target sequence or target motif. A variety of known algorithms are publicly known and commercially available, e.g. MacPattern (EMBL), BLASTN and BLASTX (NCBI). A "target sequence" can be any DNA or amino acid sequence of six or more nucleotides or two or more amino acids, preferably from about 10 to 100 amino acids or from about 30 to 300 nucleotide residues.

A "target structural motif," or "target motif," refers to any rationally selected sequence or combination of sequences in which the sequence(s) are chosen based on a three-dimensional configuration that is formed upon the folding of the target motif, or on consensus sequences of regulatory or active sites. There are a variety of target motifs known in the art. Protein target motifs include, but arc not limited to, enzyme active sites and signal sequences. Nucleic acid target motifs include, but are not limited to, hairpin structures, promoter sequences and other expression elements such as binding sites for transcription factors.

A variety of structural formats for the input and output means can be used to input and output the information in the computer-based systems of the present invention. One format for an output means ranks fragments of the genome possessing varying degrees of homology to a target sequence or target motif. Such presentation provides a skilled artisan with a ranking of sequences and identifies the degree of sequence similarity contained in the identified fragment.

A variety of comparing means can be used to compare a target sequence or target motif with the data storage means to identify sequence fragments of the genome. A skilled artisan can readily recognize that any one of the publicly available homology search programs can be used as the search means for the computer based systems of the present invention.

As discussed above, the "library" of the invention also encompasses biochemical libraries of the polynucleotides of "SEQ ID NOS: 1-5252," e.g., collections of nucleic acids representing the provided polynucleotides. The biochemical libraries can take a variety of forms, e.g., a solution of cDNAs, a pattern of probe nucleic acids stably associated with a surface of a solid support (i.e., an array) and the like. Of particular interest are nucleic acid arrays in which one or more of "SEQ ID NOS:l-5252"is represented on the array. By array is meant a an article of manufacture that has at least a substrate with at least two distinct nucleic acid targets on one of its surfaces, where the number of distinct nucleic acids can be considerably higher, typically being at least 10 nt, usually at least 20 nt and often at least 25 nt. A variety of different array formats have been developed and are known to those of skill in the art, including those described in 5,242,974; 5,384,261; 5,405,783; 5,412,087; 5,424,186; 5,429,807; 5,436,327; 5,445,934; 5,472,672; 5,527,681 ; 5,529,756; 5,545,531; 5,554,501; 5,556,752; 5,561,071; 5,599,895; 5,624,711; 5,639,603; 5,658,734; WO 93/17126; WO 95/11995; WO 95/35505; EP 742287; and EP 799897. The arrays of the subject invention find use in a variety of applications, including gene expression analysis, drug screening, mutation analysis and the like, as disclosed in the above-listed exemplary patent documents.

In addition to the above nucleic acid libraries, analogous libraries of polypeptides are also provided, where the where the polypeptides of the library will represent at least a portion of the polypeptides encoded by "SEQ ID NOS: 1-5252."

VII. Utilities

A. Use of Polynucleotide Probes in Mapping, and in Tissue Profiling Polynucleotide probes, generally comprising at least 12 contiguous nucleotides of a polynucleotide as shown in the Sequence Listing, are used for a variety of purposes, such as chromosome mapping of the polynucleotide and detection of transcription levels. Additional disclosure about preferred regions of the disclosed polynucleotide sequences is found in the Examples. A probe that hybridizes specifically to a polynucleotide disclosed herein should provide a detection signal at least 5-, 10-, or 20-fold higher than the background hybridization provided with other unrelated sequences.

Probes in Detection of Expression Levels. Nucleotide probes are used to detect expression of a gene corresponding to the provided polynucleotide. In Northern blots, mRNA is separated electrophoretically and contacted with a probe. A probe is detected as hybridizing to an mRNA species of a particular size. The amount of hybridization is quantitated to determine relative amounts of expression, for example under a particular condition. Probes are used for in situ hybridization to cells to detect expression. Probes can also be used in vivo for diagnostic detection of hybridizing sequences. Probes are typically labeled with a radioactive isotope. Other types of detectable labels can be used such as chromophores, fluors, and enzymes. Other examples of nucleotide hybridization assays are described in WO92/02526 and U.S. Patent No. 5,124,246. The Polymerase Chain Reaction (PCR) is another means for detecting small amounts of target nucleic acids (see, e.g., Mullis et al, Meth. Enzymol (1987) 755:335; U.S. Patent No. 4,683,195; and U.S. Patent No. 4,683,202). Two primer polynucleotides nucleotides hybridize with the target nucleic acids and are used to prime the reaction. The primers can be composed of sequence within or 3' and 5' to the polynucleotides of the Sequence Listing. Alternatively, if the primers are 3' and 5' to these polynucleotides, they need not hybridize to them or the complements. A thermostable polymerase creates copies of target nucleic acids from the primers using the original target nucleic acids as a template. After a large amount of target nucleic acids is generated by the polymerase, it is detected by methods such as Southern blots. When using the Southern blot method, the labeled probe will hybridize to a polynucleotide of the Sequence Listing or complement.

Furthermore, mRNA or cDNA can be detected by traditional blotting techniques described in Sambrook et al, "Molecular Cloning: A Laboratory Manual" (New York, Cold Spring Harbor Laboratory, 1989). mRNA or cDNA generated from mRNA using a polymerase enzyme can be purified and separated using gel electrophoresis. The nucleic acids on the gel are then blotted onto a solid support, such as nitrocellulose. The solid support is exposed to a labeled probe and then washed to remove any unhybridized probe. Next, the duplexes containing the labeled probe are detected. Typically, the probe is labeled with radioactivity. Mapping. Polynucleotides of the present invention are used to identify a chromosome on which the corresponding gene resides. Such mapping can be useful in identifying the function of the polynucleotide-related gene by its proximity to other genes with known function. Function can also be assigned to the polynucleotide-related gene when particular syndromes or diseases map to the same chromosome. For example, use of polynucleotide probes in identification and quantification of nucleic acid sequence aberrations is described in U.S. Patent No. 5,783,387.

For example, fluorescence in situ hybridization (FISH) on normal metaphase spreads facilitates comparative genomic hybridization to allow total genome assessment of changes in relative copy number of DNA sequences. See Schwartz and Samad, Curr. Opin. Biotechnol (1994) 3:70; Kallioniemi et al, Sem. Cancer Biol (1993) 4:41; Valdes et al, Methods in Molecular Biology (1997) 63:1, Boultwood, ed., Human Press, Totowa, NJ.

Polynucleotides are mapped to particular chromosomes using, for example, radiation hybrids or chromosome-specific hybrid panels. See Leach et al, Advances in Genetics, (1995) 33:63-99; Walter et al, Nature Genetics (1994) 7:22; Walter and

Goodfellow, Trends in Genetics (1992) 9:352. Panels for radiation hybrid mapping are available from Research Genetics, Inc., Huntsville, Alabama, USA. Databases for markers using various panels are available via the world wide web at http:/F/shgc- www.stanford.edu; and http://www-genome.wi.mit.edu/cgi-bin/contig/rhmapper.pl. The statistical program RHMAP can be used to construct a map based on the data from radiation hybridization with a measure of the relative likelihood of one order versus another. RHMAP is available via the world wide web at http://www.sph.umich.edu/group/statgen/software.

In addition, commercial programs are available for identifying regions of chromosomes commonly associated with disease, such as cancer. Polynucleotides based on the polynucleotides of the invention can be used to probe these regions. For example, if through profile searching a provided polynucleotide is identified as corresponding to a gene encoding a kinase, its ability to bind to a cancer-related chromosomal region will suggest its role as a kinase in one or more stages of tumor cell development growth. Although some experimentation would be required to elucidate the role, the polynucleotide constitutes a new material for isolating a specific protein that has potential for developing a cancer diagnostic or therapeutic.

Tissue Typing or Profiling. Expression of specific mRNA corresponding to the provided polynucleotides can vary in different cell types and can be tissue-specific. This variation of mRNA levels in different cell types can be exploited with nucleic acid probe assays to determine tissue types. For example, PCR, branched DNA probe assays, or blotting techniques utilizing nucleic acid probes substantially identical or complementary to polynucleotides listed in the Sequence Listing can determine the presence or absence of the corresponding cDNA or mRNA. For example, a metastatic lesion is identified by its developmental organ or tissue source by identifying the expression of a particular marker of that organ or tissue. If a polynucleotide is expressed only in a specific tissue type, and a metastatic lesion is found to express that polynucleotide, then the developmental source of the lesion has been identified. Expression of a particular polynucleotide is assayed by detection of either the corresponding mRNA or the protein product. Immunological methods, such as antibody staining, are used to detect a particular protein product. Hybridization methods can be used to detect particular mRNA species, including but not limited to in situ hybridization and Northern blotting.

Use of Polymorphisms. A polynucleotide of the invention will be useful in forensics, genetic analysis, mapping, and diagnostic applications if the corresponding region of a gene is polymoφhic in the human population. Particular polymoφhic forms of the provided polynucleotides can be used to either identify a sample as deriving from a suspect or rule out the possibility that the sample derives from the suspect. Any means for detecting a polymoφhism in a gene are used, including but not limited to electrophoresis of protein polymoφhic variants, differential sensitivity to restriction enzyme cleavage, and hybridization to allele-specific probes. B. Antibody Production

Expression products of a polynucleotide of the invention, the corresponding mRNA or cDNA, or the corresponding complete gene are prepared and used for raising antibodies for experimental, diagnostic, and therapeutic puφoses. For polynucleotides to which a corresponding gene has not been assigned, this provides an additional method of identifying the corresponding gene. The polynucleotide or related cDNA is expressed as described above, and antibodies are prepared. These antibodies are specific to an epitope on the polypeptide encoded by the polynucleotide, and can precipitate or bind to the corresponding native protein in a cell or tissue preparation or in a cell-free extract of an in vitro expression system.

Immunogens for raising antibodies are prepared by mixing the polypeptides encoded by the polynucleotides of the present invention with adjuvants. Alternatively, polypeptides are made as fusion proteins to larger immunogenic proteins. Polypeptides are also covalently linked to other larger immunogenic proteins, such as keyhole limpet hemocyanin. Immunogens are typically administered intradermally, subcutaneously, or intramuscularly. Immunogens are administered to experimental animals such as rabbits, sheep, and mice, to generate antibodies. Optionally, the animal spleen cells are isolated and fused with myeloma cells to form hybridomas which secrete monoclonal antibodies. Such methods are well known in the art. According to another method known in the art, the selected polynucleotide is administered directly, such as by intramuscular injection, and expressed in vivo. The expressed protein generates a variety of protein-specific immune responses, including production of antibodies, comparable to administration of the protein.

Preparations of polyclonal and monoclonal antibodies specific for polypeptides encoded by a selected polynucleotide are made using standard methods known in the art. The antibodies specifically bind to epitopes present in the polypeptides encoded by polynucleotides disclosed in the Sequence Listing. Typically, at least 6, 8, 10, or 12 contiguous amino acids are required to form an epitope. However, epitopes which involve non-contiguous amino acids may require more, for example at least 15, 25, or 50 amino acids. A short sequence of a polynucleotide may then be unsuitable for use as an epitope to raise antibodies for identifying the corresponding novel protein, because of the potential for cross-reactivity with a known protein. However, the antibodies can be useful for other puφoses, particularly if they identify common structural features of a known protein and a novel polypeptide encoded by a polynucleotide of the invention.

Antibodies that specifically bind to human polypeptides encoded by the provided polypeptides should provide a detection signal at least 5-, 10-, or 20-fold higher than a detection signal provided with other proteins when used in Western blots or other immunochemical assays. Preferably, antibodies that specifically polypeptides of the invention do not bind to other proteins in immunochemical assays at detectable levels and can immunoprecipitate the specific polypeptide from solution.

To test for the presence of serum antibodies to the polypeptide of the invention in a human population, human antibodies are purified by methods well known in the art.

Preferably, the antibodies are affinity purified by passing antiserum over a column to which the corresponding selected polypeptide or fusion protein is bound. The bound antibodies can then be eluted from the column, for example using a buffer with a high salt concentration. In addition to the antibodies discussed above, genetically engineered antibody derivatives are made, such as single chain antibodies, according to methods well known in the art.

C. Use of Polynucleotides to Construct Arrays for Diagnostics Polynucleotide arrays provide a high throughput technique that can assay a large number of polynucleotide sequences in a sample. This technology can be used as a diagnostic and as a tool to test for differential expression to determine function of an encoded protein. Arrays can be created by spotting polynucleotide probes onto a substrate (e.g., glass, nitrocelllose, etc.) in a two-dimensional matrix or array having bound probes. The probes can be bound to the substrate by either covalent bonds or by non-specific interactions, such as hydrophobic interactions. Samples of polynucleotides can be detectably labeled (e.g., using radioactive or fluorescent labels) and then hybridized to the probes. Double stranded polynucleotides, comprising the labeled sample polynucleotides bound to probe polynucleotides, can be detected once the unbound portion of the sample is washed away. Techniques for constructing arrays and methods of using these arrays are described in EP No. 0 799 897; PCT No. WO 97/29212; PCT No. WO 97/27317; EP No. 0 785 280; PCT No. WO 97/02357; U.S. Pat. No. 5,593,839; U.S. Pat. No. 5,578,832; EP No. 0 728 520; U.S. Pat. No. 5,599,695; EP No. 0 721 016; U.S. Pat. No. 5,556,752; PCT No. WO 95/22058; and U.S. Pat. No. 5,631,734. As discussed in some detail above, arrays can be used to examine differential expression of genes and can be used to determine gene function. For example, arrays of the instant polynucleotide sequences can be used to determine if any of the provided polynucleotides are differentially expressed between a test cell and control cell (e.g., cancer cells and normal cells). For example, high expression of a particular message in a cancer cell, which is not observed in a corresponding normal cell, can indicate a cancer specific protein. Exemplary uses of arrays are further described in, for example, Pappalarado et al, Sem. Radiation Oncol (1998) 3:217; and Ramsay Nature Biotechnol (1998) 76:40.

D. Differential Expression

The polynucleotides of the invention can also be used to detect differences in expression levels between two cells, e.g. , as a method to identify abnormal or diseased tissue in a human. For polynucleotides corresponding to profiles of protein families, the choice of tissue can be selected according to the putative biological function. In general, the expression of a gene corresponding to a specific polynucleotide is compared between a first tissue that is suspected of being diseased and a second, normal tissue of the human. The tissue suspected of being abnormal or diseased can be derived from a different tissue type of the human, but preferably it is derived from the same tissue type; for example an intestinal polyp or other abnormal growth should be compared with normal intestinal tissue. The normal tissue can be the same tissue as that of the test sample, or any normal tissue of the patient, especially those that express the polynucleotide-related gene of interest (e.g., brain, thymus, testis, heart, prostate, placenta, spleen, small intestine, skeletal muscle, pancreas, and the mucosal lining of the colon). A difference between the polynucleotide-related gene, mRNA, or protein in the two tissues which are compared, for example in molecular weight, amino acid or nucleotide sequence, or relative abundance, indicates a change in the gene, or a gene which regulates it, in the tissue of the human that was suspected of being diseased. Examples of detection of differential expression and its use in diagnosis of cancer are described in U.S. Patent Nos. 5,688,641 and 5,677,125. The polynucleotide-related genes in the two tissues are compared by any means known in the art. For example, the two genes can be sequenced, and the sequence of the gene in the tissue suspected of being diseased compared with the gene sequence in the normal tissue. The genes corresponding to a provided polynucleotide, or portions thereof, in the two tissues are amplified, for example using nucleotide primers based on the nucleotide sequence shown in the Sequence Listing, using the polymerase chain reaction. The amplified genes or portions of genes are hybridized to detectably labeled nucleotide probes selected from a nucleotide sequence shown in the Sequence Listing. A difference in the nucleotide sequence of the isolated gene in the tissue suspected of being diseased compared with the normal nucleotide sequence suggests a role of the gene product encoded by the subject polynucleotide in the disease, and provides guidance for preparing a therapeutic agent.

Alternatively, mRNA corresponding to a provided polynucleotide in the two tissues is compared. PolyA⁺ RNA is isolated from the two tissues as is known in the art. For example, one of skill in the art can readily determine differences in the size or amount of mRNA transcripts between the two tissues using Northern blots and detectably labeled nucleotide probes selected from the nucleotide sequence shown in the Sequence Listing. Increased or decreased expression of a given mRNA in a tissue sample suspected of being diseased, compared with the expression of the same mRNA in a normal tissue, suggests that the expressed protein has a role in the disease, and also provides a lead for preparing a therapeutic agent.

The comparison can also be accomplished by analyzing polypeptides between the matched samples. The sizes of the proteins in the two tissues are compared, for example, using antibodies of the present invention to detect polypeptides in Western blots of protein extracts from the two tissues. Other changes, such as expression levels and subcellular localization, can also be detected immunologically, using antibodies to the corresponding protein. A higher or lower level of expression of a given polypeptide in a tissue suspected of being diseased, compared with the same protein expression level in a normal tissue, is indicative that the expressed protein has a role in the disease, and provides guidance for preparing a therapeutic agent. Similarly, comparison of polynucleotide sequences or of gene expression products, e.g., mRNA and protein, between a human tissue that is suspected of being diseased and a normal tissue of a human, are used to follow disease progression or remission in the human. Such comparisons are made as described above. For example, increased or decreased expression of a gene corresponding to an inventive polynucleotide in the tissue suspected of being neoplastic can indicate the presence of neoplastic cells in the tissue. The degree of increased expression of a given gene in the neoplastic tissue relative to expression of the same gene in normal tissue, or differences in the amount of increased expression of a given gene in the neoplastic tissue over time, is used to assess the progression of the neoplasia in that tissue or to monitor the response of the neoplastic tissue to a therapeutic protocol over time.

The expression pattern of any two cell types can be compared, such as low and high metastatic tumor cell lines, malignant or non-malignant cells, or cells from tissue which have and have not been exposed to a therapeutic agent. A genetic predisposition to disease in a human is detected by comparing expression levels of an mRNA or protein corresponding to a polynucleotide of the invention in a fetal tissue with levels associated in normal fetal tissue. Fetal tissues that are used for this puφose include, but are not limited to, amniotic fluid, chorionic villi, blood, and the blastomere of an in vitro-fertilized embryo. The comparable normal polynucleotide-related gene is obtained from any tissue. The mRNA or protein is obtained from a normal tissue of a human in which the polynucleotide-related gene is expressed. Differences such as alterations in the nucleotide sequence or size of the same product of the fetal polynucleotide-related gene or mRNA, or alterations in the molecular weight, amino acid sequence, or relative abundance of fetal protein, can indicate a germline mutation in the polynucleotide-related gene of the fetus, which indicates a genetic predisposition to disease. Particular diagnostic and prognostic uses of the disclosed polynucleotides are described in more detail below. E. Diagnostic. Prognostic, and Other Uses Based On Differential Expression

In general, diagnostic methods of the invention for involve detection of a level or amount of a gene product, particularly a differentially expressed gene product, in a test sample obtained from a patient suspected of having or being susceptible to a disease (e.g., breast cancer, lung cancer, colon cancer and/or metastatic forms thereof), and comparing the detected levels to those levels found in normal cells (e.g., cells substantially unaffected by cancer) and/or other control cells (e.g., to differentiate a cancerous cell from a cell affected by dysplasia). Furthermore, the severity of the disease can be assessed by comparing the detected levels of a differentially expressed gene product with those levels detected in samples representing the levels of differentially gene product associated with varying degrees of severity of disease.

The term "differentially expressed gene" is intended to encompass a polynucleotide that can, for example, include an open reading frame encoding a gene product (e.g., a polypeptide), and/or introns of such genes and adjacent 5' and 3' non-coding nucleotide sequences involved in the regulation of expression, up to about 20 kb beyond the coding region, but possibly further in either direction. The gene can be introduced into an appropriate vector for extrachromosomal maintenance or for integration into a host genome. In general, a difference in expression level associated with a decrease in expression level of at least about 25%, usually at least about 50% to 75%, more usually at least about 90% or more is indicative of a differentially expressed gene of interest, i.e., a gene that is underexpressed or down-regulated in the test sample relative to a control sample. Furthermore, a difference in expression level associated with an increase in expression ofat least about 25%, usually at least about 50% to 75%, more usually at least about 90% and can be at least about 1 ' -fold, usually at least about 2-fold to about 10-fold, and can be about 100-fold to about 1 ,000-fold increase relative to a control sample is indicative of a differentially expressed gene of interest, i.e., an overexpressed or up- regulated gene.

"Differentially expressed polynucleotide" as used herein means a nucleic acid molecule (RNA or DNA) having a sequence that represents a differentially expressed gene, e.g., the differentially expressed polynucleotide comprises a sequence (e.g., an open reading frame encoding a gene product) that uniquely identifies a differentially expressed gene so that detection of the differentially expressed polynucleotide in a sample is correlated with the presence of a differentially expressed gene in a sample. "Differentially expressed polynucleotides" is also meant to encompass fragments of the disclosed polynucleotides, e.g., fragments retaining biological activity, as well as nucleic acids homologous, substantially similar, or substantially identical (e.g., having about 90%> sequence identity) to the disclosed polynucleotides.

Methods of the subject invention useful in diagnosis or prognosis typically involve comparison of the abundance of a selected differentially expressed gene product in a sample of interest with that of a control to determine any relative differences in the expression of the gene product, where the difference can be measured qualitatively and/or quantitatively. Quantitation can be accomplished, for example, by comparing the level of expression product detected in the sample with the amounts of product present in a standard curve. A comparison can be made visually; by using a technique such as densitometry, with or without computerized assistance; by preparing a representative library of cDNA clones of mRNA isolated from a test sample, sequencing the clones in the library to determine that number of cDNA clones corresponding to the same gene product, and analyzing the number of clones corresponding to that same gene product relative to the number of clones of the same gene product in a control sample; or by using an array to detect relative levels of hybridization to a selected sequence or set of sequences, and comparing the hybridization pattern to that of a control. The differences in expression are then correlated with the presence or absence of an abnormal expression pattern. A variety of different methods for determining the nucleic acid abundance in a sample are known to those of skill in the art, where particular methods of interest include those described in: Pietu et al Genome Res. (1996) 6:492; Zhao et al, Gene (1995) 756:207; Soares , Curr. Opin. Biotechnol. (1977) 3: 542; Raval, J Pharmacol Toxicol Methods (1994) 32:125; Chalifour et al, Anal Biochem (1994) 276:299; Stolz et al, Mol Biotechnol. (1996) 6:225; Hong et al, Bioscl Reports (1982) 2:907; and McGraw, Anal. Biochem. (1984) 743:298. Also of interest are the methods disclosed in WO 97/27317, the disclosure of which is herein incoφorated by reference.

In general, diagnostic assays of the invention involve detection of a gene product of a the polynucleotide sequence (e.g., mRNA or polypeptide) that corresponds to a sequence of "SEQ ID NOS: 1-5252." The patient from whom the sample is obtained can be apparently healthy, susceptible to disease (e.g., as determined by family history or exposure to certain environmental factors), or can already be identified as having a condition in which altered expression of a gene product of the invention is implicated.

In the assays of the invention, the diagnosis can be determined based on detected gene product expression levels of a gene product encoded by at least one, preferably at least two or more, at least 3 or more, or at least 4 or more of the polynucleotides having a sequence set forth in "SEQ ID NOS: 1-5252," and can involve detection of expression of genes corresponding to all of "SEQ ID NOS: 1-5252" and/or additional sequences that can serve as additional diagnostic markers and/or reference sequences. Where the diagnostic method is designed to detect the presence or susceptibility of a patient to cancer, the assay preferably involves detection of a gene product encoded by a gene corresponding to a polynucleotide that is differentially expressed in cancer. For example, a higher level of expression of a polynucleotide corresponding to SEQ ID NO:2024 relative to a level associated with a normal sample can indicate the presence of cancer in the patient from whom the sample is derived. In another example, detection of a lower level of a polynucleotide corresponding to SEQ ID NO:590 relative to a normal level is indicative of the presence of cancer in the patient. Further examples of such differentially expressed polynucleotides are described in the Examples below. Given the provided polynucleotides and information regarding their relative expression levels provided herein, assays using such polynucleotides and detection of their expression levels in diagnosis and prognosis will be readily apparent to the ordinarily skilled artisan. Any of a variety of detectable labels can be used in connection with the various embodiments of the diagnostic methods of the invention. Suitable detectable labels include fluorochromes,(e.g. fluorescein isothiocyanate (FITC), rhodamine, Texas Red, phycoerythrin, allophycocyanin, 6-carboxyfluorescein (6-FAM), 2',7'-dimethoxy-4',5'- dichloro-6-carboxyfluorescein, 6-carboxy-X-rhodamine (ROX), 6-carboxy-2',4',7',4,7- hexachlorofluorescein (HEX), 5 -carboxy fluorescein (5-FAM) or N,N,N',N'-tetramethyl-6- carboxyrhodamine (TAMRA)), radioactive labels, (e.g. ³²P, ³⁵S, ³H, etc.), and the like. The detectable label can involve a two stage systems (e.g., biotin-avidin, hapten-anti-hapten antibody, etc.) Reagents specific for the polynucleotides and polypeptides of the invention, such as antibodies and nucleotide probes, can be supplied in a kit for detecting the presence of an expression product in a biological sample. The kit can also contain buffers or labeling components, as well as instructions for using the reagents to detect and quantify expression products in the biological sample. Exemplary embodiments of the diagnostic methods of the invention are described below in more detail.

Polypeptide detection in diagnosis. In one embodiment, the test sample is assayed for the level of a differentially expressed polypeptide. Diagnosis can be accomplished using any of a number of methods to determine the absence or presence or altered amounts of the differentially expressed polypeptide in the test sample. For example, detection can utilize staining of cells or histological sections with labeled antibodies, performed in accordance with conventional methods. Cells can be permeabilized to stain cytoplasmic molecules. In general, antibodies that specifically bind a differentially expressed polypeptide of the invention are added to a sample, and incubated for a period of time sufficient to allow binding to the epitope, usually at least about 10 minutes. The antibody can be detectably labeled for direct detection (e.g., using radioisotopes, enzymes, fluorescers, chemiluminescers, and the like), or can be used in conjunction with a second stage antibody or reagent to detect binding (e.g., biotin with horseradish peroxidase- conjugated avidin, a secondary antibody conjugated to a fluorescent compound, e.g. fluorescein, rhodamine, Texas red, etc.). The absence or presence of antibody binding can be determined by various methods, including flow cytometry of dissociated cells, microscopy, radiography, scintillation counting, etc. Any suitable alternative methods can of qualitative or quantitative detection of levels or amounts of differentially expressed polypeptide can be used, for example ELISA, western blot, immunoprecipitation, radioimmunoassay, etc.

In general, the detected level of differentially expressed polypeptide in the test sample is compared to a level of the differentially expressed gene product in a reference or control sample, e.g., in a normal cell (negative control) or in a cell having a known disease state (positive control). mRNA detection. The diagnostic methods of the invention can also or alternatively involve detection of mRNA encoded by a gene corresponding to a differentially expressed polynucleotides of the invention. Any suitable qualitative or quantitative methods known in the art for detecting specific mRNAs can be used. mRNA can be detected by, for example, in situ hybridization in tissue sections, by reverse transcriptase-PCR, or in Northern blots containing poly A+ mRNA. One of skill in the art can readily use these methods to determine differences in the size or amount of mRNA transcripts between two samples. For example, the level of mRNA of the invention in a tissue sample suspected of being cancerous or dysplastic is compared with the expression of the mRNA in a reference sample, e.g., a positive or negative control sample (e.g., normal tissue, cancerous tissue, etc.).

Any suitable method for detecting and comparing mRNA expression levels in a sample can be used in connection with the diagnostic methods of the invention (see, e.g., U.S. 5,804,382). For example, mRNA expression levels in a sample can be determined by generation of a library of expressed sequence tags (ESTs) from the sample, where the EST library is representative of sequences present in the sample (Adams, et al., (1991) Science 252:1651). Enumeration of the relative representation of ESTs within the library can be used to approximate the relative representation of the gene transcript within the starting sample. The results of EST analysis of a test sample can then be compared to EST analysis of a reference sample to determine the relative expression levels of a selected polynucleotide, particularly a polynucleotide corresponding to one or more of the differentially expressed genes described herein. Alternatively, gene expression in a test sample can be performed using serial analysis of gene expression (SAGE) methodology (Velculescu et al., Science (1995) 270:484). In short, SAGE involves the isolation of short unique sequence tags from a specific location within each transcript. The sequence tags are concatenated, cloned, and sequenced. The frequency of particular transcripts within the starting sample is reflected by the number of times the associated sequence tag is encountered with the sequence population.

Gene expression in a test sample can also be analyzed using differential display (DD) methodology. In DD, fragments defined by specific sequence delimiters (e.g., restriction enzyme sites) are used as unique identifiers of genes, coupled with information about fragment length or fragment location within the expressed gene. The relative representation of an expressed gene with a sample can then be estimated based on the relative representation of the fragment associated with that gene within the pool of all possible fragments. Methods and compositions for carrying out DD are well known in the art, see, e.g., U.S. 5,776,683; and U.S. 5,807,680.

Alternatively, gene expression in a sample using hybridization analysis, which is based on the specificity of nucleotide interactions. Oligonucleotides or cDNA can be used to selectively identify or capture DNA or RNA of specific sequence composition, and the amount of RNA or cDNA hybridized to a known capture sequence determined qualitatively or quantitatively, to provide information about the relative representation of a particular message within the pool of cellular messages in a sample. Hybridization analysis can be designed to allow for concurrent screening of the relative expression of hundreds to thousands of genes by using, for example, array-based technologies having high density formats, including filters, microscope slides, or microchips, or solution-based technologies that use spectroscopic analysis (e.g., mass spectrometry). One exemplary use of arrays in the diagnostic methods of the invention is described below in more detail.

Use of a single gene in diagnostic applications. The diagnostic methods of the invention can focus on the expression of a single differentially expressed gene. For example, the diagnostic method can involve detecting a differentially expressed gene, or a polymoφhism of such a gene (e.g., a polymoφhism in an coding region or control region), that is associated with disease. Disease-associated polymoφhisms can include deletion or truncation of the gene, mutations that alter expression level and/or affect activity of the encoded protein, etc.

Changes in the promoter or enhancer sequence that affect expression levels of an differentially gene can be compared to expression levels of the normal allele by various methods known in the art. Methods for determining promoter or enhancer strength include quantitation of the expressed natural protein; insertion of the variant control element into a vector with a reporter gene such as β-galactosidase, luciferase, chloramphenicol acetyltransferase, etc. that provides for convenient quantitation; and the like.

A number of methods are available for analyzing nucleic acids for the presence of a specific sequence, e.g. a disease associated polymoφhism. Where large amounts of DNA are available, genomic DNA is used directly. Alternatively, the region of interest is cloned into a suitable vector and grown in sufficient quantity for analysis. Cells that express a differentially expressed gene can be used as a source of mRNA, which can be assayed directly or reverse transcribed into cDNA for analysis. The nucleic acid can be amplified by conventional techniques, such as the polymerase chain reaction (PCR), to provide sufficient amounts for analysis, and a detectable label can be included in the amplification reaction (e.g., using a detectably labeled primer or detectably labeled oligonucleotides) to facilitate detection. The use of the polymerase chain reaction is described in Saiki, et al, Science (1985) 239:487, and a review of techniques can be found in Sambrook, et al, Molecular Cloning: A Laboratory Manual, (1989) pp. 14.2. Alternatively, various methods are known in the art that utilize oligonucleotide ligation as a means of detecting polymoφhisms, for examples see Riley et al, Nucl Acids Res. (1990) 73:2887; and Delahunty et al, Am. J. Hum. Genet. (1996) 53:1239.

The sample nucleic acid, e.g. amplified or cloned fragment, is analyzed by one of a number of methods known in the art. The nucleic acid can be sequenced by dideoxy or other methods, and the sequence of bases compared to a selected sequence, e.g., to a wild- type sequence. Hybridization with the polymoφhic or variant sequence can also be used to determine its presence in a sample (e.g., by Southern blot, dot blot, etc.). The hybridization pattern of a polymoφhic or variant sequence and a control sequence to an array of oligonucleotide probes immobilized on a solid support, as described in US 5,445,934, or in WO 95/35505, can also be used as a means of identifying polymoφhic or variant sequences associated with disease. Single strand conformational polymoφhism (SSCP) analysis, denaturing gradient gel electrophoresis (DGGE), and heteroduplex analysis in gel matrices are used to detect conformational changes created by DNA sequence variation as alterations in electrophoretic mobility. Alternatively, where a polymoφhism creates or destroys a recognition site for a restriction endonuclease, the sample is digested with that endonuclease, and the products size fractionated to determine whether the fragment was digested. Fractionation is performed by gel or capillary electrophoresis, particularly acrylamide or agarose gels.

Screening for mutations in an differentially expressed gene can be based on the functional or antigenic characteristics of the protein. Protein truncation assays are useful in detecting deletions that can affect the biological activity of the protein. Various immunoassays designed to detect polymoφhisms in proteins can be used in screening. Where many diverse genetic mutations lead to a particular disease phenotype, functional protein assays have proven to be effective screening tools. The activity of the encoded protein can be determined by comparison with the wild-type protein.

Pattern matching in diagnosis using arrays. In another embodiment, the diagnostic and/or prognostic methods of the invention involve detection of expression of a selected set of genes in a test sample to produce a test expression pattern (TEP). The TEP is compared to a reference expression pattern (REP), which is generated by detection of expression of the selected set of genes in a reference sample (e.g., a positive or negative control sample). The selected set of genes includes at least one of the genes of the invention, which genes correspond to the polynucleotide sequences of "SEQ ID NOS: 1-5252." Of particular interest is a selected set of genes that includes gene differentially expressed in the disease for which the test sample is to be screened. "Reference sequences" or "reference polynucleotides" as used herein in the context of differential gene expression analysis and diagnosis/prognosis refers to a selected set of polynucleotides, which selected set includes at least one or more of the differentially expressed polynucleotides described herein. A plurality of reference sequences, preferably comprising positive and negative control sequences, can be included as reference sequences. Additional suitable reference sequences are found in Genbank, Unigene, and other nucleotide sequence databases (including, e.g., expressed sequence tag (EST), partial, and full-length sequences).

"Reference array" means an array having reference sequences for use in hybridization with a sample, where the reference sequences include all, at least one of, or any subset of the differentially expressed polynucleotides described herein. Usually such an array will include at least 3 different reference sequences, and can include any one or all of the provided differentially expressed sequences. Arrays of interest can further comprise sequences, including polymoφhisms, of other genetic sequences, particularly other sequences of interest for screening for a disease or disorder (e.g., cancer, dysplasia, or other related or unrelated diseases, disorders, or conditions). The oligonucleotide sequence on the array will usually be at least about 12 nt in length, and can be of about the length of the provided sequences, or can extend into the flanking regions to generate fragments of 100 nt to 200 nt in length or more.

A "reference expression pattern" or "REP" as used herein refers to the relative levels of expression of a selected set of genes, particularly of differentially expressed genes, that is associated with a selected cell type, e.g. , a normal cell, a cancerous cell, a cell exposed to an environmental stimulus, and the like. A "test expression pattern" or "TEP" refers to relative levels of expression of a selected set of genes, particularly of differentially expressed genes, in a test sample (e.g., a cell of unknown or suspected disease state, from which mRNA is isolated). "Diagnosis" as used herein generally includes determination of a subject's susceptibility to a disease or disorder, determination as to whether a subject is presently affected by a disease or disorder, as well as to the prognosis of a subject affected by a disease or disorder (e.g., identification of pre-metastatic or metastatic cancerous states, stages of cancer, or responsiveness of cancer to therapy). The present invention particularly encompasses diagnosis of subjects in the context of breast cancer (e.g. , carcinoma in situ (e.g., ductal carcinoma in situ), estrogen receptor (ER)-positive breast cancer, ER-negative breast cancer, or other forms and/or stages of breast cancer), lung cancer (e.g., small cell carcinoma, non-small cell carcinoma, mesothelioma, and other forms and/or stages of lung cancer), and colon cancer (e.g., adenomatous polyp, colorectal carcinoma, and other forms and/or stages of colon cancer). "Sample" or "biological sample" as used throughout here are generally meant to refer to samples of biological fluids or tissues, particularly samples obtained from tissues, especially from cells of the type associated with the disease for which the diagnostic application is designed (e.g., ductal adenocarcinoma), and the like. "Samples" is also meant to encompass derivatives and fractions of such samples (e.g., cell lysates). Where the sample is solid tissue, the cells of the tissue can be dissociated or tissue sections can be analyzed.

REPs can be generated in a variety of ways according to methods well known in the art. For example, REPs can be generated by hybridizing a control sample to an array having a selected set of polynucleotides (particularly a selected set of differentially expressed polynucleotides), acquiring the hybridization data from the array, and storing the data in a format that allows for ready comparison of the REP with a TEP. Alternatively, all expressed sequences in a control sample can be isolated and sequenced, e.g., by isolating mRNA from a control sample, converting the mRNA into cDNA, and sequencing the cDNA. The resulting sequence information roughly or precisely reflects the identity and relative number of expressed sequences in the sample. The sequence information can then be stored in a format (e.g., a computer-readable format) that allows for ready comparison of the REP with a TEP. The REP can be normalized prior to or after data storage, and/or can be processed to selectively remove sequences of expressed genes that are of less interest or that might complicate analysis (e.g., some or all of the sequences associated with housekeeping genes can be eliminated from REP data).

TEPs can be generated in a manner similar to REPs, e.g., by hybridizing a test sample to an array having a selected set of polynucleotides, particularly a selected set of differentially expressed polynucleotides, acquiring the hybridization data from the array, and storing the data in a format that allows for ready comparison of the TEP with a REP. The REP and TEP to be used in a comparison can be generated simultaneously, or the TEP can be compared to previously generated and stored REPs. In one embodiment of the invention, comparison of a TEP with a REP involves hybridizing a test sample with a reference array, where the reference array has one or more reference sequences for use in hybridization with a sample. The reference sequences include all, at least one of, or any subset of the differentially expressed polynucleotides described herein. Hybridization data for the test sample is acquired, the data normalized, and the produced TEP compared with a REP generated using an array having the same or similar selected set of differentially expressed polynucleotides. Probes that correspond to sequences differentially expressed between the two samples will show decreased or increased hybridization efficiency for one of the samples relative to the other. Reference arrays can be produced according to any suitable methods known in the art. For example, methods of producing large arrays of oligonucleotides are described in U.S. 5,134,854, and U.S. 5,445,934 using light-directed synthesis techniques. Using a computer controlled system, a heterogeneous array of monomers is converted, through simultaneous coupling at a number of reaction sites, into a heterogeneous array of polymers. Alternatively, microarrays are generated by deposition of pre-synthesized oligonucleotides onto a solid substrate, for example as described in PCT published application no. WO 95/35505.

Methods for collection of data from hybridization of samples with a reference arrays are also well known in the art. For example, the polynucleotides of the reference and test samples can be generated using a detectable fluorescent label, and hybridization of the polynucleotides in the samples detected by scanning the microarrays for the presence of the detectable label. Methods and devices for detecting fluorescently marked targets on devices are known in the art. Generally, such detection devices include a microscope and light source for directing light at a substrate. A photon counter detects fluorescence from the substrate, while an x-y translation stage varies the location of the substrate. A confocal detection device that can be used in the subject methods is described in U.S. Patent no. 5,631,734. A scanning laser microscope is described in Shalon et al., Genome Res. (1996) 6:639. A scan, using the appropriate excitation line, is performed for each fluorophore used. The digital images generated from the scan are then combined for subsequent analysis. For any particular array element, the ratio of the fluorescent signal from one sample (e.g., a test sample) is compared to the fluorescent signal from another sample (e.g., a reference sample), and the relative signal intensity determined.

Methods for analyzing the data collected from hybridization to arrays are well known in the art. For example, where detection of hybridization involves a fluorescent label, data analysis can include the steps of determining fluorescent intensity as a function of substrate position from the data collected, removing outliers, i.e. data deviating from a predetermined statistical distribution, and calculating the relative binding affinity of the targets from the remaining data. The resulting data can be displayed as an image with the intensity in each region varying according to the binding affinity between targets and probes.

In general, the test sample is classified as having a gene expression profile corresponding to that associated with a disease or non-disease state by comparing the TEP generated from the test sample to one or more REPs generated from reference samples (e.g., from samples associated with cancer or specific stages of cancer, dysplasia, samples affected by a disease other than cancer, normal samples, etc.). The criteria for a match or a substantial match between a TEP and a REP include expression of the same or substantially the same set of reference genes, as well as expression of these reference genes at substantially the same levels (e.g., no significant difference between the samples for a signal associated with a selected reference sequence after normalization of the samples, or at least no greater than about 25% to about 40% difference in signal strength for a given reference sequence. In general, a pattern match between a TEP and a REP includes a match in expression, preferably a match in qualitative or quantitative expression level, ofat least one of, all or any subset of the differentially expressed genes of the invention.

Pattern matching can be performed manually, or can be performed using a computer program. Methods for preparation of substrate matrices (e.g., arrays), design of oligonucleotides for use with such matrices, labeling of probes, hybridization conditions, scanning of hybridized matrices, and analysis of patterns generated, including comparison analysis, are described in, for example, U.S. 5,800,992.

F. Use of the Polynucleotides of the Invention in Cancer Oncogenesis involves the unbridled growth, dedifferentiation and abnormal migration of cells. Cancerous cells can have the ability to compress, invade, and destroy normal tissue. Cancerous cells may also metastasize to other parts of the body via the bloodstream or the lymph system and colonize in these other areas. Different cancers are classified by the cell from which the cancerous cell is derived and from its cellular moφhology and/or state of differentiation. Somatic genetic abnormalities cause cancer initiation and progression. Cancer generally is clonally formed, i.e. gain of function of oncogenes and loss of function of tumor suppressor genes within a single cell transform the cell to be cancerous, and that single cell grows and divides to form a cancerous lesion. The genes known to be involved in cancer initiation and progression are involved in numerous cellular functions, including developmental differentiation, cell cycle regulation, cell signaling, immunological response, DNA replication, and DNA repair.

The identification and characterization of genetic or biochemical markers in blood or tissues that will detect the earliest changes along the carcinogenesis pathway and monitor the efficacy of various therapies and preventive interventions is a major goal of cancer research. Scientists have identified genetic changes in stool specimens that indicate the stages of colon cancer, and other biomarkers such as gene mutations, hormone receptors, proteins that inhibit metastasis, and enzymes that metabolize drugs are all being used to determine the severity and predict the course of breast, prostate, lung, and other cancers. Recent advances in the pathogenesis of certain cancers has been helpful in determining patient treatment. The level of expression of certain polynucleotides can be indicative of a poorer prognosis, and therefore warrant more aggressive chemo- or radiotherapy for a patient. The correlation of novel surrogate tumor specific features with response to treatment and outcome in patients has defined certain prognostic indicators that allow the design of tailored therapy based on the molecular profile of the tumor. These therapies include antibody targeting and gene therapy. Moreover, a promising level of one or more marker polynucleotides can provide impetus for not aggressively treating a particular patient, thus sparing the patient the deleterious side effects of aggressive therapy. Determining expression of certain polynucleotides and comparison of a patients profile with known expression in normal tissue and variants of the disease allows a determination of the best possible treatment for a patient, both in terms of specificity of treatment and in terms of comfort level of the patient.

Surrogate tumor markers, such as polynucleotide expression, can also be used to better classify, and thus diagnose and treat, different forms and disease states of cancer. Two classifications widely used in oncology that can benefit from identification of the expression levels of the polynucleotides of the invention are staging of the cancerous disorder, and grading the nature of the cancerous tissue.

Staging. Staging is a process used by physicians to describe how advanced the cancerous state is in a patient. Staging assists the physician in determining a prognosis, planning treatment and evaluating the results of such treatment. Different staging systems are used for different types of cancer, but each generally involves the following determinations: the type of tumor, indicated by T; whether the cancer has metastasized to nearby lymph nodes, indicated by N; and whether the cancer has metastasized to more distant parts of the body, indicated by M. This system of staging is called the TNM system. Generally, if a cancer is only detectable in the area of the primary lesion without having spread to any lymph nodes it is called Stage I. If it has spread only to the closest lymph nodes, it is called Stage II. In Stage III, the cancer has generally spread to the lymph nodes in near proximity to the site of the primary lesion. Cancers that have spread to a distant part of the body, such as the liver, bone, brain or another site, are called Stage IV, the most advanced stage.

Currently, the determination of staging is done using pathological techniques and is based more on the presence or absence of malignant tissue rather than the characteristics of the tumor type. Presence or absence of malignant tissue is based primarily on the gross moφhology of the cells in the areas biopsied. The polynucleotides of the invention can facilitate fine-tuning of the staging process by identifying markers for the aggresivity of a cancer, e.g. the metastatic potential, as well as the presence in different areas of the body. Thus, a Stage II cancer with a polynucleotide signifying a high metastatic potential cancer can be used to change a borderline Stage II tumor to a Stage III tumor, justifying more aggressive therapy. Conversely, the presence of a polynucleotide signifying a lower metastatic potential allows more conservative staging of a tumor. Grading of cancers. Grade is a term used to describe how closely a tumor resembles normal tissue of its same type. Based on the microscopic appearance of a tumor, pathologists will identify the grade of a tumor based on parameters such as cell moφhology, cellular organization, and other markers of differentiation. As a general rule, the grade of a tumor corresponds to its rate of growth or aggressiveness. That is, undifferentiated or high-grade tumors grow more quickly than well differentiated or low- grade tumors. Information about tumor grade is useful in planning treatment and predicting prognosis.

The American Joint Commission on Cancer has recommended the following guidelines for grading tumors: 1) GX Grade cannot be assessed; 2) GI Well differentiated; G2 Moderately well differentiated; 3) G3 Poorly differentiated; 4) G4 Undifferentiated. Although grading is used by pathologists to describe most cancers, it plays a more important role in treatment planning for certain types than for others. An example is the Gleason system that is specific for prostate cancer, which uses grade numbers to describe the degree of differentiation. Lower Gleason scores indicate well-differentiated cells. Intermediate scores denote tumors with moderately differentiated cells. Higher scores describe poorly differentiated cells. Grade is also important in some types of brain tumors and soft tissue sarcomas.

The polynucleotides of the invention can be especially valuable in determining the grade of the tumor, as they not only can aid in determining the differentiation status of the cells of a tumor, they can also identify factors other than differentiation that are valuable in determining the aggressivity of a tumor, such as metastatic potential.

Familial Cancer Genes. A number of cancer syndromes are linked to Mendelian inheritance of a predisposition to develop particular cancers. The following table contains a list of cancer types that can be inherited, and for which the gene or genes responsible have been identified. Most of the cancer types listed can occur as part of several different genetic conditions, each caused by alterations in a different gene.

Cancer Type Genetic Condition Gene

Brain Li-Fraumeni syndrome TP53

Brain Neurofibromatosis 1 NF1

Neurofϊbromatosis 2 NF2 von Hippel-Lindau syndrome VHL Cancer Type Genetic Condition Gene

Tuberous sclerosis 2 TSC2

Breast Hereditary breast/ovarian cancer 1 BRCA1 Hereditary breast/ovarian cancer 2 BRCA2 Li-Fraumeni syndrome TP53 Ataxia telangiectasia ATM

Colon Familial adenomatous polyposis (FAP) APC Hereditary non-polyposis colon cancer (HNPCC) 1 HMSH2 Hereditary non-polyposis colon cancer (HNPCC) 2 hMLHl Hereditary non-polyposis colon cancer (HNPCC) 3 hPMSl Hereditary non-polyposis colon cancer (HNPCC) 4 hPMS2

Endocrine Multiple endocrine neoplasia 1 (MEN1) MEN1

(parathyroid, pituitary, GI endocrine)

Endocrine Multiple endocrine neoplasia 2 (MEN2) RET

(pheochromacytoma, medullary thyroid)

Endometrial Hereditary non-polyposis colon cancer (HNPCC) 1 hMSH2 Hereditary non-polyposis colon cancer (HNPCC) 2 hMLHl Hereditary non-polyposis colon cancer (HNPCC) 3 hPMSl Hereditary non-polyposis colon cancer (HNPCC) 4 hPMS2

Eye Hereditary retinoblastoma RBI

Hematologic Li-Fraumeni syndrome TP53 (lymphomas and leukemia) Ataxia telangiectasia ATM

Kidney Hereditary Wilms' tumor WT1 von Hippel-Lindau syndrome VHL Tuberous sclerosis 2 TSC2

Ovary Hereditary breast/ovarian cancer 1 BRCA1 Hereditary breast/ovarian cancer 2 BRCA2

Sarcoma Hereditary retinoblastoma RBI Li-Fraumeni syndrome TP53 Neurofϊbromatosis 1 NF1

Skin Hereditary melanoma 1 CDKN2 Hereditary melanoma 2 CDK4 Basal cell naevus (Gorlin) syndrome PTCH

Stomach Hereditary non-polyposis colon cancer (HNPCC) 1 hMSH2 Hereditary non-polyposis colon cancer (HNPCC) 2 hMLHl Hereditary non-polyposis colon cancer (HNPCC) 3 hPMSl Hereditary non-polyposis colon cancer (HNPCC) 4 hPMS2

The polynucleotides of the invention can be especially useful to monitor patients having any of the above syndromes to detect potentially malignant events at a molecular level before they are detectable at a gross moφhological level. As can be seen from the table, a number of genes are involved in multiple forms of cancer. Thus, a polynucleotide of the invention identified as important for metastatic colon cancer can also have clinical implications for a patient diagnosed with stomach cancer or endometrial cancer. Lung Cancer. Lung cancer is one of the most common cancers in the United States, accounting for about 15 percent of all cancer cases, or 170,000 new cases each year. At this time, over half of the lung cancer cases in the United States are in men, but the number found in women is increasing and will soon equal that in men. Today more women die of lung cancer than of breast cancer. Lung cancer is especially difficult to diagnose and treat because of the large size of the lungs, which allows cancer to develop for years undetected. In fact, lung cancer can spread outside the lungs without causing any symptoms. Adding to the confusion, the most common symptom of lung cancer, a persistent cough, can often be mistaken for a cold or bronchitis. Although there are more than a dozen different kinds of lung cancer, the two main types of lung cancer are small cell and nonsmall cell, which encompass about 90% of all lung cancer cases. Small cell carcinoma (also called oat cell carcinoma), which usually starts in one of the larger bronchial tubes, grows fairly rapidly, and is likely to be large by the time of diagnosis. Nonsmall cell lung cancer (NSCLC) is made up of three general subtypes of lung cancer. Epidermoid carcinoma (also called squamous cell carcinoma) usually starts in one of the larger bronchial tubes and grows relatively slowly. The size of these tumors can range from very small to quite large. Adenocarcinoma starts growing near the outside surface of the lung and can vary in both size and growth rate. Some slowly growing adenocarcinomas are described as alveolar cell cancer. Large cell carcinoma starts near the surface of the lung, grows rapidly, and the growth is usually fairly large when diagnosed. Other less common forms of lung cancer are carcinoid, cylindroma, mucoepidermoid, and malignant mesothelioma.

Currently, CT scans, MRIs, X-rays, sputum cytology, and biopsies are used to diagnose nonsmall cell lung cancer. The form and cellular origin of the lung cancer is diagnosed primarily through biopsy from either a surgical biopsy or a needle aspiration of lung tissue, and usually the biopsy is prompted from an abnormality identified on an X-ray. In some cases, sputum cytology can reveal lung cancers in patients with normal X-rays or can determine the type of lung cancer, but because it cannot pinpoint the tumor's location, a positive sputum cytology test is usually followed by further tests. Since these tests are based in large part on gross moφhology of the tissue, the diagnosis of a particular kind of tumor is largely subjective, and the diagnosis can vary significantly between clinicians. The polynucleotides of the invention can be used to distinguish types of lung cancer as well as identifying traits specific to a certain patient's cancer. For example, if the patient's biopsy expresses a polynucleotide that is associated with a low metastatic potential, it may justify leaving a larger portion of the patient's lung in surgery to remove the lesion. Alternatively, a smaller lesion with expression of a polynucleotide that is associated with high metastatic potential may justify a more radical removal of lung tissue and/or the surrounding lymph nodes, even if no metastasis can be identified through pathological examination.

Similarly, the expression of polynucleotides of the invention can be used in the diagnosis, prognosis and management of colorectal cancer. The differential expression of a polynucleotide in hypeφlasia can be used as a diagnostic marker for metastatic lung cancer. The polynucleotides of the invention that would be especially useful for this puφose are those that exhibit differential expression between high metastatic versus low metastatic lung cancer , i.e. SEQ ID NOS: 174, 254, 466, 571, 574, 590, 922, 1355, 1422, 2007, 2038, 2245, 10, 54, 65, 171, 203, 252, 253, 285, 419, 420, 491, 525, 526, 552, 693, 700, 726, 742, 746, 861, 990, 1088, 1288, 1417, 1444, 1454, 1570, 1597, 1979, 2024, 2034, and 2126. Detection of malignant lung cancer with a higher metastatic potential can be determined using expression levels of any of these sequences alone or in combination with the levels of expression of other known genes. Breast Cancer. The National Cancer Institute (NCI) estimates that about 1 in 8 women in the United States will develop breast cancer during her lifetime. Clinical breast examination and mammography are recommended as combined modalities for breast cancer screening, and the nature of the cancer will often depend upon the location of the tumor and the cell type from which the tumor is derived. The majority of breast cancers are adenocarcinomas subtypes, which can be summarized as follows:

Ductal carcinoma in situ (DCIS): Ductal carcinoma in situ is the most common type of noninvasive breast cancer. In DCIS, the malignant cells have not metastasized through the walls of the ducts into the fatty tissue of the breast. Comedocarcinoma is a type of DCIS that is more likely than other types of DCIS to come back in the same area after lumpectomy. It is more closely linked to eventual development of invasive ductal carcinoma than other forms of DCIS. Infiltrating (or invasive) ductal carcinoma (IDC): this type of cancer has metastasized through the wall of the duct and invaded the fatty tissue of the breast. At this point, it has the potential to use the lymphatic system and bloodstream for metastasis to more distant parts of the body. Infiltrating ductal carcinoma accounts for about 80% of breast cancers.

Lobular carcinoma in situ (LCIS): While not a true cancer, LCIS (also called lobular neoplasia) is sometimes classified as a type of noninvasive breast cancer. It does not penetrate through the wall of the lobules. Although it does not itself usually become an invasive cancer, women with this condition have a higher risk of developing an invasive breast cancer in the same breast, or in the opposite breast.

Infiltrating (or invasive) lobular carcinoma (ILC): ILC is similar to IDC, in that it has the potential metastasize elsewhere in the body. About 10% to 15% of invasive breast cancers are invasive lobular carcinomas. ILC can be more difficult to detect by mammogram than IDC. Inflammatory breast cancer: This rare type of invasive breast cancer accounts for about 1% of all breast cancers and is extremely aggressive. Multiple skin symptoms associated with this cancer are caused by cancer cells blocking lymph vessels or channels in the skin over the breast.

Medullary carcinoma: This special type of infiltrating breast cancer has a relatively well defined, distinct boundary between tumor tissue and normal tissue. It accounts for about 5% of breast cancers. The prognosis for this kind of breast cancer is better than for other types of invasive breast cancer.

Mucinous carcinoma: This rare type of invasive breast cancer originates from mucus-producing cells. The prognosis for mucinous carcinoma is better than for the more common types of invasive breast cancer.

Paget's disease of the nipple: This type of breast cancer starts in the ducts and spreads to the skin of the nipple and the areola. It is a rare type of breast cancer, occurring in only 1% of all cases. Paget's disease can be associated with in situ carcinoma, or with infiltrating breast carcinoma. If no lump can be felt in the breast tissue, and the biopsy shows DCIS but no invasive cancer, the prognosis is excellent. Phyllodes tumor: This very rare type of breast tumor forms from the stroma of the breast, in contrast to carcinomas which develop in the ducts or lobules. Phyllodes (also spelled phylloides) tumors are usually benign, but are malignant on rare occasions. Nevertheless, malignant phyllodes tumors are very rare and less than 10 women per year in the US die of this disease. Benign phyllodes tumors are successfully treated by removing the mass and a narrow margin of normal breast tissue.

Tubular carcinoma: Accounting for about 2%> of all breast cancers, tubular carcinomas are a special type of infiltrating breast carcinoma. They have a better prognosis than usual infiltrating ductal or lobularcarcinomas. High-quality mammography combined with clinical breast exam remains the only screening method clearly tied to reduction in breast cancer mortality. Lower dose x-rays, digitized computer rather than film images, and the use of computer programs to assist diagnosis, are almost ready for widespread dissemination. Other technologies also are being developed, including magnetic resonance imaging and ultrasound. In addition, a very low radiation exposure technique, positron emission tomography has the potential for detecting early breast cancer.

It is also possible to differentiate between non-cancerous breast tissue and malignant breast tissue by analyzing differential gene expression between tissues. In addition, there may be several possible alterations that lead to the various possible types of breast cancer. The different types of breast tumors (e.g., invasive vs. non-invasive, ductal vs. axillary lymph node) can be differentiable from one another by the identification of the differences in genes expressed by different types of breast tumor tissues (Porter- Jordan et al, Hematol Oncol Clin North Am (1994) 3.73). Breast cancer can thus be generally diagnosed by detection of expression of a gene or genes associated with breast tumors. Where enough information is available about the differential gene expression between various types of breast tumor tissues, the specific type of breast tumor can also be diagnosed.

For example, increased estrogen receptor (ER) expression in normal breast epithileum, while not itself indicative of malignant tissue, is a known risk marker for development of breast cancer. Khan S A et al, Cancer Res (1994) 54:993. Malignant breast cancer is often divided into two groups, ER-positive and ER-negative, based on the estrogen receptor status of the tissue. The ER status represents different survival length and response to hormone therapy, and is thought to represent either: 1) an indicator of different stages of the disease, or 2) an indicator that allows differentiation between two similar but distinct diseases. K. Zhu et al, Med. Hypoth. (1997) 49:69. A number of other genes are known to vary expression between either different stages of cancer or different types of similar breast cancer.

Similarly, the expression of polynucleotides of the invention can be used in the diagnosis and management of breast cancer. The differential expression of a polynucleotide in human breast tumor tissue can be used as a diagnostic marker for human breast cancer. The polynucleotides of the invention that would be especially useful for this puφose are those that exhibit differential expression between breast cancer tissue with a high metastatic potential and a low metastatic potential, i.e. SEQ ID NOS: 15, 36, 44, 89, 172, 203, 261, 419, 420, 503, 552, 564, 570, 590, 693, 707, 711, 726, 746, 756, 990, 1122, 1142, 1286, 1289, 1435, 1860, 1933, 1934, 1979, 1980, 2007, 2023, 2409, 2486, 45, 146, 154, 159, 165, 174, 183, 364, 366, 387, 496, 510, 512, 529, 560, 606, 644, 646, 754, 875, 902, 921, 942, 1095, 1104, 1131, 1170, 1184, 1205, 1354, 1387, 1535, 1751, 1764, 1777, 1795, 1869, 1882, 1890, 1915, 2040, 2059, 2223, 2245, 2300, 2325, 2462, 2488, 2492; Detection of breast cancer can be determined using expression levels of any of these sequences alone or in combination. Determination of the aggressive nature and/or the metastatic potential of a breast cancer can also be determined by comparing levels of one or more polynucleotides of the invention and comparing levels of another sequence known to vary in cancerous tissue, e.g. ER expression. In addition, development of breast cancer can be detected by examining the ratio of SEQ ID NO: to the levels of steroid hormones (e.g. , testosterone or estrogen) or to other hormones (e.g. , growth hormone, insulin). Thus expression of specific marker polynucleotides can be used to discriminate between normal and cancerous breast tissue, to discriminate between breast cancers with different cells of origin, to discriminate between breast cancers with different potential metastatic rates, etc.

Diagnosis of breast cancer can also involve comparing the expression of a polynucleotide of the invention with the expression of other sequences in non-malignant breast tissue samples in comparison to one or more forms of the diseased tissue. A comparison of expression of one or more polynucleotides of the invention between the samples provides information on relative levels of these polynucleotides as well as the ratio of these polynucleotides to the expression of other sequences in the tissue of interest compared to normal.

This risk of breast cancer is elevated significantly by the presence of an inherited risk for breast cancer, such as a mutation in BRCA-1 or BRCA-2. New diagnostic tools are being developed to address the needs of higher risk patients to complement mammography and physical examinations for early detection of breast cancer, particularly among younger women. The presence of antigen or expression markers in nipple aspirate fluid (NAF) samples collected from one or both breasts can be useful for useful for risk assessment or early cancer detection. Breast cytology and biomarkers obtained by random fine needle aspiration have been used to identify hypeφlasia with atypia and overexpression of p53 and EGFR. The polynucleotides of the invention can be used in multivariate analysis with expression studies with genes such as p53 and EGFR as risk predictors and as surrogate endpoint biomarkers for breast cancer. As well as being used for diagnosis and risk assessment, the expression of certain genes can also correlated to prognosis of a disease state. The expression of particular gene have been used as prognostic indicators for breast cancer including increased expression of c-erbB-2, pS2, ER, progesterone receptor, epidermal growth factor receptor (EGFR), neu, myc, bcl-2, int2, cytosolic tyrosine kinase, cyclin E,prad-1, hst, uPA, PAI-1, PAI-2, cathepsin D, as well as the presence of a number of cancer-specific antigens, e.g. CEA, CA M26, CA M29 and CA 15.3. Davis, Br. J. BiomedSci. (1996) 53:157. Poor prognosis has also been linked to a decrease in expression of certain genes, such as p53, Rb, nm23. The expression of the polynucleotides of the invention can be of prognostic value for determining the metastatic potential of a malignant breast cancer, as this molecules are differentially expressed between high and low metastatic potential tissues tumors. The levels of these polynucleotides in patients with malignant breast cancer can compared to normal tissue, malignant tissue with a known high potential metastatic level, and malignant tissue with a known lower level of metastatic potential to provide a prognosis for a particular patient. Such a prognosis is predictive of the extent and nature of the cancer. The determined prognosis is useful in determining the prognosis of a patient with breast cancer, both for initial treatment of the disease and for longer-term monitoring of the same patient. If samples are taken from the same individual over a period of time, differences in polynucleotide expression that are specific to that patient can be identified and closely watched.

Colon Cancer. Colorectal cancer is one of the most common neoplasms in humans and perhaps the most frequent form of hereditary neoplasia. Prevention and early detection are key factors in controlling and curing colorectal cancer. Indeed, colorectal cancer is the second most preventable cancer, after lung cancer. Colorectal cancer begins as polyps, which are small, benign growths of cells that form on the inner lining of the colon. Over a period of several years, some of these polyps accumulate additional mutations and become cancerous. About 20 percent of all cases of colon cancer are thought to be related to heredity. Currently, multiple familial colorectal cancer disorders have been identified, which are summarized as follows:

Familial adenomatous polyposis (FAP): This condition results in a person having hundreds or even thousands of polyps in the colon and rectum that usually first appear during the teenage years. Cancer nearly always develops in one or more of these polyps between the ages of 30 and 50.

Gardner's syndrome: Like FAP, Gardner's syndrome results in polyps and colorectal cancers that develop at a young age. It can also cause benign tumors of the skin, soft connective tissue and bones. Hereditary nonpolyposis colon cancer (HNPCC): People with this condition tend to develop colorectal cancer at a young age, without first having many polyps. HNPCC has an autosomal dominant pattern of inheritance with variable but high penetrance estimated to be about 90%. HNPCC underlies 0.5%- 10% of all cases of colorectal cancer. An understanding of the mechanisms behind the development of HNPCC is emerging, and genetic presymptomatic testing, now being conducted in research settings, soon will be available on a widespread basis for individuals identified at risk for this disease.

Familial colorectal cancer in Ashkenazi Jews: Recent research has found an inherited tendency to developing colorectal cancer among some Jews of Eastern European descent. Like people with FAP, Gardner's syndrome, and HNPCC, their increased risk is due to an inherited mutation present in about 6% of American Jews. Several tests are currently used to screen for colorectal cancer, including digital rectal examination, fecal occult blood test, sigmoidoscopy, colonoscopy, virtual colonoscopy and MRI. Each of these tests identifies potential colorectal cancer lesions, or a risk of development of these lesions, at a fairly gross moφhological level. The sequential alteration of a number of genes is associated with malignant adenocarcinoma, including the genes DCC, p53, ras, and FAP. For a review, see e.g. Fearon ER, et al, Cell (1990) 61(5):159; Hamilton SR et al, Cancer (1993) 72:957; Bodmer W, et al, Nat Genet. (1994) 4(3):2ll; Fearon ER, Ann N Y Acad Sci. (1995) 763:101. Molecular genetic alterations are thus promising as potential diagnostic and prognostic indicators in colorectal carcinoma and molecular genetics of colorectal carcinoma since it is possible to differentiate between different types of colorectal neoplasias using molecular markers. Colorectal cancer can thus be generally diagnosed by detection of expression of a gene or genes associated with colorectal tumors.

Similarly, the expression of polynucleotides of the invention can be used in the diagnosis, prognosis and management of colorectal cancer. The differential expression of a polynucleotide in hypeφlasia can be used as a diagnostic marker for colon cancer. The polynucleotides of the invention that would be especially useful for this puφose are those that exhibit differential expression between malignant metastatic colon cancer and normal patient tissue , i.e. SEQ ID NOS:228, 280, 355, 491, 603, 680, 752, 753, 1241, 1264, 1401, 1442, 1514, 1851, 1915, 2024, 2066, 33, 250, 282, 370, 387, 443, 460, 545, 560, 703, 704, 1095, 1104, 1205, 1354, 1387, 1734, 1742, 1954, 2262, 2325, 1899, 252, 253, 491, 581, 693, 726, 746, 1780, 1899, 65, 252, 253, 581, 693, 716, 726, 746, 1780, 1899, and 1780. Detection of malignant colon cancer can be determined using expression levels of any of these sequences alone or in combination with the levels of expression. Determination of the aggressive nature and/or the metastatic potential of a colon cancer can also be determined by comparing levels of one or more polynucleotides of the invention and comparing total levels of another sequence known to vary in cancerous tissue, e.g. p53 expression. In addition, development of colon cancer can be detected by examining the ratio of any of the polynucleotides of the invention to the levels of oncogenes (e.g. ras) or tumor suppressor genes (e.g. FAP or p53). Thus expression of specific marker polynucleotides can be used to discriminate between normal and cancerous breast tissue, to discriminate between breast cancers with different cells of origin, to discriminate between breast cancers with different potential metastatic rates, etc.

G. Use of Polynucleotides to Screen for Peptide Analogs and Antagonists Polypeptides encoded by the instant polynucleotides and corresponding full length genes can be used to screen peptide libraries to identify binding partners, such as receptors, from among the encoded polypeptides.

A library of peptides can be synthesized following the methods disclosed in U.S. Pat. No. 5,010,175 ('175), and in WO 91/17823. As described below in brief, one prepares a mixture of peptides, which is then screened to identify the peptides exhibiting the desired signal transduction and receptor binding activity. In the '175 method, a suitable peptide synthesis support (e.g., a resin) is coupled to a mixture of appropriately protected, activated amino acids. The concentration of each amino acid in the reaction mixture is balanced or adjusted in inverse proportion to its coupling reaction rate so that the product is an equimolar mixture of amino acids coupled to the starting resin. The bound amino acids are then deprotected, and reacted with another balanced amino acid mixture to form an equimolar mixture of all possible dipeptides. This process is repeated until a mixture of peptides of the desired length (e.g., hexamers) is formed. Note that one need not include all amino acids in each step: one can include only one or two amino acids in some steps (e.g., where it is known that a particular amino acid is essential in a given position), thus reducing the complexity of the mixture. After the synthesis of the peptide library is completed, the mixture of peptides is screened for binding to the selected polypeptide. The peptides are then tested for their ability to inhibit or enhance activity. Peptides exhibiting the desired activity are then isolated and sequenced. The method described in WO 91/17823 is similar. However, instead of reacting the synthesis resin with a mixture of activated amino acids, the resin is divided into twenty equal portions (or into a number of portions corresponding to the number of different amino acids to be added in that step), and each amino acid is coupled individually to its portion of resin. The resin portions are then combined, mixed, and again divided into a number of equal portions for reaction with the second amino acid. In this manner, each reaction can be easily driven to completion. Additionally, one can maintain separate "subpools" by treating portions in parallel, rather than combining all resins at each step. This simplifies the process of determining which peptides are responsible for any observed receptor binding or signal transduction activity.

In such cases, the subpools containing, e.g., 1-2,000 candidates each are exposed to one or more polypeptides of the invention. Each subpool that produces a positive result is then resynthesized as a group of smaller subpools (sub-subpools) containing, e.g. , 20-100 candidates, and reassayed. Positive sub-subpools can be resynthesized as individual compounds, and assayed finally to determine the peptides that exhibit a high binding constant. These peptides can be tested for their ability to inhibit or enhance the native activity. The methods described in WO 91/7823 and U.S. Patent No. 5,194,392 (herein incoφorated by reference) enable the preparation of such pools and subpools by automated techniques in parallel, such that all synthesis and resynthesis can be performed in a matter of days.

Peptide agonists or antagonists are screened using any available method, such as signal transduction, antibody binding, receptor binding, mitogenic assays, chemotaxis assays, etc. The methods described herein are presently preferred. The assay conditions ideally should resemble the conditions under which the native activity is exhibited in vivo, that is, under physiologic pH, temperature, and ionic strength. Suitable agonists or antagonists will exhibit strong inhibition or enhancement of the native activity at concentrations that do not cause toxic side effects in the subject. Agonists or antagonists that compete for binding to the native polypeptide can require concentrations equal to or greater than the native concentration, while inhibitors capable of binding irreversibly to the polypeptide can be added in concentrations on the order of the native concentration.

The end results of such screening and experimentation will be at least one novel polypeptide binding partner, such as a receptor, encoded by a gene or a cDNA corresponding to a polynucleotide of the invention, and at least one peptide agonist or antagonist of the novel binding partner. Such agonists and antagonists can be used to modulate, enhance, or inhibit receptor function in cells to which the receptor is native, or in cells that possess the receptor as a result of genetic engineering. Further, if the novel receptor shares biologically important characteristics with a known receptor, information about agonist/antagonist binding can facilitate development of improved agonists/antagonists of the known receptor. H. Pharmaceutical Compositions and Therapeutic Uses Pharmaceutical compositions can comprise polypeptides, antibodies, or polynucleotides of the claimed invention. The pharmaceutical compositions will comprise a therapeutically effective amount of either polypeptides, antibodies, or polynucleotides of the claimed invention.

The term "therapeutically effective amount" as used herein refers to an amount of a therapeutic agent to treat, ameliorate, or prevent a desired disease or condition, or to exhibit a detectable therapeutic or preventative effect. The effect can be detected by, for example, chemical markers or antigen levels. Therapeutic effects also include reduction in physical symptoms, such as decreased body temperature. The precise effective amount for a subject will depend upon the subject's size and health, the nature and extent of the condition, and the therapeutics or combination of therapeutics selected for administration. Thus, it is not useful to specify an exact effective amount in advance. However, the effective amount for a given situation is determined by routine experimentation and is within the judgment of the clinician. For puφoses of the present invention, an effective dose will generally be from about 0.01 mg/ kg to 50 mg/kg or 0.05 mg/kg to about 10 mg/kg of the DNA constructs in the individual to which it is administered.

A pharmaceutical composition can also contain a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent, such as antibodies or a polypeptide, genes, and other therapeutic agents. The term refers to any pharmaceutical carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition, and which can be administered without undue toxicity. Suitable carriers can be large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Such carriers are well known to those of ordinary skill in the art.

Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable excipients is available in Remingto 's Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991). Pharmaceutically acceptable carriers in therapeutic compositions can include liquids such as water, saline, glycerol and ethanol. Auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, can also be present in such vehicles. Typically, the therapeutic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection can also be prepared. Liposomes are included within the definition of a pharmaceutically acceptable carrier.

Delivery Methods. Once formulated, the compositions of the invention can be (1) administered directly to the subject (e.g., as polynucleotide or polypeptides); (2) delivered ex vivo, to cells derived from the subject (e.g., as in ex vivo gene therapy); or (3) delivered in vitro for expression of recombinant proteins (e.g., polynucleotides). Direct delivery of the compositions will generally be accomplished by injection, either subcutaneously, intraperitoneally, intravenously or intramuscularly, or delivered to the interstitial space of a tissue. The compositions can also be administered into a tumor or lesion. Other modes of administration include oral and pulmonary administration, suppositories, and transdermal applications, needles, and gene guns or hyposprays. Dosage treatment can be a single dose schedule or a multiple dose schedule.

Methods for the ex vivo delivery and reimplantation of transformed cells into a subject are known in the art and described in e.g., International Publication No. WO 93/14778. Examples of cells useful in ex vivo applications include, for example, stem cells, particularly hematopoetic, lymph cells, macrophages, dendritic cells, or tumor cells. Generally, delivery of nucleic acids for both ex vivo and in vitro applications can be accomplished by, for example, dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei, all well known in the art.

Once a gene corresponding to a polynucleotide of the invention has been found to correlate with a proliferative disorder, such as neoplasia, dysplasia, and hypeφlasia, the disorder can be amenable to treatment by administration of a therapeutic agent based on the provided polynucleotide or corresponding polypeptide. Preparation of antisense polynucleotides is discussed above. Neoplasias that are treated with the antisense composition include, but are not limited to, cervical cancers, melanomas, colorectal adenocarcinomas, Wilms' tumor, retinoblastoma, sarcomas, myosarcomas, lung carcinomas, leukemias, such as chronic myelogenous leukemia, promyelocytic leukemia, monocytic leukemia, and myeloid leukemia, and lymphomas, such as histiocytic lymphoma. Proliferative disorders that are treated with the therapeutic composition include disorders such as anhydric hereditary ectodermal dysplasia, congenital alveolar dysplasia, epithelial dysplasia of the cervix, fibrous dysplasia of bone, and mammary dysplasia. Hypeφlasias, for example, endometrial, adrenal, breast, prostate, or thyroid hypeφlasias or pseudoepitheliomatous hypeφlasia of the skin, are treated with antisense therapeutic compositions based upon a polynucleotide of the invention. Even in disorders in which mutations in the corresponding gene are not implicated, downregulation or inhibition of expression of a gene corresponding to a polynucleotide of the invention can have therapeutic application. For example, decreasing gene expression can help to suppress tumors in which enhanced expression of the gene is implicated.

Both the dose of the antisense composition and the means of administration are determined based on the specific qualities of the therapeutic composition, the condition, age, and weight of the patient, the progression of the disease, and other relevant factors. Administration of the therapeutic antisense agents of the invention includes local or systemic administration, including injection, oral administration, particle gun or catheterized administration, and topical administration. Preferably, the therapeutic antisense composition contains an expression construct comprising a promoter and a polynucleotide segment of at least 12, 22, 25, 30, or 35 contiguous nucleotides of the antisense strand of a polynucleotide disclosed herein. Within the expression construct, the polynucleotide segment is located downstream from the promoter, and transcription of the polynucleotide segment initiates at the promoter.

Various methods are used to administer the therapeutic composition directly to a specific site in the body. For example, a small metastatic lesion is located and the therapeutic composition injected several times in several different locations within the body of tumor. Alternatively, arteries which serve a tumor are identified, and the therapeutic composition injected into such an artery, in order to deliver the composition directly into the tumor. A tumor that has a necrotic center is aspirated and the composition injected directly into the now empty center of the tumor. The antisense composition is directly administered to the surface of the tumor, for example, by topical application of the composition. X-ray imaging is used to assist in certain of the above delivery methods. Receptor-mediated targeted delivery of therapeutic compositions containing an antisense polynucleotide, subgenomic polynucleotides, or antibodies to specific tissues is also used. Receptor-mediated DNA delivery techniques are described in, for example, Findeis et al, Trends Biotechnol (1993) 77:202; Chiou et al, Gene Therapeutics: Methods And Applications Of Direct Gene Transfer (J.A. Wolff, ed.) (1994); Wu et al, J. Biol Chem. (1988) 263:621 ; Wu et al, J. Biol Chem. (1994) 269:542; Zenke et al, Proc. Natl. Acad. Sci. (USA) (1990) 37:3655; Wu et al, J. Biol Chem. (1991) 266:338. Preferably, receptor-mediated targeted delivery of therapeutic compositions containing antibodies of the invention is used to deliver the antibodies to specific tissue.

Therapeutic compositions containing antisense subgenomic polynucleotides are administered in a range of about 100 ng to about 200 mg of DNA for local administration in a gene therapy protocol. Concentration ranges of about 500 ng to about 50 mg, about 1 μg to about 2 mg, about 5 μg to about 500 μg, and about 20 μg to about 100 μg of DNA can also be used during a gene therapy protocol. Factors such as method of action and efficacy of transformation and expression are considerations which will affect the dosage required for ultimate efficacy of the antisense subgenomic polynucleotides. Where greater expression is desired over a larger area of tissue, larger amounts of antisense subgenomic polynucleotides or the same amounts readministered in a successive protocol of administrations, or several administrations to different adjacent or close tissue portions of, for example, a tumor site, may be required to effect a positive therapeutic outcome. In all cases, routine experimentation in clinical trials will determine specific ranges for optimal therapeutic effect. A more complete description of gene therapy vectors, especially retroviral vectors, is contained in U.S. Serial No. 08/869,309, which is expressly incoφorated herein, and in section G below.

For polynucleotide-related genes encoding polypeptides or proteins with anti- inflammatory activity, suitable use, doses, and administration are described in U.S. Patent No. 5,654,173. Therapeutic agents also include antibodies to proteins and polypeptides encoded by the polynucleotides of the invention and related genes, as described in U.S. Patent No. 5,654,173.

I. Gene Therapy

The therapeutic polynucleotides and polypeptides of the present invention can be utilized in gene delivery vehicles. The gene delivery vehicle can be of viral or non- viral origin (see generally, Jolly, Cancer Gene Therapy (1994) 7:51; Kimura, Human Gene Therapy (1994) 5:845; Connelly, Human Gene Therapy (1995) 7:185; and Kaplitt, Nature Genetics (1994) 6:148). Gene therapy vehicles for delivery of constructs including a coding sequence of a therapeutic of the invention can be administered either locally or systemically. These constructs can utilize viral or non- viral vector approaches. Expression of such coding sequences can be induced using endogenous mammalian or heterologous promoters. Expression of the coding sequence can be either constitutive or regulated.

The present invention can employ recombinant retroviruses which are constructed to carry or express a selected nucleic acid molecule of interest. Retrovirus vectors that can be employed include those described in EP 0 415 731; WO 90/07936; WO 94/03622; WO 93/25698; WO 93/25234; U.S. Patent No. 5, 219,740; WO 93/11230; WO 93/10218; Vile and Hart, Cancer Res. (1993) 53:3860; Vile et al, Cancer Res. (1993) 53:962; Ram et al., Cancer Res. (1993) 53:83; Takamiya et al, J. Neurosci. Res. (1992) 33:493; Baba et al., J. Neurosurg. (1993) 79:729; U.S. Patent No. 4,777,127; GB Patent No. 2,200,651; and EP 0 345 242. Preferred recombinant retroviruses include those described in WO 91/02805. Packaging cell lines suitable for use with the above-described retroviral vector constructs can be readily prepared (see, e.g., WO 95/30763 and WO 92/05266), and used to create producer cell lines (also termed vector cell lines) for the production of recombinant vector particles. Within particularly preferred embodiments of the invention, packaging cell lines are made from human (such as HT1080 cells) or mink parent cell lines, thereby allowing production of recombinant retroviruses that can survive inactivation in human serum.

The present invention also employs alphavirus-based vectors that can function as gene delivery vehicles. Such vectors can be constructed from a wide variety of alphaviruses, including, for example, Sindbis virus vectors, Semliki forest virus (ATCC VR-67; ATCC VR-1247), Ross River virus (ATCC VR-373; ATCC VR-1246) and Venezuelan equine encephalitis virus (ATCC VR-923; ATCC VR-1250; ATCC VR 1249;

ATCC VR-532). Representative examples of such vector systems include those described in U.S. Patent Nos. 5,091,309; 5,217,879; and 5,185,440; WO 92/10578; WO 94/21792;

WO 95/27069; WO 95/27044; and WO 95/07994. Gene delivery vehicles of the present invention can also employ parvovirus such as adeno-associated virus (AAV) vectors.

Representative examples include the AAV vectors disclosed by Srivastava in WO

93/09239, Samulski et al., J Virol. (1989) 63:3822; Mendelson et al., Virol. (1988)

766:154; and Flotte et al, PNAS (1993) 90:10613.

Representative examples of adenoviral vectors include those described by Berkner, Biotechniques (1988) 6:616; Rosenfeld et al, Science (1991) 252:431; WO 93/19191;

Kolls et al, PNAS (1994) 97:215; Kass-Eisler et al, PNAS (1993) 90:11498; Guzman et al, Circulation (1993) 33:2838; Guzman et al., Cir. Res. (1993) 73:1202; Zabner et al,

Cell (1993) 75:207; Li et al, Hum. Gene Ther. (1993) 4:403; Cailaud et al, Eur. J.

Neurosci. (1993) 5:1287; Vincent et al, Nat. Genet. (1993) 5:130; Jaffe et al, Nat. Genet. (1992) 7:372; and Levrero et al, Gene (1991) 707:195. Exemplary adenoviral gene therapy vectors employable in this invention also include those described in WO 94/12649,

WO 93/03769; WO 93/19191; WO 94/28938; WO 95/11984 and WO 95/00655.

Administration of DNA linked to killed adenovims as described in Curiel, Hum. Gene

Ther. (1992) 3:147 can be employed. Other gene delivery vehicles and methods can be employed, including polycationic condensed DNA linked or unlinked to killed adenovims alone, for example Curiel, Hum.

Gene Ther. (1992) 3:147; ligand linked DNA, for example see Wu, J. Biol. Chem. (1989)

264:16985; eukaryotic cell delivery vehicles cells, for example see U.S. Pat. No. 5,814,482;

WO 95/07994; WO 96/17072; WO 95/30763; and WO 97/42338; deposition of photopolymerized hydrogel materials; hand-held gene transfer particle gun, as described in

U.S. Patent No. 5,149,655; ionizing radiation as described in U.S. Patent No. 5,206,152 and in WO92/11033; nucleic charge neutralization or fusion with cell membranes.

Additional approaches are described in Philip, Mol. Cell Biol (1994) 74:2411, and in

Woffendin, Proc. Natl Acad. Sci. (1994) 97:1581. Naked DNA can also be employed. Exemplary naked DNA introduction methods are described in WO 90/11092 and U.S. Patent No. 5,580,859. Liposomes that can act as gene delivery vehicles are described in U.S. Patent No. 5,422,120; WO 95/13796; WO 94/23697; WO 91/14445; and EP 0524968.

Further non-viral delivery suitable for use includes mechanical delivery systems such as the approach described in Woffendin et al, Proc. Natl. Acad. Sci. USA (1994) 97(24): 11581. Moreover, the coding sequence and the product of expression of such can be delivered through deposition of photopolymerized hydrogel materials. Other conventional methods for gene delivery that can be used for delivery of the coding sequence include, for example, use of hand-held gene transfer particle gun, as described in U.S. Patent No. 5,149,655; use of ionizing radiation for activating transferred gene, as described in U.S. Patent No. 5,206,152 and WO 92/11033.

The present invention will now be illustrated by reference to the following examples which set forth particularly advantageous embodiments. However, it should be noted that these embodiments are illustrative and are not to be constmed as restricting the invention in any way.

EXAMPLES

Example 1 : Source of Biological Materials and Overview of Novel Polynucleotides Expressed by the Biological Materials Human colon cancer cell line Kml2L4-A (Morika, W. A. K. et al., Cancer

Research (1988) 43:6863) was used to constmct a cDNA library from mRNA isolated from the cells. As described in the above overview, a total of 4,693 sequences expressed by the Kml2L4-A cell line were isolated and analyzed; most sequences were about 275-300 nucleotides in length. The KM12L4-A cell line is derived from the KM12C cell line. The KM12C cell line, which is poorly metastatic (low metastatic) was established in culture from a Dukes' stage B surgical specimen (Morikawa et al. Cancer Res. (1988) 43:6863). The KML4-A is a highly metastatic subline derived from KM12C (Yeatman et al. Nucl. Acids. Res. (1995) 23:4007; Bao-Ling et al. Proc. Annu. Meet. Am. Assoc. Cancer. Res. (1995) 27:3269). The KM12C and KM12C-derived cell lines (e.g., KM12L4, KM12L4-A, etc.) are well-recognized in the art as a model cell line for the study of colon cancer (see, e.g., Moriakawa et al, supra; Radinsky et al. Clin. Cancer Res. (1995) 7:19; Yeatman et al, (1995) supra; Yeatman et al. Clin. Exp. Metastasis (1996) 74:246).

The sequences were first masked to eliminate low complexity sequences using the XBLAST masking program (Claverie "Effective Large-Scale Sequence Similarity Searches," In: Computer Methods for Macromolecular Sequence Analysis. Doolittle, ed., Meth. Enzymol. 266:212-227 Academic Press, NY, NY (1996); see particularly Claverie, in "Automated DNA Sequencing and Analysis Techniques" Adams et al, eds., Chap. 36, p. 267 Academic Press, San Diego, 1994 and Claverie et al. Comput. Chem. (1993) 17:191 ). Generally, masking does not influence the final search results, except to eliminate sequences of relative little interest due to their low complexity, and to eliminate multiple "hits" based on similarity to repetitive regions common to multiple sequences, e.g., Alu repeats. Masking resulted in the elimination of 43 sequences. The remaining sequences were then used in a BLASTN vs. Genbank search with search parameters of greater than 70% overlap, 99% identity, and a p value of less than l x l 0^"40, which search resulted in the discarding of 1,432 sequences. Sequences from this search also were discarded if the inclusive parameters were met, but the sequence was ribosomal or vector-derived.

The resulting sequences from the previous search were classified into three groups (1, 2 and 3 below) and searched in a BLASTX vs. NRP (non-redundant proteins) database search: (1) unknown (no hits in the Genbank search), (2) weak similarity (greater than 45%) identity and p value of less than 1 x IO^"5), and (3) high similarity (greater than 60% overlap, greater than 80%> identity, and p value less than 1 x IO^'5). This search resulted in discard of 98 sequences as having greater than 70%> overlap, greater than 99%) identity, and p value of less than 1 x 10^"40.

The remaining sequences were classified as unknown (no hits), weak similarity, and high similarity (parameters as above). Two searches were performed on these sequences. First, a BLAST vs. EST database search resulted in discard of 1771 sequences (sequences with greater than 99% overlap, greater than 99% similarity and a p value of less than 1 x 10^"40; sequences with a p value of less than 1 x 10^"65 when compared to a database sequence of human origin were also excluded). Second, a BLASTN vs. Patent GeneSeq database resulted in discard of 15 sequences (greater than 99% identity; p value less than 1 x IO^"40; greater than 99% overlap).

The remaining sequences were subjected to screening using other mles and redundancies in the dataset. Sequences with a p value of less than 1 x 10 ^_1 ' ' in relation to a database sequence of human origin were specifically excluded. The final result provided the 2502 sequences listed in the accompanying Sequence Listing. The Sequence Listing is arranged beginning with sequences with no similarity to any sequence in a database searched, and ending with sequences with the greatest similarity. Each identified polynucleotide represents sequence from at least a partial mRNA transcript.

Polynucleotides that were determined to be novel were assigned a sequence identification number.

The novel polynucleotides were assigned sequence identification numbers SEQ ID NOS: 1-2502. The DNA sequences corresponding to the novel polynucleotides are provided in the Sequence Listing. The majority of the sequences are presented in the Sequence Listing in the 5' to 3' direction. A small number of sequences are listed in the Sequence Listing in the 5' to 3' direction but the sequence as written is actually 3' to 5'. These sequences are readily identified with the designation "AR" in the Sequence Name in Table 1 (inserted before the claims). The sequences correctly listed in the 5' to 3' direction in the Sequence Listing are designated "AF." Table 1 provides: 1) the SEQ ID NO assigned to each sequence for use in the present specification; 2) the filing date of the U.S. priority application in which the sequence was first filed; 3) the SEQ ID NO assigned to the sequence in the priority application; 4) the sequence name used as an internal identifier of the sequence; 5) the name assigned to the clone from which the sequence was isolated; and 6) the number of the cluster to which the sequence is assigned (Cluster ID; where the cluster ID is 0, the sequence was not assigned to any cluster

Because the provided polynucleotides represent partial mRNA transcripts, two or more polynucleotides of the invention may represent different regions of the same mRNA transcript and the same gene. Thus, if two or more SEQ ID NOS: are identified as belonging to the same clone, then either sequence can be used to obtain the full-length mRNA or gene. In addition, some sequences are identified with multiple SEQ ID NOS, since these sequences were present in more than one filing. For example, SEQ ID NO:87 and SEQ ID NO: 1000 represent the same sequence.

In order to confirm the sequences of SEQ ID NOS: 1-2502, inserts of the clones corresponding to these polynucleotides were re-sequenced. These "validation" sequences are provided in SEQ ID NOS:2503-5106. Of these validation sequences, SEQ ID NOS:3040, 3545, 3863, 4511, 4726, and 4749 are not tme validation sequences. Instead, SEQ ID NOS :3545, 4511, 4726, and 4749 represent "placeholder" sequences, i.e., sequences that were inserted into the Sequence Listing only to prevent renumbering of the subsequent sequences during generation of the Sequence Listing. Thus, reference to "SEQ ID NOS: 1-5252," "SEQ ID NOS: 1-5106," or other ranges of SEQ ID NOS that include these placeholder sequences should be read to exclude SEQ ID NOS:3545, 4511, 4726, and 4749.

The validation sequences were often longer than the original polynucleotide sequences they validate, and thus often provide additional sequence information. Validation sequences can be correlated with the original sequences they validate by referring to Table 1. For example, validation sequences of SEQ ID NOS:2503-3039, 3041- 3544, 3546-3862 3864-4510, and 4512-4725 share the clone name of the sequence of SEQ ID NOS: 1-2502 that they validate.

Example 2: Results of Public Database Search to Identify Function of Gene Products

SEQ ID NOS:1-2502, as well as the validation sequences SEQ ID NOS:2503-3039, 3041-3544, 3546-3862 3864-4510, and 4512-4725 xxxlf were translated in all three reading frames to determine the best alignment with the individual sequences. These amino acid sequences and nucleotide sequences are referred, generally, as query sequences, which are aligned with the individual sequences. Query and individual sequences were aligned using the BLAST programs, available over the world wide web at http://ww.ncbi.nlm.nih.gov/BLAST/. Again the sequences were masked to various extents to prevent searching of repetitive sequences or poly-A sequences, using the XBLAST program for masking low complexity as described above in Example 1. Table 2 (inserted before the claims) shows the results of the alignments. Table 2 refers to each sequence by its SEQ ID NO:, the accession numbers and descriptions of nearest neighbors from the Genbank and Non-Redundant Protein searches, and the p values of the search results.

For each of "SEQ ID NOS: 1-5106," the best alignment to a protein or DNA sequence is included in Table 2. The activity of the polypeptide encoded by "SEQ ID NOS: 1-5106" is the same or similar to the nearest neighbor reported in Table 2. The accession number of the nearest neighbor is reported, providing a reference to the activities exhibited by the nearest neighbor. The search program and database used for the alignment also are indicated as well as a calculation of the p value. Full length sequences or fragments of the polynucleotide sequences of the nearest neighbors can be used as probes and primers to identify and isolate the full length sequence of "SEQ ID NOS: 1-5106." The nearest neighbors can indicate a tissue or cell type to be used to constmct a library for the full-length sequences of "SEQ ID NOS: 1-5106."

"SEQ ID NOS: 1-5106" and the translations thereof may be human homologs of known genes of other species or novel allelic variants of known human genes. In such cases, these new human sequences are suitable as diagnostics or therapeutics. As diagnostics, the human sequences "SEQ ID NOS: 1-5106" exhibit greater specificity in detecting and differentiating human cell lines and types than homologs of other species. The human polypeptides encoded by "SEQ ID NOS 1-5106" are likely to be less immunogenic when administered to humans than homologs from other species. Further, on administration to humans, the polypeptides encoded by "SEQ ID NOS: 1-5106" can show greater specificity or can be better regulated by other human proteins than are homologs from other species.

Example 3: Members of Protein Families

The validation sequences ("SEQ ID NOS:2503-5106") were used to conduct a profile search as described in the specification above. Several of the polynucleotides of the invention were found to encode polypeptides having characteristics of a polypeptide belonging to a known protein families (and thus represent new members of these protein families) and/or comprising a known functional domain (Table 3, inserted prior to claims). Thus the invention encompasses fragments, fusions, and variants of such polynucleotides that retain biological activity associated with the protein family and/or functional domain identified herein.

Start and stop indicate the position within the individual sequences that align with the query sequence having the indicated SEQ ID NO. The direction (Dir) indicates the orientation of the query sequence with respect to the individual sequence, where forward (for) indicates that the alignment is in the same direction (left to right) as the sequence provided in the Sequence Listing and reverse (rev) indicates that the alignment is with a sequence complementary to the sequence provided in the Sequence Listing.

Some polynucleotides exhibited multiple profile hits because, for example, the particular sequence contains overlapping profile regions, and/or the sequence contains two different functional domains. These profile hits are described in more detail below. The acronyms used in Table 3 are provided in parentheses following the full name of the protein family or functional domain to which they refer. a) Seven Transmembrane Integral Membrane Proteins — Rhodopsin Family (7tm 1). Several of the validation sequences, and thus their corresponding sequence within SEQ ID NOS: 1-2502, correspond to a sequence encoding a polypeptide that is a member of the seven transmembrane receptor rhodopsin family. G-protein coupled receptors of the seven transmembrane rhodopsin family (also called R7G) are an extensive group of hormones, neurotransmitters, and light receptors which transduce extracellular signals by interaction with guanine nucleotide-binding (G) proteins (Strosberg A.D. Eur. J. Biochem. (1991) 796:1, Kerlavage A.R Curr. Opin. Struct. Biol. (1991) 7:394, Probst, et al., DNA Cell Biol. (1992) 77:1, Savarese, et al., Biochem. J. (1992) 233:1, http://www. crdb.uthscsa.edu/. http://swift.embl-heidelberg.de/7tm/. The receptors that are currently known to belong to this family are: 1) 5-hydroxytryptamine (serotonin) 1A to IF, 2A to 2C, 4, 5A, 5B, 6 and 7 (Branchek T., Curr. Biol. (1993) 3:315); 2) acetylcholine, muscarinic-type, Ml to M5; 3) adenosine Al, A2A, A2B and A3 (Stiles G.L. J. Biol. Chem. ( 1992) 267:6451 ; 4) adrenergic alpha- 1 A to - 1 C; alpha-2A to -2D; beta- 1 to -3 (Friell T. et al., Trends Neurosci. (1988) 77:321); 5) angiotensin II types I and II; 6) bombesin subtypes 3 and 4; 7) bradykinin Bl and B2; 8) c3a and C5a anaphylatoxin; 9) cannabinoid CB1 and CB2; 10) chemokines C-C CC-CKR-1 to CC-CKR-8; 11) Chemokines C-X-C CXC-CKR-1 to CXC-CKR-4; 12) Cholecystokinin-A and cholecystokinin-B/gastrin Dopamine Dl to D5 (Stevens C.F., Curr. Biol. (1991) 7:20); 13) Endothelin ET-a and ET-b (Sakurai T. et al., Trends Pharmacol. Sci. (1992) 73:103-107); 14) fMet-Leu-Phe (fMLP) (Nformyl peptide); 15) Follicle stimulating hormone (FSH-R); 16) Galanin; 17) Gastrin-releasing peptide (GRP-R); 18) Gonadotropin-releasing hormone (GNRH-R); 19) Histamine HI and H2 (gastric receptor I); 20) Lutropin- choriogonadotropic hormone (LSH-R) (Salesse R., et al., Biochimie (1991) 73:109); 21) Melanocortin MC1R to MC5R; 22) Melatonin; 23) Neuromedin B (NMB-R); 24) Neuromedin K (NK-3R); 25) Neuropeptide Y types 1 to 6; 26) Neurotensin (NT-R); 27) Octopamine (tyramine), from insects; 28) Odorants (Lancet D., et al., Curr. Biol.

(1993)3:668; 29) Opioids delta-, kappa- and mu-types (Uhl G.R., et al., Trends Neurosci. (1994) 77:89; 30) Oxytocin (OT-R); 31) Platelet activating factor (PAF-R); 32) Prostacyclin; 33) Prostaglandin D2; 34) Prostaglandin E2, EP1 to EP4 subtypes; 35) Prostaglandin F2; 36) Purinoreceptors (ATP) (Barnard E.A., et al., Trends Pharmacol Sci. (1994)75:67; 37); Somatostatin types 1 to 5; 38) Substance-K (NK-2R); Substance-P (NK- 1R); 39) Thrombin; 40) Thromboxane A2; 41) Thyrotropin (TSH-R) (Salesse R., et al., Biochimie (1991) 73:109); 42) Thyrotropin releasing factor (TRH-R); 42) Vasopressin Via, VI b and V2; 43) Visual pigments (opsins and rhodopsin) (Applebury M.L., et al., Vision Res. (1986) 26:1881; 44) Proto-oncogene mas; 45) A number of oφhan receptors (whose ligand is not known) from mammals and birds; 46) Caenorhabditis elegans putative receptors C06G4.5, C38C10.1, C43C3.2; 47) T27D1.3 and ZC84.4; 48) Three putative receptors encoded in the genome of cytomegalovirus: US27, US28, and UL33; and 49) ECRF3, a putative receptor encoded in the genome of heφesvims saimiri.

The stmcture of these receptors is thought to be identical. They have seven hydrophobic regions, each of which most probably spans the membrane. The N-terminus is located on the extracellular side of the membrane and is often glycosylated, while the C- terminus is cytoplasmic and generally phosphorylated. Three extracellular loops alternate with three intracellular loops to link the seven transmembrane regions. Most, but not all of these receptors, lack a signal peptide. The most conserved parts of these proteins are the transmembrane regions and the first two cytoplasmic loops. A conserved acidic-Arg- aromatic triplet is present in the N-terminal extremity of the second cytoplasmic loop (Attwood T.K., Eliopoulos E.E., Findlay J.B.C. Gene (1991) 93:153-159) and could be implicated in the interaction with G proteins. A consensus pattern that contains the conserved triplet and that also spans the major part of the third transmembrane helix is used to detect this widespread family of proteins: [GSTALIVMFYWC]-[GSTANCPDE]-{EDPKRH}-x(2)-[LIVMNQGA]-x(2)- [LIVMFT]- [GSTANC]-[LIVMFYWSTAC]-[DENH]-R-[FYWCSH]-x(2)- [LIVM]. b) Seven Transmembrane Integral Membrane Proteins — Secretin Family (7tm 2V

Several of the validation sequences, and thus their corresponding sequence within SEQ ID NOS:1-2502, correspond to a sequence encoding a polypeptide that is a member of the seven transmembrane receptor secretin family. A number of peptide hormones bind to G- protein coupled receptors that, while structurally similar to the majority of G-protein coupled receptors (R7G) (see profile for 7 transmembrane receptors (rhodopsin family), do not show any similarity at the level of their sequence, thus new family whose current known members (Jueppner et al. Science (1991) 254:1024; Hamann et al. Genomics (1996) 32: 144). are: 1) calcitonin receptor, 2) calcitonin gene-related peptide receptor; 3) corticotropin releasing factor receptor types 1 and 2; 4) gastric inhibitory polypeptide receptor; 5) glucagon receptor; 6) glucagon-like peptide 1 receptor; 7) growth hormone- releasing hormone receptor; 7) parathyroid hormone / parathyroid hormone-related peptide types 1 and 2; 8) pituitary adenylate cyclase activating polypeptide receptor; 9) secretin receptor; 10) vasoactive intestinal peptide receptor types 1 and 2; 10) insects diuretic hormone receptor; 11) Caenorhabditis elegans putative receptor C13B9.4; 12) Caenorhabditis elegans putative receptor ZK643.3; 13) human leucocyte CD97 (which contains 3 EGF-like domains in its N-terminal section); 14) human cell surface glycoprotein EMR1 (which contains 6 EGF-like domains in it N-terminal section); and 15) mouse cell surface glycoprotein F4/80 (which contains 7 EGF-like domains in its N- terminal section). All of 1) through 10) are coupled to G-proteins which activate both adenylyl cyclase and the phosphatidylinositol-calcium pathway.

Like classical R7G the secretin family of 7 transmembrane proteins contain seven transmembrane regions. Their N-terminus is located on the extracellular side of the membrane and potentially glycosylated, while their C-terminus is cytoplasmic. But apart from these topological similarities they do not share any region of sequence similarity and are therefore probably not evolutionary related.

Every receptor in the 7 transmember secretin family is encoded on multiple exons, and several of these functionally distinct products. The N-terminal extracellular domain of these receptors contains five conserved cysteines residues that may be involved in disulfide bonds, with a consensus pattern in the region that spans the first three cysteines. One of the most highly conserved regions spans the C-terminal part of the last transmembrane region and the beginning of the adjacent intracellular region. This second region is used as a second signature pattern. The two consensus patterns are: 1) C-x(3)-[FYWLIV]-D-x(3,4)-C-[FW]-x(2)-[STAGV]-x(8,9)-C-[PF]

2) Q-G-[LMFCA]-[LIVMFT]-[LIV]-x-[LIVFST]-[LIF]-[VFYH]-C- [LFY]-x-N-x(2)-V c) Ank Repeats (ANK). SEQ IS NO:2656, and thus its corresponding sequence within SEQ ID NOS: 1-2502, represents a polynucleotide encoding an Ank repeat- containing protein. The ankyrin motif is a 33 amino acid sequence named after the protein ankyrin which has 24 tandem 33-amino-acid motifs. Ank repeats were originally identified in the cell-cycle-control protein cdclO (Breeden et al, Nature (1987) 329:651). Proteins containing ankyrin repeats include ankyrin, myotropin, I-kappaB proteins, cell cycle protein cdclO, the Notch receptor (Matsuno et al, Development (1997) 124(21) :4265); G9a (or BAT8) of the class III region of the major histocompatibility complex (Biochem J. 290:811-818, 1993), FABP, GABP, 53BP2, Linl2, glp-1, SW14, and SW16. The functions of the ankyrin repeats are compatible with a role in protein-protein interactions (Bork, Proteins (1993) 17(4):363; Lambert and Bennet, Eur. J. Biochem. (1993) 277:1; Kerr et al, Current Op. Cell Biol. (1992) 4:496; Bennet et al, J. Biol. Chem. (1980) 255:6424). The 90 kD N-terminal domain of ankyrin contains a series of 24 33-amino-acid ank repeats. (Lux et al, Nature (1990) 344:36-42, Lambert et al, PNAS USA (1990) 37:1730.) The 24 ank repeats form four folded subdomains of 6 repeats each. These four repeat subdomains mediate interactions with at least 7 different families of membrane proteins. Ankyrin contains two separate binding sites for anion exchanger dimers. One site utilizes repeat subdomain two (repeats 7-12) and the other requires both repeat subdomains 3 and 4 (repeats 13-24). Since the anion exchangers exist in dimers, ankyrin binds 4 anion exchangers at the same time (Michaely and Bennett, J. Biol Chem. (1995) 270(37) :22050). The repeat motifs are involved in ankyrin interaction with tubulin, spectrin, and other membrane proteins. (Lux et al, Nature (1990) 344:36.) The Rel/NF-kappaB/Dorsal family of transcription factors have activity that is controlled by sequestration in the cytoplasm in association with inhibitory proteins referred to as I-kappaB. (Gilmore, Cell (1990) 62:841; Nolan and Baltimore, Curr Opin Genet Dev. (1992) 2:211 ; Baeuerle, Biochim Biophys Acta (1991) 1072:63; Schmitz et al, Trends Cell Biol. (1991) 7:130.) I-kappaB proteins contain 5 to 8 copies of 33 amino acid ankyrin repeats and certain NF-kappaB/rel proteins are also regulated by cis-acting ankyrin repeat containing domains including pl05NF-kappaB which contains a series of ankyrin repeats (Diehl and Hannink, J. Virol. (1993) 67(12):ll6l). The I-kappaBs and Cactus (also containing ankyrin repeats) inhibit activators through differential interactions with the Rel- homology domain. The gene family includes proto-oncogenes, thus broadly implicating I- kappaB in the control of both normal gene expression and the aberrant gene expression that makes cells cancerous. (Nolan and Baltimore, Curr Opin Genet Dev. (1992) 2(2) :211-220). In the case of rel/NF-kappaB and pp40/I-kappaB(, both the ankyrin repeats and the carboxy -terminal domain are required for inhibiting DNA-binding activity and direct association of pp40/I-kappaB( with rel/NF-kappaB protein. The ankyrin repeats and the carboxy -terminal of pp40/I-kappaB( form a stmcture that associates with the rel homology domain to inhibit DNA binding activity (Inoue et al, PNAS USA (1992) 39:4333).

The 4 ankyrin repeats in the amino terminus of the transcription factor subunit GABP are required for its interaction with the GABP subunit to form a functional high affinity DNA-binding protein. These repeats can be crosslinked to DNA when GABP is bound to its target sequence. (Thompson et al, Science (1991) 253:762; LaMarco et al, Science (1991) 253:789). Myotrophin, a 12.5 kDa protein having a key role in the initiation of cardiac hypertrophy, comprises ankyrin repeats. The ankyrin repeats are characteristic of a haiφin-like protmding tip followed by a helix-turn-helix motif. The V- shaped helix-tum-helix of the repeats stack sequentially in bundles and are stabilized by compact hydrophobic cores, whereas the protmding tips are less ordered. d) Eukaryotic Aspartyl Proteases (asp). Several of the validation sequences, and thus their corresponding sequence within SEQ ID NOS: 1-2502, correspond to a sequence encoding a novel eukaryotic aspartyl protease. Aspartyl proteases, known as acid proteases, (EC 3.4.23.-) are a widely distributed family of proteolytic enzymes (Foltmann B., Essays Biochem. (1981) 77:52; Davies D.R., Annu. Rev. Biophys. Chem. (1990) 79:189; Rao J.K.M., et al, Biochemistry (1991) 30:4663) known to exist in vertebrates, fungi, plants, retro vi ses and some plant vimses. Aspartate proteases of eukaryotes are monomeric enzymes which consist of two domains. Each domain contains an active site centered on a catalytic aspartyl residue. The two domains most probably evolved from the duplication of an ancestral gene encoding a primordial domain. Currently known eukaryotic aspartyl proteases include: 1) Vertebrate gastric pepsins A and C (also known as gastricsin); 2) Vertebrate chymosin (rennin), involved in digestion and used for making cheese; 3) Vertebrate lysosomal cathepsins D (EC 3.4.23.5) and E (EC 3.4.23.34); 4) Mammalian renin (EC 3.4.23.15) whose function is to generate angiotensin I from angiotensinogen in the plasma; 5) Fungal proteases such as aspergillopepsin A (EC 3.4.23.18), candidapepsin (EC 3.4.23.24), mucoropepsin (EC 3.4.23.23) (mucor rennin), endothiapepsin (EC 3.4.23.22), polyporopepsin (EC 3.4.23.29), and rhizopuspepsin (EC 3.4.23.21); and 6) Yeast saccharopepsin (EC 3.4.23.25) (proteinase A) (gene PEP4). PEP4 is implicated in posttranslational regulation of vacuolar hydrolases; 7) Yeast barrieφepsin (EC 3.4.23.35) (gene BAR1); a protease that cleaves alpha-factor and thus acts as an antagonist of the mating pheromone; and 8) Fission yeast sxal which is involved in degrading or processing the mating pheromones.

Most retrovimses and some plant vimses, such as badnavimses, encode for an aspartyl protease which is an homodimer of a chain of about 95 to 125 amino acids. In most retrovimses, the protease is encoded as a segment of a polyprotein which is cleaved during the maturation process of the vims. It is generally part of the pol polyprotein and, more rarely, of the gag polyprotein. Because the sequence around the two aspartates of eukaryotic aspartyl proteases and around the single active site of the viral proteases is conserved, a single signature pattern can be used to identify members of both groups of proteases. The consensus pattern is: [LIVMFGAC]-[LIVMTADN]-[LIVFSA]-D-[ST]-G- [STAV]-[STAPDENQ]- x-[LIVMFSTNC]-x-[LIVMFGTA], where D is the active site residue. e) ATPases Associated with Various Cellular Activities (ATPases). Several of the validation sequences, and thus their corresponding sequence within SEQ ID NOS: 1-2502, correspond to a sequence that encodes a novel member of the "ATPases Associated with diverse cellular Activities" (AAA) protein family. The AAA protein family is composed of a large number of ATPases that share a conserved region of about 220 amino acids that contains an ATP-binding site (Froehlich et al, J. Cell Biol. (1991) 774:443; Erdmann et al Cell (1991) 64:499; Peters et al, EMBOJ. (1990) 9:1757; Kunau et al, Biochimie (1993) 75:209-224; Confalonieri et al, BioEssays (1995) 77:639; http://yeamob.pci.chemie.uni- tuebingen.de/AAA/Description.html). The proteins that belong to this family either contain one or two AAA domains.

Proteins containing two AAA domains include: 1) Mammalian and drosophila NSF (N-ethylmaleimide-sensitive fusion protein) and the fungal homolog, SEC 18, which are involved in intracellular transport between the endoplasmic reticulum and Golgi, as well as between different Golgi cisternae; 2) Mammalian transitional endoplasmic reticulum ATPase (previously known as p97 or VCP), which is involved in the transfer of membranes from the endoplasmic reticulum to the golgi apparatus. This ATPase forms a ring-shaped homooligomer composed of six subunits. The yeast homolog, CDC48, plays a role in spindle pole proliferation; 3) Yeast protein PAS 1 essential for peroxisome assembly and the related protein PAS1 from Pichia pastoris; 4) Yeast protein AFG2; 5) Sulfolobus acidocaldarius protein SAV and Halobacterium salinarium cdcH, which may be part of a transduction pathway connecting light to cell division. Proteins containing a single AAA domain include: 1) Escherichia coli and other bacteria ftsH (or hflB) protein. FtsH is an ATP-dependent zinc metallopeptidase that degrades the heat-shock sigma-32 factor, and is an integral membrane protein with a large cytoplasmic C-terminal domain that contain both the AAA and the protease domains; 2) Yeast protein YME1, a protein important for maintaining the integrity of the mitochondrial compartment. YME1 is also a zinc-dependent protease; 3) Yeast protein AFG3 (or YTA10). This protein also contains an AAA domain followed by a zinc-dependent protease domain; 4) Subunits from regulatory complex of the 26S proteasome (Hilt et al, Trends Biochem. Sci. (1996) 27:96), which is involved in the ATP-dependent degradation of ubiquitinated proteins, which subunits include: a) Mammalian 4 and homologs in other higher eukaryotes, in yeast (gene YTA5) and fission yeast (gene mts2); b) Mammalian 6 (TBP7) and homologs in other higher eukaryotes and in yeast (gene YTA2); c) Mammalian subunit 7 (MSS1) and homologs in other higher eukaryotes and in yeast (gene CIM5 or YTA3); d) Mammalian subunit 8 (P45) and homologs in other higher eukaryotes and in yeast (SUG1 or CIM3 or TBY1) and fission yeast (gene letl); e) Other probable subunits include human TBPl, which influences HIV gene expression by interacting with the vims tat transactivator protein, and yeast YTA1 and YTA6; 5) Yeast protein BCS1, a mitochondrial protein essential for the expression of the Rieske iron-sulfur protein; 6) Yeast protein MSP1, a protein involved in intramitochondrial sorting of proteins; 7) Yeast protein PAS8, and the corresponding proteins PAS5 from Pichia pastoris and PAY4 from Yarrowia lipolytica; 8) Mouse protein SKD1 and its fission yeast homolog

(SpAC2Gl 1.06); 9) Caenorhabditis elegans meiotic spindle formation protein mei-1; 10) Yeast protein SAP1 ' 11) Yeast protein YTA7; and 12) Mycobacterium leprae hypothetical protein A2126A. In general, the AAA domains in these proteins act as ATP-dependent protein clamps(Confalonieri et al (1995) BioEssays 77:639). In addition to the ATP-binding 'A' and 'B' motifs, which are located in the N-terminal half of this domain, thereis a highly conserved region located in the central part of the domain which was used in the development of the signature pattern. The consensus pattern is: [LIVMT]-x-[LIVMT]- [LIVMF]-x-[GATMC]-[ST]-[NS]-x(4)-[LIVM]- D-x-A-[LIFA]-x-R. f) Bcl-2 family (Bcl-2). SEQ ID NO:3404, and thus the corresponding sequence it validates, represents a polynucleotide encoding an apoptosis regulator protein of the Bcl-2 family. Active cell suicide (apoptosis) is induced by events such as growth factor withdrawal and toxins. It is controlled by regulators, which have either an inhibitory effect on programmed cell death (anti-apoptotic) or block the protective effect of inhibitors (pro- apoptotic) (Vaux, 1993, Curr. Biol. 3:877-878, and White, 1996, Genes Dev. 10:2859- 2869). Many vimses have found a way of countering defensive apoptosis by encoding their own anti-apoptosis genes, preventing their target cells from dying prematurely. All proteins belonging to the Bcl-2 family (Reed et al., 1996, Adv. Exp. Med. Biol.

406:99-112) contain either a BH1, BH2, BH3, or BH4 domain. All anti-apoptotic proteins contain BH1 and BH2 domains; some of them contain an additional N-terminal BH4 domain (Bcl-2, Bcl-x(L), Bcl-w), which is never seen in pro-apoptotic proteins, except for Bcl-x(S). On the other hand, all pro-apoptotic proteins contain a BH3 domain (except for Bad) necessary for dimerization with other proteins of Bcl-2 family and cmcial for their killing activity; some of them also contain BH1 and BH2 domains (Bax, Bak). The BH3 domain is also present in some anti-apoptotic protein, such as Bcl-2 or Bcl-x(L). Proteins that are known to contain these domains are listed below.

1. Vertebrate protein Bcl-2. Bcl-2 blocks apoptosis; it prolongs the survival of hematopoietic cells in the absence of required growth factors and also in the presence of various stimuli inducing cellular death. Two isoforms of bcl-2 (alpha and beta) are generated by alternative splicing. Bcl-2 is expressed in a wide range of tissues at various times during development. It forms heterodimers with the Bax proteins.

2. Vertebrate protein Bcl-x. Two isoforms of Bcl-x (Bcl-x(L) and Bcl-x(S)) are generated by alternative splicing. While the longer product (Bcl-x(L)) can protect a growth-factor-dependent cell line from apoptosis, the shorter form blocks the protective effect of Bcl-2 and Bcl-x(L) and acts as an anti-anti-apoptosis protein.

3. Mammalian protein Bax. Bax blocks the anti-apoptosis ability of Bcl-2 with which it forms heterodimers. There is no evidence that Bax has any activity in the absence of Bcl-2. Three isoforms of bax (alpha, beta and gamma) are generated by alternative splicing.

4. Mammalian protein Bak, which promotes cell death and counteracts the protection from apoptosis provided by Bcl-2.

5. Mammalian protein Bcl-w, which promotes cell survival.

6. Mammalian protein bad, which promotes cell death, and counteracts the protection from apoptosis provided by Bcl-x(L), but not that of Bcl-2.

7. Human protein Bik, which promotes cell death, but cannot counteract the protection from apoptosis provided by Bcl-2.

8. Mouse protein Bid, which induces caspases and apoptosis, and counteracts the protection from apoptosis provided by Bcl-2.

9. Human induced myeloid leukemia cell differentiation protein MCL1. MCL1 is probably involved in programming of differentiation and concomitant maintenance of viability but not proliferation. Its expression increases early during phorbol ester induced differentiation in myeloid leukemia cell line ML-1.

10. Mouse hemopoietic-specific early response protein A 1.

11. Mammalian activator of apoptosis Harakiri (Inohara et al., 1997, EMBO J. 16:1686-1694) (also known as neuronal death protein Dp5). This is a small protein of 92 residues that activates apoptosis. It contains a BH3 domain, but no BHl, BH2 or BH4 domains.

The following consensus patterns have been developed for the four BH domains: l) [LVME]-[FT]-x-[GSD]-[GL]-x(l,2)-[NS]-[YW]-G-R-[LIV]- [LIVC]-[GAT]-

[LIVMF](2)-x-F-[GSAE]-[GSARY] 2) W-[LIM]-x(3)-[GR]-G-[WQ]-[DENSAV]-x-[FLGA]-[LIVFTC]

3) [LIVAT]-x(3)-L-[KARQ]-x-[IVAL]-G-D-[DESG]-[LIMFV]-[DENSHQ]-[LVSHRQ]-

[NSR]

4) [DS]-[NT]-R-[AE]-[LI]-V-x-[KD]-[FY]-[LIV]-[GHS]-Y-K-L- [SR]-Q-[RK]-G-[HY]-x-

[CW]. g Bromodomain (bromodomain). SEQ ID NOS:4036 and 4489, and thus the corresponding sequences they validate, represent polynucleotides encoding a polypeptide having a bromodomain region (Haynes et al., 1992, Nucleic Acids Res. 20:2693-2603,

Tamkun et al., 1992, Cell 68:561-572, and Tamkun, 1995, Curr. Opin. Genet. Dev. 5:473- 477), which is a conserved region of about 70 amino acids found in the following proteins: 1) Higher eukaryotes transcription initiation factor TFIID 250 Kd subunit (TBP-associated factor p250) (gene CCG1); P250 is associated with the TFIID TATA-box binding protein and seems essential for progression of the GI phase of the cell cycle. 2) Human RJNG3, a protein of unknown function encoded in the MHC class II locus; 3) Mammalian CREB- binding protein (CBP), which mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein; 4) Mammalian homologs of brabma, including three brabma-like human: SNF2a(hBRM), SNF2b, and BRG1; 5) Human BS69, a protein that binds to adenovims El A and inhibits E1A transactivation; 6) Human peregrin (or Brl40). The bromodomain is thought to be involved in protein-protein interactions and may be important for the assembly or activity of multicomponent complexes involved in transcriptional activation. The consensus pattern, which spans a major part of the bromodomain, is: [STANVF]-x(2)-F-x(4)-[DNS]-x(5,7)-[DENQTF]-Y-[HFY]-x(2)- [LIVMFY]-x(3)-[LIVM]-x(4)-[LIVM]-x(6,8)-Y-x(12,13)-[LIVM]-x(2)-N-[SACF]-x(2)- [FY]. h) Basic Region Plus Leucine Zipper Transcription Factors (BZIP). SEQ ID NO:3408, 2951, and 4850, and thus the corresponding sequences these sequences validate, represent polynucleotides encoding a novel member of the family of basic region plus leucine zipper transcription factors. The bZIP superfamily (Hurst, Protein Prof. (1995) 2:105; and Ellenberger, Curr. Opin. Struct. Biol. (1994) 4:12) of eukaryotic DNA-binding transcription factors encompasses proteins that contain a basic region mediating sequence- specific DNA-binding followed by a leucine zipper required for dimerization. Members of the family include transcription factor AP-1, which binds selectively to enhancer elements in the cis control regions of SV40 and metallothionein IIA. AP-1 , also known as c-jun, is the cellular homolog of the avian sarcoma vims 17 (AS VI 7) oncogene v-jun.

Other members of this protein family include jun-B and jun-D, probable transcription factors that are highly similar to jun/AP-1 ; the fos protein, a proto-oncogene that forms a non-covalent dimer with c-jun; the fos-related proteins fra-1, and fos B; and mammalian cAMP response element (CRE) binding proteins CREB, CREM, ATF-1, ATF-3, ATF-4, ATF-5, ATF-6 and LRF-1. The consensus pattern for this protein family is: [KR]-x(l,3)- [RKSAQ]-N-x(2)-[SAQ](2)-x-[RKTAENQ]-x-R-x-[RK]. i) Cvclins (cvclin). SEQ ID NOS:3618, 3895, and 4536, and thus the corresponding sequences these sequences validate, represent polynucleotides encoding cyclins, and SEQ ID NO:55 and 56, respectively, show the corresponding full-length polynucleotides. SEQ ID NO:57 and 58 show, respectively, the translations of SEQ ID NO:55 and 56. Cyclins (Nurse, 1990, Nature 344:503-508; Norbury et al., 1991, Curr. Biol. 1 :23-24; and Lew et al., 1992, Trends Cell Biol. 2:77-81) are eukaryotic proteins that play an active role in controlling nuclear cell division cycles. There are two main groups of cyclins. G2/M cyclins are essential for the control of the cell cycle at the G2/M (mitosis) transition. G2/M cyclins accumulate steadily during G2 and are abmptly destroyed as cells exit from mitosis (at the end of the M-phase). Gl/S cyclins are essential for the control of the cell cycle at the Gl/S (start) transition. The best conserved region is in the central part of the cyclins' sequences, known as the "cyclin-box," from which a 32 residue consensus pattern was derived: R-x(2)- [LIVMSA]-x(2)-[FYWS]-[LIVM]-x(8)-[LIVMFC]-x(4)-[LIVMFYA]-x(2)-[STAGC]- [LIVMFYQ]-x-[LIVMFYC]-[LIVMFY]-D-[RKH]-[LIVMFYW]. j) Eukaryotic thiol (cysteine) proteases active sites (Cys-protease). SEQ ID NOS:3344, 3684, 3688, and 4801, and thus also the sequences they validate, repreasent polynucleotides encoding proteins having a eukaryotic thiol (cysteine) protease active site. Eukaryotic thiol proteases (Dufour E., Biochimie (1988) 70:1335); are a family of proteolytic enzymes which contain an active site cysteine. Catalysis proceeds through a thioester intermediate and is facilitated by a nearby histidine side chain; an asparagine completes the essential catalytic triad. The proteases that belong to this family are:

1) vertebrate lysosomal cathepsins B (Kirschke H., et al., Protein Prof. (1995) 2:1587- 1643); 2) vertebrate lysosomal dipeptidyl peptidase l (also known as cathepsin C) (Kirschke H., et al., supra); 3) vertebrate calpains (Calpains are intracellular calcium- activated thiol protease that contain both an N-terminal catalytic domain and a C-terminal calcium-binding domain); 4) mammalian cathepsin K, which seems involved in osteoclastic bone resoφtion (Shi G.-P., et al., FEBS Lett. (1995) 357:129); 5) human cathepsin O ([ 4] Velasco G., Ferrando A.A., Puente X.S., Sanchez L.M., Lopez-Otin C. J. Biol. Chem. (1994) 269:27136); 6) bleomycin hydrolase (which catalyzes the inactivation of the antitumor dmg BLM (a glycopeptide)); 7) Plant enzymes such as: barley aleurain, EP-B1/B4; kidney bean EP-Cl, rice bean SH-EP; kiwi fruit actinidin; papaya latex papin, chymopapain, caricain, and proteinase IV; pea turgor-responsive protein 15 A; pineapple stem bromelain; rape COT44; rice oryzain alpha, beta, and gamma; tomato low- temperature induced, Arabidopsis thaliana A494, RD19A and RD21A; 8) - House-dust mites allergens DerPl and EurMl ; 9) cathepsin B-like proteinases from the worms Caenorhabditis elegans (genes gcp-1, cpr-3, cpr-4, cpr-5 and cpr-6), Schistosoma mansoni (antigen SM31) and Japonica (antigen SJ31), Haemonchus contortus (genes AC-1 and AC-2), and Ostertagia ostertagi (CP-1 and CP-3); 10) slime mold cysteine proteinases CP1 and CP2; 11) cruzipain from Trypanosoma cmzi and bmcei; 12) throphozoite cysteine proteinase (TCP) from various Plasmodium species; 13) proteases from Leishmania mexicana, Theileria annulata and Theileria parva; 14) Baculovimses cathepsin-like enzyme (v-cath); 15) Drosophila small optic lobes protein (gene sol), a neuronal protein that contains a calpain-like domain; 16) yeast thiol protease BLH1/YCP1/LAP3; 17) Caenorhabditis elegans hypothetical protein C06G4.2, a calpain-like protein.

In addition, two bacterial peptidases are also part of this family: 1) aminopeptidase C from Lactococcus lactis (gene pepC) (Chapot-Chartier M.P., et al., Appl Environ. Microbiol. (1993) 59:330); and 2) thiol protease tpr from Poφhyromonas gingivalis. Three other proteins are structurally related to this family, but may have lost their proteolytic activity. These include: 1) soybean oil body protein P34 (which has its active site cysteine replaced by a glycine); 2) rat testin (which is a sertoli cell secretory protein highly similar to cathepsin L but with the active site cysteine is replaced by a serine); and 3) Plasmodium falciparum serine-repeat protein (SERA) (which is the major blood stage antigen and possesses a C-terminal thiol-protease-like domain (Higgins D.G., et al., Nature (1989) 340:604), with the active site cysteine is replaced by a serine).

The sequences around the three active site residues are well conserved and can be used as signature patterns:

Consensus pattern #1 : Q-x(3)-[GE]-x-C-[YW]-x(2)-[STAGC]-[STAGCV] (where C is the active site residue) Consensus pattern #2: [LIVMGSTAN]-x-H-[GSACE]-[LIVM]-x-[LIVMAT](2)-G- x-[GSADNH] (where H is the active site residue);

Consensus patent #3: [FYCH]-[WI]-[LIVT]-x-[KRQAG]-N-[ST]-W-x(3)-[FYW]- G-x(2)-G- [LFYW]-[LIVMFYG]-x-[LIVMF] (where N is the active site residue). k) Phorbol Esters/Diacylglvcerol Binding (DAG_PE_bind). SEQ ID NO:4659, and thus the sequence it validates, represents a polynucleotide encoding a protein belonging to the family including phorbol esters/diacylglycerol binding proteins. Diacylglycerol (DAG) is an important second messenger. Phorbol esters (PE) are analogues of DAG and potent tumor promoters that cause a variety of physiological changes when administered to both cells and tissues. DAG activates a family of serine/threonine protein kinases, collectively known as protein kinase C (PKC) (Azzi et al, Eur. J. Biochem. (1992) 203:547). Phorbol esters can directly stimulate PKC. The N-terminal region of PKC, known as Cl, has been shown (Ono et al., Proc. Natl. Acad. Sci. USA (1989) 36:4868) to bind PE and DAG in a phospholipid and zinc-dependent fashion. The Cl region contains one or two copies (depending on the isozyme of PKC) of a cysteine-rich domain about 50 amino-acid residues long and essential for DAG/PE-binding. Such a domain has also been found in, for example, the following proteins.

(1) Diacylglycerol kinase (EC 2.7.1.107) (DGK) (Sakane et al, Nature (1990) 344:345), the enzyme that converts DAG into phosphatidate. It contains two copies of the DAG/PE-binding domain in its N-terminal section. At least five different forms of DGK are known in mammals; and

(2) N-chimaerin, a brain specific protein which shows sequence similarities with the BCR protein at its C-terminal part and contains a single copy of the DAG/PE-binding domain at its N-terminal part. It has been shown (Ahmed et al, Biochem. J. (1990)

272:161, and Ahmed et al, Biochem. J. (1991) 230:233) to be able to bind phorbol esters. The DAG/PE-binding domain binds two zinc ions; the ligands of these metal ions are probably the six cysteines and two histidines that are conserved in this domain. The signature pattern completely spans the DAG/PE domain. The consensus pattern is: H-x- [LIVMFYW]-x(8,l l)-C-x(2)-C-x(3)-[LIVMFC]-x(5,10)-C-x(2)-C-x(4)-[HD]-x(2)-C- x(5,9)-C. All the C and H are probably involved in binding zinc.

1) DEAD and DEAH box families ATP-dependent helicases signatures (Dead box helic). SEQ ID NOS:4821 and 5083, and thus the sequences they validate, represent polynucleotides encoding a novel member of the DEAD box family. A number of eukaryotic and prokaryotic proteins have been characterized (Schmid S.R., et al, Mol. Microbiol. (1992) 6:283; Linder P., et al., Nature (1989) 337:121; Wassarman D.A., et al., Nature (1991) 349:463) on the basis of their stmctural similarity. All are involved in ATP- dependent, nucleic-acid unwinding. Proteins currently known to belong to this family are:

1) Initiation factor eIF-4A. Found in eukaryotes, this protein is a subunit of a high molecular weight complex involved in 5 'cap recognition and the binding of mRNA to ribosomes. It is an ATP-dependent RNA-helicase.

2) PRP5 and PRP28. These yeast proteins are involved in various ATP-requiring steps of the pre-mRNA splicing process. 3) PI 10, a mouse protein expressed specifically during spermatogenesis.

4) An3, a Xenopus putative RNA helicase, closely related to PI 10.

5) SPP81/DED1 and DBPl, two yeast proteins involved in pre-mRNA splicing and related to PI 10. 6) Caenorhabditis elegans helicase glh-1.

7) MSS116, a yeast protein required for mitochondrial splicing.

8) SPB4, a yeast protein involved in the maturation of 25 S ribosomal RNA.

9) p68, a human nuclear antigen. p68 has ATPase and DNA-helicase activities in vitro. It is involved in cell growth and division. 10) Rm62 (p62), a Drosophila putative RNA helicase related to p68.

11) DBP2, a yeast protein related to p68.

12) DHH1, a yeast protein.

13) DRS1, a yeast protein involved in ribosome assembly.

14) MAK5, a yeast protein involved in maintenance of dsRNA killer plasmid. 15) ROK 1 , a yeast protein.

16) stel3, a fission yeast protein.

17) Vasa, a Drosophila protein important for oocyte formation and specification of embryonic posterior stmctures.

18) Me31B, a Drosophila maternally expressed protein of unknown function. 19) dbpA, an Escherichia coli putative RNA helicase.

20) deaD, an Escherichia coli putative RNA helicase which can suppress a mutation in the φsB gene for ribosomal protein S2.

21) rhlB, an Escherichia coli putative RNA helicase.

22) rhlE, an Escherichia coli putative RNA helicase. 23) rmB, an Escherichia coli protein that shows RNA-dependent ATPase activity, which interacts with 23 S ribosomal RNA.

24) Caenorhabditis elegans hypothetical proteins T26G10.1, ZK512.2 and ZK686.2.

25) Yeast hypothetical protein YHR065c. 26) Yeast hypothetical protein YHR169w.

27) Fission yeast hypothetical protein SpAC31A2.07c.

28) Bacillus subtilis hypothetical protein yxiN. All of the above proteins share a number of conserved sequence motifs. Some of them are specific to this family while others are shared by other ATP-binding proteins or by proteins belonging to the helicases 'superfamily' (Hodgman T.C., Nature (1988) 333:22 and Nature (1988) 333:578 (Errata); http://www.expasy.ch/www/linder/HELICASES_TEXT.html). One of these motifs, called the 'D-E-A-D-box', represents a special version of the B motif of ATP-binding proteins. Some other proteins belong to a subfamily which have His instead of the second Asp and are thus said to be 'D-E-A-H-box' proteins (Wassarman D.A., et al., Nature (1991) 349:463; Harosh I., et al., Nucleic Acids Res. (1991) 79:6331; Koonin E.V., et al., J. Gen. Virol. (1992) 73:989; http://www.expasy.ch/www/linder/HELICASES_TEXT.html). Proteins currently known to belong to this DEAH subfamily are:

1) PRP2, PRP 16, PRP22 and PRP43. These yeast proteins are all involved in various ATP -requiring steps of the pre-mRNA splicing process. 2) Fission yeast prhl, which my be involved in pre-mRNA splicing. 3) Male-less (mle), a Drosophila protein required in males, for dosage compensation of X chromosome linked genes. 4) RAD3 from yeast. RAD3 is a DNA helicase involved in excision repair of DNA damaged by UV light, bulky adducts or cross-linking agents. Fission yeast radl5 (rhp3) and mammalian DNA excision repair protein XPD (ERCC-2) are the homologs of RAD3. 5) Yeast CHL1 (or CTF1), which is important for chromosome transmission and normal cell cycle progression in G(2)/M. 6) Yeast TPSl. 7) Yeast hypothetical protein YKL078w. 8) Caenorhabditis elegans hypothetical proteins C06E1.10 and K03H1.2. 9) Poxviruses' early transcription factor 70 Kd subunit which acts with RNA polymerase to initiate transcription from early gene promoters. 10) 18, a putative vaccinia vims helicase. 11) hφA, an Escherichia coli putative RNA helicase. The following signature patterns are used to identify member for both subfamilies:

Consensus pattern: [LIVMF](2)-D-E-A-D-[RKEN]-x-[LIVMFYGSTN] Consensus pattern: [GSAH]-x-[LIVMF](3)-D-E-[ALIV]-H-[NECR]. m) EF Hand (EFhand). Several of the validation sequences, and thus the sequences they validate, correspond to polynucleotides encoding a novel protein in the family of EF- hand proteins. Many calcium-binding proteins belong to the same evolutionary family and share a type of calcium-binding domain known as the EF-hand (Kawasaki et al, Protein. Prof. (1995) 2:305-490). This type of domain consists of a twelve residue loop flanked on both sides by a twelve residue alpha-helical domain. In an EF-hand loop the calcium ion is coordinated in a pentagonal bipyramidal configuration. The six residues involved in the binding are in positions 1, 3, 5, 7, 9 and 12; these residues are denoted by X, Y, Z, -Y, -X and -Z. The invariant Glu or Asp at position 12 provides two oxygens for liganding Ca (bidentate ligand). Proteins known to contain EF-hand regions include: Calmodulin (Ca=4, except in yeast where Ca=3) ("Ca=" indicates approximate number of EF-hand regions); diacylglycerol kinase (EC 2.7.1.107) (DGK) (Ca=2); 2) FAD-dependent glycerol-3- phosphate dehydrogenase (EC 1.1.99.5) from mammals (Ca=l); guanylate cyclase activating protein (GCAP) (Ca=3); MIF related proteins 8 (MRP-8 or CFAG) and 14 (MRP- 14) (Ca=2); myosin regulatory light chains (Ca=l); oncomodulin (Ca=2); osteonectin (basement membrane protein BM-40) (SPARC); and proteins that contain an "osteonectin" domain (QR1, matrix glycoprotein SCI).

The consensus pattern includes the complete EF-hand loop as well as the first residue which follows the loop and which seem to always be hydrophobic: D-x-[DNS]- {ILVFYW}-[DENSTG]-[DNQGHRK]-{GP}-[LIVMC]-[DENQSTAGC]-x(2)-[DE]- [LIVMFYW]. n) Ets Domain fEts Nterm). SEQ ID NO:2849, and thus the sequence it validates, represents a polynucleotide encoding a polypeptide with N-terminal homology in ETS domain. Proteins of this family contain a conserved domain, the "ETS-domain," that is involved in DNA binding. The domain appears to recognize purine-rich sequences; it is about 85 to 90 amino acids in length, and is rich in aromatic and positively charged residues (Wasylyk, et al., , Eur. J. Biochem. (1993) 277:718).

The ets gene family encodes a novel class of DNA-binding proteins, each of which binds a specific DNA sequence. These proteins comprise an ets domain that specifically interacts with sequences containing the common core tri-nucleotide sequence GGA. In addition to an ets domain, native ets proteins comprise other sequences which can modulate the biological specificity of the protein. Ets genes and proteins are involved in a variety of essential biological processes including cell growth, differentiation and development, and three members are implicated in oncogenic process. o) Type II fϊbronectin collagen-binding domain (Fntvpell). A few of the validation sequences, and thus the sequences they validate, represent polynucleotides encoding a polypeptide having a type II fibronectin collagen binding domain. Fibronectin is a plasma protein that binds cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. The major part of the sequence of fibronectin consists of the repetition of three types of domains, which are called type I, II, and III (Skorstengaard K., et al., Eur. J. Biochem. (1986) 767:441). Type II domain is approximately forty residues long, contains four conserved cysteines involved in disulfide bonds and is part of the collagen-binding region of fibronectin. In fibronectin the type II domain is duplicated. Type II domains have also been found in the following proteins: 1) blood coagulation factor XII (Hageman factor) (1 copy); 2) bovine seminal plasma proteins PDC-109 (BSP-A1/A2) and BSP-A3 (Seidah N.G., et al., Biochem. J. (1987) 243:195. (twice); 3) cation-independent mannose- 6-phosphate receptor (which is also the insulin-like growth factor II receptor) Komfeld S., Annu. Rev. Biochem. (1992) 67:307) (1 copy); 4) Mannose receptor of macrophages (Taylor M.E., et al., J Biol. Chem. (1990) 265:12156) (1 copy); 5) 180 Kd secretory phospholipase A2 receptor (1 copy) Lambeau G., et al., J Biol. Chem. (1994) 269:1575; 6) DEC-205 receptor (1 copy); 6) Jiang W., et al., Nature (1995) 375:151); 7) 72 Kd type IV collagenase (EC 3.4.24.24) (MMP-2) (Collier I.E., et al., J. Biol. Chem. (1988) 263:6579) (3 copies); 7) 92 Kd type IV collagenase (EC 3.4.24.24) (MMP-9) (3 copies); 8)

Hepatocyte growth factor activator (Miyazawa K., et al., J. Biol. Chem. (1993) 263:10024) (1 copy).

A schematic representation of the position of the invariant residues and the topology of the disulfide bonds in fibronectin type II domain is shown below: xxCxxPFx#xxxxxxxCxxxxxxxxWCxxxxx#xxx#x#Cxx where 'C represents the conserved cysteine involved in a disulfide bond and '#' represents a large hydrophobic residue. The consensus pattern for identifying members of this family, which pattern spans this entire domain, is: C-x(2)-P-F-x-[FYWI]-x(7)-C-x(8,10)-W-C- x(4)-[DNSR]-[FYW]- x(3,5)-[FYW]-x-[FYWI]-C (where the four C's are involved in disulfide bonds). p) G-Protein Alpha Subunit (G-alpha). Several of the validation sequences, and thus the sequences they validate, correspond to a gene encoding a novel polypeptide of the G-protein alpha subunit family. Guanine nucleotide binding proteins (G-proteins) are a family of membrane-associated proteins that couple extracellularly-activated integral- membrane receptors to intracellular effectors, such as ion channels and enzymes that vary the concentration of second messenger molecules. G-proteins are composed of 3 subunits (alpha, beta and gamma) which, in the resting state, associate as a trimer at the inner face of the plasma membrane. The alpha subunit has a molecule of guanosine diphosphate (GDP) bound to it. Stimulation of the G-protein by an activated receptor leads to its exchange for GTP (guanosine triphosphate). This results in the separation of the alpha from the beta and gamma subunits, which always remain tightly associated as a dimer. Both the alpha and beta-gamma subunits are then able to interact with effectors, either individually or in a cooperative manner. The intrinsic GTPase activity of the alpha subunit hydrolyses the bound GTP to GDP. This returns the alpha subunit to its inactive conformation and allows it to reassociate with the beta-gamma subunit, thus restoring the system to its resting state. G-protein alpha subunits are 350-400 amino acids in length and have molecular weights in the range 40-45 kDa. Seventeen distinct types of alpha subunit have been identified in mammals. These fall into 4 main groups on the basis of both sequence similarity and function: alpha-s, alpha-q, alpha-i and alpha-12 (Simon et al, Science (1993) 252:802). Many alpha subunits are substrates for ADP-ribosylation by cholera or pertussis toxins. They are often N-terminally acylated, usually with myristate and/or palmitoylate, and these fatty acid modifications are probably important for membrane association and high- affinity interactions with other proteins. The atomic stmcture of the alpha subunit of the G-protein involved in mammalian vision, transducin, has been elucidated in both GTP- and GDB-bound forms, and shows considerable similarity in both primary and tertiary stmcture in the nucleotide-binding regions to other guanine nucleotide binding proteins, such as p21 -ras and EF-Tu. q) Helicases conserved C-terminal domain (helicase C). SEQ ID NOS:2503, 4469, and 5020, and thus the sequences they validate, represent polynucleotides encoding novel members of the DEAD/H helicase family. The DEAD and DEAH families are described above. r) Homeobox domain (homeobox). SEQ ID NO: 4241, and thus the sequence it validates, represents a polynucleotide encoding a protein having a homeobox domain. The 'homeobox' is a protein domain of 60 amino acids (Gehring In: Guidebook to the Homebox Genes, Duboule D., Ed., ppl-10, Oxford University Press, Oxford, (1994); Buerglin In: Guidebook to the Homebox Genes, pp25-72, Oxford University Press, Oxford, (1994); Gehring Trends Biochem. Sci. (1992) 77:277-280; Gehring et alAnnu. Rev. Genet. (1986) 20:147-173; Schofield Trends Neurosci. (1987) 70:3-6; http://copan.bioz.unibas.ch/ homeo.html) first identified in number of Drosophila homeotic and segmentation proteins. It is extremely well conserved in many other animals, including vertebrates. This domain binds DNA through a helix-tum-helix type of structure. Several proteins that contain a homeobox domain play an important role in development. Most of these proteins are sequence-specific DNA-binding transcription factors. The homeobox domain is also very similar to a region of the yeast mating type proteins. These are sequence-specific DNA- binding proteins that act as master switches in yeast differentiation by controlling gene expression in a cell type-specific fashion.

A schematic representation of the homeobox domain is shown below. The helix- turn-helix region is shown by the symbols Η' (for helix), and 't' (for turn).

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxHHHHHHHHtttHHHHHHHHHxxxxxxxxxx

1 60

The pattern detects homeobox sequences 24 residues long and spans positions 34 to 57 of the homeobox domain. The consensus pattern is as follows: [LIVMFYG]-[ASLVR]-x(2)- [LIVMSTACN]-x-[LIVM]-x(4)-[LIV]-[RKNQESTAIY]-[LIVFSTNKH]-W-[FYVC]-x- [NDQTAH]-x(5)-[RKNAIMW]. x) MAP kinase kinase (mkk). Several validation sequences, and thus the sequences they validate, represent novel members of the MAP kinase kinase family. MAP kinases (MAPK) are involved in signal transduction, and are important in cell cycle and cell growth controls. The MAP kinase kinases (MAPKK) are dual-specificity protein kinases which phosphorylate and activate MAP kinases. MAPKK homologues have been found in yeast, invertebrates, amphibians, and mammals. Moreover, the MAPKK/MAPK phosphorylation switch constitutes a basic module activated in distinct pathways in yeast and in vertebrates. MAPKK regulation studies have led to the discovery ofat least four MAPKK convergent pathways in higher organisms. One of these is similar to the yeast pheromone response pathway which includes the stel 1 protein kinase. Two other pathways require the activation of either one or both of the serine/threonine kinase-encoded oncogenes c-Raf-1 and c-Mos. Additionally, several studies suggest a possible effect of the cell cycle control regulator cyclin-dependent kinase 1 (cdc2) on MAPKK activity. Finally, MAPKKs are apparently essential transducers through which signals must pass before reaching the nucleus. For review, see, e.g., Biologique Biol Cell (1993) 79:193-207; Nishida et al, Trends Biochem Sci (1993) 73:128-31; Ruderman Curr Opin Cell Biol (1993) 5:207-13; Dhanasekaran et al, Oncogene (1998) 77:1447-55; Kiefer et al, Biochem Soc Trans (1997) 25:491-8; and Hill, Cell Signal (1996) 3:533-44. y) 3'5'-cyclic nucleotide phosphodiesterases signature (PDEase). SEQ ID NO:4482, and thus the sequence it validates, represents a polynucleotide encoding a novel 3'5'-cyclic nucleotide phosphodiesterases (PDEases). PDEases catalyze the hydrolysis of cAMP or cGMP to the corresponding nucleoside 5' monophosphates (Charbonneau H., et al, Proc. Natl Acad. Sci. U.S.A. (1986) 33:9308). There are at least seven different subfamilies of PDEases (Beavo J.A., et al., Trends Pharmacol. Sci. (1990) 77:150; http://weber.u.washington.edu/~pde/: 1) Type 1, calmodulin/calcium-dependent PDEases; 2) Type 2, cGMP-stimulated PDEases; 3) Type 3, cGMP-inhibited PDEases; 4) Type 4, cAMP-specific PDEases.; 5) Type 5, cGMP-specific PDEases; 6) Type 6, rhodopsin- sensitive cGMP-specific PDEases; and 7) Type 7, High affinity cAMP-specific PDEases. All PDEase forms share a conserved domain of about 270 residues. The signature pattern is determined from a stretch of 12 residues that contains two conserved histi dines: H-D-[LIVMFY]-x-H-x-[AG]-x(2)-[NQ]-x-[LIVMFY]. z) Protein Kinase (protkinase). Several validation sequences, and thus the sequences they validate, represent polynucleotides encoding protein kinases. Protein kinases catalyze phosphorylation of proteins in a variety of pathways, and are implicated in cancer. Eukaryotic protein kinases (Hanks S.K., et al., FASEB J. (1995) 9:576; Hunter T., Meth. Enzymol (1991) 200:3; Hanks S.K., et al, Meth. Enzymol (1991) 200:38; Hanks S.K., Curr. Opin. Struct. Biol (1991) 7:369; Hanks S.K., et al, Science (1988) 247:42) are enzymes that belong to a very extensive family of proteins which share a conserved catalytic core common to both serine/threonine and tyrosine protein kinases. There are a number of conserved regions in the catalytic domain of protein kinases. Two of the conserved regions are the basis for the signature pattern in the protein kinase profile. The first region, which is located in the N-terminal extremity of the catalytic domain, is a glycine-rich stretch of residues in the vicinity of a lysine residue, which has been shown to be involved in ATP binding. The second region, which is located in the central part of the catalytic domain, contains a conserved aspartic acid residue which is important for the catalytic activity of the enzyme (Knighton D.R., et al, Science (1991) 253:407). The protein kinase profile includes two signature patterns for this second region: one specific for serine/threonine kinases and the other for tyrosine kinases. A third profile is based on the alignment in (Hanks S.K., et al, FASEB J. (1995) 9:576) and covers the entire catalytic domain. The consensus patterns are as follows: 1) Consensus pattern: [LIV]-G-{P}-G-{P}-[FYWMGSTNH]-[SGA]-{PW}- [LIVCAT]-{PD}-x-[GSTACLIVMFY]-x(5,18)-[LIVMFYWCSTAR]-[AIVP]- [LIVMFAGCKR]-K, where K binds ATP. The majority of known protein kinases are detected by this pattern. Proteins kinases that are not detected by this consensus include viral kinases, which are quite divergent in this region and are completely missed bythis pattern.

2) Consensus pattern: [LIVMFYC]-x-[HY]-x-D-[LIVMFY]-K-x(2)-N- [LIVMFYCT](3), where D is an active site residue. This consensus sequence identifies most serine/threonine-specific protein kinases with only 10 exceptions. Half of the exceptions are viral kinases, while the other exceptions include Epstein-Barr virus BGLF4 and Drosophila ninaC, which have Ser and Arg, respectively, instead of the conserved Lys. These latter two protein kinases are detected by the tyrosine kinase specific pattern described below.

3) Consensus pattern: [LIVMFYC]-x-[HY]-x-D-[LIVMFY]-[RSTAC]-x(2)-N- [LIVMFYC], where D is an active site residue. All tyrosine-specific protein kinases are detected by this consensus pattern, with the exception of human ERBB3 and mouse blk. This pattern also detects most bacterial aminoglycoside phosphotransferases (Benner S., Nature (1987) 329:21; Kirby R., J. Mol Evol. (1992) 30:489) and heφesviruses ganciclovir kinases (Littler E., et al, Nature (1992) 353:160), which are structurally and evolutionary related to protein kinases.

The protein kinase profile also detects receptor guanylate cyclases and 2-5A- dependent ribonucleases. Sequence similarities between these two families and the eukaryotic protein kinase family have been noticed previously. The profile also detects Arabidopsis thaliana kinase-like protein TMKL1 which seems to have lost its catalytic activity.

If a protein analyzed includes the two of the above protein kinase signatures, the probability of it being a protein kinase is close to 100%. Eukaryotic-type protein kinases have also been found in prokaryotes such as Myxococcus xanthus (Munoz-Dorado J., et al, Cell (1991) 67:995) and Yersinia pseudotuberculosis. The patterns shown above has been updated since their publication in (Bairoch A., et al. , Nature (1988) 337 :22). aa) Ras family proteins (ras). SEQ IDNO:3671, and thus the sequence it validates, represent polynucleotides encoding the ras family of small GTP/GDP-binding proteins (Valencia et al., 1991, Biochemistry 30:4637-4648). Ras family members generally require a specific guanine nucleotide exchange factor (GEF) and a specific GTPase activating protein (GAP) as stimulators of overall GTPase activity. Among ras-related proteins, the highest degree of sequence conservation is found in four regions that are directly involved in guanine nucleotide binding. The first two constitute most of the phosphate and Mg2+ binding site (PM site) and are located in the first half of the G-domain. The other two regions are involved in guanosine binding and are located in the C-terminal half of the molecule. Motifs and conserved stmctural features of the ras-related proteins are described in Valencia et al., 1991, Biochemistry 30:4637-4648.

A major consensus pattern of ras proteins is: D-T-A-G-Q-E-K-[LF]-G-G-L-R- [DE]-G-Y-Y. bb) Thioredoxin family active site (Thioredox). SEQ ID NO:3936, and thus the sequence it validates, represent a polynucleotide encoding a protein having a thioredoxin family active site. Thioredoxins (Holmgren A., Annu. Rev. Biochem. (1985) 54:237; Gleason F.K., et al., FEMS Microbiol Rev. (1988) 54:271; Holmgren A. J Biol. Chem. (1989) 264:13963; Eklund H., et al. Proteins (1991) 77:13) are small proteins of approximately one hundred amino- acid residues which participate in various redox reactions via the reversible oxidation of an active center disulfide bond. They exist in either a reduced form or an oxidized form where the two cysteine residues are linked in an intramolecular disulfide bond. Thioredoxin is present in prokaryotes and eukaryotes and the sequence around the redox-active disulfide bond is well conserved.

A number of eukaryotic proteins contain domains evolutionary related to thioredoxin, and all of them are protein disulphide isomerases (PDI). PDI (Freedman R.B., et al., Biochem. Soc. Trans. (1988) 76:96; Kivirikko K.I., et al., FASEB J. (1989) 3:1609; Freedman R.B., et al. Trends Biochem. Sci. (1994) 79:331) is an endoplasmic reticulum enzyme that catalyzes the rearrangement of disulfide bonds in various proteins. The various forms of PDI which are currently known are: 1) PDI major isozyme; a multifunctional protein that also function as the beta subunit of prolyl 4-hydroxylase (EC 1.14.11.2), as a component of oligosaccharyl transferase (EC 2.4.1.119), as thyroxine deiodinase, as glutathione-insulin transhydrogenase, and as a thyroid hormone-binding protein; 2) ERp60 (ER-60; 58 Kd microsomal protein), which is a protease; 3) ERp72; and 4) P5.

All PDI contains two or three (ERp72) copies of the thioredoxin domain. The consensus pattern is: [LIVMF]-[LIVMSTA]-x-[LIVMFYC]-[FYWSTHE]-x(2)- [FYWGTN]-C- [GATPLVE]-[PHYWSTA]-C-x(6)-[LIVMFYWT] (where the two C's form the redox-active bond. cc) TNFR/NGFR family cvsteine-rich region (TNFR c6). SEQ ID NO:3927, and thus the sequence it validates, represent a polynucleotide encoding a protein having a TNFR/NGFR family cysteine-rich region. A number of proteins, some of which are known to be receptors for growth factors, have been found to contain a cysteine-rich domain of about 110 to 160 amino acids in their N-terminal part, that can be subdivided into four (or in some cases, three) modules of about 40 residues containing 6 conserved cysteines. Proteins known to belong to this family (Mallet S., et al., Immunol Today (1991) 12:220; Sprang S.R., Trends Biochem. Sci. (1990) 15:366; Krammer P.H., et al., Curr. Biol. (1992) 2:383; Bazan J.F., Curr. Biol. (1993) 3:603) are: 1) Tumor Necrosis Factor type I and type II receptors (TNFR) (Both receptors bind TNF-alpha and TNF-beta, but are only similar in the cysteine-rich region.); 2) Shope fibroma vims soluble TNF receptor (protein T2); 3) Lymphotoxin alpha/beta receptor; 4) Low-affinity nerve growth factor receptor (LA-NGFR); 5) CD40 (Bp50), the receptor for the CD40L (or TRAP) cytokine; 6) CD27, the receptor for the CD27L cytokine; 8) CD30, the receptor for the CD30L cytokine; 9) T-cell protein 4- IBB, the receptor for the 4-1BBL putative cytokine; 10) FAS antigen (or APO-1), the receptor for FASL, a protein involved in apoptosis (programmed cell death); 11) T-cell antigen OX40, the receptor for the OX40L cytokine; 12) Wsl-1, a receptor (for a yet undefined ligand) that mediates apoptosis; 13) Vaccinia vims protein A53 (SalF19R).

The six cysteines all involved in intrachain disulfide bonds (Banner D.W., et al, Cell (1993) 73:431). A schematic representation of the stmcture of the 40 residue module of these receptors is shown below: xCxxxxxxxxxxxxxCxCxxCxxxxxxxxxCxxxxCxx where 'C represents the conserved cysteine involved in a disulfide bond. The signature pattern for the cysteine-rich region is based mainly on the position of the six conserved cysteines in each of the repeats: Consensus pattern: C-x(4,6)-[FYH]-x(5,10)-C-x(0,2)-C- x(2,3)-C-x(7,l l)-C-x(4,6)-[DNEQSKP]-x(2)-C (where the six C's are involved in disulfide bonds). dd) Four Transmembrane Integral Membrane Proteins (transmembrane4). Several of the validation sequences, and thus the sequences they validate, correspond to a sequence encoding a polypeptide that is a member of the 4 transmembrane segments integral membrane protein family (transmembrane 4 family). The transmembrane 4 family of proteins includes a number of evolutionarily-related eukaryotic cell surface antigens (Levy et al, J. Biol. Chem., (1991) 266:14597; Tomlinson et al, Eur. J. Immunol (1993) 23:136; Barclay et al. The leucocyte antigen factbooks. (1993) Academic Press, London/San Diego). The proteins belonging to this family include: 1) Mammalian antigen CD9

(MIC3), which is involved in platelet activation and aggregation; 2) Mammalian leukocyte antigen CD37, expressed on B lymphocytes; 3) Mammalian leukocyte antigen CD53 (OX- 44), which is implicated in growth regulation in hematopoietic cells; 4) Mammalian lysosomal membrane protein CD63 (melanoma-associated antigen ME491; antigen AD1); 5) Mammalian antigen CD81 (cell surface protein TAPA-1), which is implicated in regulation of lymphoma cell growth; 6) Mammalian antigen CD82 (protein R2; antigen C33; Kangai 1 (KAI1)), which associates with CD4 or CD8 and delivers costimulatory signals for the TCR/CD3 pathway; 7) Mammalian antigen CD151 (SFA-1; platelet- endothelial tetraspan antigen 3 (PETA-3)); 8) Mammalian cell surface glycoprotein A15 (TALLA- 1 ; MXS 1 ); 9) Mammalian novel antigen 2 (NAG-2); 10) Human tumor- associated antigen CO-029; 1 1) Schistosoma mansoni and japonicum 23 Kd surface antigen (SM23 / SJ23).

The members of the 4 transmembrane family share several characteristics. First, they all are apparently type III membrane proteins, which are integral membrane proteins containing an N-terminal membrane-anchoring domain which is not cleaved during biosynthesis and which functions both as a translocation signal and as a membrane anchor. The family members also contain three additional transmembrane regions, at least seven conserved cysteines residues, and are of approximately the same size (218 to 284 residues). These proteins are collectively know as the "transmembrane 4 superfamily" (TM4) because they span plasma membrane four times.

A schematic diagram of the domain stmcture of these proteins is as follows: +.+ + + — + + + + +- — +

1 1 TMa I Extra | TM2| Cyt | TM3 | Extracellular | TM4 | Cyt|

+.+. — + + — c C + CC C- — C—+- — C — +

where Cyt is the cytoplasmic domain, TMa is the transmembrane anchor; TM2 to TM4 represents transmembrane regions 2 to 4, 'C are conserved cysteines, and '* 'indicates the position of the consensus pattern. The consensus pattern spans a conserved region including two cysteines located in a short cytoplasmic loop between two transmembrane domains: Consensus pattern: G-x(3)-[LIVMF]-x(2)-[GSA]-[LIVMF](2)-G-C-x-[GA]- [STA]- x(2)-[EG]-x(2)-[CWN]-[LIVM](2). ee) Trypsin (trypsin). SEQ ID NOS:3381, 4684, and 4688, and thus the sequences they validate, correspond to novel serine proteases of the trypsin family. The catalytic activity of the serine proteases from the trypsin family is provided by a charge relay system involving an aspartic acid residue hydrogen-bonded to a histidine, which itself is hydrogen- bonded to a serine. The sequences in the vicinity of the active site serine and histidine residues are well conserved in this family of proteases (Brenner S., Nature (1988) 334:528). Proteases known to belong to the trypsin family include: 1) Acrosin; 2) Blood coagulation factors VII, IX, X, XI and XII, thrombin, plasminogen, and protein C; 3) Cathepsin G; 4) Chymotrypsins; 5) Complement components Clr, Cls, C2, and complement factors B, D and I; 6) Complement-activating component of RA-reactive factor; 7) Cytotoxic cell proteases (granzymes A to H); 8) Duodenase I; 9) Elastases 1, 2, 3A, 3B (protease E), leukocyte (medullasin).; 10) Enterokinase (EC 3.4.21.9) (enteropeptidase); 11) Hepatocyte growth factor activator; 12) Hepsin; 13) Glandular (tissue) kallikreins (including EGF-binding protein types A, B, and C, NGF-gamma chain, gamma-renin, prostate specific antigen (PSA) and tonin); 14) Plasma kallikrein; 15) Mast cell proteases (MCP) 1 (chymase) to 8; 16) Myeloblastin (proteinase 3) (Wegener's autoantigen); 17) Plasminogen activators (urokinase-type, and tissue-type); 18) Trypsins I, II, III, and IV; 19) Tryptases; 20) Snake venom proteases such as ancrod, batroxobin, cerastobin, flavoxobin, and protein C activator; 21) Collagenase from common cattle gmb and collagenolytic protease from Atlantic sand fiddler crab; 22) Apolipoprotein(a); 23) Blood fluke cercarial protease; 24) Drosophila trypsin like proteases: alpha, easter, snake- locus; 25) Drosophila protease stubble (gene sb); and 26) Major mite fecal allergen Der p III. All the above proteins belong to family SI in the classification of peptidases (Rawlings N.D., et al, Meth. Enzymol. (1994) 244:19; http://www.expasy.ch/cgi- bin/lists 7peptidas.txt) and originate from eukaryotic species. It should be noted that bacterial proteases that belong to family S2A are similar enough in the regions of the active site residues that they can be picked up by the same patterns.

The consensus patterns for this trypsin protein family are: 1) [LIVM]-[ST]-A- [STAGJ-H-C, where H is the active site residue. All sequences known to belong to this class detected by the pattern, except for complement components Clr and Cls, pig plasminogen, bovine protein C, rodent urokinase, ancrod, gyroxin and two insect trypsins; 2) [DNSTAGC]-[GSTAPIMVQH]-x(2)-G-[DE]-S-G-[GS]-[SAPHV]- [LIVMFYWH]-

[LIVMFYSTANQH], where S is the active site residue. All sequences known to belong to this family are detected by the above consensus sequences, except for 18 different proteases which have lost the first conserved glycine. If a protein includes both the serine and the histidine active site signatures, the probability of it being a trypsin family serine protease is 100%. ff) WD Domain, G-Beta Repeats (WD domain). A few of the validation sequences, and the sequences they validate, represent novel members of the WD domain/G-beta repeat family. Beta-transducin (G-beta) is one of the three subunits (alpha, beta, and gamma) of the guanine nucleoti de-binding proteins (G proteins) which act as intermediaries in the transduction of signals generated by transmembrane receptors

(Gilman, Annu. Rev. Biochem. (1987) 56:615). The alpha subunit binds to and hydrolyzes GTP; the functions of the beta and gamma subunits are less clear but they seem to be required for the replacement of GDP by GTP as well as for membrane anchoring and receptor recognition. In higher eukaryotes, G-beta exists as a small multigene family of highly conserved proteins of about 340 amino acid residues. Structurally, G-beta consists of eight tandem repeats of about 40 residues, each containing a central Tφ-Asp motif (this type of repeat is sometimes called a WD-40 repeat). Such a repetitive segment has been shown to exist in a number of other proteins including: human LIS1, a neuronal protein involved in type-1 lissencephaly; and mammalian coatomer beta' subunit (beta'-COP), a component of a cytosolic protein complex that reversibly associates with Golgi membranes to form vesicles that mediate biosynthetic protein transport.

The consensus pattern for the WD domain/G-Beta repeat family is: [LIVMSTAC]- [LIVMFYWSTAGC]-[LIMSTAG]-[LIVMSTAGC]-x(2)-[DN]-x(2)-[LIVMWSTAC]-x- [LIVMFSTAG]-W-[DEN]-[LIVMFSTAGCN]. gg) wnt Family of Developmental Signaling Proteins (Wnt dev sign). Several of the validation sequences, and thus the sequences they validate, correspond to novel members of the wnt family of developmental signaling proteins. Wnt-1 (previously known as int-1), the seminal member of this family, (Nusse R., Trends Genet. (1988) 4:291) is a proto-oncogene induced by the integration of the mouse mammary tumor vims. It is thought to play a role in intercellular communication and seems to be a signalling molecule important in the development of the central nervous system (CNS). The sequence of wnt-1 is highly conserved in mammals, fish, and amphibians. Wnt-1 was found to be a member of a large family of related proteins (Nusse R., et al, Cell (1992) 69:1073; McMahon A.P., Trends Genet. (1992) 3:1; Moon R.T., BioEssays (1993) 75:91) that are all thought to be developmental regulators. These proteins are known as wnt-2 (also known as iφ), wnt-3, - 3 A, -4, -5 A, -5B, -6, -7A, -7B, -8, -8B, -9 and -10. At least four members of this family are present in Drosophila; one of them, wingless (wg), is implicated in segmentation polarity. All these proteins share the following features characteristics of secretory proteins: a signal peptide, several potential N-glycosylation sites and 22 conserved cysteines that are probably involved in disulfide bonds. The Wnt proteins seem to adhere to the plasma membrane of the secreting cells and are therefore likely to signal over only few cell diameters. The consensus pattern, which is based upon a highly conserved region including three cysteines, is as follows: C-K-C-H-G-[LIVMT]-S-G-x-C. All sequences known to belong to this family are detected by the provided consensus pattern. hh) Protein Tyrosine Phosphatase (Y phosphatase). Several of the validation sequences, and thus the sequences they validate, represent a polynucleotide encoding a protein tyrosine kinase. Tyrosine specific protein phosphatases (EC 3.1.3.48) (PTPase) (Fischer et al, Science (1991) 253:401; Charbonneau et al, Annu. Rev. Cell Biol (1992) 3:463; Trowbridge, J. Biol. Chem. (1991) 266:23517; Tonks et al, Trends Biochem. Sci. (1989) 74:497; and Hunter, Cell (1989) 53:1013) catalyze the removal of a phosphate group attached to a tyrosine residue. These enzymes are very important in the control of cell growth, proliferation, differentiation and transformation. Multiple forms of PTPase have been characterized and can be classified into two categories: soluble PTPases and transmembrane receptor proteins that contain PTPase domain(s). Soluble PTPases include PTPN3 (HI) and PTPN4 (MEG), enzymes that contain an N-terminal band 4.1 -like domain and could act at junctions between the membrane and cytoskeleton; PTPN6 (PTP-1C; HCP; SHP) and PTPN11 (PTP-2C; SH-PTP3; Syp), enzymes that contain two copies of the SH2 domain at its N-terminal extremity. Dual specificity PTPases include DUSP 1 (PTPN 10; MAP kinase phosphatase- 1 ;

MKP-1) which dephosphorylates MAP kinase on both Thr- 183 and Tyr-185; and DUSP2 (PAC-1), a nuclear enzyme that dephosphorylates MAP kinases ERK1 and ERK2 on both Thr and Tyr residues.

Structurally, all known receptor PTPases are made up of a variable length extracellular domain, followed by a transmembrane region and a C-terminal catalytic cytoplasmic domain. Some of the receptor PTPases contain fibronectin type III (FN-III) repeats, immunoglobulin-like domains, MAM domains or carbonic anhydrase-like domains in their extracellular region. The cytoplasmic region generally contains two copies of the PTPAse domain. The first seems to have enzymatic activity, while the second is inactive but seems to affect substrate specificity of the first. In these domains, the catalytic cysteine is generally conserved but some other, presumably important, residues are not.

PTPase domains consist of about 300 amino acids. There are two conserved cysteines and the second one has been shown to be absolutely required for activity. Furthermore, a number of conserved residues in its immediate vicinity have also been shown to be important. The consensus pattern for PTPases is: [LIVMF]-H-C-x(2)-G-x(3)- [STC]-[STAGP]-x-[LIVMFY]; C is the active site residue. ii)Zinc Finger, C2H2 Type (Zincfing C2H2). Several of the validation sequences, and thus the sequences they validate, correspond to polynucleotides encoding novel members of the of the C2H2 type zinc finger protein family. Zinc finger domains (Klug et al, Trends Biochem. Sci. (1987) 72:464; Evans et al, Cell (1988) 52:1; Payre et al, FEBS Lett. (1988) 234:245; Miller et al, EMBOJ. (1985) 4:1609; and Berg, Proc. Natl. Acad. Sci. USA (1988) 35:99) are nucleic acid-binding protein stmctures first identified in the Xenopus transcription factor TFIIIA. These domains have since been found in numerous nucleic acid-binding proteins. A zinc finger domain is composed of 25 to 30 amino acid residues. Two cysteine or histidine residues are positioned at both extremities of the domain, which are involved in the tetrahedral coordination of a zinc atom. It has been proposed that such a domain interacts with about five nucleotides.

Many classes of zinc fingers are characterized according to the number and positions of the histidine and cysteine residues involved in the zinc atom coordination. In the first class to be characterized, called C2H2, the first pair of zinc coordinating residues are cysteines, while the second pair are histidines. A number of experimental reports have demonstrated the zinc-dependent DNA or RNA binding property of some members of this class.

Mammalian proteins having a C2H2 zipper include (number in parenthesis indicates number of zinc finger regions in the protein): basonuclin (6), BCL-6/LAZ-3 (6), erythroid krueppel-like transcription factor (3), transcription factors Spl (3), Sp2 (3), Sp3 (3) and Sp(4) 3, transcriptional repressor YYl (4), Wilms' tumor protein (4), EGRl/Krox24 (3), EGR2/Krox20 (3), EGR3/Pilot (3), EGR4/AT133 (4), Evi-1 (10), GLIl (5), GLI2 (4+), GLI3 (3+), HIV-EP1/ZNF40 (4), HIV-EP2 (2), KR1 (9+), KR2 (9), KR3 (15+), KR4 (14+), KR5 (11+), HF.12 (6+), REX-1 (4), ZfX (13), Zf (13), Zfp-35 (18), ZNF7 (15), ZNF8 (7), ZNF35 (10), ZNF42/MZF-1 (13), ZNF43 (22), ZNF46/Kup (2), ZNF76 (7), ZNF91 (36), ZNF133 (3). In addition to the conserved zinc ligand residues, it has been shown that a number of other positions are also important for the stmctural integrity of the C2H2 zinc fingers. (Rosenfeld et al, J. Biomol Struct. Dyn. (1993) 77:557) The best conserved position is found four residues after the second cysteine; it is generally an aromatic or aliphatic residue. The consensus pattern for C2H2 zinc fingers is: C-x(2,4)-C-x(3)-[LIVMFYWC]- x(8)-H-x(3,5)-H. The two C's and two H's are zinc ligands. ii) Zinc finger. C3HC4 type fRTNG finger), signature (Zincfing C3H4). SEQ ID NOS:3774 and 4477, and thus the sequences they validate, represent polynucleotides encoding a polypeptide having a C3HC4 type zinc finger signature. A number of eukaryotic and viral proteins contain this signature, which is primarily a conserved cysteine-rich domain of 40 to 60 residues (Borden K.L.B., et al., Curr. Opin. Struct. Biol. (1996) 6:395) that binds two atoms of zinc, and is probably involved in mediating protein- protein interactions. The 3D stmcture of the zinc ligation system is uniqueto the RING domain and is refered to as the "cross-brace" motif. The spacing of the cysteines in such a domain is C-x(2)-C-x(9 to 39)-C-x(l to 3)-H-x(2 to 3)-C-x(2)-C-x(4 to 48)-C-x(2)-C. Proteins that include the C3HC4 domain include:

1) Mammalian V(D)J recombination activating protein (RAG1). RAG1 activates the rearrangement of immunoglobulin and T-cell receptor genes.

2) Mouse φt-1. Rpt-1 is a trans-acting factor that regulates gene expression directed by the promoter region of the interleukin-2 receptor alpha chainor the LTR promoter region of HIV- 1.

3) Human rfp. Rfp is a developmentally regulated protein that may function in male germ cell development. Recombination of the N-terminal section of rfp with a protein tyrosine kinase produces the ret transforming protein.

4) Human 52 Kd Ro/SS-A protein. A protein of unknown function from the Ro/SS- A ribonucleoprotein complex. Sera from patients with systemic lupus erythematosus or primary Sjogren's syndrome often contain antibodies that react with the Ro proteins.

5) Human histocompatibility locus protein RINGl. 6) Human PML, a probable transcription factor. Chromosomal translocation ofPML with retinoic receptor alpha creates a fusion protein which is thecause of acute promyelocytic leukemia (APL).

7) Mammalian breast cancer type 1 susceptibility protein (BRCA1) ([El] http://bioinformatics.weizmann.ac.il/hotmolecbase/entries/brcal.htm). 8) Mammalian cbl proto-oncogene.

9) Mammalian bmi-1 proto-oncogene.

10) Vertebrate CDK-activating kinase (CAK) assembly factor MATl, a protein that stabilizes the complex between the CDK7 kinase and cyclin H (MATl stands for 'Menage A Trois'). 11) Mammalian mel-18 protein. Mel- 18 which is expressed in a variety of tumorcells is a transcriptional repressor that recognizes and bind a specific DNA sequence.

12) Mammalian peroxisome assembly factor- 1 (PAF-1) (PMP35), which is somewhat involved in the biogenesis of peroxisomes. In humans, defects in PAF-1 are responsible for a form of Zellweger syndrome, an autosomal recessivedisorder associated with peroxisomal deficiencies.

13) Human MATl protein, which interacts with the CDK7-cyclin H complex.

14) Human RINGl protein.

15) Xenopus XNF7 protein, a probable transcription factor. 16) Trypanosoma protein ESAG-8 (T-LR), which may be involved in the postranscriptional regulation of genes in VSG expression sites or may interact with adenylate cyclase to regulate its activity.

17) Drosophila proteins Posterior Sex Combs (Psc) and Suppressor two of zeste (Su(z)2). The two proteins belong to the Polycomb group of genes needed to maintain the segment-specific repression of homeotic selector genes.

18) Drosophila protein male-specific msl-2, a DNA-binding protein which is involved in X chromosome dosage compensation (the elevation of transcription of the male single X chromosome).

19) Arabidopsis thaliana protein COP1 which is involved in the regulation ofphotomoφhogenesis.

20) Fungal DNA repair proteins RAD5, RAD16, RAD18 and rad8.

21) Heφesvimses trans-acting transcriptional protein ICP0/IE110. This protein which has been characterized in many different heφesvimses is a trans-activator and/or - repressor of the expression of many viral and cellular promoters.

22) Baculovimses protein CG30.

23) Baculovimses major immediate early protein (PE-38).

24) Baculovimses immediate-early regulatory protein IE-N/IE-2. 25) Caenorhabditis elegans hypothetical proteins F54G8.4, R05D3.4 and T02C 1.1.

26) Yeast hypothetical proteins YER116c and YKR017c. The signature pattern for the C3HC4 finger is based on the central region of the domain:

Consensus pattern: C-x-H-x-[LIVMFY]-C-x(2)-C-[LIVMYA].

Example 4: Differential Expression of Polynucleotides of the Invention: Description of Libraries and Detection of Differential Expression

The relative expression levels of the polynucleotides of the invention was assessed in several libraries prepared from various sources, including cell lines and patient tissue samples. Table 4 provides a summary of these libraries, including the shortened library name (used hereafter), the mRNA source used to prepared the cDNA library, the "nickname" of the library that is used in the tables below (in quotes), and the approximate number of clones in the library.

Table 4 Description of cDNA Libraries

The KM12L4 and KM12C cell lines are described in Example 1 above. The MDA- MB-231 cell line was originally isolated from pleural effusions (Cailleau, J. Natl. Cancer. Inst. (1974) 53:661), is of high metastatic potential, and forms poorly differentiated adenocarcinoma grade II in nude mice consistent with breast carcinoma. The MCF7 cell line was derived from a pleural effusion of a breast adenocarcinoma and is non-metastatic. The MV-522 cell line is derived from a human lung carcinoma and is of high metastatic potential. The UCP-3 cell line is a low metastatic human lung carcinoma cell line; the MV-522 is a high metastatic variant of UCP-3. These cell lines are well-recognized in the art as models for the study of human breast and lung cancer (see, e.g., Chandrasekaran et al, Cancer Res. (1979) 39:870 (MDA-MB-231 and MCF-7); Gastpar et al. JMed Chem (1998) 47:4965 (MDA-MB-231 and MCF-7); Ranson et al, Br J Cancer (1998) 77:1586 (MDA-MB-231 and MCF-7); Kuang et al , Nucleic Acids Res (1998) 26: 1116 (MDA-MB- 231 and MCF-7); Varki et al, IntJ Cancer (1987) 40:46 (UCP-3); Varki et al, Tumour Biol. (1990) 77:327; (MV-522 and UCP-3); Varki et al , Anticancer Res. (1990) 70:637; (MV-522); Kelner et al, Anticancer Res (1995) 75:867 (MV-522); and Zhang et al, Anticancer Drugs (1997) 3:696 (MV522)). The samples of libraries 15-20 are derived from two different patients (UC#2, and UC#3). The bFGF-treated HMEC were prepared by incubation with bFGF at 1 Ong/ml for 2 hrs; the VEGF -treated HMEC were prepared by incubation with 20ng/ml BEGF for 2 hrs. Following incubation with the respective growth factor, the cells were washed and lysis buffer added for RNA preparation.

Each of the libraries is composed of a collection of cDNA clones that in turn are representative of the mRNAs expressed in the indicated mRNA source. In order to facilitate the analysis of the millions of sequences in each library, the sequences were assigned to clusters. The concept of "cluster of clones" is derived from a sorting/grouping of cDNA clones based on their hybridization pattern to a panel of roughly 300 7bp oligonucleotide probes (see Drmanac et al, Genomics (1996) 37(1):29). Random cDNA clones from a tissue library are hybridized at moderate stringency to 300 7bp oligonucleotides. Each oligonucleotide has some measure of specific hybridization to that specific clone. The combination of 300 of these measures of hybridization for 300 probes equals the "hybridization signature" for a specific clone. Clones with similar sequence will have similar hybridization signatures. By developing a sorting/grouping algorithm to analyze these signatures, groups of clones in a library can be identified and brought together computationally. These groups of clones are termed "clusters". Depending on the stringency of the selection in the algorithm (similar to the stringency of hybridization in a classic library cDNA screening protocol), the "purity" of each cluster can be controlled. For example, artifacts of clustering may occur in computational clustering just as artifacts can occur in "wet-lab" screening of a cDNA library with 400 bp cDNA fragments, at even the highest stringency. The stringency used in the implementation of cluster herein provides groups of clones that are in general from the same cDNA or closely related cDNAs. Closely related clones can be a result of different length clones of the same cDNA, closely related clones from highly related gene families, or splice variants of the same cDNA.

Differential expression for a selected cluster was assessed by first determining the number of cDNA clones corresponding to the selected cluster in the first library (Clones in 1^st), and the determining the number of cDNA clones corresponding to the selected cluster in the second library (Clones in 2^nd). Differential expression of the selected cluster in the first library relative to the second library is expressed as a "ratio" of percent expression between the two libraries. In general, the "ratio" is calculated by: 1) calculating the percent expression of the selected cluster in the first library by dividing the number of clones corresponding to a selected cluster in the first library by the total number of clones analyzed from the first library; 2) calculating the percent expression of the selected cluster in the second library by dividing the number of clones corresponding to a selected cluster in a second library by the total number of clones analyzed from the second library; 3) dividing the calculated percent expression from the first library by the calculated percent expression from the second library. If the "number of clones" corresponding to a selected cluster in a library is zero, the value is set at 1 to aid in calculation. The formula used in calculating the ratio takes into account the "depth" of each of the libraries being compared, i.e., the total number of clones analyzed in each library. In general, a polynucleotide is said to be significantly differentially expressed between two samples when the ratio value is greater than at least about 2, preferably greater than at least about 3, more preferably greater than at least about 5 , where the ratio value is calculated using the method described above. The significance of differential expression is determined using a z score test (Zar, Biostatistical Analysis, Prentice Hall, Inc., USA, "Differences between Proportions," pp 296-298 (1974).

Example 5: Polynucleotides Differentially Expressed in High Metastatic Potential Breast Cancer Cells Versus Low Metastatic Breast Cancer Cells A number of polynucleotide sequences have been identified that are differentially expressed between cells derived from high metastatic potential breast cancer tissue and low metastatic breast cancer cells. Expression of these sequences in breast cancer can be valuable in determining diagnostic, prognostic and/or treatment information. For example, sequences that are highly expressed in the high metastatic potential cells can be indicative of increased expression of genes or regulatory sequences involved in the metastatic process. A patient sample displaying an increased level of one or more of these polynucleotides may thus warrant more aggressive treatment. In another example, sequences that display higher expression in the low metastatic potential cells can be associated with genes or regulatory sequences that inhibit metastasis, and thus the expression of these polynucleotides in a sample may warrant a more positive prognosis than the gross pathology would suggest.

The differential expression of these polynucleotides can be used as a diagnostic marker, a prognostic marker, for risk assessment, patient treatment and the like. These polynucleotide sequences can also be used in combination with other known molecular and/or biochemical markers.

The following tables summarize polynucleotides that are differentially expressed between high metastatic potential breast cancer cells and low metastatic potential breast cancer cells.

Table 5. Differentially expressed polynucleotides: Higher expression in high metastatic potential breast cancer (lib3) relative to low metastatic breast cancer cells (lib4)

SEQ ID Sequence Name Cluster ^• Lib3 Lib4 Iib3/lib4 Zscore

NOS: ID clones clones

45 RTA00000197AR.f.l2.1 3513 17 5 3.317240 2.287632

146 RTA00000185AF.a.l9.2 5749 9 0 8.780930 2.629923

154 RTA00000196F.e.7.1 1039 10 2 4.878294 1.978215

159 RTA00000182AF.1.12.1 1027 41 17 2.353059 2.926571

165 RTA00000192AF.g.23.1 6455 6 0 5.853953 2.011224

174 RTA00000181AF.e.22.3 3442 17 4 4.146550 2.562391

183 RTA00000198AF.C.17.1 6923 6 0 5.853953 2.011224

364 RTA00000187AF.g.l3.1 2991 10 1 9.756589 2.371428

366 RTA00000192AF.O.19.1 3549 10 1 9.756589 2.371428

387 RTA00000191AF.J.14.1 1002 42 20 2.048883 2.570309

496 RTA00000190AF.p.3.1 2378 34 0 33.17240 5.588184

510 RTA00000178AF.n.23.1 3298 12 1 1 1.70790 2.729313

512 RTA00000191AF.C.3.1 3549 10 1 9.756589 2.371428

529 RTA00000178AF.b.l3.1 31 14 9 1 8.780930 2.174815

560 RTA00000184AF.i.23.3 1577 25 3 8.130490 3.903813

606 RTA00000179AR.e.01.4 2493 33 9 3.577416 3.469507 SEQ ID Sequence Name Cluster Lib3 Lib4 Iib3/lib4 Zscore

NOS: ID clones clones

644 RTA00000197F. 2.1 3605 14 1 13.65922 3.050936

646 RTA00000186AF.d.24.1 3114 9 1 8.780930 2.174815

754 RTA00000T 87AF.1.1 1.1 4482 14 3 4.553074 2.374769

875 RTA00000401F.m.02.1 1573 34 7 4.738914 3.982056

902 RTA00000422F.C.02.1 2902 18 5 3.512372 2.443314

921 RTA00000418F.m.l9.1 8890 6 0 5.853953 2.011224

942 RTA00000351R.g.l l .l 3077 17 4 4.146550 2.562391

1095 RTA00000408F.1.13.1 4423 12 1 11.70790 2.729313

1 104 RTA00000404F.m.l0.2 779 60 22 2.660887 3.974953

1 131 RTA00000400F.k.22.1 2512 7 0 6.829612 2.235371

1 170 RTA00000340R.f.05.1 3202 18 3 5.853953 2.998867

1184 RTA00000422F.C.17.1 1360 26 11 2.306102 2.226876

1205 RTA00000118A.a.23.1 3500 12 3 3.902635 2.018050

1354 RTA00000401F.k.l4.1 211 121 43 2.745458 5.856098

2124 RTA00000191AFJ.14.1 1002 42 20 2.048883 2.570309

1535 RTA00000405F.1.11.1 2055 29 8 3.536763 3.213373

1751 RTA00000423F.J.03.1 5391 6 0 5.853953 2.011224

1764 RTA00000399F.O.24.1 2272 17 1 16.58620 3.483575

1777 RTA00000401F.J.15.1 3061 14 0 13.65922 3.428594

1795 RTA00000348R.O.12.1 2263 6 0 5.853953 2.011224

1869 RTA00000340F.f.22.1 1720 57 8 6.951569 5.855075

1882 RTA00000401F.g.22.1 1147 28 12 2.276537 2.294031

1890 RTA00000346F.O.16.1 176 170 44 3.769591 8.366611

1915 RTA00000400F.g.02.1 1508 21 5 4.097767 2.879196

2040 RTA00000527F.J.02.2 4896 11 0 10.73224 2.974502

2059 RTA00000528F.i.22.1 2478 17 5 3.317240 2.287632

2223 RTA00000528F.J.11.1 1070 26 6 4.227855 3.289393

2245 RTA00000527F.k.09.1 213 17 4 4.146550 2.562391

2300 RTA00000528F.b.03.1 2078 1 1 2 5.366124 2.174565

2325 RTA00000525F.d.l3.1 349 77 1 75.12573 8.384408

2462 RTA00000528F.g.22.2 920 76 32 2.317189 4.010278

2488 RTA00000528F.h.02.2 1701 18 4 4.390465 2.714073

2492 RTA00000528F.C.11.1 1701 18 4 4.390465 2.714073

Table 6. Differentially expressed polynucleotides: Higher expression in low metastatic breast cancer cells (lib4) relative to high metastatic potential breast cancer (lib3)

SEQ ID Sequence Name Cluster ID Lib4 Lib 3 Iib4/lib3 Zscore

NOS: Clones Clones

15 RTA00000177AR.n.8.1 4188 4 13 3.33108 1.99126

36 RTA00000181AF.p.4.3 40392 1 8 8.19958 2.03713

44 RTA00000199F.f.08.2 12445 0 11 11.2744 3.05623

89 RTA00000177AF.n.8.3 4188 4 13 3.33108 1.99126

172 RTA00000186AF.p.09.2 6879 3 43 14.6909 5.83444

203 RTA00000201F.d.09.1 1827 37 157 4.34910 8.71727

261 RTA00000192AF.a.24.1 13183 0 7 7.17463 2.30057

419 RTA00000182AF.J.20.1 4769 2 20 10.2494 3.68254

420 RTA00000181AF.C.11.1 4769 2 20 10.2494 3.68254

503 RTA00000197AF.k.9.1 3138 1 10 10.2494 2.45316

552 RTA00000193AF.b.24.1 35 386 1967 5.22298 33.2328

564 RTA00000200AF.g.l8.1 1600 0 23 23.5738 4.64683 SEQ ID Sequence Name Cluster ID Lib4 Lib 3 Iib4/lib3 Zscore

NOS: Clones Clones

570 RTA00000183AF.a.l9.2 3788 0 6 6.14969 2.07158

590 RTA00000190AF.d.2.1 2444 26 55 2.16815 3.22244

693 RTA00000198F.m.l2.1 4 987 2807 2.91492 30.3819

707 RTA00000179AF.p.l5.1 5622 2 13 6.66216 2.62993

711 RTA00000198F.L2.1 8076 0 9 9.22453 2.70385

726 RTA00000200R.f.l0.1 4 987 2807 2.91492 30.3819

746 RTA00000178AF.i.01.2 4 987 2807 2.91492 30.3819

756 RTA00000404F.a.02.1 9738 1 13 13.3243 2.98623

990 RTA00000126A.O.23.1 6268 3 18 6.14969 3.11179

1122 RTA00000401F.O.06.1 2679 4 23 5.89345 3.52846

1142 RTA00000411F.a.l5.1 73812 0 12 12.2993 3.21838

1286 RTA00000345F.n.l2.1 7337 3 16 5.46639 2.80694

1289 RTA00000126A.g.7.1 1902 13 48 3.78442 4.45002

1435 RTA00000345F.e.l l .l 4392 1 8 8.19958 2.03713

1860 RTA00000340F.p.l8.1 287 6 173 29.5526 12.5749

1933 RTA00000400F.f.l l.l 4088 0 82 84.0457 9.05778

1934 RTA00000341F.O.12.1 2883 9 21 2.39154 2.07600

1979 RTA00000122A.h.24.1 48 412 1020 2.53749 16.5262

1980 RTA00000346FJ.13.1 5337 5 17 3.48482 2.40321

2007 RTA00000400F.g.08.1 1275 15 32 2.18655 2.41857

2023 RTA00000523F.d.l9.1 26489 1 8 8.19958 2.03713

2409 RTA00000526F.d.l7.1 2757 4 16 4.09979 2.51500

1220 RTA00000528F.d.04.1 2395 12 37 3.16025 3.51521

Example 6: Polynucleotides Differentially Expressed in High Metastatic Potential Lung

Cancer Cells Versus Low Metastatic Lung Cancer Cells A number of polynucleotide sequences have been identified that are differentially expressed between cells derived from high metastatic potential lung cancer tissue and low metastatic lung cancer cells. Expression of these sequences in lung cancer tissue can be valuable in determining diagnostic, prognostic and/or treatment information. For example, sequences that are highly expressed in the high metastatic potential cells are associated can be indicative of increased expression of genes or regulatory sequences involved in the metastatic process. A patient sample displaying an increased level of one or more of these polynucleotides may thus warrant more aggressive treatment. In another example, sequences that display higher expression in the low metastatic potential cells can be associated with genes or regulatory sequences that inhibit metastasis, and thus the expression of these polynucleotides in a sample may warrant a more positive prognosis than the gross pathology would suggest.

The differential expression of these polynucleotides can be used as a diagnostic marker, a prognostic marker, for risk assessment, patient treatment and the like. These polynucleotide sequences can also be used in combination with other known molecular and/or biochemical markers.

The following tables summarize polynucleotides that are differentially expressed between high metastatic potential lung cancer cells and low metastatic potential lung cancer cells:

Table 7 Differentially expressed polynucleotides: Higher expression in high metastatic potential lung cancer cells (lib8) relative to low metastatic lung cancer cells (lib9)

SEQ ID Sequence Name Cluster ID Lib8 Lib9 Iib8/lib9 Zscore

NO: clones clones

10 RTA00000198AF.n.l6.1 3721 9 0 12.5772 3.20845

54 RTA00000200F.O.22.1 983 8 1 1 1.1797 2.53243

65 RTA00000198AF.m.l6.1 51 348 66 7.36849 17.4315

171 RTA00000198R.C.07.1 19181 6 0 8.38484 2.48169

203 RTA00000201F.d.09.1 1827 45 15 4.19242 5.09891

252 RTA00000181AF.e.l8.3 8 1355 122 15.5211 39.0214

253 RTA00000181AF.e.l7.3 8 1355 122 15.5211 39.0214

285 RTA00000181AR.J.14.3 5399 12 0 16.7696 3.80239

419 RTA00000182AF.J.20.1 4769 10 3 4.65824 2.29362

420 RTA00000181AF.C.11.1 4769 10 3 4.65824 2.29362

491 RTA00000196F.k.l l.l 3 986 392 3.51507 22.4683

525 RTA00000198AF.C.7.1 19181 6 0 8.38484 2.48169

526 RTA00000185AF.e.20.1 5865 12 0 16.7696 3.80239

552 RTA00000193AF.b.24.1 35 868 11 1 10.273 34.2897

693 RTA00000198F.m.l2.1 4 506 209 3.38335 15.7309

700 RTA00000183AF.U8.2 40129 7 0 9.78231 2.74441

726 RTA00000200R.f.l0.1 4 506 209 3.38335 15.7309

742 RTA00000177AF.m.l.l 14929 23 16 2.00886 2.02420

746 RTA00000178AF.i.01.2 4 506 209 3.38335 15.7309

861 RTA00000339F.f.l l.l 5832 5 0 6.98736 2.18988

990 RTA00000126A.O.23.1 6268 5 0 6.98736 2.18988

1088 RTA00000399F.f.l l.l 40167 8 0 1 1.1797 2.98512

1288 RTA00000423F.e.l l.l 2566 11 2 7.68610 2.85611

1417 RTA00000339F.O.07.1 2566 11 2 7.68610 2.85611

1444 RTA00000419F.p.03.1 1937 10 3 4.65824 2.29362

1454 RTA00000340F.1.05.1 38935 7 0 9.78231 2.74441

1570 RTA00000403F.a.l7.1 13686 8 0 11.1797 2.98512

1597 RTA00000401F.n.23.1 1552 8 1 1 1.1797 2.53243

1979 RTA00000122A.h.24.1 48 342 155 3.08345 12.2138

2024 RTA00000528F.b.23.1 1605 22 4 7.68610 4.23808

2034 RTA00000528F.m.l6.1 4468 6 1 8.38484 1.97787

2126 RTA00000526F.d.01.1 4468 6 1 8.38484 1.97787 Table 8 Differentially expressed polynucleotides: Higher expression in low metastatic lung cancer cells (lib9) relative to high metastatic potntial lung cancer cells SEQ ID Sequence Name Cluster Lib8 Lib9 Iib9/lib8 Zscore NO: ID clones clones

174 RTA00000181AF.e.22.3 3442 5 23 3.291654 2.368262

254 RTA00000178AF.n.2.1 17083 0 8 5.724617 2.034117

466 RTA00000177AF.p.20.1 4141 4 27 4.830145 3.070829

571 RTA00000198AF.b.l4.1 801 16 46 2.057284 2.411087

574 RTA00000192AF.f.3.1 5257 5 25 3.577885 2.596857

590 RTA00000190AF.d.2.1 2444 12 37 2.206362 2.299984

922 RTA00000399F.1.14.1 3354 5 20 2.862308 1.998763

1355 RTA00000406F.m.04.1 14959 1 1 41 2.667151 2.865855

1422 RTA00000405F.h.07.2 4984 3 16 3.816411 2.058861

2007 RTA00000400F.g.08.1 1275 10 42 3.005423 3.147111

2038 RTA00000527F.p.06.1 1292 8 33 2.951755 2.724411

2245 RTA00000527F.k.09.1 213 137 403 2.104945 7.661033

Example 7: Polynucleotides Differentially Expressed in High Metastatic Potential Colon Cancer Cells Versus Low Metastatic Colon Cancer Cells

A number of polynucleotide sequences have been identified that are differentially expressed between cells derived from high metastatic potential colon cancer tissue and low metastatic colon cancer cells. Expression of these sequences in colon cancer tissue can be valuable in determining diagnostic, prognostic and/or treatment information. For example, sequences that are highly expressed in the high metastatic potential cells can be indicative of increased expression of genes or regulatory sequences involved in the metastatic process. A patient sample displaying an increased level of one or more of these polynucleotides may thus warrant more aggressive treatment. In another example, sequences that display higher expression in the low metastatic potential cells can be associated with genes or regulatory sequences that inhibit metastasis, and thus the expression of these polynucleotides in a sample may warrant a more positive prognosis than the gross pathology would suggest. The differential expression of these polynucleotides can be used as a diagnostic marker, a prognostic marker, for risk assessment, patient treatment and the like. These polynucleotide sequences can also be used in combination with other known molecular and/or biochemical markers.

The following table summarizes identified polynucleotides with differential expression between high metastatic potential colon cancer cells and low metastatic potential colon cancer cells: Table 9 Differentially expressed polynucleotides: Higher expression in high metastatic potential colon cancer (libl) relative to low metastatic colon cancer cells (lib2) SEQ ID Sequence Name Cluster ID Libl Lib2 Hbl/lib2 Zscore NO: clones clones 228 RTA00000187AR.h.l5.2 6660 7 0 6.489973399 2.169320547

280 RTA00000193AF.b.l 8.1 7542 8 0 7.417112456 2.36964728

355 RTA00000184AR.b.24.1 5777 9 1 8.344251513 2.09555146

491 RTA00000196F.k.l l.l 3 5268 2164 2.257009497 32.96556438

603 RTA00000183AR.d.l l.3 6420 8 0 7.417112456 2.36964728

680 RTA00000177AF.f.l0.1 6420 8 0 7.4171 12456 2.36964728

752 RTA00000192AF.O.7.1 5275 11 2 5.099264814 2.083995588

753 RTA00000192AF.O.17.1 5275 11 2 5.099264814 2.083995588

1241 RTA00000346F.1.13.1 7542 8 0 7.417112456 2.36964728

1264 RTA00000349R.g.l0.1 5777 9 1 8.344251513 2.09555146

1401 RTA00000421F.m.l4.1 3524 21 6 3.2449867 2.499690198

1442 RTA00000350R.g.l0.1 9026 7 0 6.489973399 2.169320547

1514 RTA00000399F.O.06.1 13574 7 0 6.489973399 2.169320547

1851 RTA00000421F.a.06.1 2385 27 4 6.258188635 3.743586088

1915 RTA00000400F.g.02.1 1508 46 17 2.508729213 3.230059264

2024 RTA00000528F.b.23.1 1605 36 1 1 3.034273278 3.244010467

2066 RTA00000528F.m.l2.1 5768 12 0 3.046665462

Table 10 Differentially expressed polynucleotides: Higher expression in low metastatic colon cancer cells (lib2)relative to high metastatic potential colon cancer (libl)

SEQ ID Sequence Name Cluster Libl Lib2 lib2/libl Zscore

NOS: ID clones clones

33 RTA00000178AR.a.20.1 945 9 21 2.51670 2.21703

250 RTA00000192AFJ.21.1 2289 3 23 8.26916 3.92187

282 RTA00000193AF.C.15.1 3726 3 14 5.03340 2.58312

370 RTA00000179AF.C.15.3 2995 4 13 3.50540 2.09770

387 RTA00000191AF.J.14.1 1002 12 65 5.84234 6.26259

443 RTA00000197AR.i.l7.1 3516 5 17 3.66719 2.52439

460 RTA00000179AF.C.15.1 2995 4 13 3.50540 2.09770

545 RTA00000196F.a.2.1 3575 5 14 3.02004 2.00158

560 RTA00000184AF.i.23.3 1577 12 40 3.59528 4.01991

703 RTA00000198F.1.09.1 361 1 2 13 7.01081 2.73040

704 RTA00000190AF.O.12.1 3438 5 14 3.02004 2.00158 1095 RTA00000408F.1.13.1 4423 1 8 8.62869 2.11495 1104 RTA00000404F.m.l0.2 779 27 54 2.15717 3.23169 1205 RTA00000118A.a.23.1 3500 3 13 4.67387 2.40298 1354 RTA00000401F.k.l4.1 211 109 206 2.03843 6.08597 1387 RTA00000191AFJ.14.1 1002 12 65 5.84234 6.26259 1734 RTA00000345F.b.l7.1 945 9 21 2.51670 2.21703 1742 RTA00000422F.b.22.1 2368 14 34 2.61942 3.00662 1954 RTA00000401F.J.23.1 570 59 148 2.70560 6.66631 2262 RTA00000527F.O.12.1 688 29 60 2.23155 3.53946 2325 RTA00000525F.d.l3.1 349 69 138 2.15717 5.27497 Example 8: Polynucleotides Differentially Expressed in High Metastatic Potential Colon Cancer Patient Tissue Versus Normal Patient Tissue

A number of polynucleotide sequences have been identified that are differentially expressed between cells derived from high metastatic potential colon cancer tissue and normal tissue. Expression of these sequences in colon cancer tissue can be valuable in determining diagnostic, prognostic and/or treatment information. For example, sequences that are highly expressed in the high metastatic potential cells are associated can be indicative of increased expression of genes or regulatory sequences involved in the advanced disease state which involves processes such as angiogenesis, dedifferentiation, cell replication, and metastasis. A patient sample displaying an increased level of one or more of these polynucleotides may thus warrant more aggressive treatment.

The differential expression of these polynucleotides can be used as a diagnostic marker, a prognostic marker, for risk assessment, patient treatment and the like. These polynucleotide sequences can also be used in combination with other known molecular and/or biochemical markers.

The following tables summarize polynucleotides that are differentially expressed between high metastatic potential colon cancer cells and normal colon cells:

Table 11 Differentially expressed polynucleotides isolated from samples from two patients (UC#2 and UC#3) : Higher expression in high metastatic potential colon tissue (UC#2:libl7; UC#3:lib20) vs. normal colon tissue (UC#2:libl5; UC#3:libl8)

SEQ ID Sequence Name Cluster lib 15 lib 17 Iibl7/libl5 Zscore

NO: ID clones clones

65 RTA00000198AF.m.l6.1 51 1 10 9.27022 2.28830

1780 RTA00000118A.J.24.1 18 4 23 5.33037 3.27028

1899 RTA00000345F.J.09.1 13 14 80 5.29727 6.34580

SEQ ID Sequence Name Cluster lib 18 lib20 Iib20/libl8 Zscore

NO: ID clones clones

1899 RTA00000345F.J.09.1 13 12 23 2.24234 2.16077

Table 12 Differentially expressed polynucleotides isolated from samples from two patients (UC#2 and UC#3) : Higher expression in normal colon tissue (UC#2:libl5; UC#3:libl8)vs. high metastatic potential colon tissue (UC#2:libl7; UC#3:lib20).

SEQ ID Sequence Name Cluster Lib5 Llib7 Iibl5/libl7 Z Score: NO: ID Clones Clones >2.5899%; > 1.96

491 RTA00000196F.k.l l.l 3 242 26 10.04 13.78900072

SEQ ID Sequence Name Cluster Lib 18 Lib20 Iibl 8/lib20 Zscore NO: ID clones clones

491 RTA00000196F.k.l l . l 3 409 46 7.59993 15.3998

Example 9: Polynucleotides Differentially Expressed in High Colon Tumor Potential Patient Tissue Versus Metastasized Colon Cancer Patient Tissue

A number of polynucleotide sequences have been identified that are differentially expressed between cells derived from high tumor potential colon cancer tissue and cells derived from high metastatic potential colon cancer cells. Expression of these sequences in colon cancer tissue can be valuable in determining diagnostic, prognostic and/or treatment information associated with the transformation of precancerous tissue to malignant tissue. This information can be useful in the prevention of achieving the advanced malignant state in these tissues, and can be important in risk assessment for a patient.

The following table summarizes identified polynucleotides with differential expression between high tumor potential colon cancer tissue and cells derived from high metastatic potential colon cancer cells:

Table 13 Differentially expressed polynucleotides High tumor potential colon tissue vs. metastatic colon tissue SEQ ID Sequence Name Cluster ID L19 L20 Iibl9/lib20 Zscore NO: clones clones 252 RTA00000181AF.e.l8.3 8 14 1 10.4712 2.56699 253 RTA00000181AF.e.l7.3 8 14 1 10.4712 2.56699 491 RTA00000196F.k.l l.l 3 328 46 5.33318 11.8962 581 RTA00000191AF.p.3.2 17 24 2 8.97535 3.41950 693 RTA00000198F.m.l2.1 4 26 8 2.43082 2.09705 726 RTA00000200R.f.l0.1 4 26 8 2.43082 2.09705 746 RTA00000178AF.i.01.2 4 26 8 2.43082 2.09705 1780 RTA00000118A.J.24.1 18 80 13 4.60274 5.51440 1899 RTA00000345FJ.09.1 13 148 23 4.81287 7.68618

Example 10: Polynucleotides Differentially Expressed in High Tumor Potential Colon

Cancer Patient Tissue Versus Normal Patient Tissue

A number of polynucleotide sequences have been identified that are differentially expressed between cells derived from high tumor potential colon cancer tissue and normal tissue. Expression of these sequences in colon cancer tissue can be valuable in determining diagnostic, prognostic and/or treatment information associated with the prevention of achieving the malignant state in these tissues, and can be important in risk assessment for a patient. For example, sequences that are highly expressed in the potential colon cancer cells are associated with or can be indicative of increased expression of genes or regulatory sequences involved in early tumor progression. A patient sample displaying an increased level of one or more of these polynucleotides may thus warrant closer attention or more frequent screening procedures to catch the malignant state as early as possible.

The following tables summarize polynucleotides that are differentially expressed between high metastatic potential colon cancer cells and normal colon cells:

Table 14 Differentially expressed polynucleotides detected in samples from two patients (UC#2 and UC#3): Higher expression in tumor potential colon tissue (UC#2:libl6; UC#3:libl9)vs. normal colon tissue (UC#2:libl5; UC#3:libl8)

SEQ ID Sequence Name Cluster Lib 15 Lib 16 Iibl6/libl5 Zscore

NO: ID clones clones

1899 RTA00000345F.J.09.1 13 14 50 3.43709 4.22436

SEQ ID Sequence Name Cluster Libl 8 Lib 19 Iibl9/libl8 Zscore

NO: ID clones clones

65 RTA00000198AF.m.l6.1 51 0 14 12.2505 3.23250

252 RTA00000181AF.e.l8.3 8 1 14 12.2505 2.84687

253 RTA00000181AF.e.l7.3 8 1 14 12.2505 2.84687

581 RTA00000191AF.p.3.2 17 4 24 5.25021 3.24580

693 RTA00000198F.m.l2.1 4 6 26 3.79182 2.98901

716 RTA00000200F.p.05.1 3984 0 7 6.12525 2.09621

726 RTA00000200R.f.l0.1 4 6 26 3.79182 2.98901

746 RTA00000178AF.i.01.2 4 6 26 3.79182 2.98901

1780 RTA00000118A.J.24.1 18 10 80 7.00028 6.65963

1899 RTA00000345F.J.09.1 13 12 148 10.7921 9.86174

Table 15 Differentially expressed polynucleotides: Higher expression in normal colon tissue (UC#2:libl5) vs. tumor potential colon tissue (UC#2:libl6)

SEQ ID Sequence Name Cluster Lib 15 Lib 16 Iibl5/libl6 Zscore

NO: ID clones clones

491 RTA00000196F.k.l l.l 3 242 39 6.44765 12.3988

Example 11 : Polynucleotides Differentially Expressed in Growth Factor-Stimulated Human Microvascular Endothelial Cells (HMEC) Relative to Untreated HMEC

A number of polynucleotide sequences have been identified that are differentially expressed between human microvascular endothelial cells (HMEC) that have been treated with growth factors relative to untreated HMEC.

Sequences that are differentially expressed between growth factor-treated HMEC and untreated HMEC can represent sequences encoding gene products involved in angiogenesis, metastasis (cell migration), and other development and oncogenic processes.

For example, sequences that are more highly expressed in HMEC treated with growth factors (such as bFGF or VEGF) relative to untreated HMEC can serve as markers of cancer cells of higher metastatic potential. Detection of expression of these sequences in colon cancer tissue can be valuable in determining diagnostic, prognostic and/or treatment information associated with the prevention of achieving the malignant state in these tissues, and can be important in risk assessment for a patient. A patient sample displaying an increased level of one or more of these polynucleotides may thus warrant closer attention or more frequent screening procedures to catch the malignant state as early as possible.

The following table summarizes identified polynucleotides with differential expression between growth factor-treated and untreated HMEC.

Table 16 Differentially expressed polynucleotides: Higher expression in bFGF treated HMEC (libl 3) vs. untreated HMEC (lib 12)

SEQ ID Sequence Name Cluster Lib 12 Lib 13 Iibl3/libl2 Zscore

NO: ID clones clones

648 RTA00000199F.i.9.1 7 25 52 2.07199 2.94741

Table 17 Differentially expressed polynucleotides: Higher expression in VEGF treated HMEC (libl 4) vs. untreated HMEC (libl 2) SEQ ID Sequence Name Cluster Lib 12 Lib 14 ibl4/libl2 Zscore NO: ID clones clones

648 RTA00000199F.i.9.1 7 25 67 >.62449 4.17666

1899 RTA00000345F.J.09.1 13 22 49 ..181 14 2.99887

Example 12: Polynucleotides Differentially Expressed Across Multiple Libraries

A number of polynucleotide sequences have been identified that are differentially expressed between cancerous cells and normal cells across all three tissue types tested (i.e., breast, colon, and lung). Expression of these sequences in a tissue or any origin can be valuable in determining diagnostic, prognostic and/or treatment information associated with the prevention of achieving the malignant state in these tissues, and can be important in risk assessment for a patient. These polynucleotides can also serve as non-tissue specific markers of, for example, risk of metastasis of a tumor. The following table summarizes identified polynucleotides that were differentially expressed but without tissue type- specificity in the breast, colon, and lung libraries tested.

Table 18 Polynucleotides Differentially Expressed Across Multiple Library

Comparisons

SEQ ID Cluster Clones in 1st Clones in 2nd Ratio Cell or Tissue Sample and Cancer

NO. Lib Lib State Compared

(Z Score) SEQ ID Cluster Clones in 1st Clones in 2nd Ratio Cell or Tissue Sample and Cancer NO. Lib Lib State Compared (Z Score)

2024 1605 libl lib2 libl/lib2 colon: high met > low met

36 11 3.0342732 (3.2440104) lib8 lib9 Iib8/lib9 lung: high met > low met

22 4 7.6861036 (4.2380835)

65 51 lib8 lib9 Iib8/lib9 lung: high met > low met

348 66 7.3684960 (17.431560) lib 18 libl9 libl 9/lib 18 pt #3 colon: tumor > normal

0 14 12.250507 (3.2325073) libl5 lib 17 Iibl7/libl5 pt #2 colon: met > normal

1 10 9.2702249 (2.2883061)

174 3442 lib8 lib9 Iib9/lib8 lung: low met > high met

5 23 3.2916548 (2.3682625) lib3 lib4 Iib3/lib4 breast: high met > low met

17 4 4.1465504 (2.5623912)

203 1827 lib8 lib9 Iib8/lib9 lung: high met > low met

45 15 4.1924201 (5.0989192) lib3 lib4 Iib4/lib3 breast: low met > high met

37 157 4.3491051 (8.7172773)

2245 213 lib8 lib9 Iib9/lib8 lung: low met > high met

137 403 2.1049458 (7.6610331) lib3 lib4 Iib3/lib4 breast: high met > low met

17 4 4.1465504 (2.5623912)

990 6268 lib8 lib9 Iib8/lib9 lung: high met > low met

5 0 6.9873669 (2.1898837) lib3 lib4 Iib4/lib3 breast: low met > high met

3 18 6.1496901 (3.1 117967)

252 8 lib8 lib9 Iib8/lib9 lung: high met > low met

1355 122 15.521118 (39.021411) lib 19 lib20 Iibl9/lib20 pt. #3 colon: tumor > met

14 1 10.471247 (2.5669948) lib 18 libl9 Iibl9/libl8 pt #3 colon: tumor > normal

1 14 12.250507 (2.8468716)

253 8 lib8 lib9 Iib8/lib9 lung: high met > low met

1355 122 15.521118 (39.021411) lib 19 lib20 Iibl9/lib20 pt. #3 colon: tumor > met

14 1 10.471247 (2.5669948) liblδ lib 19 Iibl9/libl8 pt #3 colon: tumor > normal

1 14 12.250507 (2.8468716)

2325 349 lib3 lib4 Iib3/lib4 breast: high met > low met 77 1 75.125736 (8.3844087) libl lib2 lib2/libl colon: low met > high met 69 138 2.1571737 (5.2749799) SEQ ID Cluster Clones in 1st Clones in 2nd Ratio Cell or Tissue Sample and Cancer NO. Lib Lib State Compared (Z Score)

1095 4423 lib3 Hb4 Hb3/lib4 breast: high met > low met

12 1 1 1.707907 (2.7293134) libl lib2 lib2/libl colon: low met > high met

1 8 8.6286948 (2.1149516)

1124 779 Hb3 lib4 Iib3/lib4 breast: high met > low met

60 22 2.6608879 (3.9749537) libl lib2 lib2/libl colon: low met > high met

27 54 2.1571737 (3.2316908)

387 1002 Hb3 lib4 Iib3/lib4 breast: high met > low met

42 20 2.0488837 (2.5703094) libl lib2 lib2/libl colon: low met > high met

12 65 5.8423454 (6.2625969)

419 4769 lib8 lib9 Iib8/lib9 lung: high met > low met

10 3 4.6582446 (2.2936274) lib3 lib4 Iib4/lib3 breast: low met > high met

2 20 10.249483 (3.6825426)

420 4769 lib8 lib9 Iib8/lib9 lung: high met > low met

10 3 4.6582446 (2.2936274) lib3 lib4 Iib4/lib3 breast: low met > high met

2 20 10.249483 (3.6825426)

1205 3500 lib3 lib4 Iib3/lib4 breast: high met > low met

12 3 3.9026356 (2.0180506) libl lib2 lib2/libl colon: low met > high met

3 13 4.6738763 (2.4029818)

491 3 libl lib2 libl/lib2 colon: high met > low met

5268 2164 2.2570094 (32.965564) lib8 lib9 Iib8/lib9 lung: high met > low met

986 392 3.5150733 (22.468331) lib 19 lib20 Iibl9/lib20 pt #3 colon: tumor > met

328 46 5.3331820 (11.896271) lib 18 lib20 Iibl8/lib20 pt #3 colon: normal > met

409 46 7.5999342 (15.399861) lib 15 lib 17 Iibl5/libl7 pt#2 colon: normal > met

242 26 10.04 (13.789000) lib 15 lib 16 Iibl5/libl6 pt#2 colon: normal > tumor

242 39 6.44765 12.39883

552 35 lib^β lib9 Iib8/lib9 lung: high met > low met

868 11 110.27335 (34.289704) lib3 lib4 Iib4/lib3 breast: low met > high met

386 1967 5.2229880 (33.232871)

560 1577 >3 lib4 Iib3/lib4 breast: high met > low met

25 3 8.1304909 (3.9038139) SEQ ID Cluster Clones in 1st Clones in 2nd Ratio Cell or Tissue Sample and Cancer NO. Lib Lib State Compared (Z Score) libl lib2 lib2/libl colon: low met > high met

12 40 3.5952895 (4.0199130)

581 17 libl9 lib20 Iibl9/lib20 pt #3 colon: tumor > met

24 2 8.9753551 (3.4195074) lib 18 lib 19 Iibl9/libl8 pt #3 colon: tumor > normal

4 24 5.2502174 (3.2458055)

590 2444 lib3 lib4 Iib4/lib3 breast: low met > high met

26 55 2.1681599 (3.2224421) lib8 lib9 Iib9/lib8 lung: low met > high met

12 37 2.2063628 (2.2999846)

1354 21 1 lib3 lib4 Iib3/lib4 breast: high met > low met

121 43 2.7454588 (5.8560985) libl lib2 lib2/libl colon: low met > high met

109 206 2.0384302 (6.0859794)

1387 1002 lib3 lib4 Iib3/lib4 breast: high met > low met

42 20 2.0488837 (2.5703094) libl lib2 lib2/libl colon: low met > high met

12 65 5.8423454 (6.2625969)

648 7 libl2 lib 14 Iibl4/libl2 HMEC: VEGF > untreated

25 67 2.6244913 (4.1766696) lib 12 lib 13 Iibl3/libl2 HMEC: bFGF > untreated

25 52 2.0719962 (2.9474155)

693 4 lib8 lib9 Iib8/lib9 lung: high met > low met

506 209 3.3833566 (15.730912) lib3 lib4 Iib4/lib3 breast: low met > high met

987 2807 2.9149240 (30.381945) lib 19 lib20 Iibl9/lib20 pt#3 colon: tumor > met

26 8 2.4308253 (2.0970580) lib 18 lib 19 Iibl9/libl8 pt#3 colon: tumor > normal

6 26 3.7918237 (2.9890107)

726 4 lib8 lib9 Iib8/lib9 lung: high met > low met

506 209 3.3833566 (15.730912) lib3 lib4 Iib4/lib3 breast: low met > high met

987 2807 2.9149240 (30.381945) libl9 lib20 Iibl9/lib20 pt#3 colon: tumor > met

26 8 2.4308253 (2.0970580) lib 18 lib 19 libl 9/lib 18 pt#3 colon: tumor > normal

6 26 3.7918237 (2.9890107)

746 Iib8 lib9 Iib8/lib9 lung: high met > low met

506 209 3.3833566 (15.730912) lib3 lib4 Iib4/lib3 breast: low met > high met 987 2807 2.9149240 (30.381945) SEQ ID Cluster Clones in 1st Clones in 2nd Ratio Cell or Tissue Sample and Cancer NO. Lib Lib State Compared (Z Score) lib 19 lib20 Iibl9/lib20 pt#3 colon: tumor > met

26 8 2.4308253 (2.0970580) lib 18 lib 19 libl 9/lib 18 pt#3 colon: tumor > normal

6 26 3.7918237 (2.9890107)

1780 18 lib 19 lib20 Iibl9/lib20 pt#3 colon: tumor > met

80 13 4.6027462 (5.5144093) lib 18 libl9 libl 9/lib 18 pt#3 colon: tumor > normal

10 80 7.0002899 (6.6596394) lib 15 libl 7 Iibl7/libl5 pt#3 colon: met > normal

4 23 5.3303793 (3.2702852)

1899 13 lib 19 lib20 Iibl9/lib20 pt#3 colon: tumor > met

148 23 4.8128716 (7.6861840) libl8 lib20 Iib20/libl8 pt#3 colon: met > normal

12 23 2.2423439 (2.1607719) lib 18 libl9 libl 9/lib 18 pt#3 colon: tumor > normal

12 148 10.7921 13 (9.8617485) lib 15 lib 17 Iibl7/libl5 pt#2 colon: met > normal

14 80 5.2972714 (6.3458044) lib 15 lib 16 Iibl6/libl5 pt#2 colon: tumor > normal

14 50 3.4370927 (4.2243697) lib 12 lib 14 Iibl4/libl2 HMEC: VEGF > untreated

22 49 2.1811410 (2.9988774)

1915 1508 libl lib2 libl/lib2 colon: high met > low met

46 17 2.5087292 (3.2300592) lib3 lib4 Iib3/lib4 breast: high met > low met

21 5 4.0977674 (2.8791960)

1979 48 lib8 lib9 Iib8/lib9 lung: high met > low met

342 155 3.0834574 (12.213852) lib3 lib4 Iib4/lib3 breast: low met > high met

412 1020 2.5374934 (16.526285)

2007 1275 lib3 lib4 Iib4/lib3 breast: low met > high met 15 32 2.1865564 (2.4185764) lib8 lib9 Iib9/lib8 lung: low met > high met 10 42 3.0054239 3.1471113 high met = high metastatic potential; low met = low metastatic potential; met = metastasized; tumor = non-metastasized tumor; pt = patient; #2 = UC#2; #3 = UC#3;

HMEC = human microvascular endothelial cell; bFGF = bFGF treated; VEGF = VEGF treated Example 12: Polynucleotides Exhibiting Colon-Specific Expression

The cDNA libraries described herein were also analyzed to identify those polynucleotides that were specifically expressed in colon cells or tissue, i.e., the polynucleotides were identified in libraries prepared from colon cell lines or tissue, but not in libraries of breast or lung origin. The polynucleotides that were expressed in a colon cell line and/or in colon tissue, but were present in the breast or lung cDNA libraries described herein, are shown in Table 19 (inserted before claims).

No clones corresponding to the colon-specific polynucleotides in the table above were present in any of Libraries 3, 4, 8, 9, 12, 13, 14, or 15. The polynucleotide provided above can be used as markers of cells of colon origin, and find particular use in reference arrays, as described above.

Example 13: Identification of Contiguous Sequences Having a Polynucleotide of the Invention The novel polynucleotides were used to screen publicly available and proprietary databases to determine if any of the polynucleotides of SEQ ID NOS: 1-2502 would facilitate identification of a contiguous sequence, e.g., the polynucleotides would provide sequence that would result in 5' extension of another DNA sequence, resulting in production of a longer contiguous sequence composed of the provided polynucleotide and the other DNA sequence(s). Contiging was performed using the Gelmerge application (default settings) of GCG from the Univ. of Wisconsin.

Using these parameters, 146 contiged sequences were generated. These contiged sequences are provided as SEQ ID NOS:5107-5252 (see Table 1). The contiged sequences can be correlated with the sequences of SEQ ID NOS: 1-2502 upon which the contiged sequences are based by, for example, identifying those sequences of SEQ ID NOS: 1 -2502 and the contiged sequences of SEQ ID NOS: 5107-5252 that share the same clone name in Table 1.

The contiged sequences (SEQ ID NO:5107-5252) thus represent longer sequences that encompass a polynucleotide sequence of the invention. The contiged sequences were then translated in all three reading frames to determine the best alignment with individual sequences using the BLAST programs as described above for SEQ ID NOS: 1-2502 and the validation sequences "SEQ ID NOS:2503-5106." Again the sequences were masked using the XBLAST program for masking low complexity as described above in Example 1 (Table 2). Several of the contiged sequences were found to encode polypeptides having characteristics of a polypeptide belonging to a known protein families (and thus represent new members of these protein families) and/or comprising a known functional domain (Table 20). Thus the invention encompasses fragments, fusions, and variants of such polynucleotides that retain biological activity associated with the protein family and/or functional domain identified herein.

Table 20 Profile hits using contiged sequences

SEQ Biological Activity (Profile) Start Stop Score Direction Sequence Name ID NO

5111 7tm_2 71 915 8090 for RTA00000399F.O.01.1

5120 7tm_2 101 919 8475 rev RTA00000341F.m.21.1

5174 7tm_2 3 963 9431 for RTA00000192AF.h.l9.1

5197 7tm_2 214 1073 8528 rev RTA00000192AF.f.3.1

5208 ANK 546 629 4920 for RTA00000190AF.f.5.1

5120 asp 126 1067 6620 rev RTA00000341F.m.21.1.

5241 asp 1 12 1094 6553 for RTA00000418F.i.06.1

5243 asp 347 1028 5981 for RTA00000339F.b.02.1

5197 ATPases 1 13 781 5690 for RTA00000192AF.f.3.1

5239 ATPases 1 348 15955 for RTA00000401F.m.07.1

5241 ATPases 110 823 6782 for RTA00000418F.i.06.1

5243 ATPases 338 874 5832 for RTA00000339F.b.02.1

5125 protkinase 59 685 5791 for RTA00000182AF.C.5.1

5217 protkinase 75 1035 5405 for RTA00000181AF.p.l2.3

5237 protkinase 25 546 5107 rev RTA000001 18A.n.5.1

5248 protkinase 14 422 5103 rev RTA00000419F.k.05.1

5252 protkinase 89 755 5499 for RTA00000404F.m.l7.2

5120 Wnt_dev_sign 3 948 11036 for RTA00000341F.m.21.1

All stop/start sequences are provided in the forward direction.

Descriptions of the profiles for the indicated protein families and functional domains are provided in Example 3 above.

Those skilled in the art will recognize, or be able to ascertain, using not more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such specific embodiments and equivalents are intended to be encompassed by the following claims. All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

Deposit Information:

The following materials were deposited with the American Type Culture Collection: CMCC = (Chiron Master Culture Collection)

cDNA Libraries Deposited with ATCC

cDNA Library ES25 cDNA Library ES26

January 22, 1999 January 22, 1999

ATCC No. ATCC No.

M00001675D:B08 M00001479C:F10

M00001589B:E12 M00003842D:F08

M00001607D:A11 M00003901A:C09

M00001636A:E07 M00003982A:B06

M00001530A:B12 M00003824A:A06

M00001495B:B08 M00003845D:C03

M00001487C:F01 M00003856A:B07

M00001644B:D06 M00004104B:A02

M00003751C:A04 M00004110C:E03

In addition, libraries of selected clones were deposited. The details of these deposits are provided in Tables 21-24.

This deposit is provided merely as convenience to those of skill in the art, and is not an admission that a deposit is required under 35 U.S.C. §112. The sequence of the polynucleotides contained within the deposited material, as well as the amino acid sequence of the polypeptides encoded thereby, are incorporated herein by reference and are controlling in the event of any conflict with the written description of sequences herein. A license may be required to make, use, or sell the deposited material, and no such license is granted hereby.

Retrieval of Individual Clones from Deposit of Pooled Clones

Where the ATCC deposit is composed of a pool of cDNA clones, the deposit was prepared by first transfecting each of the clones into separate bacterial cells. The clones were then deposited as a pool of equal mixtures in the composite deposit. Particular clones can be obtained from the composite deposit using methods well known in the art. For example, a bacterial cell containing a particular clone can be identified by isolating single colonies, and identifying colonies containing the specific clone through standard colony hybridization techniques, using an oligonucleotide probe or probes designed to specifically hybridize to a sequence of the clone insert (e.g., a probe based upon unmasked sequence of the encoded polynucleotide having the indicated SEQ ID NO). The probe should be designed to have a T_m of approximately 80°C (assuming 2°C for each A or T and 4°C for each G or C). Positive colonies can then be picked, grown in culture, and the recombinant clone isolated. Alternatively, probes designed in this manner can be used to PCR to isolate a nucleic acid molecule from the pooled clones according to methods well known in the art, e.g., by purifying the cDNA from the deposited culture pool, and using the probes in PCR reactions to produce an amplified product having the corresponding desired polynucleotide sequence.

Table 1.

SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

1 1/28/98 1 RTA00000197AF.i. l 6.1 M00001490A:D1 1 16402 n 1/28/98 2 RTA00000188AF.n.15.1 M00003804A:H04 0

3 1/28/98 3 RTA00000197AF.e.24.1 M00001456B:F10 39250

4 1/28/98 4 RTA00000198R.f.04.1 M00001607D:F07 5023

5 1/28/98 5 RTA00000195R.C.1 1.1 M0000381 1A:E03 66087

6 1/28/98 6 RTA00000195AF.C.16.1 M00003829C:A1 1 23508

7 1/28/98 7 RTA00000197AR.e.l2.1 M00001454B:G07 22095

8 1/28/98 8 RTA00000200AF.h. l l .2 M00004146A:C08 8399

9 1/28/98 9 RTA00000177AF.g.22.1 M00001347C:G08 7031

10 1/28/98 10 RTA00000198AF.n.l 6.1 M00001694C:H10 3721

1 1 1/28/98 1 1 RTA00000199AF.i.l 7.1 M00003880C:F10 9615

12 1/28/98 12 RTA00000183AF.L15.2 M00001529B:C04 2642

13 1/28/98 13 RTA00000190AF.i.5.1 M00003919A:A10 0

14 1/28/98 14 RTA00000196R.C.1 1.2 M00001352A:E12 13658

15 1/28/98 15 RTA00000177AR.n.8.1 M00001356D:F06 4188

16 1/28/98 16 RTA00000196AF.e. l6.1 M00001363C:H02 39252

17 1/28/98 17 RTA00000183AR.e.l4.2 M00001506B:D09 17437

18 1/28/98 18 RTA00000196AF.C.17.1 M00001352C:F06 39602

19 1/28/98 19 RTA00000185AF.a.8.1 M00001570D:A03 4868

20 1/28/98 20 RTA00000181 AF.1.14.2 M00001454D:D06 2364

21 1/28/98 21 RTA00000131A.g.l9.2 M00001449A:G10 36535

22 1/28/98 22 RTA00000187AR.O.10.2 M00001718D:F07 8984

23 1/28/98 23 RTA00000198R.b.08.1 M00001567C:H12 22636

24 1/28/98 24 RTA00000200AF.f.l l .l M000041 1 1 D:D1 1 0

25 1/28/98 25 RTA00000196AF.C.1.1 M00001349C:C05 8171

26 1/28/98 26 RTA00000200R.g.09.1 M00004131 B:H09 22785

27 1/28/98 27 RTA00000192AF.i.l2.1 M00004169C:C12 5319

28 1/28/98 28 RTA00000178AR.O.01.5 M00001387B:H07 0

29 1/28/98 29 RTA00000200AF.b.l 9.1 M00004042D:H02 22847

30 1/28/98 30 RTA00000184AR.n.07.2 M00001561 C:F06 0

31 1/28/98 31 RTA00000200F.m.l 5.1 M00004236C:D10 22601

32 1/28/98 32 RTA00000198R.m. l9.1 M00001680D:D02 40041

33 1/28/98 33 RTA00000178AR.a.20.1 M00001362C:H1 1 945

34 1/28/98 34 RTA00000197AF.n.8.1 M00001536D:A12 4101

35 1/28/98 35 RTA00000191AF.n.17.1 M00004091 B:D1 1 7848

36 1/28/98 36 RTA00000181AF.p.4.3 M00001460A:A03 40392

37 1/28/98 37 RTA00000181AF.n.l 5.2 M00001457A:B07 86128

38 1/28/98 38 RTA00000196R.k.07.1 M00001399C:D09 22443

39 1/28/98 39 RTA00000189AR.b.l 9.1 M00003832B:E01 5294

40 1/28/98 40 RTA00000200AR.e.02.1 M00004090A:F09 36059

41 1/28/98 41 RTA00000184F.k. l2.1 M00001557D:D09 8761

42 1/28/98 42 RTA00000184F.J.21.1 M00001557A:D02 7065

43 1/28/98 43 RTA00000179AF.C.14.3 M00001392D:H04 0

44 1/28/98 44 RTA00000199F.f.08.2 M00003841 D:E03 12445

45 1/28/98 45 RTA00000197AR.f.l2.1 M00001458C:E01 3513

46 1/28/98 46 RTA00000182AF.f.l3.1 M00001470C:B10 8010

47 1/28/98 47 RTA00000192AF.m.l2.1 M00004191 D:B 1 1 0

48 1/28/98 48 RTA00000177AR.a.23.5 M00001339D:G02 6995

49 1/28/98 49 RTA00000198R.O.05.1 M00003750A:D01 26702 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

50 1/28/98 50 RTA00000201 R.a.02.1 M00004295B:D02 35362

51 1/28/98 51 RTA00000199R. 07.1 M00003901 C:A03 12973

52 1/28/98 52 RTA00000201R.b.02.1 M00004319D:G09 22660

53 1/28/98 53 RTA00000199AF.p.9.1 M00003988A:E10 10430

54 1/28/98 54 RTA00000200F.O.22.1 M00004282B:A04 983

55 1/28/98 55 RTA00000186AF.i.21.1 M00001636C:H09 6033

56 1/28/98 56 RTA00000177AF.e.9.1 M00001343D:C04 37442

57 1/28/98 57 RTA00000198AF.k.20.1 M00001660C:B12 22553

58 1/28/98 58 RTA00000199F.b.01.2 M00003778A:D08 191 18

59 1/28/98 59 RTA00000195AF.b.l3.1 M00001560D:A03 12605

59 2/24/98 78 RTA00000195AF.b.l3.1 M00001560D:A03 12605

60 1/28/98 60 RTA00000196AR.U2.3 M00001389D:G1 1 38800

61 1/28/98 61 RTA00000197AF.h.l l .l M00001476D:G03 22264

62 1/28/98 62 RTA00000190AF.a.l8.2 M00003900D:B10 0

63 1/28/98 63 RTA00000184AF.R.19.1 M00001558B:D08 8022

64 1/28/98 64 RTA00000198AF.p.l2.1 M00003763D:E10 8878

65 1/28/98 65 RTA00000198AF.m.l 6.1 M00001679D:D05 51

66 1/28/98 66 RTA00000199F.C.09.2 M00003800A:C09 16824

67 1/28/98 67 RTA00000200AF.g.07.1 M00004128B:G01 0

68 1/28/98 68 RTA00000184F.k. l9.1 M00001558B:D08 8022

69 1/28/98 69 RTA00000186AF.h.8.1 M00001632C:C09 35547

70 1/28/98 70 RTA00000192AF.e.3.1 M00004138B:H02 13272

71 1/28/98 71 RTA00000193AR.O.16.3 M00004409B:A1 1 52972

72 1/28/98 72 RTA00000200F.a.6.1 M00004029B:F1 1 36952

73 1/28/98 73 RTA00000177AF.e.21.3 M00001344A:H07 4306

74 1/28/98 74 RTA00000196AF.h.20.1 M00001385B.-F10 0

75 1/28/98 75 RTA00000180AR.h.l9.2 M00001428A:H10 84182

76 1/28/98 76 RTA00000200AF.h.05.2 M00004142D:E10 10950

77 1/28/98 77 RTA00000197AF.n.2.1 M00001535A:D02 6229

78 1/28/98 78 RTA00000199R.f.09.1 M00003842B:D09 22907

79 1/28/98 79 RTA00000199AF.p.4.1 M00003985C:F01 10282

80 1/28/98 80 RTA00000196AF.p.l3.2 M00001432A:E06 6125

81 1/28/98 81 RTA00000196AF.b.l5.1 M00001347B:E01 5102

82 1/28/98 82 RTA00000183AF.1.18.1 MO0001535D:C01 3484

83 1/28/98 83 RTA00000186AFT.24.2 M00001629B:E06 0

84 1/28/98 84 RTA00000191AF.h.l4.1 M00004056B:D09 13553

85 1/28/98 85 RTA00000200R.O.03.1 M00004257C:H06 22807

86 1/28/98 86 RTA00000189AF.1.22.1 M00003879C:G10 33333

87 2/24/98 245 RTA00000195AF.d.20.1 M000041 17A:D1 1 37574

87 1/28/98 87 RTA00000195AF.d.20.1 M000041 17A:D1 1 37574

88 1/28/98 88 RTA00000197AF.e.23.1 M00001456B:C09 37157

89 1/28/98 89 RTA00000177AF.n.8.3 M00001356D:F06 4188

90 1/28/98 90 RTA00000199F.f.l 5.2 M00003845A:H12 8772

91 1/28/98 91 RTA00000198AF.J.19.1 M00001653C:F12 38914

92 1/28/98 92 RTA00000198AF.J.18.1 M00001653B:G07 22759

93 1/28/98 93 RTA00000200F.O.1 1.1 M00004270A:F1 1 0

94 1/28/98 94 RTA00000195AF.b.4.1 M00001490C:D07 0

95 1/28/98 95 RTA00000180AF.g.3.1 M00001425A:C1 1 9024

96 1/28/98 96 RTA00000197AF.J.20.1 M00001496C:C1 1 4915

97 1/28/98 97 RTA00000197AF.O.2.1 M00001541 C:B07 5739 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

98 1/28/98 98 RTA00000200AF.f.l4.1 M000041 15D:C08 22051

99 1/28/98 99 RTA00000184AF.d.8.1 M00001548A:A08 4393

100 1/28/98 100 RTA00000200R.f.l4.1 M000041 15D:C08 22051

101 1/28/98 101 RTA00000191 AF.d.08.2 M00003997B:G07 970

102 1/28/98 102 RTA00000199R.J.08.1 M00003884D:G07 37844

103 1/28/98 103 RTA00000199F.e.l 0.1 M00003822A:F02 22906

104 1 /28/98 104 RTA00000196R.h.03.1 M00001381 A:D02 6636

105 1/28/98 105 RTA00000179AF.g.l 2.3 M00001398A:G03 36390

106 1/28/98 106 RTA00000197AF.n.21.1 M00001540B:C09 0

107 1/28/98 107 RTA00000196R.i.l 3.1 M00001390A:A09 9857

108 1/28/98 108 RTA00000183AR.h.23.2 M00001528A:F09 18957

109 1/28/98 109 RTA00000197AF.d.l2.1 M00001451 D:C10 39546

1 10 1/28/98 1 10 RTA00000197R.H.01.1 M00001470A:H01 13075

1 1 1 1/28/98 1 1 1 RTA00000198AF.O.12.1 M00003751 D:B02 22038

1 12 1/28/98 1 12 RTA00000177AF.m.8.1 M00001354C:C10 8010

1 13 1/28/98 1 13 RTA00000196AF.d.09.1 M00001354B:B 10 16934

1 14 1/28/98 1 14 RTA00000200R.f.02.1 M00004108A:A09 7138

1 15 1/28/98 1 15 RTA00000179AR.O.20.3 M00001409D:F1 1 2409

1 16 1/28/98 1 16 RTA00000181 AR.k.24.3 M00001454B:C12 7005

1 17 1/28/98 1 17 RTA00000199AF.J.18.1 M00003889D:B09 5140

1 18 1/28/98 1 18 RTA00000199F.b.24.2 M00003794A:B03 0

1 19 1/28/98 1 19 RTA00000181 AR.L24.2 M00001454B:C12 7005

120 1/28/98 120 RTA00000178AR.m. l9.5 M00001384D:H07 0

121 1/28/98 121 RTA00000199AF.O.16.1 M00003979A:F03 16721

122 1/28/98 122 RTA00000197AF.1.15.1 M00001517B:G08 4947

123 1/28/98 123 RTA00000191 AF. 6.1 M00004078B:A1 1 5451

124 1/28/98 124 RTA00000199AR.m.06.1 M00003933C:D06 19122

125 1/28/98 125 RTA00000197AF.k.l 5.1 M00001504D:D1 1 22750

126 1/28/98 126 RTA00000201 F.d. l6.1 M00004388B:A08 0

127 1/28/98 127 RTA00000178AF.k.l 8.1 M00001382A:F04 9755

128 1/28/98 128 RTA00000196F.U2.1 M00001389D:G1 1 38800

129 1/28/98 129 RTA00000134A.d.l 0.1 M00001528A:F09 18957

130 1/28/98 130 RTA00000196AF.h.23.1 M00001386A:C02 13357

131 1/28/98 131 RTA00000185AF.d.l l .2 M00001579D:C03 6539

132 1/28/98 132 RTA00000178AF.f.20.3 M00001372C:F07 39881

133 1/28/98 133 RTA00000181AR.n.20.3 M00001457B:E03 0

134 1/28/98 134 RTA00000197F.e.l l .l M00001454B:G03 2306

135 1/28/98 135 RTA00000196AF.C.22.1 M00001352D:C05 22548

136 1/28/98 136 RTA00000197AF.C.10.1 M00001448B:F06 10400

137 1/28/98 137 RTA00000181 AF.m.4.3 M00001455A:E09 13238

138 1/28/98 138 RTA00000182AF.a.3.3 M00001462B:A10 0

139 1/28/98 139 RTA00000191AF.d.01.2 M00003996A:A06 7031

140 1/28/98 140 RTA00000199F.a.2.1 M00003772A:D07 12674

141 1/28/98 141 RTA00000196AF.C.6.1 M00001350A:D06 23148

142 1/28/98 142 RTA00000198AF. 19.1 M00001660B:C04 75879

143 1/28/98 143 RTA00000199R.h.09.1 M00003867C:H09 76020

144 1/28/98 144 RTA00000198AF.O.18.1 M00003755A:A09 13018

145 1/28/98 145 RTA00000178AF.h.24.1 M00001376B:C06 6745

146 1/28/98 146 RTA00000185AF.a.l 9.2 M00001571 C:H06 5749

147 1/28/98 147 RTA00000185AF.C.24.2 M00001578B:E04 23001 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

148 1/28/98 148 RTA00000199F.h.l 7.2 M00003871 A:A05 36254

149 1/28/98 149 RTA00000181AR.h.06.3 M00001450D:D04 87226

150 1/28/98 150 RTA00000184F.k.09.1 M00001557C:H07 7065

151 1/28/98 151 RTA00000200R.1.17.1 M00004217C:D03 12771

152 1/28/98 152 RTA00000196AF.C.20.1 M00001352C:H02 8934

153 1/28/98 153 RTA00000200F.n.l 7.2 M00004252C:E03 19064

154 1/28/98 154 RTA00000196F.e.7.1 M00001360D:E1 1 1039

155 1/28/98 155 RTA00000197F.e.8.1 M00001454A:C 1 1 3135

156 1/28/98 156 RTA00000199R.O.12.1 M00003977A:E04 16128

157 1/28/98 157 RTA00000188AF.n.01.1 M00003801A:B10 36412

158 1/28/98 158 RTA00000198AF.k.03.1 M00001655A:F06 22765

159 1/28/98 159 RTA00000182AF.I.12.1 M00001487A:A05 1027

160 1/28/98 160 RTA00000192AF.b.20.1 M000041 18D:E08 0

161 1/28/98 161 RTA00000183AF.e.23.2 M00001506D:A09 0

162 1/28/98 162 RTA00000201 F.e.l5.1 M00004444B:D1 1 9960

163 1/28/98 163 RTA00000192AR.e.l3.3 M00004142A:B12 9457

164 1/28/98 164 RTA00000193AR.i. l4.4 M00004307C:A06 9457

165 1/28/98 165 RTA00000192AF.g.23.1 M00004157C:A09 6455

166 1/28/98 166 RTA00000198AF.f.21.1 M00001614D:D09 22676

167 1/28/98 167 RTA00000179AF.d.22.3 M00001394C:C1 1 7955

168 1/28/98 168 RTA00000177AR.k.23.1 M00001352D:D02 35550

169 1/28/98 169 RTA00000196AF.g.24.1 M00001380C:F02 8685

170 1/28/98 170 RTA00000197AF.d.23.1 M00001453A:E1 1 16130

171 1/28/98 171 RTA00000198R.C.07.1 M00001575D:G05 19181

172 1/28/98 172 RTA00000186AF.p.09.2 M00001655C:E04 6879

173 1/28/98 173 RTA00000200AR.b.07.1 M00004039C:C01 17125

174 1/28/98 174 RTA00000181AF.e.22.3 M00001448D:F09 3442

175 1/28/98 175 RTA00000200F.i.5.1 M00004156B:A12 22892

176 1/28/98 176 RTA00000183AF.h.l9.1 M00001528A:A01 5175

177 1/28/98 177 RTA00000197AF.C.3.1 M00001447C:C01 3145

178 1/28/98 178 RTA00000200F.O.03.1 M00004257C:H06 22807

179 1/28/98 179 RTA00000179AF.f.20.3 M00001397B:B09 16154

180 1/28/98 180 RTA00000199AF.J.12.1 M00003887A:A06 22461

181 1/28/98 181 RTA00000198AF.d.2.1 M00001585A:F07 0

182 1/28/98 182 RTA00000196AF.h.l6.1 M00001384C:E03 39895

183 1/28/98 183 RTA00000198AF.C.17.1 M00001579C:E08 6923

184 1/28/98 184 RTA00000197AF.f.7.1 M00001457C:C1 1 19261

185 2/24/98 234 RTA00000195AF.d.4.1 M00003881 D:D06 22766

185 1/28/98 185 RTA00000195AF.d.4.1 M00003881D:D06 22766

186 1/28/98 186 RTA00000198R.p.09.1 M00003761D:E02 10473

187 1/28/98 187 RTA00000180AR.J.04.4 M00001429C:G12 22300

188 1/28/98 188 RTA00000188AF.O.05.1 M00003806D:G05 4668

189 1/28/98 189 RTA00000197AF.h. l 0.1 M00001476B:F10 15554

190 1/28/98 190 RTA00000134A.C.7.1 M00001528A:A01 5175

191 1/28/98 191 RTA00000187AF.p.23.1 M00003748B:F02 39804

192 1/28/98 192 RTA00000185AF.m.7.1 M00001605C:D12 39804

193 1/28/98 193 RTA00000199AF.n.3.1 M00003946D:C1 1 0

194 1/28/98 194 RTA00000200R.k.01.1 M00004188C:A09 40049

195 1/28/98 195 RTA00000198AF.C.10.1 M00001577B:H02 77149

196 1/28/98 196 RTA00000198F.e.l0.1 M00001599B:E09 9727 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

197 1/28/98 197 RTA00000198F.1.12.1 M00001669C:B01 8592

198 1/28/98 198 RTAOOOOO 197AR.e.07.1 M00001453D:G12 86969

199 1/28/98 199 RTAOOOOO 199R.C.09.1 M00003800A:C09 16824

200 1/28/98 200 RTAOOOOO 182AF 2.1 M00001469D:D02 4794

201 1/28/98 201 RTAOOOOO 198AF.p.18.1 M00003769B:D03 23081

202 1/28/98 202 RTA00000200R.1.17.2 M00004217C:D03 12771

203 1/28/98 203 RTA00000201 F.d.09.1 M00004380B:A05 1827

204 1/28/98 204 RTA00000180AR.O.5.2 M00001437D:C04 7848

205 1/28/98 205 RTA00000189AF.g. l l . l M00003858D:F12 0

206 1/28/98 206 RTA00000181AF.O.04.2 M00001457C:C12 22205

207 1/28/98 207 RTAOOOOO 199AF.1.19.1 M00003924B:D04 22460

208 1/28/98 208 RTAOOOOO 198AF.h.22.1 M00001635C:A03 22366

209 1/28/98 209 RTAOOOOO 182AF.C.5.1 M00001464D:F06 6397

210 1/28/98 210 RTAOOOOO 189AR.b.12.1 M00003829B:G03 17233

21 1 1/28/98 21 1 RTA00000199AF.m. l 5.1 M00003939A:A02 10101

212 1/28/98 212 RTAOOOOO 197 AF.j .9.1 M00001494B:C01 13236

213 1/28/98 213 RTA00000200F.O.04.1 M00004260D:C12 12514

214 1/28/98 214 RTA00000200AF.f.22.1 M00004121 C:F06 16521

215 1/28/98 215 RTAOOOOO 192AR.e.14.3 M00004142A:D08 3300

216 1/28/98 216 RTAOOOOO 188AF.g.9.1 M00003774B:B08 4959

217 1/28/98 217 RTAOOOOO 198 AF.h.3.1 M00001625D:C07 22562

218 1/28/98 218 RTAOOOOO 188AF.0.18.1 M0000381 1 D:A12 13678

219 1/28/98 219 RTAOOOOO 198AF.m.19.1 M00001680D:D02 40041

220 1/28/98 220 RTA00000200AF.h.01.2 M00004141 D:A09 0

221 1/28/98 221 RTAOOOOO 189AF.L 17.1 M00003868C:H10 16814

222 1/28/98 222 RTAOOOOO 185 AF.i.4.1 M00001594A:B12 13942

223 1/28/98 223 RTA00000197F.i.9.1 M00001488D:C10 0

224 1/28/98 224 RTAOOOOO 188AF.m.1 1.1 M00003799A:D09 0

225 1/28/98 225 RTA00000189AF.b.5.1 M00003828A:E04 3784

226 1/28/98 226 RTA00000191AR.O.09.4 M00004096A:G02 0

227 1/28/98 227 RTA00000201 R.d.02.2 M00004375A:H01 2599

228 1/28/98 228 RTA00000187AR.h.l 5.2 M00001679A:A06 6660

229 1/28/98 229 RTA00000198 AF.g.3.1 M00001615C:F03 0

230 1/28/98 230 RTAOOOOO 185AR.b.18.1 M00001575B:C09 12171

231 1/28/98 231 RTA00000192AF.1.13.2 M00004185C:C03 1 1443

232 1/28/98 232 RTAOOOOO 186 AF.j .03.2 M00001638A:E07 0

233 1/28/98 233 RTA00000197AF.1.8.1 M0000151 1 B:C06 39954

234 1/28/98 234 RTA00000191 AF.f.8.1 M00004035A:A04 6541

235 1/28/98 235 RTA00000201 AF.a.02.1 M00004295B:D02 35362

236 1/28/98 236 RTA00000183AR.h.23.1 M00001528A:F09 18957

237 1/28/98 237 RTAOOOOO 197AF. 10.1 M00001500D:B1 1 0

238 1/28/98 238 RTAOOOOO 187AR.L 12.1 M00001679D:F02 78415

239 1/28/98 239 RTA00000201 R.d.02.1 M00004375A:H01 2599

240 1/28/98 240 RTAOOOOO 178AF.e.1.1 M00001369A:H12 2664

241 1/28/98 241 RTA00000200AF.1.17.1 M00004217C:D03 12771

242 1/28/98 242 RTAOOOOO 198AF.m.17.1 M00001679D:F06 77992

243 1/28/98 243 RTA00000181 AF.m. l 5.3 M00001455D:A1 1 12081

244 1/28/98 244 RTAOOOOO 199F.f.12.2 M00003844C:A08 8131

245 1/28/98 245 RTA00000200AF.L7.1 M00004193C:G1 1 0

246 1/28/98 246 RTAOOOOO 199 AF.1.4.1 M0000391 1 D:B04 4410 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

247 1/28/98 247 RTA00000198AF. 08.1 M00001656C:G08 17436

248 1/28/98 248 RTAOOOOO 198R.C.14.1 M00001578D:C04 39814

249 1/28/98 249 RTA00000200R.O.03.2 M00004257C:H06 22807

250 1/28/98 250 RTAOOOOO 192 AF.j .21.1 M00004176D:B12 2289

251 1/28/98 251 RTA00000192AF.n.13.1 M00004197D:H01 8210

252 1/28/98 252 RTA00000181 AF.e.l 8.3 M00001448D:C09 8

253 1/28/98 253 RTA00000181AF.e.l 7.3 M00001448D:C09 8

254 1/28/98 254 RTAOOOOO 178AF.n.2.1 M00001385C:H1 1 17083

255 1/28/98 255 RTA00000199AF.J.17.1 M00003889A:D10 5121

256 1/28/98 256 RTAOOOOO 184AR.e.15.1 M00001549C:E06 16347

257 1/28/98 257 RTA00000198AF.e.20.1 M00001604C:E09 9810

258 1/28/98 258 RTAOOOOO 199F.h.12.2 M00003868B:D12 16621

259 1/28/98 259 RTAOOOOO 197AF.J .4.1 M00001492D:A1 1 17209

260 1/28/98 260 RTAOOOOO 198R.m.17.1 M00001679D:F06 77992

261 1/28/98 261 RTAOOOOO 192 AF.a.24.1 M000041 14C:F1 1 13183

262 1/28/98 262 RTA00000186AF.C.17.1 M00001619D:G05 8551

263 1/28/98 263 RTAOOOOO 190AF.n.6.1 M00003965A:B1 1 0

264 1/28/98 264 RTAOOOOO 179 AF.k.3.3 M00001401A:H07 0

265 1/28/98 265 RTAOOOOO 177AF.e.14.1 M00001343D:H07 23255

266 1/28/98 266 RTAOOOOO 199FT.21.2 M00003847C:E09 13344

267 1/28/98 267 RTAOOOOO 186AF.g.1 1.2 M00001630B:H09 5214

268 1/28/98 268 RTAOOOOO 186AF.h.01.2 M00001632A:F12 0

269 1/28/98 269 RTA00000183AF. 13.1 M00001534B:C12 0

270 1/28/98 270 RTA00000178R.1.08.1 M00001383A:C03 39648

271 1/28/98 271 RTA00000201 F.d.02.1 M00004375A:H01 2599

272 1/28/98 272 RTAOOOOO 199F.g.08.2 M00003853D:G08 0

273 1/28/98 273 RTA00000201 F.C.08.1 M00004353C:H07 0

274 1/28/98 274 RTA00000191AF.O.17.1 M00004102A:H02 5957

275 1/28/98 275 RTA00000191AF.O.17.2 M00004102A:H02 ^"5957

276 1/28/98 276 RTAOOOOO 198 AF.j.15.1 M00001653B:E09 4369

277 1/28/98 277 RTAOOOOO 198AR.i.08.1 M00001639A:F10 9807

278 1/28/98 278 RTA00000198AF.p. l 6.1 M00003768A:E02 71877

279 1/28/98 279 RTAOOOOO 196AF.h.24.1 M00001386A:D1 1 7308

280 1/28/98 280 RTA00000193AF.b. l 8.1 M00004233C:H09 7542

281 1/28/98 281 RTAOOOOO 188AF.n.10.1 M00003802D:B1 1 10283

282 1/28/98 282 RTA00000193AF.C.15.1 M00004248B:E08 3726

283 1/28/98 283 RTAOOOOO 177AF.Ϊ.8.4 M00001350A:H01 7187

284 1/28/98 284 RTA00000199F.d.l0.2 M00003808C:B05 22049

285 1/28/98 285 RTA00000181ARJ.14.3 M00001453B:E10 5399

286 1/28/98 286 RTA00000181AR.k.2.3 M00001453C:A1 1 0

287 1/28/98 287 RTA00000200AF.b.07.1 M00004039C:C01 17125

288 1/28/98 288 RTA00000181AR.i.06.3 M00001452A:C07 191 19

289 1/28/98 289 RTA00000196F.k.07.1 M00001399C:D09 22443

290 1/28/98 290 RTA00000201 F.f. l 0.1 M00004498D:D05 5231

291 1/28/98 291 RTA00000200AF.e.l6.1 M00004101 C:G08 12068

292 1/28/98 292 RTAOOOOO 199AF.m.18.1 M00003939C:F04 0

293 1/28/98 293 RTA00000197AF.e. l3.1 M00001454C:F02 662

294 1/28/98 294 RTA00000198AF. 23.1 M00001661 B:C08 8995

295 1/28/98 295 RTA00000181AR.U9.2 M00001452C:B06 16970

296 1/28/98 296 RTAOOOOO 196AFT.20.1 M00001371 D:G01 22774 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

297 1/28/98 297 RTAOOOOO 178AF.f.9.3 M00001371 C:E09 7172

298 1/28/98 298 RTA00000197AR.e. l l . l M00001454B:G03 2306

299 1/28/98 299 RTAOOOOO 196AF.f.5.1 M00001366D:G02 1 1937

300 2/24/98 464 RTAOOOOO 195AF.C.12.1 M00003818B:G12 37582

300 1/28/98 300 RTAOOOOO 195AF.C.12.1 M00003818B:G12 37582

301 1/28/98 301 RTA00000181 AR.i.19.3 M00001452C:B06 16970

302 1/28/98 302 RTA00000186AF.d.l .2 M00001621 C:C08 40044

303 1/28/98 303 RTAOOOOO 186 AR.e.03.3 M00001623D:C 10 221 10

304 1/28/98 304 RTA00000182AR.C.5.1 M00001464D:F06 6397

305 1/28/98 305 RTA00000200AF.b.l 5.1 M00004040D:F01 10627

306 1/28/98 306 RTAOOOOO 199AF.p.12.1 M00003989A:H 1 1 12578

307 1/28/98 307 RTA00000200F.n.05.2 M00004246C:A09 18989

308 1/28/98 308 RTAOOOOO 178 AF.j .20.1 M00001380C:E05 15066

309 1/28/98 309 RTAOOOOO 198AF.h.12.1 M00001632C:A02 9503

310 1/28/98 310 RTA00000188AF.m.08.1 M00003798D:H08 22155

31 1 1/28/98 31 1 RTA00000191AR.J.4.2 M00004071 D:A10 5198

312 1/28/98 312 RTAOOOOO 193 AF.h.2.1 M00004290A:B03 3273

313 1/28/98 313 RTA00000183AF.O.1 1.1 M00001540D:D02 0

314 1/28/98 314 RTA00000182AF.O.5.1 M00001493B:D09 5007

315 1/28/98 315 RTA00000199R.d.23.1 M00003815D:H09 37477

316 1/28/98 316 RTAOOOOO 198 AF.h.24.1 M00001636C:C01 8390

317 1/28/98 317 RTA00000198AF.p.09.1 M00003761D:E02 10473

318 1/28/98 318 RTA00000200AF.g.l 7.1 M00004138A:H09 0

319 1/28/98 319 RTA00000200F.n.05.1 M00004246C.-A09 18989

320 1/28/98 320 RTAOOOOO 196AF.m.13.1 M00001415B:E09 16290

321 1/28/98 321 RTA00000181AR.b.21.1 M00001444C:D05 3266

322 1/28/98 322 RTAOOOOO 184 AR.b.21.1 M00001546B:B02 39788

323 1/28/98 323 RTAOOOOO 182AF.m.21.1 M00001490C:C12 18699

324 1/28/98 324 RTAOOOOO 184F.J.06.1 M00001556B:G02 1 1294

325 1/28/98 325 RTAOOOOO 182AF.d.18.4 M00001467D:H05 37435

326 1/28/98 326 RTAOOOOO 197AR.e.19.1 M00001455D:A09 8047

327 1/28/98 327 RTAOOOOO 182AF.L 1.3 M00001479B:A01 7033

328 1/28/98 328 RTA00000200AF.g.09.1 M00004131 B:H09 22785

329 1/28/98 329 RTA00000186AF.b.9.1 M00001616C:F07 0

330 1/28/98 330 RTA00000177AR.m.l 7.4 M00001355B:G10 14391

331 1/28/98 331 RTAOOOOO 197AR.C.20.1 M00001449D:A06 16282

332 1/28/98 332 RTA00000193AR.n.04.3 M00004375C:D01 9850

333 1/28/98 333 RTA00000196F.k.l 5.1 M00001400A:F06 8320

334 1/28/98 334 RTA00000181AR.b.21.3 M00001444C:D05 3266

335 1/28/98 335 RTAOOOOO 182 AF.e.3.2 M00001468B:H06 0

336 1/28/98 336 RTAOOOOO 186AFT.24.1 M00001629B:E06 0

337 1/28/98 337 RTA00000177AR.m.l 7.3 M00001355B:G10 14391

338 1/28/98 338 RTAOOOOO] 84AF.i.1.1 M00001554B:C07 0

339 1/28/98 339 RTAOOOOO 193 AF.d.1.1 M00004250D:D10 0

340 1/28/98 340 RTA00000185AF.n.8.1 M00001608B:A03 0

341 1/28/98 341 RTA00000181AF.1.06.2 M00001454C:C08 0

342 1/28/98 342 RTAOOOOO 196AF.d.10.1 M00001354C:B06 22256

343 1/28/98 343 RTA00000201 F.a.l 8.1 M00004314B:G07 16837

344 1/28/98 344 RTA00000198AF.O.02.1 M00003748A:B07 68756

345 1/28/98 345 RTAOOOOO 187AF.h.21.1 M00001679A:F01 39171 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

346 1/28/98 346 RTAOOOOO 197AR. 22.1 M00001505C:H01 1 1394

347 1/28/98 347 RTAOOOOO 199F.b.03.2 M00003779B:E12 38340

348 1/28/98 348 RTA00000200F.n.07.2 M00004247C:C12 8663

349 1/28/98 349 RTAOOOOO 191 AF.j.15.1 M00004073B:B01 6308

350 1/28/98 350 RTA00000193AR.C.7.2 M00004241 D:F1 1 9850

351 1/28/98 351 RTAOOOOO 179AF.C.22.1 M00001393B:B09 22515

352 1/28/98 352 RTA00000197AF.p.3.1 M00001550A:A03 7239

353 1/28/98 353 RTA00000198F.a.9.1 M00001557D:C08 0

354 1/28/98 354 RTAOOOOO 198R. 03.1 M00001655A:F06 22765

355 1/28/98 355 RTA00000184AR.b.24.1 M00001546B:C05 5777

356 1/28/98 356 RTAOOOOO 180AF.1.12.2 M00001433B:H1 1 0

357 1/28/98 357 RTA00000184AF.O.15.1 M00001564D:C09 0

358 1 /28/98 358 RTAOOOOO 198AF.g.7.1 M00001616C:C09 13386

359 1/28/98 359 RTAOOOOO 196AF.b.17.1 M00001348A:D04 12193

360 1/28/98 360 RTA00000198F.i.5.1 M00001638A:D10 39989

361 1/28/98 361 RTAOOOOO 177AR.g.16.4 M00001347A:B10 13576

362 1/28/98 362 RTAOOOOO 197AR.C.24.1 M00001450A:B 12 82498

363 1/28/98 363 RTAOOOOO 196AF.e.14.1 M00001362C:A10 12850

364 1/28/98 364 RTAOOOOO 187AF.g.13.1 M00001676C:C1 1 2991

365 1/28/98 365 RTAOOOOO 196F.1.20.2 M00001410B:G05 22678

366 1/28/98 366 RTA00000192AF.O.19.1 M00004208D:H08 3549

367 1/28/98 367 RTA00000196FL24.1 M00001392C:D10 4233

368 1/28/98 368 RTAOOOOO 198AF. 18.1 M00001660A:C12 17432

369 1/28/98 369 RTAOOOOO 196F.m.3.1 M00001413A:F02 10453

370 1/28/98 370 RTAOOOOO 179AF.C.15.3 M00001392D:H06 2995

371 1/28/98 371 RTAOOOOO 197F.e.7.1 M00001453D:G12 86969

372 1/28/98 372 RTAOOOOO 186AF.d.23.1 M00001623B:G07 22187

373 1/28/98 373 RTA00000196F.e.l2.1 M00001361C:H1 1 10147

374 1/28/98 374 RTAOOOOO 178AF.1.1 1.1 M00001383A:G04 23286

375 1/28/98 375 RTAOOOOO 177AF.m.18.1 M00001355B:G1 1 0

376 1/28/98 376 RTA00000177AF.m.l8.3 M0O0O1355B:Gl l 0

377 1/28/98 377 RTAOOOOO 178AF.m.19.1 M00001384D:H07 0

378 1/28/98 378 RTA00000181AF. 24.3 M00001454B:C 12 7005

379 1/28/98 379 RTAOOOOO 180AF.1.06.2 M00001433A:G07 5625

380 1/28/98 380 RTAOOOOO 182 AF.k.24.1 M00001485D:B10 5625

381 1/28/98 381 RTAOOOOO 199AF.m.14.1 M00003938A:B04 10580

382 1/28/98 382 RTA00000200AF.J.6.1 M00004176B:E08 22902

383 1/28/98 383 RTAOOOOO 199FT.20.2 M00003847B:G03 0

384 1/28/98 384 RTAOOOOO 196AF.h.17.1 M00001384C:F12 39215

385 1/28/98 385 RTA00000201 F.C.24.1 M00004374D:E10 35731

386 1/28/98 386 RTAOOOOO 197 AR.j.04.1 M00001492D:A1 1 17209

387 2/24/98 632 RTAOOOOO 191 AF.j.l 4.1 M00004073A:H12 1002

387 1/28/98 387 RTA00000191AF.J.14.1 M00004073A:H12 1002

388 1/28/98 388 RTAOOOOO 185AF.n.17.1 M00001609B:A1 1 5336

389 1/28/98 389 RTA00000181 AR. 2.2 M00001453C:A1 1 0

390 1/28/98 390 RTAOOOOO 197AR.f.07.1 M00001457C:C 1 1 19261

391 1/28/98 391 RTAOOOOO 179 AF.e.20.3 M00001396A:C03 4009

392 1/28/98 392 RTA00000185AF.D.1 1.2 M00001573C:D03 9024

393 1/28/98 393 RTAOOOOO 188AF.b.14.1 M00003754D:D02 0

394 1/28/98 394 RTAOOOOO 198 AF.p.22.1 M00003771A:G10 0 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

395 1/28/98 395 RTAOOOOO 196R.C.21.2 M00001352C:H 10 0

396 1/28/98 396 RTAOOOOO 179AR.b.02.3 M00001391 B:G12 0

397 1/28/98 397 RTAOOOOO 198AF.b.22.1 M00001571 B:E03 38956

398 1/28/98 398 RTA00000177AR.1.13.3 M00001353A:G12 8078

399 1/28/98 399 RTA00000186AF.m. l 5.2 M00001649C:B10 40122

400 1/28/98 400 RTAOOOOO 186AR.e.07.3 M00001623D:G03 4175

401 1/28/98 401 RTAOOOOO 195F.e.04.1 M00004465B:D04 6731

402 1/28/98 402 RTAOOOOO 177AF.b.21.4 M00001341A:F12 4443

403 1/28/98 403 RTAOOOOO 184AFT.13.1 M00001550D:H02 3784

404 1/28/98 404 RTA00000195AF.b.6.1 M00001496C:G10 39490

405 1/28/98 405 RTAOOOOO 197 AF.b.24.1 M00001446C:D09 23171

406 1/28/98 406 RTAOOOOO 199FT.09.2 M00003842B:D09 22907

407 1/28/98 407 RTAOOOOO 178AF.e.20.1 M00001370D:E12 3135

408 1/28/98 408 RTA00000183AR.I.15.1 M00001535C:E01 39383

409 1/28/98 409 RTAOOOOO 180AF.d.1.3 M00001418D:B06 8526

410 1/28/98 410 RTA00000201 F.a.20.1 M00004316A:G09 22639

41 1 1/28/98 41 1 RTAOOOOO 179AF.J.13.3 M00001400B:H06 0

412 2/24/98 678 RTAOOOOO 195 AF.c.24.1 M00003860D:H07 0

412 1/28/98 412 RTAOOOOO 195 AF.c.24.1 M00003860D:H07 0

413 1/28/98 413 RTA00000200F.a.l2.1 M00004031D:B05 16751

414 1/28/98 414 RTA00000185AR.b.l 5.1 M00001573D:F04 39813

415 1/28/98 415 RTA00000200AF.f.09.1 M000041 1 1 C:E1 1 12863

416 1/28/98 416 RTAOOOOO 199F.a.5.1 M00003773B:G01 22134

417 1/28/98 417 RTA00000200R.d.l 6.1 M00004085A:B02 39875

418 1/28/98 418 RTAOOOOO 187AR. 01.1 M00001679D:B05 78356

419 1/28/98 419 RTAOOOOO 182AF.J .20.1 M00001483B:D03 4769

420 1/28/98 420 RTA00000181AF.C.11.1 M00001445D:A06 4769

421 1/28/98 421 RTA00000200AF.i.21.1 M00004167D:A07 5316

422 1/28/98 422 RTAOOOOO 189AF.b.12.1 M00003829B:G03 17233

423 1/28/98 423 RTAOOOOO 188AR.b.17.1 M00003755A:B03 10662

424 1/28/98 424 RTAOOOOO 187AR.J.24.1 M00001679D:B05 78356

425 1/28/98 425 RTA00000200AF.C.16.1 M00004064D:A1 1 23433

426 1/28/98 426 RTAOOOOO 199AF.0.19.1 M00003980D:E09 36927

427 1/28/98 427 RTA00000187AR.d.9.2 M00001664D:G07 5483

428 1/28/98 428 RTAOOOOO 185AF.b.15.2 M00001573D:F04 39813

429 1/28/98 429 RTAOOOOO 196F.i.19.1 M00001390C:C1 1 39498

430 1/28/98 430 RTA00000198R. 23.1 M00001661 B:C08 8995

431 1/28/98 431 RTAOOOOO 199AF. 15.1 M00003905C:G10 8275

432 1/28/98 432 RTAOOOOO 198AF.O.05.1 M00003750A:D01 26702

433 1/28/98 433 RTAOOOOO 198R.J.18.1 M00001653B:G07 22759

434 1/28/98 434 RTAOOOOO 187AR.d.2.2 M00001664C:H10 4892

435 1/28/98 435 RTAOOOOO 182 AR.c.22.1 M00001467A:D08 16283

436 1/28/98 436 RTA00000200AF.k.l l . l M00004197C:F03 9796

437 1/28/98 437 RTA00000198R.a.23.1 M00001563B:D1 1 10700

438 1/28/98 438 RTAOOOOO! 80AR.g.03.4 M00001425A:C1 1 9024

439 1/28/98 439 RTAOOOOO 185AF.d.14.2 M00001579D:G07 8071

440 1/28/98 440 RTAOOOOO 177ART.13.4 M00001345A:G1 1 10480

441 1/28/98 441 RTA00000185AF.e.6.1 M00001583B:E10 0

442 1/28/98 442 RTA00000191 AF.1.9.1 M00004081 C:H06 0

443 1/28/98 443 RTA00000197AR.i. l 7.1 M00001490A:E1 1 3516 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

444 1/28/98 444 RTAOOOOO 189AF.1.16.1 M00003879A:G05 0

445 1/28/98 445 RTA00000196AF.n.l3.1 M00001422C:F12 8396

446 1/28/98 446 RTA00000182AF.a.23.3 M00001463A:F06 9755

447 1/28/98 447 RTAOOOOO 198AF.d.8.1 M00001587A:H03 0

448 1/28/98 448 RTA00000200AF.J.9.1 M00004177C:A01 8608

449 1/28/98 449 RTA00000181 AF.m.22.3 M00001455D:F09 9283

450 1/28/98 450 RTA00000181 AF.m.21.3 M00001455D:F09 9283

451 1/28/98 451 RTA00000200AF.b.20.1 M00004043A:D02 40403

452 1/28/98 452 RTA00000199F.d. l9.2 M00003813D:H12 6707

453 1/28/98 453 RTA00000199AF.i.20.1 M00003881A:D09 9544

454 1/28/98 454 RTA00000200R.d.04.1 M00004078A:A06 5506

455 1/28/98 455 RTA00000198AF.d. l2.1 M00001589A:C01 21 142

456 1/28/98 456 RTA00000200AF.b.l2.1 M00004040B:F10 22053

457 1/28/98 457 RTA00000191AR.1.7.2 M00004081 C:D12 14391

458 1/28/98 458 RTAOOOOO 199R.d.16.1 M00003812C:A05 24191

459 1/28/98 459 RTAOOOOO 179AF.C.22.3 M00001393B:B09 22515

460 1/28/98 460 RTAOOOOO] 79AF.C.15.1 M00001392D:H06 2995

461 1/28/98 461 RTA00000190AF.e.l3.1 M00003908A:H09 38961

462 1/28/98 462 RTA00000196AF.n.l 7.1 M00001423D:A09 12477

463 1/28/98 463 RTAOOOOO 177 AR.k.23.4 M00001352D:D02 35550

464 1/28/98 464 RTA00000199AF.1.14.1 M00003917A:D02 22865

465 1/28/98 465 RTAOOOOO 187AF.k.20.1 M00001680B:C01 3648

466 1/28/98 466 RTAOOOOO 177AF.p.20.1 M00001361A:A05 4141

467 1/28/98 467 RTAOOOOO 195AF.b.19.1 M00001589A:D12 77678

468 1/28/98 468 RTAOOOOO 198AF.a.18.1 M00001561C.Ε11 0

469 1/28/98 469 RTAOOOOO 190AF.n.2.1 M00003963A:E03 5650

470 1/28/98 470 RTA000O0198AF.f.l6.1 M00001614A:E06 0

471 1/28/98 471 RTAOOOOO 188AF.e.2.1 M00003763B:H01 0

472 1/28/98 472 RTAOOOOO 192AF.p.17.1 M00004214C:H05 1 1451

473 1/28/98 473 RTAOOOOO 196F.i.3.1 M00001387A:E10 0

474 1/28/98 474 RTAOOOOO 192 AR.d.1.3 M00004130D:H01 14507

475 1/28/98 475 RTA00000187AR.m.3.3 M00001682C:B12 17055

476 1/28/98 476 RTA00000200R.g.l 5.1 M00004135B:G01 22898

477 1/28/98 477 RTAOOOOO 180AR.e.22.2 M00001423A:G05 7714

478 1/28/98 478 RTAOOOOO 192 AR.o.24.2 M00004210B:B05 7191

479 1/28/98 479 RTA00000197R.1.22.1 M00001528A:C1 1 6962

480 1/28/98 480 RTA00000181AF.O.08.2 M00001457C:H12 849

481 1/28/98 481 RTAOOOOO 179AR.1.22.2 M00001405B:E09 4314

482 1/28/98 482 RTAOOOOO 187AF.J.7.1 M00001679C:F01 78091

483 1/28/98 483 RTA00000192AF.h.l9.1 M00004162C:A07 4642

484 1/28/98 484 RTAOOOOO 199F.g.20.2 M00003860D:A01 15767

485 1/28/98 485 RTA00000196AF.C.14.1 M00001352B:F04 23105

486 1/28/98 486 RTAOOOOO 190AR.p.22.2 M00003979A:E1 1 16368

487 1/28/98 487 RTA00000198F.i.8.1 M00001639A:F10 9807

488 1/28/98 488 RTA00000179AR.1.22.4 M00001405B:E09 4314

489 1/28/98 489 RTAOOOOO 186AF.h.22.1 M00001634B:C10 16485

490 1/28/98 490 RTAOOOOO 198AF.n.05.1 M00001687A:G01 24157

491 1/28/98 491 RTAOOOOO 196F.k.1 1.1 M00001399C:H12 3

492 1/28/98 492 RTA00000198AF.b.8.1 M00001567C:H12 22636

493 1/28/98 493 RTA00000177AF.m. l 7.1 M00001355B:G10 14391 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

494 1/28/98 494 RTA00000200AF.k. l .l M00004188C:A09 40049

495 1/28/98 495 RTAOOOOO 185 AF.j .21.1 M00001597A:E12 0

496 1/28/98 496 RTAOOOOO 190 AF.p.3.1 M00003975B:F03 2378

497 1/28/98 497 RTA00000198AF.O.09.1 M00003751 B:A05 4310

498 1/28/98 498 RTAOOOOO 190AF.h.12.1 M00003917C:D03 12977

499 1/28/98 499 RTAOOOOO 199F.b.22.2 M00003791 C:E09 17018

500 1/28/98 500 RTAOOOOO 179AR.m.07.5 M00001405D:D1 1 0

501 1/28/98 501 RTA00000200R.U 1.1 M00004197C:F03 9796

502 1/28/98 502 RTA00000197AF.O.23.1 M00001549A:A09 12682

503 1/28/98 503 RTAOOOOO 197AF.k.9.1 M00001500C:C08 3138

504 1/28/98 504 RTA00000198AF.g.2.1 M00001615C:D02 16640

505 1/28/98 505 RTA00000188AF.n.03.1 M00003801 B:B10 9443

506 1 /28/98 506 RTAOOOOO 198R.O.09.1 M00003751 B:A05 4310

507 1/28/98 507 RTA00000198AF.C.5.1 M00001573D:F10 53802

508 1/28/98 508 RTAOOOOO 187AF.i.14.2 M00001679B:H07 19406

509 1/28/98 509 RTAOOOOO 183AF.p.17.1 M00001543A:H12 5158

510 1/28/98 510 RTA00000178AF.n.23.1 M00001387B:E02 3298

51 1 1/28/98 51 1 RTAOOOOO 196AF.g.10.1 M00001376B:A02 12498

512 1/28/98 512 RTA00000191 AF.C.3.1 M00003987D:D06 3549

513 1/28/98 513 RTA00000197AF.h.l4.1 M00001477B:F04 7045

514 1/28/98 514 RTA00000196AF.n.02.1 M00001417D:A04 39260

515 1/28/98 515 RTAOOOOO 196AF .18.1 M00001370D:A12 14506

516 1/28/98 516 RTA00000200AF.e.23.1 M00004107B:A06 14686

517 1/28/98 517 RTAOOOOO 184AF.e.14.1 M00001549C:D02 16347

518 1/28/98 518 RTAOOOOO 199 AF.n.22.1 M00003971A:A06 23064

519 1/28/98 519 RTA00000183AF.a.24.2 M00001499B:A1 1 10539

520 1/28/98 520 RTA00000195AF.C.8.1 M00001678B:H01 0

520 2/24/98 958 RTA00000195AF.C.8.1 M00001678B:H01 0

521 1/28/98 521 RTAOOOOO 197AF.p.12.1 M00001552B:G05 0

522 1/28/98 522 RTA00000178AR.h.l 7.2 M00001376A:C05 23824

523 1/28/98 523 RTA00000198AF.d.4.1 M00001586D:E02 22435

524 1/28/98 524 RTAOOOOO 191 AF.j .24.1 M00004076B:G03 0

525 1/28/98 525 RTAOOOOO 198AF.C.7.1 M00001575D:G05 19181

526 1/28/98 526 RTAOOOOO 185 AF.e.20.1 M00001585A:D06 5865

527 1/28/98 527 RTAOOOOO 198R.m.23.1 M00001684B:G03 38469

528 1/28/98 528 RTA00000200F.n.09.2 M00004249D:B08 12391

529 1/28/98 529 RTA00000178AF.b.l3.1 M00001364A:E1 1 31 14

530 1/28/98 530 RTAOOOOO 185 AF.d.24.2 M00001582D:F05 0

531 1/28/98 531 RTA00000195F.a.3.1 M00001368A:A03 27179

532 1/28/98 532 RTAOOOOO 177AF.o.4.1 M00001358C:C06 0

533 1/28/98 533 RTA00000177AR.m.l3.4 M00001355A:C12 4175

534 1/28/98 534 RTA00000201AF.e.01.1 M00004405D:C04 1 1397

535 1/28/98 535 RTA00000196AF.n.l9.1 M00001423D:D12 6881

536 1/28/98 536 RTAOOOOO 193 AR.a.2.3 M00004216D:D03 0

537 1/28/98 537 RTAOOOOO 188AF.g.14.1 M00003774C:D02 0

538 1/28/98 538 RTAOOOOO 177AR.m.13.3 M00001355A:C 12 4175

539 1/28/98 539 RTA00000197AR.b.l3.1 M00001445B:E04 9560

540 1/28/98 540 RTAOOOOO 179AF.b.10.3 M00001391D:D10 0

541 1/28/98 541 RTAOOOOO 197AR.b.16.1 M00001445C:A08 0

542 1/28/98 542 RTA00000198R.p.l2.1 M00003763D:E10 8878 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID

Priority Priority

Appln Appln

543 1/28/98 543 RTA00000200AF.i.l 9.1 M00004167A:H03 14722

544 1/28/98 544 RTAOOOOO 196F.J.13.1 M00001396D:B03 23170

545 1/28/98 545 RTA00000196F.a.2.1 M00001338B:E02 3575

546 1/28/98 546 RTA00000197F.i.6.1 M00001487C:D06 12149

547 1/28/98 547 RTAOOOOO 196AF.g.8.1 M00001375B:G12 39665

548 1/28/98 548 RTAOOOOO 179 AF.f.23.3 M00001397B:G03 35258

549 1/28/98 549 RTAOOOOO 198AF.C.16.1 M00001579C:B1 1 26801

550 1/28/98 550 RTAOOOOO 183AF.g.14.1 M00001513D:A03 0

551 1/28/98 551 RTA00000200AR.C.24.1 M00004076D:D04 15972

552 1/28/98 552 RTAOOOOO 193 AF.b.24.1 M00004237D:D08 35

553 1/28/98 553 RTA00000201 F.b.22.1 M00004344B:H04 35728

554 1/28/98 554 RTAOOOOO 186AR.e.07.4 M00001623D:G03 4175

555 1/28/98 555 RTA00000198AFJ.08.1 M00001651 B:A1 1 10983

556 1/28/98 556 RTAOOOOO 199F.f.17.2 M00003845D:B04 22905

557 1/28/98 557 RTAOOOOO 198 AF.d.9.1 M0000I 587D:A10 8841

558 1/28/98 558 RTA00000186AR.h. l 4.1 M00001632D:H07 0

559 1/28/98 559 RTA00000197AF.p.20.1 M00001554B:B07 22795

560 1/28/98 560 RTAOOOOO 184AF.i.23.3 M00001556A:F1 1 1577

561 1/28/98 561 RTA00000185AR.d.l 0.1 M00001579C:H10 0

562 1/28/98 562 RTAOOOOO 196F.J.12.1 M00001396A:H03 19294

563 1/28/98 563 RTA00000192AR.O.16.2 M00004208B:F05 9061

564 1/28/98 564 RTA00000200AF.g.l 8. I M00004138B:B1 1 1600

565 1/28/98 565 RTA00000191AF.C.10.1 M00003989B:F1 1 40422

566 1/28/98 566 RTA00000195F.a.4.1 M00001372C:G12 20470

567 1/28/98 567 RTA00000177AR.m.l3.1 M00001355A:C12 4175

568 1/28/98 568 RTAOOOOO 196AF.p.01.2 M00001430A:A02 87143

569 1/28/98 569 RTA00000196AF.1.23.1 M00001412A:E04 12052

570 1/28/98 570 RTAOOOOO 183AF.a.19.2 M00001499A:A05 3788

571 1/28/98 571 RTAOOOOO 198AF.b.14.1 M00001569C:B06 801

572 1/28/98 572 RTA00000181AF.1.16.2 M00001454D:E05 13532

573 1/28/98 573 RTA00000196AF.b.7.1 M00001344A:G07 7774

574 1/28/98 574 RTAOOOOO 192 AF.f.3.1 M00004146C:CU 5257

575 1/28/98 575 RTA00000186AF.1.12.2 M00001645A:C12 19267

576 1/28/98 576 RTA00000196AF.C.7.1 M00001350B:G1 1 0

577 1/28/98 577 RTA00000190AF.a.24.2 M00003901B:A05 0

578 1/28/98 578 RTAOOOOO 180AF.g.17.1 M00001426A:A09 16653

579 1/28/98 579 RTA00000200F.i.7.1 M00004157D:B03 22322

580 1/28/98 580 RTAOOOOO 197F.a.12.1 M00001438B:B09 7895

581 1/28/98 581 RTA00000191AF.p.3.2 M00004104B:F1 1 17

582 1/28/98 582 RTA00000178AR.d.l2.4 M00001368A:D07 2476

583 1/28/98 583 RTAOOOOO 190AR.h.12.2 M00003917C:D03 12977

584 1/28/98 584 RTAOOOOO 190AR.C.03.1 M00003904C:A08 0

585 1/28/98 585 RTAOOOOO 198AF.n.18.1 M00001771A:A07 16715

586 1/28/98 586 RTAOOOOO 199R.0.1 1.1 M00003976C:A10 23172

587 1/28/98 587 RTAOOOOO 199F.a.3.1 M00003772D:E10 16617

588 1/28/98 588 RTA00000191AF.b.4.1 M00003983C:F03 14936

589 1/28/98 589 RTAOOOOO 192AF.1.1.1 M00004183C:D07 16392

590 1/28/98 590 RTA00000190AF.d.2.1 M00003906B:F12 2444

591 1/28/98 591 RTA00000197AF.h. l .l M00001470A:H01 13075

592 1/28/98 592 RTA00000186AF.e. l 8.1 M00001624C:A06 0 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

593 1/28/98 593 RTAOOOOO 196R.C 14.2 M00001352B:F04 23105

594 1/28/98 594 RTA00000181AR.e.04.3 M00001448A:G09 1 1825

595 1/28/98 595 RTAOOOOO 195R.a.06.1 M00001394A:E04 35265

595 2/24/98 1065 RTAOOOOO 195 R.a.06.1 M00001394A:E04 35265

596 1/28/98 596 RTAOOOOO 184AF.d.9.1 M00001548A:B1 1 6515

597 1/28/98 597 RTAOOOOO 198F.a.4.1 M00001557A:F01 9635

598 1/28/98 598 RTAOOOOO 197F.e.10.1 M00001454B:D08 13154

599 1/28/98 599 RTA00000179AF.O.5.1 M00001408D:D04 6172

600 1/28/98 600 RTAOOOOO 177AF.g.4.1 M00001346B:B07 41 19

601 1/28/98 601 RTA00000184AF.i.l0.2 M00001555A:B01 3744

602 1/28/98 602 RTA00000195AF.b.21.1 M00001595B:A09 39055

602 2/24/98 317 RTAOOOOO 195 AF.b.21.1 M00001595B:A09 39055

603 1/28/98 603 RTA00000183AR.d.l l .3 M00001504D:G06 6420

604 1/28/98 604 RTA00000200AF.J.15.1 M00004185D:E04 5849

605 1/28/98 605 RTAOOOOO 196F.e.9.1 M00001361A:H07 23300

606 1/28/98 606 RTA00000179AR.e.01.4 M00001395A:C09 2493

607 1/28/98 607 RTA00000200AF.k. l2.1 M00004198B:D02 7359

608 1/28/98 608 RTAOOOOO 192 AF.p.8.1 M00004212B:C07 2379

609 1/28/98 609 RTAOOOOO 196AF.n.05.1 M00001418B:F07 12531

610 1/28/98 610 RTA00000200AF.k.2.1 M00004188D:G08 35924

61 1 1/28/98 61 1 RTA00000196F.1.13.2 M00001408A:H04 0

612 1/28/98 612 RTA00000197AR.e.22.1 M00001456A:H02 78758

613 1/28/98 613 RTAOOOOO 177AF.k.18.4 M00001352C:A05 53729

614 1/28/98 614 RTA00000201F.f.03.1 M00004493B:D09 22633

615 1/28/98 615 RTAOOOOO 197R.p.20.1 M00001554B:B07 22795

616 1/28/98 616 RTAOOOOO 188AF.m.07.1 M00003798D:E03 23183

617 1/28/98 617 RTAOOOOO 179AF.d.13.3 M00001394A:F01 6583

618 1/28/98 618 RTAOOOOO 192AF.a.14.1 M000041 1 1 D:A08 6874

619 1/28/98 619 RTA00000201 F.g.08.1 M00004692A:E07 0

620 1/28/98 620 RTA00000201 R.g.08.1 M00004692A:E07 0

621 1/28/98 621 RTA00000201 R.g.08.2 M00004692A:E07 0

622 1/28/98 622 RTAOOOOO 186AR.m.14.2 M00001649B:G12 9800

623 1/28/98 623 RTAOOOOO 198R.b.24.1 M00001571D:B1 1 19047

624 1/28/98 624 RTA00000200F.O.15.1 M00004275A:B03 7866

625 1/28/98 625 RTAOOOOO 196AF.C 19.1 M00001352C:G09 5935

626 1/28/98 626 RTAOOOOO 185 AR.d.1 1.1 M00001579D:C03 6539

627 1/28/98 627 RTAOOOOO 199F.h.15.2 M00003870A:C05 22269

628 1/28/98 628 RTAOOOOO 198AF.g.16.1 M00001621 D:D03 6602

629 1/28/98 629 RTA00000199R.m.23.1 M00003945A:E09 40166

630 1/28/98 630 RTAOOOOO 183 AR.g.03.2 M00001512D:G09 3956

631 1/28/98 631 RTA00000200AF.h.l9.2 M00004151D:E03 0

632 1/28/98 632 RTAOOOOO 183 AR.g.03.1 M00001512D:G09 3956

633 1/28/98 633 RTA00000197F.i.8.1 M00001488A:E01 6292

634 1/28/98 634 RTAOOOOO 192 AF.j.6.1 M00004172C:D08 1 1494

635 1/28/98 635 RTAOOOOO] 8 lAF.p.7.3 M00001460A:E01 38773

636 1/28/98 636 RTAOOOOO 196F.k.20.1 M00001402B:F12 6324

637 1/28/98 637 RTA00000200AF.g. l 5.1 M00004135B:G01 22898

638 1/28/98 638 RTA00000193AF.1.05.2 M00004348A:A02 2815

639 1/28/98 639 RTAOOOOO 199AF.J.1.1 M00003881 C:G09 6006

640 1/28/98 640 RTAOOOOO 190 AF.f.5.1 M00003909A:H04 5015 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

641 1/28/98 641 RTA00000198F.3.10.1 M00001558A:E1 1 6695

642 1/28/98 642 RTA00000189AF.U4.1 M00003868B:G1 1 0

643 1/28/98 643 RTAOOOOO 184AF.C.9.1 M00001546C:G10 16245

644 1/28/98 644 RTA00000197F. 2.1 M00001489B:A06 3605

645 1/28/98 645 RTAOOOOO 177AF.k.9.1 M00001352A:E02 16245

646 1/28/98 646 RTAOOOOO 186 AF.d.24.1 M00001623C:H07 31 14

647 1/28/98 647 RTA00000197F.m. l l .l M00001530B:D10 16488

648 1/28/98 648 RTA00000199F.i.9.1 M00003878C:E04 7

649 1/28/98 649 RTA00000190AR.1.19.2 M00003946A:H10 88204

650 1/28/98 650 RTAOOOOO 183 AR.n.17.1 M00001539B:H06 9800

651 1/28/98 651 RTAOOOOO 189AR.d.22.2 M00003844C:B1 1 6539

652 1/28/98 652 RTAOOOOO 178 AR.m.21.4 M00001385A:F12 7861

653 1/28/98 653 RTAOOOOO 178 AR.m.21.5 M00001385A:F12 7861

654 1/28/98 654 RTAOOOOO 186AF.J.21.2 M00001639D:B07 22506

655 1/28/98 655 RTA00000186AF.g.8.2 M00001630B:A1 1 8065

656 1/28/98 656 RTA00000178AR.h.22.3 M00001376B:A08 19230

657 1/28/98 657 RTAOOOOO 178AR.h.22.2 M00001376B:A08 19230

658 1/28/98 658 RTAOOOOO 193 AF.3.1.1 M00004216D:C03 16501

659 1/28/98 659 RTAOOOOO 185 AR.k.23.2 M00001601A:E09 0

660 1/28/98 660 RTAOOOOO 197AF.p.16.1 M00001552D:G08 6013

661 1/28/98 661 RTA00000198R.b.04.1 M00001565A:H09 0

662 1/28/98 662 RTA00000201 R.3.15.1 M00004312B:H07 57347

663 1/28/98 663 RTAOOOOO 199F.g.21.2 M00003861C:H02 34826

664 1/28/98 664 RTAOOOOO 195R.3.23.1 M00001449C:H12 86432

665 1/28/98 665 RTA00000197AF.1.22.1 M00001528A:C1 1 6962

666 1/28/98 666 RTAOOOOO 198F.i.10.1 M00001640B:F03 12792

667 1/28/98 667 RTAOOOOO 197AF.d.16.1 M00001452A:E07 23505

668 1/28/98 668 RTA00000178AF.U 7.1 M00001377C:E12 0

669 1/28/98 669 RTA00000192AF.C.2.1 M00004121B:G01 0

670 1/28/98 670 RTAOOOOO 186AF.p.17.3 M00001656B:A07 38383

671 1/28/98 671 RTAOOOOO] 85 AR.d.08.1 M00001579C:E09 6562

672 1/28/98 672 RTA00000196AF.h.09.1 M00001382B:F12 8015

673 1/28/98 673 RTA00000199F.m.3.1 M00003931 B:A1 1 0

674 1/28/98 674 RTAOOOOO 197AR.e.24.1 M00001456B:F10 39250

675 1/28/98 675 RTAOOOOO 179 AR.b.21.3 M00001392C:D05 4366

676 1/28/98 676 RTA00000197AR.m.l4.1 M00001531 B:E09 14879

677 1/28/98 611 RTAOOOOO 197AF.L 19.1 M00001490B:H1 1 39554

678 1/28/98 678 RTAOOOOO 190 AF.j .3.1 M00003922A:D02 2705

679 1/28/98 679 RTAOOOOO 197AF.d.1 1.1 M00001451C:E01 27260

680 1/28/98 680 RTAOOOOO 177AFT.10.1 M00001345A:E01 6420

681 1/28/98 681 RTA00000180AF.1.04.2 M00001432D:F05 1 1 159

682 1/28/98 682 RTA00000125A.J.16.1 M00001544A:E06 0

683 1/28/98 683 RTAOOOOO 187AR.J.01.1 M00001679C:D01 79028

684 1/28/98 684 RTA00000200AR.b.l l .l M00004040A:G12 12043

685 1/28/98 685 RTA00000200F.i.9.1 M00004159C:F09 36756

686 1/28/98 686 RTA00000201F.f.07.1 M00004497A:H03 51 1 16

687 1/28/98 687 RTAOOOOO 197AF.g.4.1 M00001464B:B03 8821

688 1/28/98 688 RTAOOOOO 193 AF.g.3.1 M00004050D:A06 5567

689 1/28/98 689 RTAOOOOO 197 AF.o.4.1 M00001542B:C06 4121

690 1/28/98 690 RTA00000198R.1.21.1 M00001673A:A04 19194 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Dste of NO: in ID Priority Priority Appln Appln

691 1/28/98 691 RTAOOOOO 195F.3.10.1 M00001401 C:H03 6803

692 1/28/98 692 RTAOOOOO 199F.e.4.1 M00003820B:C05 0

693 1/28/98 693 RTA00000198F.m. l2.1 M00001679C:D05 4

694 1/28/98 694 RTA00000201 R.C.19.1 M00004370A:G05 22357

695 1/28/98 695 RTA00000197F.m.5.1 M00001528C:H04 10872

696 1/28/98 696 RTAOOOOO 180AR.d.16.3 M00001419D:C10 1 1393

697 1/28/98 697 RTA00000193AF.e.21.1 M00004271 B:B06 0

698 1/28/98 698 RTAOOOOO 179AF.g.1.3 M00001397C:A10 7588

699 1/28/98 699 RTAOOOOO 178AF.3.12.1 M00001362B:H06 0

700 1/28/98 700 RTA00000183AF.i.l 8.2 M00001529D:H02 40129

701 1/28/98 701 RTAOOOOO 199AF.0.10.1 M00003974C:E04 0

702 1/28/98 702 RTAOOOOO 177AR.b.8.5 M00001340B:A06 17062

703 1/28/98 703 RTAOOOOO 198F.1.09.1 M00001664B:D06 361 1

704 1/28/98 704 RTAOOOOO 190AF.0.12.1 M00003972D:C09 3438

705 1/28/98 705 RTAOOOOO] 96F.i.5.1 M00001387B:A06 0

706 1/28/98 706 RTA00000177AF.i.6.4 M00001350A:B08 0

707 1/28/98 707 RTAOOOOO 179AF.p.15.1 M0000141 1 D:F05 5622

708 1/28/98 708 RTA00000201 F.f.06.1 M00004496C:H03 23771

709 1/28/98 709 RTAOOOOO 192AF.d.18.1 M00004135D:G02 0

710 1/28/98 710 RTA00000196AF.1.3.1 M00001405B:D07 20864

71 1 1/28/98 71 1 RTA00000198F.i.2.1 M00001637B:E07 8076

712 1/28/98 712 RTA00000201F.b.21.1 M00004341 B:G03 9071

713 1/28/98 713 RTAOOOOO 198AF.g.21.1 M00001624A:F09 6273

714 1/28/98 714 RTA00000199R.g.07.1 M00003853D:D03 0

715 1/28/98 715 RTAOOOOO 197 AR.k.1 1.1 M00001500D:E10 53758

716 1/28/98 716 RTA00000200F.p.05.1 M00004285C:A08 3984

717 1/28/98 717 RTA00000200F.O.10.2 M00004269B:C08 36432

718 1/28/98 718 RTA00000196F.1.14.2 M00001408B:G06 23144

719 1/28/98 719 RTAOOOOO 183AF.b.12.1 M00001500A:B02 0

720 1/28/98 720 RTAOOOOO 197AF.f.14.1 M00001459B:C09 3732

721 1/28/98 721 RTAOOOOO 180AF.C.4.1 M00001417B:C04 5415

722 1/28/98 722 RTAOOOOO 199R.J .24.1 M00003895C:A10 0

723 1/28/98 723 RTAOOOOO 183 AF.p.24.1 M00001543C:F01 31 16

724 1/28/98 724 RTA00000177AR.f.l 5.4 M00001345B:E10 9062

725 1/28/98 725 RTA00000197AF.b.l .l M00001441D:E04 12134

726 1/28/98 726 RTA00000200R.f.l0.1 M000041 1 1D:B07 4

727 1/28/98 727 RTAOOOOO 184AF.n.12.2 M00001561D:C 1 1 3727

728 1/28/98 728 RTAOOOOO 177 ART.17.4 M00001345C:B01 8594

729 1/28/98 729 RTAOOOOO 184AF.3.19.1 M00001544C:C06 2628

730 1/28/98 730 RTAOOOOO 192 AF.o.1 1.1 M00004205D:F06 0

731 1/28/98 731 RTAOOOOO 184F.k.02.1 M00001557B:H10 5192

732 1/28/98 732 RTAOOOOO 186AF.p.01.2 M00001654D:G1 1 40440

733 1/28/98 733 RTA00000200AF.d.20.1 M00004087A:G08 26600

734 1/28/98 734 RTA00000200AF.d.21.1 M00004087C:D03 0

735 1/28/98 735 RTAOOOOO 192AF.b.1 1.1 M000041 17A:G01 40014

736 1/28/98 736 RTA00000196AF.O.13.1 M00001428B:A09 0

737 1/28/98 737 RTA00000189AR.m.9.1 M00003880B:C08 2917

738 1/28/98 738 RTAOOOOO 183 AF.o.8.1 M00001540C:B10 8927

739 1/28/98 739 RTA00000181AF.p.l2.3 M00001460C:H02 22204

740 1/28/98 740 RTAOOOOO 198AF.d.15.1 M00001590C:H08 5997 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

741 1/28/98 741 RTA00000196AF.n.22.1 M00001424B:H04 9572

742 1/28/98 742 RTAOOOOO 177AF.m.1.1 M00001353D:D10 14929

743 1/28/98 743 RTAOOOOO 178 AF.k.9.1 M00001381 B:F06 16342

744 1/28/98 744 RTAOOOOO 196F.m.4.1 M00001413A:F03 7958

745 1/28/98 745 RTAOOOOO 183 AF.m.1 1.1 M00001536D:G02 8927

746 1/28/98 746 RTA00000178AF.Ϊ.01.2 M00001376B:F03 4

747 1/28/98 747 RTAOOOOO 190AF.C.6.1 M00003904D:D10 4780

748 1/28/98 748 RTA00000198AF.b.24.1 M00001571 D:B 1 1 19047

749 1/28/98 749 RTAOOOOO 178AR.L 13.4 M00001377B:H01 0

750 1/28/98 750 RTA00000198AF.a.l 9.1 M00001561 D:C05 0

751 1/28/98 751 RTAOOOOO 179AF.C.4.3 M00001392D:B1 1 0

752 1/28/98 752 RTA00000192AF.O.7.1 M00004204D:C03 5275

753 1/28/98 753 RTAOOOOO 192AF.0.17.1 M00004208D:B10 5275

754 1/28/98 754 RTA00000187AF.1.1 1.1 M00001681A:F03 4482

755 1/28/98 755 RTAOOOOO 199F.C.21.2 M00003803C:D09 5070

756 2/24/98 1 RTA00000404F.a.02.1 M00001589B:E12 9738

757 2/24/98 2 RTA00000406F.d. l 6.1 M00003875C:G02 15040

758 2/24/98 3 RTA00000420F.d. l 8.1 M00004105C:B05 63074

759 2/24/98 4 RTA00000339F.i.20.1 M00001438D:C06 4356

760 2/24/98 5 RTA00000408F.O.12.2 M00001572A:A10 78578

761 2/24/98 6 RTAOOOOO 1 19A.J.15.1 M00001460A:E1 1 79623

762 2/24/98 7 RTA00000413F.d.l2.1 M00004088C:A12 66467

763 2/24/98 8 RTA00000423F.U2.1 M00003914D:E03 91 18

764 2/24/98 9 RTA00000406F.n.02.1 M00003918C:H10 15051

765 2/24/98 10 RTA00000350R.C.12.1 M00001550D:A04 9728

766 2/24/98 1 1 RTA0000041 1F.k.05.1 M00003850D:B05 64777

767 2/24/98 12 RTA00000339F.b.l 7.1 M00001366D:E12 10020

768 2/24/98 13 RTA00000406FT.18.1 M00003879B:G02 38587

769 2/24/98 14 RTA00000419F.b.09.1 M00001694C:F12 78128

770 2/24/98 15 RTA00000419F.C.19.1 M00003820A:A08 64346

771 2/24/98 16 RTA00000399F.a.02.1 M00001366D:C12 0

772 2/24/98 17 RTA0000041 1 F.m.l 5.1 M00003868D:B09 78014

773 2/24/98 18 RTA00000420F.g.l2.1 M00004895B:G04 0

774 2/24/98 19 RTAOOOOO 123 A.k.23.1 M00001533A:G05 80313

775 2/24/98 20 RTA00000404F.m.04.2 M00001641A:A1 1 22720

776 2/24/98 21 RTA0000041 1F.g.08.1 M00003822D:D04 45815

777 2/24/98 22 RTA00000130A.m.l 5.1 M00001622A:H12 81630

778 2/24/98 23 RTA0000041 1 F.k.20.1 M00003854B:A07 64973

779 2/24/98 24 RTA00000423F.1.09.1 M000041 18A:H08 9752

780 2/24/98 25 RTA00000418F.k.05.1 M00001637A:A06 73021

781 2/24/98 26 RTA00000423F.h.l 8.1 M00003876C:D02 37972

782 2/24/98 27 RTA00000420F.n.l9.2 M00005259B:C01 0

783 2/24/98 28 RTA00000422F.p.06.2 M00001661 A:B1 1 39282

784 2/24/98 29 RTA00000404F.n.l6.2 M00001649C:D05 39095

785 2/24/98 30 RTA0000041 1 F.m.24.1 M00003870B:B08 77568

786 2/24/98 31 RTAOOOOO 134A.J.10.1 M00001534A:G06 81383

787 2/24/98 32 RTA00000409FJ.02.1 M0000161 1 B:E06 76417

788 2/24/98 33 RTA00000403F.J..15.1 M00001539B:G07 23840

789 2/24/98 34 RTA0000041 1 F.n.l l . l M00003875A:B01 77276

790 2/24/98 35 RTA00000339F.U3.1 M00001434A:B10 5970 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

791 2/24/98 36 RTA00000414F.e.22.1 M00005257D:A06 0

792 2/24/98 37 RTA00000406F.O.15.1 M00003988D:A08 37482

793 2/24/98 38 RTA00000412F.g.04.2 M00003971 B:B07 64457

794 2/24/98 39 RTA00000187AF.I.7.1 M00001680D:F08 10539

795 2/24/98 40 RTA00000352R.1.06.1 M00004187D:H06 40343

796 2/24/98 41 RTA00000419F.b. l2.1 M00003806B:C09 63148

797 2/24/98 42 RTA00000423F. 17.2 M00004038A:F02 37512

798 2/24/98 43 RTA00000420F.g.04.1 M00004891 B:B12 0

799 2/24/98 44 RTA00000418F. 4.1 M00001639A:H06 76133

800 2/24/98 45 RTA00000409F.1.12.1 M00001615A:D06 26755

801 2/24/98 46 RTA00000404F.C.20.1 M00001594A:D08 39088

802 2/24/98 47 RTA00000423F.g.09.1 M00003904C:B06 38958

803 2/24/98 48 RTA0000041 1 F.b.24.1 M00001677B:A12 30041

804 2/24/98 49 RTA00000406F.d.l2.1 M00003875C:A01 38575

805 2/24/98 50 RTA0000041 1 F.f.02.1 M00003813A:D08 63386

806 2/24/98 51 RTAOOOOO 129 A.n.21.1 M00001604A:C 1 1 79381

807 2/24/98 52 RTA00000409F.m.l2.1 M00001618B:D09 73490

808 2/24/98 53 RTA00000410F.C.04.1 M00001633D:G09 74099

809 2/24/98 54 RTA00000399F.O.01.1 M00001595C:E01 3055

810 2/24/98 55 RTA00000406F.m.09.1 M00003914C:H05 26891

81 1 2/24/98 56 RTA0000041 1 F.b.06.1 M00001676C:A04 77884

812 2/24/98 57 RTA00000409F.1.21.1 M00001615B:G07 73143

813 2/24/98 58 RTA00000420F.m.l 8.1 M00005254D:A10 0

814 2/24/98 59 RTA00000346F.J.08.1 M00003879B:A06 39951

815 2/24/98 60 RTA00000413F.p.l 7.2 M00005136D:G06 0

816 2/24/98 61 RTA00000410F.n.07.1 M00001662A:G01 78823

817 2/24/98 62 RTA00000339F.n.l0.1 M00001453B:F08 13719

818 2/24/98 63 RTA00000404F.1.20.2 M00001639B:H05 38638

819 2/24/98 64 RTA00000413F.d. l 8.1 M00004090B:B04 65305

820 2/24/98 65 RTA00000404F.p.04.2 M00001652D:E05 39069

821 2/24/98 66 RTA00000405F.g.l9.2 M00001673A:G08 37150

822 2/24/98 67 RTA00000409F.a.22.1 M00001583B:F02 75200

823 2/24/98 68 RTA00000339F.n.03.1 M00001449B:B03 0

824 2/24/98 69 RTA00000405F.O.18.1 M00003839A:D07 1 1016

825 2/24/98 70 RTA00000409F.m. l3.1 M00001618B:E05 0

826 2/24/98 71 RTAOOOOO 120A.d.24.1 M00001464A:E10 5085

827 2/24/98 72 RTA00000347F.a.08.1 M00001592C:G04 3135

828 2/24/98 73 RTA00000413F.p.l5.2 M00005136D:D06 0

829 2/24/98 74 RTA00000408F.e.22.2 M00001476B:F08 26930

830 2/24/98 75 RTA00000350R.i.22.1 M00001608B:A03 0

831 2/24/98 76 RTA00000413F.d. l6.1 M00004088C:F01 63331

832 2/24/98 77 RTA00000420F.J.22.1 M00005173B:F01 0

833 1/28/98 59 RTA00000195AF.b. l3.1 M00001560D:A03 12605

833 2/24/98 78 RTA00000195AF.D.13.1 M00001560D:A03 12605

834 2/24/98 79 RTA00000419F.g.08.1 M00003842C:D1 1 66700

835 2/24/98 80 RTA00000122A.g. l 6.1 M00001514A:B04 81366

836 2/24/98 81 RTA00000419F.C.16.1 M00003819D:B01 65254

837 2/24/98 82 RTA0000041 1 F.b.03.1 M00001676B:E01 23634

838 2/24/98 83 RTA00000405F.e.l l .2 M00001663D:C06 9331

839 2/24/98 84 RTA00000352R.U5.1 M00004153B:B03 4363 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

840 2/24/98 85 RTA00000339F.k.22.1 M00001427C:D01 5556

841 2/24/98 86 RTA00000346F.g.22.1 M00003794D:G03 6371

842 2/24/98 87 RTA00000403F.1.20.1 M00001573A:A06 18267

843 2/24/98 88 RTA00000420F.i.24.1 M00005134B:E08 0

844 2/24/98 89 RTA00000406F.C.08.1 M00003870C:A10 22387

845 2/24/98 90 RTA0000041 1 F.a.02.1 M00001675B:E02 78537

846 2/24/98 91 RTA00000355R.e.l 5.1 M00004316A:G09 22639

847 2/24/98 92 RTA00000412F.1.04.1 M00003989D:F12 66372

848 2/24/98 93 RTA00000413F.p.24.1 M00005139A:H03 0

849 2/24/98 94 RTA00000406F.a.23.1 M00003867B:D10 38712

850 2/24/98 95 RTA00000423F.h.05.1 M00003906A:F04 14837

851 2/24/98 96 RTAOOOOO 120A.n.19.3 M00001467A:H07 80004

852 2/24/98 97 RTA00000403F.e.01.1 M00001473A:C1 1 38965

853 2/24/98 98 RTA0000041 1 F.1.03.1 M00003854D:A12 62702

854 2/24/98 99 RTA00000420F.m.l9.1 M00005254D:B08 0

855 2/24/98 100 RTA00000339F.O.23.1 M00001473C:D09 7801

856 2/24/98 101 RTAOOOOO 121 A.m.2.1 M00001507A:A1 1 81064

857 2/24/98 102 RTA00000420F.g.06.1 M00004891 C:D04 0

858 2/24/98 103 RTA00000418F.J.12.1 M00001626C:G08 73316

859 2/24/98 104 RTA00000421 F.n.03.1 M00001675C:A04 1638

860 2/24/98 105 RTA00000346F.d.08.1 M00001671A:A10 39955

861 2/24/98 106 RTA00000339F.f.l l .l M00001391 C:H02 5832

862 2/24/98 107 RTA00000125A.g. l6.1 M00001544A:C09 21497

863 2/24/98 108 RTA00000418F.O.18.1 M00001661 B:F06 78676

864 2/24/98 109 RTA00000422F.p.24.2 M00001658A:G09 5823

865 2/24/98 1 10 RTA00000408F.k.l4.1 M00001486B:E12 73856

866 2/24/98 1 1 1 RTA00000128A.i.20.1 M00001560A:F03 9900

867 2/24/98 1 12 RTA00000422F.C.1 1.1 M00003841 D:A04 2643

868 2/24/98 1 13 RTA00000401 F.e.02.1 M00003805B:C04 0

869 2/24/98 1 14 RTA00000341 F.m.21.1 M00004051 D:E01 0

870 2/24/98 1 15 RTA00000418F.h.l9.1 M00001590B:C05 0

871 2/24/98 1 16 RTA00000403F.O.15.1 M00001582B:E12 39140

872 2/24/98 1 17 RTA00000341 F.m.l3.1 M00003987B:E12 26502

873 2/24/98 1 18 RTA00000408F.h.03.1 M00001479D:H03 78382

874 2/24/98 1 19 RTA00000423F.k.05.1 M00004036D:F02 37472

875 2/24/98 120 RTA00000401 F.m.02.1 M00003907A:F01 1573

876 2/24/98 121 RTA00000418F.p. l9.1 M00001677D:B01 78544

877 2/24/98 122 RTA00000420F.f.06.1 M000041 15D:D08 64812

878 2/24/98 123 RTAOOOOO 122A.J.18.1 M00001516A:D05 81317

879 2/24/98 124 RTA00000420F.d.05.1 M00004092B:E05 64432

880 2/24/98 125 RTA00000403F.m. l 8.1 M00001576A:B09 39185

881 2/24/98 126 RTA00000422F .20.1 M00001653A:G07 22388

882 2/24/98 127 RTA0000041 1 F.J.05.1 M00003841 C:F06 40709

883 2/24/98 128 RTA00000403F.a.04.1 M00001448A:B12 23529

884 2/24/98 129 RTAOOOOO 1 18A.d.24.1 M00001416A:H02 81488

885 2/24/98 130 RTA00000406F.f.l2.1 M00003879A:C 1 1 21895

886 2/24/98 131 RTA00000418F.g.22.1 M00001585B:F01 74837

887 2/24/98 132 RTA00000418F.m.05.1 M00001650B:C 10 73600

888 2/24/98 133 RTA00000404F.1.20.1 M00001639B:H05 38638

889 2/24/98 134 RTA00000408F.i.08.2 M00001482A:H05 7581 1 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

890 2/24/98 135 RTA00000122A.d.5.1 M00001513A:F05 81 155

891 2/24/98 136 RTA00000419F.1.12.1 M00003901 C:B01 75710

892 2/24/98 137 RTA00000339R.a.06.1 M00001346A:E04 58694

893 2/24/98 138 RTA00000406F.f.03.1 M00003878C:D08 38687

894 2/24/98 139 RTA00000419F.b.l9.1 M00003809A:C01 65534

895 2/24/98 140 RTA00000128A.J.6.2 M00001560A:H10 5316

896 2/24/98 141 RTA00000418F. 19.1 M00001639C:C02 74932

897 2/24/98 142 RTA00000420F.J.19.1 M00005140C:B10 0

898 2/24/98 143 RTA00000420F.h. l3.1 M00004899D:G06 0

899 2/24/98 144 RTA00000349R .15.1 M00001472A:D08 75097

900 2/24/98 145 RTA00000419F.g.l2.1 M00003842C:G03 66171

901 2/24/98 146 RTA00000404F.n.l l .2 M00001649A:E1 1 38001

902 2/24/98 147 RTA00000422F.C.02.1 M000041 18B:A03 2902

903 2/24/98 148 RTA00000419F.n.04.1 M00003975C:F07 13102

904 2/24/98 149 RTA00000419F.O.24.1 M00004031A:F07 65092

905 2/24/98 150 RTA00000419F.L 19.1 M00003877C:G 12 75447

906 2/24/98 151 RTA00000341 F.C.21.1 M00003789C:F06 7899

907 2/24/98 152 RTA00000127A.i.20.1 M00001555A:B12 81418

908 2/24/98 153 RTA00000422F.g.22.1 M00001585B:A06 22561

909 2/24/98 154 RTA00000340F.b.21.1 M00001533D:A08 8001

910 2/24/98 155 RTA00000413F.h.l3.1 M00004107A:D01 65190

91 1 2/24/98 156 RTA00000125A.k.l .l M00001545A:B12 0

912 2/24/98 157 RTA00000339F.3.23.1 M00001361B:C07 4022

913 2/24/98 158 RTA00000348R.J.16.1 M00001410A:D07 7005

914 2/24/98 159 RTA00000348R.J.17.1 M00001391 D:C06 2641

915 2/24/98 160 RTA00000414F.f i 9.1 M00005260B:E1 1 0

916 2/24/98 161 RTA00000418F.n.22.1 M00001659D:B05 79062

917 2/24/98 162 RTA00000406F.1.08.1 M00003908D:D12 39016

918 2/24/98 163 RTA00000422F.1.23.1 M00001616D:C1 1 4240

919 2/24/98 164 RTA00000345F.k.06.1 M00001475A:A12 0

920 2/24/98 165 RTA00000409F.J.07.1 M0000161 1C:H1 1 75190

921 2/24/98 166 RTA00000418F.m.l9.1 M00001654D:A03 8890

922 2/24/98 167 RTA00000399F.1.14.1 M00001590B:G08 3354

923 2/24/98 168 RTA0000041 1 F.e.22.1 M00003812B:D07 63638

924 2/24/98 169 RTA00000347F.a.l 7.1 M00001366D:C06 16723

925 2/24/98 170 RTA00000422F.n.08.1 M00001632B:E05 38655

926 2/24/98 171 RTA00000404F.n.20.1 M00001650A:C1 1 26865

927 2/24/98 172 RTA00000420F.U 7.1 M00005101C:B09 0

928 2/24/98 173 RTA00000418F.d.l3.1 M00001570A:H01 74309

929 2/24/98 174 RTA00000404F.b.02.1 M00001591B:B12 38984

930 2/24/98 175 RTA00000410F.d.09.1 M00001635B:H01 76964

931 2/24/98 176 RTA00000403F.b. l0.1 M00001455C:G07 73268

932 2/24/98 177 RTA00000406F. 2.1 M00003903D:H1 1 39080

933 2/24/98 178 RTA00000406F.h.08.1 M00003901 C:A08 16228

934 2/24/98 179 RTA00000418F.i.l9.1 M00001596D:E03 79180

935 2/24/98 180 RTA00000400F.J.19.1 M00001653C:D10 4086

936 2/24/98 181 RTA00000412F.h.21.1 M00003974D:F02 64348

937 2/24/98 182 RTA00000404F.g.l4.1 M00001614D:B08 8858

938 2/24/98 183 RTAOOOOO 120A.g.18.1 M00001465A:C12 81255

939 2/24/98 184 RTAOOOOO 133 A.j.13.1 M00001507A:B02 16846 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

940 2/24/98 185 RTA00000423F.J.05.1 M00003903C:C05 37958

941 2/24/98 186 RTAOOOOO 132 A.k.6.1 M00001464A:E07 81284

942 2/24/98 187 RTA00000351 R.g.l l .l M00003779D:E08 3077

943 2/24/98 188 RTA00000406F.p.04.1 M00004030D:F1 1 37458

944 2/24/98 189 RTA00000347F.3.13.1 M00001402D:F02 22446

945 2/24/98 190 RTA00000419F.p.23.1 M00004039B:A05 64748

946 2/24/98 191 RTA00000419F.d.l 7.1 M00003828B:F09 64353

947 2/24/98 192 RTA00000421 F.k.l 5.1 M00001613D:B03 2222

948 2/24/98 193 RTA00000347F.b.l0.1 M00001546C:C07 8044

949 2/24/98 194 RTAOOOOO 124A.k.5.1 M00001538A:F12 80252

950 2/24/98 195 RTA00000404F.h.22.1 M00001619C:C07 18735

951 2/24/98 196 RTA00000418F.k.l0.1 M00001639A:G07 74454

952 2/24/98 197 RTA00000410F.O.05.1 M00001669A:B02 75262

953 2/24/98 198 RTA00000339R.1.14.1 M00001452A:C07 191 19

954 2/24/98 199 RTA00000403F.m.l3.2 M00001575D:A10 39077

955 2/24/98 200 RTA00000339F.C.02.1 M00001381 C:B08 12975

956 2/24/98 201 RTA00000404F.1.09.1 M00001638B:E12 39176

957 2/24/98 202 RTA00000419F.g.22.1 M00003845D:A09 64515

958 2/24/98 203 RTA00000404F.g.21.1 M00001615C:A1 1 37947

959 2/24/98 204 RTA00000351 R.k.l9.1 M00003841B:E03 936

960 2/24/98 205 RTAOOOOO 138A.n.4.1 M00001624A:G1 1 21920

961 2/24/98 206 RTA00000410F.b.l5.1 M00001633C:F09 77100

962 2/24/98 207 RTA00000414F.b.08.1 M00005212C:H02 0

963 2/24/98 208 RTA00000419F.J.23.1 M00003871A:C1 1 74470

964 2/24/98 209 RTA0000041 1 F.J.02.1 M00003841C:D07 65310

965 2/24/98 210 RTA00000419F.p.24.1 M00004039B:E12 63477

966 2/24/98 21 1 RTA00000404F.a.l9.1 M00001590B:C07 38624

967 2/24/98 212 RTA00000408F.k.06.1 M00001485C:H10 78393

968 2/24/98 213 RTAOOOOO 123 A.f.3.1 M00001531 A:H07 44017

969 2/24/98 214 RTA00000404F.h.l9.1 M00001619A:E05 8096

970 2/24/98 215 RTA00000403F.J.18.1 M00001539D:E10 5790

971 2/24/98 216 RTA00000420F.i.l 8.1 M00005101 C:E09 0

972 2/24/98 217 RTA00000399F.O.17.1 M00001599D:A09 1 106

973 2/24/98 218 RTA00000346F.e.l3.1 M00001660B:D03 74653

974 2/24/98 219 RTA00000419F.C.18.1 M00003819D:B1 1 41394

975 2/24/98 220 RTA00000413F.k.02.1 M00004690A:G08 0

976 2/24/98 221 RTA00000414FT.13.1 M00005259D:H08 0

977 2/24/98 222 RTA00000405F.e.09.1 M00001663C:F12 38978

978 2/24/98 223 RTA00000404F.e.22.1 M00001610A:H05 1 1344

979 2/24/98 224 RTA00000341 F.g.21.1 M00003914C:F09 8823

980 2/24/98 225 RTA00000414F.d.07.1 M00005229D:H09 0

981 2/24/98 226 RTAOOOOO 125A.k.10.1 M00001545A:F02 81644

982 2/24/98 227 RTA00000347F.C.06.1 M00001444D:C01 18846

983 2/24/98 228 RTA0000041 1 F.k.l9.1 M00003852D:E08 64200

984 2/24/98 229 RTA00000345F.i.09.1 M00001450A:D08 27250

985 2/24/98 230 RTA00000423F.k.01.1 M00004034D:E09 40426

986 2/24/98 231 RTA00000408F.d.06.1 M00001458D:C1 1 78997

987 2/24/98 232 RTAOOOOO 128 A.b.20.1 M00001558A:GO9 79761

988 2/24/98 233 RTA00O00403F. 08.1 M00001485C:B10 6176

989 2/24/98 234 RTA00000195AF.d.4.1 M00003881 D:D06 22766 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

989 1/28/98 185 RTAOOOOO 195 AF.d.4.1 M00003881 D:D06 22766

990 2/24/98 235 RTA00000126A.O.23.1 M00001551 A:B10 6268

991 2/24/98 236 RTA00000403F.h. l2.1 M00001483C:G09 15205

992 2/24/98 237 RTAOOOOO 1 19A.J .22.1 M00001460A:F07 80336

993 2/24/98 238 RTA00000340F.J.12.1 M00001624A:B06 3277

994 2/24/98 239 RTA00000346F.J.02.1 M00003832B:E01 5294

995 2/24/98 240 RTAOOOOO 126A.n.7.2 M00001551 A:D06 79557

996 2/24/98 241 RTA00000339F.d. l3.1 M00001395C:F1 1 0

997 2/24/98 242 RTA00000404F.J.08.1 M00001629B:B08 39066

998 2/24/98 243 RTA00000410F.C.14.1 M00001634A:H05 77809

999 2/24/98 244 RTAOOOOO 120A.g.23.1 M00001465A:E10 81 189

1000 2/24/98 245 RTAOOOOO 195 AF.d.20.1 M000041 17A:D1 1 37574

1000 1/28/98 87 RTA00000195AF.d.20.1 M000041 17A:D1 1 37574

1001 2/24/98 246 RTA00000414F.C.14.1 M00005218A:G05 0

1002 2/24/98 247 RTA00000412F.J.17.1 M00003982C:G04 64071

1003 2/24/98 248 RTA00000404F.k.24.1 M00001636A:C03 15256

1004 2/24/98 249 RTA000001 19A.J.10.1 M00001460A:C10 79646

1005 2/24/98 250 RTA00000410F.O.12.1 M00001669A:G 12 77376

1006 2/24/98 251 RTA000001 19A.i.9.1 M00001457A:G03 0

1007 2/24/98 252 RTA00000412F.g.24.1 M00003973C:C03 28741

1008 2/24/98 253 RTA00000400F.f. l 8.1 M00001637A:E10 3764

1009 2/24/98 254 RTA00000341 F.1.15.1 M00003986B:A08 5294

1010 2/24/98 255 RTA00000419F.O.16.1 M00003989C:G05 62867

101 1 2/24/98 256 RTA00000404F.m.03.2 M00001640A:H02 1 1799

1012 2/24/98 257 RTA0000041 1 F.C.17.1 M00001678D:G03 77664

1013 2/24/98 258 RTA00000406F.k.l 5.1 M00003907C:C04 38549

1014 2/24/98 259 RTA00000406F.a.02.1 M00003855C:F10 37744

1015 2/24/98 260 RTA00000414F.e.08.1 M00005236A:E04 0

1016 2/24/98 261 RTA00000341 F.b.06.1 M00003794A:E12 17008

1017 2/24/98 262 RTA00000409F.n.l4.1 M00001621 B:G05 78190

1018 2/24/98 263 RTA00000410F.p. l 7.1 M00001674D:C 10 47425

1019 2/24/98 264 RTA00000345FJ.08.1 M00001451 B:A04 16731

1020 2/24/98 265 RTA00000340F.k. l 6.1 M00001647B:C09 13157

1021 2/24/98 266 RTA00000419F.g. l5.1 M00003844D:A07 32519

1022 2/24/98 267 RTA00000423F.a.l 9.1 M00001676D:A02 21396

1023 2/24/98 268 RTA00000403F.e.23.1 M00001476A:D1 1 9626

1024 2/24/98 269 RTA00000422F.e.08.1 M00001573A:E01 39020

1025 2/24/98 270 RTA0000041 1 F.d.l5.1 M00001692A:B06 74890

1026 2/24/98 271 RTA00000414F.e.l 6.1 M00005236B:H 10 0

1027 2/24/98 272 RTA0000041 1 F.1.15.1 M00003857C:F 1 1 66704

1028 2/24/98 273 RTA00000400F.a. l l . l M00001612B:D1 1 0

1029 2/24/98 274 RTA00000405F.e.08.1 M00001663C:F10 37916

1030 2/24/98 275 RTA00000353RJ.24.1 M00001428B:D01 23089

1031 2/24/98 276 RTA00000423F.a. l 8.1 M00001675A:G 10 26761

1032 2/24/98 277 RTA00000418F.O.06.1 M00001660C:D1 1 75930

1033 2/24/98 278 RTA00000404F.C.10.1 M00001593B:E1 1 23534

1034 2/24/98 279 RTA00000418FL21 .1 M00001596D:E10 78728

1035 2/24/98 280 RTA00000418F.p.l5.1 M00001671C:C1 1 31066

1036 2/24/98 281 RTA0000041 1 F.I.13.1 M00003857C:C09 431 14

1037 2/24/98 282 RTA00000407F.a.24.1 M00004083A:E08 37560 SEQ ID Filing SEQ ID Sequence Nsme Clone Nsme Cluster

NO: Dste of NO: in ID

Priority Priority

Appln Appln

1038 2/24/98 283 RTA00000346F.n.06.1 M00004139C:A12 12439

1039 2/24/98 284 RTA00000412F.1.21.1 M00004029C:G10 65183

1040 2/24/98 285 RTA00000413F.i.02.1 M00004110D:A10 65857

1041 2/24/98 286 RTA00000404F.i.l9.1 M00001625B:C10 38698

1042 2/24/98 287 RTA00000410F.n.09.1 M00001662C:A04 11736

1043 2/24/98 288 RTA00000403F.a.ll.1 M00001448C.-F10 73109

1044 2/24/98 289 RTA00000420F.n.08.1 M00005257A:H11 0

1045 2/24/98 290 RTA00000411F.k.l6.1 M00003852C:B06 64759

1046 2/24/98 291 RTA00000405F.C.01.1 M00001657D:A04 19236

1047 2/24/98 292 RTA00000423F.U8.1 M00003918A:D08 14996

1048 2/24/98 293 RTA00000403F.1.04.1 M00001571C:A04 39278

1049 2/24/98 294 RTA00000405F.1.17.1 M00003805A.-F02 17225

1050 2/24/98 295 RTA00000406F.a.07.1 M00003856C:H09 26607

1051 2/24/98 296 RTA00000347F.d.06.1 M00001457C:F02 39122

1052 2/24/98 297 RTA00000419F.b.l8.1 M00003808D:D08 67034

1053 2/24/98 298 RTA00000406F.h.07.1 M00003901B:H04 38003

1054 2/24/98 299 RTA00000405F.1.15.1 M00001694A.Ε03 19575

1055 2/24/98 300 RTA00000406F.g.l7.1 M00003881B:F10 37979

1056 2/24/98 301 RTA00000401F.m.23.1 M00003914C:C02 2801

1057 2/24/98 302 RTA00000356RT.18.1 M00004692A:H10 0

1058 2/24/98 303 RTAOOOOO 130A.h.22.1 M00001617A:D06 80933

1059 2/24/98 304 RTA00000403F.n.l8.2 M00001577D:H06 8811

1060 2/24/98 305 RTA00000418F.p.06.1 M00001664A:F08 32628

1061 2/24/98 306 RTA00000404F.d.l3.1 M00001595D:A04 39036

1062 2/24/98 307 RTA00000420F.1.12.2 M00005230B:H09 0

1063 2/24/98 308 RTA00000353R.d.ll.l M00004692A:H08 0

1064 2/24/98 309 RTA00000340F.n.01.1 M00001679A:G06 39081

1065 2/24/98 310 RTA00000419F.d.06.1 M00003820B:D07 65496

1066 2/24/98 311 RTA00000419F.n.09.1 M00003977C:A06 66070

1067 2/24/98 312 RTA00000399F.i.08.1 M00001575D:B10 38927

1068 2/24/98 313 RTA00000406F.g.07.1 M00003880C:E11 37925

1069 2/24/98 314 RTA00000423F.g.l3.1 M00003905A:E07 38028

1070 2/24/98 315 RTA00000419F.p.l2.1 M00004037A:E04 13767

1071 2/24/98 316 RTA00000414F.a.02.1 M00005178D:H04 0

1072 2/24/98 317 RTA00000195AF.b.21.1 M00001595B:A09 39055

1072 1/28/98 602 RTA00000195AF.b.21.1 M00001595B:A09 39055

1073 2/24/98 318 RTA00000403F.h.05.1 M00001482D:A04 39096

1074 2/24/98 319 RTA00000420F.b.21.1 M00004088D:B10 65057

1075 2/24/98 320 RTA00000422F.p.07.2 M00001661A:E06 39024

1076 2/24/98 321 RTA00000339F.C.21.1 M00001389C:A08 5325

1077 2/24/98 322 RTA00000339F.C.24.1 M00001364B:B06 5516

1078 2/24/98 323 RTA00000421F.n.l9.1 M00001679A:D10 16409

1079 2/24/98 324 RTA00000340F.p.l7.1 M00003750C:H05 0

1080 2/24/98 325 RTA00000345F. 21.1 M00001464B:C11 40204

1081 2/24/98 326 RTA00000419F.b.l5.1 M00003806D:D11 43969

1082 2/24/98 327 RTA00000405F.3.11.1 M00001655A:B11 39124

1083 2/24/98 328 RTA00000423F.L19.2 M00003985D:E10 17615

1084 2/24/98 329 RTA00000413F.e.l6.1 M00004093C:C02 63836

1085 2/24/98 330 RTA00000403F.i.04.1 M00001485B:D09 8930

1086 2/24/98 331 RTA00000404F.O.18.2 M00001651C:C05 39110 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: D3te of NO: in ID Priority Priority Appln Appln

1087 2/24/98 332 RTA00000409F.i.24.1 M00001611B:A09 76967

1088 2/24/98 333 RTA00000399F.f.ll.l M00001487C:F01 40167

1089 2/24/98 334 RTA00000408F.p.05.1 M00001575B:B02 9649

1090 2/24/98 335 RTA00000413F.d.02.1 M00004087B:A12 66172

1091 2/24/98 336 RTA00000340F.n.l3.1 M00001688D:B10 17055

1092 2/24/98 337 RTA00000340F.p.04.1 M00001679D:B02 78533

1093 2/24/98 338 RTA00000411F.C.05.1 M00001677B:H06 73368

1094 2/24/98 339 RTA00000403F.g.l0.1 M00001481A:G06 20211

1095 2/24/98 340 RTA00000408F.I.13.1 M00001530A:B12 4423

1096 2/24/98 341 RTA00000412F.g.20.2 M00003972C:F08 25018

1097 2/24/98 342 RTA00000404F.i.02.1 M00001619D:D10 39015

1098 2/24/98 343 RTA00000422F.g.21.1 M00001583A:F07 17232

1099 2/24/98 344 RTA00000403F.m.l5.2 M00001575D:D12 26901

1100 2/24/98 345 RTA00000412F.h.23.2 M00003974D:H04 65118

1101 2/24/98 346 RTA00000418F.J.08.1 M00001626C:C11 73382

1102 2/24/98 347 RTAOOOOO 125 A.n.4.1 M00001546A:D08 81984

1103 2/24/98 348 RTA00000412F.1.19.1 M00004029C:C05 65825

1104 2/24/98 349 RTA00000404F.m.l0.2 M00001641D:E02 779

1105 2/24/98 350 RTAOOOOO 129A.p.3.1 M00001604A:B08 32644

1106 2/24/98 351 RTA00000340F.p.20.1 M00003752B:C02 17008

1107 2/24/98 352 RTA00000411F.3.10.1 M00001675C:G01 73073

1108 2/24/98 353 RTA00000409F.n.l7.1 M00001621C:C10 76725

1109 2/24/98 354 RTA00000404F.C.03.2 M00001592C:F11 39198

1110 2/24/98 355 RTA00000420F.a.l9.1 M00004076A:D12 34192

1111 2/24/98 356 RTA00000409F.m.24.1 M00001620D:H02 3942

1112 2/24/98 357 RTA00000406F.n.l6.1 M00003972A:G09 5660

1113 2/24/98 358 RTA00000414F.e.06.1 M00005235A:A03 0

1114 2/24/98 359 RTA00000420F.d.l2.1 M00004096D:H03 64095

1115 2/24/98 360 RTA00000409F.J.19.1 M00001613A:F03 73792

1116 2/24/98 361 RTA00000422F.d.l6.1 M00001570C:G03 39133

1117 2/24/98 362 RTA00000418F.m.l6.1 M00001653B:E06 74986

1118 2/24/98 363 RTA00000405F.C.11.1 M00001659A:D12 39068

1119 2/24/98 364 RTA00000404F. 22.1 M00001635D:C12 39084

1120 2/24/98 365 RTA00000418F.k.07.1 M00001637A:F10 75067

1121 2/24/98 366 RTA00000403F.C.10.1 M00001456D:F05 75261

1122 2/24/98 367 RTA00000401F.O.06.1 M00004029C:C12 2679

1123 2/24/98 368 RTA00000346F.O.08.1 M00004149C:B02 0

1124 2/24/98 369 RTA00000410F.m.05.1 M00001657B:B04 74964

1125 2/24/98 370 RTA00000405F.i.20.1 M00001677A:G11 38532

1126 2/24/98 371 RTA00000403F.J.17.1 M00001539D:B10 38563

1127 2/24/98 372 RTA00000408F.p.24.1 M00001579A:E03 74286

1128 2/24/98 373 RTA00000418F.k.l8.1 M00001639C:A10 75385

1129 2/24/98 374 RTA00000422F.rn.04.] M00001615B:A09 38702

1130 2/24/98 375 RTA00000405F.g.l6.2 M00001672D:D04 9021

1131 2/24/98 376 RTA00000400F.L22.1 M00001656A:B07 2512

1132 2/24/98 377 RTA00000346F.i.01.1 M00003797A:D06 22260

1133 2/24/98 378 RTA00000403F.a.07.1 M00001448B:F09 73559

1134 2/24/98 379 RTA00000349R.J.07.1 M00001529B:C04 2642

1135 2/24/98 380 RTA00000403F.b.l9.1 M00001456B:A06 22327

1136 2/24/98 381 RTA00000418F.m.23.1 M00001654D:F11 77195 SEQ ID Filing SEQ ID Sequence Name Clone N3me Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

1137 2/24/98 382 RTA00000341F.h.l0.1 M00003901B:G11 0

1138 2/24/98 383 RTA00000404F.U8.1 M00001621C:H12 21912

1139 2/24/98 384 RTA00000422F.U4.1 M00001487A:F10 39300

1140 2/24/98 385 RTA00000418F.m.l4.1 M00001651B:E06 75711

1141 2/24/98 386 RTA00000406F.O.12.1 M00003986D:D02 37459

1142 2/24/98 387 RTA00000411F.a.l5.1 M00001675D:B08 73812

1143 2/24/98 388 RTA00000411F.a.07.1 M00001675C:C03 74547

1144 2/24/98 389 RTA00000411F.C.02.1 M00001677B:B04 72852

1145 2/24/98 390 RTA00000355R.3.14.1 M00004187D:G09 10207

1146 2/24/98 391 RTA00000130A.h.16.1 M00001617A:A08 80761

1147 2/24/98 392 RTA00000410F.p.23.1 M00001675B:C01 73948

1148 2/24/98 393 RTA00000418F.m.24.1 M00001654D:F12 77114

1149 2/24/98 394 RTA00000420F.m.02.1 M00005233A:G08 0

1150 2/24/98 395 RTA00000408F.J.19.2 M00001485C:C08 73752

1151 2/24/98 396 RTA00000406F.e.21.1 M00003877D:G05 9090

1152 2/24/98 397 RTA00000118A.d.l7.1 M00001416A:D09 81921

1153 2/24/98 398 RTA00000407F.b.04.1 M00004086D:B09 63221

1154 2/24/98 399 RTA00000411F.e.07.1 M00003810C:A03 65008

1155 2/24/98 400 RTA00000403F.f.08.1 M00001477A:G07 19107

1156 2/24/98 401 RTA00000132A.C.11.1 M00001454A:G03 87278

1157 2/24/98 402 RTA00000420F.e.l6.1 M00004110A:E04 63639

1158 2/24/98 403 RTA00000403F.d.22.1 M00001473A:A07 10692

1159 2/24/98 404 RTA00000404F.b.ll.l M00001591D:F06 39079

1160 2/24/98 405 RTA00000418F. 17.1 M00001639C:A09 75390

1161 2/24/98 406 RTAOOOOO 129A. 12.1 M00001601A:A06 79322

1162 2/24/98 407 RTA00000340R.m.07.1 M00001679D:F02 78415

1163 2/24/98 408 RTA00000405F.d.l4.1 M00001662A:C12 35209

1164 2/24/98 409 RTA00000406F.f.ll.l M00003879A:B08 38601

1165 2/24/98 410 RTA00000120A.h.5.1 M00001465A:G06 80344

1166 2/24/98 411 RTA00000420F.m.l2.1 M00005234D:B04 0

1167 2/24/98 412 RTA00000411F.g.06.1 M00003822D:C06 66065

1168 2/24/98 413 RTA00000408F.d.l6.1 M00001459B:D03 76318

1169 2/24/98 414 RTAOOOOO 120A.p.18.1 M00001468A:C05 6478

1170 2/24/98 415 RTA00000340RT.05.1 M00001569B:G11 3202

1171 2/24/98 416 RTA00000404F.C.19.1 M00001594A:D06 39026

1172 2/24/98 417 RTA00000423F.1.02.1 M00003978C:A03 5639

1173 2/24/98 418 RTA00000410F.3.01.1 M00001631D:B10 73354

1174 2/24/98 419 RTA00000408F.h.08.1 M00001480A:D03 74575

1175 2/24/98 420 RTA00000422F.b.l6.1 M00003813B:A11 17045

1176 2/24/98 421 RTA00000419F.f.l0.1 M00003835D:G06 66193

1177 2/24/98 422 RTA00000418F.I.04.1 M00001641C:D02 74140

1178 2/24/98 423 RTA00000410F.3.16.1 M00001633A:E06 73548

1179 2/24/98 424 RTA00000138A.e.l3.1 M00001605A:E06 79608

1180 2/24/98 425 RTA00000130A.b.5.] M00001605A:E09 79579

1181 2/24/98 426 RTA00000408F.J.15.2 M00001485B:F05 74759

1182 2/24/98 427 RTA00000410F.m.20.1 M00001660B:E03 74285

1183 2/24/98 428 RTA00000422F.f.14.1 M00001478B:D07 2036

1184 2/24/98 429 RTA00000422F.C.17.1 M00004099D:F01 1360

1185 2/24/98 430 RTA00000419F.e.04.1 M00003831C:G05 62963

1186 2/24/98 431 RTA00000399F.J.15.1 M00001578C:G06 1261 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

1 187 2/24/98 432 RTA00000418F.g.05.1 M00001579C:H06 73075

1 188 2/24/98 433 RTA00000419F.n.02.1 M00003958B:H08 65963

1 189 2/24/98 434 RTA00000348R.b. l 6.1 M00001347B:H04 6510

1 190 2/24/98 435 RTA00000340F.b.02.1 M00001503C:G05 10185

1 191 2/24/98 436 RTAOOOOO] 19A.m.15.1 M00001461 A:E05 80989

1 192 2/24/98 437 RTA00000403F.m.20.2 M00001576A:F1 1 707

1 193 2/24/98 438 RTA00000195R.d.09.1 M00003981 C:B04 8537

1 194 2/24/98 439 RTA00000413F.g.23.1 M00004103B:E09 40700

1 195 2/24/98 440 RTA00000403F.a. l 8.1 M00001448D:F12 75726

1 196 2/24/98 441 RTA00000404F.m.20.2 M00001647A:H08 39144

1 197 2/24/98 442 RTA00000347F.b.02.1 M00001450A:A02 39304

1 198 2/24/98 443 RTA00000414F. i 5.1 M00005260A:A12 0

1 199 2/24/98 444 RTA00000419F.h.04.1 M00003846A:D03 65034

1200 2/24/98 445 RTA00000408F.d.l2.1 M00001459B:A12 75782

1201 2/24/98 446 RTA00000133A.m. l 9.2 M00001512A:G05 80167

1202 2/24/98 447 RTA00000423F.b.04.3 M00001675D:E10 631 1

1203 2/24/98 448 RTAOOOOO 127A.3.3.1 M00001552A:H 10 13232

1204 2/24/98 449 RTA0000041 1 F.J.16.1 M00003843A:E08 17237

1205 2/24/98 450 RTAOOOOO 1 18A.a.23.1 M00001395A:H02 3500

1206 2/24/98 451 RTAOOOOO 126A.o.22.1 M00001551A:A1 1 81752

1207 2/24/98 452 RTA00000419F.n.13.1 M00003977D:A06 66026

1208 2/24/98 453 RTA00000130A.h.13.1 M00001617A:A01 80790

1209 2/24/98 454 RTA00000418F.n.19.1 M00001659C:F02 28761

1210 2/24/98 455 RTA00000399F.d.23.1 M00001481 B:A07 3310

121 1 2/24/98 456 RTA00000413F.O.06.1 M00005100A:B02 0

1212 2/24/98 457 RTA0000041 1 F.m.l9.1 M00003868D:D1 1 74924

1213 2/24/98 458 RTAOOOOO 130A.a.19.1 M00001605A:A06 0

1214 2/24/98 459 RTA00000419F.k.06.1 M00003871 D:A10 78493

1215 2/24/98 460 RTA00000341 F.J.12.1 M00003987C:G03 12195

1216 2/24/98 461 RTA00000412F.d. l 6.1 M00003906B:H06 26829

1217 2/24/98 462 RTAOOOOO 1 19A.J.23.1 M00001460A:G07 79835

1218 2/24/98 463 RTA00000403F.O.22.1 M00001583A:D01 25076

1219 2/24/98 464 RTA00000195AF.C.12.1 M00003818B:G 12 37582

1219 1/28/98 300 RTAOOOOO 195AF.C.12.1 M00003818B:G 12 37582

1220 2/24/98 465 RTA00000350R.p.l 8.1 M00001676B:F05 1 1460

1221 2/24/98 466 RTA00000406F. 24.1 M00003904D:B12 12767

1222 2/24/98 467 RTAOOOOO 123 A.n.13.2 M00001534A:D03 39167

1223 2/24/98 468 RTA00000423F.C.19.1 M00001680B:E10 40472

1224 2/24/98 469 RTA00000405F.g.24.1 M00001673D:D06 39076

1225 2/24/98 470 RTA0000041 1 FJ.06.1 M00003841C:H08 63545

1226 2/24/98 471 RTA00000419F.C.1 1.1 M00003817B:C04 65504

1227 2/24/98 472 RTA00000135AT.14.2 M00001542A:G 12 79969

1228 2/24/98 473 RTA00000403F.a.05.1 M00001448A:E1 1 18808

1229 2/24/98 474 RTA00000405F.e.l 7.1 M00001669A:C 10 38662

1230 2/24/98 475 RTA0000041 1 F.d.05.1 M00001681C:A08 75812

1231 2/24/98 476 RTA00000345F.h.01. l M00001441 B:D1 1 10834

1232 2/24/98 477 RTA00000418F.d.03.1 M00001567B:G 1 1 76824

1233 2/24/98 478 RTA00000418F.h.08.1 M00001589B:E07 76401

1234 2/24/98 479 RTA00000418F.m.l0.1 M00001651 A:H 1 1 791 10

1235 2/24/98 480 RTA0000041 1 F.i. l 5.1 M00003837C:G08 31612 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

1236 2/24/98 481 RTA00000413F.i.23.1 M000041 18B:F01 63073

1237 2/24/98 482 RTA0000041 1 F.e.24.1 M00003813A:B02 64781

1238 2/24/98 483 RTA00000406F.g.22.1 M00003881 D:C 12 38590

1239 2/24/98 484 RTAOOOOO 126A.n.13.2 M00001551 A:H06 79735

1240 2/24/98 485 RTA00000419F.a.02.1 M00001678A:F05 77993

1241 2/24/98 486 RTA00000346F.I.13.1 M00003980B:C 1 1 7542

1242 2/24/98 487 RTA00000420F.g.05.1 M00004891 B:D01 0

1243 2/24/98 488 RTA00000339F. 23.1 M00001429D:H 12 0

1244 2/24/98 489 RTA00000406F.J.19.1 M00003906A:F12 1685

1245 2/24/98 490 RTAOOOOO 120A.d.15.1 M00001464A:B02 80533

1246 2/24/98 491 RTA00000418FT.21.1 M00001579B:F04 75157

1247 2/24/98 492 RTA00000340F.O.18.1 M00001669D:C03 4261

1248 2/24/98 493 RTAOOOOO 129A.d.1.2 M00001587A:F05 80058

1249 2/24/98 494 RTA00000419F.k.l2.1 M00003876C:F02 0

1250 2/24/98 495 RTA00000400F.O.21.1 M00001669C:C08 16259

1251 2/24/98 496 RTA00000419F.m.20.1 M00003914A:B07 76720

1252 2/24/98 497 RTA00000350R.f.21.1 M00001610C:E07 221 10

1253 2/24/98 498 RTA00000406F.e. l 5.1 M00003877C:A1 1 39074

1254 2/24/98 499 RTAOOOOO 126A.p.18.2 M00001552A:E10 80881

1255 2/24/98 500 RTA0000041 1 F.C.10.1 M00001678D:B1 1 731 17

1256 2/24/98 501 RTA00000414F.f.05.1 M00005257D:H1 1 0

1257 2/24/98 502 RTA00000341 F.d.08.1 M00003824C:D07 0

1258 2/24/98 503 RTA00000420F.m.08.1 M00005233B:D04 0

1259 2/24/98 504 RTA00000413F.d.05.1 M00004087C:A01 64788

1260 2/24/98 505 RTA00000121 A.O.3.1 M0000151 1 A:A02 81437

1261 2/24/98 506 RTA00000403F.f.09.1 M00001477B:C02 0

1262 2/24/98 507 RTA00000420F.e.02.1 M00004107B:D07 40259

1263 2/24/98 508 RTA00000420F.i.20.1 M00005101 C:E12 0

1264 2/24/98 509 RTA00000349R.g. l 0.1 M00001495B:B08 5777

1265 2/24/98 510 RTA00000131 A.g.l 6.2 M00001449A:F01 0

1266 2/24/98 51 1 RTA00000341 F.b.l3.1 M00003762B:H09 0

1267 2/24/98 512 RTA00000414F.C.16.1 M00005228A:B03 0

1268 2/24/98 513 RTA00000126A. 7.2 M00001550A:E07 79866

1269 2/24/98 514 RTA00000404F.e.l3.1 M00001608D:E09 12046

1270 2/24/98 515 RTA00000419F.1.03.1 M00003879A:D02 79060

1271 2/24/98 516 RTA00000339FT.20.1 M00001399A:C03 6494

1272 2/24/98 517 RTA000001 18A.3.2.1 M00001395A:A12 38067

1273 2/24/98 518 RTA00000410F.m. l 8.1 M00001660B:A09 76365

1274 2/24/98 519 RTA00000404F.1.10.1 M00001638B:F10 23136

1275 2/24/98 520 RTA00000406F.C.20.1 M00003871 D:G06 38578

1276 2/24/98 521 RTA00000413F.b. l4.1 M00004078A:C 1 1 66591

1277 2/24/98 522 RTA00000406F.C.18.1 M00003871C:F12 14368

1278 2/24/98 523 RTA00000418F.J.09.1 M00001626C:D12 76352

1279 2/24/98 524 RTA00000419FT.23.1 M00003840D:H 10 65002

1280 2/24/98 525 RTA00000348R.d.24.1 M00001349B:G05 5774

1281 2/24/98 526 RTA0000041 1 F.3.05.1 M00001675B:H03 76699

1282 2/24/98 527 RTA00000419F.m.21.1 M00003914A:E04 77947

1283 2/24/98 528 RTA00000405F.n. l6.1 M00003825B:B10 21503

1284 2/24/98 529 RTA00000422F.O.19.2 M00001655C:E01 13084

1285 2/24/98 530 RTA00000408F.n.02.2 M00001539A:E01 76993 SEQ ID Filing SEQ ID Sequence Nsme Clone Nsme Cluster

NO: Dste of NO: in ID

Priority Priority

Appln Appln

1286 2/24/98 531 RTA00000345F.n.12.1 M00001528A:C04 7337

1287 2/24/98 532 RTA00000403F.a.24.1 M00001455B:A09 24128

1288 2/24/98 RTA00000423F.e. l l .1 M00003809B:E10 2566

1289 2/24/98 534 RTA00000126A.g.7.1 M00001548A:H04 1902

1290 2/24/98 535 RTAOOOOO 1 19A.g.7.1 M00001454A:F1 1 83580

1291 2/24/98 536 RTA0000041 1 F.i.02.1 M00003835B:H 1 1 66975

1292 2/24/98 537 RTA00000408F.1.09.1 M00001530A:A09 75487

1293 2/24/98 538 RTA00000423F.g.04.1 M00003903D:C 12 23012

1294 2/24/98 539 RTA00000346F.m. l 5.1 M00004037B:C04 13553

1295 2/24/98 540 RTA00000418F.U 8.1 M00001595C:B05 78024

1296 2/24/98 541 RTA0000041 1 F.h.l 5.1 M00003832A:A09 65160

1297 2/24/98 542 RTA00000410F.U 9.1 M00001641 B:C 10 78988

1298 2/24/98 543 RTA00000419F.L24.1 M00003878C:G08 75596

1299 2/24/98 544 RTA00000420F.1.21.2 M00005232A:H12 0

1300 2/24/98 545 RTA00000420F.e. l 5.1 M000041 10A:A10 20190

1301 2/24/98 546 RTA00000409F.i.09.1 M00001610B:C07 75279

1302 2/24/98 547 RTA00000419F.h.02.1 M00003845D:G08 63985

1303 2/24/98 548 RTA00000413F.b.l2.1 M00004077B:H1 1 64932

1304 2/24/98 549 RTA00000121A.li.18.1 M00001471 A:B04 16376

1305 2/24/98 550 RTA0000041 1 F.n.20.1 M00003875C:A09 75816

1306 2/24/98 551 RTA00000340F.b.05.1 M00001513A:G07 0

1307 2/24/98 552 RTA0000041 1 F.n.l2.1 M00003875A:C04 73308

1308 2/24/98 553 RTA00000408F.J.12.2 M00001485B:C03 18226

1309 2/24/98 554 RTA00000409F.i.03.1 M00001610A:E09 75968

1310 2/24/98 555 RTAOOOOO 133 A.d.22.1 M00001469A:G1 1 1 1797

131 1 2/24/98 556 RTA00000400F.U 1.1 M00001649C:H10 2587

1312 2/24/98 557 RTA00000409F.J.05.1 M0000161 1 C:C12 74128

1313 2/24/98 558 RTA00000419F.m.04.1 M00003906C:C05 74367

1314 2/24/98 559 RTA00000418F. 03.1 M00001634D:G1 1 78901

1315 2/24/98 560 RTA00000419F.d.l 6.1 M00003828B:E07 64357

1316 2/24/98 561 RTA00000420F.e.l 0.1 M00004108D:G04 65899

1317 2/24/98 562 RTA00000401 F.J.1 7.1 M00003901 B:C05 5483

1318 2/24/98 563 RTA00000406F.b.08.1 M00003867D:A06 18258

1319 2/24/98 564 RTA00000418F.k.08.1 M00001639A:C03 18259

1320 2/24/98 565 RTA00000420F.k.l 7.2 M00005217B:A06 0

1321 2/24/98 566 RTA00000414F.d.05.1 M00005229D:H03 0

1322 2/24/98 567 RTA00000410F.C.02.1 M00001633D:D12 75055

1323 2/24/98 568 RTA00000403F.m.03.1 M00001573D:D10 39179

1324 2/24/98 569 RTA00000403F.h. l 8.1 M00001484C:A04 39241

1325 2/24/98 570 RTA00000405F.n.l3.1 M00003824A:G 10 23810

1326 2/24/98 571 RTA00000355R.e. l4.1 M00004314B:G07 16837

1327 2/24/98 572 RTA00000422F.1.03.1 M00001610D:D05 39147

1328 2/24/98 573 RTA00000414F.C.23.1 M00005229B:G 12 0

1329 2/24/98 574 RTA00000403F.O.14.1 M00001579D:H09 38971

1330 2/24/98 575 RTA00000345F.3.1 8.1 M00001351 C:B06 5517

1331 2/24/98 576 RTA00000401 F.d.l 5.2 M00001693C:C 12 5297

1332 2/24/98 577 RTA00000419F.e.l l . l M00003833B:C 12 36780

1333 2/24/98 578 RTA00000127A.f.l l . l M00001554A:A08 81463

1334 2/24/98 579 RTA00000413F.m. l 6.1 M00004898C:F03 0

1335 2/24/98 580 RTA00000403F.O.07.1 M00001579C:A01 39037 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Dste of NO: in ID Priority Priority Appln Appln

1336 2/24/98 581 RTA00000403F.d. l9.1 M00001472C:A01 39243

1337 2/24/98 582 RTA00000414F.e.l4.1 M00005236B.-F10 0

1338 2/24/98 583 RTA00000406F.i. l 7.1 M00003904B:C03 37902

1339 2/24/98 584 RTA00000418F.d.22.1 M00001573B:C06 75324

1340 2/24/98 585 RTA00000340R.O.12.1 M00003746C:E02 53732

1341 2/24/98 586 RTAOOOOO 125 A.g.24.1 M00001544A:F05 80397

1342 2/24/98 587 RTAOOOOO 130A.O.21.1 M00001623A:F04 80218

1343 2/24/98 588 RTA00000420F.3.23.1 M00004078B:F12 42158

1344 2/24/98 589 RTA0000041 1 F.m. l 8.1 M00003868D:D09 75629

1345 2/24/98 590 RTA00000407F.b.22.1 M00004108B:B02 37487

1346 2/24/98 591 RTA00000409F.3.16.1 M00001583A:A05 73990

1347 2/24/98 592 RTA00000421 F.p.l8.1 M00003877B:H 10 750

1348 2/24/98 593 RTA00000341 F. 12.1 M00004103C:D04 62985

1349 2/24/98 594 RTAOOOOO 129A.C.18.2 M00001587A:B10 37216

1350 2/24/98 595 RTA00000410F.d. l0.1 M00001635B:H02 77561

1351 2/24/98 596 RTA00000351 R.i.03.1 M00003846B:D06 6874

1352 2/24/98 597 RTA00000135A.1.1.2 M00001545A:B 10 39426

1353 2/24/98 598 RTA00000420F.b. l 8.1 M00004086D:G08 66136

1354 2/24/98 599 RTA00000401 F.k. l4.1 M00003903A:H09 21 1

1355 2/24/98 600 RTA00000406F.m.04.1 M00003914B:A1 1 14959

1356 2/24/98 601 RTA00000403F.O.13.1 M00001579D:F04 39049

1357 2/24/98 602 RTA0000041 1F.f.06.1 M00003813B:E09 64186

1358 2/24/98 603 RTA00000399F.O.19.1 M00001607A:F1 1 2594

1359 2/24/98 604 RTA00000351 R.C.13.1 M00003747D:C05 1 1476

1360 2/24/98 605 RTA00000403F.C.14.1 M00001457D:A07 0

1361 2/24/98 606 RTA00000420F.1.20.2 M00005232A:C 10 0

1362 2/24/98 607 RTA00000420F.d.l6.1 M00004103D:F10 64485

1363 2/24/98 608 RTA00000404F.i.l2.1 M00001620D:G 1 1 39001

1364 2/24/98 609 RTA00000404F.O.10.2 M00001651 B:B12 16785

1365 2/24/98 610 RTA00000419F.d.07.1 M00003820B:D10 21421

1366 2/24/98 61 1 RTA00000404F.p.02.2 M00001652D:A06 39097

1367 2/24/98 612 RTAOOOOO 125A. 14.1 M00001545A:G05 79457

1368 2/24/98 613 RTAOOOOO 122A.J.22.1 M00001516A:F06 81 151

1369 2/24/98 614 RTA00000406F. 13.1 M00003904A:C04 37904

1370 2/24/98 615 RTAOOOOO 135 A.b.23.1 M00001538A:D12 35241

1371 2/24/98 616 RTA00000423F.C.1 1.1 M00001677D:B02 0

1372 2/24/98 61 7 RTA00000423FT.23.1 M00003816C:E09 15390

1373 2/24/98 618 RTA00000423F.1.04.1 M00004039B:G08 14320

1374 2/24/98 619 RTA00000420F.b.04.1 M00004081A:E02 63820

1375 2/24/98 620 RTA00000420F.3.07.1 M00004072C:F08 63405

1376 2/24/98 621 RTA00000408F.U 8.2 M00001482C:D02 74410

1377 2/24/98 622 RTA00000404F.1.07.1 M00001637C:C06 10798

1378 2/24/98 623 RTA00000341 F.J.05.1 M00003963D:B05 36177

1379 2/24/98 624 RTA00000420F.a. l 6.1 M00004075D:C 10 63345

1380 2/24/98 625 RTAOOOOO 126A.h.22.2 M00001549A:F01 0

1381 2/24/98 626 RTA00000410F.J.01.1 M00001641 B:F12 73399

1382 2/24/98 627 RTA00000408F.p.21.1 M00001579A:C03 77930

1383 2/24/98 628 RTA00000412F.d.l9.1 M00003907B:C03 75743

1384 2/24/98 629 RTA00000352R.C.04.1 M00003924A:D08 71976

1385 2/24/98 630 RTA00000413F.f. l9.1 M00004100B:C07 65189 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID

Priority Priority

Appln Appln

1386 2/24/98 631 RTA0000041 1 F.e.03.1 M00001694D:C12 73648

1387 2/24/98 632 RTAOOOOO 191 AF.j.14.1 M00004073A:H12 1002

1387 1/28/98 387 RTA00000191 AF.J.14.1 M00004073A:H12 1002

1388 2/24/98 633 RTA00000341 F.d.02.1 M00003797A:G03 4706

1389 2/24/98 634 RTA00000418F.C.04.1 M00001487B:A1 1 41587

1390 2/24/98 635 RTA00000418F.O.17.1 M00001661 B:F03 79069

1391 2/24/98 636 RTA00000418F.e.21.1 M00001577B:A03 74773

1392 2/24/98 637 RTA00000419F.d. l4.1 M00003828A:D05 64945

1393 2/24/98 638 RTA00000418F.b.09.1 M00001478B:H08 19700

1394 2/24/98 639 RTA00000414F.d.09.1 M0000523 1 C:B01 0

1395 2/24/98 640 RTA00000405F.f.02.1 M00001669B:G02 38665

1396 2/24/98 641 RTA00000410F.J.20.1 M00001642D:G 10 73601

1397 2/24/98 642 RTA00000341 F.li.19.1 M00003916C:C05 0

1398 2/24/98 643 RTA00000420F.1.14.2 M00005230D:F06 0

1399 2/24/98 644 RTA000001 19A.J.9.1 M00001460A:B 12 82060

1400 2/24/98 645 RTA00000422F.p. l2.2 M00001661 C:F10 9840

1401 2/24/98 646 RTA00000421 F.m. l 4.1 M00001642A:F03 3524

1402 2/24/98 647 RTA00000418F.b.23.1 M00001485A:C05 28767

1403 2/24/98 648 RTA00000340F.U3.1 M00001624B:B10 79299

1404 2/24/98 649 RTA00000412F.g.03.1 M00003971 B:A10 64740

1405 2/24/98 650 RTAOOOOO 122A.g.17.1 M00001514A:B08 32655

1406 2/24/98 651 RTA00000403F.g. l l .l M00001481 A:H08 24238

1407 2/24/98 652 RTA00000419F.n.l2.1 M00003977D:A03 66086

1408 2/24/98 653 RTA00000352R.m.l2.1 M00004212B:C07 2379

1409 2/24/98 654 RTA00000421 F.a.05.1 M00001570C:G06 5278

1410 2/24/98 655 RTA00000351 R.p. l4.1 M00003915C:H04 13166

141 1 2/24/98 656 RTA00000403F.e.08.1 M00001473D:B 1 1 19126

1412 2/24/98 657 RTAOOOOO 124A. 20.1 M00001538A:C08 80913

1413 2/24/98 658 RTA00000121 A.n.2.1 M0000151 1 A:A05 33585

1414 2/24/98 659 RTA00000422F.m.24.1 M00001641 D:C04 39159

1415 2/24/98 660 RTA00000408F.e.24.2 M00001476C:C 1 1 75002

1416 2/24/98 661 RTA00000341 F.1.16.1 M00003986D:C08 8479

1417 2/24/98 662 RTA00000339F.O.07.1 M00001473D:G01 2566

1418 2/24/98 663 RTA00000403F.b. l2.1 M00001455D:A06 78775

1419 2/24/98 664 RTA00000404F.3.09.1 M00001589C:E06 38985

1420 2/24/98 665 RTA00000419F.p.20.1 M00004039A:C03 9458

1421 2/24/98 666 RTA00000403F.O.19.1 M00001582D:F02 78615

1422 2/24/98 667 RTA00000405F.h.07.2 M00001674A:G1 1 4984

1423 2/24/98 668 RTA00000408F.m.05.2 M00001530C:G 10 23384

1424 2/24/98 669 RTA00000410F.b. l0.1 M00001633C:B09 74504

1425 2/24/98 670 RTA00000131 A.i.6.1 M00001450A:B08 0

1426 2/24/98 671 RTA00000413F.h. l2.1 M00004107A:A12 66929

1427 2/24/98 672 RTA00000406F.L 14.1 M00003907C:C02 38651

1428 2/24/98 673 RTA00000406F.d.09.1 M00003875B:F12 38591

1429 2/24/98 674 RTA0000041 1 F.f. l 7.1 M00003814B:F12 65661

1430 2/24/98 675 RTA0000041 1 F. 10.1 M00003850D:H 1 1 64506

1431 2/24/98 676 RTA0000041 1 F.g.21.1 M00003823D:G05 64500

1432 2/24/98 677 RTAOOOOO 1 19A.h.24.1 M00001457A:C05 82266

1433 1/28/98 412 RTAOOOOO 195 AF.c.24.1 M00003860D:H07 0

1433 2/24/98 678 RTA00000195AF.C.24.1 M00003860D:H07 0 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

1434 2/24/98 679 RTA00000408F.m.22.2 M00001539A:C 12 72949

1435 2/24/98 680 RTA00000345F.e.l l . l M00001391C:C04 4392

1436 2/24/98 681 RTAOOOOO 120 A.c.24.1 M00001464A:D03 34278

1437 2/24/98 682 RTA00000410F.i.l 7.1 M00001641 B:B01 78147

1438 2/24/98 683 RTA00000403F.J.21.1 M00001540D:E02 24723

1439 2/24/98 684 RTA00000339F.k.20.1 M00001426D:D12 6662

1440 2/24/98 685 RTA00000129A.a. l3.2 M00001582A:A03 79780

1441 2/24/98 686 RTAOOOOO 129A.L21.1 M00001601 A:E12 82067

1442 2/24/98 687 RTA00000350R.g.l 0.1 M00001587C:C10 9026

1443 2/24/98 688 RTA00000413F.d.23.1 M00004090B:H06 66030

1444 2/24/98 689 RTA00000419F.p.03.1 M00004035A:G10 1937

1445 2/24/98 690 RTA00000341 F.b.05.1 M00003793D:A1 1 0

1446 2/24/98 691 RTA00000354R.n.08.1 M00003835A:A09 8802

1447 2/24/98 692 RTA0000041 1 F.d. l 0.1 M00001681 D:C 12 76445

1448 2/24/98 693 RTA00000404F.b. l9.1 M00001592B:A04 39281

1449 2/24/98 694 RTA00000418F.C.07.1 M00001529D:C05 73245

1450 2/24/98 695 RTA00000418F.J.15.1 M00001632C:H07 74855

1451 2/24/98 696 RTA00000404F.p. l2.2 M00001653B:C06 0

1452 2/24/98 697 RTA00000412F.d. l4.1 M00003905D:CO8 76757

1453 2/24/98 698 RTA00000413F.b.l 6.1 M00004078A:E05 65126

1454 2/24/98 699 RTA00000340F.1.05.1 M00001644B:D06 38935

1455 2/24/98 700 RTA00000350R.m. l4.1 M00001644C:B07 39171

1456 2/24/98 701 RTA00000418F.1.1 1.1 M00001641C:H07 77158

1457 2/24/98 702 RTA00000130A.d.5.1 M00001605A:H03 82051

1458 2/24/98 703 RTA00000339F.n.05.1 M00001449D:B01 39648

1459 2/24/98 704 RTA00000355R.a. l2.1 M00004159C:F09 36756

1460 2/24/98 705 RTA00000407F.a.23.1 M00004081 C:A10 23489

1461 2/24/98 706 RTA00000403F.a.09.1 M00001448B:H05 77820

1462 2/24/98 707 RTA00000403F.Ii.1 1.1 M00001483B:D04 39219

1463 2/24/98 708 RTA00000406F.J.13.1 M00003905D:B08 38688

1464 2/24/98 709 RTA00000352R.p.09.1 M00004228C:H03 16915

1465 2/24/98 710 RTA00000413F.g.24.1 M00004104D:A04 65481

1466 2/24/98 71 1 RTA00000404F.1.03.2 M00001636B:G 1 1 40272

1467 2/24/98 712 RTA00000407F.b. l 8.1 M00004102C:D09 37569

1468 2/24/98 713 RTA00000414F.b.l0.1 M00005212D:D09 0

1469 2/24/98 714 RTA00000420F.a.08.1 M00004073A:D10 19473

1470 2/24/98 715 RTA00000418F.b.01.1 M00001475C:G1 1 76040

1471 2/24/98 716 RTA00000420F.1.03.2 M00005217D:F12 0

1472 2/24/98 717 RTA00000404F.i.22.1 M00001625C:G05 39082

1473 2/24/98 718 RTA00000124A.L23.1 M00001538A:D03 81350

1474 2/24/98 719 RTA00000404F.e.l l .l M00001608C:E1 1 38991

1475 2/24/98 720 RTAOOOOO 129A.d.2.4 M00001587A:G06 801 19

1476 2/24/98 721 RTA00000422F.k. l4.1 M00001649D:A08 0

1477 2/24/98 722 RTA0000041 1 F.1.22.1 M00003858B:G05 64439

1478 2/24/98 723 RTA00000419F.O.15.1 M00003989C:D03 32487

1479 2/24/98 724 RTAOOOOO 1 19A.m.17.1 M00001461 A:F05 79536

1480 2/24/98 725 RTA00000410F.b.07.1 M00001633C:A05 78916

1481 2/24/98 726 RTA00000420F.b.l9.1 M00004088D:A1 1 36873

1482 2/24/98 727 RTA00000414F.d.02.1 M00005229B:H06 0

1483 2/24/98 728 RTA0000041 1 F.b.21.1 M00001677B:A02 10051 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

1484 2/24/98 729 RTA00000403F.m.20.1 M00001576A:F1 1 707

1485 2/24/98 730 RTA00000356R.C.16.1 M00004294C:C08 16915

1486 2/24/98 73 1 RTAOOOOO 1 19A.d.17.1 M00001453A:B01 0

1487 2/24/98 732 RTA00000412F.h. l l . l M00003974B:B1 1 63175

1488 2/24/98 733 RTA00000405F.d. l 8.1 M00001662C:B02 10494

1489 2/24/98 734 RTA00000414F.e.09.1 M00005236A:G 10 0

1490 2/24/98 735 RTA00000420F.a.l l . l M00004073C:D04 66460

1491 2/24/98 736 RTAOOOOO 120A.C.7.1 M00001462A:D03 80985

1492 2/24/98 737 RTA00000404F.e. l 5.1 M00001609B:C09 39101

1493 2/24/98 738 RTA00000422F.n.20.1 M00001669B:B12 38676

1494 2/24/98 739 RTA00000423F.h.20.1 M00003914A:G06 38639

1495 2/24/98 740 RTA00000399F.1.19.1 M00001590D:G07 40145

1496 2/24/98 741 RTA00000414F.b. l2.1 M00005212D:H01 0

1497 2/24/98 742 RTA00000410F.b.l 8.1 M00001633C:H 1 1 76701

1498 2/24/98 743 RTA00000345F.i.08.1 M00001449D:G 10 0

1499 2/24/98 744 RTA00000423F.g. l 5.1 M00003905A:F09 35173

1500 2/24/98 745 RTA00000413F.b.04.1 M00004076D:H07 66427

1501 2/24/98 746 RTA00000345F.e.02.1 M00001395A:E03 0

1502 2/24/98 747 RTA00000413F.n.24.1 M00004960C:E10 0

1503 2/24/98 748 RTA00000346F.f.l l . l M00003793C:D09 38528

1504 2/24/98 749 RTA00000351 R.i.l3.1 M00003858D:F12 0

1505 2/24/98 750 RTA00000403F.C.05.1 M00001456C:C1 1 74935

1506 2/24/98 751 RTA00000422F.i.02.1 M00001456C:B12 76436

1507 2/24/98 752 RTA00000410F.a.08.1 M00001632A:B10 73324

1508 2/24/98 753 RTA00000345F.O.13.1 M00001546B:F12 1 1500

1509 2/24/98 754 RTA00000419F.e.02.1 M00003830C:A03 65010

1510 2/24/98 755 RTA00000423F.d.l 7.1 M00001663A:C1 1 20630

151 1 2/24/98 756 RTA00000403F.g.l 3.1 M00001481 B:D09 38718

1512 2/24/98 757 RTA00000423F.h.l3.1 M00003871A:B09 14398

1513 2/24/98 758 RTA00000407F.3.01.1 M00004039A:H 1 1 12501

1514 2/24/98 759 RTA00000399F.O.06.1 M00001595D:G03 13574

1515 2/24/98 760 RTA00000423F.d.04.1 M00001694A:B 12 1 1307

1516 2/24/98 761 RTA0000041 1 F.f.l4.1 M00003814B:C12 62984

1517 2/24/98 762 RTA0000041 1 F.C.04.1 M00001677B:E06 76858

1518 2/24/98 763 RTA00000135A.m. l 8.1 M00001545A:C03 19255

1519 2/24/98 764 RTA00000413F.C.17.1 M00004085B:B05 36831

1520 2/24/98 765 RTA00000137A.J.15.4 M00001559A:C08 4213

1521 2/24/98 766 RTA00000404F.J.01.1 M00001625D:G10 26859

1522 2/24/98 767 RTA00000138A.p. l 0.1 M00001644A:H01 81625

1523 2/24/98 768 RTA00000121 A.k.5.1 M00001507A:E04 17530

1524 2/24/98 769 RTA00000340F.L10.1 M00001618A:F10 38561

1525 2/24/98 770 RTA00000421 F.f.05.1 M00001477B:E02 5266

1526 2/24/98 771 RTA00000423F.h.07.1 M0000391 1 B:F08 37933

1527 2/24/98 772 RTA00000413F.e.04.1 M00004090C:C07 64176

1528 2/24/98 773 RTA00000406F.h.03.1 M00003901 B:A09 38585

1529 2/24/98 774 RTA00000403F.e.24.1 M00001476B:D10 16432

1530 2/24/98 775 RTA00000405F.C.22.1 M00001660C:B06 39053

1531 2/24/98 776 RTA00000403F...1 1.1 M00001485D:E05 23535

1532 2/24/98 777 RTA00000419F.g.02.1 M00003842A:A03 62839

1533 2/24/98 778 RTA00000347F.e.05.1 M00001578D:C04 39814 SEQ ID Filing SEQ ID Sequence Name Clone Nsme Cluster

NO: Date of NO: in ID

Priority Priority

Appln Appln

1534 2/24/98 779 RTA00000408F.1.16.1 M00001530A:F12 73468

1535 2/24/98 780 RTA00000405F.I.1 1.1 M00001693D:E08 2055

1536 2/24/98 781 RTA00000423F.f.09.1 M00003808C:A05 64823

1537 2/24/98 782 RTA00000419F.k.03.1 M00003871 C:B05 40822

1538 2/24/98 783 RTA00000406F.b.02.1 M00003867B:G08 38744

1539 2/24/98 784 RTA00000418F.O.14.1 M00001661 B:B05 33524

1540 2/24/98 785 RTA00000404F.1.03.1 M00001636B:G 1 1 40272

1541 2/24/98 786 RTA00000404F.b.09.1 M00001591 D:C07 39166

1542 2/24/98 787 RTA00000345F.i.24.1 M00001449C:C05 0

1543 2/24/98 788 RTA00000419F.i.04.1 M00003860B:F1 1 65791

1544 2/24/98 789 RTA00000423F.b.l3.1 M00001676C:E07 20619

1545 2/24/98 790 RTA00000345F.n.08.1 M00001517A:B1 1 0

1546 2/24/98 791 RTA00000399F.n. l5.1 M00001594D:C03 3213

1547 2/24/98 792 RTA00000406F.k. l l . l M00003907B:D05 38715

1548 2/24/98 793 RTA00000414F.e.21 .1 M00005257C:G01 0

1549 2/24/98 794 RTA00000406F.C.06.1 M00003870C:A01 37924

1550 2/24/98 795 RTA00000418F.n.07.1 M00001658B:A07 76316

1551 2/24/98 796 RTA00000419F.n.15.1 M00003977D:D04 63484

1552 2/24/98 797 RTA00000408F.n.06.2 M00001539A:H 12 76642

1553 2/24/98 798 RTA00000420F.C.04.1 M00004089A:B08 65007

1554 2/24/98 799 RTA0000041 1 F.J.15.1 M00003843A:E04 66871

1555 2/24/98 800 RTA00000403F.m.l2.1 M00001575D:A02 16933

1556 2/24/98 801 RTA00000128A.m.23.1 M00001561A:D01 81441

1557 2/24/98 802 RTA00000406F.g.03.1 M00003880B:D1 1 38690

1558 2/24/98 803 RTA00000405F.h.05.2 M00001674A:G07 75706

1559 2/24/98 804 RTAOOOOO 129A.n.24.1 M00001604A:C07 81409

1560 2/24/98 805 RTA00000406F.J.08.1 M00003905B:C06 6688

1561 2/24/98 806 RTA00000345F.f.08.1 M00001413B:H09 0

1562 2/24/98 807 RTA00000418F.11.1 1.1 M00001658D:G12 78977

1563 2/24/98 808 RTA00000418F.p.08.1 M00001669D:D06 73983

1564 2/24/98 809 RTA00000420F.i.23.1 M00005134A:D1 1 0

1565 2/24/98 810 RTAOOOOO 120A.h.9.1 M00001465A:B 12 80736

1566 2/24/98 81 1 RTA00000413F.a.l2.1 M00004072D:F09 63403

1567 2/24/98 812 RTA00000412F.O.05.1 M00004034A:A01 63575

1568 2/24/98 813 RTA00000346F.O.06.1 M00004136D:B02 4937

1569 2/24/98 814 RTA00000408F.1.24.1 M00001530B:G09 34263

1570 2/24/98 815 RTA00000403F.3.17.1 M00001448D:E12 13686

1571 2/24/98 816 RTA00000354R.11.04.1 M00003808C:B05 22049

1572 2/24/98 81 7 RTA00000420F.1.08.2 M00005228C:C05 0

1573 2/24/98 818 RTA00000406F.h.05.1 M00003901 B:C03 38542

1574 2/24/98 819 RTA00000410F.b.24.1 M00001633D:D09 75104

1575 2/24/98 820 RTA00000423F.d. l l . l M00001678C:C06 38950

1576 2/24/98 821 RTA00000420F.h.l 6.1 M00004927A:E06 0

1577 2/24/98 822 RTA00000419F.O.21.1 M00004031A:E01 10336

1578 2/24/98 823 RTAOOOOO 1 19A. 1.1 M00001460A:H1 1 81282

1579 2/24/98 824 RTA00000420F.f.07.1 M000041 19A:C09 66312

1580 2/24/98 825 RTA00000404F.k.22.2 M00001635D:C12 39084

1581 2/24/98 826 RTA00000422F.e.07.1 M00001579C:G05 38964

1582 2/24/98 827 RTA00000410FT.12.1 M00001637C:E03 73883

1583 2/24/98 828 RTA00000419F.n.05.1 M00003976C:D06 63713 SEQ ID Filing SEQ ID Sequence Name Clone Nsme Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

1584 2/24/98 829 RTA0000041 1 F.m. l l . l M00003867A:D12 73196

1585 2/24/98 830 RTA00000347F.b.08.1 M00001541 B:E05 17591

1586 2/24/98 831 RTA00000420F.d.21.1 M00004107B:B04 65313

1587 2/24/98 832 RTA00000403F.O.10.2 M00001579C:G05 38964

1588 2/24/98 833 RTA00000420F.J.20.1 M00005140D:C06 0

1589 2/24/98 834 RTA00000407F.b. l l . l M00004090C:C10 0

1590 2/24/98 835 RTA00000413F.C.10.1 M00004083B:C01 65600

1591 2/24/98 836 RTA0000041 1 F.b. l 7.1 M00001676D:B02 72893

1592 2/24/98 837 RTA00000420F.h.01.1 M00004897C:D06 0

1593 2/24/98 838 RTA00000408F.U 9.1 M00001487C:G03 77593

1594 2/24/98 839 RTA00000414F.b.01.1 M00005212B:A02 0

1595 2/24/98 840 RTA00000420F.b.20.1 M00004088D:B05 0

1596 2/24/98 841 RTA000001 19A.i.8.1 M00001457A:G 12 82593

1597 2/24/98 842 RTA00000401 F.n.23.1 M00003982A:B06 1552

1598 2/24/98 843 RTA00000418F.g.03.1 M00001579C:E06 78737

1599 2/24/98 844 RTA0000041 1 F.3.09.1 M00001675C:F01 78629

1600 2/24/98 845 RTA00000348R.b.04.1 M00001342B:E01 1890

1601 2/24/98 846 RTA00000419F.J.1 1.1 M00003868C:C07 73183

1602 2/24/98 847 RTA00000403F.1.1 1.1 M00001571 D:F05 25073

1603 2/24/98 848 RTA00000404F.n.l 8.2 M00001649C:E1 1 37169

1604 2/24/98 849 RTA00000122A.n. l 6.1 M00001517A:G08 80553

1605 2/24/98 850 RTA00000420F.C.07.1 M00004089A:E02 65555

1606 2/24/98 851 RTA00000423F.d.07.1 M00001678B:B12 0

1607 2/24/98 852 RTA00000414F.f.03.1 M00005257D:G07 0

1608 2/24/98 853 RTA00000408F .13.2 M00001485B:D10 42275

1609 2/24/98 854 RTA00000345F.3.07.1 M00001338C:E10 0

1610 2/24/98 855 RTA00000423F.3.01.1 M00001659C:F10 39103

161 1 2/24/98 856 RTA00000408F.d.02.1 M00001458D:A01 79169

1612 2/24/98 857 RTA00000404F.e.09.1 M00001608B:A09 39121

1613 2/24/98 858 RTA00000341 F.e.20.1 M00003891 D:B 10 67422

1614 2/24/98 859 RTA00000419F.m.22.1 M00003914A:G09 75600

1615 2/24/98 860 RTA00000419F.m.23.1 M00003958B:E1 1 64263

1616 2/24/98 861 RTA00000419F.b.06.1 M00001694B:B08 76728

1617 2/24/98 862 RTA00000414F.C.07.1 M00005216A:H01 0

1618 2/24/98 863 RTA00000406F.p.08.1 M00004032C:B02 37573

1619 2/24/98 864 RTA00000129A.n.17.1 M00001604A:A09 7981 1

1620 2/24/98 865 RTA00000414F.C.03.1 M00005216A:D09 0

1621 2/24/98 866 RTA00000407F.b.08.1 M00004088D:B03 37513

1622 2/24/98 867 RTA00000339F.1.21.1 M00001455D:D1 1 9781

1623 2/24/98 868 RTA00000406F.i.08.1 M00003903C:E12 37946

1624 2/24/98 869 RTA00000403F.h.07.1 M00001482D:H 1 1 26856

1625 2/24/98 870 RTA00000418F.n.24.1 M00001659D:C09 73153

1626 2/24/98 871 RTA00000403F.f.23.1 M00001479C:E01 39223

1627 2/24/98 872 RTA00000409F.1.20.1 M00001615B:G01 74394

1628 2/24/98 873 RTA00000418F.1.06.1 M00001641 C:F01 73317

1629 2/24/98 874 RTA00000346F.O.22.1 M00004300C:H09 7381

1630 2/24/98 875 RTAOOOOO 129A. 22.1 M00001601 A:E02 79639

1631 2/24/98 876 RTA00000423F.d. l 6.1 M00001678D:C 1 1 39173

1632 2/24/98 877 RTA00000418F.m.22.1 M00001654D:E12 74567

1633 2/24/98 878 RTA00000413F.C.12.1 M00004083B:G03 65334 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Dste of NO: in ID

Priority' Priority

Appln Appln

1634 2/24/98 879 RTA00000409F.b. l 9.1 M00001584D:H02 14479

1635 2/24/98 880 RTA00000418F.g.20.1 M00001585B:C03 74626

1636 2/24/98 881 RTA00000413F.d. l 5.1 M00004088C:E04 64943

1637 2/24/98 882 RTA00000355R.C.03.1 M00004244C:G07 3986

1638 2/24/98 883 RTA00000406F.C.09.1 M00003870C:E10 5671

1639 2/24/98 884 RTA00000412F.C.10.1 M00003903C:C04 76372

1640 2/24/98 885 RTA00000122A.J.17.1 M00001516A:D02 62736

1641 2/24/98 886 RTA00000420F.m.l 5.1 M00005235B:F10 0

1642 2/24/98 887 RTA00000339F.p.06.1 M00001484A:A10 4880

1643 2/24/98 888 RTA00000339R.C.04.1 M00001362D:H01 1805

1644 2/24/98 889 RTA00000346F.b. l 6.1 M00001615C:G05 16485

1645 2/24/98 890 RTA00000418F.J.19.1 M00001634D:D02 78399

1646 2/24/98 891 RTA00000137A.p. l 2.1 M00001587A:B01 80614

1647 2/24/98 892 RTA00000339F.m. l 7.1 M00001453B:H 12 20854

1648 2/24/98 893 RTA00000418F.p.l 0.1 M00001669D:F05 75323

1649 2/24/98 894 RTA00000408F.k. l 2.1 M00001486B:D07 77246

1650 2/24/98 895 RTAOOOOO 137A.j.1 1.4 M00001559A:A1 1 79752

1651 2/24/98 896 RTA00000423F.1.20.1 M00004105C:E09 12580

1652 2/24/98 897 RTA00000419F.H.24.1 M00003980A:F04 65995

1653 2/24/98 898 RTA00000418F.1.03.1 M00001641 C:C06 79058

1654 2/24/98 899 RTA00000406F.h.l0.1 M00003901 C:F09 22732

1655 2/24/98 900 RTA00000419F.m.l 3.1 M00003908A:F12 79052

1656 2/24/98 901 RTA00000418F .14.1 M00001632C:B10 32623

1657 2/24/98 902 RTA00000403F.3.10.1 M00001448C:E1 1 73952

1658 2/24/98 903 RTA00000420F.3.21.1 M00004078B:C1 1 66241

1659 2/24/98 904 RTA00000127A.e.6.1 M00001553A:E07 5885

1660 2/24/98 905 RTA00000405F.g.21.2 M00001673B:F07 38966

1661 2/24/98 906 RTA00000405F.g.21.1 M00001673B:F07 38966

1662 2/24/98 907 RTA00000419F.m.06.1 M00003906C:D06 75749

1663 2/24/98 908 RTA00000423F.g.03.1 M00003905C:G1 1 38007

1664 2/24/98 909 RTA00000420F.i.04.1 M00004959D:H 12 0

1665 2/24/98 910 RTA00000418F.f.03.1 M00001577B:F10 7891 1

1666 2/24/98 91 1 RTA00000406F.p. l3.1 M00004034C:G02 8584

1667 2/24/98 912 RTA00000404F.g. l3.1 M00001614C:E06 9436

1668 2/24/98 913 RTAOOOOO 120A.C.20.1 M00001464A:B07 43235

1669 2/24/98 914 RTA00000138A.m.l 5.1 M00001624A:A03 41603

1670 2/24/98 915 RTA00000408F.f.l4.2 M00001476D:F03 73024

1671 2/24/98 916 RTA00000418F.p.20.1 M00001677D:B07 78023

1672 2/24/98 917 RTA00000423F.e.21.1 M00003806B:G05 66961

1673 2/24/98 918 RTA00000419F.J.22.1 M00003871 A:A02 73525

1674 2/24/98 919 RTA00000410F.d. l 8.1 M00001635D:D05 75458

1675 2/24/98 920 RTA00000403F.b.24.1 M00001456B:G01 78838

1676 2/24/98 921 RTA00000422F.J.02.1 M00001594D:B08 10368

1677 2/24/98 922 RTA00000410F.e.09.1 M00001636A:F08 76093

1678 2/24/98 923 RTAOOOOO 126A.d.19.1 M00001548A:G01 79474

1679 2/24/98 924 RTA00000354R.m.02.1 MO0003890B:C08 12766

1680 2/24/98 925 RTA00000353R.li.10.1 M00001390C:C 1 1 39498

1681 2/24/98 926 RTA00000399F. 20.1 MO0OO1585C:D10 3003

1682 2/24/98 927 RTA0000041 1 F.d.21.1 M00001692B:E01 74794

1683 2/24/98 928 RTA00000340F.m.04.1 M00001679B:H07 19406 SEQ ID Filing SEQ ID Sequence Nsme Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

1684 2/24/98 929 RTA0000041 1 F.n.09.1 M00003875A:A07 78962

1685 2/24/98 930 RTAOOOOO 127A.h.22.2 M00001554A:E04 13155

1686 2/24/98 931 RTA00000420F.e.09.1 M00004108D:E07 66325

1687 2/24/98 932 RTA00000405F.p.03.1 M00003844A:A1 1 1 1346

1688 2/24/98 933 RTA00000419F.3.18.1 M00001680A:B02 78484

1689 2/24/98 934 RTA00000414F.e.01.1 M00005233D:H07 0

1690 2/24/98 935 RTA00000420F.L07.1 M00004960A:B08 0

1691 2/24/98 936 RTA00000121 A.n.23.1 M0000151 1 A:G01 26981

1692 2/24/98 937 RTA00000121 A.11.15.1 M0000151 1 A:G08 40849

1693 2/24/98 938 RTA00000403F.i.23.1 M00001487B:E10 1 1364

1694 2/24/98 939 RTA00000405F.a.03.1 M00001654C:E04 39065

1695 2/24/98 940 RTA00000414F .17.1 M00005260A:F04 0

1696 2/24/98 941 RTA00000419F.p.08.1 M00004036D:B04 65560

1697 2/24/98 942 RTA00000126A.n.6.2 M00001551 A:D04 79917

1698 2/24/98 943 RTA00000413F.C.03.1 M00004081 D:H09 64527

1699 2/24/98 944 RTA00000422F.L24.1 M00001610C:E06 391 18

1700 2/24/98 945 RTA00000412F.C.17.1 M00003905A:A06 75620

1701 2/24/98 946 RTA00000414F.b.07.1 M00005212C:D02 0

1702 2/24/98 947 RTA00000347F.g.08.1 M00004096B:F05 23121

1703 2/24/98 948 RTA00000419F.O.06.1 M00003986C:D09 64643

1704 2/24/98 949 RTA00000340R.J.07.1 M00001654C:D05 38954

1705 2/24/98 950 RTA00000423F.J.02.1 M00003903B:C02 38617

1706 2/24/98 951 RTA00000419F.C.04.1 M00003815C:D12 63749

1707 2/24/98 952 RTA0000041 1 F.3.01.1 M00001675B:D02 74524

1708 2/24/98 953 RTA00000406F.f.05.1 M00003878C:F06 22961

1709 2/24/98 954 RTA00000410F.n.05.1 M00001662A:C07 77830

1710 2/24/98 955 RTA00000404F.e.06.1 M00001607D:F06 39315

171 1 2/24/98 956 RTA00000423F.I.06.1 M00004062A:H06 38136

1712 2/24/98 957 RTA0000041 1 F.C.03.1 M00001677B:B06 79280

1713 2/24/98 958 RTA00000195AF.C.8.1 M00001678B:H01 0

1713 1/28/98 520 RTAOOOOO 195 AF.c.8.1 M00001678B:H01 0

1714 2/24/98 959 RTA00000340F.g.20.1 M00001609D:G 10 4089

1715 2/24/98 960 RTA00000404F.1.19.2 M00001639B:H01 16196

1716 2/24/98 961 RTA00000420F.n.21.2 M00005259B:D12 0

1717 2/24/98 962 RTA00000404F.p.05.2 M00001652D:E09 1896

1718 2/24/98 963 RTA00000405F.1.07.1 M00001693C:E09 38636

1719 2/24/98 964 RTA00000423F.1.15.1 M00004075B:G09 1 1219

1720 2/24/98 965 RTA0000041 1 F.11.06.1 M00003871 D:E1 1 73886

1721 2/24/98 966 RTA00000422F.k. l 5.1 M00001594A:G09 19253

1722 2/24/98 967 RTA00000406F.h. l6.1 M00003902B:D06 38618

1723 2/24/98 968 RTA00000419F.f.24.1 M00003841 B:E06 18717

1724 2/24/98 969 RTA0000041 1 F.d.l 8.1 M00001692A:G06 76063

1725 2/24/98 970 RTA00000414F.e. l 5.1 M00005236B:G03 0

1726 2/24/98 971 RTA0000041 1 F.Ϊ.1 1.1 M00003837C:E05 66849

1727 2/24/98 972 RTA00000408F.d. l 5.1 M00001459B:C1 1 78467

1728 2/24/98 973 RTA00000339F.b.22.1 M00001373D:B03 6867

1729 2/24/98 974 RTA00000340F.h.07.1 M00001608D:D1 1 19254

1730 2/24/98 975 RTA0000041 1 F.n.02.1 M00003870B:F04 78049

1731 2/24/98 976 RTA00000419F.b. l 7.1 M00003808D:D04 63261

1732 2/24/98 977 RTA00000350R.p. l 2.1 M00001657C:C07 0 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Dste of NO: in ID

Priority Priority

Appln Appln

1733 2/24/98 978 RTA00000130A.e.20.1 M00001606A:H09 79502

1734 2/24/98 979 RTA00000345F.b.l7.1 M00001362C:H11 945

1735 2/24/98 980 RTA00000411F.i.l3.1 M00003837C:F10 66138

1736 2/24/98 981 RTA00000420F.e.20.1 M00004110B:A07 64762

1737 2/24/98 982 RTAOOOOO 126A.p.23.2 M00001552A:F06 80915

1738 2/24/98 983 RTA00000423F.f.ll.l M00003809A:H04 0

1739 2/24/98 984 RTA00000406F.g.08.1 M00003880C:H03 37963

1740 2/24/98 985 RTA00000409F.a.08.1 M00001582D:B01 74978

1741 2/24/98 986 RTA00000406F.d.24.1 M00003876B:C05 37997

1742 2/24/98 987 RTA00000422F.b.22.1 M00004117B:A12 2368

1743 2/24/98 988 RTA00000407F.3.22.1 M00004081A:G01 15570

1744 2/24/98 989 RTA00000418F.U2.1 M00001592A:E02 78971

1745 2/24/98 990 RTA00000121A.h.l9.1 M00001471A:D04 80334

1746 2/24/98 991 RTA00000419F.b.l0.1 M00001694C:G04 78566

1747 2/24/98 992 RTA00000406F.m.l0.1 M00003914D:B02 38004

1748 2/24/98 993 RTA00000406F.O.05.1 M00003985B:G04 37894

1749 2/24/98 994 RTA00000408F.b.04.2 M00001455A:F04 39933

1750 2/24/98 995 RTA00000411F.k.04.1 M00003850D:A05 65407

1751 2/24/98 996 RTA00000423F.J.03.1 M00003903B:D03 5391

1752 2/24/98 997 RTAOOOOO 134A.1.9.1 M00001535A:D10 81814

1753 2/24/98 998 RTA00000341F.g.22.1 M00003914D:D10 0

1754 2/24/98 999 RTA00000418F.k.04.1 M00001637A:A03 75864

1755 2/24/98 1000 RTA00000351R.J.21.1 M00003859D:C05 31604

1756 2/24/98 1001 RTA00000413F.p.07.2 M00005102C:D03 0

1757 2/24/98 1002 RTA00000419F.p.l8.1 M00004038D:G06 63002

1758 2/24/98 1003 RTA00000420F. 08.2 M00005176C:C09 0

1759 2/24/98 1004 RTA00000419F.a.24.1 M00001680B:D02 79290

1760 2/24/98 1005 RTA00000339F.e.l7.1 M00001397D:G08 7568

1761 2/24/98 1006 RTAOOOOO 129A.e.14.1 M00001587A:F08 80053

1762 2/24/98 1007 RTA00000404F.a.01.1 M00001589B:B08 19251

1763 2/24/98 1008 RTA00000414F.f.07.1 M00005259C:B05 0

1764 2/24/98 1009 RTA00000399F.O.24.1 M00001607D:A11 2272

1765 2/24/98 1010 RTA00000408F.n.l6.2 M00001540C:B03 73720

1766 2/24/98 1011 RTA00000400F.C.04.1 M00001618A:F08 6445

1767 2/24/98 1012 RTA00000403F.g.06.1 M00001480C:A05 10505

1768 2/24/98 1013 RTA00000404F.b.l8.1 M00001592A:H05 13669

1769 2/24/98 1014 RTA00000412F.1.14.1 M00004029B:F01 62792

1770 2/24/98 1015 RTA00000129A.b.6.2 M00001582A:H01 39111

1771 2/24/98 1016 RTA00000406F.n.l2.1 M00003960A:G07 37517

1772 2/24/98 1017 RTA00000418F.e.03.1 M00001573B:G08 73442

1773 2/24/98 1018 RTA00000413F.J.21.1 M00004688A:A02 0

1774 2/24/98 1019 RTA00000403F.g.03.1 M00001479D:G06 23537

1775 2/24/98 1020 RTA00000412F.p.06.1 M00004038B:H10 65485

1776 2/24/98 1021 RTA00000419F.b.21.1 M00003809A:F0! 65366

1777 2/24/98 1022 RTA00000401F.J.15.1 M00003901A:C09 3061

1778 2/24/98 1023 RTA00000404F.f.l2.1 M00001611B:A05 39209

1779 2/24/98 1024 RTA00000351R.J.16.1 M00003857B:F07 64773

1780 2/24/98 1025 RTAOOOOO 118A.J .24.1 M00001450A:B03 18

1781 2/24/98 1026 RTA00000419FT.18.1 M00003839D:E11 64047

1782 2/24/98 1027 RTA00000423F.i.l6.1 M00003907D:A12 38604 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

1783 2/24/98 1028 RTA00000346F.d.l2.1 M00001676B:B09 1 1777

1784 2/24/98 1029 RTA0000041 1 F.f.04.1 M00003813A:G04 64526

1785 2/24/98 1030 RTAOOOOO 125A.C 17.1 M00001542A:E04 80619

1786 2/24/98 1031 RTA00000404F.g.08.1 M00001613D:H 10 38980

1787 2/24/98 1032 RTA00000423F.C.13.1 M00001678A:A1 1 39059

1788 2/24/98 1033 RTA00000414F.e.l9.1 M00005257C:E05 0

1789 2/24/98 1034 RTAOOOOO 124A.f.16.3 M00001536A:F1 1 47430

1790 2/24/98 1035 RTA00000404F.k. l 5.1 M00001634A:B04 18225

1791 2/24/98 1036 RTA00000339F. 08.1 M00001439B:A10 8133

1792 2/24/98 1037 RTA00000339F.1.12.1 M00001450A:G1 1 771 1

1793 2/24/98 1038 RTA00000406F.b.01.1 M00003867B:G07 39006

1794 2/24/98 1039 RTA00000407F.C.08.1 M000041 18D:B05 37549

1795 2/24/98 1040 RTA00000348R.O.12.1 M00001433C:F10 2263

1796 2/24/98 1041 RTA00000403F.b.05.1 M00001455B:E07 74300

1797 2/24/98 1042 RTA00000339F.g. l 0.1 M00001400C:D02 6327

1798 2/24/98 1043 RTA00000423F.b. l 7.1 M00001662B:F06 8200

1799 2/24/98 1044 RTA00000419F.n. l l . l M00003977C:B03 66477

1800 2/24/98 1045 RTA00000408F.J.05.2 M00001483C:G06 73878

1801 2/24/98 1046 RTA00000346F.J.06.1 M00003879A:A02 5767

1802 2/24/98 1047 RTA00000419F.C.14.1 M00003819B:G01 65727

1803 2/24/98 1048 RTA00000413F.O.07.2 M00005100A:C01 0

1804 2/24/98 1049 RTA00000405F.f.05.1 M00001669C:D09 14359

1805 2/24/98 1050 RTA00000405F.f.05.2 M00001669C:D09 14359

1806 2/24/98 1051 RTA00000346F.h.24.1 M00003797A:C1 1 4379

1807 2/24/98 1052 RTA00000420F.b.02.1 M00004081 A:A08 64013

1808 2/24/98 1053 RTA00000413F.b.24.1 M00004080A:F01 651 17

1809 2/24/98 1054 RTA00000412F.d.08.1 M00003905C:B02 75328

1810 2/24/98 1055 RTA00000346F.a.04.1 M00001607B:C05 5382

181 1 2/24/98 1056 RTA00000419F.m.l 8.1 M00003908C:G09 76014

1812 2/24/98 1057 RTA00000419F.I.24.1 M00003904D:B10 74628

1813 2/24/98 1058 RTA00000408F.C.06.1 M00001456D:E08 78619

1814 2/24/98 1059 RTA00000405F.h.21.2 M00001675C:D12 39072

1815 2/24/98 1060 RTA00000346F.g.02.1 M00003792A:B10 6901

1816 2/24/98 1061 RTA00000405F.g.05.2 M00001671 D:E10 38987

1817 2/24/98 1062 RTA0000041 1 F.f.20.1 M00003816C:C01 63501

1818 2/24/98 1063 RTA00000132A.n.7.1 M00001466A:F08 0

1819 2/24/98 1064 RTA00000420F.d.l9.1 M00004105C:C08 43146

1820 1/28/98 595 RTA00000195R.a.06.1 M00001394A:E04 35265

1820 2/24/98 1065 RTA00000195R.3.06.1 M00001394A:E04 35265

1821 2/24/98 1066 RTA00000123A.f.2.1 M0000153 1A:H03 80379

1822 2/24/98 1067 RTA0000041 1 F.J.1 1.1 M00003841 D:F06 66154

1823 2/24/98 1068 RTA00000341 F.f.03.1 M00003850A:F06 0

1824 2/24/98 1069 RTA00000346F.L05.1 M00003904C:A08 0

1825 2/24/98 1070 RTA00000346F.n.22.1 M00004137A:D06 0

1826 2/24/98 1071 RTA00000404F.k. l 8.2 M00001635A:C06 5475

1827 2/24/98 1072 RTA00000419F.J.03.1 M00003868B:G06 77578

1828 2/24/98 1073 RTA00000418F.3.10.1 M00001475B:C04 15245

1829 2/24/98 1074 RTA00000423F.h.l l .l M00003867C:E1 1 38977

1830 2/24/98 1075 RTA00000413F.b. l 7.1 M00004078A:F07 21704

1831 2/24/98 1076 RTA00000423F. 09.1 M00004035B:H09 26630 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

1832 2/24/98 1077 RTA00000414F.e.ll.l M00005236B:A12 0

1833 2/24/98 1078 RTA00000423F.f.03.1 M00003829C:D10 63852

1834 2/24/98 1079 RTA00000419F.e.l0.1 M00003833B:B03 63225

1835 2/24/98 1080 RTA00000351R.g.06.1 M00003771D:G05 0

1836 2/24/98 1081 RTA00000403F.d.02.1 M00001458D:D01 39224

1837 2/24/98 1082 RTA00000137A.O.22.1 M00001587A:D01 0

1838 2/24/98 1083 RTA00000418F.J.20.1 M00001634D:D04 77101

1839 2/24/98 1084 RTA00000403F.O.22.2 M00001583A:D01 25076

1840 2/24/98 1085 RTA00000403F.n.22.1 M00001578B:B05 26775

1841 2/24/98 1086 RTA00000403F.n.22.2 M00001578B:B05 26775

1842 2/24/98 1087 RTA00000401F.O.13.1 M00004040C:A01 3220

1843 2/24/98 1088 RTA00000339R.b.02.1 M00001344B:F12 0

1844 2/24/98 1089 RTA00000406F.J.21.1 M00003906A:H07 17822

1845 2/24/98 1090 RTA00000405F.g.22.1 M00001673C:A02 527

1846 2/24/98 1091 RTA00000356R.h.05.1 M00004107C:C02 35052

1847 2/24/98 1092 RTA00000125A.C.2.1 M00001542A:F06 40148

1848 2/24/98 1093 RTA00000340F.i.l5.1 M00001629C:E07 26815

1849 2/24/98 1094 RTA00000405F.li.03.2 M00001673D:F10 20633

1850 2/24/98 1095 RTA00000345F.C.12.1 M00001376A:C05 23824

1851 2/24/98 1096 RTA00000421F.a.06.1 M00001589C:A11 2385

1852 2/24/98 1097 RTA00000412F.O.03.1 M00004033D:D07 65039

1853 2/24/98 1098 RTA00000409F.d.l6.1 M00001590C:F10 76090

1854 2/24/98 1099 RTA00000400F.m.l6.I M00001660B:E04 3307

1855 2/24/98 1100 RTA00000414F.a.l2.1 M00005210A:E06 0

1856 2/24/98 1101 RTA00000408F.J.17.2 M00001485B:H03 78935

1857 2/24/98 1102 RTAOOOOO 126A.J.15.2 M00001549A:H11 40425

1858 2/24/98 1103 RTA00000346F.a.l6.1 M00001593A:B07 12082

1859 2/24/98 1104 RTAOOOOO 126A.b.10.1 M00001547A:F06 0

1860 2/24/98 1105 RTA00000340F-P-18.1 M00003751C:A04 287

1861 2/24/98 1106 RTA00000410F.b.l7.1 M00001633C:H05 77458

1862 2/24/98 1107 RTA00000419F.1.22.1 M00003903D:C06 78444

1863 2/24/98 1108 RTA00000346F.C.16.1 M00001652B:G10 9579

1864 2/24/98 1109 RTA00000422F.f.22.1 M00001584A:G03 38703

1865 2/24/98 1110 RTA00000404F.J.24.1 M00001631D:G05 39067

1866 2/24/98 1111 RTA00000406F.m.20.1 M00003918C:C12 38038

1867 2/24/98 1112 RTA00000418F.C.05.1 M00001487B:F02 76475

1868 2/24/98 1113 RTA00000418F.p.21.1 M00001677D:F03 78068

1869 2/24/98 1114 RTA00000340F.f.22.1 M00001594B:F12 1720

1870 2/24/98 1115 RTA00000340F.L08.1 M00001615B:F07 12005

1871 2/24/98 1116 RTA00000410F.O.04.1 M00001664D:F04 79018

1872 2/24/98 1117 RTA00000411F.1.16.1 M00003857C:G01 16122

1873 2/24/98 1118 RTA00000411F.J.03.1 M00003841C:F01 66263

1874 2/24/98 1119 RTAOOOOO 126A. 24.1 M00001550A:F07 39428

1875 2/24/98 1120 RTA00000353R.1.23.1 M00001418B:F07 12531

1876 2/24/98 1121 RTA00000120A.111.10.3 M00001467A:B03 81376

1877 2/24/98 1122 RTA00000419F.f.l6.1 M00003839D:E02 64679

1878 2/24/98 1123 RTA00000408F.C.23.1 M00001458C:D10 42261

1879 2/24/98 1124 RTAOOOOO 123 A.h.22.1 M00001532A:C01 17124

1880 2/24/98 1125 RTA00000118A.n.5.1 M00001451A:C10 0

1881 2/24/98 1126 RTAOOOOO 136A.h.6.1 M00001550A:D09 81620 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

1882 2/24/98 127 RTA00000401F.g.22.1 M00003871A:G09 1147

1883 2/24/98 128 RTA00000423F.a.02.3 M00001656B:A08 39210

1884 2/24/98 129 RTA00000401F.m.07.1 M00003907D:F11 2893

1885 2/24/98 130 RTA00000354R.p.01.1 M00004104C:H12 0

1886 2/24/98 131 RTA00000418F.e.20.1 M00001576C:G05 73741

1887 2/24/98 132 RTA00000119A.C.12.1 M00001453A:D08 4882

1888 2/24/98 133 RTA00000405F.1.03.1 M00001692D:B01 38580

1889 2/24/98 134 RTA00000418F.m.02.1 M00001650A:A12 74550

1890 2/24/98 135 RTA00000346F.O.16.1 M00004358D:C02 176

1891 2/24/98 136 RTA00000406F.C.05.1 M00003870A:H01 22077

1892 2/24/98 137 RTA00000345F.d.03.1 M00001376B:A08 19230

1893 2/24/98 1 138 RTA00000411F.k.21.1 M00003854B:D04 65349

1894 2/24/98 139 RTA00000404F.h.20.1 M00001619B:A09 15564

1895 2/24/98 140 RTA00000339F.C.05.1 M00001365A:H10 3908

1896 2/24/98 141 RTA00000347F.f.08.1 M00003972D:H02 5948

1897 2/24/98 142 RTA00000418F.i.06.1 M00001591B:B06 75151

1898 2/24/98 143 RTA00000423F.a.03.1 M00001656B:D05 26796

1899 2/24/98 144 RTA00000345F.J.09.1 M00001451B:F01 13

1900 2/24/98 145 RTA00000423F.k.21.2 M00003984D:B08 37499

1901 2/24/98 146 RTA00000347F.h.02.1 M00004072D:H12 562

1902 2/24/98 147 RTA00000404F.C.18.1 M00001594A:C01 38982

1903 2/24/98 148 RTA00000345F.d.23.1 M00001390D:E03 5862

1904 2/24/98 149 RTA00000339F.b.02.1 M00001344B:F12 0

1905 2/24/98 150 RTA00000411F.g.24.1 M00003825B:B11 65233

1906 2/24/98 151 RTA00000405F.g.l8.2 M00001672D:E08 5255

1907 2/24/98 152 RTA00000405F.m.07.1 M00003809B:B02 37733

1908 2/24/98 153 RTA00000411F.J.07.1 M00003841C:H11 66963

1909 2/24/98 154 RTA00000403F.m.09.2 M00001575B:G01 26814

1910 2/24/98 155 RTA00000353R.h.04.1 M00001375B:C06 17123

1911 2/24/98 156 RTA00000408F.f.l0.2 M00001476D:C05 75309

1912 2/24/98 157 RTA00000422F.m.l8.1 M00001647B:E04 23829

1913 2/24/98 158 RTA00000405F.O.03.1 M00003829C:H05 37575

1914 2/24/98 159 RTA00000413F.b.l8.1 M00004078C:F04 39873

1915 2/24/98 160 RTA00000400F.g.02.1 M00001638B:E03 1508

1916 2/24/98 161 RTA00000346F.m.05.1 M00003983B:C08 5644

1917 2/24/98 162 RTA00000408F.C.10.1 M00001458A:A11 18247

1918 2/24/98 163 RTA00000341F.b.l4.1 M00003763A:C01 5992

1919 2/24/98 164 RTA00000405F.m.21.1 M00003815C:C06 24218

1920 2/24/98 165 RTA00000408F.C.08.1 M00001456D:G11 73473

1921 2/24/98 166 RTA00000347F.h.01.1 M00004040A:G12 12043

1922 2/24/98 167 RTA00000410F.C.06.1 M00001633D:H06 77784

1923 2/24/98 168 RTA00000421F.b.06.1 M00001567A:B09 2113

1924 2/24/98 169 RTA00000405F.b.08.1 M00001656B:E01 39182

1925 2/24/98 170 RTA00000409F.I.24.1 M00001616C:A02 73174

1926 2/24/98 171 RTA00000406F.J.06.1 M00003905A:F10 38952

1927 2/24/98 172 RTA00000423F.h.03.1 M00003875D:D09 37903

1928 2/24/98 173 RTA00000339R.b.07.1 M00001360A:G10 6826

1929 2/24/98 1174 RTA00000121A.k.22.1 M00001507A:C05 79523

1930 2/24/98 175 RTA00000414F.b.04.1 M00005212B:E01 0

1931 2/24/98 1176 RTA00000411F.m.06.1 M00003858D:G06 24195 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID

Priority Priority

Appln Appln

1932 2/24/98 1177 RTAOOOOO 126A.b.9.1 M00001547A:F11 81279

1933 2/24/98 1178 RTA00000400F.f.ll.l M00001636A:E07 4088

1934 2/24/98 1179 RTA00000341F.O.12.1 M00004144A:F04 2883

1935 2/24/98 1180 RTA00000404F.1.05.1 M00001636D:F09 38671

1936 2/24/98 1181 RTA00000346F.f.l4.1 M00003800B:F03 16998

1937 2/24/98 1182 RTA00000346F.d.21.1 M00001670B:G12 6641

1938 2/24/98 1183 RTA00000346F.J.21.1 M00003879D:A08 3095

1939 2/24/98 1184 RTA00000345F.H.08.1 M00001419D:C10 11393

1940 2/24/98 1185 RTA00000413F.b.20.1 M00004079D:G08 66063

1941 2/24/98 1186 RTA00000419F.p.l0.1 M00004036D:B09 41448

1942 2/24/98 1187 RTAOOOOO 120A.C.19.1 M00001464A:B03 81016

1943 2/24/98 1188 RTA00000341F.O.18.1 M00004169D:B11 37189

1944 2/24/98 1189 RTA00000339F.O.18.1 M00001469B:B01 6641

1945 2/24/98 1190 RTA00000405F.g.02.2 M00001671B:G05 10567

1946 2/24/98 1191 RTA00000340F.i.05.1 M00001614B:E08 0

1947 2/24/98 1192 RTA00000406F.m.l7.1 M00003918A:F09 0

1948 2/24/98 1193 RTA00000411F.k.l4.1 M00003851A:C10 63987

1949 2/24/98 1194 RTA00000420F.e.05.1 M00004107D:E12 63908

1950 2/24/98 1195 RTA00000422F.e.23.1 M00001567D:B03 19246

1951 2/24/98 1196 RTA00000413F.I.18.1 M00004895D:G07 0

1952 2/24/98 1197 RTAOOOOO 128 A.j.10.1 M00001560A:H06 80085

1953 2/24/98 1198 RTA00000412F.f.l0.2 M00003959A:A03 65405

1954 2/24/98 1199 RTA00000401F.J.23.1 M00003901C:D03 570

1955 2/24/98 1200 RTA00000422F.k.17.1 M00001652A:A01 38955

1956 2/24/98 1201 RTA00000409F.m.02.1 M00001616C:A11 9157

1957 2/24/98 1202 RTA00000347F.h.l0.1 M00004206A:E02 22779

1958 2/24/98 1203 RTA00000413F.e.l0.1 M00004092C:B03 31033

1959 2/24/98 1204 RTA00000419F.1.02.1 M00003879A:C01 75736

1960 2/24/98 1205 RTA00000419F. 05.1 M00003871C:E04 11757

1961 2/24/98 1206 RTA00000418F.b.20.1 M00001484D:G05 73560

1962 2/24/98 1207 RTA00000401F.J.21.1 M00003901B:F10 0

1963 2/24/98 1208 RTA00000347F.e.24.1 M00003823B:F07 8188

1964 2/24/98 1209 RTA00000408F.n.05.2 M00001539A:H02 77883

1965 2/24/98 1210 RTA00000419F.O.09.1 M00003987B:F08 66396

1966 2/24/98 1211 RTA00000399FT.14.1 M00001487D:C11 11483

1967 2/24/98 1212 RTA00000349R.O.03.1 M00001551D:H07 23006

1968 2/24/98 1213 RTA00000135A.a.23.1 M00001537A:H05 27054

1969 2/24/98 1214 RTA00000339F.J.07.1 M00001428D:B10 5673

1970 2/24/98 1215 RTA00000422F.O.08.2 M00001659D:D03 26832

1971 2/24/98 1216 RTA00000404F.e.07.1 M00001608A:D03 9034

1972 2/24/98 1217 RTA00000410F.J.17.1 M00001642D:F02 72912

1973 2/24/98 1218 RTA00000418F.m.l8.1 M00001653B:G10 76479

1974 2/24/98 1219 RTA00000347F.e.20.1 M00003771B:E05 39911

1975 2/24/98 1220 RTA00000419F.e.23.1 M00003834B:G04 65772

1976 2/24/98 1221 RTA00000403F.O.17.1 M00001582D:A02 23085

1977 2/24/98 1222 RTA00000423F.e.l3.1 M00003848A:C09 10998

1978 2/24/98 1223 RTA00000347F.a.l4.1 M00001429D:F11 7421

1979 2/24/98 1224 RTAOOOOO 122A.h.24.1 M00001514A:A12 48

1980 2/24/98 1225 RTA00000346F.J.13.1 M00003841C:E04 5337

1981 2/24/98 1226 RTA00000414F.C.12.1 M00005218A:F09 0 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

1982 2/24/98 1227 RTA0000041 1 F.g.05.1 M00003822D:B10 64664

1983 2/24/98 1228 RTA00000404F.h.l0.1 M00001618A:A03 37148

1984 2/24/98 1229 RTA00000422F.ιι.14.1 M00001642C:G02 26787

1985 2/24/98 1230 RTA00000399F.J.14.1 M00001578C:F05 16942

1986 2/24/98 1231 RTA00000120A.m.l 3.3 M00001467A:C 10 80608

1987 2/24/98 1232 RTA00000412F .03.1 M00003975D:C06 65617

1988 2/24/98 1233 RTA00000418F.1.02.1 M00001641 C:C05 39316

1989 2/24/98 1234 RTA00000352R.C.20.1 M00003982A:B12 7339

1990 2/24/98 1235 RTA0000041 1 F.J.04.1 M00003841 C:F03 66219

1991 2/24/98 1236 RTA00000414F.b.06.1 M00005212C:C03 0

1992 2/24/98 1237 RTA00000414F.C.24.1 M00005229B:H04 0

1993 2/24/98 1238 RTA00000420F.g.09.1 M00004895B:E12 0

1994 2/24/98 1239 RTA00000340F.O.22.1 M00001673B:B07 7356

1995 2/24/98 1240 RTA00000404F.a.l 8.1 M00001590B:B02 36267

1996 2/24/98 1241 RTA00000408F.1.14.1 M00001530A:E10 12001

1997 2/24/98 1242 RTA00000405F.d. l 0.1 M00001661 C:F1 1 39000

1998 2/24/98 1243 RTA00000404F.J.19.1 M00001630D:H 10 0

1999 2/24/98 1244 RTA00000418F.h.23.1 M00001591A:B08 75153

2000 2/24/98 1245 RTA00000422F.L22.1 M00001592C:E05 4098

2001 2/24/98 1246 RTA00000418F.J.1 1.1 M00001626C:E04 73853

2002 2/24/98 1247 RTA00000408F.O.13.1 M00001572A:B05 74895

2003 2/24/98 1248 RTA00000419F.O.07.1 M00003986C:E09 14059

2004 2/24/98 1249 RTA00000419F.n.l 7.1 M00003978D:G04 63186

2005 2/24/98 1250 RTA00000403FT.15.1 M00001477D:F10 22768

2006 2/24/98 1251 RTA00000408F.d.03.1 M00001458D:A02 22768

2007 2/24/98 1252 RTA00000400F.g.08.1 M00001639A:C 1 1 1275

2008 2/24/98 1253 RTA00000346F.f.02.1 M00003772C:B 12 62757

2009 2/24/98 1254 RTA00000341 F.p. l l .l M00004159C:G 12 0

2010 2/24/98 1255 RTA00000413F.i.21.1 M000041 18B:B04 64066

201 1 2/24/98 1256 RTA00000401 F. 19.1 M00003903D:D10 799

2012 2/24/98 1257 RTA00000419F.h.21.1 M00003856C:B08 64828

2013 2/24/98 1258 RTA00000403F.p.05.2 M00001583D:B08 24528

2014 2/24/98 1259 RTA00000420F.1.19.2 M00005231A:H04 0

2015 2/24/98 1260 RTA00000422F.f. l 8.1 M00001583D:B08 24528

2016 2/24/98 1261 RTA00000404F.m.l 7.2 M00001643B:E05 0

2017 2/24/98 1262 RTA00000122A.h.4.1 M00001514A:G03 33576

2018 2/24/98 1263 RTA00000341 F.i.22.1 M0000391 1 A:F10 7825

2019 2/24/98 1264 RTA00000345F.e.l 3.1 M00001392C:D05 4366

2020 2/24/98 1265 RTA00000340F.d.07.1 M00001532D:A06 0

2021 2/24/98 1266 RTA00000121A.a.2.1 M00001468A:H10 81843

2022 3/24/98 1 RTA00000527F.g. l 3.1 M00003845D:A04 36035

2023 3/24/98 2 RTA00000523F.d. l9.1 M00003824A:A06 26489

2024 3/24/98 3 RTA00000528F.b.23.1 M00001479C:F10 1605

2025 3/24/98 4 RTA00000426F.li.1 1.1 M00003905B:H05 75479

2026 3/24/98 5 RTA00000426F.p.04.1 M00004029B:H08 34149

2027 3/24/98 6 RTA00000523F.1.10.1 M00005134B:E01 0

2028 3/24/98 7 RTA00000523F.O.20.1 M00005177B:H02 0

2029 3/24/98 8 RTA00000428F.b.06.1 M00005228A:A09 0

2030 3/24/98 9 RTA00000522F.b.22.1 M00001573B:H12 75181

2031 3/24/98 10 RTA00000527FT.12.1 M00003829D:D12 5945 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

2032 3/24/98 1 1 RTA00000427F.1.1 1.1 M00005139A:F01 0

2033 3/24/98 12 RTA00000522F.a.23.1 M00001570C:A05 38613

2034 3/24/98 13 RTA00000528F.m.16.1 M00003845D:C03 4468

2035 3/24/98 14 RTA00000523F.b.02.1 M00003806C:A06 65163

2036 3/24/98 15 RTA00000425F.J.14.1 M00001639D:C12 73397

2037 3/24/98 16 RTA00000426F.m.22.1 M00003983A:G02 30002

2038 3/24/98 17 RTA00000527F.p.06.1 M00004029B:G 10 1292

2039 3/24/98 18 RTA00000522F.e.l 6.1 M00001590A:C08 75283

2040 3/24/98 19 RTA00000527F.J.02.2 M00003856A:B07 4896

2041 3/24/98 20 RTA00000522F.O.06.1 M00001659D:A09 26860

2042 3/24/98 21 RTA00000523F.h. l 7.1 M00003852A:B03 65586

2043 3/24/98 22 RTA00000527F.U 5.1 M00003982A:G03 22688

2044 3/24/98 23 RTA00000522F.p.07.1 M00001670A:C 1 1 76888

2045 3/24/98 24 RTA00000522F.n.08.1 M00001656A:D10 76343

2046 3/24/98 25 RTA00000425F.C.06.1 M00001585D:D1 1 78041

2047 3/24/98 26 RTA00000427F.b.23.1 M00003973D:F08 64297

2048 3/24/98 27 RTA00000527F.p.02.1 M00004029B:A01 36844

2049 3/24/98 28 RTA00000427F.d.08.1 M00003980C:E12 63967

2050 3/24/98 29 RTA00000524F.b.03.1 M00005212A:D10 0

2051 3/24/98 30 RTA00000426F.m.07.1 M00004028A:G03 63504

2052 3/24/98 31 RTA00000427F.C.10.1 M00003976B:E06 65478

2053 3/24/98 32 RTA00000424F.n.l4.1 M00001584D:C1 1 73008

2054 3/24/98 33 RTA00000524F.b.21.1 M00005216C:B09 0

2055 3/24/98 34 RTA00000424F.m.l 5.1 M00001612D:F06 73759

2056 3/24/98 35 RTA00000426F.f.l l .l M00003823C:B01 63102

2057 3/24/98 36 RTA00000428F.a.l6.1 M00005212D:F08 0

2058 3/24/98 37 RTA00000426FX.20.1 M00003854C:F01 65134

2059 3/24/98 38 RTA00000528F.i.22.1 M00001661 D:D05 2478

2060 3/24/98 39 RTA00000527F.C.23.1 M00003822C:A07 37742

2061 3/24/98 40 RTA00000426F.h.23.1 M0000391 1A:D12 75964

2062 3/24/98 41 RTA00000525F.b. l 7.1 M00004037B:A04 24715

2063 3/24/98 42 RTA00000527F.J.19.2 M00003853C:C06 38089

2064 3/24/98 43 RTA00000527F.p.07.1 M00004029C:B03 23343

2065 3/24/98 44 RTA00000527F.p.l 7.1 M00004030C:D12 17223

2066 3/24/98 45 RTA00000528F.m.l2.1 M00003842D:F08 5768

2067 3/24/98 46 RTA00000523F.C.09.1 M00003813C:D08 47389

2068 3/24/98 47 RTA00000523F.e.l 8.1 M00003829D:A1 1 62898

2069 3/24/98 48 RTA00000527F.L21.1 M00003982B:H 10 36051

2070 3/24/98 49 RTA00000527F.n.22.1 M00004027A:A08 24175

2071 3/24/98 50 RTA00000522F.k.l 5.1 M00001652D:G06 76866

2072 3/24/98 51 RTA00000522F.n.02.1 M00001655D:E08 74959

2073 3/24/98 52 RTA00000523F.1.07.1 M00004927C:H 1 1 0

2074 3/24/98 53 RTA00000525F.C.17.1 M00004040A:C08 38160

2075 3/24/98 54 RTA00000425F.f. l 9.1 M00001653D:G07 32635

2076 3/24/98 55 RTA00000528F.e.23.1 M00001593B:D10 19242

2077 3/24/98 56 RTA00000522F.n. l 6.1 M00001657D:A10 26769

2078 3/24/98 57 RTA00000427F.C.20.1 M00003978A:E01 26527

2079 3/24/98 58 RTA00000527F.k.06.1 M00003981 B:B12 12469

2080 3/24/98 59 RTA00000427F.n. l4.1 M00004960B:D12 0

2081 3/24/98 60 RTA00000523F.i.06.1 M00003855A:A01 66341 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID

Priority Priority

Appln Appln

2082 3/24/98 61 RTA00000427F.f.21.1 M000041 18B:C1 1 36853

2083 3/24/98 62 RTA00000427F.J.19.1 M00004077A:G 12 41395

2084 3/24/98 63 RTA00000522F.b.01.1 M00001570C:B02 75691

2085 3/24/98 64 RTA00000424F.i.24.1 M00001596A:G06 79101

2086 3/24/98 65 RTA00000523F.C.01.1 M00003810A:A02 65710

2087 3/24/98 66 RTA00000427F.b. l 5.1 M00003971 C:F09 66891

2088 3/24/98 67 RTA00000527F.e.03.1 M00003825D:F01 25560

2089 3/24/98 68 RTA00000523F.11.04.1 M00005138B:D12 0

2090 3/24/98 69 RTA00000522F.J.15.2 M00001651 C:G12 76535

2091 3/24/98 70 RTA00000525F.e.07.1 M000041 15C:G03 38147

2092 3/24/98 71 RTA00000527F.J.20.2 M00003860D:E06 37603

2093 3/24/98 72 RTA00000426F.f. l 9.1 M00003854C:C09 66701

2094 3/24/98 73 RTA00000524F.b. l2.1 M00005213C:G01 0

2095 3/24/98 74 RTA00000527F.d. l9.1 M00003825B:F10 486

2096 3/24/98 75 RTA00000523F.i.22.1 M00003857A:E12 64688

2097 3/24/98 76 RTA00000523F.I.18.1 M00005134D:A06 0

2098 3/24/98 77 RTA00000425F.i. l 7.1 M00001633A:F1 1 43213

2099 3/24/98 78 RTA00000427F.O.05.1 M00004958B:D01 0

2100 3/24/98 79 RTA00000523F.1.15.1 M00005134C:E1 1 0

2101 3/24/98 80 RTA00000425F.p.l2.1 M00001638C:G01 73219

2102 3/24/98 81 RTA00000427F.J.07.1 M00004105A:B10 64819

2103 3/24/98 82 RTA00000523F.h.l 5.1 M00003851C:F09 65137

2104 3/24/98 83 RTA00000527F.i.05.2 M00003851C:B06 37481

2105 3/24/98 84 RTA00000527F.k. l 8.1 M00003982B:C 10 1 1332

2106 3/24/98 85 RTA00000427F.m.21.1 M00004900C:E1 1 0

2107 3/24/98 86 RTA00000523F.k.01.1 M00003966C:F03 41437

2108 3/24/98 87 RTA00000425F.J.1 1.1 M00001637C:H12 76667

2109 3/24/98 88 RTA00000424F.b.22.4 M00001530A:F1 1 72971

21 10 3/24/98 89 RTA00000527F.n.02.1 M00003986C:G 1 1 24190

21 1 1 3/24/98 90 RTA00000525F.a.03.1 M00004031 D:F05 36786

21 12 3/24/98 91 RTA00000527F.i.21.2 M00003855A:F01 37490

21 13 3/24/98 92 RTA00000424F.a.24.4 M00001448D:E1 1 73951

21 14 3/24/98 93 RTA00000522F.U 4.1 M00001652D:G02 74280

21 15 3/24/98 94 RTA00000522F.n.05.1 M00001655D:H 1 1 73260

21 16 3/24/98 95 RTA00000523F.C.18.1 M00003817C:A10 66179

21 17 3/24/98 96 RTA00000523F.b.l3.1 M00003809B:A03 66330

21 18 3/24/98 97 RTA00000522F.J.14.2 M00001651 C:D1 1 73123

21 19 3/24/98 98 RTA00000527F.p.l6.1 M00004030C:C02 23798

2120 3/24/98 99 RTA00000425F.C.20.1 M00001626D:A02 73581

2121 3/24/98 100 RTA00000424F.i.21.1 M00001596A:E07 73482

2122 3/24/98 101 RTA00000523F.J.19.1 M00003966B:D02 65910

2123 3/24/98 102 RTA00000522F.g. l 9.1 M00001595C:A01 781 19

2124 3/24/98 103 RTA00000424F.b.22.1 M00001530A:F 1 1 72971

2125 3/24/98 104 RTA00000527F.b. l 8.1 M00003810D:H09 37469

2126 3/24/98 105 RTA00000526F.d.01.1 M00004104B:A02 4468

2127 3/24/98 106 RTA00000424F.J.14.1 M00001592B:B02 7431 1

2128 3/24/98 107 RTA00000523F.n.20.1 M00005174D:H02 0

2129 3/24/98 108 RTA00000525F.e.l 6.1 M000041 17B:G01 36837

2130 3/24/98 109 RTA00000424F.a.01.4 M00001575A:D05 43214

2131 3/24/98 1 10 RTA00000522F.d.08.1 M00001578B:A06 74284 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

2132 3/24/98 1 1 1 RTA00000425F.d.08.1 M00001631 A:F06 74350

2133 3/24/98 1 12 RTA00000523F.il.12.1 M00005173C:A02 0

2134 ^■ 3/24/98 1 13 RTA00000527F.g.07.1 M00003840C:C02 37488

2135 3/24/98 1 14 RTA00000524F.a.23.1 M0000521 1 C:E09 0

2136 3/24/98 1 15 RTA00000525F.b.05.1 M00004034C:F05 21 1 16

2137 3/24/98 1 16 RTA00000425F.n.05.1 M00001647D:G07 73965

2138 3/24/98 1 17 RTA00000523F.d. l 8.1 M00003822B:G01 64072

2139 3/24/98 1 18 RTA00000525F.a.02.1 M00004031 C:H10 37454

2140 3/24/98 1 19 RTA00000523F.p.06.1 M00005177D:F09 0

2141 3/24/98 120 RTA00000426F.h.09.1 M00003905B:G03 78797

2142 3/24/98 121 RTA00000427F.n.02.1 M00004900D:B 10 0

2143 3/24/98 122 RTA00000523F.O.12.1 M00005177A:B06 0

2144 3/24/98 123 RTA00000427F.g.05.1 M00004069C:C08 63138

2145 3/24/98 124 RTA00000424F.m.12.1 M00001586C:H07 77675

2146 3/24/98 125 RTA00000424F.a.01.1 M00001575A:D05 43214

2147 3/24/98 126 RTA00000527F.m.05.1 M00003985A:C01 17240

2148 3/24/98 127 RTA00000523F.n. l 0.1 M00005140D:G09 0

2149 3/24/98 128 RTA00000428F.C.02.1 M00005229D:H07 0

2150 3/24/98 129 RTA00000527F.p.l 8.1 M00004030D:B06 31635

2151 3/24/98 130 RTA00000427F.h. l2.1 M00004092C:D08 36894

2152 3/24/98 131 RTA00000523F.C.15.1 M00003813D:G06 36935

2153 3/24/98 132 RTA00000427F.U 7.1 M00004101A:F07 64965

2154 3/24/98 133 RTA00000425F.f.04.1 M00001607A:B06 24633

2155 3/24/98 134 RTA00000424F.C.14.3 M00001476D:A09 76614

2156 3/24/98 135 RTA00000522F.k. l 0.2 M00001652D:B09 77619

2157 3/24/98 136 RTA00000424F.m.22.1 M00001614C:E1 1 72943

2158 3/24/98 137 RTA00000527F.h.17.1 M00003848D:G02 37799

2159 3/24/98 138 RTA00000527F.C.22.1 M00003822B:G12 37496

2160 3/24/98 139 RTA00000425F. 22.1 M00001633C:E12 78123

2161 3/24/98 140 RTA00000424F.m. l4.1 M00001612D:D12 77491

2162 3/24/98 141 RTA00000522F.k. l 9.1 M00001653A:A05 32625

2163 3/24/98 142 RTA00000523F.U 8.1 M00003856B:C04 64463

2164 3/24/98 143 RTA00000425F.J.22.1 M00001633B:E03 73882

2165 3/24/98 144 RTA00000527F.g.23.1 M00003846C:F08 37538

2166 3/24/98 145 RTA00000426F.m.24.1 M00003981 A:A07 63943

2167 3/24/98 146 RTA00000527F.L17.2 M00003853B:C08 37539

2168 3/24/98 147 RTA00000425F.d.21.1 M00001631 B:H04 78920

2169 3/24/98 148 RTA00000427F.n.l 8.1 M00004891 D:C1 1 0

2170 3/24/98 149 RTA00000424F.d.04.3 M00001478A:F12 76505

2171 3/24/98 150 RTA00000424F.d.04.1 M00001478A:F12 76505

2172 3/24/98 151 RTA00000427F.C.12.1 M00003976B:H07 66995

2173 3/24/98 152 RTA00000425F.d.07.1 M00001631 A:F12 43197

2174 3/24/98 153 RTA00000527F.1.13.1 M00003983C:F10 36904

2175 3/24/98 154 RTA00000522F.h. l 3.1 M00001596C:F09 40823

2176 3/24/98 155 RTA00000424F.1.19.1 M00001609C:A 12 75454

2177 3/24/98 156 RTA00000525F.b.22.1 M00004037C:D07 16679

2178 3/24/98 157 RTA00000523F.g.l 0.1 M00003848B:E07 40694

2179 3/24/98 158 RTA00000427F.a.06.1 M00004036A:A 1 1 66550

2180 3/24/98 159 RTA00000525F.C.19.1 M00004040B:F07 38159

2181 3/24/98 160 RTA00000523F.f.06.1 M00003833D:H08 62871 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID

Priority Priority

Appln Appln

2182 3/24/98 161 RTA00000424F.h. l0.1 M00001485C:G06 72925

2183 3/24/98 162 RTA00000522F.a.l 2.1 M00001567A:H05 33515

2184 3/24/98 163 RTA00000522F.h.01.1 M00001595C:E05 75010

2185 3/24/98 164 RTA00000523F.n.l 7.1 M00005174D:B02 0

2186 3/24/98 165 RTA00000425F.e.21.1 M00001629D:D10 77203

2187 3/24/98 166 RTA00000523F.f.07.1 M00003833D:H10 62799

2188 3/24/98 167 RTA00000424F.i.20.1 M00001596A:D01 44010

2189 3/24/98 168 RTA00000424F.J.12.1 M00001594C:E05 73827

2190 3/24/98 169 RTA00000425F.f.05.1 M00001607A:D10 24090

2191 3/24/98 170 RTA00000523F.d.l2.1 M00003822B:D08 64888

2192 3/24/98 171 RTA00000523F.e.l 0.1 M00003829A:F03 62878

2193 3/24/98 172 RTA00000425F.f. l l . l M00001656C:C04 79275

2194 3/24/98 173 RTA00000426F.m. l 8.1 M00003986D:G07 62974

2195 3/24/98 174 RTA00000424F.b.21.4 M00001530A:B02 24686

2196 3/24/98 175 RTA00000528F.d. l 8.1 M00001582C:E01 2684

2197 3/24/98 176 RTA00000522F.g. l 5.1 M00001595B:G07 76536

2198 3/24/98 177 RTA00000522F.il.12.1 M00001656A:H 12 741 17

2199 3/24/98 178 RTA00000428F.a.l 2.1 M00005179B:H02 0

2200 3/24/98 179 RTA00000424F.d.l0.3 M00001530D:A1 1 731 10

2201 3/24/98 180 RTA00000523F.k.02.1 M00004687A:C03 0

2202 3/24/98 181 RTA00000523F.b.06.1 M00003808A:F09 28736

2203 3/24/98 182 RTA00000524F.b.l 7.1 M00005214B:A06 0

2204 3/24/98 183 RTA00000527F.C.04.1 M00003813C:H08 23090

2205 3/24/98 184 RTA00000524F.b.l 8.1 M00005214B:D1 1 0

2206 3/24/98 185 RTA00000527F.h.21.1 M00003850C:G09 37630

2207 3/24/98 186 RTA00000425F.C.07.1 M00001585D:F03 76042

2208 3/24/98 187 RTA00000428F.b.23.1 M00005231 D:H10 0

2209 3/24/98 188 RTA00000525F.C.15.1 M00004040A:A07 7692

2210 3/24/98 189 RTA00000424F.d.22.3 M00001448B:G07 76189

221 1 3/24/98 190 RTA00000523F.h. l 2.1 M00003851C:D07 65745

2212 3/24/98 191 RTA00000522F.g.22.1 M00001595C:B12 77504

2213 3/24/98 192 RTA00000523F.m.02.1 M00005134D:H03 0

2214 3/24/98 193 RTA00000428F.b. l2.1 M00005231 C:B07 0

2215 3/24/98 194 RTA00000522F.J.12.2 M00001651 C:A04 74341

2216 3/24/98 195 RTA00000523F.i.08.1 M00003855A:C12 65099

2217 3/24/98 196 RTA00000523FT.12.1 M00003840A:C 10 63751

2218 3/24/98 197 RTA00000425F.J.20.1 M00001633B:A12 26760

2219 3/24/98 198 RTA00000523F.O.05.1 M00005175B:H04 0

2220 3/24/98 199 RTA00000427F.f.24.1 M00004076D:B09 64572

2221 3/24/98 200 RTA00000527F.a.l 3.1 M00003805D:E06 37740

2222 3/24/98 201 RTA00000427F.n.l 7.1 M00004891 D:A07 0

2223 3/24/98 202 RTA00000528F.J.1 1.1 M00001669B:C12 1070

2224 3/24/98 203 RTA00000427F.p.l 0.2 M00005102C:F09 0

2225 3/24/98 204 RTA00000424F.a.09.4 M00001575C:C 1 1 77833

2226 3/24/98 205 RTA00000426F.h.l2.1 M00003905C:F12 78093

2227 3/24/98 206 RTA00000525F.f.07.1 M000041 19A:A06 37500

2228 3/24/98 207 RTA00000424F.J.07.1 M00001596B:C 1 1 7921 1

2229 3/24/98 208 RTA00000424F.m.10.1 M00001586C:E06 34251

2230 3/24/98 209 RTA00000427F.g. l 6.1 M00004069A:E12 6301 1

2231 3/24/98 210 RTA00000522F.g.06.1 M00001594D:G 1 1 78221 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

2232 3/24/98 21 1 RTA00000424F.lι.03.1 M00001487C:G09 74447

2233 3/24/98 212 RTA00000424F.n.06.1 M00001613A:D02 74737

2234 3/24/98 213 RTA00000427F.C.22.1 M00003978A:E09 63990

2235 3/24/98 214 RTA00000424F. 12.1 M00001610C:B07 77666

2236 3/24/98 215 RTA00000425F.f.02.1 M00001 607A:A01 76982

2237 3/24/98 216 RTA00000427F.Ii.1 1 .1 M00004092C:B 12 26494

2238 3/24/98 217 RTA00000425F.J.16.1 M00001639D:F02 75631

2239 3/24/98 218 RTA00000427F.U 9.1 M00004102C:D01 64206

2240 3/24/98 219 RTA00000427F.f. l 7.1 M000041 15A:B 12 63803

2241 3/24/98 220 RTA00000522F.O.18.1 M00001669B:H06 76366

2242 3/24/98 221 RTA00000427F.J.22.1 M00004097D:B05 66367

2243 3/24/98 222 RTA00000426F.p. l 0.1 M00004033D:C05 65845

2244 3/24/98 223 RTA00000522F.m.02.1 M00001654C:G07 76834

2245 3/24/98 224 RTA00000527F. 09.1 M00003981 C:F05 213

2246 3/24/98 225 RTA00000527F.d.09.1 M00003824A:G 1 1 10848

2247 3/24/98 226 RTA00000425F.e. l 5.1 M00001608D:F1 1 75921

2248 3/24/98 227 RTA00000427F.U 1 .1 M00004097C:H08 26635

2249 3/24/98 228 RTA00000523F.O.14.1 M00005177A:H09 0

2250 3/24/98 229 RTA00000424F.n. l 3.1 M00001584D:B06 74942

2251 3/24/98 230 RTA00000424F.g. l 4.1 M00001572A:B06 74879

2252 3/24/98 23 1 RTA00000426F.e. l 7.1 M00003810C:B06 64089

2253 3/24/98 232 RTA00000527F.U 3.2 M00003852B:G04 2924

2254 3/24/98 233 RTA00000426F.f. l 3.1 M00003851 A:A06 65384

2255 3/24/98 234 RTA00000524F.C.16.1 M00005218D:G 10 0

2256 3/24/98 235 RTA00000427F.g. l 9.1 M00004087A:B05 6461 1

2257 3/24/98 236 RTA00000527F.O.01 .1 M00004027A:D06 19088

2258 3/24/98 237 RTA00000522F.C.01 .1 M00001576A:C 1 1 74938

2259 3/24/98 238 RTA00000522F.g. l 7.1 M00001595B:G 10 76486

2260 3/24/98 239 RTA00000523F.J.17.1 M00003966B:A04 63610

2261 3/24/98 240 RTA00000522F.11.14.1 M00001657C:C 1 1 73410

2262 3/24/98 241 RTA00000527F.O.12.1 M00004028B:G08 688

2263 3/24/98 242 RTA00000523F.e.20.1 M00003829D:F03 65164

2264 3/24/98 243 RTA00000424F.C.15.3 M00001476D:F12 73533

2265 3/24/98 244 RTA00000426F.p.09.1 M00004033D:B07 66665

2266 3/24/98 245 RTA00000522F.p.09.1 M00001670A:F09 75204

2267 3/24/98 246 RTA00000426F.m.21 .1 M00003983A:F06 64915

2268 3/24/98 247 RTA00000425F.J.21 .1 M00001633B:B 1 1 77373

2269 3/24/98 248 RTA00000527F.I.14.1 M00003983D:A09 14935

2270 3/24/98 249 RTA00000523F.h.21 .1 M00003853B:C 10 41440

2271 3/24/98 250 RTA00000427F.li.24. ] M00004091 B:H09 65193

2272 3/24/98 251 RTA00000425F.f.24.1 M00001656D:C04 40841

2273 3/24/98 252 RTA00000425F.m.03.1 M00001642D:G08 76045

2274 3/24/98 253 RTA00000426F.m.08.1 M00004030B:A 12 63781

2275 3/24/98 254 RTA00000523F.d.24.1 M00003824D:D08 64799

2276 3/24/98 255 RTA00000523F.C.14.1 M00003813D:C02 66015

2277 3/24/98 256 RTA00000523F.b.20.1 M00003809C:H07 66492

2278 3/24/98 257 RTA00000522F.h.07.1 M00001595D:C 1 1 75149

2279 3/24/98 258 RTA00000527F.g. l0.1 M00003845A:E12 37820

2280 3/24/98 259 RTA00000528F.m.04.1 M00003830D:H 1 1 10815

2281 3/24/98 260 RTA00000524F.b.02.1 M00005212A:A02 0 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID

Priority Priority

Appln Appln

2282 3/24/98 261 RTA00000427F.i.22.1 M00004104D:B05 63199

2283 3/24/98 262 RTA00000424F. 03.1 M00001590D:B04 21289

2284 3/24/98 263 RTA00000527F.H.07.1 M00003986D:H 12 15939

2285 3/24/98 264 RTA00000425F.e.09.1 M00001608C:G04 75550

2286 3/24/98 265 RTA00000427F.h.02.1 M00004085B:G01 63652

2287 3/24/98 266 RTA00000426F.f. l 6.1 M00003813B:F02 65613

2288 3/24/98 267 RTA00000425F.i.21.1 M00001635B:B02 75305

2289 3/24/98 268 RTA00000427F. 19.1 M00004103B:B07 62851

2290 3/24/98 269 RTA00000427F.p.02.2 M00005100B:D02 0

2291 3/24/98 270 RTA00000426F.g. l 6.1 M00003814B:C01 41446

2292 3/24/98 271 RTA00000527F.1.05.1 M00003983A:D02 13016

2293 3/24/98 272 RTA00000426F.m.02.1 M00004034C:C06 66237

2294 3/24/98 273 RTA00000424F.a.02.4 M00001575A:D06 78806

2295 3/24/98 274 RTA00000523F.h.06.1 M00003851 B:D03 28745

2296 3/24/98 275 RTA00000522F.1.22.1 M00001654C:D10 75801

2297 3/24/98 276 RTA00000427F.li.19. ! M00004092D:B1 1 63047

2298 3/24/98 277 RTA00000427F.e.08.1 M00003974D:E01 47387

2299 3/24/98 278 RTA00000522F.g.21.1 M00001595C:A09 77310

2300 3/24/98 279 RTA00000528F.b.03.1 M00001455A:D10 2078

2301 3/24/98 280 RTA00000522F.g.20.1 M00001595C:A05 77688

2302 3/24/98 281 RTA00000527F. 20.1 M00003982B:H07 17148

2303 3/24/98 282 RTA00000427F.h.22.1 M00004108C:E01 64547

2304 3/24/98 283 RTA00000425F.k.20.1 M00001633C:A08 74048

2305 3/24/98 284 RTA00000524F.b. l9.1 M00005216B:D02 0

2306 3/24/98 285 RTA00000522F.b.07.1 M00001570D:E05 78634

2307 3/24/98 286 RTA00000426F.g.l9.1 M00003858B:G02 63672

2308 3/24/98 287 RTA00000525F.d.19. l M000041 14B:D09 36860

2309 3/24/98 288 RTA00000427F.1.04.1 M00005136D:C01 0

2310 3/24/98 289 RTA00000427F.d. l 0.1 M00003978C:A12 40685

231 1 3/24/98 290 RTA00000427F.1.03.1 M00005136D:B07 0

2312 3/24/98 291 RTA00000523F.O.23.1 M00005177C:G04 0

2313 3/24/98 292 RTA00000424F.a.05.4 M00001575B:C01 77976

2314 3/24/98 293 RTA00000525F.C.02.1 M00004038A:E05 14618

2315 3/24/98 294 RTA00000424F.a.05.1 M00001575B:C01 77976

2316 3/24/98 295 RTA00000522F.1.15.1 M00001654B:A01 74691

2317 3/24/98 296 RTA00000425F.e.02.1 M00001625C:F10 76143

2318 3/24/98 297 RTA00000525F.C.1 1.1 M00004039C:E02 37895

2319 3/24/98 298 RTA00000527F.e.08.1 M00003826B:B04 19015

2320 3/24/98 299 RTA00000522F.C.14.1 M00001577A:A03 75449

2321 3/24/98 300 RTA00000424F.m.08.1 M00001584A:A07 19402

2322 3/24/98 301 RTA00000527FT.18.1 M00003830D:B1 1 37577

2323 3/24/98 302 RTA00000427F.p.04.2 M00005100B:H07 0

2324 3/24/98 303 RTA00000522F.a.06.1 M00001567A:C1 1 73662

2325 3/24/98 304 RTA00000525F.d. l3.1 M000041 10C:E03 349

2326 3/24/98 305 RTA00000523F.n. l 6.1 M00005173D:H02 0

2327 3/24/98 306 RTA00000522F.d.23.1 M00001579D:F02 73868

2328 3/24/98 307 RTA00000427F.p.03.2 M00005100B:G1 1 0

2329 3/24/98 308 RTA00000424F.k.23.1 M00001614A:B 10 31061

2330 3/24/98 309 RTA00000523F.J.10.1 M00003860B:G09 63384

2331 3/24/98 310 RTA00000527F.p.08.1 M00004029C:F02 36013 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

2332 3/24/98 31 1 RTA00000428F.b.02.1 M00005214D:D 10 0

2333 3/24/98 312 RTA00000426F.f. l 7.1 M0000381 1 C:C02 66334

2334 3/24/98 313 RTA00000523F.J.21.1 M00003966C:A 12 36925

2335 3/24/98 3 14 RTA00000522F.e.09.1 M00001589D:A01 32599

2336 3/24/98 315 RTA00000427F.il.19.1 M00004891 D:E07 0

2337 3/24/98 316 RTA00000523F.h. l 6.1 M00003851 D:H 1 1 6603 1

2338 3/24/98 3 1 7 RTA00000428F.a.01.1 M00004897D:G05 0

2339 3/24/98 31 8 RTA00000523F.a.01 .1 M00001671 C:F1 1 74923

2340 3/24/98 319 RTA00000523F.p. l 5.1 M00005178B:H01 0

2341 3/24/98 320 RTA00000427F.J.06.1 M00004102D:B05 63676

2342 3/24/98 321 RTA00000424F.m.04.1 M00001609C:G05 7901 7

2343 3/24/98 322 RTA00000523F.U 7.1 M00003856B:A 12 65779

2344 3/24/98 323 RTA00000524F.C.12.1 M00005218B:D09 0

2345 3/24/98 324 RTA00000523F.O.09.1 M00005176A:C 12 0

2346 3/24/98 325 RTA00000525F.C.18.1 M00004040B:C05 24208

2347 3/24/98 326 RTA00000527F.e.09. 1 M00003826B:E1 1 37521

2348 3/24/98 327 RTA00000424F.J.08.1 M00001596B:D09 73972

2349 3/24/98 328 RTA00000523F.n.01 .1 M00005137A:E01 0

2350 3/24/98 329 RTA00000527F.C.09.1 M00003817C:G06 64859

2351 3/24/98 330 RTA00000523F.d.23.1 M00003824C:A 10 63633

2352 3/24/98 331 RTA00000528F.k. l 0.1 M00001678C:F09 1981

2353 3/24/98 332 RTA00000523F.C.03.1 M00003810B:B 1 1 36913

2354 3/24/98 333 RTA00000427F.k.21 .1 M00004090D:F12 62880

2355 3/24/98 334 RTA00000427F.n. l l . l M00004960B:A09 0

2356 3/24/98 335 RTA00000427F.d.09.1 M00003980C:F 12 66486

2357 3/24/98 336 RTA00000426F.ιι.17.1 M00004039D:B 10 66572

2358 3/24/98 337 RTA00000525F.e.08.1 M000041 15C:H04 24193

2359 3/24/98 338 RTA00000523F.e. l 5.1 M00003829C:E08 7919

2360 3/24/98 339 RTA00000426F.m.03.1 M00004034C:E08 66480

2361 3/24/98 340 RTA00000424F.h.06.1 M00001485C:D07 77552

2362 3/24/98 341 RTA00000425F.d.06.1 M0000163 1 A:D03 77660

2363 3/24/98 342 RTA00000427F.e. l 2.1 M00003959C:G06 62813

2364 3/24/98 343 RTA00000527F.C.1 1.1 M00003817D:D12 37484

2365 3/24/98 344 RTA00000425F.p. l 5.1 M00001638C:H07 31680

2366 3/24/98 345 RTA00000426F.n.23.1 M00004030C:A08 18176

2367 3/24/98 346 RTA00000522F.m.19.1 M00001655C:C07 41544

2368 3/24/98 347 RTA00000522F.a.05.1 M00001567A:C04 3261 1

2369 3/24/98 348 RTA00000427F.i.09.1 M00004097C:E03 65916

2370 3/24/98 349 RTA00000424F.J.09.1 M00001 596B:H05 74387

2371 3/24/98 350 RTA00000424F.n. l l . l M00001582C:C04 73874

2372 3/24/98 351 RTA00000523F.1.03.1 M00004927A:A02 0

2373 3/24/98 352 RTA00000527F.e. l 3.1 M00003826C:F05 37588

2374 3/24/98 353 RTA00000428F.3.18.1 M00005214C:A09 0

2375 3/24/98 354 RTA00000425F.J.19.1 M00001639D:G06 77925

2376 3/24/98 355 RTA00000522F.g. l 2. 1 M00001595A:E07 78783

2377 3/24/98 356 RTA00000523F.a.07.1 M00001693A:H06 75804

2378 3/24/98 357 RTA00000425F.e.19. l M00001629D:B10 73409

2379 3/24/98 358 RTA00000425F.il.19.1 M00001638B:C08 78324

2380 3/24/98 359 RTA00000523F.d.21 .1 M00003824B:C09 33424

2381 3/24/98 360 RTA00000523F.J.03.1 M00003860A:A08 64535 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID

Priority Priority

Appln Appln

2382 3/24/98 361 RTA00000523F.p.08.1 M00005178A:A07 0

2383 3/24/98 362 RTA00000523F.p.09.1 M00005178A:A08 0

2384 3/24/98 363 RTA00000427F. 07.1 M00004099A:F1 1 63742

2385 3/24/98 364 RTA00000523F.m.07.1 M00005136A:D10 0

2386 3/24/98 365 RTA00000527F. 16.1 M00003982B:B06 1015

2387 3/24/98 366 RTA00000522F.a. l 7.1 M00001567C:B08 79032

2388 3/24/98 367 RTA00000527F.1.19.1 M00003983D:E08 36856

2389 3/24/98 368 RTA00000424F.U 1.1 M00001485D:A05 41569

2390 3/24/98 369 RTA00000524F.C.08.1 M00005217C:C01 0

2391 3/24/98 370 RTA00000424F.d.l9.3 M00001448B:A07 73180

2392 3/24/98 371 RTA00000522F.J.09.2 M00001650D:F1 1 78522

2393 3/24/98 372 RTA00000424F.m.24.1 M00001614C:G07 77045

2394 3/24/98 373 RTA00000522FJ.19.2 M00001652B:D06 76224

2395 3/24/98 374 RTA00000528F.f. l 0.1 M00001596C:G05 3600

2396 3/24/98 375 RTA00000427F.p. l 9.2 M00004895C:G05 0

2397 3/24/98 376 RTA00000525F.b.21.1 M00004037C:D04 9486

2398 3/24/98 377 RTA00000527F.J.12.2 M00003857C:E05 37503

2399 3/24/98 378 RTA00000522F.g.l l . l M00001595A:D12 75432

2400 3/24/98 379 RTA00000522F.k.02.2 M00001652C:B09 77622

2401 3/24/98 380 RTA00000427F.e. l3.1 M00003959D:A04 66080

2402 3/24/98 381 RTA00000426F.f.l 8.1 M00003854C:C02 63271

2403 3/24/98 382 RTA00000427F.a.l2.1 M00003982C:H 10 63377

2404 3/24/98 383 RTA00000424F.b.23.4 M00001530A:H05 77322

2405 3/24/98 384 RTA00000527F.p.03.1 M00004029B:A06 5940

2406 3/24/98 385 RTA00000426F.f.l2.1 M00003823C:C04 19096

2407 3/24/98 386 RTA00000523F.1.16.1 M00005134C:G04 0

2408 3/24/98 387 RTA00000427F.f.02.1 M000041 18D:A1 1 36822

2409 3/24/98 388 RTA00000526F.d.l 7.1 M00004235A:A12 2757

2410 3/24/98 389 RTA00000424F. 5.1 M00001596A:A02 78043

241 1 3/24/98 390 RTA00000524F.a.l l . l M00005210D:C09 0

2412 3/24/98 391 RTA00000522F.m.03.1 M00001654C:G09 79194

2413 3/24/98 392 RTA00000522F.a.20.1 M00001567C:E07 74070

2414 3/24/98 393 RTA00000424F.b.l 5.4 M00001539B:B10 74958

2415 3/24/98 394 RTA00000527F.g. l4.1 M00003845D:B02 37532

2416 3/24/98 395 RTA00000522F.d.06.1 M00001578B:A02 74809

2417 3/24/98 396 RTA00000528F.g.05.2 M00001615C:E07 3770

2418 3/24/98 397 RTA00000427F.e.l 0.1 M00003974D:H07 64599

2419 3/24/98 398 RTA00000527F.C.16.1 M00003821A:H09 22908

2420 3/24/98 399 RTA00000524F.C.07.1 M00005217A:G10 0

2421 3/24/98 400 RTA00000523F.f.l 7.1 M00003840B:E08 63984

2422 3/24/98 401 RTA00000525F.C.16.1 M00004040A:B04 38209

2423 3/24/98 402 RTA00000527F.p.24.1 M00004031 B:A06 36832

2424 3/24/98 403 RTA00000425F.11.17.1 M00001636A:H 12 78304

2425 3/24/98 404 RTA00000522F.b. l 8.1 M00001573B:A06 3460

2426 3/24/98 405 RTA00000425F.e.07.1 M00001608C:D02 75992

2427 3/24/98 406 RTA00000523F.O.07.1 M00005176A:A05 0

2428 3/24/98 407 RTA00000523F.h.08.1 M00003851 B:E01 62893

2429 3/24/98 408 RTA00000522F.O.10.1 M00001660D:E05 78798

2430 3/24/98 409 RTA00000425F.1.10.1 M00001638A:C08 26893

2431 3/24/98 410 RTA00000427F.f.l 6.1 M000041 19D:H06 64122 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority' Priority Appln Appln

2432 3/24/98 41 1 RTA00000424F.ιι.12.1 M00001582C:G02 41589

2433 3/24/98 412 RTA00000425F.U 1.1 M00001664B:F06 21716

2434 3/24/98 413 RTA00000425F.i. l 0.1 M00001664B:E08 78736

2435 3/24/98 414 RTA00000426F.m.l2.1 M00004030B:D08 63740

2436 3/24/98 415 RTA00000527F.g. l 2.1 M00003845C:D04 37746

2437 3/24/98 416 RTA00000527F.U2.2 M00003852B:D1 1 0

2438 3/24/98 417 RTA00000524F.b. l 0.1 M00005213C:A01 0

2439 3/24/98 418 RTA00000425F.U 8.1 M00001633A:G10 42255

2440 3/24/98 419 RTA00000428F.b.22.1 M00005231 D:B09 0

2441 3/24/98 420 RTA00000424F.J.13.1 M00001594C:H03 74485

2442 3/24/98 421 RTA00000523F.i. l 0.1 M00003855B:B09 64876

2443 3/24/98 422 RTA00000527F.f.03.1 M00003829A:B08 17788

2444 3/24/98 423 RTA00000427F.p.06.2 M00005102C:C01 0

2445 3/24/98 424 RTA00000424F. 0.1 M00001592D:H02 73232

2446 3/24/98 425 RTA00000522F.i.07.2 M00001649A:E10 78377

2447 3/24/98 426 RTA00000424F.k.21.1 M00001614A:A04 73197

2448 3/24/98 427 RTA00000522F.b.08.1 M00001570D:E06 26915

2449 3/24/98 428 RTA00000522F.1.08.1 M00001654A:E08 78781

2450 3/24/98 429 RTA00000525F.a.l4.1 M00004033B:C02 37566

2451 3/24/98 430 RTA00000424F.g.08.1 M00001482C:F09 74928

2452 3/24/98 431 RTA00000425F.I.09.1 M00001638A:B04 75251

2453 3/24/98 432 RTA00000522F.O.20.1 M00001669C:B09 74853

2454 3/24/98 433 RTA00000527F.J.04.2 M00003856A:G04 1 1809

2455 3/24/98 434 RTA00000522F.C.1 1.1 M00001576C:H02 31064

2456 3/24/98 435 RTA00000523F.C.13.1 M00003813D:B12 40668

2457 3/24/98 436 RTA00000427F.Ϊ.21.1 M00004102C:F03 65540

2458 3/24/98 437 RTA00000427F.n. l0.1 M00004960B:A08 0

2459 3/24/98 438 RTA00000522F.h.02.1 M00001595C:E09 74947

2460 3/24/98 439 RTA00000522F.g. l0.1 M00001595A:C07 74294

2461 3/24/98 440 RTA00000523F.O.22.1 M00005177C:B04 0

2462 3/24/98 441 RTA00000528F.g.22.2 M00001630C:F09 920

2463 3/24/98 442 RTA00000425F.d.l4.1 M00001629A:H09 13417

2464 3/24/98 443 RTA00000425F. 16.1 M00001640A:F05 75282

2465 3/24/98 444 RTA00000525F.b.09.1 M00004035B:F05 23472

2466 3/24/98 445 RTA00000522F.J.08.2 M00001650D:D10 76613

2467 3/24/98 446 RTA00000425FT.20.1 M00001653D:H07 74071

2468 3/24/98 447 RTA00000523F.f.l9.1 M00003840B:F05 34169

2469 3/24/98 448 RTA00000425F.J.18.1 M00001639D:G 12 75561

2470 3/24/98 449 RTA00000426F.m.04.1 M00004028A:B10 36865

2471 3/24/98 450 RTA00000527F.g.21.1 M00003846B:C05 36028

2472 3/24/98 451 RTA00000527F.i. l 5.2 M00003852C:F07 14235

2473 3/24/98 452 RTA00000525F.a.22.1 M00004033D:G06 36848

2474 3/24/98 453 RTA00000522F.p.22.1 M00001671 B:F02 73322

2475 3/24/98 454 RTA00000424F.d.l2.2 M00001530D:E06 74342

2476 3/24/98 455 RTA00000424F.g.24.1 M00001487C:A1 1 79156

2477 3/24/98 456 RTA00000427F.a.l 0.1 M00004038B:D01 65370

2478 3/24/98 457 RTA00000426F.h.20.1 M00003905A:H 1 1 23187

2479 3/24/98 458 RTA00000424F.d. l2.3 M00001530D:E06 74342

2480 3/24/98 459 RTA00000425F.C.03.1 M00001585D:B12 74643

2481 3/24/98 460 RTA00000523F.f. l 6.1 M00003840B:E07 26522 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

2482 3/24/98 461 RTA00000427F.f. l 5.1 M000041 19D:A07 66734

2483 3/24/98 462 RTA00000427F.p. l3.2 M00004695B:E04 0

2484 3/24/98 463 RTA00000523F.p. l 6.1 M00005179D:B03 0

2485 3/24/98 464 RTA00000522F.p. l 8.1 M00001671 A:H06 76376

2486 3/24/98 465 RTA00000528F.d.04.1 M00001570D:E07 2395

2487 3/24/98 466 RTA00000427F.d.06.1 M00003980B:C06 33446

2488 3/24/98 467 RTA00000528F.h.02.2 M00001632C:D08 1701

2489 3/24/98 468 RTA00000524F.a.l 8.1 M0000521 1 A:E09 0

2490 3/24/98 469 RTA00000522F.e.20.1 M00001590B:H10 26770

2491 3/24/98 470 RTA00000427F.p.24.2 M00004897D:F03 0

2492 3/24/98 471 RTA00000528F.C.1 1.1 M00001486D:D12 1701

2493 3/24/98 472 RTA00000522F.g. l 8.1 M00001595B:H 1 1 73226

2494 3/24/98 473 RTA00000523F.O.21.1 M00005177C:A01 0

2495 3/24/98 474 RTA00000522F.H.05.1 M00001595C:H1 1 73358

2496 3/24/98 475 RTA00000427F.i.06.1 M00004097B:D03 41450

2497 3/24/98 476 RTA00000425F.n. l 6.1 M00001636A:C02 18265

2498 3/24/98 477 RTA00000527F.1.21.1 M00003983D:H02 36439

2499 3/24/98 478 RTA00000527F.p.09.1 M00004029C:F05 7694

2500 3/24/98 479 RTA00000527F.1.23.1 M00003984A:B06 36018

2501 3/24/98 480 RTA00000424F.d. l 7.3 M00001455A:E1 1 73958

2502 3/24/98 481 RTA00000523F.J.02.1 M00003857A:H10 62853

2503 2/24/98 1 132 RTA000001 19A.C.12.1 M00001453A:D08 4882

2504 2/24/98 6 RTAOOOOO 1 19A.J.15.1 M00001460A:E1 1 79623

2505 2/24/98 1041 RTA00000403F.b.05.1 M00001455B:E07 74300

2506 2/24/98 994 RTA00000408F.b.04.2 M00001455A:F04 39933

2507 2/24/98 401 RTAOOOOO 132A.C.1 1.1 M00001454A:G03 87278

2508 2/24/98 535 RTAOOOOO 1 19A.g.7.1 M00001454A:F1 1 83580

2509 2/24/98 867 RTA00000339F.1.21.1 M00001455D:D1 1 9781

2510 2/24/98 62 RTA00000339F.n.l0.1 M00001453B:F08 13719

251 1 2/24/98 380 RTA00000403F.b. l9.1 M00001456B:A06 22327

2512 1/28/98 288 RTA00000181 AR.i.06.3 M00001452A:C07 191 19

2512 2/24/98 198 RTA00000339R.1.14.1 M00001452A:C07 191 19

2513 1/28/98 288 RTA00000181 AR.i.06.3 M00001452A:C07 191 19

2513 2/24/98 198 RTA00000339R.1.14.1 M00001452A:C07 191 19

2514 2/24/98 264 RTA00000345F.J.08.1 M00001451 B:A04 16731

2515 2/24/98 1 125 RTA000001 18A.n.5.1 M00001451 A:C 10 0

2516 2/24/98 229 RTA00000345F.L09.1 M00001450A:D08 27250

2517 2/24/98 670 RTA00000131 A.Ϊ.6.1 M00001450A:B08 0

2518 2/24/98 892 RTA00000339F.m.17.1 M00001453B:H12 20854

2519 2/24/98 1 123 RTA00000408F.C.23.1 M00001458C:D10 42261

2520 2/24/98 680 RTA00000345F.e.l ! . l M00001391 C:C04 4392

2521 2/24/98 644 RTAOOOOO 1 19A.J.9.1 M00001460A:B 12 82060

2522 2/24/98 972 RTA00000408F.d.l 5.1 M00001459B:C 1 1 78467

2523 2/24/98 1081 RTA00000403F.d.02.1 M00001458D:D01 39224

2524 2/24/98 23 1 RTA00000408F.d.06.1 M00001458D:C 1 1 78997

2525 2/24/98 663 RTA00000403F.b.l2.1 M00001455D:A06 78775

2526 2/24/98 856 RTA00000408F.d.02.1 M00001458D:A01 79169

2527 2/24/98 743 RTA00000345F.i.08.1 M00001449D:G10 0

2528 2/24/98 1 162 RTA00000408F.C.10.1 M00001458A:A1 1 18247

2529 2/24/98 841 RTAOOOOO 1 19A.i.8.1 M00001457A:G 12 82593 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

2530 2/24/98 677 RTAOOOOO 1 19A.li.24. ] M00001457A:C05 82266

2531 2/24/98 750 RTA00000403F.C.05.1 M00001456C:C 1 1 74935

2532 2/24/98 751 RTA00000422F.i.02.1 M00001456C:B12 76436

2533 2/24/98 920 RTA00000403F.b.24.1 M00001456B:G01 78838

2534 2/24/98 1251 RTA00000408F.d.03.1 M00001458D:A02 22768

2535 2/24/98 450 RTA000001 18A.a.23.1 M00001395A:H02 3500

2536 2/24/98 85 RTA00000339F.L22.1 M00001427C:D01 5556

2537 2/24/98 684 RTA00000339F.L20.1 M00001426D:D12 6662

2538 2/24/98 129 RTAOOOOO 1 18A.d.24.1 M00001416A:H02 81488

2539 2/24/98 397 RTAOOOOO 1 18A.d.17.1 M00001416A:D09 81921

2540 2/24/98 158 RTA00000348R.J.16.1 M00001410A:D07 7005

2541 2/24/98 1025 RTAOOOOO 1 18A.J.24.1 M00001450A:B03 18

2542 2/24/98 1005 RTA00000339F.e.l 7.1 M00001397D:G08 7568

2543 2/24/98 1040 RTA00000348R.O.12.1 M00001433C:F10 2263

2544 2/24/98 746 RTA00000345F.e.02.1 M00001395A:E03 0

2545 2/24/98 517 RTAOOOOO 1 18A.3.2.1 M00001395A:A 12 38067

2546 2/24/98 1065 RTA00000195R.a.06.1 M00001394A:E04 35265

2546 1/28/98 595 RTA00000195R.a.06.1 M00001394A:E04 35265

2547 1/28/98 595 RTAOOOOO 195R.3.06.1 M00001394A:E04 35265

2547 2/24/98 1065 RTA00000195R.3.06.1 M00001394A:E04 35265

2548 1/28/98 675 RTAOOOOO 179 AR.b.21.3 M00001392C:D05 4366

2548 2/24/98 1264 RTA00000345F.e.l3.1 M00001392C:D05 4366

2549 1/28/98 562 RTA00000196F.J.12.1 M00001396A:H03 19294

2550 2/24/98 1042 RTA00000339F.g.l 0.1 M00001400C:D02 6327

2551 2/24/98 706 RTA00000403F.3.09.1 M00001448B:H05 77820

2552 2/24/98 823 RTAOOOOO 1 19A.L 1.1 M00001460A:H 1 1 81282

2553 2/24/98 703 RTA00000339F.n.05.1 M00001449D:B01 39648

2554 2/24/98 787 RTA00000345F.i.24.1 M00001449C:C05 0

2555 2/24/98 68 RTA00000339F.n.03.1 M00001449B:B03 0

2556 2/24/98 440 RTA00000403F.3.18.1 M00001448D:F12 75726

2557 2/24/98 815 RTA00000403F.3.17.1 M00001448D:E12 13686

2558 2/24/98 275 RTA00000353R.J.24.1 M00001428B:D01 23089

2559 2/24/98 902 RTA00000403F.3.10.1 M00001448C:E1 1 73952

2560 2/24/98 1214 RTA00000339F.J.07.1 M00001428D:B10 5673

2561 2/24/98 378 RTA00000403F.a.07.1 M00001448B:F09 73559

2562 2/24/98 473 RTA00000403F.3.05.1 M00001448A:E1 1 18808

2563 2/24/98 128 RTA00000403F.3.04.1 M00001448A:B12 23529

2564 2/24/98 227 RTA00000347F.C.06.1 M00001444D:C01 18846

2565 2/24/98 35 RTA00000339F.U3.1 M00001434A:B 10 5970

2566 2/24/98 442 RTA00000347F.b.02.1 M00001450A:A02 39304

2567 2/24/98 288 RTA00000403F.3.1 1.1 00001448C:F10 73109

2568 2/24/98 853 RTA00000408F.J.13.2 M00001485B:D10 42275

2569 2/24/98 249 RTA000001 19A.J.10.1 M00001460A:C10 79646

2570 2/24/98 634 RTA00000418F.C.04.1 M00001487B:A1 1 41587

2571 2/24/98 1 10 RTA00000408F. 14.1 M00001486B:E12 73856

2572 2/24/98 894 RTA00000408F.k.l2.1 M00001486B:D07 77246

2573 2/24/98 395 RTA00000408F.J.19.2 M00001485C:C08 73752

2574 2/24/98 509 RTA00000349R.g.l 0.1 M00001495B:B08 5777

2575 2/24/98 426 RTA00000408F.J.15.2 M00001485B:F05 74759

2576 2/24/98 101 RTA00000121 A.m.2.1 M00001507A:A 1 1 81064 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID

Priority Priority

Appln Appln

2577 2/24/98 330 RTA00000403F.i.04.1 M00001485B:D09 8930

2578 2/24/98 647 RTA00000418F.b.23.1 M00001485A:C05 28767

2579 2/24/98 569 RTA00000403F.h. l 8.1 M00001484C:A04 39241

2580 2/24/98 236 RTA00000403F.li.12.1 M00001483C:G09 15205

2581 2/24/98 707 RTA00000403F.h. l l . l M00001483B:D04 39219

2582 2/24/98 869 RTA00000403F.h.07.1 M00001482D:H 1 1 26856

2583 2/24/98 1 101 RTA00000408F.J.17.2 M00001485B:H03 78935

2584 2/24/98 344 RTA00000403F.m. l 5.2 M00001575D:D 12 26901

2585 2/24/98 768 RTA00000121 A.k.5.1 M00001507A:E04 1 7530

2586 2/24/98 1 1 74 RTA00000121 A. 22.1 M00001507A:C05 79523

2587 2/24/98 184 RTA00000133A.J.13.1 M00001507A:B02 16846

2588 2/24/98 1230 RTA00000399F.J.14.1 M00001578C:F05 16942

2589 2/24/98 304 RTA00000403F.n.18.2 M00001577D:H06 881 1

2590 2/24/98 938 RTA00000403F.i.23.1 M00001487B:E 10 1 1364

2591 2/24/98 1 131 RTA0000041 8F.e.20.1 M00001576C:G05 73741

2592 2/24/98 651 RTA00000403F.g. l l . l M00001481 A:H08 24238

2593 2/24/98 3 12 RTA00000399F.i.08.1 M00001575D:B 10 38927

2594 2/24/98 800 RTA00000403F.m. l 2.1 M00001575D:A02 16933

2595 2/24/98 1017 RTA00000418F.e.03.1 M00001573B:G08 73442

2596 2/24/98 269 RTA00000422F.e.08.1 M00001573A:E01 39020

2597 2/24/98 1247 RTA00000408F.O.13.1 M00001572A:B05 74895

2598 2/24/98 847 RTA00000403F.1.1 1.1 M00001571 D:F05 25073

2599 2/24/98 910 RTA0000041 8F.f.03.1 M00001577B:F10 7891 1

2600 2/24/98 244 RTA00000120A.g.23.1 M00001465A:E10 81 189

2601 2/24/98 1 189 RTA00000339F.O.18.1 M00001469B:B01 6641

2602 2/24/98 1266 RTA00000121 A.a.2.1 M00001468A:H 10 81843

2603 2/24/98 414 RTAOOOOO 120A.p.1 8.1 M00001468A:C05 6478

2604 2/24/98 96 RTAOOOOO 120A.n.19.3 M00001467A:H07 80004

2605 2/24/98 1231 RTAOOOOO 120A.ni.13.3 M00001467A:C10 80608

2606 2/24/98 134 RTA00000408F.i.08.2 M00001482A:H05 7581 1

2607 2/24/98 410 RTA00000120A.h.5.1 M00001465A:G06 80344

2608 2/24/98 403 RTA00000403F.d.22.1 M00001473A:A07 10692

2609 2/24/98 183 RTA00000120A.g. l 8.1 M00001465A:C 12 81255

2610 2/24/98 810 RTAOOOOO 120A.h.9.1 M00001465A:B12 80736

261 1 2/24/98 71 RTAOOOOO 120A.d.24.1 M00001464A:E10 5085

2612 2/24/98 490 RTA00000120A.d. l 5.1 00001464A:B02 80533

2613 2/24/98 736 RTA00000120A.C.7.1 M00001462A:D03 80985

2614 2/24/98 724 RTA000001 19A.m. l 7.1 M00001461 A:F05 79536

2615 2/24/98 1063 RTA00000132A.n.7.1 M00001466A:F08 0

2616 2/24/98 74 RTA00000408F.e.22.2 M00001476B:F08 26930

2617 1/28/98 656 RTAOOOOO 178AR.h.22.3 M00001376B:A08 19230

2617 1/28/98 657 RTAOOOOO 178AR.h.22.2 M00001376B:A08 19230

261 7 2/24/98 1 137 RTA00000345F.d.03.1 M00001376B:A08 19230

2618 2/24/98 1012 RTA00000403F.g.06.1 M00001480C:A05 10505

2619 2/24/98 419 RTA00000408F.h.08.1 M00001480A:D03 74575

2620 2/24/98 871 RTA00000403F.f.23.1 M00001479C:E01 39223

2621 2/24/98 638 RTA0000041 8F.b.09.1 M00001478B:H08 19700

2622 2/24/98 ^• 770 RTA00000421 F.f.05.1 M00001477B:E02 5266

2623 2/24/98 549 RTA00000121 A.h. l 8.1 M00001471 A:B04 16376

2624 2/24/98 660 RTA00000408F.e.24.2 M00001476C:C 1 1 75002 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

2625 2/24/98 144 RTA00000349R.f. l 5.1 M00001472A:D08 75097

2626 2/24/98 774 RTA00000403F.e.24.1 M00001476B:D10 16432

2627 2/24/98 268 RTA00000403F.e.23.1 M00001476A:D1 1 9626

2628 2/24/98 715 RTA00000418F.b.01.1 M00001475C:G 1 1 76040

2629 2/24/98 1073 RTA00000418F.a.l 0.1 M00001475B:C04 15245

2630 2/24/98 100 RTA00000339F.O.23.1 M00001473C:D09 7801

2631 2/24/98 756 RTA00000403F.g.l 3.1 M00001481 B:D09 38718

2632 2/24/98 915 RTA00000408F.f.l4.2 M00001476D:F03 73024

2633 1/28/98 389 RTA00000181 AR.k.2.2 M00001453C:A1 1 0

2633 1/28/98 286 RTA00000181 AR. 2.3 M00001453C:A1 1 0

2634 1/28/98 565 RTA00000191 AF.C.10.1 M00003989B:F1 1 40422

2635 1/28/98 449 RTA00000181 AF.m.22.3 M00001455D:F09 9283

2635 1/28/98 450 RTA00000181AF.m.21.3 M00001455D:F09 9283

2636 1/28/98 449 RTA00000181 AF.m.22.3 M00001455D:F09 9283

2636 1/28/98 450 RTA00000181 AF.m.21.3 M00001455D:F09 9283

2637 1/28/98 449 RTA00000181 AF.m.22.3 M00001455D:F09 9283

2637 1/28/98 450 RTAOOOOO 181 AF.m.21.3 M00001455D:F09 9283

2638 1/28/98 449 RTA00000181 AF.m.22.3 M00001455D:F09 9283

2638 1/28/98 450 RTAOOOOO 181 AF.m.21.3 M00001455D:F09 9283

2639 1/28/98 390 RTAOOOOO 197ART.07.1 M00001457C:C1 1 19261

2639 1/28/98 184 RTAOOOOO 197AFT.7.1 M00001457C:C1 1 19261

2640 1/28/98 598 RTA00000197F.e.l0.1 M00001454B:D08 13154

2641 1/28/98 184 RTAOOOOO 197AFT.7.1 M00001457C:C1 1 19261

2641 1/28/98 390 RTAOOOOO 197ART.07.1 M00001457C:C 1 1 19261

2642 1/28/98 286 RTA00000181AR. 2.3 M00001453C:A1 1 0

2642 1/28/98 389 RTAOOOOO 181 AR.k.2.2 M00001453C:A1 1 0

2643 1 /28/98 667 RTAOOOOO 197AF.d.16.1 M00001452A:E07 23505

2644 1/28/98 679 RTAOOOOO 197AF.d.1 1.1 M00001451 C:E01 27260

2645 1/28/98 664 RTA00000195R.a.23.1 M00001449C:H12 86432

2646 1/28/98 594 RTA00000181 AR.e.04.3 M00001448A:G09 1 1825

2647 1/28/98 405 RTAOOOOO 197AF.b.24.1 M00001446C:D09 23171

2648 1/28/98 572 RTA00000181 AF.1.16.2 M00001454D:E05 13532

2649 1 /28/98 590 RTAOOOOO 190AF.d.2.1 M00003906B:F12 2444

2650 1/28/98 675 RTAOOOOO 179AR.b.21.3 M00001392C:D05 4366

2650 2/24/98 1264 RTA00000345F.e.l 3.1 M00001392C:D05 4366

2651 1/28/98 486 RTAOOOOO 190AR.p.22.2 M00003979A:E1 1 16368

2652 1/28/98 701 RTAOOOOO 199AF.0.10.1 M00003974C:E04 0

2653 1/28/98 704 RTAOOOOO 190AF.0.12.1 M00003972D:C09 3438

2654 1 /28/98 469 RTAOOOOO 190AF.n.2.1 M00003963A:E03 5650

2655 1/28/98 612 RTA00000197AR.e.22.1 M00001456A:H02 78758

2656 1/28/98 640 RTA00000190AF.f.5.1 M00003909A:H04 5015

2657 1/28/98 539 RTAOOOOO 197AR.b.13.1 M00001445B:E04 9560

2658 1/28/98 431 RTA00000199AF. 15.1 M00003905C:G 10 8275

2659 1/28/98 747 RTAOOOOO! 90 AF.c.6.1 M00003904D:D10 4780

2660 1/28/98 584 RTAOOOOO 190AR.C.03.1 M00003904C:A08 0

2660 2/24/98 1069 RTA00000346F.L05.1 M00003904C:A08 0

2661 1/28/98 584 RTAOOOOO 190AR.C.03.1 M00003904C:A08 0

2661 2/24/98 1069 RTA00000346F.L05.1 M00003904C:A08 0

2662 1/28/98 577 RTAOOOOO 190 AF.a.24.2 M00003901 B:A05 0

2663 1/28/98 639 RTAOOOOO 199 AF.j.1.1 M00003881 C:G09 6006 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

2664 1/28/98 649 RTA00000190AR.1.19.2 M00003946A:H 10 . 88204

2665 1 /28/98 488 RTA00000179AR.1.22.4 M00001405B:E09 4314

2665 1/28/98 481 RTAOOOOO 179AR.1.22.2 M00001405B:E09 4314

2666 1/28/98 721 RTAOOOOO 180AF.C.4.1 M00001417B:C04 5415

2667 1/28/98 744 RTA00000196F.m.4.1 M00001413A:F03 7958

2668 1/28/98 569 RTA00000196AF.1.23.1 M00001412A:E04 12052

2669 1 /28/98 707 RTA00000179AF.p.15.1 M0000141 1 D:F05 5622

2670 1/28/98 599 RTA00000179AF.O.5.1 M00001408D:D04 6172

2671 1 /28/98 420 RTA00000181 AF.C.1 1.1 M00001445D:A06 4769

2672 1/28/98 500 RTAOOOOO 179AR.m.07.5 M00001405D:D1 1 0

2673 1 /28/98 609 RTA00000196AF.n.05.1 M00001418B:F07 12531

2673 2/24/98 1 120 RTA00000353R.1.23.1 M00001418B:F07 12531

2674 1 /28/98 481 RTA00000179AR.1.22.2 M00001405B:E09 4314

2674 1 /28/98 488 RTAOOOOO 179AR.I.22.4 M00001405B:E09 4314

2675 1 /28/98 481 RTA00000179AR.I.22.2 M00001405B:E09 4314

2675 1/28/98 488 RTAOOOOO 179 AR.1.22.4 M00001405B:E09 4314

2676 1/28/98 481 RTA00000179AR.1.22.2 M00001405B:E09 4314

2676 1/28/98 488 RTA00000179AR.1.22.4 M00001405B:E09 4314

2677 1/28/98 636 RTAOOOOO 196F. 20.1 M00001402B:F12 6324

2678 1/28/98 691 RTA00000195F.3.10.1 M00001401C:H03 6803

2679 2/24/98 161 RTA00000418F.n.22.1 M00001659D:B05 79062

2680 1/28/98 61 1 RTA00000196F.1.13.2 M00001408A:H04 0

2681 1/28/98 535 RTAOOOOO 196AF.il.19.1 M00001423D:D12 6881

2682 1/28/98 413 RTA00000200F.a.l2.1 M00004031 D:BO5 16751

2683 1/28/98 580 RTAOOOOO 197F.3.12.1 M00001438B:B09 7895

2684 1/28/98 681 RTAOOOOO 180AF.1.04.2 M00001432D:F05 1 1 159

2685 1/28/98 568 RTA00000196AF.p.01.2 M00001430A:A02 87143

2686 1/28/98 736 RTAOOOOO 196 AF.o.13.1 M00001428B:A09 0

2687 1/28/98 438 RTA00000180AR.g.03.4 M00001425A:C 1 1 9024

2687 1 /28/98 95 RTAOOOOO 180 AF.g.3.1 M00001425A:C1 1 9024

2688 1/28/98 514 RTA00000196AF.n.02.1 M00001417D:A04 39260

2689 1/28/98 741 RTAOOOOO 196AF.n.22.1 M00001424B:H04 9572

2690 1 /28/98 609 RTAOOOOO 196AF.n.05.1 M00001418B:F07 12531

2690 2/24/98 1 120 RTA00000353R.1.23.1 M00001418B:F07 12531

2691 1/28/98 462 RTAOOOOO 196AF.il.17.1 M00001423D:A09 12477

2692 1 /28/98 477 RTAOOOOO 180AR.e.22.2 M00001423A:G05 7714

2693 1/28/98 445 RTA00000196AF.n.l 3.1 M00001422C:F12 8396

2694 1 /28/98 696 RTAOOOOO 180AR.d.16.3 M00001419D:C 10 1 1393

2694 2/24/98 1 184 RTA00000345F.h.08.1 M00001419D:C 10 1 1393

2695 1 /28/98 696 RTAOOOOO 180AR.d.16.3 M00001419D:C 10 1 1393

2695 2/24/98 1 184 RTA00000345F.h.08.1 M00001419D:C 10 1 1393

2696 1 /28/98 541 RTAOOOOO 197AR.b.16.1 M00001445C:A08 0

2697 1/28/98 95 RTAOOO00180AF.g.3.1 M00001425A:C 1 1 9024

2697 1/28/98 438 RTAOOOOO 180AR.g.03.4 M00001425A:C 1 1 9024

2698 1 /28/98 536 RTAOOOOO 193 AR.a.2.3 M00004216D:D03 0

2699 1/28/98 588 RTA00000191 AF.b.4.1 M00003983C:F03 14936

2700 1/28/98 401 RTA00000195F.e.04.1 M00004465B:D04 6731

2701 2/24/98 91 RTA00000355R.e. l 5.1 M00004316A:G09 22639

2701 1/28/98 410 RTA00000201 F.a.20.1 M00004316A:G09 22639

2702 1/28/98 410 RTA00000201 F.a.20.1 M00004316A:G09 22639 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

2702 2/24/98 91 RTA00000355R.e. l 5.1 M00004316A:G09 22639

2703 1 /28/98 716 RTA00000200F.p.05.1 M00004285C:A08 3984

2704 2/24/98 434 RTA00000348R.b. l 6.1 M00001347B:H04 6510

2705 1/28/98 528 RTA00000200F.n.09.2 M00004249D:B08 12391

2706 2/24/98 575 RTA00000345F.a. l 8.1 M00001351 C:B06 5517

2707 1/28/98 658 RTAOOOOO 193 AF.a.1.1 M00004216D:C03 16501

2708 1/28/98 472 RTAOOOOO 192AF.p.17.1 M00004214C:H05 1 1451

2709 1/28/98 478 RTAOOOOO 192AR.o.24.2 M00004210B:B05 7191

2710 1/28/98 753 RTAOOOOO 192AF.0.17.1 M00004208D:B10 5275

271 1 1/28/98 563 RTAOOOOO 192AR.0.16.2 M00004208B:F05 9061

2712 1/28/98 730 RTAOOOOO 192 AF.o.1 1.1 M00004205D:F06 0

2713 1/28/98 624 RTA00000200F.O.15.1 M00004275A:B03 7866

2714 2/24/98 169 RTA00000347F.3.17.1 M00001366D:C06 16723

2715 1/28/98 656 RTAOOOOO 178AR.h.22.3 M00001376B:A08 19230

2715 1/28/98 657 RTAOOOO0178 AR.h.22.2 M00001376B:A08 19230

2715 2/24/98 1 137 RTA00000345F.d.03.1 M00001376B:A08 19230

2716 1/28/98 657 RTAOOOOO 1 78AR.h.22.2 M00001376B:A08 19230

2716 1/28/98 656 RTAOOOOO 178AR.h.22.3 M00001376B:A08 19230

2716 2/24/98 1 137 RTA00000345F.d.03.1 M00001376B:A08 19230

2717 1/28/98 522 RTA00000178AR.li.17.2 M00001376A:C05 23824

2717 2/24/98 1095 RTA00000345F.C.12.1 M00001376A:C05 23824

2718 1/28/98 522 RTA00000178AR.h.l 7.2 M00001376A:C05 23824

2718 2/24/98 1095 RTA00000345F.C.12.1 M00001376A:C05 23824

2719 2/24/98 1 155 RTA00000353R.h.04.1 M00001375B:C06 17123

2720 1/28/98 614 RTA00000201 F.f.03.1 M00004493B:D09 22633

2721 2/24/98 16 RTA00000399F.3.02.1 M00001366D:C 12 0

2722 1/28/98 436 RTA00000200AF.k.l l . l M00004197C:F03 9796

2722 1/28/98 501 RTA00000200R.k.l l . l M00004197C:F03 9796

2723 2/24/98 1 140 RTA00000339F.C.05.1 M00001365A:H10 3908

2724 2/24/98 322 RTA00000339F.C.24.1 M00001364B:B06 5516

2725 2/24/98 888 RTA00000339R.C.04.1 M00001362D:H01 1805

2726 1/28/98 33 RTAOOOOO 178AR.3.20.1 M00001362C:H1 1 945

2726 2/24/98 979 RTA00000345F.b.l 7.1 M00001362C:H 1 1 945

2727 1/28/98 33 RTA00000178AR.a.20.1 M00001362C:H 1 1 945

2727 2/24/98 979 RTA00000345F.b.l 7.1 M00001362C:H1 1 945

2728 2/24/98 1 173 RTA00000339R.b.07.1 M00001360A:G 10 6826

2729 2/24/98 973 RTA00000339F.b.22.1 M00001373D:B03 6867

2730 1/28/98 581 RTA00000191 AF.p.3.2 M00004104B:F1 1 17

2731 1/28/98 637 RTA00000200AF.g. l 5.1 M00004135B:G01 22898

2731 1/28/98 476 RTA00000200R.g. l 5.1 M00004135B:G01 22898

2732 1/28/98 637 RTA00000200AF.g.l 5.1 M00004135B:G01 22898

2732 1/28/98 476 RTA00000200R.g. l 5.1 M00004135B:G01 22898

2733 1/28/98 474 RTAOOOOO 192 AR.d.1.3 M00004130D:H01 14507

2734 1/28/98 735 RTAOOOOO 192 AF.b.1 1.1 M000041 17A:G01 40014

2735 1/28/98 726 RTA00000200R.f. l 0.1 M000041 1 1 D:B07 4

2736 1/28/98 752 RTAOOOOO 192AF.0.7.1 M00004204D:C03 5275

2737 1/28/98 516 RTA00000200AF.e.23.1 M00004107B:A06 14686

2738 1/28/98 685 RTA00000200F .9.1 M00004159C:F09 36756

2738 2/24/98 704 RTA00000355R.3.12.1 M00004159C:F09 36756

2739 1/28/98 417 RTA00000200R.d. l 6.1 M00004085A:B02 39875 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID

Priority Priority

Appln Appln

2740 1 /28/98 454 RTA00000200R.d.04.1 M00004078A:A06 5506

2741 1/28/98 551 RTA00000200AR.C.24.1 M00004076D:D04 15972

2742 1/28/98 524 RTAOOOO0191 AF.j.24.1 M00004076B:G03 0

2743 2/24/98 1 166 RTA00000347F.h.01.1 M00004040A:G 12 12043

2743 1/28/98 684 RTA00000200AR.b. l l .l M00004040A:G12 12043

2744 2/24/98 1 166 RTA00000347F.h.01.1 M00004040A:G 12 12043

2744 1/28/98 684 RTA00000200AR.b.l l .l M00004040A:G 12 12043

2745 1/28/98 415 RTA00000200AF.f.09.1 M000041 1 1 C:E1 1 12863

2746 1/28/98 448 RTA00000200AF.J.9.1 M00004177C:A01 8608

2747 2/24/98 446 RTA00000133A.m.l9.2 M00001512A:G05 80167

2748 1/28/98 436 RTA00000200AF.k.1 1.1 M00004197C:F03 9796

2748 1/28/98 501 RTA00000200R.k. l l .1 M00004197C:F03 9796

2749 1/28/98 436 RTA00000200AF.k. l l . l M00004197C:F03 9796

2749 1/28/98 501 RTA00000200R.k. l l . l M00004197C:F03 9796

2750 1 /28/98 436 RTA00000200AF.k.l l . l M00004197C:F03 9796

2750 1/28/98 501 RTA00000200R. 1 1.1 M00004197C:F03 9796

2751 1/28/98 610 RTA00000200AF.k.2.1 M00004188D:G08 35924

2752 1/28/98 494 RTA00000200AF.k. l . l M00004188C:A09 40049

2752 1/28/98 194 RTA00000200R.k.01.1 M00004188C:A09 40049

2753 1/28/98 574 RTAOOOOO 192 AF.f.3.1 M00004146C:C 1 1 5257

2754 1/28/98 604 RTA00000200AF.J.15.1 M00004185D:E04 5849

2755 1/28/98 579 RTA00000200F.i.7.1 M00004157D:B03 22322

2756 1/28/98 634 RTAOOOOO 192 AF.j .6.1 M00004172C:D08 1 1494

2757 1/28/98 421 RTA00000200AF.i.21.1 M00004167D:A07 5316

2758 1/28/98 543 RTA00000200AF.i.l9.1 M00004167A:H03 14722

2759 1/28/98 483 RTA00000192AF.h.l9.1 M00004162C:A07 4642

2760 2/24/98 704 RTA00000355R.3.12.1 M00004159C:F09 36756

2760 1/28/98 685 RTA00000200F.i.9.1 M00004159C:F09 36756

2761 1/28/98 607 RTA00000200AF. 12.1 M00004198B:D02 7359

2762 1/28/98 494 RTA00000200AF.k.l . l M00004188C:A09 40049

2762 1/28/98 194 RTA00000200R.k.01.1 M00004188C:A09 40049

2763 2/24/98 554 RTA00000409F.i.03.1 M00001610A:E09 75968

2764 2/24/98 1228 RTA00000404F.h.l 0.1 M00001618A:A03 37148

2765 2/24/98 332 RTA00000409F.L24.1 M0000161 1 B:A09 76967

2766 2/24/98 1023 RTA00000404F.f.l2.1 M0000161 1B:A05 39209

2767 2/24/98 572 RTA00000422F.1.03.1 M00001610D:D05 39147

2768 2/24/98 497 RTA00000350R.f.21.1 M00001610C:E07 221 10

2769 2/24/98 557 RTA00000409F.J.05.1 M0000161 1 C:C12 74128

2770 2/24/98 223 RTA00000404F.e.22.1 M00001610A:H05 1 1344

2771 2/24/98 165 RTA00000409F.J.07.1 M0000161 1 C:H 1 1 75190

2772 2/24/98 959 RTA00000340F.g.20.1 M00001609D:G 10 4089

2773 2/24/98 737 RTA00000404F.e.l 5.1 M00001609B:C09 39101

2774 2/24/98 974 RTA00000340F.h.07.1 M00001608D:D1 1 19254

2775 2/24/98 857 RTA00000404F.e.09.1 M00001608B:A09 39121

2776 1/28/98 340 RTA00000185AF.n.8.1 M00001608B:A03 0

2776 2/24/98 75 RTA00000350R.i.22.1 M00001608B:A03 0

2777 1/28/98 340 RTA00000185AF.n.8.1 M00001608B:A03 0

2777 2/24/98 75 RTA00000350R.i.22.1 M00001608B:A03 0

2778 2/24/98 546 RTA00000409F.i.09.1 M00001610B:C07 75279

2779 2/24/98 374 RTA00000422F.m.04.1 M00001615B:A09 38702 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

2780 2/24/98 505 RTA00000121 A.O.3.1 M0000151 1A:A02 81437

2781 2/24/98 453 RTA00000130A.h.l 3.1 M00001617A:A01 80790

2782 2/24/98 163 RTA00000422F.1.23.1 M00001616D:C 1 1 4240

2783 2/24/98 889 RTA00000346F.b.l6.1 M00001615C:G05 16485

2784 2/24/98 203 RTA00000404F.g.21.1 M00001615C:A1 1 37947

2785 2/24/98 32 RTA00000409F.J.02.1 M0000161 1 B:E06 76417

2786 2/24/98 872 RTA00000409F.1.20.1 M00001615B:G01 74394

2787 2/24/98 978 RTA00000130A.e.20.1 M00001606A:H09 79502

2788 2/24/98 45 RTA00000409F.I.12.1 M00001615A:D06 26755

2789 2/24/98 182 RTA00000404F.g.l4.1 M00001614D:B08 8858

2790 2/24/98 912 RTA00000404F.g. l 3.1 M00001614C:E06 9436

2791 2/24/98 1 191 RTA00000340F.i.05.1 M00001614B:E08 0

2792 2/24/98 192 RTA00000421 F.k.l 5.1 M00001613D:B03 2222

2793 2/24/98 360 RTA00000409F.J.19.1 M00001613A:F03 73792

2794 2/24/98 57 RTA00000409F.1.21.1 M00001615B:G07 73143

2795 2/24/98 354 RTA00000404F.C.03.2 M00001592C:F1 1 39198

2796 2/24/98 791 RTA00000399F.n. l 5.1 M00001594D:C03 3213

2797 2/24/98 921 RTA00000422F.J.02.1 M00001594D:B08 10368

2798 2/24/98 1 1 14 RTA00000340F.f.22.1 M00001594B:F12 1720

2799 2/24/98 966 RTA00000422F.k. l 5.1 M00001594A:G09 19253

2800 2/24/98 46 RTA00000404F.C.20.1 M00001594A:D08 39088

2801 2/24/98 955 RTA00000404F.e.06.1 M00001607D:F06 39315

2802 2/24/98 1 103 RTA00000346F.a.l6.1 M00001593A:B07 12082

2803 2/24/98 540 RTA00000418F.i. l 8.1 M00001595C:B05 78024

2804 2/24/98 1245 RTA00000422F.k.22.1 M00001592C:E05 4098

2805 2/24/98 693 RTA00000404F.b. l9.1 M00001592B:A04 39281

2806 2/24/98 1013 RTA00000404F.b.l8.1 M00001592A:H05 13669

2807 2/24/98 989 RTA00000418F.i.l2.1 M00001592A:E02 78971

2808 2/24/98 404 RTA00000404F.b. l l . l M00001591 D:F06 39079

2809 2/24/98 786 RTA00000404F.b.09.1 M00001591 D:C07 39166

2810 2/24/98 1 147 RTA00000404F.C.18.1 M00001594A:C01 38982

281 1 2/24/98 686 RTAOOOOO 129A. 21.1 M00001601 A:E12 82067

2812 2/24/98 101 1 RTA00000400F.C.04.1 M00001618A:F08 6445

2813 2/24/98 702 RTAOOOOO 130A.d.5.1 M00001605A:H03 82051

2814 2/24/98 425 RTAOOOOO 130A.b.5.1 M00001605A:E09 79579

2815 2/24/98 ^' 458 RTAOOOOO 130A.a.19.1 M00001605A:A06 0

2816 2/24/98 51 RTAOOOOO 129A.n.21.1 M00001604A:C 1 1 79381

2817 2/24/98 804 RTAOOOOO 129A.n.24.1 M00001604A:C07 81409

2818 2/24/98 317 RTAOOOOO 195 AF.b.21.1 M00001595B:A09 39055

2818 1/28/98 602 RTAOOOOO 195 AF.b.21.1 M00001595B:A09 39055

2819 2/24/98 864 RTAOOOOO 129A.n.17.1 M00001604A:A09 7981 1

2820 2/24/98 317 RTAOOOOO 195 AF.b.21.1 M00001595B:A09 39055

2820 1/28/98 602 RTAOOOOO 195 AF.b.21.1 M00001595B:A09 39055

2821 2/24/98 875 RTA00000129A.k.22.1 M00001601 A:E02 79639

2822 2/24/98 406 RTA00000129A. 12.1 M00001601A:A06 79322

2823 2/24/98 179 RTA00000418F.i. l9.1 M00001596D:E03 79180

2824 2/24/98 759 RTA00000399F.O.06.1 M00001595D:G03 13574

2825 2/24/98 306 RTA00000404F.d.l3.1 M00001595D:A04 39036

2826 2/24/98 1055 RTA00000346F.a.04.1 M00001607B:C05 5382

2827 2/24/98 350 RTAOOOOO 129 A.p.3.1 M00001604A:B08 32644 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

2828 2/24/98 721 RTA00000422F. 14.1 M00001649D:A08 0

2829 2/24/98 391 RTAOOOOO 130A.li.16.1 M00001617A:A08 80761

2830 2/24/98 962 RTA00000404F.p.05.2 M00001652D:E09 1896

2831 2/24/98 65 RTA00000404F.p.04.2 M00001652D:E05 39069

2832 2/24/98 1108 RTA00000346F.C.16.1 M00001652B:G10 9579

2833 2/24/98 1200 RTA00000422F.k.l7.1 M00001652A:A01 38955

2834 2/24/98 1218 RTA00000418F.m.l8.1 M00001653B:G10 76479

2835 2/24/98 171 RTA00000404F.n.20.1 M00001650A:C11 26865

2836 2/24/98 180 RTA00000400F.J.19.1 M00001653C:D10 4086

2837 2/24/98 556 RTA00000400F.i.ll.l M00001649C:H10 2587

2838 2/24/98 848 RTA00000404F.ιι.18.2 M00001649C:E11 37169

2839 2/24/98 29 RTA00000404F.n.l6.2 M00001649C:D05 39095

2840 2/24/98 146 RTA00000404F.n.ll.2 M00001649A:E11 38001

2841 2/24/98 700 RTA00000350R.m.l4.1 M00001644C:B07 39171

2842 2/24/98 699 RTA00000340F.I.05.1 M00001644B:D06 38935

2843 2/24/98 479 RTA00000418F.rn.10.] M00001651A:H11 79110

2844 2/24/98 1169 RTA00000405F.b.08.1 M00001656B:E01 39182

2845 2/24/98 855 RTA00000423F.a.01.1 M00001659C:F10 39103

2846 2/24/98 363 RTA00000405F.C.11.1 M00001659A:D12 39068

2847 2/24/98 807 RTA00000418F.n.11.1 M00001658D:G12 78977

2848 2/24/98 795 RTA00000418F.n.07.1 M00001658B:A07 76316

2849 2/24/98 109 RTA00000422F.p.24.2 M00001658A:G09 5823

2850 2/24/98 696 RTA00000404F.p.l2.2 M00001653B:C06 0

2851 2/24/98 369 RTA00000410F.m.05.1 M00001657B:B04 74964

2852 2/24/98 1229 RTA00000422F.n.l4.1 M00001642C:G02 26787

2853 2/24/98 529 RTA00000422F.O.19.2 M00001655C:E01 13084

2854 2/24/98 327 RTA00000405F.a.ll.l M00001655A:B11 39124

2855 2/24/98 393 RTA00000418F.m.24.1 M00001654D:F12 77114

2856 2/24/98 381 RTA00000418F.m.23.1 M00001654D:F11 77195

2857 2/24/98 877 RTA00000418F.rn.22.! M00001654D:E12 74567

2858 2/24/98 166 RTA00000418F.m.l9.1 M00001654D:A03 8890

2859 2/24/98 291 RTA00000405F.C.01.1 M00001657D:A04 19236

2860 2/24/98 356 RTA00000409F.m.24.1 M00001620D:H02 3942

2861 2/24/98 717 RTA00000404F...22.1 M00001625C:G05 39082

2862 2/24/98 648 RTA00000340F.i.l3.1 M00001624B:B10 79299

2863 2/24/98 914 RTA00000138A.m.l5.1 M00001624A:A03 41603

2864 2/24/98 587 RTAOOOOO 130A.O.21.1 M00001623A:F04 80218

2865 2/24/98 22 RTA00000130A.m.l5.1 M00001622A:H12 81630

2866 2/24/98 767 RTAOOOOO 138A.p.10.1 M00001644A:H01 81625

2867 2/24/98 262 RTA00000409F.n.l4.1 M00001621B:G05 78190

2868 2/24/98 960 RTA00000404F.1.19.2 M00001639B:H01 16196

2869 2/24/98 608 RTA00000404F.U2.1 M00001620D:G11 39001

2870 2/24/98 342 RTA00000404F.i.02.1 M00001619D:D10 39015

2871 2/24/98 195 RTA00000404F.h.22.1 M00001619C:C07 18735

2872 2/24/98 214 RTA00000404F.h.l9.1 M00001619A:E05 8096

2873 2/24/98 52 RTA00000409F.m.l2.1 M00001618B:D09 73490

2874 2/24/98 769 RTA00000340F.i.l0.1 M00001618A:F10 38561

2875 2/24/98 383 RTA00000404F.U8.1 M00001621C:H12 21912

2876 2/24/98 256 RTA00000404F.1T1.03.2 M00001640A:H02 11799

2877 2/24/98 519 RTA00000404F.1.10.1 M00001638B:F10 23136 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

2878 2/24/98 646 RTA00000421 F.m. l 4.1 M00001642A:F03 3524

2879 2/24/98 659 RTA00000422F.m.24.1 M00001641 D:C04 39159

2880 2/24/98 701 RTA0000041 8F.I.1 1 .1 M00001641 C:H07 77158

2881 2/24/98 873 RTA00000418F.1.06.1 M00001641 C:F01 73317

2882 2/24/98 422 RTA00000418F.1.04.1 M00001641 C:D02 74140

2883 2/24/98 766 RTA00000404FJ.01 .1 M00001625D:G 10 26859

2884 2/24/98 20 RTA00000404F.m.04.2 M00001641 A:A1 1 22720

2885 2/24/98 346 RTA00000418F.J.08.1 M00001626C:C 1 1 73382

2886 2/24/98 141 RTA00000418F.k. l 9.1 M00001639C:C02 74932

2887 2/24/98 373 RTA00000418F. 18.1 M00001639C:A10 75385

2888 2/24/98 405 RTA00000418F.k. l 7.1 M00001639C:A09 75390

2889 2/24/98 63 RTA00000404F.1.20.2 M00001639B:H05 38638

2889 2/24/98 133 RTA00000404F.1.20.1 M00001639B:H05 38638

2890 2/24/98 133 RTA00000404F.1.20.1 M00001639B:H05 38638

2890 2/24/98 63 RTA00000404F.1.20.2 M00001639B:H05 38638

2891 2/24/98 1261 RTA00000404F.m. l 7.2 M00001643B:E05 0

2892 2/24/98 626 RTA00000410F.J.01 .1 M00001641 B:F 12 73399

2893 2/24/98 982 RTAOOOOO 126 A.p.23.2 M00001 552A:F06 80915

2894 2/24/98 196 RTA00000418F. 10.1 M00001639A:G07 74454

2895 2/24/98 765 RTA00000137A.J.15.4 M00001559A:C08 4213

2896 2/24/98 895 RTAOOOOO 137AJ.1 1 .4 M00001559A:A1 1 79752

2897 2/24/98 232 RTAOOOOO 128 A.b.20.1 M00001558A:G09 79761

2898 2/24/98 152 RTA00000127A.L20.1 M00001555A:B 12 81418

2899 2/24/98 78 RTA00000195AF.b. l 3.1 M00001560D:A03 12605

2899 1 /28/98 59 RTA00000195AF.b. l 3.1 M00001560D:A03 12605

2900 2/24/98 448 RTA00000127A.a.3.1 M00001552A:H10 13232

2901 2/24/98 801 RTAOOOOO 128 A.m.23.1 M00001561 A:D01 81441

2902 2/24/98 499 RTAOOOOO 126A.p.18.2 M00001552A:E10 80881

2903 2/24/98 1212 RTA00000349R.O.03.1 M00001551 D:H07 23006

2904 2/24/98 484 RTA00000126A.n. l 3.2 M00001551 A:H06 79735

2905 2/24/98 240 RTAOOOOO 126A.n.7.2 M0000155 1 A:D06 79557

2906 2/24/98 45 1 RTAOOOOO 126A.0.22.1 M00001551 A:A 1 1 81752

2907 2/24/98 513 RTAOOOOO 126A.k.7.2 M00001550A:E07 79866

2908 2/24/98 578 RTAOOOOO 127A.f.1 1 .1 M00001554A:A08 81463

2909 2/24/98 372 RTA00000408F.p.24.1 M00001579A:E03 74286

2910 2/24/98 985 RTA00000409F.a.08.1 M00001582D:B01 74978

291 1 2/24/98 685 RTAOOOOO 129A.a.13.2 M00001582A:A03 79780

2912 2/24/98 574 RTA00000403F.O.14.1 M00001579D:H09 38971

2913 2/24/98 601 RTA00000403F.O.13.1 M00001579D:F04 39049

2914 2/24/98 432 RTA0000041 8F.g.05.1 M00001579C:H06 73075

2915 1 /28/98 59 RTAOOOOO 195AF.b.13.1 M00001560D:A03 12605

2915 2/24/98 78 RTAOOOOO 195AF.b.13.1 M00001560D:A03 12605

2916 2/24/98 491 RTA0000041 8F.f.21 . 1 M00001579B:F04 75157

2917 2/24/98 612 RTA00000125A. 14.1 M00001545A:G05 79457

2918 1 /28/98 248 RTAOOOOO 198R.C.14.1 M00001578D:C04 39814

2918 2/24/98 778 RTA00000347F.e.05.1 M00001 578D:C04 39814

2919 1 /28/98 248 RTA00000198R.C.14.1 M00001578D:C04 39814

2919 2/24/98 778 RTA00000347F.e.05.1 M00001578D:C04 39814

2920 2/24/98 361 RTA00000422F.d. l 6.1 M00001570C:G03 39133

2921 2/24/98 173 RTA00000418F.d. l 3.1 M00001570A:H01 74309 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID

Priority Priority

Appln Appln

2922 2/24/98 1 195 RTA00000422F.e.23.1 M00001567D:B03 19246

2923 2/24/98 1 168 RTA00000421 F.b.06.1 M00001567A:B09 21 13

2924 2/24/98 580 RTA00000403F.O.07.1 M00001579C:A01 39037

2925 2/24/98 53 1 RTA00000345F.n. l2.1 M00001528A:C04 7337

2926 2/24/98 154 RTA00000340F.b.21.1 M00001533D:A08 8001

2927 2/24/98 19 RTAOOOOO 123 A.k.23.1 M00001533A:G05 80313

2928 2/24/98 1265 RTA00000340F.d.07.1 M00001532D:A06 0

2929 2/24/98 1 124 RTAOOOOO 123 A.h.22.1 M00001532A:C01 17124

2930 2/24/98 1241 RTA00000408F.1.14.1 M00001530A:E10 12001

2931 2/24/98 534 RTAOOOOO 126A.g.7.1 M00001548A:H04 1902

2932 2/24/98 694 RTA00000418F.C.07.1 M00001529D:C05 73245

2933 2/24/98 1034 RTAOOOOO 124A.f.16.3 M00001536A:F1 1 47430

2934 2/24/98 790 RTA00000345F.n.08.1 M00001517A:B 1 1 0

2935 2/24/98 613 RTAOOOOO 122A.J .22.1 M00001 516A:F06 81 151

2936 2/24/98 885 RTAOOOOO 122AJ.17.1 M00001516A:D02 62736

2937 2/24/98 1262 RTAOOOOO 122A.h.4.1 M00001514A:G03 33576

2938 2/24/98 135 RTAOOOOO 122A.d.5.1 M00001513A:F05 81 155

2939 1/28/98 391 RTAOOOOO 179AF.e.20.3 M00001396A:C03 4009

2940 2/24/98 537 RTA00000408F.1.09.1 M00001530A:A09 75487

2941 2/24/98 683 RTA00000403F.J.21 .1 M00001540D:E02 24723

2942 2/24/98 343 RTA00000422F.g.21.1 M00001583A:F07 17232

2943 2/24/98 226 RTAOOOOO 125A.k.10.1 M00001545A:F02 81644

2944 2/24/98 763 RTA00000135A.m. l 8.1 M00001545A:C03 19255

2945 2/24/98 156 RTA00000125A.U .1 M00001545A:B12 0

2946 2/24/98 597 RTAOOOOO 135A.1.1 .2 M00001545A:B10 39426

2947 2/24/98 586 RTAOOOOO 125 A.g.24.1 M00001544A:F05 80397

2948 2/24/98 467 RTAOOOOO 123A.n.13.2 M00001534A:D03 39167

2949 2/24/98 830 RTA00000347F.b.08.1 M00001541 B:E05 17591

2950 2/24/98 997 RTA00000134A.1.9.1 M00001535A:D 10 81814

2951 2/24/98 371 RTA00000403F.J.17.1 M00001539D:B 10 38563

2952 2/24/98 33 RTA00000403F.J.15.1 M00001539B:G07 23840

2953 2/24/98 1209 RTA00000408F.n.05.2 M00001539A:H02 77883

2954 2/24/98 530 RTA00000408F.n.02.2 M00001539A:E01 76993

2955 2/24/98 1213 RTA00000135A.a.23.1 M00001537A:H05 27054

2956 2/24/98 347 RTA00000125A.n.4.1 M00001546A:D08 81984

2957 2/24/98 472 RTAOOOOO 135A.f.14.2 M00001542A:G 12 79969

2958 2/24/98 243 RTA00000410F.C.14.1 M00001634A:H05 77809

2959 2/24/98 919 RTA00000410F.d. l 8.1 M00001635D:D05 75458

2960 2/24/98 825 RTA00000404F.k.22.2 M00001635D:C 12 39084

2960 2/24/98 364 RTA00000404F. 22.1 M00001635D:C12 39084

2961 2/24/98 825 RTA00000404F.k.22.2 M00001635D:C 12 39084

2961 2/24/98 364 RTA00000404F. 22.1 M00001635D:C 12 39084

2962 2/24/98 595 RTA00000410F.d. l 0.1 M00001635B:H02 77561

2963 2/24/98 175 RTA00000410F.d.09.1 M00001635B:H01 76964

2964 2/24/98 206 RTA00000410F.b. l 5.1 M00001633C:F09 77100

2965 2/24/98 1083 RTA0000041 8F.J.20.1 M00001634D:D04 77101

2966 2/24/98 922 RTA00000410F.e.09.1 M00001636A:F08 76093

2967 2/24/98 1035 RTA00000404F.k. l 5.1 M00001634A:B04 18225

2968 2/24/98 1 167 RTA00000410F.C.06.1 M00001633D:H06 77784

2969 2/24/98 53 RTA00000410F.C.04.1 M00001633D:G09 74099 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID

Priority Priority

Appln Appln

2970 2/24/98 567 RTA00000410F.C.02.1 M00001633D:D12 75055

2971 2/24/98 819 RTA00000410F.b.24.1 M00001633D:D09 75104

2972 2/24/98 666 RTA00000403F.O.19.1 M00001582D:F02 78615

2973 2/24/98 559 RTA00000418F.k.03.1 M00001634D:G 1 1 78901

2974 2/24/98 999 RTA00000418F. 04.1 M00001637A:A03 75864

2975 2/24/98 936 RTA00000121 A.n.23.1 M0000151 1 A:G01 26981

2976 2/24/98 201 RTA00000404F.I.09.1 M00001638B:E12 39176

2977 2/24/98 1 160 RTA00000400F.g.02.1 M00001638B:E03 1508

2978 2/24/98 827 RTA00000410F.f. l 2.1 M00001637C:E03 73883

2979 2/24/98 622 RTA00000404F.1.07.1 M00001637C:C06 10798

2980 2/24/98 365 RTA00000418F.k.07.1 M00001637A:F10 75067

2981 2/24/98 248 RTA00000404F. 24.1 M00001636A:C03 15256

2982 2/24/98 25 RTA00000418F. 05.1 M00001637A:A06 73021

2983 2/24/98 1 178 RTA00000400F.f. l l . l M00001636A:E07 4088

2984 2/24/98 1 180 RTA00000404F.1.05.1 M00001636D:F09 38671

2985 2/24/98 71 1 RTA00000404F.I.03.2 M00001636B:G 1 1 40272

2985 2/24/98 785 RTA00000404F.I.03.1 M00001636B:G 1 1 40272

2986 2/24/98 785 RTA00000404F.1.03.1 M00001636B:G1 1 40272

2986 2/24/98 71 1 RTA00000404F.1.03.2 M00001636B:G 1 1 40272

2987 2/24/98 71 1 RTA00000404F.1.03.2 M00001636B:G1 1 40272

2987 2/24/98 785 RTA00000404F.1.03.1 M00001636B:G1 1 40272

2988 2/24/98 71 1 RTA00000404F.1.03.2 M00001636B:G 1 1 40272

2988 2/24/98 785 RTA00000404F.I.03.1 M00001636B:G 1 1 40272

2989 2/24/98 1 106 RTA00000410F.b. l 7.1 M00001633C:H05 77458

2990 2/24/98 253 RTA00000400F.f.l 8.1 M00001637A:E10 3764

2991 2/24/98 562 RTA00000401 F.J.17.1 M00003901 B:C05 5483

2992 2/24/98 1082 RTA00000137A.O.22.1 M00001587A:D01 0

2993 2/24/98 594 RTAOOOOO 129A.C.18.2 M00001587A:B10 37216

2994 2/24/98 891 RTAOOOOO 137A.p.12.1 M00001587A:B01 80614

2995 2/24/98 131 RTA00000418F.g.22.1 M00001585B:F01 74837

2996 2/24/98 880 RTA00000418F.g.20.1 M00001585B:C03 74626

2997 2/24/98 742 RTA00000410F.b. l 8.1 M00001633C:H1 1 76701

2998 2/24/98 879 RTA00000409F.b. l9.1 M00001584D:H02 14479

2999 2/24/98 167 RTA00000399F.1.14.1 M00001590B:G08 3354

3000 2/24/98 1260 RTA00000422F.f.l 8.1 M00001583D:B08 24528

3000 2/24/98 1258 RTA00000403F.p.05.2 M00001583D:B08 24528

3001 2/24/98 1260 RTA00000422F.f.l 8.1 M00001583D:B08 24528

3001 2/24/98 1258 RTA00000403F.p.05.2 M00001583D:B08 24528

3002 2/24/98 1260 RTA00000422F.f. l 8.1 M00001583D:B08 24528

3002 2/24/98 1258 RTA00000403F.p.05.2 M00001583D:B08 24528

3003 2/24/98 1260 RTA00000422F.f. l 8.1 M00001583D:B08 24528

3003 2/24/98 1258 RTA00000403F.p.05.2 M00001583D:B08 24528

3004 2/24/98 67 RTA00000409F.a.22.1 M00001583B:F02 75200

3005 2/24/98 564 RTA00000418F.k.08.1 M00001639A:C03 18259

3006 1/28/98 282 RTAOOOOO 193AF.C.15.1 M00004248B:E08 3726

3007 2/24/98 242 RTA00000404F.J.08.1 M00001629B:B08 39066

3008 2/24/98 669 RTA00000410F.b. l 0.1 M00001633C:B09 74504

3009 2/24/98 725 RTA00000410F.b.07.1 M00001633C:A05 78916

3010 2/24/98 423 RTA00000410F.a.l 6.1 M00001633A:E06 73548

301 1 2/24/98 695 RTA00000418F.J.15.1 M00001632C:H07 74855 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID

Priority Priority

Appln Appln

3012 2/24/98 901 RTA00000418F.J.14.1 M00001632C:B10 32623

3013 2/24/98 752 RTA00000410F.a.08.1 M00001632A:B 10 73324

3014 2/24/98 1007 RTA00000404F.a.01.1 M00001589B:B08 19251

3015 2/24/98 1093 RTA00000340F.U 5.1 M00001629C:E07 26815

3016 2/24/98 664 RTA00000404F.a.09.1 M00001589C:E06 38985

3017 2/24/98 1246 RTA00000418F.J.1 1.1 M00001626C:E04 73853

3018 2/24/98 174 RTA00000404F.b.02.1 M00001591 B:B12 38984

3019 2/24/98 1 142 RTA00000418F.i.06.1 M00001591 B:B06 75151

3020 2/24/98 740 RTA00000399F.I.19.1 M00001590D:G07 40145

3021 2/24/98 1098 RTA00000409F.d. l6.1 M00001590C:F10 76090

3022 2/24/98 591 RTA00000409F.a. l 6.1 M00001583A:A05 73990

3023 2/24/98 1 1 10 RTA00000404F.J.24.1 M00001631 D:G05 39067

3024 1/28/98 108 RTA00000183 AR.lι.23.2 M00001528A:F09 18957

3024 1/28/98 236 RTAOOOOO 183 AR.h.23.1 M00001528A:F09 18957

3024 1/28/98 129 RTAOOOOO 134A.d.10.1 M00001528A:F09 18957

3025 1/28/98 68 RTAOOOOO 184F.k.19.1 M00001558B:D08 8022

3025 1/28/98 63 RTAOOOOO 184AF.k.19.1 M00001558B:D08 8022

3026 1/28/98 269 RTA00000183AF.k.l3.1 M00001534B:C 12 0

3027 1/28/98 129 RTAOOOOO 134A.d.10.1 M00001528A:F09 18957

3027 1/28/98 108 RTAOOOOO 183 AR.h.23.2 M00001528A:F09 18957

3027 1/28/98 236 RTAOOOOO 183 AR.h.23.1 M00001528A:F09 18957

3028 1/28/98 129 RTAOOOOO 134A.d.10.1 M00001528A:F09 18957

3028 1/28/98 108 RTAOOOOO 183 AR.h.23.2 M00001528A:F09 18957

3028 1/28/98 236 RTAOOOOO 183 AR.h.23.1 M00001528A:F09 18957

3029 1/28/98 236 RTAOOOOO 183 AR.h.23.1 M00001528A:F09 18957

3029 1/28/98 108 RTA00000183AR.h.23.2 M00001528A:F09 18957

3029 1/28/98 129 RTA00000134A.d.l 0.1 M00001528A:F09 18957

3030 1/28/98 34 RTA00000197AF.n.8.1 M00001536D:A12 4101

3031 1/28/98 108 RTAOOOOO 183 AR.h.23.2 M00001528A:F09 18957

3031 1/28/98 129 RTA00000134A.d. l 0.1 M00001528A:F09 18957

3031 1/28/98 236 RTAOOOOO 183 AR.h.23.1 M00001528A:F09 18957

3032 1/28/98 106 RTAOOOOO 197AF.n.21.1 M00001540B:C09 0

3033 1/28/98 236 RTAOOOOO 183 AR.h.23.1 M00001528A:F09 18957

3033 1/28/98 129 RTA00000134A.d.l 0.1 M00001528A:F09 18957

3033 1/28/98 108 RTAOOOOO 183 AR.h.23.2 M00001528A:F09 18957

3034 1/28/98 108 RTAOOOOO 183 AR.h.23.2 M00001528A:F09 18957

3034 1/28/98 236 RTA00000183AR.h.23.1 M00001528A:F09 18957

3034 1/28/98 129 RTAOOOOO 134A.d.10.1 M00001528A:F09 18957

3035 1/28/98 129 RTAOOOOO 134A.d.10.1 M00001528A:F09 18957

3035 1/28/98 108 RTAOOOOO] 83AR.h.23.2 M00001528A:F09 18957

3035 1/28/98 236 RTA00000183 AR.h.23.1 M00001528A:F09 18957

3036 1/28/98 233 RTA00000197AF.1.8.1 M0000151 1 B:C06 39954

3037 1/28/98 323 RTA00000182AF.m.21.1 M00001490C:C 12 18699

3038 1/28/98 223 RTA00000197F.i.9.1 M00001488D:C 10 0

3039 1/28/98 236 RTA00000183AR.h.23.1 M00001528A:F09 18957

3039 1/28/98 108 RTA00000183AR.h.23.2 M00001528A:F09 18957

3039 1/28/98 129 RTAOOOOO 134A.d.10.1 M00001528A:F09 18957

3040 1/28/98 352 RTAOOOOO 197AF.p.3.1 M00001550A:A03 7239

3041 1/28/98 301 RTA0OOOO181 AR.i.l 9.3 M00001452C:B06 16970

3041 1/28/98 295 RTA00000181 AR.U 9.2 M00001452C:B06 16970 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

3042 1/28/98 68 RTAOOOOO 184F.k.19.1 M00001558B:D08 8022

3042 1/28/98 63 RTA00000184AF.k.l9.1 M00001558B:D08 8022

3043 1/28/98 63 RTAOOOOO 184AF.k.19.1 M00001558B:D08 8022

3043 1/28/98 68 RTAOOOOO 184F.k.19.1 M00001558B:D08 8022

3044 1/28/98 41 RTA00000184F.k.l2.1 M00001557D:D09 8761

3045 1/28/98 150 RTAOOOOO 184F.k.09.1 M00001557C:H07 7065

3046 1/28/98 82 RTA00000183AF.1.18.1 M00001535D:C01 3484

3047 1/28/98 338 RTAOOOOO 184AF.i.1.1 M00001554B:C07 0

3048 1/28/98 327 RTAOOOOO 182AF.L 1.3 M00001479B:A01 7033

3049 1/28/98 256 RTA00000184AR.e.l5.1 M00001549C:E06 16347

3050 1/28/98 99 RTAOOOOO 184AF.d.8.1 M00001548A:A08 4393

3051 1/28/98 355 RTAOOOOO 184AR.b.24.1 M00001546B:C05 5777

3052 1/28/98 322 RTAOOOOO 184AR.b.21.1 M00001546B:B02 39788

3053 1/28/98 97 RTAOOOOO 197AF.o.2.1 M00001541C:B07 5739

3054 1/28/98 313 RTA00000183AF.O.11.1 M00001540D:D02 0

3055 1/28/98 42 RTAOOOOO] 84F.J.21.1 M00001557A:D02 7065

3056 1/28/98 378 RTA00000181AF. 24.3 M00001454B:C12 7005

3056 1/28/98 119 RTA00000181AR. 24.2 M00001454B:C12 7005

3056 1/28/98 116 RTA00000181AR. 24.3 M00001454B:C12 7005

3057 1/28/98 134 RTAOOOOO 197F.e.11.1 M00001454B:G03 2306

3057 1/28/98 298 RTAOOOOO 197 AR.e.11.1 M00001454B:G03 2306

3058 1/28/98 134 RTAOOOOO 197F.e.11.1 M00001454B:G03 2306

3058 1/28/98 298 RTAOOOOO 197 AR.e.11.1 M00001454B:G03 2306

3059 1/28/98 134 RTAOOOOO 197F.e.11.1 M00001454B:GO3 2306

3059 1/28/98 298 RTAOOOOO 197AR.e.11.1 M00001454B:G03 2306

3060 1/28/98 116 RTA00000181AR.L24.3 M00001454B:C12 7005

3060 1/28/98 378 RTA00000181AF. 24.3 M00001454B:C12 7005

3060 1/28/98 119 RTA00000181AR. 24.2 M00001454B:C12 7005

3061 1/28/98 116 RTA00000181AR. 24.3 M00001454B:C12 7005

3061 1/28/98 378 RTA00000181AF. 24.3 M00001454B:C12 7005

3061 1/28/98 119 RTA00000181AR.k.24.2 M00001454B:C12 7005

3062 1/28/98 159 RTAOOOOO 182AF.1.12.1 M00001487A:A05 1027

3063 1/28/98 119 RTA00000181AR. 24.2 M00001454B:C12 7005

3063 1/28/98 116 RTA00000181AR. 24.3 M00001454B:C12 7005

3063 1/28/98 378 RTA00000181AF.k.24.3 M00001454B:C12 7005

3064 1/28/98 341 RTA00000181AF.1.06.2 M00001454C:C08 0

3065 1/28/98 116 RTA00000181AR. 24.3 M00001454B:C12 7005

3065 1/28/98 119 RTA00000181AR.k.24.2 M00001454B:C12 7005

3065 1/28/98 378 RTA00000181AF. 24.3 M00001454B:C12 7005

3066 1/28/98 378 RTA0000018 lAF.k.24.3 M00001454B:C12 7005

3066 1/28/98 116 RTA00000181AR. 24.3 M00001454B:C12 7005

3066 1/28/98 119 RTA00000181AR. 24.2 M00001454B:C12 7005

3067 1/28/98 378 RTA00000181AF. 24.3 M00001454B:C12 7005

3067 1/28/98 116 RTA00000181AR.k.24.3 M00001454B:C12 7005

3067 1/28/98 119 RTA00000181AR. 24.2 M00001454B:C12 7005

3068 1/28/98 378 RTA00000181AF.k.24.3 M00001454B:C12 7005

3068 1/28/98 116 RTA00000181AR. 24.3 M00001454B:C12 7005

3068 1/28/98 119 RTAOOOOO] 81 AR.k.24.2 M00001454B:C12 7005

3069 1/28/98 170 RTA00000197AF.d.23.1 M00001453A:E11 16130

3070 1/28/98 491 RTAOOOOO 196F. 11.1 M00001399C:H12 J) SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

3071 1/28/98 1 19 RTA00000181 AR.k.24.2 M00001454B:C12 7005

3071 1/28/98 378 RTA00000181 AF. 24.3 M00001454B:C 12 7005

3071 1/28/98 1 16 RTA00000181 AR. 24.3 M00001454B:C12 7005

3072 1/28/98 674 RTAOOOOO 197AR.e.24.1 M00001456B:F10 39250

3072 1/28/98 3 RTAOOOOO 197 AF.e.24.1 M00001456B:F10 39250

3073 2/24/98 78 RTA00000195AF.b. l3.1 M00001560D:A03 12605

3073 1/28/98 59 RTA00000195AF.b. l3.1 M00001560D:A03 12605

3074 1/28/98 189 RTAOOOOO 197AF.li.10.1 M00001476B:F10 15554

3075 1/28/98 46 RTAOOOOO 182AF.f.13.1 M00001470C:B10 8010

3076 1/28/98 200 RTA00000182AF.f.2.1 M00001469D:D02 4794

3077 1/28/98 325 RTA00000182AF.d. l 8.4 M00001467D:H05 37435

3078 1/28/98 45 RTA00000197AR.f.l2.1 M00001458C:E01 3513

3079 1/28/98 298 RTAOOOOO 197 AR.e.1 1.1 M00001454B:G03 2306

3079 1/28/98 134 RTA00000197F.e.l l .l M00001454B:G03 2306

3080 1/28/98 37 RTA00000181 AF.H.15.2 M00001457A:B07 86128

3081 1/28/98 7 RTAOOOOO 197AR.e.12.1 M00001454B:G07 22095

3082 1/28/98 674 RTAOOOOO 197AR.e.24.1 M00001456B:F10 39250

3082 1/28/98 j _^ RTAOOOOO 197 AF.e.24.1 M00001456B:F10 39250

3083 1/28/98 88 RTAOOOOO 197 AF.e.23.1 M00001456B:C09 37157

3084 1/28/98 243 RTA00000181 AF.m.15.3 M00001455D:A1 1 12081

3085 1/28/98 326 RTA00000197AR.e. l9.1 M00001455D:A09 8047

3086 1/28/98 293 RTA00000197AF.e. l3.1 M00001454C:F02 662

3087 1/28/98 380 RTAOOOOO 182 AF.k.24.1 M00001485D:B10 5625

3088 1/28/98 206 RTA00000181AF.O.04.2 M00001457C:C12 22205

3089 1/28/98 228 RTA00000187AR.h.l 5.2 M00001679A:A06 6660

3090 1/28/98 68 RTAOOOOO 184F. 19.1 M00001558B:D08 8022

3090 1/28/98 63 RTA00000184AF.k.19.1 M00001558B:D08 8022

3091 1/28/98 191 RTA00000187AF.p.23.1 M00003748B:F02 39804

3092 1/28/98 10 RTAOOOOO 198AF.n.16.1 M00001694C:H 10 3721

3093 1/28/98 219 RTAOOOOO 198AF.m.19.1 M00001680D:D02 40041

3093 1/28/98 32 RTAOOOOO 198R.m.19.1 M00001680D:D02 40041

3094 1/28/98 32 RTAOOOOO 198R.m.19.1 M00001680D:D02 40041

3094 1/28/98 219 RTA00000198AF.m. l 9.1 M00001680D:D02 40041

3095 1/28/98 317 RTA00000198AF.p.09.1 M00003761 D:E02 10473

3095 1/28/98 186 RTA00000198R.p.09.1 M00003761D:E02 10473

3096 1/28/98 219 RTA00000198AF.m. l9.1 M00001680D:D02 40041

3096 1/28/98 32 RTA00000198R.m. l 9.1 M00001680D:D02 40041

3097 1/28/98 64 RTA00000198AF.p.l2.1 M00003763D:E10 8878

3097 1/28/98 542 RTA00000198R.p.l 2.1 M00003763D:E10 8878

3098 1/28/98 364 RTAOOOOO 187 AF.g.13.1 M00001676C:C1 1 2991

3099 1/28/98 430 RTA00000198R.k.23.1 M00001661 B:C08 8995

3099 1/28/98 294 RTAOOOOO 198 AF.k.23.1 M00001661 B:C08 8995

3100 1/28/98 430 RTA00000198R.k.23.1 M00001661 B:C08 8995

3100 1/28/98 294 RTAOOOOO 198 AF.k.23.1 M00001661 B:C08 8995

3101 1/28/98 57 RTA00000198AF. 20.1 M00001660C:B12 22553

3102 1/28/98 368 RTA00000198AF. 8.1 M00001660A:C12 17432

3103 1/28/98 247 RTA00000198AF.k.08.1 M00001656C:G08 17436

3104 1/28/98 219 RTA00000198AF.m.l9.1 M00001680D:D02 40041

3104 1/28/98 32 RTA00000198R.m. l 9.1 M00001680D:D02 40041

3105 1/28/98 199 RTA00000199R.C.09.1 M00003800A:C09 16824 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

3105 1/28/98 66 RTA00000199F.C.09.2 M00003800A:C09 16824

3106 1/28/98 225 RTA00000189AF.b.5.1 M00003828A:E04 3784

3107 1/28/98 5 RTA00000195R.C.11.1 M00003811A:E03 66087

3108 1/28/98 284 RTAOOOOO 199F.d.10.2 M00003808C:B05 22049

3108 2/24/98 816 RTA00000354R.n.04.1 M00003808C:B05 22049

3109 1/28/98 284 RTAOOOOO 199F.d.10.2 M00003808C:B05 22049

3109 2/24/98 816 RTA00000354R.n.04.1 M00003808C:B05 22049

3110 1/28/98 2 RTA00000188AF.n.l5.1 M00003804A:H04 0

3111 1/28/98 317 RTAOOOOO 198 AF.p.09.1 M00003761D:E02 10473

3111 1/28/98 186 RTA00000198R.p.09.1 M00003761D:E02 10473

3112 1/28/98 199 RTAOOOOO 199R.C.09.1 M00003800A:C09 16824

3112 1/28/98 66 RTAOOOOO 199F.C.09.2 M00003800A:C09 16824

3113 1/28/98 487 RTA00000198F.i.8.1 M00001639A:F10 9807

3113 1/28/98 277 RTA00000198AR.i.08.1 M00001639A:F10 9807

3114 1/28/98 66 RTAOOOOO 199F.C.09.2 M00003800A:C09 16824

3114 1/28/98 199 RTAOOOOO 199R.C.09.1 M00003800A:C09 16824

3115 1/28/98 224 RTAOOOOO 188AF.m.11.1 M00003799A:D09 0

3116 1/28/98 58 RTA00000199F.b.01.2 M00003778A:D08 19118

3117 1/28/98 216 RTAOOOOO 188 AF.g.9.1 M00003774B:B08 4959

3118 1/28/98 201 RTAOOOOO 198AF.p.18.1 M00003769B:D03 23081

3119 1/28/98 542 RTAOOOOO 198R.p.12.1 M00003763D:E10 8878

3119 1/28/98 64 RTAOOOOO 198AF.p.12.1 M00003763D:E10 8878

3120 1/28/98 199 RTAOOOOO 199R.C.09.1 M00003800A:C09 16824

3120 1/28/98 66 RTA00000199F.C.09.2 M00003800A:C09 16824

3121 1/28/98 146 RTAOOOOO 185AF.a.19.2 M00001571C:H06 5749

3122 1/28/98 248 RTA00000198R.C.14.1 M00001578D:C04 39814

3122 2/24/98 778 RTA00000347F.e.05.1 M00001578D:C04 39814

3123 1/28/98 248 RTA00000198R.C.14.1 M00001578D:C04 39814

3123 2/24/98 778 RTA00000347F.e.05.1 M00001578D:C04 39814

3124 1/28/98 147 RTA00000185AF.C.24.2 M00001578B:E04 23001

3125 1/28/98 195 RTA00000198AF.C.10.1 M00001577B:H02 77149

3126 1/28/98 171 RTAOOOOO 198R.C.07.1 M00001575D:G05 19181

3126 1/28/98 525 RTAOOOOO 198AF.C.7.1 M00001575D:G05 19181

3127 1/28/98 172 RTAOOOOO 186AF.p.09.2 M00001655C:E04 6879

3128 1/28/98 230 RTA00000185AR.b.l8.1 M00001575B:C09 12171

3129 1/28/98 192 RTA00000185AF.m.7.1 M00001605C:D12 39804

3130 1/28/98 19 RTA00000185AF.a.8.1 M00001570D:A03 4868

3131 1/28/98 492 RTA00000198AF.b.8.1 M00001567C:H12 22636

3131 1/28/98 23 RTA00000198R.b.08.1 M00001567C:H12 22636

3132 1/28/98 23 RTAOOOOO 198R.b.08.1 M00001567C:H12 22636

3132 1/28/98 492 RTA00000198AF.b.8.1 M00001567C:H12 22636

3133 1/28/98 357 RTAOOOOO 184AF.0.15.1 M00001564D:C09 0

3134 1/28/98 30 RTA00000184AR.n.07.2 M00001561C:F06 0

3135 1/28/98 59 RTA00000195AF.b.l3.1 M00001560D:A03 12605

3135 2/24/98 78 RTA00000195AF.b.l3.1 M00001560D:A03 12605

3136 1/28/98 525 RTA00000198AF.C.7.1 M00001575D:G05 19181

3136 1/28/98 171 RTAOOOOO 198R.C.07.1 M00001575D:G05 19181

3137 1/28/98 303 RTAOOOOO 186AR.e.03.3 M00001623D:C10 22110

3138 1/28/98 295 RTA00000181AR.i.l9.2 M00001452C:B06 16970

3138 1/28/98 301 RTA00000181AR.i.l9.3 M00001452C:B06 16970 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID

Priority Priority

Appln Appln

3 139 1/28/98 232 RTAOOOOO 186 AF.j .03.2 M00001638A:E07 0

3140 1/28/98 309 RTAOOOOO 198AF.li.12.1 M00001632C:A02 9503

3141 1/28/98 268 RTAOOOOO 186AF.h.01.2 M00001632A:F12 0

3142 1/28/98 267 RTAOOOOO 186AF.g.1 1.2 M00001630B:H09 5214

3143 1/28/98 83 RTAOOOOO 186AF.f.24.2 M00001629B:E06 0

3143 1/28/98 336 RTAOOOOO 186AF.f.24.1 M00001629B:E06 0

3144 1/28/98 222 RTA00000185AF.i.4.1 M00001594A:B12 13942

3145 1/28/98 217 RTAOOOOO 198 AF.h.3.1 M00001625D:C07 22562

3146 1/28/98 196 RTA00000198F.e. l 0.1 M00001599B:E09 9727

3147 1/28/98 372 RTAOOOOO 186 AF.d.23.1 M00001623B:G07 22187

3148 1/28/98 302 RTAOOOOO 186AF.d.1.2 M00001621 C:C08 40044

3149 1/28/98 262 RTA00000186AF.C.17.1 M00001619D:G05 8551

3150 1/28/98 358 RTA00000198AF.g.7.1 M00001616C:C09 13386

3151 1/28/98 166 RTAOOOOO 198 AF.f.21 .1 M00001614D.D09 22676

3152 1 /28/98 277 RTAOOOOO 198AR.i.08.1 M00001639A:F10 9807

3152 1/28/98 487 RTA00000198F.i.8.1 M00001639A:F10 9807

3153 1/28/98 336 RTAOOOOO 186AFT.24.1 M00001629B:E06 0

3153 1/28/98 83 RTAOOOOO 186AFT.24.2 M00001629B:E06 0

3154 1 /28/98 352 RTAOOOOO 197AF.p.3.1 M00001550A:A03 7239

3155 1/28/98 251 RTA00000192AF.ιι.13.1 M00004197D:H01 8210

3156 1/28/98 41 RTAOOOOO 184F.k.12.1 M00001557D:D09 8761

3157 1/28/98 731 RTAOOOOO 184F.k.02.1 M00001557B:H10 5192

3158 1/28/98 42 RTAOOOOO 184FJ.21.1 M00001557A:D02 7065

3159 1/28/98 42 RTAOOOOO 184F.J.21.1 M00001557A:D02 7065

3160 1/28/98 302 RTA00000186AF.d. l .2 M00001621 C:C08 40044

3161 1/28/98 560 RTA00000184AF.i.23.3 M00001556A:F1 1 1577

3162 1/28/98 558 RTAOOOOO 186AR.h.14.1 M00001632D:H07 0

3163 1/28/98 256 RTA00000184AR.e.l 5.1 M00001549C:E06 16347

3164 1/28/98 682 RTA00000125A.J.16.1 M00001544A:E06 0

3165 1/28/98 129 RTA00000134A.d. l 0.1 M00001528A:F09 18957

3165 1/28/98 108 RTA00000183AR.h.23.2 M00001528A:F09 18957

3165 1/28/98 236 RTAOOOOO 183 AR.h.23.1 M00001528A:F09 18957

3166 1/28/98 129 RTAOOOOO 134A.d.10.1 M00001528A:F09 18957

3166 1/28/98 108 RTA00000183 AR.h.23.2 M00001528A:F09 18957

3166 1/28/98 236 RTA00000183AR.h.23.1 M00001528A:F09 18957

3167 1/28/98 108 RTA00000183AR.h.23.2 M00001528A:F09 18957

3167 1/28/98 236 RTAOOOOO 183 AR.h.23.1 M00001528A:F09 18957

3167 1/28/98 129 RTAOOOOO 134A.d.10.1 M00001528A:F09 18957

3168 2/24/98 531 RTA00000345F.n. l2.1 M00001528A:C04 7337

3169 1/28/98 324 RTAOOOOO 184F.J.06.1 M00001556B:G02 1 1294

3170 2/24/98 604 RTA00000351 R.C.13.1 M00003747D:C05 1 1476

3171 1/28/98 301 RTA00000181 AR.i. l 9.3 M00001452C:B06 16970

3171 1/28/98 295 RTA00000181 AR.U9.2 M00001452C:B06 16970

3172 1/28/98 231 RTA00000192AF.1.13.2 M00004185C:C03 1 1443

3173 1/28/98 634 RTAOOOOO 192 AF.j .6.1 M00004172C:D08 1 1494

3174 1/28/98 165 RTAOOOOO 192 AF.g.23.1 M00004157C:A09 6455

3175 1/28/98 574 RTAOOOOO 192 AF.f.3.1 M00004146C:C 1 1 5257

3176 1/28/98 146 RTA00000185AF.a.l9.2 M00001571C:H06 5749

3177 1/28/98 651 RTAOOOOO 189AR.d.22.2 M00003844C:B 1 1 6539

3178 1/28/98 161 RTAOOOOO 183 AF.e.23.2 M00001506D:A09 0 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID

Priority Priority

Appln Appln

3179 1 /28/98 475 RTAOOOOO 187 AR.m.3.3 M00001682C:B 12 17055

3180 2/24/98 39 RTA00000187AF.1.7.1 M00001680D:F08 10539

3181 1/28/98 228 RTAOOOOO 187AR.h.15.2 M00001679A:A06 6660

3182 2/24/98 465 RTA00000350R.p.l 8.1 M00001676B:F05 1 1460

3183 1/28/98 575 RTAOOOOO 186AF.1.12.2 M00001645A:C12 19267

3184 2/24/98 700 RTA00000350R.m. l4.1 M00001644C:B07 39171

3185 1/28/98 261 RTAOOOOO 192AF.a.24.1 M000041 14C:F1 1 13183

3186 1/28/98 236 RTA00000183AR.h.23.1 M00001528A:F09 18957

3186 1/28/98 108 RTA00000183 AR.h.23.2 M00001528A:F09 18957

3186 1/28/98 129 RTA00000134A.d. l 0.1 M00001528A:F09 18957

3187 1/28/98 398 RTA00000177AR.1.13.3 M00001353A:G 12 8078

3188 1 /28/98 645 RTA00000177AF.k.9.1 M00001352A:E02 16245

3189 1/28/98 283 RTA00000177AF.i.8.4 M00001350A:H01 7187

3190 1/28/98 361 RTAOOOOO 177AR.g.16.4 M00001347A:B 10 13576

3191 1/28/98 680 RTAOOOOO 177AFT 10.1 M00001345A:E01 6420

3192 1 /28/98 632 RTA00000183AR.g.03.1 M00001512D:G09 3956

3192 1/28/98 630 RTA00000183AR.g.03.2 M00001512D:G09 3956

3193 1/28/98 702 RTA00000177AR.b.8.5 M00001340B:A06 17062

3194 1/28/98 330 RTA00000177AR.m. l 7.4 M00001355B:G 10 14391

3194 1 /28/98 493 RTAOOOOO 177 AF.m.17.1 M00001355B:G 10 14391

3194 1/28/98 337 RTA00000177AR.m. l 7.3 M00001355B:G10 14391

3195 1/28/98 236 RTA00000183 AR.h.23.1 M00001528A:F09 18957

3195 1/28/98 129 RTA00000134A.d. l 0.1 M00001528A:F09 18957

3195 1/28/98 108 RTA00000183 AR.h.23.2 M00001528A:F09 18957

3196 1/28/98 129 RTAOOOOO 134A.d.10.1 M00001528A:F09 18957

3196 1/28/98 236 RTA000O0183AR.h.23.1 M00001528A:F09 18957

3196 1/28/98 108 RTA00000183 AR.h.23.2 M00001528A:F09 18957

3197 1/28/98 435 RTAOOOOO 182AR.C.22.1 M00001467A:D08 16283

3198 1/28/98 635 RTA00000181 AF.p.7.3 M00001460A:E01 38773

3199 1/28/98 362 RTAOOOOO 197 AR.c.24.1 M00001450A:B12 82498

3200 2/24/98 442 RTA00000347F.b.02.1 M00001450A:A02 39304

3201 1/28/98 265 RTA00000177AF.e. l4.1 M00001343D:H07 23255

3202 1/28/98 270 RTA00000178R.1.08.1 M00001383A:C03 39648

3203 1/28/98 472 RTAOOOOO 192AF.p.17.1 M00004214C:H05 1 1451

3204 1/28/98 603 RTAO0OO0183AR.d.l l .3 M00001504D:G06 6420

3205 1/28/98 519 RTAOOOOO 183 AF.a.24.2 M00001499B:A1 1 10539

3206 1/28/98 435 RTA00000182AR.C.22.1 M00001467A:D08 16283

3207 2/24/98 158 RTA00000348R.J.16.1 M00001410A:D07 7005

3208 1/28/98 41 1 RTA00000179AF.J.13.3 M00001400B:H06 0

3209 1/28/98 742 RTAOOOOO 177AF.m.1.1 M00001353D:D10 14929

3210 1/28/98 270 RTA00000178R.1.08.1 M00001383A:C03 39648

321 1 1/28/98 337 RTAO0OO0177AR.m. l 7.3 M00001355B:G10 14391

321 1 1/28/98 493 RTAOOOOO 177AF.m.17.1 M00001355B:G 10 14391

321 1 1/28/98 330 RTA00000177AR.m.17.4 M00001355B:G 10 14391

3212 1/28/98 297 RTAOOOOO 178 AF.f.9.3 M00001371 C:E09 7172

3213 1/28/98 33 RTAOOOOO 178AR.a.20.1 M00001362C:H 1 1 945

3213 2/24/98 979 RTA00000345F.b.l 7.1 M00001362C:H 1 1 945

3214 1/28/98 33 RTAOOOOO 178 AR.a.20.1 M00001362C:H 1 1 945

3214 2/24/98 979 RTA00000345F.b. l 7.1 M00001362C:H1 1 945

3215 1/28/98 466 RTAOOOOO 177AF.p.20.1 M00001361 A:A05 4141 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID

Priority Priority

Appln Appln

3216 1/28/98 330 RTA00000177AR.m.l7.4 MOOOO1355B:G10 14391

3216 1/28/98 493 RTA00000177AF.m.l7.1 M00001355B:G10 14391

3216 1/28/98 337 RTA00000177AR.m.l7.3 M00001355B:G10 14391

3217 1/28/98 632 RTA00000183AR.g.03.1 M00001512D:G09 3956

3217 1/28/98 630 RTA00000183AR.g.03.2 M00001512D:G09 3956

3218 1/28/98 391 RTA00000179AF.e.20.3 M00001396A:C03 4009

3219 1/28/98 370 RTA00000179AF.C.15.3 M00001392D:H06 2995

3219 1/28/98 460 RTA00000179AF.C.15.1 M00001392D:H06 2995

3220 1/28/98 47 RTAOOOOO 192AF.m.12.1 M00004191D:B11 0

3221 1/28/98 438 RTAOOOOO 180 AR.g.03.4 M00001425A:C11 9024

3221 1/28/98 95 RTA00000180AF.g.3.1 M00001425A:C11 9024

3222 1/28/98 438 RTAOOOOO 180 AR.g.03.4 M00001425A:C11 9024

3222 1/28/98 95 RTAOOOOO 180 AF.g.3.1 M00001425A:C11 9024

3223 1/28/98 320 RTAOOOOO 196AF.m.13.1 M00001415B:E09 16290

3224 1/28/98 365 RTA00000196F.I.20.2 M00001410B:G05 22678

3225 1/28/98 80 RTA00000196AF.p.l3.2 M00001432A:E06 6125

3226 1/28/98 179 RTAOOOOO 179AF.f.20.3 M00001397B:B09 16154

3227 1/28/98 379 RTA00000180AF.1.06.2 M00001433A:G07 5625

3228 1/28/98 460 RTAOOOOO 179AF.C.15.1 M00001392D:H06 2995

3228 1/28/98 370 RTAOOOOO 179 AF.c.15.3 M00001392D:H06 2995

3229 1/28/98 107 RTA00000196R. 13.1 M00001390A:A09 9857

3230 1/28/98 120 RTAOOOOO 178AR.m.19.5 M00001384D:H07 0

3230 1/28/98 377 RTAOOOOO 178AF.m.19.1 M00001384D:H07 0

3231 1/28/98 120 RTAOOOOO 178AR.m.19.5 M00001384D:H07 0

3231 1/28/98 377 RTA00000178AF.m.l9.1 M00001384D:H07 0

3232 1/28/98 384 RTAOOOOO 196AF.h.17.1 M00001384C:F12 39215

3233 1/28/98 182 RTA00000196AF.h.l6.1 M00001384C:E03 39895

3234 1/28/98 105 RTAOOOOO 179AF.g.12.3 M00001398A:G03 36390

3235 1/28/98 252 RTA00000181AF.e.l8.3 M00001448D:C09 8

3235 1/28/98 253 RTA00000181AF.e.l7.3 M00001448D:C09 8

3236 1/28/98 301 RTA00000181AR.i.l9.3 M00001452C:B06 16970

3236 1/28/98 295 RTAOOOOO] 8 lAR.i.19.2 M00001452C:B06 16970

3237 1/28/98 288 RTA00000181AR.i.06.3 M00001452A:C07 19119

3237 2/24/98 198 RTA00000339R.1.14.1 M00001452A:C07 19119

3238 1/28/98 288 RTA00000181AR.i.06.3 M00001452A:C07 19119

3238 2/24/98 198 RTA00000339R.1.14.1 M00001452A:C07 19119

3239 1/28/98 109 RTA00000197AF.d.l2.1 M00001451D:C10 39546

3240 1/28/98 149 RTA00000181AR.h.06.3 M00001450D:D04 87226

3241 1/28/98 75 RTAOOOOO 180AR.h.19.2 M00001428A:H10 84182

3242 1/28/98 21 RTA00000131A.g.l9.2 M00001449A:G10 36535

3243 1/28/98 308 RTAOOOOO 178AF.J .20.1 M00001380C:E05 15066

3244 1/28/98 253 RTA00000181AF.e.l7.3 M00001448D:C09 8

3244 1/28/98 252 RTA00000181AF.e.l8.3 M00001448D:C09 8

3245 1/28/98 252 RTA00000181AF.e.l8.3 M00001448D:C09 8

3245 1/28/98 253 RTA00000181AF.e.l7.3 M00001448D:C09 8

3246 1/28/98 253 RTA00000181AF.e.l7.3 M00001448D:C09 8

3246 1/28/98 252 RTA00000181AF.e.l8.3 M00001448D:C09 8

3247 1/28/98 136 RTA00000197AF.C.10.1 M00001448B:F06 10400

3248 1/28/98 177 RTA00000197AF.C.3.1 M00001447C:C01 3145

3249 1/28/98 204 RTA00000180AR.O.5.2 M00001437D:C04 7848 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

3250 1/28/98 362 RTAOOOOO 197AR.C.24.1 M00001450A:B12 82498

3251 1/28/98 81 RTA00000196AF.b.l5.1 M00001347B:E01 5102

3252 1/28/98 342 RTAOOOOO 196AF.d.10.1 M00001354C:B06 22256

3253 1/28/98 113 RTAOOOOO 196AF.d.09.1 M00001354B:B10 16934

3254 1/28/98 463 RTA00000177AR. 23.4 M00001352D:D02 35550

3254 1/28/98 168 RTAOOOOO 177 AR.k.23.1 M00001352D:D02 35550

3255 1/28/98 463 RTA00000177 AR.k.23.4 M00001352D:D02 35550

3255 1/28/98 168 RTAOOOOO] 77AR.k.23.1 M00001352D:D02 35550

3256 1/28/98 135 RTA00000196AF.C.22.1 M00001352D:C05 22548

3257 1/28/98 270 RTA00000178R.1.08.1 M00001383A:C03 39648

3258 1/28/98 359 RTAOOOOO 196AF.b.17.1 M00001348A:D04 12193

3259 1/28/98 493 RTA00000177AF.m.l7.1 M00001355B:G10 14391

3259 1/28/98 337 RTA00000177AR.m.l7.3 M00001355B:G10 14391

3259 1/28/98 330 RTA00000177AR.m.l7.4 M00001355B:G10 14391

3260 1/28/98 361 RTA00000177AR.g.l6.4 M00001347A:B10 13576

3261 1/28/98 265 RTA00000177AF.e.l4.1 M00001343D:H07 23255

3262 1/28/98 56 RTAOOOOO 177AF.e.9.1 M00001343D:C04 37442

3263 1/28/98 48 RTAOOOOO 177 AR.a.23.5 M00001339D:G02 6995

3264 2/24/98 308 RTA00000353R.d.ll.l M00004692A:H08 0

3265 1/28/98 164 RTA00000193AR. 14.4 M00004307C:A06 9457

3266 1/28/98 283 RTA00000177AF.i.8.4 M00001350A:H01 7187

3267 1/28/98 15 RTAOOOOO 177AR.n.8.1 M00001356D:F06 4188

3267 1/28/98 89 RTAOOOOO 177AF.n.8.3 M00001356D:F06 4188

3268 1/28/98 383 RTAOOOOO 199FT.20.2 M00003847B:G03 0

3269 1/28/98 132 RTAOOOOO 178AFT.20.3 M00001372C:F07 39881

3270 1/28/98 296 RTAOOOOO 196AF.f.20.1 M00001371D:G01 22774

3271 1/28/98 297 RTAOOOOO 178 AF.f.9.3 M00001371C:E09 7172

3272 1/28/98 240 RTAOOOOO 178 AF.e.1.1 M00001369A:H12 2664

3273 1/28/98 16 RTAOOOOO 196AF.e.16.1 M00001363C:H02 39252

3274 1/28/98 112 RTA00000177AF.m.8.1 M00001354C:C10 8010

3275 1/28/98 154 RTA00000196F.e.7.1 M00001360D:E11 1039

3276 1/28/98 330 RTA00000177AR.m.l7.4 M00001355B:G10 14391

3276 1/28/98 493 RTA00000177AF.m.l7.1 M00001355B:G10 14391

3276 1/28/98 337 RTA00000177AR.m.l7.3 M00001355B:G10 14391

3277 1/28/98 89 RTAOOOOO 177AF.n.8.3 M00001356D:F06 4188

3277 1/28/98 15 RTAOOOOO 177AR.n.8.1 M00001356D:F06 4188

3278 1/28/98 493 RTAOOOOO 177 AF.m.17.1 M00001355B:G10 14391

3278 1/28/98 337 RTA00000177AR.m.l7.3 M00001355B:G10 14391

3278 1/28/98 330 RTA00000177AR.m.l7.4 M00001355B:G10 14391

3279 1/28/98 337 RTA00000177AR.m.l7.3 M00001355B:G10 14391

3279 1/28/98 330 RTA00000177AR.m.l7.4 M00001355B:G10 14391

3279 1/28/98 493 RTA00000177AF.m.l7.1 M00001355B:G10 14391

3280 1/28/98 330 RTAOOOOO 177AR.m.17.4 M00001355B:G10 14391

3280 1/28/98 493 RTAOOOOO 177AF.m.17.1 M00001355B:G10 14391

3280 1/28/98 337 RTAOOOOO 177AR.ni.17.3 M00001355B:G10 14391

3281 1/28/98 337 RTAOOOOO 177AR.ni.17.3 M00001355B:G10 14391

3281 1/28/98 493 RTAOOOOO 177 AF.m.17.1 M00001355B:G10 14391

3281 1/28/98 330 RTAOOOOO] 77AR.ni.17.4 M00001355B:G10 14391

3282 1/28/98 169 RTA00000196AF.g.24.1 M00001380C:F02 8685

3283 1/28/98 363 RTA00000196AF.e.l4.1 M00001362C:A10 12850 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID

Priority Priority

Appln Appln

3284 1/28/98 92 RTAOOOOO 198AF.J.18.1 M00001653B:G07 22759

3284 1/28/98 433 RTA00000198RJ.18.1 M00001653B:G07 22759

3285 1/28/98 537 RTAOOOOO 188AF.g.14.1 M00003774C:D02 0

3286 1/28/98 434 RTAOOOOO 187AR.d.2.2 M00001664C:H 10 4892

3287 1/28/98 703 RTA00000198F.1.09.1 M00001664B:D06 361 1

3288 1/28/98 430 RTAOOOOO 198R. 23.1 M00001661 B:C08 8995

3288 1/28/98 294 RTA00000198AF. 23.1 M00001661 B:C08 8995

3289 1/28/98 294 RTA00000198AF. 23.1 M00001661 B:C08 8995

3289 1/28/98 430 RTAOOOOO 198R.L23.1 M00001661 B:C08 8995

3290 1/28/98 754 RTA00000187AF.1.1 1.1 M00001681A:F03 4482

3291 1/28/98 732 RTAOOOOO 186AF.p.01.2 M00001654D:G1 1 40440

3292 1/28/98 475 RTA00000187AR.m.3.3 M00001682C:B12 17055

3293 1/28/98 433 RTA00000198RJ.18.1 M00001653B:G07 22759

3293 1/28/98 92 RTA00000198AF.J.18.1 M00001653B:G07 22759

3294 1/28/98 555 RTAOOOOO 198AF.J.08.1 M00001651 B:A 1 1 10983

3295 1/28/98 399 RTA00000186AF.m. l 5.2 M00001649C:B10 40122

3296 1/28/98 575 RTAOOOOO 186AF.1.12.2 M00001645A:C 12 19267

3297 1/28/98 666 RTA00000198F.i.l 0.1 M00001640B:F03 12792

3298 1/28/98 654 RTAOOOOO 186AF.J.21.2 M00001639D:B07 22506

3299 1/28/98 670 RTA00000186AF.p.l 7.3 M00001656B:A07 38383

3300 1/28/98 393 RTA00000188AF.b.l4.1 M00003754D:D02 0

3301 1/28/98 422 RTA00000189AF.b.l2.1 M00003829B:G03 17233

3301 1/28/98 210 RTA00000189AR.b.l2.1 M00003829B:G03 17233

3302 1/28/98 587 RTAOOOOO 199F.a.3.1 M00003772D:E10 16617

3303 1/28/98 394 RTAOOOOO 198AF.p.22.1 M00003771A:G10 0

3304 1/28/98 542 RTAOOOOO 198R.p.12.1 M00003763D:E10 8878

3304 1/28/98 64 RTAOOOOO 198AF.p.12.1 M00003763D:E10 8878

3305 1/28/98 64 RTAOOOOO 198AF.p.12.1 M00003763D:E10 8878

3305 1/28/98 542 RTAOOOOO 198R.p.12.1 M00003763D:E10 8878

3306 1/28/98 465 RTA00000187AF. 20.1 M00001680B:C01 3648

3307 1/28/98 423 RTA00000188AR.b.17.1 M00003755A:B03 10662

3308 1/28/98 71 1 RTA00000198F. 2.1 M00001637B:E07 8076

3309 1/28/98 497 RTAOOOOO 198 AF.o.09.1 M00003751 B:A05 4310

3309 1/28/98 506 RTA00000198R.O.09.1 M00003751 B:A05 4310

3310 1/28/98 506 RTAOOOOO 198R.O.09.1 M00003751 B:A05 4310

3310 1/28/98 497 RTA00000198AF.O.09.1 M00003751 B:A05 4310

331 1 1/28/98 432 RTA00000198AF.O.05.1 M00003750A:D01 26702

331 1 1/28/98 49 RTA00000198R.O.05.1 M00003750A:D01 26702

3312 1/28/98 49 RTA00000198R.O.05.1 M00003750A:D01 26702

3312 1/28/98 432 RTA00000198AF.O.05.1 M00003750A:D01 26702

3313 1/28/98 585 RTAOOOOO! 98AF.n.18.1 M00001771 A:A07 16715

3314 1/28/98 527 RTA00000198R.m.23.1 M00001684B:G03 38469

3315 1/28/98 471 RTA00000188AF.e.2.1 M00003763B:H01 0

3316 1/28/98 171 RTAOOOOO] 98R.C.07.1 M00001575D:G05 19181

3316 1/28/98 525 RTA00000198AF.C.7.1 M00001575D:G05 19181

3317 1/28/98 557 RTA00000198AF.d.9.1 M00001587D:A10 8841

3318 1/28/98 523 RTA00000198AF.d.4.1 M00001586D:E02 22435

3319 1/28/98 441 RTA00000185AF.e.6.1 M00001583B:E 10 0

3320 1/28/98 439 RTA00000185AF.d. l 4.2 M00001579D:G07 8071

3321 1/28/98 561 RTAOOOOO 185AR.d.10.1 M00001579C:H 10 0 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

3322 1/28/98 277 RTAOOOOO 198AR.Ϊ.08.1 M00001639A:F10 9807

3322 1/28/98 487 RTAOOOOO 198F. 8.1 M00001639A:F10 9807

3323 1/28/98 525 RTAOOOOO 198AF.C.7.1 M00001575D:G05 19181

3323 1/28/98 171 RTA00000198R.C.07.1 M00001575D:G05 19181

3324 2/24/98 317 RTA00000195AF.b.21.1 M00001595B:A09 39055

3324 1/28/98 602 RTA00000195AF.b.21.1 M00001595B:A09 39055

3325 1/28/98 507 RTA00000198AF.C.5.1 M00001573D:F10 53802

3326 1/28/98 414 RTA00000185AR.b. l 5.1 M00001573D:F04 39813

3326 1/28/98 428 RTA00000185AF.b.l 5.2 M00001573D:F04 39813

3327 1/28/98 428 RTA00000185AF.b.l5.2 M00001573D:F04 39813

3327 1/28/98 414 RTA00000185AR.b. l 5.1 M00001573D:F04 39813

3328 1/28/98 414 RTAOOOOO 185AR.b.15.1 M00001573D:F04 39813

3328 1/28/98 428 RTA00000185AF.b.l 5.2 M00001573D:F04 39813

3329 1/28/98 428 RTAOOOOO 185AF.b.15.2 M00001573D:F04 39813

3329 1/28/98 414 RTA00000185AR.b.l 5.1 M00001573D:F04 39813

3330 1/28/98 392 RTA00000185AF.b.l l .2 M00001573C:D03 9024

3331 1/28/98 549 RTA00000198AF.C.16.1 M00001579C:B1 1 26801

3332 1/28/98 628 RTAOOOOO 198AF.g.16.1 M00001621 D:D03 6602

3333 1/28/98 616 RTA00000188AF.m.07.1 M00003798D:E03 23183

3334 1/28/98 489 RTAOOOOO 186 AF.h.22.1 M00001634B:C10 16485

3335 1/28/98 655 RTA00000186AF.g.8.2 M00001630B:A1 1 8065

3336 1/28/98 592 RTA00000186AF.e. l 8.1 M00001624C:A06 0

3337 1/28/98 713 RTAOOOOO 198 AF.g.21.1 M00001624A:F09 6273

3338 1/28/98 554 RTAOOOOO 186AR.e.07.4 M00001623D:G03 4175

3338 1/28/98 400 RTAOOOOO 186AR.e.07.3 M00001623D:G03 4175

3339 1/28/98 467 RTAOOOOO 195AF.b.19.1 M00001589A:D12 77678

3340 1/28/98 646 RTAOOOOO 186AF.d.24.1 M00001623C:H07 31 14

3341 1/28/98 740 RTA00000198AF.d.l 5.1 M00001590C:H08 5997

3342 1/28/98 504 RTA00000198AF.g.2.1 M00001615C:D02 16640

3343 1/28/98 470 RTA00000198AF.f.l 6.1 M00001614A:E06 0

3344 1/28/98 388 RTAOOOOO 185AF.ιι.17.1 M00001609B:A1 1 5336

3345 1/28/98 495 RTA00000185AF.J.21.1 M00001597A:E12 0

3346 2/24/98 317 RTAOOOOO 195 AF.b.21.1 M00001595B:A09 39055

3346 1/28/98 602 RTA00000195AF.b.21.1 M00001595B:A09 39055

3347 1/28/98 487 RTA00000198F.i.8.1 M00001639A:F10 9807

3347 1/28/98 277 RTAOOOOO 198AR. 08.1 M00001639A:F10 9807

3348 1/28/98 554 RTAOOOOO 186AR.e.07.4 M00001623D:G03 4175

3348 1/28/98 400 RTAOOOOO 186AR.e.07.3 M00001623D:G03 4175

3349 1/28/98 699 RTAOOOOO 178AF.a.12.1 M00001362B:H06 0

3350 1/28/98 416 RTA00000199F.a.5.1 M00003773B:G01 22134

3351 1/28/98 656 RTAOOOOO 178AR.h.22.3 M00001376B:A08 19230

3351 1/28/98 657 RTA00000178AR.h.22.2 M00001376B:A08 19230

3351 2/24/98 1 137 RTA00000345F.d.03.1 M00001376B:A08 19230

3352 1/28/98 656 RTA00000178AR.h.22.3 M00001376B:A08 19230

3352 1/28/98 657 RTAOOOOO 178AR.h.22.2 M00001376B:A08 19230

3352 2/24/98 1 137 RTA00000345F.d.03.1 M00001376B:A08 19230

3353 1/28/98 522 RTA00000178AR.h.l 7.2 M00001376A:C05 23824

3353 2/24/98 1095 RTAOO000345F.C.12.1 M00001376A:C05 23824

3354 1/28/98 522 RTAOO000178AR.h.l 7.2 M00001376A:C05 23824

3354 2/24/98 1095 RTA00000345F.C.12.1 M00001376A:C05 23824 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

3355 1/28/98 656 RTAOOOOO 178 AR.h.22.3 MO0001376B:A08 19230

3355 1/28/98 657 RTAOOOOO 178AR.h.22.2 M00001376B:A08 19230

3355 2/24/98 1 137 RTA00000345F.d.03.1 M00001376B:A08 19230

3356 1/28/98 566 RTA00000195F.a.4.1 M00001372C:G 12 20470

3357 1/28/98 657 RTAOOOOO 178AR.h.22.2 M00001376B:A08 19230

3357 1/28/98 656 RTAOOOOO 178AR.h.22.3 M00001376B:A08 19230

3357 2/24/98 1 137 RTA00000345F.d.03.1 M00001376B:A08 19230

3358 1/28/98 605 RTAOOOOO 196F.e.9.1 M00001361 A:H07 23300

3359 1/28/98 532 RTAOOOOO 177AF.o.4.1 M00001358C:C06 0

3360 1/28/98 493 RTAOOOOO 177AF.m.17.1 M00001355B:G10 14391

3360 1/28/98 330 RTAOOOOO 177AR.m.17.4 M00001355B:G 10 14391

3360 1/28/98 337 RTA00000177AR.m.l 7.3 M00001355B:G10 14391

3361 1/28/98 330 RTA00000177AR.m. l 7.4 M00001355B:G10 14391

3361 1/28/98 493 RTA00000177AF.ni.17.1 M00001355B:G 10 14391

3361 1/28/98 337 RTAOOOOO 177AR.m.17.3 M00001355B:G10 14391

3362 1/28/98 337 RTA00000177AR.m.l 7.3 M00001355B:G 10 14391

3362 1/28/98 493 RTAOOOOO 177AF.m.17.1 M00001355B:G 10 14391

3362 1/28/98 330 RTA00000177AR.m.l 7.4 M00001355B:G 10 14391

3363 1/28/98 742 RTAOOOOO 177AF.m.1.1 M00001353D:D10 14929

3364 1/28/98 547 RTA00000196AF.g.8.1 M00001375B:G 12 39665

3365 1/28/98 510 RTA00000178AF.n.23.1 M00001387B:E02 3298

3366 1/28/98 606 RTA00000179AR.e.01.4 M00001395A:C09 2493

3367 2/24/98 1065 RTA00000195 R.a.06.1 M00001394A:E04 35265

3367 1/28/98 595 RTA00000195R.a.06.1 M00001394A:E04 35265

3368 2/24/98 1065 RTA00000195R.a.06.1 M00001394A:E04 35265

3368 1/28/98 595 RTA00000195R.a.06.1 M00001394A:E04 35265

3369 1/28/98 370 RTA00000179AF.C.15.3 M00001392D:H06 2995

3369 1/28/98 460 RTA00000179AF.C.15.1 M00001392D:H06 2995

3370 1/28/98 370 RTAOOOOO 179AF.C.15.3 M00001392D:H06 2995

3370 1/28/98 460 RTA00000179AF.C.15.1 M00001392D:H06 2995

3371 1/28/98 657 RTA00000178AR.h.22.2 M00001376B:A08 19230

3371 1/28/98 656 RTAOOOOO 178AR.h.22.3 M00001376B:A08 19230

3371 2/24/98 1 137 RTA00000345F.d.03.1 M00001376B:A08 19230

3372 1/28/98 675 RTA00000179AR.b.21.3 M00001392C:D05 4366

3372 2/24/98 1264 RTA00000345F.e.l3.1 M00001392C:D05 4366

3373 1/28/98 168 RTA00000177AR.L23.1 M00001352D:D02 35550

3373 1/28/98 463 RTAOOOOO 177 AR.k.23.4 M00001352D:D02 35550

3374 1/28/98 652 RTA00000178AR.m.21.4 MO0001385A:F12 7861

3374 1/28/98 653 RTA00000178AR.m.21.5 M00001385A:F12 7861

3375 1/28/98 653 RTA00000178AR.m.21.5 M00001385A:F 12 7861

3375 1/28/98 652 RTA00000178AR.m.21 .4 M00001385A:F12 7861

3376 1/28/98 672 RTAOOOOO 196AF.h.09.1 M00001382B:F12 8015

3377 1/28/98 668 RTA00000178AF.i.l 7.1 M00001377C:E12 0

3378 1/28/98 746 RTA00000178AF.i.01.2 M00001376B:F03 4

3379 1/28/98 656 RTAOOOOO 178AR.h.22.3 M00001376B:A08 19230

3379 1/28/98 657 RTA00000178AR.h.22.2 M00001376B:A08 19230

3379 2/24/98 1 137 RTA00000345F.d.03.1 M00001376B:A08 19230

3380 1/28/98 675 RTAOOOOO 179 AR.b.21.3 M00001392C:D05 4366

3380 2/24/98 1264 RTA00000345F.e. l 3.1 M00001392C:D05 4366

3381 1/28/98 651 RTAOOOOO 189AR.d.22.2 M00003844C:B 1 1 6539 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

3382 1/28/98 444 RTA00000189AF.1.16.1 M00003879A:G05 0

3383 1/28/98 648 RTA00000199F.i.9.1 M00003878C:E04 7

3384 2/24/98 678 RTAOOOOO 195 AF.c.24.1 M00003860D:H07 0

3384 1/28/98 412 RTA00000195AF.C.24.1 M00003860D:H07 0

3385 1/28/98 412 RTAOOOOO 195 AF.c.24.1 M00003860D:H07 0

3385 2/24/98 678 RTA00000195 AF.c.24.1 M00003860D:H07 0

3386 1/28/98 484 RTAOOOOO 199F.g.20.2 M00003860D:A01 15767

3387 1/28/98 398 RTA00000177AR.1.13.3 M00001353A:G12 8078

3388 1/28/98 556 RTAOOOOO 199FT.17.2 M00003845D:B04 22905

3389 1/28/98 545 RTA00000196F.a.2.1 M00001338B:E02 3575

3390 1/28/98 406 RTAOOOOO 199F.f.09.2 M00003842B:D09 22907

3390 1/28/98 78 RTAOOOOO 199R.f.09.1 M00003842B:D09 22907

3391 1/28/98 78 RTAOOOOO 199R.f.09.1 M00003842B:D09 22907

3391 1/28/98 406 RTA00000199F.f.09.2 M00003842B:D09 22907

3392 1/28/98 692 RTA00000199F.e.4.1 M00003820B:C05 0

3393 1/28/98 458 RTA00000199R.d.l6.1 M00003812C:A05 24191

3394 1/28/98 755 RTAOOOOO 199F.C.21.2 M00003803C:D09 5070

3395 1/28/98 505 RTA00000188AF.11.03.1 M00003801B:B10 9443

3396 1/28/98 714 RTA00000199R.g.07.1 M00003853D:D03 0

3397 1/28/98 724 RTAOOOOO 177ART.15.4 M00001345B:E10 9062

3398 1/28/98 623 RTAOOOOO 198R.b.24.1 M00001571D:B11 19047

3398 1/28/98 748 RTAOOOOO 198 AF.b.24.1 M00001571D:B11 19047

3399 1/28/98 395 RTAOOOOO 196R.C.21.2 M00001352C:H10 0

3400 1/28/98 593 RTAOOOOO 196R.C.14.2 M00001352B:F04 23105

3400 1/28/98 485 RTAOOOOO 196AF.C.14.1 M00001352B:F04 23105

3401 1/28/98 485 RTA00000196AF.C.14.1 M00001352B:F04 23105

3401 1/28/98 593 RTA00000196R.C.14.2 M00001352B:F04 23105

3402 1/28/98 645 RTA00000177AF.L9.1 M00001352A:E02 16245

3403 1/28/98 576 RTAOOOOO 196AF.C.7.1 M00001350B:G11 0

3404 1/28/98 737 RTA00000189AR.m.9.1 M00003880B:C08 2917

3405 1/28/98 728 RTA00000177ART.17.4 M00001345C:B01 8594

3406 1/28/98 453 RTA00000199AF. 20.1 M00003881A:D09 9544

3407 1/28/98 440 RTAOOOOO 177AR .13.4 M00001345A:G11 10480

3408 1/28/98 680 RTAOOOOO 177AFT.10.1 M00001345A:E01 6420

3409 1/28/98 573 RTAOOOOO 196AF.b.7.1 M00001344A:G07 7774

3410 1/28/98 402 RTAOOOOO 177AF.b.21.4 M00001341A:F12 4443

3411 1/28/98 702 RTA00000177AR.b.8.5 M00001340B:A06 17062

3412 1/28/98 463 RTA00000177AR.k.23.4 M00001352D:D02 35550

3412 1/28/98 168 RTA00000177AR. 23.1 M00001352D:D02 35550

3413 1/28/98 600 RTAOOOOO 177AF.g.4.1 M00001346B:B07 4119

3414 1/28/98 280 RTAOOOOO 193AF.b.18.1 M00004233C:H09 7542

3415 1/28/98 748 RTAOOOOO 198 AF.b.24.1 M00001571D:B11 19047

3415 1/28/98 623 RTA00000198R.b.24.1 M00001571D-.B11 19047

3416 1/28/98 249 RTA00000200R.O.03.2 M00004257C:H06 22807

3416 1/28/98 178 RTA00000200F.O.03.1 M00004257C-.H06 22807

3416 1/28/98 85 RTA00000200R.O.03.1 M00004257C:H06 22807

3417 1/28/98 282 RTAOOOOO 193AF.C.15.1 M00004248B:E08 3726

3418 1/28/98 307 RTA00000200F.n.05.2 M00004246C:A09 18989

3418 1/28/98 319 RTA00000200F.n.05.1 M00004246C:A09 18989

3419 1/28/98 319 RTA00000200F.ii.05.! M00004246C:A09 18989 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority' Priority Appln Appln

3419 1/28/98 307 RTA00000200F.n.05.2 M00004246C:A09 18989

3420 1/28/98 85 RTA00000200R.O.03.1 M00004257C:H06 22807

3420 1/28/98 249 RTA00000200R.O.03.2 M00004257C:H06 22807

3420 1/28/98 178 RTA00000200F.O.03.1 M00004257C:H06 22807

3421 1/28/98 307 RTA00000200F.n.05.2 M00004246C:A09 18989

3421 1/28/98 319 RTA00000200F.n.05.1 M00004246C:A09 18989

3422 1/28/98 50 RTA00000201 R.a.02.1 M00004295B:D02 35362

3422 1/28/98 235 RTA00000201 AF.a.02.1 M00004295B:D02 35362

3423 1/28/98 251 RTAOOOOO 192AF.n.13.1 M00004197D:H01 8210

3424 1/28/98 47 RTAOOOOO 192 AF.m.12.1 M00004191 D:B1 1 0

3425 1/28/98 494 RTA00000200AF.k. l . l M00004188C:A09 40049

3425 1/28/98 194 RTA00000200R.k.01.1 M00004188C:A09 40049

3426 1/28/98 494 RTA00000200AF. 1.1 M00004188C:A09 40049

3426 1/28/98 194 RTA00000200R.k.01.1 M00004188C:A09 40049

3427 1/28/98 231 RTA00000192AF.I.13.2 M00004185C:C03 1 1443

3428 1/28/98 382 RTA00000200AF.J.6.1 M00004176B:E08 22902

3429 1/28/98 307 RTA00000200F.11.05.2 M00004246C:A09 18989

3429 1/28/98 319 RTA00000200F.n.05.1 M00004246C:A09 18989

3430 1/28/98 52 RTA00000201 R.b.02.1 M00004319D:G09 22660

3431 1/28/98 271 RTA00000201 F.d.02.1 M00004375A:H01 2599

3431 1/28/98 239 RTA00000201 R.d.02.1 M00004375A:II01 2599

3431 1/28/98 227 RTA00000201 R.d.02.2 M00004375A:H01 2599

3432 1/28/98 227 RTA00000201 R.d.02.2 M00004375A:H01 2599

3432 1/28/98 239 RTA00000201 R.d.02.1 M00004375A:H01 2599

3432 1/28/98 271 RTA00000201 F.d.02.1 M00004375A:H01 2599

3433 1/28/98 227 RTA00000201 R.d.02.2 M00004375A:H01 2599

3433 1/28/98 271 RTA00000201 F.d.02.1 M00004375A:H01 2599

3433 1/28/98 239 RTA00000201 R.d.02.1 M00004375A:H01 2599

3434 1/28/98 271 RTA00000201 F.d.02.1 M00004375A:H01 2599

3434 1/28/98 239 RTA00000201 R.d.02.1 M00004375A:H01 2599

3434 1/28/98 227 RTA00000201 R.d.02.2 M00004375A:H01 2599

3435 1/28/98 227 RTA00000201 R.d.02.2 M00004375A:H01 2599

3435 1/28/98 271 RTA00000201 F.d.02.1 M00004375A:H01 2599

3435 1/28/98 239 RTA00000201 R.d.02.1 M00004375A:H01 2599

3436 1/28/98 178 RTA00000200F.O.03.1 M00004257C:H06 22807

3436 1/28/98 249 RTA00000200R.O.03.2 M00004257C:H06 22807

3436 1/28/98 85 RTA00000200R.O.03.1 M00004257C:H06 22807

3437 1/28/98 273 RTA00000201 F.C.08.1 M00004353C:H07 0

3438 1/28/98 328 RTA00000200AF.g.09.1 M00004131 B:H09 22785

3438 1/28/98 26 RTA00000200R.g.09.1 M00004131 B:H09 22785

3439 2/24/98 571 RTA00000355R.e.l4.1 M00004314B:G07 16837

3439 1/28/98 343 RTA00000201 F.a.l 8.1 M00004314B:G07 16837

3440 1/28/98 343 RTA00000201 F.a.l 8.1 M00004314B:G07 16837

3440 2/24/98 571 RTA00000355R.e.l4.1 M00004314B:G07 16837

3441 1/28/98 164 RTAOOOOO 193AR.i.14.4 M00004307C:A06 9457

3442 1/28/98 50 RTA00000201 R.a.02.1 M00004295B:D02 35362

3442 1/28/98 235 RTA00000201AF.a.02.1 M00004295B:D02 35362

3443 1/28/98 235 RTA00000201AF.a.02.1 M00004295B:D02 35362

3443 1/28/98 50 RTA00000201 R.a.02.1 M00004295B:D02 35362

3444 1/28/98 50 RTA00000201 R.a.02.1 M00004295B:D02 35362 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

3444 1/28/98 235 RTA00000201 AF.a.02.1 M00004295B:D02 35362

3445 1/28/98 227 RTA00000201 R.d.02.2 M00004375A:H01 2599

3445 1 /28/98 271 RTA00000201 F.d.02.1 M00004375A:H01 2599

3445 1/28/98 239 RTA00000201 R.d.02.1 M00004375A:H01 2599

3446 1/28/98 13 RTA00000190AF.L5.1 M00003919A:A10 0

3447 1/28/98 72 RTA00000200F.a.6.1 M00004029B:F1 1 36952

3448 1/28/98 101 RTAOOOOO 191 AF.d.08.2 M00003997B:G07 970

3449 1/28/98 79 RTAOOOOO 199AF.p.4.1 M00003985C:F01 10282

3450 1/28/98 121 RTAOOOOO 199AF.0.16.1 M00003979A:F03 16721

3451 1/28/98 193 RTAOOOOO 199AF.n.3.1 M00003946D:C1 1 0

3452 1/28/98 165 RTAOOOOO 192 AF.g.23.1 M00004157C:A09 6455

3453 1/28/98 381 RTAOOOOO 199AF.ni.14.1 M00003938A:B04 10580

3454 1/28/98 123 RTAOOOOO 191 AF.k.6.1 M00004078B:A1 1 5451

3455 1/28/98 102 RTAOOOOO 199R.J.08.1 M00003884D:G07 37844

3456 1/28/98 86 RTA00000189AF.1.22.1 M00003879C:G 10 33333

3457 1 /28/98 148 RTAOOOOO 199F.li.17.2 M00003871 A:A05 36254

3458 1/28/98 143 RTA00000199R.h.09.1 M00003867C:H09 76020

3459 1/28/98 266 RTAOOOOO 199FT.21.2 M00003847C:E09 13344

3460 2/24/98 153 RTA00000422F.g.22.1 M00001585B:A06 22561

3461 1/28/98 292 RTAOOOOO 199AF.ni.18.1 M00003939C:F04 0

3462 1/28/98 275 RTA00000191 AF.O.17.2 M00004102A:H02 5957

3462 1/28/98 274 RTA00000191 AF.O.17.1 M00004102A:H02 5957

3463 1/28/98 239 RTA00000201 R.d.02.1 M00004375A:H01 2599

3463 1/28/98 271 RTA00000201 F.d.02.1 M00004375A:H01 2599

3463 1/28/98 227 RTA00000201 R.d.02.2 M00004375A:H01 2599

3464 1 /28/98 328 RTA00000200AF.g.09.1 M00004131 B:H09 22785

3464 1/28/98 26 RTA00000200R.g.09.1 M00004131 B:H09 22785

3465 1 /28/98 214 RTA00000200AF.f.22.1 M00004121 C:F06 16521

3466 1/28/98 160 RTAOOOOO 192 AF.b.20.1 M000041 18D:E08 0

3467 1 /28/98 98 RTA00000200AF.f.l4.1 M000041 15D:C08 22051

3467 1/28/98 100 RTA00000200R.f.l4.1 M000041 15D:C08 22051

3468 1/28/98 98 RTA00000200AFT.14.1 M000041 15D:C08 22051

3468 1/28/98 100 RTA00000200RT.14.1 M000041 15D:C08 22051

3469 1/28/98 305 RTA00000200AF.b. l 5.1 M00004040D:F01 10627

3470 1/28/98 98 RTA00000200AFT.14.1 M000041 15D:C08 22051

3470 1/28/98 100 RTA00000200RT.14.1 M000041 15D:C08 22051

3471 1/28/98 29 RTA00000200AF.b.l 9.1 M00004042D:H02 22847

3472 1/28/98 274 RTA00000191 AF.O.17.1 M00004102A:H02 5957

3472 1/28/98 275 RTAOOOOO 191 AF.o.17.2 M00004102A:H02 5957

3473 1/28/98 274 RTA00000191AF.O.17.1 M00004102A:H02 5957

3473 1/28/98 275 RTAOOOOO 191 AF.o.17.2 M00004102A:H02 5957

3474 1/28/98 275 RTAOOOOO 191 AF.o.17.2 M00004102A:H02 5957

3474 1/28/98 274 RTA00000191 AF.O.17.1 M00004102A:H02 5957

3475 1/28/98 226 RTAOOOOO 191 AR.o.09.4 M00004096A:G02 0

3476 1/28/98 40 RTA00000200AR.e.02.1 M00004090A:F09 36059

3477 1/28/98 175 RTA00000200F. 5.1 M00004156B:A12 22892

3478 1 /28/98 98 RTA00000200AF.f.l 4.1 M000041 15D:C08 22051

3478 1/28/98 100 RTA00000200R.f. l4.1 M000041 15D:C08 22051

3479 1/28/98 643 RTA00000184AF.C.9.1 M00001546C:G10 16245

3480 1/28/98 615 RTA00000197R.p.20.1 M00001554B:B07 22795 SEQ ID Filing SEQ ID Sequence Name Clone Nsme Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

3480 1/28/98 559 RTA00000197AF.p.20.1 M00001554B:B07 22795

3481 1/28/98 660 RTAOOOOO 197AF.p.16.1 M00001552D:G08 6013

3482 1/28/98 521 RTAOOOOO 197AF.p.12.1 M00001552B:G05 0

3483 1/28/98 403 RTA00000184AF.f.l3.1 M00001550D:H02 3784

3484 1/28/98 517 RTAOOOOO 184AF.e.14.1 M00001549C:D02 16347

3485 1/28/98 676 RTAOOOOO 197AR.m.14.1 M00001531B:E09 14879

3486 1/28/98 596 RTAOOOOO 184AF.d.9.1 M00001548A:B11 6515

3487 1/28/98 559 RTA00000197AF.p.20.1 M00001554B:B07 22795

3487 1/28/98 615 RTA00000197R.p.20.1 M00001554B:B07 22795

3488 1/28/98 729 RTAOOOOO 184AF.3.19.1 M00001544C:C06 2628

3489 1/28/98 682 RTA00000125A.J.16.1 M00001544A:E06 0

3490 1/28/98 723 RTAOOOOO 183 AF.p.24.1 M00001543C:F01 3116

3491 1/28/98 509 RTAOOOOO 183AF.p.17.1 M00001543A:H12 5158

3492 1/28/98 738 RTA00000183AF.O.8.1 M00001540C:B10 8927

3493 1/28/98 227 RTA00000201R.d.02.2 M00004375A:H01 2599

3493 1/28/98 271 RTA00000201F.d.02.1 M00004375A:H01 2599

3493 1/28/98 239 RTA00000201R.d.02.1 M00004375A:H01 2599

3494 1/28/98 502 RTAOOOOO 197AF.0.23.1 M00001549A:A09 12682

3495 1/28/98 468 RTA00000198AF.3.18.1 M00001561C:E11 0

3496 1/28/98 210 RTAOOOOO 189AR.b.12.1 M00003829B:G03 17233

3496 1/28/98 422 RTAOOOOO 189AF.b.12.1 M00003829B:G03 17233

3497 1/28/98 748 RTAOOOOO 198AF.b.24.1 M00001571D:B11 19047

3497 1/28/98 623 RTA00000198R.b.24.1 M00001571D:B11 19047

3498 1/28/98 397 RTAOOOOO 198AF.b.22.1 M00001571B:E03 38956

3499 1/28/98 571 RTAOOOOO 198AF.b.14.1 M00001569C:B06 801

3500 1/28/98 492 RTAOOOOO 198AF.b.8.1 M00001567C:H12 22636

3500 1/28/98 23 RTA00000198R.b.08.1 M00001567C:H12 22636

3501 1/28/98 492 RTAOOOOO 198AF.b.8.1 M00001567C:H12 22636

3501 1/28/98 23 RTA00000198R.b.08.1 M00001567C:H12 22636

3502 1/28/98 559 RTA00000197AF.p.20.1 M00001554B:B07 22795

3502 1/28/98 615 RTA00000197R.p.20.1 M00001554B:B07 22795

3503 1/28/98 727 RTA00000184AF.il.12.2 M00001561D:C11 3727

3504 1/28/98 559 RTA00000197AF.p.20.1 M00001554B:B07 22795

3504 1/28/98 615 RTA00000l97R.p.20.1 M00001554B:B07 22795

3505 1/28/98 641 RTA00000198F.3.10.1 M00001558A:E11 6695

3506 1/28/98 731 RTA00000184F.k.02.1 M00001557B:H10 5192

3507 1/28/98 597 RTA00000198F.a.4.1 M00001557A:F01 9635

3508 1/28/98 560 RTA00000184AF. 23.3 M00001556A:F11 1577

3509 1/28/98 601 RTA00000184AF.i.l0.2 M00001555A:B01 3744

3510 1/28/98 700 RTA00000183AF. 18.2 M00001529D:H02 40129

3511 1/28/98 437 RTAOOOOO 198R.3.23.1 M00001563B:D11 10700

3512 1/28/98 591 RTAOOOOO 197AF.h.1.1 M00001470A:H01 13075

3512 1/28/98 110 RTA00000197R.h.01.1 M00001470A:H01 13075

3513 1/28/98 259 RTAOOOOO 197 AF.j .4.1 M00001492D:A11 17209

3513 1/28/98 386 RTAOOOOO 197AR.J .04.1 M00001492D:A11 17209

3514 1/28/98 386 RTA00000197AR.J.04.1 M00001492D:A11 17209

3514 1/28/98 259 RTAOOOOO 197 AF.j .4.1 M00001492D:A11 17209

3515 1/28/98 644 RTAOOOOO 197F.i.12.1 M00001489B:A06 3605

3516 1/28/98 633 RTA00000197F.i.8.1 M00001488A:E01 6292

3517 1/28/98 546 RTA00000197F.i.6.1 M00001487C:D06 12149 SEQ ID Filing SEQ ID Sequence Nsme Clone Nsme Cluster

NO: D3te of NO: in ID

Priority Priority

Appln Appln

3518 1/28/98 650 RTAOOOOO 183AR.n.17.1 M00001539B:H06 9800

3519 1/28/98 513 RTA00000197AF.h. l4. ] M00001477B:F04 7045

3520 1/28/98 519 RTAOOOOO 183 AF.a.24.2 M00001499B:A1 1 10539

3521 1/28/98 1 10 RTAOOOOO 197R.h.01.1 M00001470A:H01 13075

3521 1/28/98 591 RTAOOOOO 197AF.h.1.1 M00001470A:H01 13075

3522 1/28/98 446 RTAOOOOO 182 AF.a.23.3 M00001463A:F06 9755

3523 1/28/98 739 RTA00000181 AF.p.l2.3 M00001460C:H02 22204

3524 1/28/98 635 RTA00000181 AF.p.7.3 M00001460A:E01 38773

3525 1/28/98 720 RTAOOOOO 197AFT.14.1 M00001459B:C09 3732

3526 1/28/98 623 RTAOOOOO 198R.b.24.1 M00001571 D:B1 1 19047

3526 1/28/98 748 RTAOOOOO 198 AF.b.24.1 M00001571 D:B1 1 19047

3527 1/28/98 419 RTAOOOOO 182AF.J .20.1 M00001483B:D03 4769

3528 1/28/98 632 RTA00000183AR.g.03.1 M00001512D:G09 3956

3528 1/28/98 630 RTAOOOOO 183 AR.g.03.2 M00001512D:G09 3956

3529 1/28/98 695 RTAOOOOO 197F.m.5.1 M00001528C:H04 10872

3530 1/28/98 479 RTA00000197R.1.22.1 M00001528A:C 1 1 6962

3530 1/28/98 665 RTAOOOOO 197AF.1.22.1 M00001528A:C 1 1 6962

3531 1/28/98 479 RTAOOOOO 197R.1.22.1 M00001528A:C 1 1 6962

3531 1/28/98 665 RTA00000197AF.1.22.1 M00001528A:C1 1 6962

3532 1/28/98 479 RTA00000197R.1.22.1 M00001528A:C1 1 6962

3532 1/28/98 665 RTAOOOOO 197AF.1.22.1 M00001528A:C1 1 6962

3533 1/28/98 479 RTA00000197R.1.22.1 M00001528A:C1 1 6962

3533 1/28/98 665 RTAOOOOO 197AF.1.22.1 M00001528A:C1 1 6962

3534 1/28/98 550 RTAOOOOO 183AF.g.14.1 M00001513D:A03 0

3535 1/28/98 404 RTAOOOOO 195 AF.b.6.1 M00001496C:G10 39490

3536 1/28/98 630 RTAOOOOO 183 AR.g.03.2 M00001512D:G09 3956

3536 1/28/98 632 RTAOOOOO 183 AR.g.03.1 M00001512D:G09 3956

3537 1/28/98 570 RTA00000183AF.3.19.2 M00001499A:A05 3788

3538 1/28/98 630 RTA00000183AR.g.03.2 M00001512D:G09 3956

3538 1/28/98 632 RTAOOOOO 183 AR.g.03.1 M00001512D:G09 3956

3539 1/28/98 603 RTAOOOOO 183 AR.d.1 1 .3 M00001504D:G06 6420

3540 1/28/98 715 RTA00000197AR.k. l l . l M00001500D:E10 53758

3541 1/28/98 503 RTAOOOOO 197AF.L9.1 M00001500C:C08 3138

3542 1/28/98 719 RTAOOOOO 183AF.b.12.1 M00001500A:B02 0

3543 1/28/98 271 RTA00000201 F.d.02.1 M00004375A:H01 2599

3543 1/28/98 239 RTA00000201 R.d.02.1 M00004375A:H01 2599

3543 1/28/98 227 RTA00000201 R.d.02.2 M00004375A:H01 2599

3544 1/28/98 630 RTAOOOOO 183 AR.g.03.2 M00001512D:G09 3956

3544 1/28/98 632 RTAOOOOO 183 AR.g.03.1 M00001512D:G09 3956

3545 3/24/98 15 RTA00000425F.J.14.1 M00001639D:C 12 73397

3546 3/24/98 1 1 1 RTA00000425F.d.08.1 M00001631 A:F06 74350

3547 3/24/98 152 RTA00000425F.d.07.1 M00001631 A:F12 43197

3548 3/24/98 147 RTA00000425F.d.21.1 M00001631 B:H04 78920

3549 3/24/98 77 RTA00000425F.U 7.1 M00001633A:F1 1 43213

3550 3/24/98 418 RTA00000425F.i.l 8.1 M00001633A:G 10 42255

3551 3/24/98 197 RTA00000425F.J.20.1 M00001633B:A12 26760

3552 3/24/98 143 RTA00000425F.J.22.1 M00001633B:E03 73882

3553 3/24/98 283 RTA00000425F.k.20.1 M00001633C:A08 74048

3554 3/24/98 139 RTA00000425F. 22.1 M00001633C:E12 78123

3555 2/24/98 870 RTA00000418F.n.24.1 M00001659D:C09 73153 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

3556 3/24/98 403 RTA00000425F.n. l 7.1 M00001636A:H 12 78304

3557 2/24/98 1 109 RTA00000422FT.22.1 M00001584A:G03 38703

3558 3/24/98 150 RTA00000424F.d.04.1 M00001478A:F12 76505

3558 3/24/98 149 RTA00000424F.d.04.3 M00001478A:F12 76505

3559 3/24/98 358 RTA00000425F.n. l 9.1 M00001638B:C08 78324

3560 3/24/98 165 RTA00000425F.e.21.1 M00001629D:D10 77203

3561 3/24/98 443 RTA00000425F.k. l 6.1 M00001640A:F05 75282

3562 3/24/98 252 RTA00000425F.IT1.03.1 M00001642D:G08 76045

3563 3/24/98 1 16 RTA00000425F.n.05.1 M00001647D:G07 73965

3564 3/24/98 425 RTA00000522F.L07.2 M00001649A:E10 78377

3565 ' 3/24/98 445 RTA00000522F.J.08.2 M00001650D:D10 76613

3566 3/24/98 371 RTA00000522F.J.09.2 M00001650D:F1 1 78522

3567 3/24/98 97 RTA00000522F.J.14.2 M00001651C:D1 1 73123

3568 3/24/98 69 RTA00000522F.J.15.2 M00001651 C:G12 76535

3569 3/24/98 373 RTA00000522F.J.19.2 M00001652B:D06 76224

3570 3/24/98 93 RTA00000522F. 14.1 M00001652D:G02 74280

3571 3/24/98 50 RTA00000522F.k. l 5.1 M00001652D:G06 76866

3572 3/24/98 141 RTA00000522F. 19.1 M00001653A:A05 32625

3573 3/24/98 409 RTA00000425F.1.10.1 M00001638A:C08 26893

3574 2/24/98 443 RTA00000414F.f. l 5.1 M00005260A:A12 0

3575 2/24/98 886 RTA00000420F.m. l 5.1 M00005235B:F10 0

3576 2/24/98 260 RTA00000414F.e.08.1 M00005236A:E04 0

3577 2/24/98 734 RTA00000414F.e.09.1 M00005236A:G10 0

3578 2/24/98 1077 RTA00000414F.e.l l .l M00005236B:A12 0

3579 2/24/98 970 RTA00000414F.e.l5.1 M00005236B:G03 0

3580 2/24/98 271 RTA00000414F.e.l6.1 M00005236B:H10 0

3581 2/24/98 58 RTA00000420F.m.l 8.1 M00005254D:A10 0

3582 2/24/98 289 RTA00000420F.n.08.1 M00005257A:H1 1 0

3583 2/24/98 1033 RTA00000414F.e.l 9.1 M00005257C:E05 0

3584 2/24/98 793 RTA00000414F.e.21.1 M00005257C:G01 0

3585 2/24/98 36 RTA00000414F.e.22.1 M00005257D:A06 0

3586 2/24/98 852 RTA00000414F.f.03.1 M00005257D:G07 0

3587 3/24/98 341 RTA00000425F.d.06.1 M00001631A:D03 77660

3588 2/24/98 961 RTA00000420F.n.21.2 M00005259B:D12 0

3589 3/24/98 441 RTA00000528F.g.22.2 M00001630C:F09 920

3590 2/24/98 940 RTA00000414FT.17.1 M00005260A:F04 0

3591 2/24/98 160 RTA00000414FT.19.1 M00005260B:E1 1 0

3592 3/24/98 140 RTA00000424F.m. l4.1 M00001612D:D12 77491

3593 3/24/98 34 RTA00000424F.m.l 5.1 M00001612D:F06 73759

3594 3/24/98 212 RTA00000424F.n.06.1 M00001613A:D02 74737

3595 3/24/98 308 RTA00000424F.k.23.1 M00001614A:B10 31061

3596 3/24/98 372 RTA00000424F.m.24.1 M00001614C:G07 77045

3597 3/24/98 396 RTA00000528F.g.05.2 M00001615C:E07 3770

3598 3/24/98 296 RTA00000425F.e.02.1 M00001625C:F10 76143

3599 3/24/98 99 RTA00000425F.C.20.1 M00001626D:A02 73581

3600 3/24/98 442 RTA00000425F.d. l4.1 M00001629A:H09 13417

3601 3/24/98 357 RTA00000425F.e. l 9.1 M00001629D:B10 73409

3602 2/24/98 210 RTA00000419F.p.24.1 M00004039B:E12 63477

3603 2/24/98 501 RTA00000414F.f.05.1 M00005257D:H 1 1 0

3604 2/24/98 561 RTA00000420F.e.10.1 M00004108D:G04 65899 SEQ ID Filing SEQ ID Sequence Name Clone Nsrne Cluster

NO: Date of NO: in ID

Priority Priority

Appln Appln

3605 2/24/98 758 RTA00000407F.a.01.1 M00004039A:H 1 1 12501

3606 2/24/98 688 RTA00000413F.d.23.1 M00004090B:H06 66030

3607 2/24/98 124 RTA00000420F.d.05.1 M00004092B:E05 64432

3608 2/24/98 329 RTA00000413F.e.l 6.1 M00004093C:C02 63836

3609 2/24/98 359 RTA00000420F.d.l2.1 M00004096D:H03 64095

3610 2/24/98 429 RTA00000422F.C.17.1 M00004099D:F01 1360

361 1 2/24/98 630 RTA00000413F.f. l 9.1 M00004100B:C07 65189

3612 2/24/98 439 RTA00000413F.g.23.1 M00004103B:E09 40700

3613 2/24/98 3 RTA00000420F.d. l 8.1 M00004105C:B05 63074

3614 2/24/98 1064 RTA00000420F.d.l9.1 M00004105C:C08 43146

3615 2/24/98 671 RTA00000413F.h. l2.1 M00004107A:A12 66929

3616 2/24/98 507 RTA00000420F.e.02.1 M00004107B:D07 40259

3617 2/24/98 319 RTA00000420F.b.21.1 M00004088D:B10 65057

3618 2/24/98 931 RTA00000420F.e.09.1 M00004108D:E07 66325

3619 2/24/98 840 RTA00000420F.b.20.1 M00004088D:B05 0

3620 2/24/98 545 RTA00000420F.e.l 5.1 M000041 10A:A10 20190

3621 2/24/98 981 RTA00000420F.e.20.1 M000041 10B:A07 64762

3622 3/24/98 370 RTA00000424F.d.l9.3 M00001448B:A07 73180

3623 3/24/98 370 RTA00000424F.d. l9.3 M00001448B:A07 73180

3624 3/24/98 189 RTA00000424F.d.22.3 M00001448B:G07 76189

3625 3/24/98 189 RTA00000424F.d.22.3 M00001448B:G07 76189

3626 3/24/98 92 RTA00000424F.a.24.4 M00001448D:E1 1 73951

3627 3/24/98 92 RTA00000424F.a.24.4 M00001448D:E1 1 73951

3628 3/24/98 279 RTA00000528F.b.03.1 M00001455A:D10 2078

3629 3/24/98 279 RTA00000528F.b.03.1 M00001455A:D10 2078

3630 3/24/98 480 RTA00000424F.d.l 7.3 M00001455A:E1 1 73958

3631 3/24/98 480 RTA00000424F.d. l 7.3 M00001455A:E1 1 73958

3632 2/24/98 583 RTA00000406F.U 7.1 M00003904B:C03 37902

3633 2/24/98 590 RTA00000407F.b.22.1 M00004108B:B02 37487

3634 2/24/98 1075 RTA00000413F.b. l 7.1 M00004078A:F07 21704

3635 2/24/98 544 RTA00000420F.1.21.2 M00005232A:H12 0

3636 1/28/98 684 RTA00000200AR.b.l l . l M00004040A:G12 12043

3636 2/24/98 1 166 RTA00000347F.h.01.1 M00004040A:G12 12043

3637 1/28/98 684 RTA00000200AR.b. l l . l M00004040A:G12 12043

3637 2/24/98 1 166 RTA00000347F.h.01.1 M00004040A:G12 12043

3638 2/24/98 1087 RTA00000401 F.O.13.1 M00004040C:A01 3220

3639 2/24/98 1 14 RTA00000341 F.m.21.1 M00004051 D:E01 0

3640 2/24/98 81 1 RTA00000413F.a.l2.1 M00004072D:F09 63403

3641 2/24/98 714 RTA00000420F.a.08.1 M00004073A:D10 19473

3642 1/28/98 387 RTA00000191 AF.j.14.1 M00004073A:H 12 1002

3642 2/24/98 632 RTA00000191 AF.J.14.1 M00004073A:H12 1002

3643 1/28/98 387 RTA00000191 AF.J.14.1 M00004073A:H 12 1002

3643 2/24/98 632 RTAOOOOO 191 AF.j.14.1 M00004073A:H12 1002

3644 2/24/98 964 RTA00000423F.1.15.1 M00004075B:G09 1 1219

3645 2/24/98 355 RTA00000420F.3.19.1 M00004076A:D12 34192

3646 2/24/98 745 RTA00000413F.b.04.1 M00004076D:H07 66427

3647 2/24/98 64 RTA00000413F.d. l 8.1 M00004090B:B04 65305

3648 2/24/98 698 RTA00000413F.b.l6.1 M00004078A:E05 65126

3649 2/24/98 190 RTA00000419F.p.23.1 M00004039B:A05 64748

3650 2/24/98 903 RTA00000420F.a.21.1 M00004078B:C1 1 66241 SEQ ID Filing SEQ ID Sequence Name Clone Nsme Cluster

NO: Date of NO: in ID

Priority Priority

Appln Appln

3651 2/24/98 588 RTA00000420F.3.23.1 M00004078B:F12 42158

3652 2/24/98 1 1 85 RTA00000413F.b.20.1 M00004079D:G08 66063

3653 2/24/98 619 RTA00000420F.b.04.1 M00004081 A:E02 63820

3654 2/24/98 988 RTA00000407F.a.22.1 M00004081 A:G01 15570

3655 2/24/98 705 RTA00000407F.3.23.1 M00004081 C:A10 23489

3656 2/24/98 282 RTA00000407F.3.24.1 M00004083A:E08 37560

3657 2/24/98 835 RTA00000413F.C.10.1 M00004083B:C01 65600

3658 2/24/98 598 RTA00000420F.b. l 8.1 M00004086D:G08 66136

3659 2/24/98 335 RTA00000413F.d.02.1 M00004087B:A12 661 72

3660 2/24/98 504 RTA00000413F.d.05.1 M00004087C:A01 64788

3661 2/24/98 76 RTA00000413F.d. l 6.1 M00004088C:F01 63331

3662 2/24/98 726 RTA00000420F.b. l 9.1 M00004088D:A1 1 36873

3663 2/24/98 521 RTA00000413F.b. l4.1 M00004078A:C 1 1 66591

3664 2/24/98 255 RTA00000419F.O.16.1 M00003989C:G05 62867

3665 2/24/98 665 RTA00000419F.p.20.1 M00004039A:C03 9458

3666 2/24/98 1234 RTA00000352R.C.20.1 M00003982A:B 12 7339

3667 2/24/98 247 RTA00000412F.J.17.1 M00003982C:G04 64071

3668 2/24/98 1 145 RTA00000423F. 21 .2 M00003984D:B08 37499

3669 2/24/98 993 RTA00000406F.O.05.1 M00003985B:G04 37894

3670 2/24/98 328 RTA00000423F. 19.2 M00003985D:E10 17615

3671 2/24/98 254 RTA00000341 F.1.15.1 M00003986B:A08 5294

3672 2/24/98 948 RTA00000419F.O.06.1 M00003986C:D09 64643

3673 2/24/98 661 RTA00000341 F.1.16.1 M00003986D:C08 8479

3674 2/24/98 1 1 7 RTA00000341 F.m. l3.1 M00003987B:E12 26502

3675 2/24/98 1210 RTA00000419F.O.09.1 M00003987B:F08 66396

3676 2/24/98 460 RTA00000341 F.J.12.1 M00003987C:G03 12195

3677 2/24/98 486 RTA00000346F.1.13.1 M00003980B:C 1 1 7542

3678 2/24/98 723 RTA00000419F.O.15.1 M00003989C:D03 32487

3679 2/24/98 897 RTA00000419F.n.24.1 M00003980A:F04 65995

3680 2/24/98 92 RTA00000412F.I.04.1 M00003989D:F12 66372

3681 2/24/98 1014 RTA00000412F.I.14.1 M00004029B:F01 62792

3682 2/24/98 348 RTA00000412F.1.19.1 M00004029C:C05 65825

3683 2/24/98 284 RTA00000412F.1.21.1 M00004029C:G 10 65183

3684 2/24/98 188 RTA00000406F.p.04.1 M00004030D:F 1 1 37458

3685 2/24/98 812 RTA00000412F.O.05.1 M00004034A:A01 63575

3686 2/24/98 91 1 RTA00000406F.p. l3.1 M00004034C:G02 8584

3687 2/24/98 230 RTA00000423F.k.01.1 M00004034D:E09 40426

3688 2/24/98 1076 RTA00000423F. 09.1 M00004035B:H09 26630

3689 2/24/98 941 RTA00000419F.p.08.1 M00004036D:B04 65560

3690 2/24/98 1 186 RTA00000419F.p. l 0.1 M00004036D:B09 41448

3691 2/24/98 42 RTA00000423F. 17.2 M00004038A:F02 37512

3692 2/24/98 934 RTA00000414F.e.01.1 M00005233D:H07 0

3693 2/24/98 37 RTA00000406F.O.15. 1 M00003988D:A08 37482

3694 2/24/98 1016 RTA00000406F.ii.12. ! M00003960A:G07 37517

3695 1 /28/98 584 RTAOOOOO 190 AR.c.03.1 M00003904C:A08 0

3695 2/24/98 1069 RTA00000346F. 05.1 M00003904C:A08 0

3696 1 /28/98 584 RTAOOOOO 190AR.C.03.1 M00003904C:A08 0

3696 2/24/98 1069 RTA00000346F. 05.1 M00003904C:A08 0

3697 2/24/98 489 RTA00000406F.J.19.1 M00003906A:F12 1685

3698 2/24/98 461 RTA00000412F.d. l 6.1 M00003906B:H06 26829 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

3699 2/24/98 558 RTA00000419F.m.04.1 M00003906C:C05 74367

3700 2/24/98 120 RTA00000401 F.m.02.1 M00003907A:F01 1573

3701 2/24/98 628 RTA00000412F.d. l 9.1 M00003907B:C03 75743

3702 2/24/98 792 RTA00000406F.k.l l . l M00003907B:D05 38715

3703 2/24/98 292 RTA00000423F.i.l 8.1 M00003918A:D08 14996

3704 2/24/98 1 192 RTA00000406F.m. l 7.1 M00003918A:F09 0

3705 2/24/98 9 RTA00000406F.n.02.1 M00003918C:H10 15051

3706 2/24/98 629 RTA00000352R.C.04.1 M00003924A:D08 71976

3707 2/24/98 438 RTAOOOOO 195R.d.09.1 M00003981 C:B04 8537

3708 2/24/98 433 RTA00000419F.n.02.1 M00003958B:H08 .65963

3709 2/24/98 147 RTA00000422F.C.02.1 M000041 18B:A03 2902

3710 2/24/98 649 RTA00000412F.g.03.1 M00003971 B:A10 64740

371 1 2/24/98 1 141 RTA00000347F.f.08.1 M00003972D:H02 5948

3712 2/24/98 252 RTA00000412F.g.24.1 M00003973C:C03 28741

3713 2/24/98 732 RTA00000412F.H.1 1.1 M00003974B:B 1 1 63175

3714 2/24/98 1 81 RTA00000412F.H.21.1 M00003974D:F02 64348

3715 2/24/98 345 RTA00000412F.h.23.2 M00003974D:H04 651 18

3716 2/24/98 148 RTA00000419F.11.04.1 M00003975C:F07 13102

371 7 2/24/98 31 1 RTA00000419F.n.09.1 M00003977C:A06 66070

3718 2/24/98 1044 RTA00000419F.n.1 1 .1 M00003977C:B03 66477

3719 2/24/98 652 RTA00000419F.n. l2.1 M00003977D:A03 66086

3720 2/24/98 452 RTA00000419F.n.l3.1 M00003977D:A06 66026

3721 2/24/98 796 RTA00000419F.n.l 5.1 M00003977D:D04 63484

3722 2/24/98 1249 RTA00000419F.n.l 7.1 M00003978D:G04 63186

3723 2/24/98 860 RTA00000419F.m.23.1 M00003958B:E1 1 64263

3724 2/24/98 713 RTA00000414F.b.l0.1 M00005212D:D09 0

3725 2/24/98 1002 RTA00000419F.p.l 8.1 M00004038D:G06 63002

3726 2/24/98 1048 RTA00000413F.O.07.2 M00005100A:C01 0

3727 2/24/98 508 RTA00000420F.i.20.1 M00005101 C:E12 0

3728 2/24/98 1001 RTA00000413F.p.07.2 M00005102C:D03 0

3729 2/24/98 88 RTA00000420F.L24.1 M00005134B:E08 0

3730 2/24/98 93 RTA00000413F.p.24.1 M00005139A:H03 0

3731 2/24/98 142 RTA00000420FJ.19.1 M00005140C:B 10 0

3732 2/24/98 833 RTA00000420FJ.20.1 M00005140D:C06 0

3733 2/24/98 316 RTA00000414F.a.02.1 M00005178D:H04 0

3734 2/24/98 1 100 RTA00000414F.a.l2.1 M00005210A:E06 0

3735 2/24/98 1 175 RTA00000414F.b.04.1 M00005212B:E01 0

3736 2/24/98 1236 RTA00000414F.b.06.1 M00005212C:C03 0

3737 2/24/98 747 RTA00000413F.n.24.1 M00004960C:E10 0

3738 2/24/98 207 RTA00000414F.b.08.1 M00005212C:H02 0

3739 2/24/98 935 RTA00000420F.i.07.1 M00004960A:B08 0

3740 2/24/98 741 RTA00000414F.b. l2.1 M00005212D:H01 0

3741 2/24/98 865 RTA00000414F.C.03.1 M00005216A:D09 0

3742 2/24/98 862 RTA00000414F.C.07.1 M00005216A:H01 0

3743 2/24/98 565 RTA00000420F.k.l 7.2 M00005217B:A06 0

3744 2/24/98 1226 RTA00000414F.C.12.1 M00005218A:F09 0

3745 2/24/98 512 RTA00000414F.C.16.1 M00005228A:B03 0

3746 2/24/98 817 RTA00000420F.1.08.2 M00005228C:C05 0

3747 2/24/98 573 RTA00000414F.C.23.1 M00005229B:G12 0

3748 2/24/98 1237 RTA00000414F.C.24.1 M00005229B:H04 0 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: D3te of NO: in ID Priority Priority Appln Appln

3749 2/24/98 727 RTA00000414F.d.02.1 M00005229B:H06 0

3750 2/24/98 566 RTA00000414F.d.05.1 M00005229D:H03 0

3751 2/24/98 307 RTA00000420F.I.12.2 M00005230B:H09 0

3752 3/24/98 149 RTA00000424F.d.04.3 M00001478A:F12 76505

3752 3/24/98 150 RTA00000424F.d.04.1 M00001478A:F12 76505

3753 2/24/98 946 RTA00000414F.b.07.1 M00005212C:D02 0

3754 1/28/98 343 RTA00000201 F.3.18.1 M00004314B:G07 16837

3754 2/24/98 571 RTA00000355R.e. l4.1 M00004314B:G07 16837

3755 2/24/98 481 RTA00000413F.i.23.1 M000041 18B:F01 63073

3756 2/24/98 1039 RTA00000407F.C.08.1 M000041 18D:B05 37549

3757 2/24/98 824 RTA00000420F.f.07.1 M000041 19A:C09 66312

3758 2/24/98 813 RTA00000346F.O.06.1 M00004136D:B02 4937

3759 2/24/98 1070 RTA00000346F.n.22.1 M00004137A:D06 0

3760 2/24/98 283 RTA00000346F.n.06.1 M00004139C:A12 12439

3761 2/24/98 368 RTA00000346F.O.08.1 M00004149C:B02 0

3762 2/24/98 704 RTA00000355R.3.12.1 M00004159C:F09 36756

3762 1/28/98 685 RTA00000200F.i.9.1 M00004159C:F09 36756

3763 1/28/98 685 RTA00000200F.Ϊ.9.1 M00004159C:F09 36756

3763 2/24/98 704 RTA00000355R.a. l2.1 M00004159C:F09 36756

3764 2/24/98 1254 RTA00000341 F.p. l l .l M00004159C:G12 0

3765 2/24/98 1 188 RTA00000341 F.O.18.1 M00004169D:B1 1 37189

3766 2/24/98 40 RTA00000352R.1.06.1 M00004187D:H06 40343

3767 2/24/98 456 RTA00000413F.O.06.1 M00005100A:B02 0

3768 2/24/98 882 RTA00000355R.C.03.1 M00004244C:G07 3986

3769 2/24/98 503 RTA00000420F.m.08.1 M00005233B:D04 0

3770 2/24/98 571 RTA00000355R.e.l4.1 M00004314B:G07 16837

3770 1/28/98 343 RTA00000201 F.3.18.1 M00004314B:G07 16837

3771 2/24/98 91 RTA00000355R.e.l5.1 M00004316A:G09 22639

3771 1/28/98 410 RTA00000201 F.3.20.1 M00004316A:G09 22639

3772 2/24/98 91 RTA00000355R.e. l 5.1 M00004316A:G09 22639

3772 1/28/98 410 RTA00000201 F.3.20.1 M00004316A:G09 22639

3773 2/24/98 1 135 RTA00000346F.O.16.1 M00004358D:C02 176

3774 2/24/98 220 RTA00000413F. 02.1 M00004690A:G08 0

3775 2/24/98 487 RTA00000420F.g.05.1 M00004891 B:D01 0

3776 2/24/98 102 RTA00000420F.g.06.1 M00004891 C:D04 0

3777 2/24/98 1238 RTA00000420F.g.09.1 M00004895B:E12 0

3778 2/24/98 18 RTA00000420F.g.l2.1 M00004895B:G04 0

3779 2/24/98 1 196 RTA00000413F.I.18.1 M00004895D:G07 0

3780 2/24/98 579 RTA00000413F.m.l 6.1 M00004898C:F03 0

3781 2/24/98 143 RTA00000420F.h.l3.1 M00004899D:G06 0

3782 2/24/98 909 RTA00000420F.i.04.1 M00004959D:H 12 0

3783 2/24/98 709 RTA00000352R.p.09.1 M00004228C:H03 16915

3784 3/24/98 221 RTA00000427F.J.22.1 M00004097D:B05 66367

3785 3/24/98 188 RTA00000525F.C.15.1 M00004040A:A07 7692

3786 3/24/98 401 RTA00000525F.C.16.1 M00004040A:B04 38209

3787 3/24/98 53 RTA00000525F.C.17.1 M00004040A:C08 38160

3788 3/24/98 325 RTA00000525F.C.18.1 M00004040B:C05 24208

3789 3/24/98 159 RTA00000525F.C.19.1 M00004040B:F07 38159

3790 3/24/98 209 RTA00000427F.g.l 6.1 M00004069A:E12 6301 1

3791 3/24/98 123 RTA00000427F.g.05.1 M00004069C:C08 63138 SEQ ID Filing SEQ ID Sequence Name Clone Nsme Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

3792 3/24/98 62 RTA00000427F.J.19.1 M00004077A:G 12 41395

3793 3/24/98 265 RTA00000427F.h.02.1 M00004085B:G01 63652

3794 3/24/98 235 RTA00000427F.g. l 9.1 M00004087A:B05 6461 1

3795 3/24/98 333 RTA00000427F.k.21.1 M00004090D:F12 62880

3796 3/24/98 130 RTA00000427F.h.l2.1 M00004092C:D08 36894

3797 3/24/98 243 RTA00000424F.C.15.3 M00001476D:F12 73533

3798 3/24/98 227 RTA00000427F.U 1.1 M00004097C:H08 26635

3799 3/24/98 456 RTA00000427F.a.l 0.1 M00004038B:D01 65370

3800 3/24/98 7 RTA00000523F.O.20.1 M00005177B:H02 0

3801 3/24/98 291 RTA00000523F.O.23.1 M00005177C:G04 0

3802 3/24/98 1 19 RTA00000523F.p.06.1 M00005177D:F09 0

3803 3/24/98 178 RTA00000428F.3.12.1 M00005179B:H02 0

3804 3/24/98 463 RTA00000523F.p. l 6.1 M00005179D:B03 0

3805 3/24/98 390 RTA00000524F.3.1 1.1 M00005210D:C09 0

3806 3/24/98 468 RTA00000524F.3.18.1 M0000521 1 A:E09 0

3807 3/24/98 1 14 RTA00000524F.3.23.1 M0000521 1 C:E09 0

3808 3/24/98 29 RTA00000524F.b.03.1 M00005212A:D10 0

3809 3/24/98 36 RTA00000428F.3.16.1 M00005212D:F08 0

3810 3/24/98 417 RTA00000524F.b. l 0.1 M00005213C:A01 0

381 1 3/24/98 182 RTA00000524F.b. l 7.1 M00005214B:A06 0

3812 3/24/98 348 RTA00000427F.i.09.1 M00004097C:E03 65916

3813 3/24/98 384 RTA00000527F.p.03.1 M00004029B:A06 5940

3814 3/24/98 84 RTA00000527F.L 18.1 M00003982B:C 10 1 1332

3815 3/24/98 48 RTA00000527F.k.21.1 M00003982B:H 10 36051

3816 3/24/98 271 RTA00000527F.1.05.1 M00003983A:D02 13016

3817 3/24/98 246 RTA00000426F.m.21.1 M00003983A:F06 64915

3818 3/24/98 16 RTA00000426F.m.22.1 M00003983A:G02 30002

3819 3/24/98 367 RTA00000527F.1.19.1 M00003983D:E08 36856

3820 3/24/98 477 RTA00000527F.1.21.1 M00003983D:H02 36439

3821 3/24/98 126 RTA00000527F.m.05.1 M00003985A:C01 17240

3822 3/24/98 89 RTA00000527F.n.02.1 M00003986C:G 1 1 24190

3823 3/24/98 263 RTA00000527F.n.07.1 M00003986D:H 12 15939

3824 3/24/98 49 RTA00000527F.n.22.1 M00004027A:A08 24175

3825 3/24/98 449 RTA00000426F.m.04.1 M00004028A:B10 36865

3826 3/24/98 336 RTA00000426F.n.l 7.1 M00004039D:B10 66572

3827 3/24/98 27 RTA00000527F.p.02.1 M00004029B:A01 36844

3828 3/24/98 297 RTA00000525F.C.1 1.1 M00004039C:E02 37895

3829 3/24/98 17 RTA00000527F.p.06.1 M00004029B:G10 1292

3830 3/24/98 310 RTA00000527F.p.08.1 M00004029C:F02 36013

3831 3/24/98 478 RTA00000527F.p.09.1 M00004029C:F05 7694

3832 3/24/98 253 RTA00000426F.m.08.1 M00004030B:A12 63781

3833 3/24/98 414 RTA00000426F.m. l 2.1 M00004030B:D08 63740

3834 3/24/98 345 RTA00000426F.n.23.1 M00004030C:A08 18176

3835 3/24/98 98 RTA00000527F.p.l6.1 M00004030C:C02 23798

3836 3/24/98 1 15 RTA00000525F.b.05.1 M00004034C:F05 21 1 16

3837 3/24/98 444 RTA00000525F.b.09.1 M00004035B:F05 23472

3838 3/24/98 158 RTA00000427F.3.06.1 M00004036A:A 1 1 66550

3839 3/24/98 376 RTA00000525F.D.21.1 M00004037C:D04 9486

3840 3/24/98 293 RTA00000525F.C.02.1 M00004038A:E05 14618

3841 3/24/98 138 RTA00000527F.C.22.1 M00003822B:G 12 37496 SEQ ID Filing SEQ ID Sequence Name Clone Nsme Cluster

NO: D3te of NO: in ID Priority Priority Appln Appln

3842 3/24/98 30 RTA00000426F.m.07.1 M00004028A:G03 63504

3843 3/24/98 322 RTA00000523F.i. l 7.1 M00003856B:A12 65779

3844 3/24/98 31 1 RTA00000428F.b.02.1 M00005214D:D10 0

3845 3/24/98 233 RTA00000426F.f.l 3.1 M00003851 A:A06 65384

3846 3/24/98 274 RTA00000523F.h.06.1 M00003851 B:D03 28745

3847 3/24/98 407 RTA00000523F.h.08.1 M00003851 B:E01 62893

3848 3/24/98 82 RTA00000523F.h. l 5.1 M00003851 C:F09 65137

3849 3/24/98 316 RTA00000523F.h. l 6.1 M00003851 D:H 1 1 66031

3850 3/24/98 232 RTA00000527F.i. l 3.2 M00003852B:G04 2924

3851 3/24/98 451 RTA00000527F.i.l 5.2 M00003852C:F07 14235

3852 3/24/98 249 RTA00000523F.h.21.1 M00003853B:C 10 41440

3853 3/24/98 72 RTA00000426F.f. l 9.1 M00003854C:C09 66701

3854 3/24/98 60 RTA00000523F.i.06.1 M00003855A:A01 66341

3855 3/24/98 91 RTA00000527F.i.21.2 M00003855A:F01 37490

3856 3/24/98 137 RTA00000527F.li.17.1 M00003848D:G02 37799

3857 3/24/98 433 RTA00000527F.J.04.2 M00003856A:G04 1 1809

3858 3/24/98 157 RTA00000523F.g. l 0.1 M00003848B:E07 40694

3859 3/24/98 75 RTA00000523F.i.22.1 M00003857A:E12 64688

3860 3/24/98 481 RTA00000523F.J.02.1 M00003857A:H10 62853

3861 3/24/98 377 RTA00000527F.J.12.2 M00003857C:E05 37503

3862 3/24/98 286 RTA00000426F.g.l 9.1 M00003858B:G02 63672

3863 3/24/98 71 RTA00000527F.J.20.2 M00003860D:E06 37603

3864 3/24/98 205 RTA00000426F.h.l2.1 M00003905C:F12 78093

3865 3/24/98 40 RTA00000426F.h.23.1 M0000391 1 A:D12 75964

3866 3/24/98 369 RTA00000524F.C.08.1 M00005217C:C01 0

3867 3/24/98 234 RTA00000524F.C.16.1 M00005218D:G10 0

3868 3/24/98 8 RTA00000428F.b.06.1 M00005228A:A09 0

3869 3/24/98 193 RTA00000428F.b.l2.1 M00005231 C:B07 0

3870 3/24/98 419 RTA00000428F.b.22.1 M00005231 D:B09 0

3871 2/24/98 486 RTA00000346F.1.13.1 M00003980B:C 1 1 7542

3872 3/24/98 421 RTA00000523F.i.l 0.1 M00003855B:B09 64876

3873 3/24/98 10 RTA00000527F.f.l2.1 M00003829D:D12 5945

3874 3/24/98 145 RTA00000426F.m.24.1 M00003981A:A07 63943

3875 3/24/98 39 RTA00000527F.C.23.1 M00003822C:A07 37742

3876 3/24/98 35 RTA00000426F.f.l l .l M00003823C:B01 63102

3877 3/24/98 385 RTA00000426F.f.l2.1 M00003823C:C04 19096

3878 3/24/98 2 RTA00000523F.d. l9.1 M00003824A:A06 26489

3879 3/24/98 225 RTA00000527F.d.09.1 M00003824A:G 1 1 10848

3880 3/24/98 359 RTA00000523F.d.21.1 M00003824B:C09 33424

3881 3/24/98 330 RTA00000523F.d.23.1 M00003824C:A10 63633

3882 3/24/98 254 RTA00000523F.d.24.1 M00003824D:D08 64799

3883 3/24/98 74 RTA00000527F.d. l9.1 M00003825B:F 10 486

3884 3/24/98 67 RTA00000527F.e.03.1 M00003825D:F01 25560

3885 3/24/98 352 RTA00000527F.e.l 3.1 M00003826C:F05 37588

3886 3/24/98 185 RTA00000527F.h.21.1 M00003850C:G09 37630

3887 3/24/98 338 RTA00000523F.e.l 5.1 M00003829C:E08 7919

3888 3/24/98 284 RTA00000524F.b.l9.1 M00005216B:D02 0

3889 3/24/98 242 RTA00000523F.e.20.1 M00003829D:F03 65164

3890 3/24/98 301 RTA00000527F.f. l 8.1 M00003830D:B 1 1 37577

3891 3/24/98 259 RTA00000528F.m.04.1 M00003830D:H 1 1 10815 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

3892 3/24/98 160 RTA00000523F.f.06.1 M00003833D:H08 62871

3893 3/24/98 166 RTA00000523F.f.07.1 M00003833D:H10 62799

3894 3/24/98 196 RTA00000523F.f. l2.1 M00003840A:C10 63751

3895 3/24/98 447 RTA00000523F.f. l9.1 M00003840B:F05 34169

3896 3/24/98 1 13 RTA00000527F.g.07.1 M00003840C:C02 37488

3897 3/24/98 45 RTA00000528F.m.12.1 M00003842D:F08 5768

3898 3/24/98 415 RTA00000527F.g. l2.1 M00003845C:D04 37746

3899 3/24/98 1 RTA00000527F.g. l 3.1 M00003845D:A04 36035

3900 3/24/98 450 RTA00000527F.g.21.1 M00003846B:C05 36028

3901 3/24/98 144 RTA00000527F.g.23.1 M00003846C:F08 37538

3902 3/24/98 422 RTA00000527F.f.03.1 M00003829A:B08 17788

3903 3/24/98 176 RTA00000522F.g.15.1 M00001595B:G07 76536

3904 3/24/98 264 RTA00000425F.e.09.1 M00001608C:G04 75550

3905 3/24/98 32 RTA00000424F.n.l4.1 M00001584D:C 1 1 73008

3906 3/24/98 459 RTA00000425F.C.03.1 M00001585D:B12 74643

3907 3/24/98 124 RTA00000424F.m.12.1 M00001586C:H07 77675

3908 3/24/98 314 RTA00000522F.e.09.1 M00001589D:A01 32599

3909 3/24/98 262 RTA00000424F.k.03.1 M00001590D:B04 21289

3910 3/24/98 106 RTA00000424FJ.14.1 M00001592B:B02 7431 1

391 1 3/24/98 424 RTA00000424F.k. l 0.1 M00001592D:H02 73232

3912 3/24/98 168 RTA00000424F.J.12.1 00001594C:E05 73827

3913 3/24/98 420 RTA00000424F.J.13.1 M00001594C:H03 74485

3914 3/24/98 210 RTA00000522F.g.06.1 M00001594D:G1 1 78221

3915 3/24/98 439 RTA00000522F.g. l 0.1 M00001595A:C07 74294

3916 3/24/98 300 RTA00000424F.m.08.1 M00001584A:A07 19402

3917 3/24/98 355 RTA00000522F.g.l2.1 M00001595A:E07 78783

3918 3/24/98 41 1 RTA00000424F.n.l2.1 M00001582C:G02 41589

3919 3/24/98 238 RTA00000522F.g. l 7.1 M00001595B:G10 76486

3920 3/24/98 472 RTA00000522F.g. l 8.1 M00001595B:H1 1 73226

3921 3/24/98 102 RTA00000522F.g.l 9.1 M00001595C:A01 781 19

3922 3/24/98 280 RTA00000522F.g.20.1 M00001595C:A05 77688

3923 3/24/98 191 RTA00000522F.g.22.1 M00001595C:B12 77504

3924 3/24/98 163 RTA00000522F.h.01.1 M00001595C:E05 75010

3925 3/24/98 438 RTA00000522F.h.02.1 M00001595C:E09 74947

3926 3/24/98 257 RTA00000522F.h.07.1 M00001595D:C 1 1 75149

3927 3/24/98 389 RTA00000424F.i.l 5.1 M00001596A:A02 78043

3928 3/24/98 167 RTA00000424F.i.20.1 M00001596A:D01 44010

3929 3/24/98 374 RTA00000528F.f.l 0.1 M00001596C:G05 3600

3930 3/24/98 215 RTA00000425F.f.02.1 M00001607A:A01 76982

3931 3/24/98 22 RTA00000527F.k. l 5.1 M00003982A:G03 22688

3932 3/24/98 378 RTA00000522F.g.l l . l M00001595A:D12 75432

3933 3/24/98 63 RTA00000522F.b.01.1 M00001570C:B02 75691

3934 3/24/98 430 RTA00000424F.g.08.1 M00001482C:F09 74928

3935 3/24/98 340 RTA00000424F.h.06.1 M00001485C:D07 77552

3936 3/24/98 161 RTA00000424F.li.10. ] M00001485C:G06 72925

3937 3/24/98 368 RTA00000424F.i.l l . l M00001485D:A05 41569

3938 3/24/98 455 RTA00000424F.g.24.1 M00001487C:A1 1 79156

3939 3/24/98 21 1 RTA00000424F.h.03.1 M00001487C:G09 74447

3940 3/24/98 174 RTA00000424F.b.21 .4 M00001530A:B02 24686

3941 3/24/98 383 RTA00000424F.b.23.4 M00001530A:H05 77322 SEQ ID Filing SEQ ID Sequence Name Clone Nsme Cluster

NO: Date of NO: in ID

Priority Priority

Appln Appln

3942 3/24/98 179 RTA00000424F.d.l0.3 M00001530D:A1 1 731 10

3943 3/24/98 393 RTA00000424F.b.l 5.4 M00001539B:B10 74958

3944 3/24/98 347 RTA00000522F.a.05.1 M00001567A:C04 3261 1

3945 3/24/98 303 RTA00000522F.3.06.1 M00001567A:C1 1 73662

3946 3/24/98 229 RTA00000424F.n. l3.1 M00001584D:B06 74942

3947 3/24/98 392 RTA00000522F.a.20.1 M00001567C:E07 74070

3948 3/24/98 226 RTA00000425F.e.l 5.1 M00001608D:F1 1 75921

3949 3/24/98 285 RTA00000522F.b.07.1 M00001570D:E05 78634

3950 3/24/98 465 RTA00000528F.d.04.1 M00001570D:E07 2395

3951 3/24/98 404 RTA00000522F.b.l 8.1 M00001573B:A06 3460

3952 3/24/98 9 RTA00000522F.b.22.1 M00001573B:H12 75181

3953 3/24/98 109 RTA00000424F.a.01.4 M00001575A:D05 43214

3953 3/24/98 125 RTA00000424F.a.01.1 M00001575A:D05 43214

3954 3/24/98 125 RTA00000424F.a.01.1 M00001575A:D05 43214

3954 3/24/98 109 RTA00000424F.3.01.4 M00001575A:D05 43214

3955 3/24/98 294 RTA00000424F.a.05.1 M00001575B:C0 ! 77976

3955 3/24/98 292 RTA00000424F.a.05.4 M00001575B:C01 77976

3956 3/24/98 292 RTA00000424F.3.05.4 M00001575B:C01 77976

3956 3/24/98 294 RTA00000424F.3.05.1 M00001575B:C01 77976

3957 3/24/98 434 RTA00000522F.C.1 1.1 M00001576C:H02 31064

3958 3/24/98 299 RTA00000522F.C.14.1 M00001577A:A03 75449

3959 3/24/98 1 10 RTA00000522F.d.08.1 M00001578B:A06 74284

3960 3/24/98 306 RTA00000522F.d.23.1 M00001579D:F02 73868

3961 3/24/98 350 RTA00000424F.n.l l . l M00001582C:C04 73874

3962 3/24/98 366 RTA00000522F.3.17.1 M00001567C:B08 79032

3963 3/24/98 239 RTA00000523F.J.17.1 M00003966B:A04 63610

3964 3/24/98 405 RTA00000425F.e.07.1 M00001608C:D02 75992

3965 3/24/98 231 RTA00000426F.e.l 7.1 M00003810C:B06 64089

3966 3/24/98 104 RTA00000527F.b.l 8.1 M00003810D:H09 37469

3967 3/24/98 312 RTA00000426FT.17.1 M0000381 1 C:C02 66334

3968 3/24/98 266 RTA00000426F.f.l 6.1 M00003813B:F02 65613

3969 3/24/98 183 RTA00000527F.C.04.1 M00003813C:H08 23090

3970 3/24/98 435 RTA00000523F.C.13.1 M00003813D:B12 40668

3971 3/24/98 255 RTA00000523F.C.14.1 M00003813D:C02 66015

3972 3/24/98 131 RTA00000523F.C.15.1 M00003813D:G06 36935

3973 3/24/98 270 RTA00000426F.g.l 6.1 M00003814B:C01 41446

3974 3/24/98 95 RTA00000523F.C.18.1 M00003817C:A10 66179

3975 3/24/98 329 RTA00000527F.C.09.1 M00003817C:G06 64859

3976 3/24/98 65 RTA00000523F.C.01.1 M00003810A:A02 65710

3977 3/24/98 398 RTA00000527F.C.16.1 M00003821A:H09 22908

3978 3/24/98 96 RTAO00O0523F.b. l3.1 M00003809B:A03 66330

3979 3/24/98 313 RTA00000523F.J.21.1 M00003966C:A12 36925

3980 3/24/98 86 RTA00000523F. 01.1 M00003966C:F03 41437

3981 3/24/98 26 RTA00000427F.b.23.1 M00003973D:F08 64297

3982 3/24/98 277 RTA00000427F.e.08.1 M00003974D:E01 47387

3983 3/24/98 397 RTA00000427F.e.l 0.1 M00003974D:H07 64599

3984 3/24/98 31 RTA00000427F.C.10.1 M00003976B:E06 65478

3985 3/24/98 151 RTA00000427F.C.12.1 M00003976B:H07 66995

3986 3/24/98 57 RTA00000427F.C.20.1 M00003978A:E01 26527

3987 3/24/98 213 RTA00000427F.C.22.1 M00003978A:E09 63990 SEQ ID Filing SEQ ID Sequence Nsme Clone Nsme Cluster

NO: Dste of NO: in ID Priority Priority Appln Appln

3988 3/24/98 289 RTA00000427F.d. l 0.1 M00003978C:A 12 40685

3989 3/24/98 28 RTA00000427F.d.08.1 M00003980C:E12 63967

3990 3/24/98 335 RTA00000427F.d.09.1 M00003980C:F12 66486

3991 3/24/98 267 RTA00000425F.i.21 .1 M00001635B:B02 75305

3992 3/24/98 343 RTA00000527F.C.1 1 .1 M0000381 7D:D12 37484

3993 3/24/98 251 RTA00000425F.f.24.1 M00001656D:C04 40841

3994 3/24/98 155 RTA00000424F.I.19.1 M00001609C:A 12 75454

3995 3/24/98 321 RTA00000424F.m.04.1 M00001609C:G05 79017

3996 3/24/98 214 RTA00000424F.U 2.1 M00001610C:B07 77666

3997 3/24/98 446 RTA00000425F.f.20.1 M00001653D:H07 74071

3998 3/24/98 428 RTA00000522F.1.08.1 M00001654A:E08 78781

3999 3/24/98 295 RTA00000522F.1.15.1 M00001654B:A01 74691

4000 3/24/98 275 RTA00000522F.1.22.1 M00001654C:D10 75801

4001 3/24/98 223 RTA00000522F.m.02.1 M00001654C:G07 76834

4002 3/24/98 391 RTA00000522F.m.03.1 M00001654C:G09 79194

4003 3/24/98 346 RTA00000522F.m. l 9.1 M00001655C:C07 41544

4004 3/24/98 51 RTA00000522F.n.02.1 M00001655D:E08 74959

4005 3/24/98 94 RTA00000522F.n.05.1 M00001655D:H 1 1 73260

4006 3/24/98 332 RTA00000523F.C.03.1 M00003810B:B1 1 36913

4007 3/24/98 172 RTA00000425F.f. l l . l M00001656C:C04 79275

4008 3/24/98 58 RTA00000527F.L06.1 M00003981 B:B12 12469

4009 3/24/98 240 RTA00000522F.n. l4.1 M00001657C:C 1 1 73410

4010 3/24/98 56 RTA00000522F.n. l 6.1 M00001657D:A10 26769

401 1 3/24/98 20 RTA00000522F.O.06.1 M00001659D:A09 26860

4012 3/24/98 38 RTA00000528F.i.22.1 M00001661 D:D05 2478

4013 3/24/98 413 RTA00000425F.U 0.1 M00001664B:E08 78736

4014 3/24/98 412 RTA00000425F.i. l l . l M00001664B:F06 21716

4015 3/24/98 202 RTA00000528F.J.1 1 .1 M00001669B:C 12 1070

4016 3/24/98 432 RTA00000522F.O.20.1 M00001669C:B09 74853

4017 3/24/98 245 RTA00000522F.p.09.1 M00001670A:F09 75204

4018 3/24/98 33 1 RTA00000528F.L 10.1 M00001678C:F09 1981

4019 3/24/98 356 RTA00000523F.3.07.1 M00001693A:H06 75804

4020 3/24/98 200 RTA00000527F.3.13.1 M00003805D:E06 37740

4021 3/24/98 14 RTA00000523F.b.02.1 M00003806C:A06 65163

4022 3/24/98 1 77 RTA00000522F.n. l2.1 M00001656A:H 12 741 17

4023 2/24/98 1 158 RTA00000405F.O.03.1 M00003829C:H05 37575

4024 2/24/98 1 1 81 RTA00000346FT.14.1 M00003800B:F03 16998

4025 2/24/98 610 RTA00000419F.d.07.1 M00003820B:D10 21421

4026 2/24/98 1227 RTA0000041 1 F.g.05.1 M00003822D:B 10 64664

4027 2/24/98 412 RTA0000041 1 F.g.06.1 M00003822D:C06 66065

4028 2/24/98 21 RTA0000041 1 F.g.08.1 M00003822D:D04 45815

4029 2/24/98 1208 RTA00000347F.e.24.1 M00003823B:F07 8188

4030 2/24/98 502 RTA00000341 F.d.08.1 M00003824C:D07 0

4031 2/24/98 528 RTA00000405F.n. l 6.1 M00003825B:B 10 21503

4032 2/24/98 15 RTA00000419F.C.19.1 M00003820A:A08 64346

4033 2/24/98 637 RTA00000419F.d. l 4.1 M00003828A:D05 64945

4034 2/24/98 81 RTA00000419F.C.16.1 M00003819D:B01 65254

4035 2/24/98 754 RTA00000419F.e.02.1 M00003830C:A03 65010

4036 2/24/98 430 RTA00000419F.e.04.1 M00003831 C:G05 62963

4037 2/24/98 541 RTA0000041 1 F.h. l 5.1 M00003832A:A09 65160 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID

Priority Priority

Appln Appln

4038 2/24/98 1079 RTA00000419F.e.l0.1 M00003833B:B03 63225

4039 2/24/98 577 RTA00000419F.e.ll.l M00003833B:C12 36780

4040 2/24/98 1220 RTA00000419F.e.23.1 M00003834B:G04 65772

4041 2/24/98 691 RTA00000354R.n.08.1 M00003835A:A09 8802

4042 2/24/98 536 RTA00000411F.i.02.1 M00003835B:H11 66975

4043 2/24/98 421 RTA00000419F.f.l0.1 M00003835D:G06 66193

4044 2/24/98 1150 RTA00000411F.g.24.1 M00003825B:B11 65233

4045 2/24/98 533 RTA00000423F.e.ll.l M00003809B:E10 2566

4046 2/24/98 520 RTA00000406F.C.20.1 M00003871D:G06 38578

4047 2/24/98 41 RTA00000419F.b.l2.1 M00003806B:C09 63148

4048 2/24/98 917 RTA00000423F.e.21.1 M00003806B:G05 66961

4049 2/24/98 326 RTA00000419F.b.l5.1 M00003806D:D11 43969

4050 2/24/98 297 RTA00000419F.b.l8.1 M00003808D:D08 67034

4051 2/24/98 139 RTA00000419F.b.l9.1 M00003809A:C01 65534

4052 2/24/98 1021 RTA00000419F.b.21.1 M00003809A:F01 65366

4053 2/24/98 1152 RTA00000405F.m.07.1 M00003809B:B02 37733

4054 2/24/98 310 RTA00000419F.d.06.1 M00003820B:D07 65496

4055 2/24/98 120 RTA00000401F.m.02.1 M00003907A:F01 1573

4056 2/24/98 69 RTA00000405F.O.18.1 M00003839A:D07 11016

4057 2/24/98 482 RTA00000411F.e.24.1 M00O03813A:B02 64781

4058 2/24/98 50 RTA00000411F.f.02.1 M00003813A:D08 63386

4059 2/24/98 602 RTA00000411F.f.06.1 M00003813B:E09 64186

4060 2/24/98 761 RTA00000411F.f.l4.1 M00003814B:C12 62984

4061 2/24/98 674 RTA00000411F.f.l7.1 M00003814B:F12 65661

4062 2/24/98 1164 RTA00000405F.m.21.1 M00003815C:C06 24218

4063 2/24/98 951 RTA00000419F.C.04.1 M00003815C:D12 63749

4064 2/24/98 471 RTA00000419F.C.11.1 M00003817B:C04 65504

4065 2/24/98 1047 RTA00000419F.C.14.1 M00003819B:G01 65727

4066 2/24/98 1178 RTA00000400F.f.ll.l M00001636A:E07 4088

4067 2/24/98 89 RTA00000406F.C.08.1 M00003870C:A10 22387

4068 2/24/98 94 RTA00000406F.3.23.1 M00003867B:D10 38712

4069 2/24/98 1038 RTA00000406F.b.01.1 M00003867B:G07 39006

4070 2/24/98 783 RTA00000406F.b.02.1 M00003867B:G08 38744

4071 2/24/98 563 RTA00000406F.b.08.1 M00003867D:A06 18258

4072 2/24/98 1072 RTA00000419F.J.03.1 M00003868B:G06 77578

4073 2/24/98 846 RTA00000419F.J.11.1 M00003868C:C07 73183

4074 2/24/98 17 RTA00000411 F.m.15.1 M00003868D:B09 78014

4075 2/24/98 589 RTA00000411F.m.l8.1 M00003868D:D09 75629

4076 2/24/98 971 RTA00000411F.i.ll.l M00003837C:E05 66849

4077 2/24/98 794 RTA00000406F.C.06.1 M00003870C:A01 37924

4078 2/24/98 788 RTA00000419F.i.04.1 M00003860B:F11 65791

4079 2/24/98 883 RTA00000406F.C.09.1 M00003870C:E10 5671

4080 2/24/98 918 RTA00000419F.J.22.1 M00003871A:A02 73525

4081 2/24/98 757 RTA00000423F.h.l3.1 M00003871A:B09 14398

4082 2/24/98 208 RTA00000419F.J.23.1 M00003871A:C11 74470

4083 2/24/98 1127 RTA00000401F.g.22.1 M00003871A:G09 1147

4084 2/24/98 1205 RTA00000419F.k.05.1 M00003871C:E04 11757

4085 2/24/98 522 RTA00000406F.C.18.1 M00003871C:F12 14368

4086 2/24/98 459 RTA00000419F.k.06.1 M00003871D:A10 78493

4087 2/24/98 965 RTA00000411F.n.06.1 M00003871D:E11 73886 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: D3te of NO: in ID Priority Priority Appln Appln

4088 2/24/98 457 RTA00000411F.m.l9.1 M00003868D:D11 74924

4089 2/24/98 145 RTA00000419F.g.l2.1 M00003842C:G03 66171

4090 2/24/98 633 RTA00000341F.d.02.1 M00003797A:G03 4706

4091 2/24/98 1026 RTA00000419F.f.l8.1 M00003839D:E11 64047

4092 2/24/98 524 RTA00000419F.f.23.1 M00003840D:H10 65002

4093 2/24/98 204 RTA00000351R.k.l9.1 M00003841B:E03 936

4094 2/24/98 968 RTA00000419F.f.24.1 M00003841B:E06 18717

4095 2/24/98 209 RTA00000411F.J.02.1 M00003841C:D07 65310

4096 2/24/98 1118 RTA00000411F.J.03.1 M00003841C:F01 66263

4097 2/24/98 470 RTA00000411F.J.06.1 M00003841C:H08 63545

4098 2/24/98 1153 RTA00000411F.J.07.1 M00003841C:H11 66963

4099 1/28/98 412 RTAOOOOO 195 AF.c.24.1 M00003860D:H07 0

4099 2/24/98 678 RTA00000195AF.C.24.1 M00003860D:H07 0

4100 2/24/98 777 RTA00000419F.g.02.1 M00003842A:A03 62839

4101 2/24/98 678 RTAOOOOO 195 AF.c.24.1 M00003860D:H07 0

4101 1/28/98 412 RTAOOOOO 195 AF.c.24.1 M00003860D:H07 0

4102 2/24/98 799 RTA00000411F.J.15.1 M00003843A:E04 66871

4103 2/24/98 932 RTA00000405F.p.03.1 M00003844A:A11 11346

4104 2/24/98 266 RTA00000419F.g.l5.1 M00003844D:A07 32519

4105 2/24/98 547 RTA00000419F.h.02.1 M00003845D:G08 63985

4106 2/24/98 290 RTA00000411F.k.l6.1 M00003852C:B06 64759

4107 2/24/98 23 RTA00000411F.k.20.1 M00003854B:A07 64973

4108 2/24/98 1138 RTA00000411F.k.21.1 M00003854B:D04 65349

4109 2/24/98 1000 RTA00000351R.J.21.1 M00003859D:C05 31604

4110 2/24/98 980 RTA00000411F.i.l3.1 M00003837C:F10 66138

4111 2/24/98 112 RTA00000422F.C.11.1 M00003841D:A04 2643

4112 2/24/98 905 RTA00000405F.g.21.2 M00001673B:F07 38966

4112 2/24/98 906 RTA00000405F.g.21.1 M00001673B:F07 38966

4113 2/24/98 294 RTA00000405F.1.17.1 M00003805A:F02 17225

4114 2/24/98 105 RTA00000346F.d.08.1 M00001671A:A10 39955

4115 2/24/98 1190 RTA00000405F.g.02.2 M00001671B:G05 10567

4116 2/24/98 280 RTA00000418F.p.l5.1 M00001671C:C11 31066

4117 2/24/98 1151 RTA00000405F.g.l8.2 M00001672D:E08 5255

4118 2/24/98 66 RTA00000405F.g.l9.2 M00001673A:G08 37150

4119 2/24/98 1239 RTA00000340F.O.22.1 M00001673B:B07 7356

4120 2/24/98 906 RTA00000405F.g.21.1 M00001673B:F07 38966

4120 2/24/98 905 RTA00000405F.g.21.2 M00001673B:F07 38966

4121 2/24/98 893 RTA00000418F.p.l0.1 M00001669D:F05 75323

4122 2/24/98 906 RTA00000405F.g.21.1 M00001673B:F07 38966

4122 2/24/98 905 RTA00000405F.g.21.2 M00001673B:F07 38966

4123 2/24/98 808 RTA00000418F.p.08.1 M00001669D:D06 73983

4124 2/24/98 469 RTA00000405F.g.24.1 M00001673D.-D06 39076

4125 2/24/98 1094 RTA00000405F.h.03.2 M00001673D:F10 20633

4126 2/24/98 803 RTA00000405F.h.05.2 M00001674A:G07 75706

4127 2/24/98 667 RTA00000405F.h.07.2 M00001674A:G11 4984

4128 2/24/98 276 RTA00000423F.a.l8.1 M00001675A:G10 26761

4129 2/24/98 1050 RTA00000405F.f.05.2 M00001669C:D09 14359

4129 2/24/98 1049 RTA00000405FT.05.1 M00001669C:D09 14359

4130 2/24/98 1050 RTA00000405F.f.05.2 M00001669C:D09 14359

4130 2/24/98 1049 RTA00000405F.f.05.1 M00001669C:D09 14359 SEQ ID Filing SEQ ID Sequence Name Clone Nsme Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

4131 2/24/98 104 RTA00000421F.n.03.1 M00001675C:A04 1638

4132 2/24/98 388 RTA00000411F.3.07.1 M00001675C:C03 74547

4133 2/24/98 906 RTA00000405F.g.21.1 M00001673B:F07 38966

4133 2/24/98 905 RTA00000405F.g.21.2 M00001673B:F07 38966

4134 2/24/98 222 RTA00000405F.e.09.1 M00001663C:F12 38978

4135 2/24/98 518 RTA00000410F.m.l8.1 M00001660B:A09 76365

4136 2/24/98 218 RTA00000346F.e.l3.1 M00001660B:D03 74653

4137 2/24/98 427 RTA00000410F.m.20.1 M00001660B:E03 74285

4138 2/24/98 1099 RTA00000400F.m.l6.1 M00001660B:E04 3307

4139 2/24/98 775 RTA00000405F.C.22.1 M00001660C:B06 39053

4140 2/24/98 28 RTA00000422F.p.06.2 M00001661A:B11 39282

4141 2/24/98 108 RTA00000418F.O.18.1 M00001661B:F06 78676

4142 2/24/98 954 RTA00000410F.n.05.l M00001662A:C07 77830

4143 2/24/98 1182 RTA00000346F.d.21.1 M00001670B:G12 6641

4144 2/24/98 1043 RTA00000423F.b.l7.1 M00001662B:F06 8200

4145 2/24/98 447 RTA00000423F.b.04.3 M00001675D:E10 6311

4146 2/24/98 305 RTA00000418F.p.06.1 M00001664A:F08 32628

4147 2/24/98 1116 RTA00000410F.O.04.1 M00001664D:F04 79018

4148 2/24/98 320 RTA00000422F.p.07.2 M00001661A:E06 39024

4149 2/24/98 197 RTA00000410F.O.05.1 M00001669A:B02 75262

4150 2/24/98 738 RTA00000422F.n.20.1 M00001669B:B12 38676

4151 2/24/98 495 RTA00000400F.O.21.1 M00001669C:C08 16259

4152 2/24/98 1050 RTA00000405F.f.05.2 M00001669C:D09 14359

4152 2/24/98 1049 RTA00000405F.f.05.1 M00001669C:D09 14359

4153 2/24/98 1049 RTA00000405F.f.05.1 M00001669C:D09 14359

4153 2/24/98 1050 RTA00000405F.f.05.2 M00001669C:D09 14359

4154 2/24/98 492 RTA00000340F.O.18.1 M00001669D:C03 4261

4155 2/24/98 61 RTA00000410F.n.07.1 M00001662A:G01 78823

4156 2/24/98 299 RTA00000405F.1.15.1 M00001694A:E03 19575

4157 2/24/98 475 RTA00000411F.d.05.1 M00001681C:A08 75812

4158 2/24/98 692 RTA00000411F.d.l0.1 M00001681D:C12 76445

4159 2/24/98 336 RTA00000340F.n.l3.1 M00001688D:B10 17055

4160 2/24/98 270 RTA00000411F.d.l5.1 M00001692A:B06 74890

4161 2/24/98 969 RTA00000411F.d.l8.1 M00001692A:G06 76063

4162 2/24/98 927 RTA00000411F.d.21.1 M00001692B:E01 74794

4163 2/24/98 1133 RTA00000405F.1.03.1 M00001692D:B01 38580

4164 2/24/98 576 RTA00000401F.d.l5.2 M00001693C:C12 5297

4165 2/24/98 1059 RTA00000405F.h.21.2 M00001675C:D12 39072

4166 2/24/98 780 RTA00000405F.1.11.1 M00001693D:E08 2055

4167 2/24/98 933 RTA00000419F.3.18.1 M00001680A:B02 78484

4168 2/24/98 631 RTA00000411F.e.03.1 M00001694D:C12 73648

4169 2/24/98 585 RTA00000340R.O.12.1 M00003746C:E02 53732

4170 2/24/98 604 RTA00000351R.C.13.1 M00003747D:C05 11476

4171 2/24/98 187 RTA00000351R.g.ll.l M00003779D:E08 3077

4172 2/24/98 1060 RTA00000346F.g.02.1 M00003792A:B10 6901

4173 2/24/98 690 RTA00000341F.b.05.1 M00003793D:A11 0

4174 2/24/98 86 RTA00000346F.g.22.1 M00003794D:G03 6371

4175 2/24/98 1051 RTA00000346F.h.24.1 M00003797A:C11 4379

4176 2/24/98 377 RTA00000346F.i.01.1 M00003797A:D06 22260

4177 2/24/98 963 RTA00000405F.1.07.1 M00001693C:E09 38636 SEQ ID Filing SEQ ID Sequence Name Clone Nsme Cluster

NO: Date of NO: in ID

Priority Priority

Appln Appln

4178 2/24/98 121 RTA00000418F.p.l9.1 M00001677D:B01 78544

4179 2/24/98 781 RTA00000423F.f.09.1 M00003808C:A05 64823

4180 2/24/98 1028 RTA00000346F.d.l2.1 M00001676B:B09 11777

4181 2/24/98 82 RTA00000411F.b.03.1 M00001676B:E01 23634

4182 2/24/98 465 RTA00000350R.p.l8.1 M00001676B:F05 11460

4183 2/24/98 56 RTA00000411F.b.06.1 M00001676C:A04 77884

4184 2/24/98 789 RTA00000423F.b.l3.1 M00001676C:E07 20619

4185 2/24/98 267 RTA00000423F.a.l9.1 M00001676D:A02 21396

4186 2/24/98 836 RTA00000411F.b.l7.1 M00001676D:B02 72893

4187 2/24/98 370 RTA00000405F.i.20.1 M00001677A:G11 38532

4188 2/24/98 39 RTAOOOOO 187AF.1.7.1 M00001680D:F08 10539

4189 2/24/98 389 RTA00000411F.C.02.1 M00001677B:B04 72852

4190 2/24/98 1004 RTA00000419F.a.24.1 M00001680B:D02 79290

4191 2/24/98 958 RTA00000195AF.C.8.1 M00001678B:H01 0

4191 1/28/98 520 RTA00000195AF.C.8.1 M00001678B:H01 0

4192 2/24/98 958 RTA00000195AF.C.8.1 M00001678B:H01 0

4192 1/28/98 520 RTA00000195AF.C.8.1 M00001678B:H01 0

4193 2/24/98 500 RTA00000411F.C.10.1 M00001678D:B11 73117

4194 2/24/98 323 RTA00000421F.n.l9.1 M00001679A:D10 16409

4195 2/24/98 309 RTA00000340F.n.01.1 M00001679A:G06 39081

4196 2/24/98 337 RTA00000340F.p.04.1 M00001679D:B02 78533

4197 1/28/98 238 RTAOOOOO 187AR.L 12.1 M00001679D:F02 78415

4197 2/24/98 407 RTA00000340R.m.07.1 M00001679D:F02 78415

4198 1/28/98 238 RTAOOOOO 187AR.L 12.1 M00001679D:F02 78415

4198 2/24/98 407 RTA00000340R.m.07.1 M00001679D:F02 78415

4199 2/24/98 387 RTA00000411F.3.15.1 M00001675D:B08 73812

4200 2/24/98 48 RTA00000411F.b.24.1 M00001677B:A12 30041

4201 2/24/98 234 RTA00000195AF.d.4.1 M00003881D:D06 22766

4201 1/28/98 185 RTA00000195AF.d.4.1 M00003881D:D06 22766

4202 2/24/98 130 RTA00000406F.f.l2.1 M00003879A:C11 21895

4203 2/24/98 953 RTA00000406F.f.05.1 M00003878C:F06 22961

4204 2/24/98 138 RTA00000406F.f.03.1 M00003878C:D08 38687

4205 2/24/98 673 RTA00000406F.d.09.1 M00003875B:F12 38591

4206 2/24/98 136 RTA00000419F.I.12.1 M00003901C:B01 75710

4207 2/24/98 300 RTA00000406F.g.17.1 M00003881B:F10 37979

4208 2/24/98 2 RTA00000406F.d.l6.1 M00003875C:G02 15040

4209 2/24/98 1207 RTA00000401F.J.21.1 M00003901B:F10 0

4210 2/24/98 494 RTA00000419F. 2.1 M00003876C:F02 0

4211 2/24/98 515 RTA00000419F.1.03.1 M00003879A:D02 79060

4212 2/24/98 26 RTA00000423F.h.l8.1 M00003876C:D02 37972

4213 2/24/98 49 RTA00000406F.d.l2.1 M00003875C:A01 38575

4214 2/24/98 986 RTA00000406F.d.24.1 M00003876B:C05 37997

4215 2/24/98 150 RTA00000419F.L19.1 M00003877C:G12 75447

4216 2/24/98 538 RTA00000423F.g.04.1 M00003903D:C12 23012

4217 2/24/98 1046 RTA00000346F.J.06.1 M00003879A:A02 5767

4218 2/24/98 868 RTA00000406F.i.08.1 M00003903C:E12 37946

4219 2/24/98 409 RTA00000406F.f.ll.1 M00003879A:B08 38601

4220 2/24/98 924 RTA00000354R.m.02.1 M00003890B:C08 12766

4221 2/24/98 543 RTA00000419F.k.24.1 M00003878C:G08 75596

4222 1/28/98 185 RTA00000195AF.d.4.1 M00003881D:D06 22766 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID

Priority Priority

Appln Appln

4222 2/24/98 234 RTAOOOOO 195 AF.d.4.1 M00003881 D:D06 22766

4223 2/24/98 382 RTA00000341 F.li.10.1 M00003901 B:G 1 1 0

4224 2/24/98 550 RTA0000041 1 F.n.20.1 M00003875C:A09 75816

4225 2/24/98 614 RTA00000406F.U 3.1 M00003904A:C04 37904

4226 2/24/98 13 RTA00000406F.f. l 8.1 M00003879B:G02 38587

4227 2/24/98 1256 RTA00000401 F. 19.1 M00003903D:D10 799

4228 2/24/98 185 RTA00000423F.J.05.1 M00003903C:C05 37958

4229 2/24/98 1 77 RTA00000406F.i.l 2.1 M00003903D:H1 1 39080

4230 2/24/98 802 RTA00000406F.g.03.1 M00003880B:D1 1 38690

4231 2/24/98 34 RTA0000041 1 F.11.1 1.1 M00003875A:B01 77276

4232 2/24/98 498 RTA00000406F.e. l 5.1 M00003877C:A1 1 39074

4233 2/24/98 929 RTA0000041 1 F.n.09.1 M00003875A:A07 78962

4234 2/24/98 984 RTA00000406F.g.08.1 M00003880C:H03 37963

4235 2/24/98 818 RTA00000406F.h.05.1 M00003901 B:C03 38542

4236 2/24/98 592 RTA00000421 F.p.l 8.1 M00003877B:H 10 750

4237 2/24/98 313 RTA00000406F.g.07.1 M00003880C:E1 1 37925

4238 1/28/98 324 RTA00000184F.J.06.1 M00001556B:G02 1 1294

4239 2/24/98 773 RTA00000406F.h.03.1 M00003901 B:A09 38585

4240 3/24/98 244 RTA00000426F.p.09.1 M00004033D:B07 66665

4241 3/24/98 222 RTA00000426F.p. l0.1 M00004033D:C05 65845

4242 1/28/98 181 RTA00000198AF.d.2.1 M00001585A:F07 0

4243 1/28/98 77 RTA00000197AF.n.2.1 M00001535A:D02 6229

4244 2/24/98 844 RTA0000041 1 F.3.09.1 M00001675C:F01 78629

4245 2/24/98 352 RTA0000041 1 F.a. l 0.1 M00001675C:G01 73073

4246 3/24/98 272 RTA00000426F.m.02.1 M00004034C:C06 66237

4247 3/24/98 429 RTA00000525F.a. l4.1 M00004033B:C02 37566

4248 2/24/98 1 18 RTA00000408F.h.03.1 M00001479D:H03 78382

4249 3/24/98 156 RTA00000525F.b.22.1 M00004037C:D07 16679

4250 2/24/98 70 RTA00000409F.m. l3.1 M00001618B:E05 0

4251 2/24/98 1 198 RTA00000412F.f.l 0.2 M00003959A:A03 65405

4252 2/24/98 1 139 RTA00000404F.h.20.1 M00001619B:A09 15564

4253 3/24/98 41 RTA00000525F.b. l 7.1 M00004037B:A04 24715

4254 3/24/98 452 RTA00000525F.3.22.1 M00004033D:G06 36848

4255 2/24/98 1019 RTA00000403F.g.03.1 M00001479D:G06 23537

4256 2/24/98 532 RTA00000403F.3.24.1 M00001455B:A09 24128

4257 3/24/98 5 RTA00000426F.p.04.1 M00004029B:H08 34149

4258 3/24/98 43 RTA00000527F.p.07.1 M00004029C:B03 23343

4259 2/24/98 562 RTA00000401 F.J.17.1 M00003901 B:C05 5483

4260 2/24/98 303 RTA00000130A.h.22.1 M00001617A:D06 80933

4261 2/24/98 1201 RTA00000409F.m.02.1 M00001616C:A1 1 9157

4262 3/24/98 241 RTA00000527F.O.12.1 M00004028B:G08 688

4263 2/24/98 1 170 RTA00000409F.1.24.1 M00001616C:A02 73174

4264 2/24/98 1 76 RTA00000403F.b. l 0.1 M00001455C:G07 73268

4265 1/28/98 131 RTA00000185AF.d. l l .2 M00001579D:C03 6539

4265 1/28/98 626 RTAOOOOO 185 AR.d.1 1.1 M00001579D:C03 6539

4266 1/28/98 190 RTAOOOOO 134A.C.7.1 M00001528A:A01 5175

4266 1/28/98 176 RTAOOOOO 183AF.h.19.1 M00001528A:A01 5175

4267 3/24/98 90 RTA00000525F.3.03.1 M00004031 D:F05 36786

4268 3/24/98 236 RTA00000527F.O.01.1 M00004027A:D06 19088

4269 3/24/98 339 RTA00000426F.m.03.1 M00004034C:E08 66480 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

4270 1/28/98 183 RTAOOOOO 198AF.C.17.1 M00001579C:E08 6923

4271 3/24/98 44 RTA00000527F.p. l 7.1 M00004030C:D12 17223

4272 3/24/98 129 RTA00000527F.p. l 8.1 M00004030D:B06 31635

4273 3/24/98 402 RTA00000527F.p.24.1 M00004031 B:A06 36832

4274 3/24/98 1 18 RTA00000525F.a.02.1 M00004031 C:H 10 37454

4275 1/28/98 353 RTAOOOOO] 98F.a.9.1 M00001557D:C08 0

4276 2/24/98 1250 RTA00000403F.f.l 5.1 M00001477D:F10 22768

4277 1/28/98 13 1 RTA00000185AF.d. l l .2 M00001579D:C03 6539

4277 1/28/98 626 RTAOOOOO 185 AR.d.1 1.1 M00001579D:C03 6539

4278 2/24/98 428 RTA00000422F.f.l4.1 M00001478B:D07 2036

4279 1/28/98 209 RTAOOOOO 182AF.C.5.1 M00001464D:F06 6397

4279 1 /28/98 304 RTA00000182AR.C.5.1 M00001464D:F06 6397

4280 2/24/98 205 RTA00000138A.n.4.1 M00001624A:G 1 1 21920

4281 2/24/98 251 RTAOOOOO 1 19A.Ϊ.9.1 M00001457A:G03 0

4282 3/24/98 250 RTA00000427F.h.24.1 M00004091 B:H09 65193

4283 1/28/98 61 RTAOOOOO 197AF.h.1 1.1 M00001476D:G03 22264

4284 3/24/98 216 RTA00000427F.h. l l . l M00004092C:B 12 26494

4285 1/28/98 1 10 RTAOOOOO 197R.h.01.1 M00001470A:H01 13075

4285 1/28/98 591 RTAOOOOO 197AF.h.1.1 M00001470A:H01 13075

4286 1/28/98 1 10 RTAOOOOO 197R.h.01.1 M00001470A:H01 13075

4286 1/28/98 591 RTAOOOOO 197AF.li.1.1 M00001470A:H01 13075

4287 3/24/98 276 RTA00000427F.h.l9.1 M00004092D:B1 1 63047

4288 1/28/98 335 RTAOOOOO 182AF.e.3.2 M00001468B:H06 0

4289 3/24/98 475 RTA00000427F.i.06.1 M00004097B:D03 41450

4290 2/24/98 286 RTA00000404F.i.l9.1 M00001625B:C10 38698

4291 1/28/98 209 RTAOOOOO 182AF.C.5.1 M00001464D:F06 6397

4291 1/28/98 304 RTA00000182AR.C.5.1 M00001464D:F06 6397

4292 2/24/98 1 165 RTA00000408F.C.08.1 M00001456D:G 1 1 73473

4293 1/28/98 304 RTA00000182AR.C.5.1 M00001464D:F06 6397

4293 1/28/98 209 RTA00000182AF.C.5.1 M00001464D:F06 6397

4294 1/28/98 138 RTAOOOOO 182AF.a.3.3 M00001462B:A10 0

4295 1/28/98 36 RTA00000181 AF.p.4.3 M00001460A:A03 40392

4296 2/24/98 523 RTA00000418F.J.09.1 M00001626C:D12 76352

4297 2/24/98 296 RTA00000347F.d.06.1 M00001457C:F02 39122

4298 1/28/98 390 RTAOOOOO 197AR.f.07.1 M00001457C:C1 1 19261

4298 1/28/98 184 RTAOOOOO 197 AF.f.7.1 M00001457C:C1 1 19261

4299 1/28/98 184 RTAOOOOO 197 AF.f.7.1 M00001457C:C1 1 19261

4299 1/28/98 390 RTAOOOOO 197AR.f.07.1 M00001457C:C1 1 19261

4300 1/28/98 133 RTA00000181 AR.n.20.3 M00001457B:E03 0

4301 3/24/98 132 RTA00000427F. 17.1 M00004101 A:F07 64965

4302 3/24/98 218 RTA00000427F.i. l9.1 M00004102C:D01 64206

4303 3/24/98 436 RTA00000427F.i.21.1 M00004102C:F03 65540

4304 1/28/98 209 RTA00000182AF.C.5.1 M00001464D:F06 6397

4304 1/28/98 304 RTAOOOOO 182AR.C.5.1 M00001464D:F06 6397

4305 1/28/98 176 RTAOOOOO 183AF.h.19.1 M00001528A:A01 5175

4305 1/28/98 190 RTAOOOOO 134A.C.7.1 M00001528A:A01 5175

4306 1/28/98 12 RTA00000183AF.i.l 5.2 M00001529B:C04 2642

4306 2/24/98 379 RTA00000349R.J.07.1 M00001529B:C04 2642

4307 2/24/98 1 156 RTA00000408FT.10.2 M00001476D:C05 75309

4308 2/24/98 366 RTA00000403F.C.10.1 M00001456D:F05 75261 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

4309 2/24/98 353 RTA00000409F.n.17.1 M00001621 C:C10 76725

4310 2/24/98 526 RTA0000041 1 F.a.05.1 M00001675B:H03 76699

431 1 2/24/98 90 RTA0000041 1 F.a.02.1 M00001675B:E02 78537

4312 2/24/98 952 RTA0000041 1 F.a.01.1 M00001675B:D02 74524

4313 2/24/98 392 RTA00000410F.p.23.1 M00001675B:C01 73948

4314 2/24/98 238 RTA00000340F.J.12.1 M00001624A:B06 3277

4315 1/28/98 176 RTAOOOOO 183AF.h.19.1 M00001528A:A01 5175

4315 1/28/98 190 RTAOOOOO 134A.C.7.1 M00001528A:A01 5175

4316 2/24/98 298 RTA00000406F.h.07.1 M00003901 B:H04 38003

4317 1/28/98 190 RTA00000134A.C.7.1 M00001528A:A01 5175

4317 1/28/98 176 RTAOOOOO 183AF.h.19.1 M00001528A:A01 5175

4318 1/28/98 12 RTA00000183AF.U 5.2 M00001529B:C04 2642

4318 2/24/98 379 RTA00000349R.J.07.1 M00001529B:C04 2642

4319 1/28/98 122 RTAOOOOO 197AF.1.15.1 M00001517B:G08 4947

4320 3/24/98 199 RTA00000427F.f.24.1 M00004076D:B09 64572

4321 1/28/98 161 RTA00000183AF.e.23.2 M00001506D:A09 0

4322 1/28/98 17 RTA00000183 AR.e.14.2 M00001506B:D09 17437

4323 1/28/98 346 RTAOOOOO 197 AR.k.22.1 M00001505C:H01 1 1394

4324 1/28/98 125 RTA00000197AF.k.l5.1 M00001504D:D1 1 22750

4325 1/28/98 212 RTAOOOOO 197 AF.j.9.1 M00001494B:C01 13236

4326 1/28/98 314 RTA00000182AF.O.5.1 M00001493B:D09 5007

4327 1/28/98 386 RTAOOOOO 197AR.J.04.1 M00001492D:A1 1 17209

4327 1/28/98 259 RTA00000197AF.J.4.1 M00001492D:A1 1 17209

4328 1/28/98 259 RTAOOOOO 197AF.J .4.1 M00001492D:A1 1 17209

4328 1/28/98 386 RTAOOOOO 197 AR.j .04.1 M00001492D:A1 1 17209

4329 1/28/98 94 RTAOOOOO 195 AF.b.4.1 M00001490C:D07 0

4330 1/28/98 336 RTAOOOOO 186AFT.24.1 M00001629B:E06 0

4330 1/28/98 83 RTAOOOOO 186AFT.24.2 M00001629B:E06 0

4331 2/24/98 1037 RTA00000339F.1.12.1 M00001450A:G1 1 771 1

4332 1/28/98 432 RTA00000198AF.O.05.1 M00003750A:D01 26702

4332 1/28/98 49 RTA00000198R.O.05.1 M00003750A:D01 26702

4333 2/24/98 468 RTA00000423F.C.19.1 M00001680B:E10 40472

4334 2/24/98 1009 RTA00000399F.O.24.1 M00001607D:A1 1 2272

4335 1/28/98 281 RTAOOOOO 188AF.n.10.1 M00003802D:B1 1 10283

4336 1/28/98 157 RTAOOOOO 188 AF.n.01.1 M00003801A:B10 36412

4337 2/24/98 842 RTA00000401 F.n.23.1 M00003982A:B06 1552

4338 2/24/98 1216 RTA00000404F.e.07.1 M00001608A:D03 9034

4339 2/24/98 1045 RTA00000408F.J.05.2 M00001483C:G06 73878

4340 2/24/98 483 RTA00000406F.g.22.1 M00003881 D:C 12 38590

4341 1/28/98 310 RTA00000188AF.m.08.1 M00003798D:H08 22155

4342 1/28/98 1 18 RTAOOOOO 199F.b.24.2 M00003794A:B03 0

4343 1/28/98 218 RTA00000188AF.O.18.1 M0000381 1 D:A12 13678

4344 3/24/98 380 RTA00000427F.e.l3.1 M00003959D:A04 66080

4345 1/28/98 315 RTA00000199R.d.23.1 M00003815D:H09 37477

4346 1/28/98 140 RTAOOOOO 199F.a.2.1 M00003772A:D07 12674

4347 3/24/98 101 RTA00000523F.J.19.1 M00003966B:D02 65910

4348 1/28/98 278 RTA00000198AF-P- 16.1 M00003768A:E02 71877

4349 2/24/98 514 RTA00000404F.e. l 3.1 M00001608D:E09 12046

4350 1/28/98 508 RTA00000187AF.i.l4.2 M00001679B:H07 19406

4350 2/24/98 928 RTA00000340F.m.04.1 M00001679B:H07 19406 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID

Priority Priority

Appln Appln

4351 1/28/98 317 RTA00000198AF.p.09.1 M00003761 D:E02 10473

4351 1 /28/98 186 RTAOOOOO 198R.p.09.1 M00003761 D:E02 10473

4352 1/28/98 317 RTAOOOOO 198 AF.p.09.1 M00003761 D:E02 10473

4352 1/28/98 186 RTAOOOOO 198R-P-09.1 M00003761 D:E02 10473

4353 3/24/98 66 RTA00000427F.b.l 5.1 M00003971 C:F09 66891

4354 1 /28/98 508 RTA00000187AF.U4.2 M00001679B:H07 19406

4354 2/24/98 928 RTA00000340F.m.04.1 M00001679B:H07 19406

4355 1 /28/98 144 RTAOOOOO 198 AF.o.18.1 M00003755A:A09 13018

4356 3/24/98 248 RTA00000527F.I.14.1 M00003983D:A09 14935

4357 1/28/98 347 RTA00000199F.b.03.2 M00003779B:E12 38340

4358 1 /28/98 272 RTAOOOOO 199F.g.08.2 M00003853D:G08 0

4359 1/28/98 263 RTAOOOOO] 90AF.n.6.1 M00003965A:B1 1 0

4360 2/24/98 1 183 RTA00000346F.J.21.1 M00003879D:A08 3095

4361 2/24/98 553 RTA00000408F.J.12.2 M00001485B:C03 18226

4362 3/24/98 181 RTA00000523F.b.06.1 M00003808A:F09 28736

4363 1 /28/98 246 RTAOOOOO 199AF.1.4.1 M0000391 1 D:B04 4410

4364 1 /28/98 51 RTAOOOOO 199R.k.07.1 M00003901 C:A03 12973

4365 1/28/98 62 RTAOOOOO 190AF.a.18.2 M00003900D:B 10 0

4366 1/28/98 1 17 RTAOOOOO 199AF.J.18.1 M00003889D:B09 5140

4367 1/28/98 255 RTAOOOOO 199 AF.j.17.1 M00003889A:D10 5121

4368 1/28/98 180 RTA00000199AF.J.12.1 M00003887A:A06 22461

4369 3/24/98 256 RTA00000523F.b.20.1 M00003809C:H07 66492

4370 2/24/98 603 RTA00000399F.O.19.1 M00001607A:F1 1 2594

4371 2/24/98 510 RTA00000131A.g.l6.2 M00001449A:F01 0

4372 1/28/98 49 RTA00000198R.O.05.1 M00003750A:D01 26702

4372 1/28/98 432 RTAOOOOO 198AF.O.05.1 M00003750A:D01 26702

4373 2/24/98 424 RTA00000138A.e.l3.1 M00001605A:E06 79608

4374 1/28/98 90 RTAOOOOO 199F.f.15.2 M00003845A:H12 8772

4375 1/28/98 244 RTAOOOOO 199F.f.12.2 M00003844C:A08 8131

4376 1/28/98 78 RTA00000199R.f.09.1 M00003842B:D09 22907

4376 1/28/98 406 RTAOOOOO 199FT.09.2 M00003842B:D09 22907

4377 1/28/98 406 RTAOOOOO 199F.f.09.2 M00003842B:D09 22907

4377 1/28/98 78 RTAOOOOO 199RT.09.1 M00003842B:D09 22907

4378 1/28/98 44 RTAOOOOO 199F .08.2 M00003841 D:E03 12445

4379 1/28/98 39 RTAOOOOO 189AR.b.19.1 M00003832B:E01 5294

4379 2/24/98 239 RTA00000346F.J.02.1 M00003832B:E01 5294

4380 1/28/98 39 RTAOOOOO 189AR.b.19.1 M00003832B:E01 5294

4380 2/24/98 239 RTA00000346F.J.02.1 M00003832B:E01 5294

4381 2/24/98 1 161 RTA00000346F.m.05.1 M00003983B:C08 5644

4382 2/24/98 887 RTA00000339F.p.06.1 M00001484A:A10 4880

4383 3/24/98 46 RTA00000523F.C.09.1 M00003813C:D08 47389

4384 2/24/98 1206 RTA00000418F.b.20.1 M00001484D:G05 73560

4385 1 /28/98 336 RTAOOOOO 186AF.f.24.1 M00001629B:E06 0

4385 1/28/98 83 RTAOOOOO 186AFT.24.2 M00001629B:E06 0

4386 1/28/98 1 1 1 RTAOOOOO 198 AF.o.12.1 M00003751 D:B02 22038

4387 3/24/98 365 RTA00000527F.U 6.1 M00003982B:B06 1015

4388 2/24/98 1 1 13 RTA00000418F.p.21.1 M00001677D:F03 78068

4389 3/24/98 281 RTA00000527F.k.20.1 M00003982B:H07 17148

4390 1/28/98 360 RTA00000198F.i.5.1 M00001638A:D10 39989

4391 1/28/98 55 RTAOOOOO 186AF.i.21.1 M00001636C:H09 6033 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

4392 1/28/98 316 RTAOOOOO 198AF.h.24.1 M00001636C:C01 8390

4393 1/28/98 208 RTAOOOOO 198AF.h.22.1 M00001635C:A03 22366

4394 2/24/98 1031 RTA00000404F.g.08.1 M00001613D:H 10 38980

4395 3/24/98 382 RTA00000427F.a. l2.1 M00003982C:H 10 63377

4396 2/24/98 916 RTA00000418F.p.20.1 M00001677D:B07 78023

4397 1/28/98 91 RTAOOOOO 198 AF.j.19.1 M00001653C:F12 38914

4398 2/24/98 858 RTA00000341 F.e.20.1 M00003891 D:B 10 67422

4399 1/28/98 354 RTA00000198R.k.03.1 M00001655A:F06 22765

4399 1/28/98 158 RTA00000198AF.k.03.1 M00001655A:F06 22765

4400 3/24/98 219 RTA00000427F.f.l 7.1 M000041 15A:B12 63803

4401 3/24/98 153 RTA00000527F.1.13.1 M00003983C:F10 36904

4402 3/24/98 320 RTA00000427F.J.06.1 M00004102D:B05 63676

4403 2/24/98 762 RTA0000041 1 F.C.04.1 M00001677B:E06 76858

4404 2/24/98 957 RTA0000041 1 F.C.03.1 M00001677B:B06 79280

4405 3/24/98 479 RTA00000527F.1.23.1 M00003984A:B06 36018

4406 1/28/98 329 RTAOOOOO 186AF.b.9.1 M00001616C:F07 0

4407 2/24/98 1 1 15 RTA00000340F.i.08.1 M00001615B:F07 12005

4408 2/24/98 1022 RTA00000401 F.J.15.1 M00003901 A:C09 3061

4409 1/28/98 4 RTAOOOOO 198RT.04.1 M00001607D:F07 5023

4410 3/24/98 173 RTA00000426F.m. l 8.1 M00003986D:G07 62974

441 1 2/24/98 616 RTA00000423F.C.1 1.1 M00001677D:B02 0

4412 1/28/98 345 RTA00000187AF.h.21.1 M00001679A:F01 39171

4413 2/24/98 621 RTA00000408F.i.l 8.2 M00001482C:D02 74410

4414 1/28/98 344 RTA00000198AF.O.02.1 M00003748A:B07 68756

4415 2/24/98 257 RTA0000041 1 F.C.17.1 M00001678D:G03 77664

4416 2/24/98 944 RTA00000422F.L24.1 M00001610C:E06 391 18

4417 2/24/98 876 RTA00000423F.d.l6.1 M00001678D:C1 1 39173

4418 2/24/98 1 144 RTA00000345F.J.09.1 M00001451 B:F01 13

4419 1/28/98 242 RTAOOOOO 198 AF.m.17.1 M00001679D:F06 77992

4419 1/28/98 260 RTA00000198R.m. l 7.1 M00001679D:F06 77992

4420 1/28/98 260 RTAOOOOO 198R.m.17.1 M00001679D:F06 77992

4420 1/28/98 242 RTAOOOOO 198AF.ni.17.1 M00001679D:F06 77992

4421 1/28/98 242 RTAOOOOO 198AF.m.17.1 M00001679D:F06 77992

4421 1/28/98 260 RTAOOOOO 198R.m.17.1 M00001679D:F06 77992

4422 1/28/98 260 RTA00000198R.m. l 7. l M00001679D:F06 77992

4422 1/28/98 242 RTAOOOOO 198AF.m.17.1 M00001679D:F06 77992

4423 1/28/98 238 RTA0000O187AR. 12.1 M00001679D:F02 78415

4423 2/24/98 407 RTA00000340R.m.07.1 M00001679D:F02 78415

4424 1/28/98 276 RTA00000198AF.J.15.1 M00001653B:E09 4369

4425 1/28/98 65 RTAOOOOO 198 AF.m.16.1 M00001679D:D05 51

4426 1/28/98 257 RTAOOOOO 198AF.e.20.1 M00001604C:E09 9810

4427 2/24/98 820 RTA00000423F.d. l l . l M00001678C:C06 38950

4428 3/24/98 466 RTA00000427F.d.06.1 M00003980B:C06 33446

4429 2/24/98 455 RTA00000399F.d.23.1 M00001481 B:A07 3310

4430 2/24/98 851 RTA00000423F.d.07.1 M00001678B:B12 0

4431 1/28/98 142 RTAOOOOO 198AF. 19.1 M00001660B:C04 75879

4432 2/24/98 485 RTA00000419F.a.02.1 M00001678A:F05 77993

4433 3/24/98 224 RTA00000527F.k.09.1 M00003981C:F05 213

4434 2/24/98 1032 RTA00000423F.C.13.1 M00001678A:A1 1 39059

4435 1/28/98 354 RTAOOOOO 198R. 03.1 M00001655A.-F06 22765 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

4435 1/28/98 158 RTAOOOOO 198 AF.k.03.1 M00001655A:F06 22765

4436 1/28/98 354 RTA00000198R. 03.1 M00001655A:F06 22765

4436 1 /28/98 158 RTA00000198AF.k.03.1 M00001655A:F06 22765

4437 1/28/98 158 RTA00000198AF.k.03.1 M00001655A:F06 22765

4437 1/28/98 354 RTA00000198R.k.03.1 M00001655A:F06 22765

4438 1/28/98 238 RTAOOOOO 187AR.L 12.1 M00001679D:F02 78415

4438 2/24/98 407 RTA00000340R.m.07.1 M00001679D:F02 78415

4439 1/28/98 669 RTA00000192AF.C.2.1 M00004121 B:G01 0

4440 3/24/98 394 RTA00000527F.g. l 4.1 M00003845D:B02 37532

4441 1/28/98 608 RTAOOOOO] 92AF.p.8.1 M00004212B:C07 2379

4441 2/24/98 653 RTA00000352R.m. l2.1 M00004212B:C07 2379

4442 1/28/98 608 RTA00000192AF.p.8.1 M00004212B:C07 2379

4442 2/24/98 653 RTA00000352R.m.l2.1 M00004212B:C07 2379

4443 1/28/98 730 RTAOOOOO 192 AF.o.1 1.1 M00004205D:F06 0

4444 2/24/98 1 157 RTA00000422F.m. l 8.1 M00001647B:E04 23829

4445 2/24/98 1 187 RTA00000120A.C.19.1 M00001464A:B03 81016

4446 2/24/98 913 RTA00000120A.C.20.1 M00001464A:B07 43235

4447 1/28/98 589 RTA00000192AF.1.1.1 M00004183C:D07 16392

4448 2/24/98 640 RTA00000405F.f.02.1 M00001669B.-G02 38665

4449 1/28/98 27 RTAOOOOO 192AF.i.12.1 M00004169C:C12 5319

4450 2/24/98 681 RTA00000120A.C.24.1 M00001464A:D03 34278

4451 2/24/98 265 RTA00000340F. 16.1 M00001647B:C09 13157

4452 1/28/98 70 RTAOOOOO 192 AF.e.3.1 M00004138B:H02 13272

4453 3/24/98 171 RTAO0O00523F.e.l 0.1 M00003829A:F03 62878

4454 2/24/98 1 134 RTA00000418F.m.02.1 M00001650A:A12 74550

4455 1/28/98 618 RTA00000192AF.a.l4.1 M000041 1 1D:A08 6874

4456 1/28/98 457 RTA00000191AR.1.7.2 M00004081 C:D12 14391

4457 2/24/98 596 RTA00000351 R.L03.1 M00003846B:D06 6874

4458 3/24/98 460 RTA00000523F.f. l 6.1 M00003840B:E07 26522

4459 3/24/98 400 RTA00000523F.f. l 7.1 M00003840B:E08 63984

4460 2/24/98 1 129 RTA00000401 F.m.07.1 M00003907D:F1 1 2893

4461 2/24/98 132 RTA00000418F.m.05.1 M00001650B:C 10 73600

4462 1/28/98 482 RTA00000187AF.J.7.1 M00001679C:F01 78091

4463 2/24/98 1 107 RTA00000419F.1.22.1 M00003903D:C06 78444

4464 2/24/98 609 RTA00000404F.O.10.2 M00001651 B:B12 16785

4465 1/28/98 376 RTA00000177AF.m.l 8.3 M00001355B:G1 1 0

4465 1/28/98 375 RTA00000177AF.m.l 8.1 M00001355B:G 1 1 0

4466 2/24/98 186 RTA00000132A.k.6.1 M00001464A:E07 81284

4467 1/28/98 18 RTA00000196AF.C.17.1 M00001352C:F06 39602

4468 3/24/98 282 RTA00000427F.h.22.1 M00004108C:E01 64547

4469 2/24/98 859 RTA00000419F.m.22.1 M00003914A:G09 75600

4470 3/24/98 33 RTA00000524F.b.21.1 M00005216C:B09 0

4471 3/24/98 170 RTA00000523F.d. l2.1 M00003822B:D08 64888

4472 3/24/98 1 17 RTA00000523F.d.l 8.1 M00003822B:G01 64072

4473 2/24/98 739 RTA00000423F.h.20.1 M00003914A:G06 38639

4474 2/24/98 527 RTA00000419F.m.21 .1 M00003914A:E04 77947

4475 2/24/98 237 RTAOOOOO 1 19AJ.22. I M00001460A:F07 80336

4476 2/24/98 349 RTA00000404F.m.l 0.2 M00001641 D:E02 779

4477 2/24/98 462 RTAOOOOO 1 19A.J.23.1 M00001460A:G07 79835

4478 2/24/98 1263 RTA00000341 F. 22.1 M0000391 1 A:F10 7825 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

4479 3/24/98 47 RTA00000523F.e.l8.1 M00003829D:A11 62898

4480 1/28/98 152 RTA00000196AF.C.20.1 M00001352C:H02 8934

4481 3/24/98 13 RTA00000528F.m.l6.1 M00003845D:C03 4468

4482 1/28/98 14 RTAOOOOO 196R.C.11.2 M00001352A:E12 13658

4483 2/24/98 641 RTA00000410F.J.20.1 M00001642D:G10 73601

4484 1/28/98 141 RTAOOOOO 196AF.C.6.1 M00001350A:D06 23148

4485 1/28/98 25 RTA00000196AF.C.1.1 M00001349C:C05 8171

4486 2/24/98 436 RTAOOOOO 119A.m.15.1 M00001461A:E05 80989

4487 1/28/98 9 RTAOOOOO 177 AF.g.22.1 M00001347C:G08 7031

4488 2/24/98 162 RTA00000406F.I.08.1 M00003908D:D12 39016

4489 2/24/98 1056 RTA00000419F.rn.18.] M00003908C:G09 76014

4490 1/28/98 73 RTAOOOOO 177 AF.e.21.3 M00001344A:H07 4306

4491 3/24/98 326 RTA00000527F.e.09.1 M00003826B:E11 37521

4492 2/24/98 900 RTA00000419F.m.l3.1 M00003908A:F12 79052

4493 2/24/98 441 RTA00000404F.m.20.2 M00001647A:H08 39144

4494 2/24/98 1217 RTA00000410F.J.17.1 M00001642D:F02 72912

4495 3/24/98 309 RTA00000523F.J.10.1 M00003860B:G09 63384

4496 2/24/98 385 RTA00000418F.m.l4.1 M00001651B:E06 75711

4497 2/24/98 1121 RTA00000120A.m.10.3 M00001467A:B03 81376

4498 1/28/98 617 RTAOOOOO 179AF.d.13.3 M00001394A:F01 6583

4499 2/24/98 1242 RTA00000405F.d.l0.1 M00001661C:F11 39000

4500 3/24/98 19 RTA00000527F.J.02.2 M00003856A:B07 4896

4501 2/24/98 645 RTA00000422F.p.l2.2 M00001661C:F10 9840

4502 3/24/98 142 RTA00000523F.i.l8.1 M00003856B:C04 64463

4503 2/24/98 376 RTA00000400F.L22.1 M00001656A:B07 2512

4504 1/28/98 532 RTA00000177AF.O.4.1 M00001358C:C06 0

4505 2/24/98 1128 RTA00000423F.a.02.3 M00001656B:A08 39210

4506 2/24/98 1143 RTA00000423F.a.03.1 M00001656B:D05 26796

4507 2/24/98 408 RTA00000405F.d.l4.1 M00001662A:C12 35209

4508 3/24/98 360 RTA00000523F.J.03.1 M00003860A:A08 64535

4509 1/28/98 409 RTAOOOOO 180AF.d.1.3 M00001418D:B06 8526

4510 2/24/98 784 RTA00000418F.O.14.1 M00001661B:B05 33524

4511 3/24/98 120 RTA00000426F.h.09.1 M00003905B:G03 78797

4512 1/28/98 706 RTA00000177AF.i.6.4 M00001350A:B08 0

4513 3/24/98 4 RTA00000426F.h.ll.l M00003905B:H05 75479

4514 2/24/98 697 RTA00000412F.d.l4.1 M00003905D:C08 76757

4515 2/24/98 908 RTA00000423F.g.03.1 M00003905C:G11 38007

4516 3/24/98 342 RTA00000427F.e.l2.1 M00003959C:G06 62813

4517 2/24/98 97 RTA00000403F.e.01.1 M00001473A:C11 38965

4518 2/24/98 555 RTA00000133A.d.22.1 M00001469A:G11 11797

4519 2/24/98 454 RTA00000418F.n.19.1 M00001659C:F02 28761

4520 2/24/98 562 RTA00000401F.J.17.1 M00003901B:C05 5483

4521 2/24/98 1215 RTA00000422F.O.08.2 M00001659D:D03 26832

4522 2/24/98 635 RTA00000418F.O.17.1 M00001661B:F03 79069

4523 3/24/98 190 RTA00000523F.li.12.1 M00003851C:D07 65745

4524 1/28/98 267 RTAOOOOO 186 AF.g.11.2 M00001630B:HO9 5214

4525 2/24/98 238 RTA00000340F.J.12.1 M00001624A:B06 3277

4526 2/24/98 331 RTA00000404F.O.18.2 M00001651C:C05 39110

4527 1/28/98 626 RTAOOOOO 185 AR.d.11.1 M00001579D:C03 6539

4527 1/28/98 131 RTA00000185AF.d.ll.2 M00001579D:C03 6539 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

4528 1/28/98 626 RTAOOOOO 185 AR.d.1 1.1 M00001579D:C03 6539

4528 1/28/98 131 RTAOOOOO 185 AF.d.1 1.2 M00001579D:C03 6539

4529 1/28/98 147 RTAOOOOO 185 AF.c.24.2 M00001578B:E04 23001

4530 2/24/98 164 RTA00000345F. 06.1 M00001475A:A12 0

4531 2/24/98 61 1 RTA00000404F.p.02.2 M00001652D:A06 39097

4532 2/24/98 274 RTA00000405F.e.08.1 M00001663C:F10 37916

4533 2/24/98 755 RTA00000423F.d.l 7.1 M00001663A:C1 1 20630

4534 2/24/98 126 RTA00000422F.J.20.1 M00001653A.-G07 22388

4535 3/24/98 195 RTA00000523F .08.1 M00003855A:C12 65099

4536 3/24/98 83 RTA00000527F.i.05.2 M00003851C:B06 37481

4537 1/28/98 375 RTAOOOOO 177AF.ni.18.1 M00001355B:G1 1 0

4537 1/28/98 376 RTAOOOOO 177AF.m.18.3 M00001355B:G1 1 0

4538 2/24/98 763 RTAOOOOO 135 A.m.18.1 M00001545A:C03 19255

4539 2/24/98 362 RTA00000418F.m.16.1 M00001653B:E06 74986

4540 2/24/98 287 RTA00000410F.n.09.1 M00001662C:A04 1 1736

4541 3/24/98 416 RTA00000527F.i.l2.2 M00003852B:D1 1 0

4542 2/24/98 662 RTA00000339F.O.07.1 M00001473D:G01 2566

4543 2/24/98 949 RTA00000340R.J.07.1 M00001654C:D05 38954

4544 3/24/98 146 RTA00000527F.U 7.2 M00003853B:C08 37539

4545 2/24/98 939 RTA00000405F.a.03.1 M00001654C:E04 39065

4546 3/24/98 42 RTA00000527F.U9.2 M00003853C:C06 38089

4547 3/24/98 381 RTA00000426F.f.l 8.1 M00003854C:C02 63271

4548 2/24/98 656 RTA00000403F.e.08.1 M00001473D:B1 1 19126

4549 3/24/98 37 RTA00000426FT.20.1 M00003854C:F01 65134

4550 2/24/98 733 RTA00000405F.d. l 8.1 M00001662C:B02 10494

4551 1/28/98 334 RTAOOOOO 181 AR.b.21.3 M00001444C:D05 3266

4551 1/28/98 321 RTAOOOOO 181 AR.b.21.1 M00001444C:D05 3266

4552 3/24/98 198 RTA00000523F.O.05.1 M00005175B:H04 0

4553 3/24/98 302 RTA00000427F.p.04.2 M00005100B:H07 0

4554 3/24/98 203 RTA00000427F.p. l 0.2 M00005102C:F09 0

4555 1/28/98 331 RTA00000197AR.C.20.1 M00001449D:A06 16282

4556 3/24/98 6 RTA00000523F.1.10.1 M00005134B:E01 0

4557 1/28/98 174 RTA00000181 AF.e.22.3 M00001448D:F09 3442

4558 3/24/98 79 RTA00000523F.1.15.1 M00005134C:E1 1 0

4559 3/24/98 386 RTA00000523F.1.16.1 M00005134C:G04 0

4560 3/24/98 76 RTA00000523F.1.18.1 M00005134D:A06 0

4561 3/24/98 192 RTA00000523F.m.02.1 M00005134D:H03 0

4562 3/24/98 290 RTA00000427F.1.03.1 M00005136D:B07 0

4563 3/24/98 269 RTA00000427F.p.02.2 M00005100B:D02 0

4564 1/28/98 321 RTAOOOOO 181 AR.b.21.1 M00001444C:D05 3266

4564 1/28/98 334 RTAOOOOO 181 AR.b.21.3 M00001444C:D05 3266

4565 3/24/98 334 RTA00000427F.ii.1 1.1 M00004960B:A09 0

4566 1/28/98 334 RTA00000181 AR.b.21.3 M00001444C:D05 3266

4566 1/28/98 321 RTAOOOOO 181 AR.b.21.1 M00001444C:D05 3266

4567 1/28/98 334 RTAOOOOO 1 81 AR.b.21.3 M00001444C:D05 3266

4567 1/28/98 321 RTAOOOOO 181 AR.b.21.1 M00001444C:D05 3266

4568 3/24/98 328 RTA00000523F.n.01.1 M00005137A:E01 0

4569 1/28/98 356 RTA00000180AF.1.12.2 M00001433B:H1 1 0

4570 3/24/98 68 RTA00000523F.n.04.1 M00005138B:D12 0

4571 3/24/98 127 RTA00000523F.n. l 0.1 M00005140D:G09 0 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

4572 1/28/98 187 RTAOOOOO 180AR.J.04.4 M00001429C:G12 22300

4573 3/24/98 1 12 RTA00000523F.n.l2.1 M00005173C:A02 0

4574 3/24/98 305 RTA00000523F.H.16.1 M00005173D:H02 0

4575 3/24/98 164 RTA00000523F.n. l 7.1 M00005174D:B02 0

4576 3/24/98 107 RTA00000523F.n.20.1 M00005174D:H02 0

4577 2/24/98 898 RTA00000418F.1.03.1 M00001641C:C06 79058

4578 3/24/98 288 RTA00000427F.1.04.1 M00005136D:C01 0

4579 3/24/98 462 RTA00000427F.p.l3.2 M00004695B:E04 0

4580 1/28/98 137 RTA00000181 AF.m.4.3 M00001455A:E09 13238

4581 1/28/98 20 RTA00000181AF.1.14.2 M00001454D:D06 2364

4582 3/24/98 105 RTA00000526F.d.01.1 M00004104B:A02 4468

4583 3/24/98 261 RTA00000427F.L22.1 M00004104D:B05 63199

4584 3/24/98 81 RTA00000427F.J.07.1 M00004105A:B10 64819

4585 3/24/98 287 RTA00000525F.d. l9.1 M000041 14B:D09 36860

4586 1/28/98 31 1 RTAOOOOO 191 AR.j.4.2 M00004071 D:A10 5198

4587 3/24/98 337 RTA00O00525F.e.08.1 M000041 15C:H04 24193

4588 3/24/98 206 RTA00000525FT.07.1 M000041 19A:A06 37500

4589 3/24/98 461 RTA00000427F.f. l 5.1 M000041 19D:A07 66734

4590 3/24/98 410 RTA00000427F.f.l 6.1 M000041 19D:H06 64122

4591 3/24/98 307 RTA00000427F.p.03.2 M00005100B:G1 1 0

4592 3/24/98 180 RTA00000523F.k.02.1 M00004687A:C03 0

4593 1/28/98 1 15 RTAOOOOO 179 AR.o.20.3 M00001409D:F1 1 2409

4594 3/24/98 315 RTA00000427F.n. l9.1 M00004891 D:E07 0

4595 3/24/98 375 RTA00000427F.p. l9.2 M00004895C:G05 0

4596 3/24/98 470 RTA00000427F.p.24.2 M00004897D:F03 0

4597 1/28/98 155 RTA00000197F.e.8.1 M00001454A:C1 1 3135

4598 1/28/98 286 RTA00000181AR. 2.3 M00001453C:A1 1 0

4598 1/28/98 389 RTA00000181 AR. 2.2 M00001453C:A1 1 0

4599 1/28/98 286 RTA00000181AR.k.2.3 M00001453C:A1 1 0

4599 1/28/98 389 RTA00000181AR.k.2.2 M00001453C:A 1 1 0

4600 1/28/98 285 RTA00000181 AR.J.14.3 M00001453B:E10 5399

4601 3/24/98 317 RTA00000428F.a.01.1 M00004897D:G05 0

4602 3/24/98 85 RTA00000427F.m.21 .1 M00004900C:E1 1 0

4603 3/24/98 121 RTA00000427F.n.02.1 M00004900D:B10 0

4604 3/24/98 78 RTA00000427F.O.05.1 M00004958B:D01 0

4605 3/24/98 437 RTA00000427F.n. l0.1 M00004960B:A08 0

4606 3/24/98 388 RTA00000526F.d.l 7.1 M00004235A:A12 2757

4607 1 /28/98 299 RTA00000196AF.f.5.1 M00001366D:G02 1 1937

4608 1/28/98 369 RTA00000196F.m.3.1 M00001413A:F02 10453

4609 3/24/98 319 RTA00000523F.p.l5.1 M00005178B:H01 0

4610 1/28/98 374 RTAOOOOO 178AF.1.1 1.1 M00001383A:G04 23286

461 1 2/24/98 1090 RTA00000405F.g.22.1 M00001673C:A02 527

4612 1/28/98 127 RTA00000178AF.k. l 8.1 M00001382A:F04 9755

4613 1/28/98 104 RTA00000196R.h.03.1 M00001381 A:D02 6636

4614 2/24/98 642 RTA00000341 F.li.19.1 M00003916C:C05 0

4615 2/24/98 655 RTA00000351 R.p. l4.1 M00003915C:H04 13166

4616 1/28/98 145 RTA00000178AF.h.24.1 M00001376B:C06 6745

4617 2/24/98 224 RTA00000341 F.g.21.1 M00003914C:F09 8823

4618 2/24/98 301 RTA00000401 F.m.23.1 M00003914C:C02 2801

4619 2/24/98 133 RTA00000404F.1.20.1 M00001639B:H05 38638 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

4619 2/24/98 63 RTA00000404F.1.20.2 M00001639B:H05 38638

4620 2/24/98 542 RTA00000410F.U 9.1 M00001641 B:C 10 78988

4621 2/24/98 63 RTA00000404F.1.20.2 M00001639B:H05 38638

4621 2/24/98 133 RTA00000404F.1.20.1 M00001639B:H05 38638

4622 2/24/98 600 RTA00000406F.m.04.1 M00003914B:A1 1 14959

4623 1/28/98 33 RTA00000178AR.a.20.1 M00001362C:H1 1 945

4623 2/24/98 979 RTA00000345F.b. l 7.1 M00001362C:H1 1 945

4624 1/28/98 33 RTAOOOOO 178 AR.a.20.1 M00001362C:H 1 1 945

4624 2/24/98 979 RTA00000345F.b. l 7.1 M00001362C:H1 1 945

4625 3/24/98 73 RTA00000524F.b. l2.1 M00005213C:G01 0

4626 1/28/98 J /j RTA00000196F.e.l 2.1 M00001361 C:H1 1 10147

4627 2/24/98 1233 RTA00000418F.1.02.1 M00001641 C:C05 39316

4628 3/24/98 184 RTA00000524F.b. l 8.1 M00005214B:D1 1 0

4629 3/24/98 353 RTA00000428F.a.l 8.1 M00005214C:A09 0

4630 1/28/98 89 RTA00000177AF.n.8.3 M00001356D:F06 4188

4630 1/28/98 15 RTA00000177AR.n.8.1 M00001356D:F06 4188

4631 1/28/98 89 RTAOOOOO 177AF.n.8.3 M00001356D:F06 4188

4631 1/28/98 15 RTAOOOOO 177AR.n.8.1 M00001356D:F06 4188

4632 1/28/98 375 RTA00000177AF.m. l 8.1 M00001355B:G1 1 0

4632 1/28/98 376 RTAOOOOO 177 AF.m.18.3 M00001355B:G1 1 0

4633 1/28/98 375 RTAOOOOO 177AF.m.18.1 M00001355B:G1 1 0

4633 1/28/98 376 RTAOOOOO 177AF.ni.18.3 M00001355B:G1 1 0

4634 2/24/98 682 RTA00000410F.i.l 7.1 M00001641 B:B01 78147

4635 1/28/98 367 RTA00000196F.i.24.1 M00001392C:D10 4233

4636 1/28/98 264 RTA00000179AF.k.3.3 M00001401A:H07 0

4637 1/28/98 333 RTA00000196F.k. l 5.1 M00001400A:F06 8320

4638 1/28/98 38 RTAOOOOO 196R. 07.1 M00001399C:D09 22443

4638 1/28/98 289 RTA00000196F. 07.1 M00001399C:D09 22443

4639 1/28/98 38 RTAOOOOO 196R. 07.1 M00001399C:D09 22443

4639 1/28/98 289 RTA00000196F.k.07.1 M00001399C:D09 22443

4640 1/28/98 289 RTA00000196F. 07.1 M00001399C:D09 22443

4640 1/28/98 38 RTA00000196R.k.07.1 M00001399C:D09 22443

4641 1/28/98 38 RTA00000196R.k.07.1 M00001399C:D09 22443

4641 1/28/98 289 RTAOOOOO 196F. 07.1 M00001399C:D09 22443

4642 3/24/98 324 RTA00000523F.O.09.1 M00005176A:C12 0

4643 3/24/98 122 RTA00000523F.O.12.1 M00005177A:B06 0

4644 1/28/98 167 RTAOOOOO 179AF.d.22.3 M00001394C:C1 1 7955

4645 1/28/98 351 RTA00000179AF.C.22.1 M00001393B:B09 22515

4645 1/28/98 459 RTA00000179AF.C.22.3 M00001393B:B09 22515

4646 1/28/98 351 RTAOOOOO 179AF.C.22.1 M00001393B:B09 22515

4646 1/28/98 459 RTA00000179AF.C.22.3 M00001393B:B09 22515

4647 3/24/98 361 RTA00000523F.p.08.1 M00005178A:A07 0

4648 1/28/98 43 RTA00000179AF.C.14.3 M00001392D:H04 0

4649 3/24/98 268 RTA00000427F. 19.1 M00004103B:B07 62851

4650 3/24/98 473 RTA00000523F.O.21.1 M00005177C:A01 0

4651 1/28/98 60 RTA00000196AR.i.l2.3 M00001389D:G1 1 38800

4651 1/28/98 128 RTAOOOOO 196F.i.12.1 M00001389D:G1 1 38800

4652 1/28/98 128 RTA00000196F 12.1 M00001389D:G1 1 38800

4652 1/28/98 60 RTA00000196AR.U2.3 M00001389D:G1 1 38800

4653 1/28/98 60 RTA00000196AR.i.l2.3 M00001389D:G 1 1 38800 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID

Priority Priority

Appln Appln

4653 1/28/98 128 RTAOOOOO 196F.i.12.1 M00001389D:G 1 1 38800

4654 1/28/98 60 RTAOOOOO 196AR.i.12.3 M00001389D:G 1 1 38800

4654 1/28/98 128 RTAOOOOO 196F.L 12.1 M00001389D:G 1 1 38800

4655 1/28/98 28 RTAOOOOO 178AR.O.01.5 M00001387B:H07 0

4656 1/28/98 279 RTAOOOOO 196 AF.h.24.1 M00001386A:D1 1 7308

4657 1/28/98 130 RTA00000196AF.h.23.1 M00001386A:C02 13357

4658 1/28/98 254 RTA00000178AF.n.2.1 M00001385C:H1 1 17083

4659 1/28/98 74 RTAOOOOO 196AF.h.20.1 M00001385B:F10 0

4660 1/28/98 377 RTA00000178AF.m. l 9.1 M00001384D:H07 0

4660 1/28/98 120 RTA00000178AR.m.l9.5 M00001384D:H07 0

4661 1/28/98 377 RTA00000178AF.m. l 9.1 M00001384D:H07 0

4661 1 /28/98 120 RTA00000178AR.m.19.5 M00001384D:H07 0

4662 3/24/98 228 RTA00000523F.O.14.1 M00005177A:H09 0

4663 1/28/98 567 RTA00000177AR.m. l3.1 M00001355A:C12 4175

4663 1/28/98 538 RTA00000177AR.m. l 3.3 M00001355A:C12 4175

4663 1/28/98 533 RTA00000177AR.rn.13-4 M00001355A:C12 4175

4664 1/28/98 51 1 RTAOOOOO 196AF.g.10.1 M00001376B:A02 12498

4665 1/28/98 620 RTA00000201 R.g.08.1 M00004692A:E07 0

4665 1/28/98 619 RTA00000201 F.g.08.1 M00004692A:E07 0

4665 1/28/98 621 RTA00000201 R.g.08.2 M00004692A:E07 0

4666 3/24/98 194 RTA00000522F.J.12.2 M00001651C:A04 74341

4667 2/24/98 79 RTA00000419F.g.08.1 M00003842C:D1 1 66700

4668 1/28/98 619 RTA00000201 F.g.08.1 M00004692A:E07 0

4668 1/28/98 620 RTA00000201 R.g.08.1 M00004692A:E07 0

4668 1/28/98 621 RTA00000201 R.g.08.2 M00004692A:E07 0

4669 1/28/98 529 RTAOOOOO 178AF.b.13.1 M00001364A:E1 1 31 14

4670 2/24/98 1 1 1 RTAOOOOO 128A.J.20.1 M00001560A:F03 9900

4671 3/24/98 379 RTA00000522F. 02.2 M00001652C:B09 77622

4672 3/24/98 135 RTA00000522F. 10.2 M00001652D:B09 77619

4673 2/24/98 1 197 RTA00000128A.J.10.1 M00001560A:H06 80085

4674 2/24/98 140 RTA00000128A.J.6.2 M00001560A:H10 5316

4675 3/24/98 247 RTA00000425F.J.21.1 M00001633B:B1 1 77373

4676 1/28/98 538 RTAOOOOO 177AR.m.13.3 M00001355A:C12 4175

4676 1/28/98 567 RTAOOOOO 177 AR.m.13.1 M00001355A:C12 4175

4676 1/28/98 533 RTA00000177AR.m.l3.4 M00001355A:C12 4175

4677 2/24/98 729 RTA00000403F.m.20.1 M00001576A:F1 1 707

4677 2/24/98 437 RTA00000403F.m.20.2 M00001576A:F1 1 707

4678 1/28/98 533 RTAOOOOO 177AR.m.13.4 M00001355A:C12 4175

4678 1/28/98 538 RTAOOOOO 177AR.ni.13.3 M00001355A:C12 4175

4678 1/28/98 567 RTA00000177AR.m.13.1 M00001355A:C12 4175

4679 1/28/98 533 RTA00000177AR.m. l 3.4 M00001355A:C12 4175

4679 1/28/98 538 RTAOOOOO 177 AR.m.13.3 M00001355A:C 12 4175

4679 1/28/98 567 RTAOOOOO 177AR.m.13.1 M00001355A:C12 4175

4680 1/28/98 538 RTAOOOOO 177AR.m.13.3 M00001355A:C12 4175

4680 1/28/98 567 RTA00000177AR.rn.13- l M00001355A:C12 41 75

4680 1 /28/98 533 RTAOOOOO 177AR.ni.13.4 M00001355A:C12 4175

4681 1/28/98 533 RTA00000177AR.m.13.4 M00001355A:C12 4175

4681 1/28/98 538 RTA00000177AR.m. l3.3 M00001355A:C12 4175

4681 1/28/98 567 RTAOOOOO 177AR.ni.13.1 M00001355A:C12 4175

4682 1/28/98 620 RTA00000201 R.g.08.1 M00004692A:E07 0 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

4682 1/28/98 621 RTA00000201 R.g.08.2 M00004692A:E07 0

4682 1/28/98 619 RTA00000201 F.g.08.1 M00004692A:E07 0

4683 2/24/98 845 RTA00000348R.b.04.1 M00001342B:E01 1890

4684 2/24/98 1088 RTA00000339R.b.02.1 M00001344B:F12 0

4684 2/24/98 1 149 RTA00000339F.b.02.1 M00001344B:F12 0

4685 2/24/98 618 RTA00000423F.1.04.1 M00004039B:G08 14320

4686 2/24/98 1235 RTA0000041 1 F.J.04.1 M00003841C:F03 66219

4687 2/24/98 415 RTA00000340R.f.05.1 M00001569B:G1 1 3202

4688 2/24/98 1088 RTA00000339R.b.02.1 M00001344B:F12 0

4688 2/24/98 1 149 RTA00000339F.b.02.1 M00001344B:F12 0

4689 2/24/98 1067 RTA0000041 1 F.J.1 1.1 M00003841 D:F06 66154

4690 1/28/98 429 RTA00000196F.i. l 9.1 M00001390C:C1 1 39498

4690 2/24/98 925 RTA00000353R.h.l0.1 M00001390C:C1 1 39498

4691 1/28/98 508 RTA00000187AF.i.l4.2 M00001679B:H07 19406

4691 2/24/98 928 RTA00000340F.m.04.1 M00001679B:H07 19406

4692 2/24/98 10 RTA00000350R.C.12.1 M00001550D:A04 9728

4693 1/28/98 553 RTA00000201 F.b.22.1 M00004344B:H04 35728

4694 1/28/98 459 RTA00000179AF.C.22.3 M00001393B:B09 22515

4694 1/28/98 351 RTAOOOOO 179AF.C.22.1 M00001393B:B09 22515

4695 1/28/98 351 RTAOOOOO 179AF.C.22.1 M00001393B:B09 22515

4695 1/28/98 459 RTAOOOOO 179AF.C.22.3 M00001393B:B09 22515

4696 2/24/98 235 RTA00000126A.O.23.1 M00001551A:B10 6268

4697 2/24/98 942 RTAOOOOO 126A.n.6.2 M00001551A:D04 79917

4698 2/24/98 228 RTA0000041 1 F.k. l9.1 M00003852D:E08 64200

4699 1/28/98 638 RTA00000193AF.1.05.2 M00004348A:A02 2815

4700 3/24/98 431 RTA00000425F.1.09.1 M00001638A:B04 75251

4701 1/28/98 540 RTAOOOOO 179AF.b.10.3 M00001391 D:D10 0

4702 2/24/98 390 RTA00000355R.a. l4.1 M00004187D:G09 10207

4703 1/28/98 429 RTAOOOOO 196F.i.19.1 M00001390C:C1 1 39498

4703 2/24/98 925 RTA00000353R.h. l 0.1 M00001390C:C1 1 39498

4704 2/24/98 930 RTAOOOOO 127A.h.22.2 M00001554A:E04 13155

4705 2/24/98 1 193 RTA0000041 1 F.k. l 4.1 M00003851 A:C10 63987

4706 1/28/98 694 RTA00000201 R.C.19.1 M00004370A:G05 22357

4707 3/24/98 80 RTA00000425F.p.l2.1 M00001638C:G01 73219

4708 3/24/98 344 RTA00000425F.p. l5.1 M00001638C:H07 31680

4709 1/28/98 743 RTA00000178AF.k.9.1 M00001381 B:F06 16342

4710 2/24/98 202 RTA00000419F.g.22.1 M00003845D:A09 64515

471 1 1/28/98 749 RTA00000178AR.U3.4 M00001377B:H01 0

4712 3/24/98 217 RTA00000425F.J.16.1 M00001639D:F02 75631

4713 3/24/98 448 RTA00000425F.J.18.1 M00001639D:G 12 75561

4714 1/28/98 385 RTA00000201 F.C.24.1 M00004374D:E10 35731

4715 2/24/98 904 RTA00000127A.e.6.1 M00001553A:E07 5885

4716 2/24/98 620 RTA00000420F.a.07.1 M00004072C:F08 63405

4717 1/28/98 396 RTAOOOOO 179AR.b.02.3 M00001391 B:G12 0

4718 2/24/98 463 RTA00000403F.O.22.1 M00001583A:D01 25076

4718 2/24/98 1084 RTA00000403F.O.22.2 M00001583A:D01 25076

4719 2/24/98 1225 RTA00000346F.J.13.1 M00003841 C:E04 5337

4720 2/24/98 1221 RTA00000403F.O.17.1 M00001582D:A02 23085

4721 2/24/98 878 RTA00000413F.C.12.1 M00004083B:G03 65334

4722 2/24/98 764 RTA00000413F.C.17.1 M00004085B:B05 36831 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

4723 2/24/98 398 RTA00000407F.b.04.1 M00004086D:B09 63221

4724 2/24/98 1 179 RTA00000341 F.O.12.1 M00004144A:F04 2883

4725 2/24/98 7 RTA00000413F.d. l2.1 M00004088C:A 12 66467

4726 2/24/98 881 RTA00000413F.d. l 5.1 M00004088C:E04 64943

4727 2/24/98 463 RTA00000403F.O.22.1 M00001583A:D01 25076

4727 2/24/98 1084 RTA00000403F.O.22.2 M00001583A:D01 25076

4728 2/24/98 1084 RTA00000403F.O.22.2 M00001583A:D01 25076

4728 2/24/98 463 RTA00000403F.O.22.1 M00001583A:D01 25076

4729 1/28/98 506 RTAOOOOO 198R.O.09.1 M00003751 B:A05 4310

4729 1/28/98 497 RTAOOOOO 198AF.O.09.1 M00003751 B:A05 4310

4730 2/24/98 1015 RTA00000129A.b.6.2 M00001582A:H01 391 1 1

4731 2/24/98 866 RTA00000407F.b.08.1 M00004088D:B03 37513

4732 2/24/98 943 RTA00000413F.C.03.1 M00004081 D:H09 64527

4733 2/24/98 463 RTA00000403F.O.22.1 M00001583A:D01 25076

4733 2/24/98 1084 RTA00000403F.O.22.2 M00001583A:D01 25076

4734 1 /28/98 490 RTAOOOOO 198AF.11.05.1 M00001687A:G01 24157

4735 2/24/98 798 RTA00000420F.C.04.1 M00004089A:B08 65007

4736 2/24/98 850 RTA00000420F.C.07.1 M00004089A:E02 65555

4737 2/24/98 199 RTA00000403F.m.l3.2 M00001575D:A10 39077

4738 1/28/98 424 RTAOOOOO 187 AR.j .24.1 M00001679D:B05 78356

4738 1/28/98 418 RTAOOOOO 187 AR.k.01.1 M00001679D:B05 78356

4739 1/28/98 424 RTAOOOOO 187 AR.j .24.1 M00001679D:B05 78356

4739 1/28/98 418 RTAOOOOO 187 AR.k.01.1 M00001679D:B05 78356

4740 1/28/98 418 RTAOOOOO 187 AR.k.01.1 M00001679D:B05 78356

4740 1/28/98 424 RTAOOOOO 187 AR.j .24.1 M00001679D:B05 78356

4741 1/28/98 424 RTAOOOOO 187 AR.j .24.1 M00001679D:B05 78356

4741 1/28/98 418 RTAOOOOO 187 AR.k.01.1 M00001679D:B05 78356

4742 1/28/98 482 RTA00000187AF.J.7.1 M00001679C:F01 78091

4743 1/28/98 693 RTAOOOOO 198F.m.12.1 M00001679C:D05 4

4744 3/24/98 23 RTA00000522F.p.07.1 M00001670A:C1 1 76888

4745 1/28/98 497 RTAOOOOO 198 AF.o.09.1 M00003751 B:A05 4310

4745 1/28/98 506 RTAOOOOO 198R.O.09.1 M00003751 B:A05 4310

4746 1/28/98 642 RTAOOOOO 189AF.i.14.1 M00003868B:G 1 1 0

4747 2/24/98 1 1 19 RTAOOOOO 126A.k.24.1 M00001550A:F07 39428

4748 2/24/98 654 RTA00000421 F.a.05.1 M00001570C:G06 5278

4749 2/24/98 1 146 RTA00000347F.h.02.1 M00004072D:H 12 562

4750 2/24/98 137 RTA00000339R.a.06.1 M00001346A:E04 58694

4751 2/24/98 729 RTA00000403F.m.20.1 M00001576A:F1 1 707

4751 2/24/98 437 RTA00000403F.m.20.2 M00001576A:F1 1 707

4752 2/24/98 627 RTA00000408F.p.21.1 M00001579A:C03 77930

4753 2/24/98 735 RTA00000420F.3.1 1.1 M00004073C:D04 66460

4754 2/24/98 525 RTA00000348R.d.24.1 M00001349B:G05 5774

4755 2/24/98 624 RTA00000420F.a. l 6.1 M00004075D:C10 63345

4756 2/24/98 437 RTA00000403F.m.20.2 M00001576A:F1 1 707

4756 2/24/98 729 RTA00000403F.m.20.1 M00001576A:F1 1 707

4757 2/24/98 437 RTA00000403F.m.20.2 M00001576A:F1 1 707

4757 2/24/98 729 RTA00000403F.m.20.1 M00001576A:F1 1 707

4758 1/28/98 499 RTAOOOOO 199F.b.22.2 M00003791C:E09 17018

4759 2/24/98 843 RTA00000418F.g.03.1 M00001579C:E06 78737

4760 2/24/98 956 RTA00000423F.1.06.1 M00004062A:H06 38136 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: D3te of NO: in ID Priority Priority Appln Appln

4761 2/24/98 826 RTA00000422F.e.07.1 M00001579C:G05 38964

4761 2/24/98 832 RTA00000403F.O.10.2 M00001579C:G05 38964

4762 2/24/98 826 RTA00000422F.e.07.1 M00001579C:G05 38964

4762 2/24/98 832 RTA00000403F.O.10.2 M00001579C:G05 38964

4763 2/24/98 826 RTA00000422F.e.07.1 M00001579C:G05 38964

4763 2/24/98 832 RTA00000403F.O.10.2 M00001579C:G05 38964

4764 2/24/98 826 RTA00000422F.e.07.1 M00001579C:G05 38964

4764 2/24/98 832 RTA00000403F.O.10.2 M00001579C:G05 38964

4765 2/24/98 1 159 RTA00000413F.b. l 8.1 M00004078C:F04 39873

4766 2/24/98 1 122 RTA00000419F.f.l 6.1 M00003839D:E02 64679

4767 2/24/98 1053 RTA00000413F.b.24.1 M00004080A:F01 651 17

4768 2/24/98 1052 RTA00000420F.b.02.1 M00004081 A:A08 64013

4769 2/24/98 157 RTA00000339F.a.23.1 M00001361 B:C07 4022

4770 1/28/98 452 RTAOOOOO 199F.d.19.2 M00003813D:H 12 6707

4771 2/24/98 480 RTA0000041 1F.U 5.1 M00003837C:G08 31612

4772 2/24/98 125 RTA00000403F.m.18.1 M00001576A:B09 39185

4773 2/24/98 548 RTA00000413F.b. l2.1 M00004077B:H 1 1 64932

4774 2/24/98 814 RTA00000408F.1.24.1 M00001530B:G09 34263

4775 1/28/98 688 RTA00000193AF.g.3.1 M00004050D:A06 5567

4776 1/28/98 451 RTA00000200AF.b.20.1 M00004043A:D02 40403

4777 1/28/98 456 RTA00000200AF.b.l2.1 M00004040B:F10 22053

4778 2/24/98 849 RTAOOOOO 122A.n.16.1 M00001517A:G08 80553

4779 1/28/98 12 RTA00000183AF.L15.2 M00001529B:C04 2642

4779 2/24/98 379 RTA00000349R.J.07.1 M00001529B:C04 2642

4780 1/28/98 12 RTA00000183AF.U 5.2 M00001529B:C04 2642

4780 2/24/98 379 RTA00000349R.J.07.1 M00001529B:C04 2642

4781 1/28/98 512 RTA00000191AF.C.3.1 M00003987D:D06 3549

4782 2/24/98 431 RTA00000399F.J.15.1 M00001578C:G06 1261

4783 1/28/98 586 RTAOOOOO 199R.0.1 1.1 M00003976C:A10 23172

4784 1/28/98 496 RTAOOOO0190 AF.p.3.1 M00003975B:F03 2378

4785 2/24/98 340 RTA00000408F.1.13.1 M00001530A:B12 4423

4786 1/28/98 617 RTAOOOOO 179 AF.d.13.3 M00001394A:F01 6583

4787 2/24/98 779 RTA00000408F.1.16.1 M00001530A:F 12 73468

4788 1/28/98 387 RTA00000191AF.J.14.1 M00004073A:H12 1002

4788 2/24/98 632 RTAOOOOO 191 AF.j.14.1 M00004073A:H12 1002

4789 1/28/98 464 RTA00000199AF.I.14.1 M00003917A:D02 22865

4790 2/24/98 668 RTA00000408F.m.05.2 M00001530C:G10 23384

4791 2/24/98 1066 RTAOOOOO 123 A.f.2.1 M00001531 A:H03 80379

4792 2/24/98 213 RTAOOOOO 123 A.f.3.1 M00001531 A:H07 44017

4793 2/24/98 43 RTA00000420F.g.04.1 M00004891 B:B 12 0

4794 2/24/98 302 RTA00000356R.f l 8.1 M00004692A:H 10 0

4795 2/24/98 308 RTA00000353R.d.l l . l M00004692A:H08 0

4796 2/24/98 975 RTA0000041 1 F.n.02.1 M00003870B:F04 78049

4797 1/28/98 722 RTA00000199R.J.24.1 M00003895C:A10 0

4798 2/24/98 643 RTA00000420F.1.14.2 M00005230D:F06 0

4799 1/28/98 480 RTA00000181AF.O.08.2 M00001457C:H 12 849

4800 1/28/98 518 RTAOOOOO 199AF.n.22.1 M00003971A:A06 23064

4801 1/28/98 618 RTAOOOOO 192AF.a.14.1 M000041 1 1 D:A08 6874

4802 2/24/98 937 RTA00000121A.n.l 5.1 M0000151 1 A:G08 40849

4803 2/24/98 821 RTA00000420F.h.16.1 M00004927A:E06 0 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

4804 2/24/98 658 RTA00000121 A.n.2.1 M0000151 1 A:A05 33585

4805 2/24/98 551 RTA00000340F.b.05.1 M00001513A:G07 0

4806 2/24/98 172 RTA00000420F.i.l 7.1 M00005101 C:B09 0

4807 2/24/98 1224 RTA00000122A.h.24.1 M00001514A:A12 48

4808 1/28/98 631 RTA00000200AF.h. l9.2 M00004151 D:E03 0

4809 2/24/98 80 RTAOOOOO 122A.g.16.1 M00001514A:B04 81366

4810 2/24/98 809 RTA00000420F.i.23.1 M00005134A:D1 1 0

481 1 2/24/98 650 RTA00000122A.g.l 7.1 M00001514A:B08 32655

4812 2/24/98 73 RTA00000413F.p. l 5.2 M00005136D:D06 0

4813 1/28/98 425 RTA00000200AF.C.16.1 M00004064D:A1 1 23433

4814 2/24/98 60 RTA00000413F.p. l 7.2 M00005136D:G06 0

4815 1/28/98 387 RTA00000191AF.J.14.1 M00004073A:H12 1002

4815 2/24/98 632 RTA00000191 AF.J.14.1 M00004073A:H 12 1002

4816 2/24/98 837 RTA00000420F.h.^'θl .1 M00004897C:D06 0

4817 2/24/98 123 RTAOOOOO 122A.J.18.1 M00001516A:D05 81317

4818 2/24/98 77 RTA00000420F.J.22.1 M00005173B:F01 0

4819 1/28/98 734 RTA00000200AF.d.21.1 M00004087C:D03 0

4820 1/28/98 733 RTA00000200AF.d.20.1 M00004087A:G08 26600

4821 2/24/98 1003 RTA00000420F.k.08.2 M00005176C:C09 0

4822 1/28/98 442 RTA00000191 AF.1.9.1 M00004081 C:H06 0

4823 1/28/98 457 RTA00000191 AR.I.7.2 M00004081 C:D12 14391

4824 2/24/98 552 RTA0000041 1 F.n.l2.1 M00003875A:C04 73308

4825 2/24/98 782 RTA00000419F.k.03.1 M00003871C:B05 40822

4826 2/24/98 839 RTA00000414F.b.01.1 M00005212B:A02 0

4827 1/28/98 674 RTA00000197AR.e.24.1 M00001456B:F10 39250

4827 1/28/98 3 RTA00000197AF.e.24.1 M00001456B:F10 39250

4828 1/28/98 669 RTA00000192AF.C.2.1 M00004121B:G01 0

4829 1/28/98 718 RTA00000196F.1.14.2 M00001408B:G06 23144

4830 2/24/98 1259 RTA00000420F.1.19.2 M00005231 A:H04 0

4831 1/28/98 717 RTA00000200F.O.10.2 M00004269B:C08 36432

4832 2/24/98 107 RTA00000125A.g. l 6.1 M00001544A:C09 21497

4833 1/28/98 697 RTAOOOOO 193 AF.e.21.1 M00004271 B:B06 0

4834 2/24/98 829 RTA0000041 1 F.m.l l .l M00003867A:D12 73196

4835 1/28/98 409 RTAOOOOO 180AF.d.1.3 M00001418D:B06 8526

4836 3/24/98 426 RTA00000424F.k.21.1 M00001614A:A04 73197

4837 2/24/98 874 RTA00000346F.O.22.1 M00004300C:H09 7381

4838 3/24/98 136 RTA00000424F.m.22.1 M00001614C:E1 1 72943

4839 2/24/98 636 RTA00000418F.e.21.1 M00001577B:A03 74773

4840 2/24/98 1202 RTA00000347F.h.l0.1 M00004206A:E02 22779

4841 2/24/98 1030 RTA00000125A.C.17.1 M00001542A:E04 80619

4842 2/24/98 753 RTA00000345F.O.13.1 M00001546B:F12 1 1500

4843 2/24/98 221 RTA00000414F.f. l3.1 M00005259D:H08 0

4844 2/24/98 193 RTA00000347F.b. l0.1 M00001546C:C07 8044

4845 2/24/98 1 104 RTAOOOOO 126A.b.10.1 M00001547A:F06 0

4846 2/24/98 1 177 RTA00000126A.b.9.1 M00001547A:F1 1 81279

4847 2/24/98 923 RTAOOOOO 126A.d.19.1 M00001548A:G01 79474

4848 2/24/98 98 RTA0000041 1 F.1.03.1 M00003854D:A12 62702

4849 2/24/98 625 RTAOOOOO 126 A.h.22.2 M00001549A:F01 0

4850 1/28/98 710 RTAO0000196AF.1.3.1 M00001405B:D07 20864

4851 2/24/98 1 102 RTAOOOOO 126A.J.15.2 M00001549A:H1 1 40425 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

4852 3/24/98 467 RTA00000528F.h.02.2 M00001632C:D08 1701

4853 1/28/98 41 1 RTAOOOOO 179 AF.j.13.3 M00001400B:H06 0

4854 2/24/98 1 126 RTAOOOOO 136A.h.6.1 M00001550A:D09 81620

4855 1/28/98 712 RTA00000201 F.b.21.1 M00004341 B:G03 9071

4856 2/24/98 1257 RTA00000419F.h.21.1 M0O0O3856C:B08 64828

4857 2/24/98 194 RTAOOOOO 124A.k.5.1 M00001538A:F12 80252

4858 1/28/98 508 RTA00000187AF.i. l4.2 M00001679B:H07 19406

4858 2/24/98 928 RTA00000340F.m.04.1 M00001679B:H07 19406

4859 1/28/98 3 RTAOOOOO 197 AF.e.24.1 M00001456B:F10 39250

4859 1/28/98 674 RTA00000197AR.e.24.1 M00001456B:F10 39250

4860 2/24/98 606 RTA00000420F.1.20.2 M00005232A:C10 0

4861 2/24/98 30 RTA0000041 1 F.m.24.1 M00003870B:B08 77568

4862 2/24/98 31 RTAOOOOO 134A.J.10.1 M00001534A:G06 81383

4863 2/24/98 1 136 RTA00000406F.C.05.1 M00003870A:H01 22077

4864 2/24/98 41 1 RTA00000420F.m. l 2.1 M00005234D:B04 0

4865 2/24/98 1086 RTA00000403F.n.22.2 M00001578B:B05 26775

4865 2/24/98 1085 RTA00000403F.n.22.1 M00001578B:B05 26775

4866 2/24/98 1018 RTA00000413F.J.21.1 M0O004688A:A02 0

4867 2/24/98 657 RTAOOOOO 124A.L20.1 M00001538A:C08 80913

4868 2/24/98 718 RTAOOOOO 124A.k.23.1 M00001538A:D03 81350

4869 2/24/98 1092 RTAOOOOO 125 A.c.2.1 M00001542A:F06 40148

4870 2/24/98 615 RTA00000135A.b.23.1 M00001538A:D12 35241

4871 2/24/98 639 RTA00000414F.d.09.1 M00005231 C:B01 0

4872 2/24/98 1086 RTA00000403F.n.22.2 M00001578B:B05 26775

4872 2/24/98 1085 RTA00000403F.n.22.1 M00001578B:B05 26775

4873 2/24/98 99 RTA00000420F.m. l 9.1 M00005254D:B08 0

4874 2/24/98 1085 RTA00000403F.n.22.1 M00001578B:B05 26775

4874 2/24/98 1086 RTA00000403F.n.22.2 M00001578B:B05 26775

4875 2/24/98 1086 RTA00000403F.n.22.2 M00001578B:B05 26775

4875 2/24/98 1085 RTA00000403F.n.22.1 M00001578B:B05 26775

4876 1/28/98 725 RTAOOOOO 197AF.b.1.1 M00001441 D:E04 12134

4877 2/24/98 215 RTA00000403F.J.18.1 M00001539D:E10 5790

4878 2/24/98 1010 RTA00000408F.n. l 6.2 M00001540C:B03 73720

4879 2/24/98 1074 RTA00000423F.h. l l . l M00003867C:E1 1 38977

4880 2/24/98 27 RTA00000420F.n.l9.2 M00005259B:C01 0

4881 1/28/98 578 RTAOOOOO 180AF.g.17.1 M00001426A:A09 16653

4882 2/24/98 1 172 RTA00000423F.h.03.1 M00003875D:D09 37903

4883 2/24/98 1008 RTA00000414F.f.07.1 M00005259C:B05 0

4884 2/24/98 582 RTA00000414F.e.l4.1 M00005236B:F10 0

4885 1/28/98 178 RTA00000200F.O.03.1 M00004257C:H06 22807

4885 1/28/98 249 RTA00000200R.O.03.2 M00004257C:H06 22807

4885 1/28/98 85 RTA00000200R.O.03.1 M00004257C:H06 22807

4886 2/24/98 1223 RTA00000347F.a.14.1 M00001429D:F1 1 7421

4887 2/24/98 488 RTA00000339F.k.23.1 M00001429D:H12 0

4888 3/24/98 100 RTA00000424F.i.21.1 M00001596A:E07 73482

4889 3/24/98 64 RTA00000424F.i.24.1 M00001596A:G06 79101

4890 3/24/98 207 RTA00000424F.J.07.1 M00001596B:C1 1 7921 1

4891 3/24/98 327 RTA00000424F.J.08.1 M00001596B:D09 73972

4892 3/24/98 349 RTA00000424F.J.09.1 M00001596B:H05 74387

4893 3/24/98 154 RTA00000522F.h. l3.1 M00001596C:F09 40823 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

4894 2/24/98 1252 RTA00000400F.g.08.1 M00001639A:C1 1 1275

4895 2/24/98 261 RTA00000341 F.b.06.1 M00003794A:E12 17008

4896 1/28/98 312 RTA00000193AF.h.2.1 M00004290A:B03 3273

4897 1/28/98 590 RTA00000190AF.d.2.1 M00003906B:F12 2444

4898 1/28/98 213 RTA00000200F.O.04.1 M00004260D:C12 12514

4899 2/24/98 333 RTA00000399F.f. l l .l M00001487C:F01 40167

4900 1/28/98 249 RTA00000200R.O.03.2 M00004257C:H06 22807

4900 1/28/98 178 RTA00000200F.O.03.1 M00004257C:H06 22807

4900 1 /28/98 85 RTA00000200R.O.03.1 M00004257C:H06 22807

4901 1 /28/98 85 RTA00000200R.O.03.1 M00004257C:H06 22807

4901 1/28/98 178 RTA00000200F.O.03.1 M00004257C:H06 22807

4901 1/28/98 249 RTA00000200R.O.03.2 M00004257C:H06 22807

4902 1/28/98 85 RTA00000200R.O.03.1 M00004257C:H06 22807

4902 1/28/98 249 RTA00000200R.O.03.2 M00004257C:H06 22807

4902 1 /28/98 178 RTA00000200F.O.03.1 M00004257C:H06 22807

4903 1 /28/98 249 RTA00000200R.O.03.2 M00004257C:H06 22807

4903 1 /28/98 85 RTA00000200R.O.03.1 M00004257C:H06 22807

4903 1/28/98 178 RTA00000200F.O.03.1 M00004257C:H06 22807

4904 1/28/98 249 RTA00000200R.O.03.2 M00004257C:H06 22807

4904 1/28/98 85 RTA00000200R.O.03.1 M00004257C:H06 22807

4904 1/28/98 178 RTA00000200F.O.03.1 M00004257C:H06 22807

4905 3/24/98 133 RTA00000425F.f.04.1 M00001607A:B06 24633

4906 3/24/98 169 RTA00000425F.f.05.1 M00001607A:D10 24090

4907 2/24/98 44 RTA00000418F. 14.1 M00001639A:H06 76133

4908 2/24/98 1204 RTA00000419F.I.02.1 M00003879A:C01 75736

4909 2/24/98 748 RTA00000346F. l l . l M00003793C:D09 38528

4910 2/24/98 4 RTA00000339F.i.20.1 M00001438D:C06 4356

491 1 1/28/98 93 RTA00000200F.O.1 1.1 M00004270A:F1 1 0

4912 1/28/98 435 RTAOOOOO 182 AR.c.22.1 M00001467A:D08 16283

4913 1/28/98 683 RTAOOOOO 187 AR.j .01.1 M00001679C:D01 79028

4914 3/24/98 469 RTA00000522F.e.20.1 M00001590B:H10 26770

4915 1 /28/98 172 RTAOOOOO 186AF.p.09.2 M00001655C:E04 6879

4916 2/24/98 806 RTA00000345F.f.08.1 M00001413B:H09 0

4917 1/28/98 677 RTA00000197AF.i.19.1 M00001490B:H1 1 39554

4918 1/28/98 443 RTAOOOOO 197AR.i.17.1 M00001490A:E1 1 3516

4919 2/24/98 863 RTA00000406F.p.08.1 M00004032C:B02 37573

4920 3/24/98 55 RTA00000528F.e.23.1 M00001593B:D10 19242

4921 2/24/98 121 1 RTA00000399F.f. l4.1 M00001487D:C 1 1 1 1483

4922 1/28/98 609 RTA00000196AF.n.05.1 M00001418B:F07 12531

4922 2/24/98 1 120 RTA00000353R.1.23.1 M00001418B:F07 12531

4923 1/28/98 609 RTA00000196AF.n.05.1 M00001418B:F07 12531

4923 2/24/98 1 120 RTA00000353R.I.23.1 M00001418B:F07 12531

4924 3/24/98 474 RTA00000522F.h.05.1 M00001595C:H1 1 73358

4925 1/28/98 284 RTAOOOOO 199F.d.10.2 M00003808C:B05 22049

4925 2/24/98 816 RTA00000354R.n.04.1 M00003808C:B05 22049

4926 2/24/98 1 1 12 RTA00000418F.C.05.1 M00001487B:F02 76475

4927 1/28/98 687 RTA00000197AF.g.4.1 M00001464B:B03 8821

4928 2/24/98 990 RTA00000121 A.h. l9.1 M00001471A:D04 80334

4929 1/28/98 696 RTAOOOOO 180 AR.d.16.3 M00001419D:C 10 1 1393

4929 2/24/98 1 184 RTA00000345F.h.08.1 M00001419D:C 10 1 1393 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

4930 1/28/98 751 RTAOOOOO 179AF.C.4.3 M00001392D:B 1 1 0

4931 1/28/98 696 RTAOOOOO 180AR.d.16.3 M00001419D:C 10 1 1393

4931 2/24/98 1 184 RTA00000345F.h.08.1 M00001419D:C 10 1 1393

4932 1/28/98 162 RTA00000201 F.e.l 5.1 M00004444B:D1 1 9960

4933 1/28/98 126 RTA00000201 F.d. l6.1 M00004388B:A08 0

4934 1/28/98 332 RTAOOOOO 193 AR.n.04.3 M00004375C:D01 9850

4935 2/24/98 838 RTA00000408F. 19.1 M00001487C:G03 77593

4936 2/24/98 1 13 RTA00000401 F.e.02.1 M00003805B:C04 0

4937 3/24/98 278 RTA00000522F.g.21.1 M00001595C:A09 77310

4938 3/24/98 54 RTA00000425F.f. l 9.1 M00001653D:G07 32635

4939 2/24/98 976 RTA00000419F.b.l 7.1 M00003808D:D04 63261

4940 2/24/98 59 RTA00000346F.J.08.1 M00003879B:A06 39951

4941 2/24/98 151 RTA00000341 F.C.21.1 M00003789C:F06 7899

4942 1/28/98 67 RTA00000200AF.g.07.1 M00004128B:G01 0

4943 2/24/98 324 RTA00000340F.p. l 7.1 M00003750C:H05 0

4944 2/24/98 476 RTA00000345F.h.01.1 M00001441 B:D1 1 10834

4945 2/24/98 245 RTA00000195AF.d.20.1 M000041 17A:D1 1 37574

4945 1/28/98 87 RTAOOOOO 195 AF.d.20.1 M000041 17A:D1 1 37574

4946 2/24/98 245 RTAOOOOO 195 AF.d.20.1 M000041 17A:D1 1 37574

4946 1/28/98 87 RTAOOOOO 195 AF.d.20.1 M000041 17A:D1 1 37574

4947 2/24/98 991 RTA00000419F.b.l0.1 M00001694C:G04 78566

4948 2/24/98 14 RTA00000419F.b.09.1 M00001694C:F12 78128

4949 1/28/98 261 RTA00000192AF.a.24.1 M000041 14C:F1 1 13183

4950 1/28/98 24 RTA00000200AF.f.l l . l M000041 1 1 D:D1 1 0

4951 3/24/98 408 RTA00000522F.O.10.1 M00001660D:E05 78798

4952 1/28/98 328 RTA00000200AF.g.09.1 M00004131 B:H09 22785

4952 1/28/98 26 RTA00000200R.g.09.1 M00004131 B:H09 22785

4953 2/24/98 861 RTA00000419F.b.06.1 M00001694B:B08 76728

4954 3/24/98 24 RTA00000522F.n.08.1 M00001656A:D10 76343

4955 2/24/98 760 RTA00000423F.d.04.1 M00001694A:B 12 1 1307

4956 3/24/98 220 RTA00000522F.O.18.1 M00001669B:H06 76366

4957 2/24/98 279 RTA00000418F.L21.1 M00001596D:E10 78728

4958 1/28/98 84 RTA00000191 AF.li.14. ! M00004056B:D09 13553

4959 1/28/98 284 RTA00000199F.d.l0.2 M00003808C:B05 22049

4959 2/24/98 816 RTA00O00354R.n.04.1 M00003808C:B05 22049

4960 2/24/98 217 RTA00000399F.O.17.1 M00001599D:A09 1 106

4961 1/28/98 287 RTA00000200AF.b.07.1 M00004039C:C01 17125

4961 1/28/98 173 RTA00000200AR.b.07.1 M00004039C:C01 17125

4962 1/28/98 287 RTA00000200AF.b.07.1 M00004039C:C01 17125

4962 1/28/98 173 RTA00000200AR.b.07.1 M00004039C:C01 17125

4963 1/28/98 287 RTA00000200AF.b.07.1 M00004039C:C01 17125

4963 1/28/98 173 RTA00000200AR.b.07.1 M00004039C:C01 17125

4964 1/28/98 287 RTA00000200AF.b.07.1 M00004039C:C01 17125

4964 1/28/98 173 RTA00000200AR.b.07.1 M00004039C:C01 17125

4965 3/24/98 464 RTA00000522F.p.l 8.1 M00001671 A:H06 76376

4966 3/24/98 453 RTA00000522F.p.22.1 M00001671 B:F02 73322

4967 2/24/98 54 RTA00000399F.O.01.1 M00001595C:E01 3055

4968 2/24/98 1219 RTA00000347F.e.20.1 M00003771 B:E05 3991 1

4969 2/24/98 825 RTA00000404F. 22.2 M00001635D:C12 39084

4969 2/24/98 364 RTA00000404F. 22.1 M00001635D:C 12 39084 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

4970 1/28/98 241 RTA00000200AF.I.17.1 M00004217C:D03 12771

4970 1/28/98 151 RTA00000200R.1.17.1 M00004217C:D03 12771

4970 1/28/98 202 RTA00000200R.I.17.2 M00004217C:D03 12771

4971 1/28/98 241 RTA00000200AF.I.17.1 M00004217C:D03 12771

4971 1/28/98 151 RTA00000200R.1.17.1 M00004217C:D03 12771

4971 1/28/98 202 RTA00000200R.1.17.2 M00004217C:D03 12771

4972 1/28/98 241 RTA00000200AF.1.17.1 M00004217C:D03 12771

4972 1/28/98 202 RTA00000200R.1.17.2 M00004217C:D03 12771

4972 1/28/98 151 RTA00000200R.1.17.1 M00004217C:D03 12771

4973 1/28/98 241 RTA00000200AF.I.17.1 M00004217C:D03 12771

4973 1/28/98 202 RTA00000200R.1.17.2 M00004217C:D03 12771

4973 1 /28/98 151 RTA00000200R.1.17.1 M00004217C:D03 12771

4974 1/28/98 241 RTA00000200AF.1.17.1 M00004217C:D03 12771

4974 1/28/98 202 RTA00000200R.I.17.2 M00004217C:D03 12771

4974 1/28/98 151 RTA00000200R.1.17.1 M00004217C:D03 12771

4975 1/28/98 241 RTA00000200AF.1.17.1 M0000421 7C:D03 12771

4975 1/28/98 151 RTA00000200R.1.17.1 M0000421 7C:D03 12771

4975 1/28/98 202 RTA00000200R.1.17.2 M00004217C:D03 12771

4976 1/28/98 241 RTA00000200AF.1.17.1 M00004217C:D03 12771

4976 1/28/98 151 RTA00000200R.1.17.1 M00004217C:D03 12771

4976 1/28/98 202 RTA00000200R.1.17.2 M00004217C:D03 12771

4977 1/28/98 241 RTA00000200AF.1.17.1 M00004217C:D03 12771

4977 1/28/98 151 RTA00000200R.1.17.1 M 00004217C:D03 12771

4977 1/28/98 202 RTA00000200R.1.17.2 M00004217C:D03 12771

4978 1/28/98 241 RTA00000200AF.1.17.1 M00004217C:D03 12771

4978 1/28/98 151 RTA00000200R.I.17.1 M00004217C:D03 12771

4978 1/28/98 202 RTA00000200R.I.17.2 M00004217C:D03 12771

4979 1/28/98 366 RTAOOOOO 192 AF.o.19.1 M00004208D:H08 3549

4980 1/28/98 328 RTA00000200AF.g.09.1 M00004131 B:H09 22785

4980 1/28/98 26 RTA00000200R.g.09.1 M00004131 B:H09 22785

4981 1/28/98 245 RTA00000200AF. 7.1 M00004193C:G1 1 0

4982 2/24/98 1036 RTA00000339F.k.08.1 M00001439B:A10 8133

4983 2/24/98 72 RTA00000347F.a.08.1 M00001592C:G04 3135

4984 2/24/98 1 163 RTA00000341 F.b. l4.1 M00003763A:C01 5992

4985 2/24/98 278 RTA00000404F.C.10.1 M00001593B:E1 1 23534

4986 1/28/98 250 RTA00000192AF.J.21.1 M00004176D:B12 2289

4987 2/24/98 51 1 RTA00000341 F.b. l3.1 M00003762B:H09 0

4988 1/28/98 27 RTA00000192AF.i. l2.1 M00004169C:C 12 5319

4989 2/24/98 416 RTA00000404F.C.19.1 M00001594A:D06 39026

4990 2/24/98 351 RTA00000340F.p.20.1 M00003752B:C02 17008

4991 1/28/98 215 RTA00000192AR.e. l 4.3 M00004142A:D08 3300

4992 1/28/98 163 RTA00000192AR.e. l3.3 M00004142A:B12 9457

4993 1/28/98 318 RTA00000200AF.g.l 7.1 M00004138A:H09 0

4994 2/24/98 1 105 RTA00000340F.p. l 8.1 M00003751 C:A04 287

4995 2/24/98 1080 RTA00000351 R.g.06.1 M00003771 D:G05 0

4996 2/24/98 478 RTA00000418F.h.08.1 M00001589B:E07 76401

4997 2/24/98 584 RTA00000418F.d.22.1 M00001573B:C06 75324

4998 2/24/98 493 RTAOOOOO 129A.d.1.2 M00001587A:F05 80058

4999 2/24/98 402 RTA00000420F.e. l 6.1 M000041 10A:E04 63639

5000 2/24/98 1006 RTA00000129A.e. l4.1 M00001587A:F08 80053 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

5001 2/24/98 285 RTA00000413F.i.02.1 M000041 10D:A10 65857

5002 1/28/98 659 RTAOOOOO 185 AR.k.23.2 M00001601 A:E09 0

5003 2/24/98 122 RTA00000420F.f.06.1 M000041 15D:D08 64812

5004 2/24/98 245 RTAOOOOO 195 AF.d.20.1 M000041 17A:D1 1 37574

5004 1/28/98 87 RTA00000195AF.d.20.1 M000041 17A:D1 1 37574

5005 1/28/98 87 RTA00000195AF.d.20.1 M000041 17A:D1 1 37574

5005 2/24/98 245 RTAOOOOO 195 AF.d.20.1 M000041 17A:D1 1 37574

5006 2/24/98 720 RTAOOOOO 129A.d.2.4 M00001587A:G06 801 19

5007 2/24/98 687 RTA00000350R.g.l0.1 M00001587C:C10 9026

5008 3/24/98 18 RTA00000522F.e. l 6.1 M00001590A:C08 75283

5009 1/28/98 447 RTA00000198AF.d.8.1 M00001587A:H03 0

5010 1/28/98 554 RTAOOOOO 186AR.e.07.4 M00001623D:G03 4175

5010 1/28/98 400 RTAOOOOO 186AR.e.07.3 M00001623D:G03 4175

501 1 1/28/98 526 RTAOOOOO 185 AF.e.20.1 M00001585A:D06 5865

5012 2/24/98 1 RTA00000404F.a.02.1 M00001589B:E12 9738

5013 1/28/98 530 RTAOOOOO 185 AF.d.24.2 M00001582D:F05 0

5014 2/24/98 1096 RTA00000421 F.a.06.1 M00001589C:A1 1 2385

5015 1/28/98 131 RTAOOOOO 185 AF.d.1 1.2 M00001579D:C03 6539

5015 1/28/98 626 RTAOOOOO 185 AR.d.1 1.1 M00001579D:C03 6539

5016 1/28/98 626 RTAOOOOO 185 AR.d.1 1.1 M00001579D:C03 6539

5016 1/28/98 131 RTAOOOOO 185 AF.d.1 1.2 M00001579D:C03 6539

5017 2/24/98 1020 RTA00000412F.p.06.1 M00004038B:H10 65485

5018 1/28/98 671 RTA00000185AR.d.08.1 M00001579C:E09 6562

5019 2/24/98 1240 RTA00000404F.a.l 8.1 M00001590B:B02 36267

5020 2/24/98 1 15 RTA00000418F.h. l9.1 M00001590B:C05 0

5021 2/24/98 21 1 RTA00000404F.a.l9.1 M00001590B:C07 38624

5022 1/28/98 455 RTAOOOOO 198AF.d.12.1 M00001589A:C01 21 142

5023 1/28/98 622 RTAOOOOO 186AR.m.14.2 M00001649B:G 12 9800

5024 2/24/98 958 RTAOOOOO 195 AF.c.8.1 M00001678B:H01 0

5024 1/28/98 520 RTAOOOOO 195 AF.c.8.1 M00001678B:H01 0

5025 1/28/98 520 RTAOOOOO 195 AF.c.8.1 M00001678B:H01 0

5025 2/24/98 958 RTAOOOOO 195 AF.c.8.1 M00001678B:H01 0

5026 1/28/98 690 RTAOOOOO 198R.1.21.1 M00001673A:A04 19194

5027 2/24/98 772 RTA00000413F.e.04.1 M00004090C:C07 64176

5028 2/24/98 834 RTA00000407F.b. l l . l M00004090C:C 10 0

5029 2/24/98 1 154 RTA00000403F.m.09.2 M00001575B:G01 26814

5030 2/24/98 1203 RTA00000413F.e.l 0.1 M00004092C:B03 31033

5031 2/24/98 12 RTA00000339F.b.l 7.1 M00001366D:E12 10020

5032 2/24/98 947 RTA00000347F.g.08.1 M00004096B:F05 23121

5033 1/28/98 39 RTAOOOOO 189AR.b.19.1 M00003832B:E01 5294

5033 2/24/98 239 RTA00000346F.J.02.1 M00003832B:E01 5294

5034 1/28/98 39 RTAOOOOO 189AR.b.19.1 M00003832B:E01 5294

5034 2/24/98 239 RTA00000346F.J.02.1 M00003832B:E01 5294

5035 2/24/98 560 RTA00000419F.d. l 6.1 M00003828B:E07 64357

5036 2/24/98 568 RTA00000403F.m.03.1 M00001573D:D10 39179

5037 2/24/98 191 RTA00000419F.d. l 7.1 M00003828B:F09 64353

5038 2/24/98 607 RTA00000420F.d.l6.1 M00004103D:F10 64485

5039 2/24/98 1 130 RTA00000354R.p.01.1 M00004104C:H12 0

5040 2/24/98 710 RTA00000413F.g.24.1 M00004104D:A04 65481

5041 2/24/98 24 RTA00000423F.1.09.1 M000041 18A:H08 9752 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

5042 2/24/98 896 RTA00000423F.I.20.1 M00004105C:E09 12580

5043 2/24/98 1078 RTA00000423F.f.03.1 M00003829C:D10 63852

5044 1/28/98 558 RTAOOOOOl 86AR.h.14.1 M00001632D:H07 0

5045 2/24/98 155 RTA00000413F.h. l3.1 M00004107A:D01 65190

5046 2/24/98 926 RTA00000399F. 20.1 M00001585C:D10 3003

5047 2/24/98 1 194 RTA00000420F.e.05.1 M00004107D:E12 63908

5048 1/28/98 400 RTAOOOOO 186AR.e.07.3 M00001623D:G03 4175

5048 1/28/98 554 RTAOOOOOl 86AR.e.07.4 M00001623D:G03 4175

5049 2/24/98 570 RTA00000405F.n.l3.1 M00003824A:G10 23810

5050 2/24/98 334 RTA00000408F.p.05.1 M00001575B:B02 9649

5051 2/24/98 1029 RTA0000041 1 F.f.04.1 M00003813A:G04 64526

5052 3/24/98 134 RTA00000424F.C.14.3 M00001476D:A09 76614

5053 2/24/98 396 RTA00000406F.e.21.1 M00003877D:G05 9090

5054 3/24/98 230 RTA00000424F.g.l4.1 M00001572A:B06 74879

5055 2/24/98 617 RTA00000423F.f.23.1 M00003816C:E09 15390

5056 2/24/98 5 RTA00000408F.O.12.2 M00001572A:A10 78578

5057 2/24/98 689 RTA00000419F.p.03.1 M00004035A:G10 1937

5058 3/24/98 273 RTA00000424F.a.02.4 M00001575A:D06 78806

5059 2/24/98 241 RTA00000339F.d.l3.1 M00001395C:F1 1 0

5060 3/24/98 237 RTA00000522F.C.01.1 M00001576A:C 1 1 74938

5061 1/28/98 745 RTAOOOOOl 83 AF.m.1 1.1 M00001536D:G02 8927

5062 1/28/98 408 RTA00000183AR.1.15.1 M00001535C:E01 39383

5063 2/24/98 464 RTA00000195AF.C.12.1 M00003818B:G12 37582

5063 1/28/98 300 RTA00000195AF.C.12.1 M00003818B:G12 37582

5064 1/28/98 647 RTA00000197F.m.l l .l M00001530B:D10 16488

5065 2/24/98 464 RTAOOOOO 195AF.C.12.1 M00003818B:G 12 37582

5065 1/28/98 300 RTA00000195AF.C.12.1 M00003818B:G 12 37582

5066 3/24/98 395 RTA00000522F.d.06.1 M00001578B:A02 74809

5067 2/24/98 516 RTA00000339F.f.20.1 M00001399A:C03 6494

5068 2/24/98 890 RTA00000418F.J.19.1 M00001634D:D02 78399

5069 2/24/98 435 RTA00000340F.b.02.1 M00001503C:G05 10185

5070 3/24/98 175 RTA00000528F.d.l 8.1 M00001582C:E01 2684

5071 2/24/98 168 RTA0000041 1 F.e.22.1 M00003812B:D07 63638

5072 2/24/98 1071 RTA00000404F.k.l 8.2 M00001635A:C06 5475

5073 2/24/98 189 RTA00000347F.a.l3.1 M00001402D:F02 22446

5074 2/24/98 825 RTA00000404F.k.22.2 M00001635D:C12 39084

5074 2/24/98 364 RTA00000404F.k.22.1 M00001635D:C12 39084

5075 3/24/98 25 RTA00000425F.C.06.1 M00001585D:D1 1 78041

5076 3/24/98 186 RTA00000425F.C.07.1 M00001585D:F03 76042

5077 3/24/98 208 RTA00000424F.m. l 0.1 M00001586C:E06 34251

5078 2/24/98 420 RTA00000422F.b.l 6.1 M00003813B:A1 1 17045

5079 3/24/98 103 RTA00000424F.b.22.1 M00001530A:F1 1 72971

5079 3/24/98 88 RTA00000424F.b.22.4 M00001530A:F1 1 72971

5080 3/24/98 318 RTA00000523F.a.01.1 M00001671C:F1 1 74923

5081 2/24/98 676 RTA0000041 1 F.g.21 .1 M00003823D:G05 64500

5082 3/24/98 RTA00000528F.b.23.1 M00001479C:F10 1605

5083 2/24/98 1244 RTA00000418F.h.23.1 M00001591 A:B08 75153

5084 2/24/98 321 RTA00000339F.C.21.1 M00001389C:A08 5325

5085 1/28/98 429 RTAOOOOO 196F.i.19.1 M00001390C:C 1 1 39498

5085 2/24/98 925 RTA00000353R.h. l 0.1 M00001390C:C 1 1 39498 SEQ ID Filing SEQ ID Sequence Name Clone Nsme Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

5086 1/28/98 429 RTA00000196F.U9.1 M00001390C:C11 39498

5086 2/24/98 925 RTA00000353R.li.10.1 M00001390C:C11 39498

5087 3/24/98 471 RTA00000528F.C.11.1 M00001486D:D12 1701

5088 2/24/98 103 RTA00000418F.J.12.1 M00001626C:G08 73316

5089 2/24/98 1148 RTA00000345F.d.23.1 M0000I390D:E03 5862

5090 2/24/98 87 RTA00000403F.1.20.1 M00001573A:A06 18267

5091 3/24/98 427 RTA00000522F.b.08.1 M00001570D:E06 26915

5092 1/28/98 661 RTAOOOOO 198R.b.04.1 M00001565A:H09 0

5093 2/24/98 200 RTA00000339F.C.02.1 M00001381C:B08 12975

5094 2/24/98 1243 RTA00000404F.J.19.1 M00001630D:H10 0

5095 1/28/98 750 RTAOOOOO 198AF.a.19.1 M00001561D:C05 0

5096 2/24/98 418 RTA00000410F.a.01.1 M00001631D:B10 73354

5097 3/24/98 458 RTA00000424F.d.l2.3 M00001530D:E06 74342

5097 3/24/98 454 RTA00000424F.d.l2.2 M00001530D:E06 74342

5098 3/24/98 458 RTA00000424F.d.l2.3 M00001530D:E06 74342

5098 3/24/98 454 RTA00000424F.d.l2.2 M00001530D:E06 74342

5099 2/24/98 159 RTA00000348R.J.17.1 M00001391D:C06 2641

5100 2/24/98 539 RTA00000346F.m.l5.1 M00004037B:C04 13553

5101 2/24/98 170 RTA00000422F.n.08.1 M00001632B:E05 38655

5102 3/24/98 162 RTA00000522F.3.12.1 M00001567A:H05 33515

5103 2/24/98 315 RTA00000419F.p.l2.1 M00004037A:E04 13767

5104 2/24/98 119 RTA00000423F.k.05.1 M00004036D:F02 37472

5105 3/24/98 12 RTA00000522F.3.23.1 M00001570C:A05 38613

5106 3/24/98 103 RTA00000424F.b.22.1 M00001530A:F11 72971

5106 3/24/98 88 RTA00000424F.b.22.4 M00001530A:F11 72971

5107 2/24/98 21 RTA00000411F.g.08.1 M00003822D:D04 45815

5108 1/28/98 35 RTAOOOOOl 91 AF.n.17.1 M00004091B:D11 7848

5109 3/24/98 39 RTA00000527F.C.23.1 M00003822C:A07 37742

5110 1/28/98 43 RTAOOOOOl 79AF.C.14.3 M00001392D:H04 0

5111 2/24/98 54 RTA00000399F.O.01.1 M00001595C:E01 3055

5112 2/24/98 63 RTA00000404F.1.20.2 M00001639B:H05 38638

5113 1/28/98 82 RTAOOOOOl 83AF.1.18.1 M00001535D:C01 3484

5114 3/24/98 84 RTA00000527F.k.l8.1 M00003982B:C10 11332

5115 1/28/98 99 RTAOOOOO 184AF.d.8.1 M00001548A:A08 4393

5116 2/24/98 99 RTA00000420F.m.l9.1 M00005254D:B08 0

5117 2/24/98 100 RTA00000339F.O.23.1 M00001473C:D09 7801

5118 2/24/98 104 RTA00000421F.n.03.1 M00001675C:A04 1638

5119 2/24/98 105 RTA00000346F.d.08.1 M00001671A:A10 39955

5120 2/24/98 114 RTA00000341F.I11.21.1 M00004051D:E01 0

5121 1/28/98 137 RTAOOOOOl 8 lAF.m.4.3 M00001455A:E09 13238

5122 1/28/98 162 RTA00000201F.e.l5.1 M00004444B:D11 9960

5123 1/28/98 170 RTA00000197AF.d.23.1 M00001453A:E11 16130

5124 1/28/98 206 RTAOOOOOl 81 AF.o.04.2 M00001457C:C12 22205

5125 1/28/98 209 RTAOOOOOl 82AF.C.5.1 M00001464D:F06 6397

5126 2/24/98 215 RTA00000403F.J.18.1 M00001539D:E10 5790

5127 2/24/98 219 RTA00000419F.C.18.1 M00003819D:B11 41394

5128 1/28/98 229 RTAOOOOOl 98 AF.g.3.1 M00001615C:F03 0

5129 1/28/98 230 RTAOOOOOl 85AR.b.18.1 M00001575B:C09 12171

5130 3/24/98 245 RTA00000522F.p.09.1 M00001670A:F09 75204

5131 2/24/98 258 RTA00000406F. 15.1 M00003907C:C04 38549 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

5132 1/28/98 262 RTAOOOOO 186AF.C.17.1 M00001619D:G05 8551

5133 1/28/98 269 RTA00000183AF.U 3.1 M00001534B:C 12 0

5134 1/28/98 276 RTAOOOOO 198AF.J.15.1 M00001653B:E09 4369

5135 2/24/98 281 RTA0000041 1 F.I.13.1 M00003857C:C09 431 14

5136 1/28/98 284 RTAOOOOO 199F.d.10.2 M00003808C:B05 22049

5137 1/28/98 292 RTAOOOOOl 99AF.m.18.1 M00003939C:F04 0

5138 1/28/98 297 RTAOOOOOl 78 AF.f.9.3 M00001371C:E09 7172

5139 2/24/98 301 RTA00000401 F.m.23.1 M00003914C:C02 2801

5140 1/28/98 302 RTAOOOOO 186AF.d.1.2 M00001621 C:C08 40044

5141 1/28/98 315 RTAOOOOOl 99R.d.23.1 M00003815D:H09 37477

5142 2/24/98 315 RTA00000419F.p. l2.1 M00004037A:E04 13767

5143 1/28/98 321 RTAOOOOOl 81 AR.b.21.1 M00001444C:D05 3266

5144 3/24/98 323 RTA00000524F.C.12.1 M00005218B:D09 0

5145 1/28/98 329 RTAOOOOO 186AF.b.9.1 M00001616C:F07 0

5146 1/28/98 334 RTAOOOOOl 81 AR.b.21.3 M00001444C:D05 3266

5147 2/24/98 334 RTA00000408F.p.05.1 M00001575B:B02 9649

5148 1/28/98 335 RTAOOOOOl 82AF.e.3.2 M00001468B:H06 0

5149 1/28/98 336 RTAOOOOO 186AF.f.24.1 M00001629B:E06 0

5150 2/24/98 341 RTA00000412F.g.20.2 M00003972C:F08 25018

5151 2/24/98 343 RTA00000422F.g.21.1 M00001583A:F07 17232

5152 1/28/98 347 RTAOOOOO 199F.b.03.2 M00003779B:E12 38340

5153 2/24/98 354 RTA00000404F.C.03.2 M00001592C:F1 1 39198

5154 1/28/98 361 RTAOOOOO 177AR.g.16.4 M00001347A:B10 13576

5155 1/28/98 364 RTAOOOOOl 87AF.g.13.1 M00001676C:C 1 1 2991

5156 2/24/98 377 RTA00000346F.Ϊ.01.1 M00003797A:D06 22260

5157 2/24/98 389 RTA0000041 1 F.C.02.1 M00001677B:B04 72852

5158 2/24/98 403 RTA00000403F.d.22.1 M00001473A:A07 10692

5159 1/28/98 407 RTAOOOOOl 78 AF.e.20.1 M00001370D:E12 3135

5160 1/28/98 422 RTAOOOOOl 89AF.b.12.1 M00003829B:G03 17233

5161 2/24/98 429 RTA00000422F.C.17.1 M00004099D:F01 1360

5162 2/24/98 431 RTA00000399F.J.15.1 M00001578C:G06 1261

5163 1/28/98 439 RTAOOOOO 185 AF.d.14.2 M00001579D:G07 8071

5164 2/24/98 448 RTAOOOOO 127A.3.3.1 M00001552A:H 10 13232

5165 2/24/98 450 RTAOOOOOl 18A.3.23.1 M00001395A:H02 3500

5166 1/28/98 451 RTA00000200AF.b.20.1 M00004043A:D02 40403

5167 2/24/98 455 RTA00000399F.d.23.1 M00001481 B:A07 3310

5168 1/28/98 475 RTAOOOOO 187AR.m.3.3 M00001682C:B 12 17055

5169 3/24/98 475 RTA00000427F.i.06.1 M00004097B:D03 41450

5170 3/24/98 477 RTA00000527F.1.21.1 M00003983D:H02 36439

5171 1/28/98 480 RTAOOOOOl 81 AF.o.08.2 M00001457C:H12 849

5172 3/24/98 480 RTA00000424F.d.l 7.3 M00001455A:E1 1 73958

5173 3/24/98 481 RTA00000523F.J.02.1 M00003857A:H 10 62853

5174 1/28/98 483 RTA00000192AF.h.l 9.1 M00004162C:A07 4642

5175 2/24/98 489 RTA00000406F.J.19.1 M00003906A:F12 1685

5176 1/28/98 501 RTA00000200R.k.l l . l M00004197C:F03 9796

5177 2/24/98 502 RTA00000341 F.d.08.1 M00003824C:D07 0

5178 2/24/98 508 RTA00000420F.i.20.1 M00005101 C:E12 0

5179 1/28/98 510 RTAOOOOOl 78AF.n.23.1 M00001387B:E02 3298

5180 1/28/98 51 1 RTAOOOOOl 96AF.g.10.1 M00001376B:A02 12498

5181 2/24/98 519 RTA00000404F.1.10.1 M00001638B:F10 23136 SEQ ID Filing SEQ ID Sequence Name Clone Name Cluster

NO: Date of NO: in ID Priority Priority Appln Appln

5182 2/24/98 524 RTA00000419F.f.23.1 M00003840D:H 10 65002

5183 1/28/98 525 RTA00000198AF.C.7.1 M00001575D:G05 19181

5184 1/28/98 526 RTAOOOOO 185 AF.e.20.1 M00001585A:D06 5865

5185 1/28/98 527 RTAOOOOO 198R.m.23.1 M00001684B:G03 38469

5186 1/28/98 529 RTA00000178AF.b.l 3.1 M00001364A:E1 1 31 14

5187 1/28/98 530 RTAOOOOOl 85 AF.d.24.2 M00001582D:F05 0

5188 1/28/98 540 RTAOOOOOl 79AF.b.10.3 M00001391D:D10 0

5189 1/28/98 541 RTAOOOOO 197AR.b.16.1 M00001445C:A08 0

5190 1/28/98 545 RTAOOOOOl 96F.3.2.1 M00001338B:E02 3575

5191 2/24/98 547 RTA00000419F.h.02.1 M00003845D:G08 63985

5192 1/28/98 548 RTAOOOOOl 79 AF.f.23.3 M00001397B:G03 35258

5193 1/28/98 550 RTAOOOOOl 83AF.g.14.1 M00001513D:A03 0

5194 2/24/98 555 RTA00000133A.d.22.1 M00001469A:G1 1 1 1797

5195 1/28/98 569 RTAOOOOOl 96AF.I.23.1 M00001412A:E04 12052

5196 1/28/98 570 RTA00000183AF.3.19.2 M00001499A:A05 3788

5197 1/28/98 574 RTAOOOOO 192 AF.O.1 M00004146C:C 1 1 5257

5198 1/28/98 575 RTA00000186AF.1.12.2 M00001645A:C 12 19267

5199 1/28/98 576 RTAOOOOO 196AF.C.7.1 M00001350B:G1 I 0

5200 2/24/98 579 RTA00000413F.m. l 6.1 M00004898C:F03 0

5201 1/28/98 580 RTAOOOOO 197F.3.12.1 M00001438B:B09 7895

5202 2/24/98 580 RTA00000403F.O.07.1 M00001579C:A01 39037

5203 2/24/98 584 RTA00000418F.d.22.1 M00001573B:C06 75324

5204 1/28/98 585 RTAOOOOO 198AF.n.18.1 M00001771A:A07 16715

5205 1/28/98 601 RTAOOOOOl 84AF.i.l 0.2 M00001555A:B01 3744

5206 1/28/98 607 RTA00000200AF.k. l2.1 M00004198B:D02 7359

5207 1/28/98 613 RTAOOOOO 177AF. 18.4 M00001352C:A05 53729

5208 1/28/98 640 RTAOOOOOl 90 AF.f.5.1 M00003909A:H04 5015

5209 2/24/98 645 RTA00000422F.p.l2.2 M00001661 C:F10 9840

5210 1/28/98 654 RTAOOOOO 186AF.J.21.2 M00001639D:B07 22506

521 1 1/28/98 680 RTAOOOOOl 77AF.f.10.1 M00001345A:E01 6420

5212 1/28/98 699 RTAOOOOO 178AF.a.12.1 M00001362B:H06 0

5213 1/28/98 703 RTA00000198F.1.09.1 M00001664B:D06 361 1

5214 1/28/98 704 RTAOOOOO 190AF.0.12.1 M00003972D:C09 3438

5215 1/28/98 723 RTAOOOOOl 83 AF.p.24.1 M00001543C:F01 3116

5216 2/24/98 733 RTA00000405F.d. l 8.1 M00001662C:B02 10494

5217 1/28/98 739 RTAOOOOOl 8 lAF.p.12.3 M00001460C:H02 22204

5218 1/28/98 742 RTAOOOOO 177AF.m.1.1 M00001353D:D10 14929

5219 2/24/98 774 RTA00000403F.e.24.1 M00001476B:D10 16432

5220 2/24/98 775 RTA00000405F.C.22.1 M00001660C:B06 39053

5221 2/24/98 790 RTA00000345F.n.08.1 M00001517A:B 1 1 0

5222 2/24/98 816 RTA00000354R.n.04.1 M00003808C:B05 22049

5223 2/24/98 829 RTA0000041 1 F.m. l l . l M00003867A:D12 73196

5224 2/24/98 851 RTA00000423F.d.07.1 M00001678B:B12 0

5225 2/24/98 871 RTA00000403F.f.23.1 M00001479C:E01 39223

5226 2/24/98 877 RTA00000418F.m.22.1 M00001654D:E12 74567

5227 2/24/98 914 RTAOOOOO 138A.m.15.1 M00001624A:A03 41603

5228 2/24/98 923 RTAOOOOO 126A.d.19.1 M00001548A:G01 79474

5229 2/24/98 924 RTA00000354R.m.02.1 M00003890B:C08 12766

5230 2/24/98 940 RTA00000414F.f.l 7.1 M00005260A:F04 0

5231 2/24/98 1005 RTA00000339F.e.l 7.1 M00001397D:G08 7568 SEQ ID Filing SEQ ID Sequence Nβme Clone Nsme Cluster

NO: Dste of NO: in ID Priority Priority Appln Appln

5232 2/24/98 1013 RTA00000404F.b. l 8.1 M00001592A:H05 13669

5233 2/24/98 1037 RTA00000339F.1.12.1 M00001450A:G 1 1 771 1

5234 2/24/98 1055 RTA00000346F.3.04.1 M00001607B:C05 5382

5235 2/24/98 1070 RTA00000346F.n.22.1 M00004137A:D06 0

5236 2/24/98 1096 RTA00000421 F.3.06.1 M00001589C:A1 1 2385

5237 2/24/98 1 125 RTAOOOOOl 18A.H.5.1 M00001451A:C10 0

5238 2/24/98 1 128 RTA00000423F.3.02.3 M00001656B:A08 39210

5239 2/24/98 1 129 RTA00000401 F.m.07.1 M00003907D:F 1 1 2893

5240 2/24/98 1 136 RTA00000406F.C.05.1 M00003870A:H01 22077

5241 2/24/98 1 142 RTA00000418F.i.06.1 M00001591 B:B06 75151

5242 2/24/98 1 145 RTA00000423F.k.21.2 M00003984D:B08 37499

5243 2/24/98 1 149 RTA00000339F.b.02.1 M00001344B:F12 0

5244 2/24/98 1 166 RTA00000347F.h.01.1 M00004040A:G12 12043

5245 2/24/98 1 177 RTAOOOOOl 26A.b.9.1 M00001547A:F1 1 81279

5246 2/24/98 1 187 RTA00000120A.C.19.1 M00001464A:B03 81016

5247 2/24/98 1203 RTA00000413F.e. I 0.1 M00004092C:B03 31033

5248 2/24/98 1205 RTA00000419F.k.05.1 M00003871 C:E04 1 1757

5249 2/24/98 1230 RTA00000399F.J.14.1 M00001578C:F05 16942

5250 2/24/98 1233 RTA00000418F.I.02.1 M00001641 C:C05 39316

5251 2/24/98 1248 RTA00000419F.O.07.1 M00003986C:E09 14059

5252 2/24/98 1261 RTA00000404F.m. l 7.2 M00001643B:E05 0

Table 3 Polynucleotides encoding gene products of a protein family or having a known functional domain(s).

SEQ ID Validation Sequence Biological Start Stop Score Direction

NO: Activity (Profile)

3920 393.ElO.spό: 148957 7tm_l 531 710 9520 for

2667 172.F10.sp6: 133946 7tm_2 45 724 8708 rev

2758 177.C6.sp6:134733 7tm_2 41 697 9828 rev

2933 184.C7.sp6: 135556 7tm_2 3 834 8987 for

3129 121.E12.sp6: 131940 7tm_2 245 1324 9550 rev

3365 172.A7.sp6: 133883 7tm_2 94 761 8743 rev

3418 123.F9.sp6:132333 7tm_2 203 585 8785 rev

3419 123.F9.sp6: 132333 7tm_2 203 585 8785 rev

3597 394.G2.sp6: 149165 7tm_2 73 793 9209 for

3648 370.C5.sp6:141726 7tm_2 76 770 9269 for

3686 370.Bl .sp6:141710 7tm_2 89 662 8791 for

3695 368.A12.sp6:141322 7tm_2 121 719 9015 rev

3696 368.A12.sp6: 141322 7tm_2 121 719 9015 rev

4172 219.C10.sp6:139007 7tm_2 46 774 11394 rev

4216 368.Dl l .sp6: 141357 7tm_2 66 775 9384 rev

4228 368.Al l.sp6:141321 7tm_2 7 1079 9097 for

4441 99.F7.sp6: 131296 7tm_2 534 1265 10956 rev

4442 99.F7.sp6:131296 7tm_2 534 1265 10956 rev

4482 100.D2.sp6:131459 7tm_2 122 1404 9296 rev

4495 395.B12.sp6:149307 7tm_2 79 1432 10427 rev

4525 90.B4.sp6: 130874 7tm_2 4 691 9435 for

4616 100.D5.sp6:131462 7tm_2 655 1349 9255 for

4653 100.D7.sp6:131464 7tm_2 357 1346 11461 rev

4654 100.D7.sp6:131464 7tm_2 357 1346 11461 rev

4658 100.H6.sp6:131511 7tm_2 119 1035 10001 rev

4659 100.G6.sp6:131499 7tm_2 363 1 188 9901 rev

4660 100.F6.sp6: 131487 7tm_2 50 1 127 8799 for

4661 100.F6.sp6:131487 7tm_2 50 1127 8799 for

4710 367.H9.sp6:141210 7tm 2 143 1266 11883 rev

4755 370.F4.sp6:141761 7tm_2 78 704 8942 for

4856 367.Hl l.sp6:141212 7tm_2 176 1227 9975 rev

4885 123.E10.sp6: 132322 7tm_2 210 691 9071 rev

4900 123.ElO.spό: 132322 7tm_2 210 691 9071 rev

4901 123.E10.sp6: 132322 7tm 2 210 691 9071 rev

2656 176.Hl l .sp6: 134606 ANK 207 290 4450 for

2555 180.C9.sp6:135947 asp 156 670 6710 for

3632 368.Hl l.sp6:141405 asp 136 1226 6880 rev

4205 368.B5.sp6:141327 asp 309 806 6073 for

4251 369.D6.sp6: 141546 asp 434 1332 6263 rev

4253 396.F9.sp6: 149544 asp 97 1 106 5999 rev

4261 216.G10.sp6: 139247 asp 74 703 6188 rev

4365 122.H12.sp6:132168 asp 152 1040 6183 rev

4498 80.H6.sp6: 130297 asp 61 418 5944 rev

4664 172.E5.sp6:133929 asp 219 976 6434 for

4718 185.D9.sp6:135762 asp 31 872 5944 rev

4733 185.D9.sp6: 135762 asp 31 872 5944 rev

4746 176.B10.sp6: 134533 asp 253 1446 6079 rev SEQ ID Validation Sequence Biological Start Stop Score Direction

NO: Activity (Profile) 1

4822 177.F3.sp6: 134766 asp 0 894 6336 rev

4854 184.Fl l .sp6: 135596 asp 61 737 6416 rev

4856 367.Hl l .sp6:141212 asp 81 1187 6182 rev

4929 180.E6.sp6: 135968 asp 81 706 6150 for

4931 180.E6.sp6: 135968 asp 81 706 6150 for

2723 180.F2.sp6: 135976 ATPases 135 627 1 1664 for

2842 217.Hl l.sp6: 139452 ATPases 2 701 5972 for

3019 216.Bl .sp6: 139178 ATPases 170 616 6150 for

3046 121.B8.sp6:131900 ATPases 13 635 5867 rev

3190 80.D2.sp6: 130245 ATPases 13 386 6068 for

3290 176.C6.sp6:134541 ATPases 85 579 5883 for

3670 369.C10.sp6:141538 ATPases 329 730 6206 for

3998 394.H8.sp6: 149183 ATPases 21 571 5954 rev

4119 218.Fl l .sp6: 138852 ATPases 313 816 6057 for

4159 219.A7.sp6:138980 ATPases 88 662 6145 for

4223 368.F9.sp6: 141379 ATPases 178 648 5937 for

4384 181.Gl l.sp6: 135354 ATPases 362 769 5900 rev

4473 369.B4.sp6:141520 ATPases 4 412 14130 for

4540 218.C8.sp6:138813 ATPases 12 576 5782 rev

4560 404.G6.sp6: 162933 ATPases 86 605 6001 rev

4689 367.H8.sp6:141209 ATPases 17 476 5905 rev

4785 184.E5.sp6:135578 ATPases 184 632 5943 for

4792 184.C6.sp6: 135555 ATPases 333 813 5773 for

4847 184.Bl l.sp6: 135548 ATPases 14 498 6140 for

5041 377.Cl.sp6:141918 ATPases 4 655 5933 for

3404 176.F10.sp6:134581 Bcl-2 69 356 16419 for

4036 367.F5.sp6:141182 bromodomain 40 210 8810 for

4489 369.D3.sp6:141543 bromodomain 63 230 10270 for

3408 172.El .sp6:133925 BZIP 146 298 4066 for

3951 393.G5.sp6:148976 BZIP 1 16 304 5931 for

4850 172.E9.sp6:133933 BZIP 91 260 4366 for

3618 370.B12.sp6: 141721 cyclin 1 18 324 8980 for

3895 395.G6.sp6: 149361 cyclin 11 281 6930 for

4536 395.G8.sp6: 149363 cyclin 12 279 5950 for

4455 99.F5.sp6: 131294 Cys-protease 72 348 18479 for

4684 180.Dl .sp6:135951 Cys-protease 38 992 10103 rev

4688 180.Dl .sp6: 135951 Cys-protease 38 992 10103 rev

4801 177.E4.sp6:134755 Cys-protease 48 326 19999 for

4659 100.G6.sp6:131499 DAG_PE_bind 605 702 6290 rev

4821 377.C8.sp6:141925 Dead box helic 172 828 7867 rev

5083 216.Al .sp6:139166 Dead box helic 44 589 26532 for

2734 177.G4.sp6:134779 EFhand 79 153 3780 for

2893 185.Al .sp6:135718 EFhand 287 358 2580 rev

3775 377.A5.sp6:141898 EFhand 477 563 3010 for

4056 367.B7.sp6:141 136 EFhand 225 272 2500 rev

4152 218.B10.sp6:138803 EFhand 40 1 14 2640 rev

4153 218.B10.sp6: 138803 EFhand 40 1 14 2640 rev

4154 218.C10.sp6:138815 EFhand 39 113 2640 rev

4905 393.H12.sp6:148995 EFhand 145 231 4640 for

4943 219.A9.sp6:138982 EFhand 685 750 2550 rev SEQ ID Validation Sequence Biological Start : Stop Score Direction

NO: Activity (Profile)

2849 218.B5.sp6: 138798 Ets_Nterm 340 531 10400 for

2728 180.A2.sp6:135916 FNtypell 291 423 6400 rev

3018 216.Cl .sp6:139190 FNtypell 501 634 6460 for

4496 218.Gl .sp6: 138854 FNtypell 20 141 6180 rev

4914 393.H8.sp6: 148991 FNtypell 448 576 61 10 for

2504 181.C3.sp6:135298 G-alpha 66 715 8084 rev

3290 176.C6.sp6: 134541 G-alpha 62 690 9062 for

4288 121.B4.sp6:131896 G-alpha 46 447 21415 for

4444 217.D12.sp6:139405 G-alpha 15 702 40404 for

4562 404.B7.sp6: 162874 G-alpha 120 682 8424 for

2503 180.Al l .sp6:135925 helicase C 165 479 4494 for

4469 369.C4.sp6: 141532 helicase C 559 756 3732 rev

5020 185.D12.sp6:135765 helicase C 381 534 5000 for

4241 396.H8.sp6: 149567 homeobox 80 230 5170 for

2550 180.E5.sp6: 135967 mkk 342 612 5791 for

3407 172.Fl.sp6: 133937 mkk 94 669 5688 rev

3451 123.A2.sp6: 132266 mkk 26 378 7889 for

3600 394.B3.sp6: 149106 mkk 32 782 9544 for

3646 370.H4.sp6: 141785 mkk 18 307 9394 for

3680 369.Gl l .sp6:141587 mkk 182 725 5375 for

4175 219.H10.sp6:139067 mkk 280 723 15454 for

4205 368.B5.sp6: 141327 mkk 249 725 5502 for

4278 181.C9.sp6:135304 mkk 168 880 5551 rev

4322 121.F6.sp6:131946 mkk 111 730 5399 for

4777 177.E2.sp6:134753 mkk 288 636 5720 rev

4482 100.D2.sp6:131459 PDEase 849 1 195 5945 for

2578 181.Hl l.sp6:135366 protkinase 116 710 5531 for

2712 177.G7.sp6:134782 protkinase 6 511 5445 for

2835 218.Cl.sp6: 138806 protkinase 127 747 5492 for

2843 218.El .sp6:138830 protkinase 64 726 5592 rev

2971 217.F4.sp6: 139421 protkinase 83 702 5818 rev

3009 217.A4.sp6: 139361 protkinase 57 682 5395 rev

3084 121.E2.sp6:131930 protkinase 69 658 5593 rev

3226 100.D8.sp6:131465 protkinase 174 620 5453 for

3274 100.C3.sp6:131448 protkinase 228 736 5616 for

3356 172.B5.sp6:133893 protkinase 148 715 5381 for

3377 172.B6.sp6:133894 protkinase 119 775 5616 for

3451 123.A2.sp6: 132266 protkinase 24 384 9797 for

3600 394.B3.sp6:149106 protkinase 357 780 11395 for

3635 377.Gl l .sp6:141976 protkinase 117 739 5992 for

3646 370.H4.sp6: 141785 protkinase 24 275 8338 for

3665 370.F2.sp6:141759 protkinase 33 800 5658 for

3669 369.B 10.sp6: 141526 protkinase 1 482 5504 rev

3700 369.D2.sp6: 141542 protkinase 28 661 5428 for

3710 369.G6.sp6:141582 protkinase 71 631 5751 for

3791 396.Cl l .sp6:149510 protkinase 27 709 5793 rev

3905 393.H7.sp6:148990 protkinase 88 680 5470 rev

3919 393.D10.sp6:148945 protkinase 72 594 5617 for

4044 367.G4.sp6: 141 193 protkinase 30 699 5439 for

4072 368.B2.sp6:141324 protkinase 44 800 5556 for SEQ ID ' Validation Sequence Biological Starl t Stop Score Direction

NO: Activity (Profile)

41 17 218.Dl l .sp6: 138828 protkinase 38 781 6423 for

4175 219.H10.sp6:139067 protkinase 277 717 15720 for

4373 216.E5.sp6: 139218 protkinase 1 15 710 5537 for

4569 100.C10.sp6:131455 protkinase 56 783 5556 rev

4755 370.F4.sp6: 141761 protkinase 39 803 5635 for

4760 370.F3.sp6: 141760 protkinase 188 775 5771 for

4807 184.H3.sp6:135612 protkinase 23 699 5515 for

5059 180.B5.sp6: 135931 protkinase 182 671 5718 rev

5102 393.F4.sp6: 148963 protkinase 28 650 5345 for

3671 369.D10.sp6:141550 ras 12 332 9802 for

3936 393. A3. sp6: 148902 Thioredox 0 263 5887 rev

3927 393.Fl l .sp6: 148970 TNFR_c6 151 261 6445 for

2956 184.E10.sp6:135583 transmembrane4 19 483 8339 rev

2981 217.E6.sp6:139411 transmembrane4 83 728 8417 for

3836 396.C9.sp6: 149508 transmembrane4 300 924 9444 rev

4038 367.A6.sp6: 141123 transmembrane4 32 495 8407 rev

4364 123.Al .sp6:132265 transmembrane4 1289 1548 8114 rev

4406 122.Cl.sp6: 132097 transmembrane4 6 535 8122 for

4431 122.E4.sp6:132124 transmembrane4 10 530 8829 for

4441 99.F7.sp6: 131296 transmembrane4 613 1253 9443 rev

4442 99.F7.sp6: 131296 transmembrane4 613 1253 9443 rev

4653 100.D7.sp6:131464 transmembrane4 335 1207 8255 rev

4654 100.D7.sp6: 131464 transmembrane4 335 1207 8255 rev

4710 367.H9.sp6.T41210 transmembrane4 398 1 130 8352 rev

4944 180.H7.sp6: 136005 transmembrane4 356 983 8356 rev

3381 176.D9.sp6: 134556 trypsin 164 764 9670 rev

4684 180.Dl.sp6:135951 trypsin 371 1229 10479 rev

4688 180.Dl .sp6: 135951 trypsin 371 1229 10479 rev

2754 177.H6.sp6: 134793 WD domain 345 437 6510 for

3046 121.B8.sp6:131900 WD domain 98 193 6400 for

3227 100.B10.sp6:131443 WD domain 544 642 6590 for

4243 121.A8.sp6:131888 WD domain 93 188 6400 for

5046 185.F10.sp6: 135787 WD_domain 382 480 5880 for

3129 121.E12.sp6:131940 Wnt_dev_sign 101 821 12160 rev

3173 99.G6.sp6:131307 Wnt dev sign 49 880 12334 rev

3390 176.C9.sp6: 134544 Wnt_dev_sign 249 854 1 1038 rev

3391 176.C9.sp6: 134544 Wnt_dev_sign 249 854 11038 rev

3656 370.G6.sp6:141775 Wnt_dev_sign 211 785 1 1490 rev

3836 396.C9.sp6: 149508 Wnt_dev_sign 282 1017 12318 rev

4253 396.F9.sp6: 149544 Wnt_dev_sign 482 1298 11217 rev

4330 122.A2.sp6: 132074 Wnt_dev_sign 94 933 12383 rev

4359 123.B2.sp6:132278 Wnt_dev_sign 538 1435 11785 for

4364 123.Al.sp6:132265 Wnt_dev_sign 760 1544 12660 rev

4375 122.G10.sp6: 132154 Wnt_dev_sign 29 884 1 1603 rev

4385 122.A2.sp6: 132074 Wnt_dev_sign 94 933 12383 rev

4409 121.F12.sp6: 131952 Wnt_dev_sign 9 734 11 167 rev

4441 99.F7.sp6: 131296 Wnt_dev_sign 560 1399 13749 rev

4442 99.F7.sp6: 131296 Wnt_dev_sign 560 1399 13749 rev

4535 395.F10.sp6: 149353 Wnt_dev_sign 100 907 1 1535 rev

4586 123.A4.sp6: 132268 Wnt_dey_sign 80 1 122 1 1249 rev SEQ ID Validation Sequence Biological Start ; Stop Score Direction NO: Activity (Profile)

4605 404.D5.sp6: 162896 Wnt_dev_sign 31 816 11304 rev

4653 100.D7.sp6: 131464 Wnt_dev_sign 467 1314 11882 rev

4654 100.D7.sp6: 131464 Wnt_dev_sign 467 1314 1 1882 rev 4665 177.B l l .sp6: 134726 Wnt_dev_sign 137 1266 12708 rev 4668 177.B l l .sp6: 134726 Wnt_dev_sign 137 1266 12708 rev 4682 177.B l l .sp6: 134726 Wnt_dev_sign 137 1266 12708 rev 4710 367.H9.sp6: 141210 Wnt dev sign 692 1481 12886 rev 4718 185.D9.sp6: 135762 Wnt_dev_sign 129 890 11145 rev 4724 377.D2.sp6: 141931 Wnt_dev_sign 400 1227 1 1044 rev 4733 185.D9.sp6: 135762 Wnt_dev_sign 129 890 11145 rev 4856 367.Hl l .sp6: 141212 Wnt_dev_sign 295 1669 13366 rev 4866 377.D4.sp6: 141933 Wnt_dev_sign 549 1380 14522 rev 4925 219.B12.sp6: 138997 Wnt dev sign 312 1214 13188 rev 4959 219.B12.sp6: 138997 Wnt dev sign 312 1214 13188 rev 3409 172.Dl.sp6: 133913 Y_phosphatase 476 804 6932 for

3418 123.F9.sp6:132333 Y_phosphatase 28 439 6096 rev

3419 123.F9.sp6: 132333 Y_phosphatase 28 439 6096 rev 3657 370.H6.sp6:141787 Y_phosphatase 148 554 6481 for 3804 404.B10.sp6:162877 Y_phosphatase 104 466 6446 rev 3806 404.D10.sp6: 162901 Y_phosphatase 9 614 6516 for 3974 395.F2.sp6: 149345 Y_phosphatase 164 645 6093 rev 4238 121.E9.sp6:131937 Y_phosphatase 240 777 6147 rev 4263 216.F10.sp6: 139235 Y_phosphatase 21 504 6342 for 4343 122.E9.sp6:132129 Y_phosphatase 381 807 6036 rev 4363 123.Bl.sp6:132277 Y_phosphatase 61 510 6229 rev 4434 219.F4.sp6:139037 Y_phosphatase 2 261 10353 for 4473 369.B4.sp6:141520 Y_phosphatase 231 768 6110 rev 4629 404.Ell.sp6:162914 Y_phosphatase 580 920 6005 rev 5094 217.A3.sp6:139360 Y_phosphatase 263 622 6222 rev 2738 177.A6.sp6: 134709 Zincfιng_C2H2 65 127 4380 for 2760 177.A6.sp6: 134709 Zincfing_C2H2 65 127 4380 for 2832 218.B2.sp6:138795 Zincfmg C2H2 94 156 4940 for 3736 377.H8.sp6: 141985 Zincfmg_C2H2 495 557 4850 for

3762 377.G2.sp6: 141967 Zincfmg_C2H2 52 1 14 4380 for

3763 377.G2.sp6: 141967 Zincfing_C2H2 52 1 14 4380 for 4794 377.G4.sp6: 141969 Zincfϊng_C2H2 247 308 3930 for 5090 185.C4.sp6: 135745 Zincfing_C2H2 238 300 4540 for 3774 377.E4.sp6:141945 Zincfing_C3HC4 128 244 9335 for 4477 18l.E3.sp6:135322 Zincfmg C3HC4 321 445 8221 for Table 19. Polynucleotides Specifically Expressed in Colon

SEQ Sequence Name cluster lib l lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 lib 20

ID clones clones clones clones clones clones clones clones

NO:

3 RTAOOOOO 197 AF.e.24.1 39250 2 0 0 0 0 0 0 0

7 RTAOOOOO 197AR.e.12.1 22095 3 0 0 0 0 0 0 0

16 RTAOOOOO 196AF.e.16.1 39252 2 0 0 0 0 0 0 0

18 RTAOOOOO 196AF.C.17.1 39602 2 0 0 0 0 0 0 0

21 RTA00000131A.g.l9.2 36535 2 0 0 0 0 0 0 0

22 RTAOOOOO 187AR.0.10.2 8984 4 3 0 0 0 2 0 0

23 RTAOOOOO 198R.b.08.1 22636 3 0 0 0 0 0 0 0

26 RTA00000200R.g.09.1 22785 3 0 0 0 0 0 0 0

29 RTA00000200AF.b.l9.1 22847 3 0 0 0 0 0 0 0

31 RTA00000200F.m.l5.1 22601 3 0 0 0 1 0 0 0

37 RTA00000181AF.n.l5.2 86128 1 0 0 0 0 0 0 0

38 RTAOOOOO 196R.k.07.1 22443 2 0 0 0 0 0 0 1

40 RTA00000200AR.e.02.1 36059 2 0 0 0 1 1 1 0

48 RTAOOOOOl 77 AR.a.23.5 6995 4 2 0 0 0 0 0 0

49 RTAOOOOO 198R.O.05.1 26702 2 0 0 0 0 0 0 0

50 RTA00000201R.a.02.1 35362 2 0 0 0 0 0 0 0

61 RTAOOOOO 197AF. 1 1.1 22264 3 0 0 0 0 0 0 0

66 RTAOOOOO 199F.C.09.2 16824 3 1 0 0 0 0 0 0

75 RTAOOOOO 180AR. 19.2 84182 1 0 0 0 0 0 0 0

78 RTAOOOOO 199RT.09.1 22907 3 0 0 0 0 0 0 0

79 RTAOOOOO 199AF.p.4.1 10282 3 3 0 0 0 0 0 0

85 RTA00000200R.O.03.1 22807 3 0 0 0 0 0 0 0

86 RTAOOOOO 189AF.1.22.1 33333 1 1 0 0 0 0 0 0

87 RTAOOOOO 195 AF.d.20.1 37574 2 0 0 0 0 0 0 0

92 RTAOOOOO 198AF.J.18.1 22759 3 0 0 0 0 0 0 0

95 RTAOOOOO 180AF.g.3.1 9024 5 2 0 0 0 0 0 0

102 RTAOOOOO 199R.J.08.1 37844 2 0 0 0 0 0 0 0

103 RTAOOOOO 199F.e.10.1 22906 3 0 0 0 0 0 1 0

105 RTAOOOOO 179AF.g.12.3 36390 2 0 0 0 0 0 0 0

108 RTAOOOOO 183 AR.h.23.2 18957 3 0 0 0 0 0 0 0

109 RTAOOOOO 197 AF.d.12.1 39546 2 0 0 0 0 0 0 0

116 RTAOOOOOl 81 AR.k.24.3 7005 8 2 0 0 0 0 0 0

1 19 RTAOOOOOl 81 AR.k.24.2 7005 8 2 0 0 0 0 0 0

124 RTAOOOOO 199AR.m.06.1 1 199112222 3 0 0 0 0 0 0 0

129 RTAOOOOO 134A.d.10.1 18957 3 0 0 0 0 0 0 0

137 RTAOOOOOl 81 AF.m.4.3 13238 4 1 0 0 0 0 0 0

141 RTAOOOOO 196AF.C.6.1 23148 3 0 0 0 0 0 0 0

142 RTAOOOOO 198AF. 19.1 75879 1 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib 1 lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 Iii

ID clones clones clones clones clones clones clones cl

NO:

143 RTAOOOOO 199R.h.09.1 76020 1 0 0 0 0 0 0 0

144 RTAOOOOO 198AF.0.18.1 13018 4 0 0 0 1 0 0 0

148 RTAOOOOO 199F.h.17.2 36254 2 0 0 0 0 0 0 0

149 RTAOOOOOl 81 AR.h.06.3 87226 1 0 0 0 0 0 0 0

166 RTAOOOOO 198AF.f.21.1 22676 3 0 0 0 0 0 0 0

173 RTA00000200AR.b.07.1 17125 4 0 0 0 0 0 0 0

178 RTA00000200F.O.03.1 22807 3 0 0 0 0 0 0 0

180 RTA00000199AF.J.12.1 22461 3 0 0 0 0 0 0 0

185 RTAOOOOOl 95 AF.d.4.1 22766 3 0 0 0 0 0 0 0

194 RTA00000200R.k.01.1 40049 2 0 0 0 0 0 0 0

195 RTAOOOOO 198AF.C.10.1 77149 1 0 0 0 0 0 0 0

198 RTAOOOOO 197AR.e.07.1 86969 1 0 0 0 0 0 0 0

199 RTAOOOOO 199R.C.09.1 16824 3 1 0 0 0 0 0 0

206 RTA00000181AF.O.04.2 22205 3 0 0 0 0 0 0 0

207 RTAOOOOO 199AF.1.19.1 22460 3 0 0 0 0 0 0 0

208 RTAOOOOO 198AF.h.22.1 22366 2 1 0 0 0 0 0 0

211 RTAOOOOO 199 AF.m.15.1 10101 3 0 0 0 0 0 0 0

212 RTA00000197AF.J.9.1 13236 4 1 0 0 0 0 0 0

230 RTAOOOOO 185AR.b.18.1 12171 3 2 0 0 0 0 0 0

235 RTA00000201AF.a.02.1 35362 2 0 0 0 0 0 0 0

236 RTAOOOOO 183 AR.h.23.1 18957 3 0 0 0 0 0 0 0

238 RTAOOOOO 187AR.k.12.1 78415 1 0 0 0 0 0 0 0

242 RTA00000198AF.m.l7.1 77992 1 0 0 0 0 0 0 0

243 RTA00000181AF.m.l5.3 12081 4 0 0 0 0 0 0 0

248 RTAOOOOO 198R.C.14.1 39814 2 0 0 0 0 0 0 0

249 RTA00000200R.O.03.2 22807 3 0 0 0 0 0 0 0

251 RTA00000192AF.n.l3.1 8210 2 6 0 0 0 0 0 0

256 RTAOOOOO 184AR.e.15.1 16347 4 0 0 0 0 0 0 0

260 RTAOOOOO 198R.m.17.1 77992 1 0 0 0 0 0 0 0

270 RTA00000178R.1.08.1 39648 2 0 0 0 0 0 0 0

278 RTAOOOOO 198AF.p.16.1 71877 1 0 0 0 0 0 0 0

280 RTA00000193AF.b.l 8.1 7542 8 0 0 2 1 0 1 0

284 RTA00000199F.d.l0.2 22049 3 0 0 0 0 0 0 0

287 RTA00000200AF.b.07.1 17125 4 0 0 0 0 0 0 0

288 RTAOOOOOl 81 AR.i.06.3 19119 3 0 0 0 0 0 0 0

289 RTAOOOOOl 96F. 07.1 22443 2 0 0 0 0 0 0 1

294 RTAOOOOO 198AF. 23.1 8995 2 5 0 0 0 0 0 0

296 RTAOOOOO 196AFT.20.1 22774 3 0 0 0 0 0 0 0

300 RTAOOOOO 195AF.C.12.1 37582 2 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib l lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 HI

ID clones clones clones clones clones clones clones cl

NO:

302 RTAOOOOOl 86AF.d.1.2 40044 2 0 0 1 0 0 0 0

307 RTA00000200F.n.05.2 18989 3 0 0 0 0 0 0 0

308 RTAOOOOO 178 AF.j .20.1 15066 4 0 0 0 0 0 0 0

310 RTAOOOOO 188AF.m.08.1 22155 3 0 0 0 0 0 0 0

315 RTAOOOOO 199R.d.23.1 37477 2 0 0 0 0 0 0 0

319 RTA00000200F.n.05.1 18989 3 0 0 0 0 0 0 0

320 RTAOOOOO 196AF.m.13.1 16290 4 0 0 0 0 0 0 0

325 RTAOOOOO 182AF.d.18.4 37435 2 0 0 0 0 0 0 0

328 RTA00000200AF.g.09.1 22785 3 0 0 0 0 0 0 0

330 RTAOOOOO 177AR.m.17.4 14391 3 1 0 0 0 0 0 0

331 RTAOOOOO 197AR.C.20.1 16282 4 0 0 0 0 0 0 0

337 RTAOOOOO 177AR.m.17.3 14391 3 1 0 0 0 0 0 0

342 RTAOOOOO 196AF.d.10.1 22256 3 0 0 0 0 0 0 0

343 RTA00000201F.a.l8.1 16837 2 2 0 0 0 0 0 0

344 RTAOOOOOl 98 AF.o.02.1 68756 1 0 0 0 0 0 0 0

345 RTAOOOOO 187AF.h.21.1 39171 2 0 0 0 0 0 0 0

347 RTAOOOOO 199F.b.03.2 38340 2 0 0 0 0 0 0 0

358 RTAOOOOOl 98 AF.g.7.1 13386 3 2 0 0 0 0 0 0

362 RTAOOOOO 197AR.C.24.1 82498 1 0 0 0 0 0 0 0

371 RTAOOOOO 197F.e.7.1 86969 1 0 0 0 0 0 0 0

378 RTAOOOOOl 8 lAF.k.24.3 7005 8 2 0 0 0 0 0 0

382 RTA00000200AF.J.6.1 22902 3 0 0 0 0 0 0 0

384 RTAOOOOO 196AF.h.17.1 39215 2 0 0 0 0 0 0 0

392 RTAOOOOO 185AF.D.11.2 9024 5 2 0 0 0 0 0 0

397 RTAOOOOO 198AF.b.22.1 38956 2 0 0 0 0 0 0 0

399 RTAOOOOO 186AF.IΗ.15.2 40122 2 0 0 0 0 0 0 0

406 RTAOOOOO 199FT.09.2 22907 3 0 0 0 0 0 0 0

408 RTAOOOOO 183AR.1.15.1 39383 2 0 0 0 0 0 0 0

413 RTA00000200F.a.l2.1 16751 4 0 0 0 0 0 0 0

416 RTAOOOOO 199F.a.5.1 22134 3 0 0 0 0 0 0 0

418 RTAOOOOO 187AR. 01.1 78356 1 0 0 0 0 0 0 0

424 RTAOOOOO 187AR.J.24.1 78356 1 0 0 0 0 0 0 0 426 RTAOOOOO 199AF.0.19.1 36927 2 0 0 0 0 0 0 0

429 RTAOOOOO 196F.Ϊ.19.1 39498 2 0 0 0 0 0 0 0

430 RTAOOOOO 198R. 23.1 8995 2 5 0 0 0 0 0 0

432 RTA00000198AF.O.05.1 26702 2 0 0 0 0 0 0 0

433 RTAOOOOO 198RJ.18.1 22759 3 0 0 0 0 0 0 0 435 RTAOOOOO 182AR.C.22.1 16283 3 0 0 0 0 0 0 0

438 RTAOOOOO 180AR.g.03.4 9024 5 2 0 0 0 0 0 0 SEQ Sequence Name cluster lib l lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 lib 20

ID clones clones clones clones clones clones clones clones

NO:

451 RTA00000200AF.b.20.1 40403 0 0 0 0 0 0 0

455 RTAOOOOO 198AF.d.12.1 21142 1 0 0 0 0 0 0

456 RTA00000200AF.b.l2.1 22053 0 0 0 0 0 0 0

457 RTA00000191AR.1.7.2 14391 1 0 0 0 0 0 0

461 RTA00000190AF.e.l3.1 38961 0 0 0 0 0 0 0

462 RTAOOOOO 196AF.n.17.1 12477 1 0 0 0 0 0 0 467 RTAOOOOO 195AF.b.19.1 77678 1 0 0 0 0 0 0 0

475 RTAOOOOO 187AR.m.3.3 17055 4 0 0 0 0 0 0 0

476 RTA00000200R.g.l5.1 22898 0 0 0 0 0 0 0 482 RTAOOOOO 187AF.J.7.1 78091 0 0 0 0 0 0 0

485 RTAOOOOO 196AF.C.14.1 23105 0 0 0 0 0 0 0

486 RTAOOOOO 190AR.p.22.2 16368 0 0 0 0 0 0 0

492 RTAOOOOO 198AF.D.8.1 22636 0 0 0 0 0 0 0

493 RTAOOOOO 177AF.m.17.1 14391 1 0 0 0 0 0 0

494 RTA0000O200AF.k.l.l 40049 0 0 0 0 0 0 0

498 RTAOOOOO 190AF.h.12.1 12977 0 0 0 0 0 0 0

499 RTAOOOOO 199F.b.22.2 17018 0 0 0 0 0 0 0 508 RTAOOOOO 187AFX 14.2 19406 1 0 0 0 0 0 0 511 RTAOOOOO 196AF.g.10.1 12498 1 1 0 0 0 0 0 517 RTA00000184AF.e.l4.1 16347 0 0 0 0 0 0 0 522 RTAOOOOO 178AR. 17.2 23824 1 0 0 0 0 0 0 531 RTAOOOOO 195F.a.3.1 27179 0 0 0 0 0 0 0 544 RTA00000196F.J.13.1 23170 0 0 0 0 0 0 0 547 RTAOOOOO 196AF.g.8.1 39665 0 0 0 0 0 0 0 549 RTAOOOOO 198AF.C.16.1 26801 0 0 0 0 0 0 0 553 RTA00000201F.b.22.1 35728 0 0 0 0 0 0 1 559 RTAOOOOOl 97 AF.p.20.1 22795 0 0 0 0 0 0 0 563 RTAOOOOO 192AR.0.16.2 9061 2 0 0 0 0 0 0 565 RTA00000191AF.C.10.1 40422 0 0 0 0 0 0 0 568 RTAOOOOO 196AF.p.01.2 87143 0 0 0 0 0 0 0 578 RTAOOOOO 180AF.g.17.1 16653 1 0 0 0 0 0 0 583 RTAOOOOO 190AR.h.12.2 12977 0 0 0 0 0 0 0

585 RTAOOOOO 198AF.n.18.1 16715 1 0 0 0 0 0 0

586 RTAOOOOO 199R.0.11.1 23172 0 0 0 0 0 0 0

588 RTA00000191AF.b.4.1 14936 0 0 0 0 0 0 0

589 RTAOOOOO 192AF.1.1.1 16392 0 0 0 0 0 0 0 593 RTAOOOOO 196R.C.14.2 23105 0 0 0 0 0 0 0 595 RTAOOOOOl 95R.a.06.1 35265 0 1 0 0 0 0 0 602 RTAOOOOO 195 AF.b.21.1 39055 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib 1 lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 lit

ID clones clones clones clones clones clones clones cl

NO:

612 RTAOOOOO 197AR.e.22.1 78758 1 0 0 0 0 0 0 0

615 RTAOOOOO 197R.p.20.1 22795 3 0 0 0 0 0 0 0

618 RTAOOOOO 192AF.a.14.1 6874 6 3 0 0 1 0 0 0

623 RTAOOOOO 198R.b.24.1 19047 3 0 0 0 0 0 0 0

627 RTAOOOOO 199F.h.15.2 22269 3 0 0 0 0 0 0 0

628 RTAOOOOO 198AF.g.16.1 6602 1 1 0 0 0 0 0 0

634 RTAOOOOO 192AF.J.6.1 1 1494 4 0 0 0 0 0 0 0

635 RTAOOOOOl 8 lAF.p.7.3 38773 2 0 0 0 0 0 0 0

637 RTA00000200AF.g.l 5.1 22898 3 0 0 0 0 0 0 0

643 RTAOOOOO 184AF.C.9.1 16245 4 0 0 0 0 0 0 0

645 RTAOOOOO 177AF. 9.1 16245 4 0 0 0 0 0 0 0

649 RTAOOOOO 190AR.1.19.2 88204 1 0 0 0 0 0 0 0

662 RTA00000201R.a.l5.1 57347 1 0 0 0 0 0 0 0

664 RTA00000195R.a.23.1 86432 1 0 0 0 0 0 0 0

670 RTAOOOOO 186AF.p.17.3 38383 2 0 0 0 0 0 0 0

674 RTAOOOOO 197AR.e.24.1 39250 2 0 0 0 0 0 0 0

683 RTAOOOOO 187 AR.j.01.1 79028 1 0 0 0 0 0 0 0

686 RTA00000201F.f.07.1 511 16 1 0 0 0 0 0 0 0

694 RTA00000201R.C.19.1 22357 2 1 0 0 0 0 0 0

702 RTAOOOOO 177AR.b.8.5 17062 3 0 0 0 0 0 0 0

712 RTA00000201F.b.21.1 9071 3 4 0 0 0 0 0 0

717 RTA00000200F.O.10.2 36432 2 0 0 0 0 0 0 0

718 RTAOOOOO 196F.1.14.2 23144 3 0 0 0 0 0 0 0

725 RTAOOOOOl 97 AF.b.1.1 12134 1 1 0 0 0 0 0 0

733 RTA00000200AF.d.20.1 26600 2 0 0 0 0 0 0 0

743 RTAOOOOOl 78 AF.k.9.1 16342 3 0 0 0 0 0 0 0

748 RTAOOOOO 198 AF.b.24.1 19047 3 0 0 0 0 0 0 0

757 RTA00000406F.d.l6.1 15040 2 2 0 0 0 0 0 0

760 RTA00000408F.O.12.2 78578 1 0 0 0 0 0 0 0

761 RTAOOOOOl 19AJ.15.1 79623 1 0 0 0 0 0 0 0

762 RTA00000413F.d.l2.1 66467 1 0 0 0 0 0 0 0

763 RTA00000423F112.1 91 18 4 3 0 0 0 0 0 0

766 RTA00000411F.k.05.1 64777 1 0 0 0 0 0 0 0

769 RTA00000419F.b.09.1 78128 1 0 0 0 0 0 0 0

772 RTA0000041 1F.m. l5.1 78014 1 0 0 0 0 0 0 0

774 RTAOOOOO 123 A.k.23.1 80313 1 0 0 0 0 0 0 0

777 RTA00000130A.m.l5.1 81630 1 0 0 0 0 0 0 0

778 RTA0000041 1F.k.20.1 64973 1 0 0 0 0 0 0 0

780 RTA00000418F.k.05.1 73021 1 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib l lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 HI

ID clones clones clones clones clones clones clones cl

NO:

781 RTA00000423F.h.l8.1 37972 2 0 0 0 0 0 0 0

783 RTA00000422F.p.06.2 39282 2 0 0 0 0 0 0 0

784 RTA00000404F.n.l 6.2 39095 2 0 0 0 0 0 0 0

785 RTA00000411F.m.24.1 77568 1 0 0 0 0 0 0 0

786 RTA00000134A.J.10.1 81383 1 0 0 0 0 0 0 0

787 RTA00000409F.J.02.1 76417 1 0 0 0 0 0 0 0

788 RTA00000403F .15.1 23840 2 1 0 0 0 0 0 0

789 RTA00000411F.H.11.1 77276 1 0 0 0 0 0 0 0

790 RTA00000339F.Ϊ.13.1 5970 6 4 0 0 0 0 0 0

792 RTA00000406F.O.15.1 37482 2 0 0 0 0 0 0 0

793 RTA00000412F.g.04.2 64457 1 0 0 0 0 0 0 0

795 RTA00000352R.1.06.1 40343 2 0 0 0 0 0 0 0

796 RTA00000419F.b.l2.1 63148 1 0 0 0 0 0 0 0

797 RTA00000423F.k.l 7.2 37512 2 0 0 0 0 0 0 0

799 RTA00000418F.k.l4.1 76133 1 0 0 0 0 1 0 0

800 RTA00000409F.1.12.1 26755 1 0 0 0 0 0 0 0

801 RTA00000404F.C.20.1 39088 2 0 0 0 0 0 1 0

802 RTA00000423F.g.09.1 38958 2 0 0 0 0 0 0 0

804 RTA00000406F.d.l2.1 38575 2 0 0 0 0 0 0 0

805 RTA00000411F.f.02.1 63386 1 0 0 0 0 0 0 0

806 RTAOOOOO 129A.n.21.1 79381 1 0 0 0 0 0 0 0

807 RTA00000409F.m.l2.1 73490 1 0 0 0 0 0 0 0

808 RTA00000410F.C.04.1 74099 1 0 0 0 0 0 0 0

810 RTA00000406F.m.09.1 26891 2 0 0 0 0 0 0 0

81 1 RTA0000041 1F.b.06.1 77884 1 0 0 0 0 0 0 0

812 RTA00000409F.1.21.1 73143 1 0 0 0 0 0 0 0

818 RTA00000404F.1.20.2 38638 2 0 0 0 0 0 0 0

819 RTA00000413F.d.l8.1 65305 1 0 0 0 0 0 0 0

820 RTA00000404F.p.04.2 39069 2 0 0 0 0 0 0 0

821 RTA00000405F.g.l9.2 37150 2 0 0 0 0 0 0 0

822 RTA00000409F.a.22.1 75200 1 0 0 0 0 0 0 0

824 RTA00000405F.O.18.1 11016 4 2 0 0 0 0 0 0

829 RTA00000408F.e.22.2 26930 1 0 0 0 0 0 0 0

831 RTA00000413F.d.l6.1 63331 1 0 0 0 0 0 0 0

834 RTA00000419F.g.08.1 66700 1 0 0 0 0 0 0 0

835 RTA00000122A.g. l6.1 81366 1 0 0 0 0 0 0 0

836 RTA00000419F.C.16.1 65254 1 0 0 0 0 0 0 0

837 RTA0000041 1F.b.03.1 23634 1 2 0 0 0 0 0 0

842 RTA00000403F.1.20.1 18267 1 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib l lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 HI ID clones clones clones clones clones clones clones cl 845 RTA0000041 1 F.a.02.1 78537 1 0 0 0 0 0 0 0

847 RTA00000412F.1.04.1 66372 1 0 0 0 0 0 0 0

849 RTA00000406F.a.23.1 38712 2 0 0 0 0 0 0 0

851 RTAOOOOO 120A.n.19.3 80004 1 0 0 0 0 0 0 0

852 RTA00000403F.e.01.1 38965 2 0 0 0 0 0 0 0

853 RTA00000411F.1.03.1 62702 1 0 0 0 0 0 0 0

856 RTAOOOOOl 21 A.m.2.1 81064 1 0 0 0 0 0 0 0

858 RTA00000418F.J.12.1 73316 1 0 0 0 0 ^' 0 0 0

862 RTAOOOOO 125A.g.16.1 21497 2 1 0 0 0 0 0 0

863 RTA00000418F.O.18.1 78676 1 0 0 0 0 0 0 0

865 RTA00000408F. 14.1 73856 1 0 0 0 0 0 0 0

871 RTA00000403F.O.15.1 39140 2 0 0 0 0 0 0 0

872 RTA00000341F.m.l3.1 26502 1 0 0 0 0 0 0 0

873 RTA00000408F.h.03.1 78382 1 0 0 0 0 0 0 0

874 RTA00000423F.k.05.1 37472 2 0 0 0 0 0 0 0

876 RTA00000418F.p. l9.1 78544 1 0 0 0 0 0 0 0

877 RTA00000420F.f.06.1 64812 1 0 0 0 0 0 0 0

878 RTAOOOOO 122A.J.18.1 81317 1 0 0 0 0 0 0 0

879 RTA00000420F.d.05.1 64432 1 0 0 0 0 0 0 0

880 RTA00000403F.m. l8.1 39185 2 0 0 0 0 0 0 0

882 RTA00000411F.J.05.1 40709 1 1 0 0 0 0 0 0

883 RTA00000403F.a.04.1 23529 2 1 0 0 0 0 0 0

885 RTA00000406F.f.l2.1 21895 2 1 0 0 0 0 0 0

886 RTA00000418F.g.22.1 74837 1 0 0 0 0 0 0 0

888 RTA00000404F.1.20.1 38638 2 0 0 0 0 0 0 0

889 RTA00000408F.L08.2 75811 1 0 0 0 0 0 0 0

890 RTAOOOOO 122A.d.5.1 81 155 1 0 0 0 0 0 0 0

894 RTA00000419F.b.l9.1 65534 1 0 0 0 0 0 0 0

896 RTA00000418F. 19.1 74932 1 0 0 0 0 0 0 0

900 RTA00000419F.g.l2.1 66171 1 0 0 0 0 0 0 0

901 RTA00000404F.n. l l.2 38001 2 0 0 0 0 0 0 0

904 RTA00000419F.O.24.1 65092 1 0 0 0 0 0 0 0

905 RTA00000419F.k. l9.1 75447 1 0 0 0 0 0 0 0

907 RTAOOOOO 127A.i.20.1 81418 1 0 0 0 0 0 0 0

908 RTA00000422F.g.22.1 22561 3 0 0 0 0 0 0 0

910 RTA00000413F.h. l3.1 65190 1 0 0 0 0 0 0 0

913 RTA00000348R.J.16.1 7005 8 2 0 0 0 0 0 0

916 RTA00000418F.n.22.1 79062 1 0 0 0 0 0 0 0

917 RTA00000406F.1.08.1 39016 2 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib l lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 HI ID clones clones clones clones clones clones clones cl

X INl/UV.

920 RTA00000409F.J.07.1 75190 1 0 0 0 0 0 0 0

923 RTA0000041 1F.e.22.1 63638 1 0 0 0 0 0 0 0

924 RTA00000347F.a.l7.1 16723 3 1 0 0 0 0 0 0

926 RTA00000404F.n.20.1 26865 2 0 0 0 0 0 0 0

929 RTA00000404F.b.02.1 38984 2 0 0 0 0 0 0 0

931 RTA00000403F.b.l0.1 73268 1 0 0 0 0 0 0 0

932 RTA00000406F.U2.1 39080 2 0 0 0 0 0 0 0

933 RTA00000406F.h.08.1 16228 2 2 0 0 0 0 0 0

934 RTA00000418F.L19.1 79180 1 0 0 0 0 0 0 0

936 RTA00000412F.h.21.1 64348 1 0 0 0 0 0 0 0

938 RTAOOOOO 120A.g.18.1 81255 1 0 0 0 0 0 0 0

940 RTA00000423FJ.05.1 37958 2 0 0 0 0 0 0 0

941 RTAOOOOO 132A. 6.1 81284 1 0 0 0 0 0 0 0

943 RTA00000406F.p.04.1 37458 2 0 0 0 0 0 0 0

944 RTA00000347F.a.l3.1 22446 3 0 0 0 0 0 0 0

945 RTA00000419F.p.23.1 64748 1 0 0 0 0 0 0 0

946 RTA00000419F.d.l7.1 64353 1 0 0 0 0 0 0 0

949 RTAOOOOO 124A.k.5.1 80252 1 0 0 0 0 0 0 0

950 RTA00000404F.h.22.1 18735 2 1 0 0 0 0 1 0

952 RTA00000410F.O.05.1 75262 1 0 0 0 0 0 0 0

953 RTA00000339R.1.14.1 19119 3 0 0 0 0 0 0 0

954 RTA00000403F.m.l3.2 39077 2 0 0 0 0 0 0 0

957 RTA00000419F.g.22.1 64515 1 0 0 0 0 0 0 0

958 RTA00000404F.g.21.1 37947 2 0 0 0 0 0 0 0

960 RTA00000138A.n.4.1 21920 2 1 0 0 0 0 0 0

961 RTA00000410F.b.l5.1 77100 1 0 0 0 0 0 0 0

963 RTA00000419F.J.23.1 74470 1 0 0 0 0 0 0 0

964 RTA0000041 1FJ.02.1 65310 1 0 0 0 0 0 0 0

965 RTA00000419F.p.24.1 63477 1 0 0 0 0 0 0 0

966 RTA00000404F.a.l9.1 38624 2 0 0 0 0 0 0 0

973 RTA00000346F.e.l3.1 74653 1 0 0 0 0 0 0 0

974 RTA00000419F.C.18.1 41394 1 1 0 0 0 0 0 0

978 RTA00000404F.e.22.1 1 1344 3 3 0 0 0 0 0 0

981 RTA00000125A.k. l0.1 81644 1 0 0 0 0 0 0 0

982 RTA00000347F.C.06.1 18846 2 1 0 0 0 0 0 0

983 RTA0000041 1F.k.l9.1 64200 1 0 0 0 0 0 0 0

984 RTA00000345F.Ϊ.09.1 27250 2 0 0 0 0 0 0 0

985 RTA00000423F.k.01.1 40426 2 0 0 0 0 0 0 0

986 RTA00000408F.d.06.1 78997 1 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib l lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 HI

ID clones clones clones clones clones clones clones cl X INTUV.

987 RTAOOOOO 128A.b.20.1 79761 1 0 0 0 0 0 0 0

989 RTAOOOOOl 95 AF.d.4.1 22766 3 0 0 0 0 0 0 0

991 RTA00000403F.h. l2.1 15205 2 1 0 0 0 0 0 0

992 RTAOOOOOl 19A.J.22.1 80336 1 0 0 0 0 0 0 0

995 RTAOOOOO 126A.n.7.2 79557 1 0 0 1 0 0 0 0

997 RTA00000404FJ.08.1 39066 2 0 0 0 0 0 0 0

998 RTA00000410F.C.14.1 77809 1 0 0 0 0 0 0 0

999 RTAOOOOO 120A.g.23.1 81 189 1 0 0 0 0 0 0 0

1000 RTAOOOOO 195 AF.d.20.1 37574 2 0 0 0 0 0 0 0

1002 RTA00000412F.J.17.1 64071 1 0 0 0 0 0 0 0

1004 RTAOOOOOl 19A.J.10.1 79646 1 0 0 0 0 0 0 0

1010 RTA00000419F.O.16.1 62867 1 0 0 0 0 0 0 0

1012 RTA00000411F.C.17.1 77664 1 0 0 0 0 0 0 0

1013 RTA00000406F. 15.1 38549 2 0 0 0 0 0 0 0

1014 RTA00000406F.a.02.1 37744 2 0 0 0 0 0 0 0

1016 RTA00000341F.b.06.1 17008 4 0 0 0 0 0 0 0

1017 RTA00000409F.n.l4.1 78190 1 0 0 0 0 0 0 0

1019 RTA00000345FJ.08.1 16731 3 1 0 0 0 0 0 0

1021 RTA00000419F.g.l5.1 32519 1 1 0 0 0 0 0 0

1022 RTA00000423F.3.19.1 21396 1 2 0 0 0 0 0 0

1024 RTA00000422F.e.08.1 39020 2 0 0 0 0 0 0 0

1025 RTA00000411F.d.l5.1 74890 1 0 0 0 0 0 0 0

1027 RTA00000411F.1.15.1 66704 1 0 0 0 0 0 0 0

1029 RTA00000405F.e.08.1 37916 2 0 0 0 1 0 0 0

1030 RTA00000353R .24.1 23089 3 0 0 0 0 0 0 0

1032 RTA00000418F.O.06.1 75930 1 0 0 0 0 0 0 0

1033 RTA00000404F.C.10.1 23534 2 1 0 0 0 0 0 0

1034 RTA00000418F.i.21.1 78728 1 0 0 0 0 0 0 0

1036 RTA00000411F.1.13.1 43114 1 1 0 0 0 0 0 0

1037 RTA00000407F.a.24.1 37560 2 0 0 0 0 0 0 0

1038 RTA00000346F.n.06.1 12439 4 0 0 0 0 0 0 0

1039 RTA00000412F.1.21.1 65183 1 0 0 0 0 0 0 0

1040 RTA00000413F.i.02.1 65857 1 0 0 0 0 0 0 0

1041 RTA00000404F.i. l9.1 38698 2 0 0 0 0 0 0 0

1043 RTA00000403F.a.l l .l 73109 1 0 0 0 0 0 0 0

1045 RTA0000041 1F.k. l6.1 64759 1 0 0 0 0 0 1 0

1046 RTA00000405F.C.01.1 19236 2 0 0 0 0 0 0 0

1047 RTA00000423F.i.l8.1 14996 4 0 0 0 0 0 0 0

1050 RTA00000406F.a.07.1 26607 2 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib 1 lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 HI ID clones clones clones clones clones clones clones cl NO: 1051 RTA00000347F.d.06.1 39122 2 0 0 0 0 0 0 0

1052 RTA00000419F.b.l 8.1 67034 1 0 0 0 0 0 0 0

1053 RTA00000406F.h.07.1 38003 2 0 0 0 0 0 0 0

1054 RTA00000405F.1.15.1 19575 2 1 0 0 0 0 0 0

1055 RTA00000406F.g.l7.1 37979 2 0 0 0 0 0 0 0

1058 RTAOOOOO 130A.h.22.1 80933 1 0 0 0 0 0 0 0

1061 RTA00000404F.d.l3.1 39036 2 0 0 0 0 0 0 0

1064 RTA00000340F.n.01.1 39081 2 0 0 0 0 0 0 0

1065 RTA00000419F.d.06.1 65496 1 0 0 0 0 0 0 0

1066 RTA00000419F.n.09.1 66070 1 0 0 0 0 0 0 0

1067 RTA00000399F.i.08.1 38927 2 0 0 0 0 0 0 0

1069 RTA00000423F.g.l3.1 38028 2 0 0 0 0 0 0 0

1072 RTAOOOOO 195 AF.b.21.1 39055 2 0 0 0 0 0 0 0

1073 RTA00000403F.h.05.1 39096 2 0 0 0 0 0 0 0

1075 RTA00000422F.p.07.2 39024 2 0 0 1 0 0 0 0

1078 RTA00000421F.n.l9.1 16409 3 1 0 0 0 0 0 0

1080 RTA00000345F. 21.1 40204 2 0 0 0 0 0 0 0

1082 RTA00000405F.a.l l .l 39124 2 0 0 0 0 0 0 0

1084 RTA00000413F.e.l6.1 63836 1 0 0 0 0 0 0 0

1086 RTA00000404F.O.18.2 39110 2 0 0 0 0 0 0 0

1087 RTA00000409F.i.24.1 76967 1 0 0 0 0 0 0 0

1091 RTA00000340F.n.l3.1 17055 4 0 0 0 0 0 0 0

1092 RTA00000340F.p.04.1 78533 1 0 0 0 0 0 0 0

1093 RTA00000411F.C.05.1 73368 1 0 0 0 0 0 0 0

1097 RTA00000404F.i.02.1 39015 2 0 0 0 0 0 0 0

1099 RTA00000403F.m. l5.2 26901 2 0 0 0 0 0 0 0

1100 RTA00000412F.h.23.2 651 18 1 0 0 0 0 0 0 0

1101 RTA00000418F.J.08.1 73382 1 0 0 0 0 0 0 0

1102 RTAOOOOOl 25 A.n.4.1 81984 1 0 0 0 0 0 0 0

1103 RTA00000412F.1.19.1 65825 1 0 0 0 0 0 0 0

1 105 RTAOOOOO 129A.p.3.1 32644 1 1 0 0 0 0 0 0

1 106 RTA00000340F.p.20.1 17008 4 0 0 0 0 0 0 0

1 107 RTA00000411F.a. l0.1 73073 1 0 0 0 0 0 0 0

1 108 RTA00000409F.n.l7.1 76725 1 0 0 0 0 0 0 0

1 109 RTA00000404F.C.03.2 39198 2 0 0 0 0 0 0 0

1 1 10 RTA00000420F.a.l9.1 34192 1 1 0 0 0 0 0 0

1 1 14 RTA00000420F.d.l2.1 64095 1 0 0 0 0 0 0 0

1 115 RTA00000409F .19.1 73792 1 0 0 0 0 0 0 0

1116 RTA00000422F.d.l6.1 39133 2 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib l lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 HI ID clones clones clones clones clones clones clones cl NO: 1 1 17 RTA00000418F.m. l6.1 74986 1 0 0 0 0 0 0 0

1 1 18 RTA00000405F.C.1 1.1 39068 2 0 0 0 0 0 0 0

1 1 19 RTA00000404F. 22.1 39084 2 0 0 0 0 0 0 0

1 120 RTA00000418F. 07.1 75067 1 0 0 0 0 0 0 0

1 121 RTA00000403F.C.10.1 75261 1 0 0 0 0 0 0 0

1124 RTA00000410F.m.05.1 74964 1 0 0 0 0 0 0 0

1125 RTA00000405F.L20.1 38532 2 0 0 0 0 0 0 0

1127 RTA00000408F.p.24.1 74286 1 0 0 0 0 0 0 0

1 128 RTA00000418F.k. l 8.1 75385 1 0 0 0 0 0 0 0

1 129 RTA00000422F.m.04.1 38702 2 0 0 0 0 0 0 0

1 133 RTA00000403F.a.07.1 73559 1 0 0 0 0 0 0 0

1 135 RTA00000403F.b.l9.1 22327 2 1 0 0 0 0 0 0

1 136 RTA00000418F.m.23.1 77195 1 0 0 0 0 0 0 0

1138 RTA00000404F.U 8.1 21912 2 1 0 0 0 0 0 0

1139 RTA00000422F.i.l4.1 39300 2 0 0 0 0 0 0 0

1140 RTA00000418F.m.l4.1 7571 1 1 0 0 1 0 0 0 0

1141 RTA00000406F.O.12.1 37459 2 0 0 0 0 0 0 0

1143 RTA00000411F.a.07.1 74547 1 0 0 0 0 0 0 0

1144 RTA00000411F.C.02.1 72852 1 0 0 0 0 0 0 0

1146 RTAOOOOO 130A.h.16.1 80761 1 0 0 0 0 0 0 0

1147 RTA00000410F.p.23.1 73948 1 0 0 0 0 0 0 0

1148 RTA00000418F.m.24.1 77114 1 0 0 0 0 0 0 0

1150 RTA00000408F.J.19.2 73752 1 0 0 0 0 0 0 0

1152 RTAOOOOOl 18A.d.17.1 81921 1 0 0 0 0 0 0 0

1 153 RTA00000407F.b.04.1 63221 1 0 0 0 0 0 0 0

1154 RTA00000411F.e.07.1 65008 1 0 0 0 0 0 0 0

1156 RTAOOOOO 132A.C.11.1 87278 1 0 0 0 0 0 0 0

1157 RTA00000420F.e. l6.1 63639 1 0 0 0 0 0 0 0

1159 RTA00000404F.b.l l.l 39079 2 0 0 0 0 0 0 0

1160 RTA00000418F.k. l7.1 75390 1 0 0 0 0 0 0 0

1 161 RTAOOOOO 129A.k.12.1 79322 1 0 0 0 0 0 0 0

1162 RTA00000340R.m.07.1 78415 1 0 0 0 0 0 0 0

1 163 RTA00000405F.d. l4.1 35209 2 0 0 0 0 0 1 0

1164 RTA00000406F.f.l l .l 38601 2 0 0 0 0 0 0 0

1 165 RTAOOOOO 120A.h.5.1 80344 1 0 0 0 0 0 0 0

1167 RTA00000411F.g.06.1 66065 1 0 0 0 0 0 0 0

1 168 RTA00000408F.d.l6.1 76318 1 0 0 0 0 0 0 0

1 171 RTA00000404F.C.19.1 39026 2 0 0 0 0 0 0 1

1173 RTA00000410F.a.01.1 73354 1 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib l lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 HI

ID clones clones clones clones clones clones clones cl

NO:

1174 RTA00000408F.h.08.1 74575 1 0 0 0 0 0 0 0

1 175 RTA00000422F.b. l6.1 17045 4 0 0 0 0 0 0 0

1 176 RTA00000419F.f. l0.1 66193 1 0 0 0 0 0 0 0

1 177 RTA00000418F.1.04.1 74140 1 0 0 0 0 0 0 0

1178 RTA00000410F.3.16.1 73548 1 0 0 0 0 0 0 0

1 179 RTAOOOOO 138A.e.13.1 79608 1 0 0 0 0 0 0 0

1180 RTAO0O0013OA.b.5.1 79579 1 0 0 0 0 0 0 0

1 181 RTA00000408F.J.15.2 74759 1 0 0 0 0 0 0 0

1182 RTA00000410F.m.20.1 74285 1 0 0 0 0 0 0 0

1 185 RTA00000419F.e.04.1 62963 1 0 0 0 0 0 0 0

1 187 RTA00000418F.g.05.1 73075 1 0 0 0 0 0 0 0

1 188 RTA00000419F.n.02.1 65963 1 0 0 0 0 0 0 0

1 191 RTAOOOOOl 19A.m.l 5.1 80989 1 0 0 0 0 0 0 0

1 194 RTA00000413F.g.23.1 40700 1 1 0 0 0 0 0 0

1 195 RTA00000403F.a. l8.1 75726 1 0 0 0 0 0 0 0

1 196 RTA00000404F.m.20.2 39144 2 0 0 0 0 0 0 0

1 199 RTA00000419F.h.04.1 65034 1 0 0 0 0 0 0 0

1200 RTA00000408F.d.l2.1 75782 1 0 0 0 0 0 0 0

1201 RTA00000133A.m.l9.2 80167 1 0 0 0 0 0 0 0

1206 RTAOOOOO 126A.o.22.1 81752 1 0 0 0 0 0 0 0

1207 RTA00000419F.n. l3.1 66026 1 0 0 0 0 0 0 0

1208 RTAOOOOO 130A.h.13.1 80790 1 0 0 0 0 0 0 0

1212 RTA00000411F.m.l9.1 74924 1 0 0 0 0 0 0 0

1214 RTA00000419F. 06.1 78493 1 0 0 0 0 0 0 0

1216 RTA00000412F.d.l6.1 26829 1 0 0 0 0 0 0 0

1217 RTAOOOOOl 19A.J.23.1 79835 1 0 0 0 0 0 0 0

1219 RTAOOOOO 195AF.C.12.1 37582 2 0 0 0 0 0 0 0

1223 RTA00000423F.C.19.1 40472 2 0 0 0 0 0 0 0

1224 RTA00000405F.g.24.1 39076 2 0 0 0 0 0 0 0

1226 RTA00000419F.C.1 1.1 65504 1 0 0 0 0 0 0 0

1227 RTAOOOOO 135A.f.14.2 79969 1 0 0 0 0 0 0 0

1228 RTA00000403F.a.05.1 18808 1 1 0 0 0 0 0 0

1229 RTA00000405F.e.l7.1 38662 2 0 0 0 0 0 0 0

1230 RTA0000041 1F.d.05.1 75812 1 0 0 0 0 0 0 0

1232 RTA00000418F.d.03.1 76824 1 0 0 0 0 0 0 0

1233 RTA00000418F.h.08.1 76401 1 0 0 0 0 0 0 0

1234 RTA00000418F.m.l0.1 791 10 1 0 0 0 0 0 0 0

1235 RTA00000411 F.i. l5.1 31612 1 1 0 0 0 0 0 0

1236 RTA00000413F.i.23.1 63073 1 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib l lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 HI

ID clones clones clones clones clones clones clones cl X JNTΓUV.

1237 RTA0000041 1F.e.24.1 64781 1 0 0 0 0 0 0 0

1238 RTA00000406F.g.22.1 38590 2 0 0 0 0 0 0 0

1239 RTA00000126A.n.l3.2 79735 1 0 0 0 0 0 0 0

1240 RTA00000419F.a.02.1 77993 1 0 0 0 0 0 0 0

1241 RTA00000346F.1.13.1 7542 8 0 0 2 1 0 1 0

1245 RTA00000120A.d.l5.1 80533 1 0 0 0 0 0 0 0

1246 RTA00000418F.f.21.1 75157 1 0 0 0 0 0 0 0

1248 RTAOOOOO 129A.d.1.2 80058 1 0 0 0 0 0 0 0

1251 RTA00000419F.m.20.1 76720 1 0 0 0 0 0 0 0

1253 RTA00000406F.e.l5.1 39074 2 0 0 0 0 0 0 0

1255 RTA00000411F.C.10.1 73117 1 0 0 0 0 0 0 0

1259 RTA00000413F.d.05.1 64788 1 0 0 0 0 0 0 0

1260 RTAOOOOO 121 A.o.3.1 81437 1 0 0 0 0 0 0 0

1262 RTA00000420F.e.02.1 40259 2 0 0 0 0 0 0 0

1268 RTAOOOOO 126A.k.7.2 79866 1 0 0 0 0 0 0 0

1270 RTA00000419F.1.03.1 79060 1 0 0 0 0 0 0 0

1272 RTAOOOOOl 18A.a.2.1 38067 2 0 0 0 0 0 0 0

1273 RTA00000410F.m.l8.1 76365 1 0 0 0 0 0 0 0

1275 RTA00000406F.C.20.1 38578 2 0 0 0 0 0 0 0

1276 RTA00000413F.b.l4.1 66591 1 0 0 0 0 0 0 0

1277 RTA00000406F.C.18.1 14368 2 0 0 0 0 0 0 0

1278 RTA00000418F.J.09.1 76352 1 0 0 0 0 0 0 0

1279 RTA00000419FT.23.1 65002 1 0 0 0 0 0 0 0

1281 RTA00000411F.a.05.1 76699 1 0 0 0 0 0 0 0

1282 RTA00000419F.m.21.1 77947 1 0 0 0 0 0 0 0

1283 RTA00000405F.n.l6.1 21503 2 1 1 0 0 0 0 0

1284 RTA00000422F.O.19.2 13084 3 2 0 0 0 0 0 0

1285 RTA00000408F.n.02.2 76993 1 0 0 0 0 0 0 0

1290 RTAOOOOOl 19A.g.7.1 83580 1 0 0 0 0 0 0 0

1291 RTA00000411F.i.02.1 66975 1 0 0 0 0 0 0 0

1292 RTA00000408F.1.09.1 75487 1 0 0 0 0 0 0 0

1293 RTA00000423F.g.04.1 23012 2 1 0 0 0 0 0 0

1295 RTA00000418F.L 18.1 78024 1 0 0 0 0 0 0 0

1296 RTA00000411F.h.l5.1 65160 1 0 0 0 0 0 0 0

1297 RTA00000410F.i. l9.1 78988 1 0 0 0 0 0 0 0

1298 RTA00000419F. 24.1 75596 1 0 0 0 0 0 0 0

1301 RTA00000409F.i.09.1 75279 1 0 0 0 0 0 0 0

1302 RTA00000419F.h.02.1 63985 1 0 0 0 0 0 0 0

1303 RTA00000413F.b.l2.1 64932 1 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib 1 lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 HI ID clones clones clones clones clones clones clones cl NO: 1304 RTA00000121A.h.l 8.1 16376 4 0 0 0 0 0 0 0

1305 RTA0000041 1F.n.20.1 75816 1 0 0 0 0 0 0 0

1307 RTA0000041 1F.n.l2.1 73308 1 0 0 0 0 0 0 0

1308 RTA00000408FJ.12.2 18226 1 0 0 0 0 0 0 0

1309 RTA00000409F.L03.1 75968 1 0 0 0 0 0 0 0

1312 RTA00000409F .05.1 74128 1 0 0 0 0 0 0 0

1313 RTA00000419F.m.04.1 74367 1 0 0 0 0 0 0 0

1314 RTA00000418F.k.03.1 78901 1 0 0 0 0 0 0 0

1315 RTA00000419F.d.l6.1 64357 1 0 0 0 0 0 0 0

1316 RTA00000420F.e.l0.1 65899 1 0 0 0 0 0 0 0

1319 RTA00000418F.k.08.1 18259 1 0 0 0 0 0 0 0

1322 RTA00000410F.C.02.1 75055 1 0 0 0 0 0 0 0

1324 RTA00000403F.h.l8.1 39241 2 0 0 0 0 0 0 0

1325 RTA00000405F.n.l3.1 23810 2 1 0 0 0 0 0 0

1326 RTA00000355R.e.l4.1 16837 2 2 0 0 0 0 0 0

1327 RTA00000422F.1.03.1 39147 2 0 0 0 0 0 0 0

1329 RTA00000403F.O.14.1 38971 2 0 0 0 0 0 0 0

1333 RTAOOOOO 127A.f.1 1.1 81463 1 0 0 0 0 0 0 0

1335 RTA00000403F.O.07.1 39037 2 0 0 0 0 0 0 0

1336 RTA00000403F.d.l9.1 39243 2 0 0 0 0 0 0 0

1338 RTA00000406F.i.l7.1 37902 2 0 0 0 0 0 0 0

1339 RTA00000418F.d.22.1 75324 1 0 0 0 0 0 0 0

1340 RTA00000340R.O.12.1 53732 1 0 0 0 0 0 0 0

1341 RTAOOOOO 125A.g.24.1 80397 1 0 0 0 0 0 0 0

1342 RTAOOOOO 130A.O.21.1 80218 1 0 0 0 0 0 0 0

1343 RTA00000420F.3.23.1 42158 1 1 0 0 0 0 0 0

1344 RTA00000411F.m.l8.1 75629 1 0 0 0 0 0 0 0

1345 RTA00000407F.b.22.1 37487 2 0 0 0 0 0 0 0

1346 RTA00000409F.3.16.1 73990 1 0 0 0 0 0 0 0

1348 RTA00000341F.k.l2.1 62985 1 0 0 0 0 0 0 0

1349 RTAOOOOO 129A.C.18.2 37216 2 0 0 0 0 0 0 0

1350 RTA00000410F.d.l0.1 77561 1 0 0 0 0 0 0 0

1351 RTA00000351R.i.03.1 6874 6 3 0 0 1 0 0 0

1352 RTAOOOOOl 35 A.l.1.2 39426 2 0 0 0 0 0 0 0

1353 RTA00000420F.b. l 8.1 66136 1 0 0 0 0 0 0 0

1356 RTA00000403F.O.13.1 39049 2 0 0 0 0 0 0 0

1357 RTA00000411F.f.06.1 64186 1 0 0 0 0 0 0 0

1359 RTA00000351R.C.13.1 1 1476 6 0 0 0 0 0 0 0

1362 RTA00000420F.d.l6.1 64485 1 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib 1 lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 HI ID clones clones clones clones clones clones clones cl NO: 1363 RTA00000404F.U2.1 39001 2 0 0 0 0 0 0 0

1364 RTA00000404F.O.10.2 16785 2 2 0 0 0 0 0 0

1365 RTA00000419F.d.07.1 21421 1 2 0 0 0 0 0 0

1366 RTA00000404F.p.02.2 39097 2 0 1 0 0 0 0 0

1367 RTAOOOOO 125A.k.14.1 79457 1 0 0 0 0 0 0 0

1368 RTAOOOOO 122A.J.22.1 81151 1 0 0 0 0 0 0 0

1369 RTA00000406F.L 13.1 37904 2 0 0 0 0 0 0 0

1370 RTAOOOOOl 35 A.b.23.1 35241 2 0 0 0 0 0 0 0

1373 RTA00000423F.1.04.1 14320 2 0 0 0 0 0 0 0

1374 RTA00000420F.b.04.1 63820 1 0 0 0 0 0 0 0

1376 RTA00000408F. 8.2 74410 1 0 0 0 0 0 0 0

1378 RTA00000341F.J.05.1 36177 2 0 0 0 0 0 0 0

1379 RTA00000420F.a. l6.1 63345 1 0 0 0 0 0 0 0

1381 RTA00000410F .01.1 73399 1 0 0 0 0 0 0 0

1382 RTA00000408F.p.21.1 77930 1 0 0 0 0 0 0 0

1383 RTA00000412F.d.l9.1 75743 1 0 0 0 0 0 0 0

1384 RTA00000352R.C.04.1 71976 1 0 0 0 0 0 0 0

1385 RTA00000413FT.19.1 65189 1 0 0 0 0 0 0 0

1386 RTA00000411F.e.03.1 73648 1 0 0 0 0 0 0 0

1389 RTA00000418F.C.04.1 41587 1 1 0 0 0 0 0 0

1390 RTA00000418F.O.17.1 79069 1 0 0 0 0 0 0 0

1391 RTA00000418F.e.21.1 74773 1 0 0 0 0 0 0 0

1392 RTA00000419F.d.l4.1 64945 1 0 0 0 0 0 0 0

1396 RTA00000410F.J.20.1 73601 1 0 0 0 0 0 0 0

1399 RTAOOOOOl 19A.j.9.1 82060 1 0 0 0 0 0 0 0

1403 RTA00000340F.i. l3.1 79299 1 0 0 0 0 0 0 0

1404 RTA00000412F.g.03.1 64740 1 0 0 0 0 0 0 0

1405 RTAOOOOO 122A.g.17.1 32655 1 1 0 0 0 0 0 0

1407 RTA00000419F.n.l2.1 66086 1 0 0 0 0 0 0 0

1410 RTA00000351R.p. l4.1 13166 2 3 0 0 0 0 0 0

141 1 RTA00000403F.e.08.1 19126 3 0 0 0 0 0 0 0

1412 RTAOOOOO 124A.k.20.1 80913 1 0 0 0 0 0 0 0

1413 RTA00000121A.n.2.1 33585 1 1 0 0 0 0 0 0

1414 RTA00000422F.m.24.1 39159 2 0 1 0 1 1 2 2

1415 RTA00000408F.e.24.2 75002 1 0 0 0 0 0 0 0

1418 RTA00000403F.b. l2.1 78775 1 0 0 0 0 0 0 0

1419 RTA00000404F.a.09.1 38985 2 0 0 0 0 0 0 0

1421 RTA00000403F.O.19.1 78615 1 0 0 0 0 0 0 0

1424 RTA00000410F.b.l0.1 74504 1 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib 1 lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 HI ID clones clones clones clones clones clones clones cl

NO: 1426 RTA00000413F.h. l2.1 66929 1 0 0 0 0 0 0 0

1427 RTA00000406F. 14.1 38651 2 0 0 0 0 0 0 0

1429 RTA0000041 1F.f. l7.1 65661 1 0 0 0 0 0 0 0

1430 RTA0000041 1F.k. l0.1 64506 1 0 0 0 0 0 0 0

1431 RTA0000041 1F.g.21.1 64500 1 0 0 0 0 0 0 0

1432 RTAOOOOOl 19A.h.24.1 82266 1 0 0 0 0 0 0 0

1434 RTA00000408F.m.22.2 72949 1 0 0 0 0 0 0 0

1437 RTA00000410F.i. l7.1 78147 1 0 0 0 0 0 0 0

1440 RTA00000129A.3.13.2 79780 1 0 0 0 0 0 0 0

1441 RTAOOOOO 129A. 21.1 82067 1 0 0 0 0 0 0 0

1442 RTA00000350R.g. l0.1 9026 7 0 0 1 0 0 0 0

1443 RTA00000413F.d.23.1 66030 1 0 0 0 0 0 0 0

1447 RTA0000041 1F.d.l0.1 76445 1 0 0 0 0 0 0 0

1448 RTA00000404F.b.l9.1 39281 2 0 0 0 0 0 0 0

1449 RTA00000418F.C.07.1 73245 1 0 0 0 0 0 0 0

1450 RTA00000418FJ.15.1 74855 1 0 0 0 0 1 0 0

1453 RTA00000413F.b. l6.1 65126 1 0 0 0 0 0 0 0

1455 RTA00000350R.m.l4.1 39171 2 0 0 0 0 0 0 0

1456 RTA00000418F.1.11.1 77158 1 0 0 0 0 0 0 0

1457 RTAOOOOO 130A.d.5.1 82051 1 0 0 0 0 0 0 0

1458 RTA00000339F.n.05.1 39648 2 0 0 0 0 0 0 0

1460 RTA00000407F.a.23.1 23489 2 1 0 0 0 0 0 0

1462 RTA00000403F.h.l l .l 39219 2 0 0 0 0 0 0 0

1463 RTA00000406F.J.13.1 38688 2 0 0 0 0 0 0 0

1464 RTA00000352R.p.09.1 16915 4 0 0 0 0 0 0 0

1465 RTA00000413F.g.24.1 65481 1 0 0 0 0 0 0 0

1469 RTA00000420F.a.08.1 19473 1 2 0 0 0 0 0 0

1472 RTA00000404F.i.22.1 39082 2 0 0 0 0 0 0 0

1473 RTA00000124A.k.23.1 81350 1 0 0 0 0 0 0 0

1474 RTA00000404F.e.l l.l 38991 2 0 0 0 0 0 0 0

1475 RTAOOOOO 129A.d.2.4 801 19 1 0 0 0 0 0 0 0

1478 RTA00000419F.O.15.1 32487 1 1 0 0 0 0 0 0

1479 RTAOOOOOl 19A.m.17.1 79536 1 0 0 0 0 0 0 0

1480 RTA00000410F.b.07.1 78916 1 0 0 0 0 0 0 0

1481 RTA00000420F.b.l9.1 36873 2 0 0 0 0 0 0 0

1483 RTA0000041 1F.b.21.1 10051 1 0 0 0 0 0 0 0

1485 RTA00000356R.C.16.1 16915 4 0 0 0 0 0 0 0

1487 RTA00000412F.h.l l .l 63175 1 0 0 0 0 0 0 0

1490 RTA00000420F.a. l l .l 66460 1 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib l lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 HI ID clones clones clones clones clones clones clones cl

X NTfUV.

1491 RTAOOOOO 120A.C.7.1 80985 1 0 0 1 0 0 0 0

1492 RTA00000404F.e.l5.1 39101 2 0 0 0 0 0 0 0

1493 RTA00000422F.n.20.1 38676 2 0 0 0 0 0 1 0

1494 RTA00000423F.h.20.1 38639 2 0 0 0 0 0 0 0

1497 RTA00000410F.b.l 8.1 76701 1 0 0 0 0 0 0 0

1499 RTA00000423F.g.l5.1 35173 2 0 0 0 0 0 0 0

1500 RTA00000413F.b.04.1 66427 1 0 0 0 0 0 0 0

1503 RTA00000346F.f. l l .l 38528 2 0 0 0 0 0 0 0

1506 RTA00000422F.L02.1 76436 1 0 0 0 0 0 0 0

1507 RTA00000410F.a.08.1 73324 1 0 0 0 0 0 0 0

1509 RTA00000419F.e.02.1 65010 1 0 0 0 0 0 0 0

151 1 RTA00000403F.g.l3.1 38718 2 0 0 0 0 0 0 0

1513 RTA00000407F.a.01.1 12501 3 1 0 0 0 0 0 0

1516 RTA00000411F.f.l4.1 62984 1 0 0 0 0 0 0 0

1517 RTA0000041 1F.C.04.1 76858 1 0 0 0 0 0 0 0

1518 RTA00000135A.m.l8.1 19255 2 0 0 0 0 0 0 0

1519 RTA00000413F.C.17.1 36831 2 0 0 0 0 0 0 0

1521 RTA00000404F .01.1 26859 2 0 0 0 0 0 0 0

1522 RTA00000138A.p.l0.1 81625 1 0 0 0 0 0 0 0

1526 RTA00000423F.h.07.1 37933 2 0 0 0 0 0 0 0

1527 RTA00000413F.e.04.1 64176 1 0 0 0 0 0 0 0

1528 RTA00000406F.h.03.1 38585 2 0 0 0 0 0 0 0

1529 RTA00000403F.e.24.1 16432 2 2 0 0 0 0 0 0

1531 RTA00000403F.i.l l .l 23535 2 1 0 0 0 0 0 0

1532 RTA00000419F.g.02.1 62839 1 0 0 0 0 0 0 0

1533 RTA00000347F.e.05.1 39814 2 0 0 0 0 0 0 0

1534 RTA00000408F.1.16.1 73468 1 0 0 0 0 0 0 0

1536 RTA00000423F.f.09.1 64823 1 0 0 0 0 0 0 0

1537 RTA00000419F.k.03.1 40822 1 1 0 0 0 0 0 0

1538 RTA00000406F.b.02.1 38744 2 0 0 0 0 0 0 0

1539 RTA00000418F.O.14.1 33524 1 1 0 0 0 0 0 0

1541 RTA00000404F.b.09.1 39166 2 0 0 0 0 0 0 0

1547 RTA00000406F.k.l l .l 38715 2 0 0 0 0 0 0 0

1549 RTA00000406F.C.06.1 37924 2 0 0 0 0 0 0 0

1550 RTA00000418F.n.07.1 76316 1 0 0 0 0 0 0 0

1551 RTA00000419F.n. l5.1 63484 1 0 0 0 0 0 0 0

1552 RTA00000408F.n.06.2 76642 1 0 0 0 0 0 0 0

1553 RTA00000420F.C.04.1 65007 1 0 0 0 0 0 0 0

1554 RTA00000411F.J.15.1 66871 1 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib 1 lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 HI ID clones clones clones clones clones clones clones cl NO: 1556 RTAOOOOO 128A.m.23.1 81441 1 0 0 0 0 0 0 0

1557 RTA00000406F.g.03.1 38690 2 0 0 0 0 0 0 0

1558 RTA00000405F.h.05.2 75706 1 0 0 0 0 0 0 0

1559 RTAOOOOO 129A.n.24.1 81409 1 0 0 0 0 0 0 0

1562 RTA00000418F.n. l l .l 78977 1 0 0 0 0 0 0 0

1565 RTAOOOOO 120A.h.9.1 80736 1 0 0 0 0 0 0 0

1566 RTA00000413F.3.12.1 63403 1 0 0 0 0 0 0 0

1567 RTA00000412F.O.05.1 63575 1 0 0 0 0 0 0 0

1571 RTA00000354R.n.04.1 22049 3 0 0 0 0 0 0 0

1573 RTA00000406F.h.05.1 38542 2 0 0 0 0 0 0 0

1574 RTA00000410F.b.24.1 75104 1 0 0 0 0 0 0 0

1575 RTA00000423F.d. l l .l 38950 2 0 0 0 0 0 0 0

1578 RTAOOOOOl 19A. 1.1 81282 1 0 0 0 0 0 0 0

1579 RTA00000420F.f.07.1 66312 1 0 0 0 0 0 0 0

1580 RTA00000404F. 22.2 39084 2 0 0 0 0 0 0 0

1581 RTA00000422F.e.07.1 38964 2 0 0 0 0 0 0 0

1582 RTA00000410F.f.l2.1 73883 1 0 0 0 0 0 0 0

1584 RTA00000411F.m.l l .l 73196 1 0 0 0 0 0 0 0

1587 RTA00000403F.O.10.2 38964 2 0 0 0 0 0 0 0

1590 RTA00000413F.C.10.1 65600 1 0 0 0 0 0 0 0

1591 RTA00000411F.b.l7.1 72893 1 0 0 0 0 0 0 0

1593 RTA00000408F. 19.1 77593 1 0 0 0 0 0 0 0

1596 RTAOOOOOl 19A.L8.1 82593 1 0 0 0 0 0 0 0

1598 RTA00000418F.g.03.1 78737 1 0 0 0 0 0 0 0

1599 RTA0000041 1F.a.09.1 78629 1 0 0 0 0 0 0 0

1601 RTA00000419F.J.1 1.1 73183 1 0 0 0 0 0 0 0

1603 RTA00000404F.n.l 8.2 37169 2 0 0 0 0 0 0 0

1604 RTAOOOOO 122A.n.16.1 80553 1 0 0 0 0 0 0 0

1605 RTA00000420F.C.07.1 65555 1 0 0 0 0 0 0 0

1608 RTA00000408FJ.13.2 42275 1 1 0 0 0 0 0 0

1610 RTA00000423F.a.01.1 39103 2 0 0 0 0 0 0 0

1613 RTA00000341F.e.20.1 67422 1 0 0 0 0 0 0 0

1614 RTA00000419F.m.22.1 75600 1 0 0 0 0 0 0 0

1615 RTA00000419F.m.23.1 64263 1 0 0 0 0 0 0 0

1616 RTA00000419F.b.06.1 76728 1 0 0 0 0 0 0 0

1618 RTA00000406F.p.08.1 37573 2 0 0 0 0 0 0 2

1619 RTAOOOOO 129A.n.17.1 79811 1 0 0 0 0 0 0 0

1621 RTA00000407F.b.08.1 37513 2 0 0 0 0 0 0 0

1623 RTA00000406F.i.08.1 37946 2 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib l lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 HI ID clones clones clones clones clones clones clones cl

NO: 1624 RTA00000403F.h.07.1 26856 2 0 0 0 0 0 0 0

1625 RTA00000418F.n.24.1 73153 1 0 0 0 0 0 0 0

1627 RTA00000409F.1.20.1 74394 1 0 0 0 0 0 0 0

1628 RTA00000418F.1.06.1 73317 1 0 0 0 0 0 0 0

1629 RTA00000346F.O.22.1 7381 2 6 0 0 0 0 0 0

1630 RTAOOOOO 129A.k.22.1 79639 1 0 0 0 0 0 0 0

1632 RTA00000418F.m.22.1 74567 1 0 0 0 0 0 0 0

1633 RTA00000413F.C.12.1 65334 1 0 0 0 0 0 0 0

1635 RTA00000418F.g.20.1 74626 1 0 0 0 0 0 0 0

1636 RTA00000413F.d.l5.1 64943 1 0 0 0 0 0 0 0

1639 RTA00000412F.C.10.1 76372 1 0 0 0 0 0 0 0

1640 RTA00000122A.J.17.1 62736 1 0 0 0 0 0 0 0

1645 RTA00000418F.J.19.1 78399 1 0 0 0 0 0 0 0

1646 RTA00000137A.p. l2.1 80614 1 0 0 0 0 0 0 0

1648 RTA00000418F.p.l0.1 75323 1 0 0 0 0 0 0 0

1649 RTA00000408F.k.l2.1 77246 1 0 0 0 0 0 0 0

1650 RTA00000137A.J.1 1.4 79752 1 0 0 0 0 0 0 0

1652 RTA00000419F.n.24.1 65995 1 0 0 0 0 0 0 0

1653 RTA00000418F.1.03.1 79058 1 0 0 0 0 0 0 0

1655 RTA00000419F.m.l3.1 79052 1 0 0 0 0 0 0 0

1656 RTA00000418F.J.14.1 32623 1 1 0 0 0 0 0 0

1657 RTA00000403F.a.l0.1 73952 1 0 0 0 0 0 0 0

1658 RTA00000420F.a.21.1 66241 1 0 0 0 0 0 0 0

1659 RTAOOOOO 127A.e.6.1 5885 4 2 0 0 0 0 0 0

1660 RTA00000405F.g.21.2 38966 2 0 0 0 0 0 0 0

1661 RTA00000405F.g.21.1 38966 2 0 0 0 0 0 0 0

1662 RTA00000419F.m.06.1 75749 1 0 0 0 0 0 0 0

1663 RTA00000423F.g.03.1 38007 2 0 0 0 0 0 0 0

1665 RTA00000418F.f.03.1 7891 1 1 0 0 0 0 0 0 0

1668 RTAOOOOO 120A.C.20.1 43235 1 1 0 0 0 1 0 0

1669 RTA00000138A.m.l5.1 41603 1 1 0 0 0 0 0 0

1670 RTA00000408F.f.l4.2 73024 1 0 0 0 0 0 0 0

1671 RTA00000418F.p.20.1 78023 1 0 0 0 0 0 0 0

1672 RTA00000423F.e.21.1 66961 1 0 0 0 0 0 0 0

1673 RTA00000419F.J.22.1 73525 1 0 0 0 0 0 0 0

1674 RTA00000410F.d.l8.1 75458 1 0 0 0 0 0 0 0

1675 RTA00000403F.b.24.1 78838 1 0 0 0 0 0 0 0

1677 RTA00000410F.e.09.1 76093 1 0 0 0 0 0 0 0

1680 RTA00000353R.h. l0.1 39498 2 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib l lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 HI

ID clones clones clones clones clones clones clones cl 1682 RTA0000041 1F.d.21.1 74794 1 0 0 0 0 0 0 0

1683 RTA00000340F.m.04.1 19406 2 1 0 0 0 0 0 0

1684 RTA0000041 1F.n.09.1 78962 1 0 0 0 0 0 0 0

1685 RTAOOOOO 127A.h.22.2 13155 2 3 0 0 0 0 0 0

1686 RTA00000420F.e.09.1 66325 1 0 0 0 0 0 0 0

1687 RTA00000405F.p.03.1 1 1346 3 3 0 0 0 0 0 0

1688 RTA00000419F.a.l 8.1 78484 1 0 0 0 0 0 0 0

1691 RTAOOOOOl 21 A.n.23.1 26981 2 0 0 0 0 0 0 0

1692 RTA00000121A.n.l5.1 40849 1 1 0 0 0 0 0 0

1693 RTA00000403F.L23.1 1 1364 4 2 0 0 0 0 0 0

1694 RTA00000405F.3.03.1 39065 2 0 0 0 0 0 0 0

1696 RTA00000419F.p.08.1 65560 1 0 0 0 0 0 0 0

1697 RTAOOOOO 126A.n.6.2 79917 1 0 0 0 0 0 0 0

1698 RTA00000413F.C.03.1 64527 1 0 0 1 0 0 0 0

1699 RTA00000422F.k.24.1 39118 2 0 0 0 0 0 0 0

1700 RTA00000412F.C.17.1 75620 1 0 0 0 0 0 0 0

1702 RTA00000347F.g.08.1 23121 3 0 0 0 0 0 0 0

1703 RTA00000419F.O.06.1 64643 1 0 0 0 0 0 0 0

1704 RTA00000340R.J.07.1 38954 2 0 0 0 0 0 0 0

1705 RTA00000423F.J.02.1 38617 2 0 0 0 0 0 0 0

1706 RTA00000419F.C.04.1 63749 1 0 0 0 0 0 0 0

1707 RTA00000411F.a.01.1 74524 1 0 0 0 0 0 0 0

1708 RTA00000406F.f.05.1 22961 2 1 0 0 0 0 1 0

1709 RTA00000410F.n.05.1 77830 1 0 0 0 0 0 0 0

1710 RTA00000404F.e.06.1 39315 2 0 0 0 0 0 0 0

1712 RTA00000411F.C.03.1 79280 1 0 0 0 0 0 0 0

1718 RTA00000405F.1.07.1 38636 2 0 0 0 0 0 0 0

1720 RTA00000411F.n.06.1 73886 1 0 0 0 0 0 0 0

1721 RTA00000422F.k.l5.1 19253 2 0 0 0 0 0 0 0

1722 RTA00000406F.h. l6.1 38618 2 0 0 0 0 0 0 0

1723 RTA00000419FT.24.1 18717 1 1 0 0 0 0 0 0

1724 RTA00000411F.d.l8.1 76063 1 0 0 0 0 0 0 0

1727 RTA00000408F.d. l5.1 78467 1 0 0 0 0 0 0 0

1728 RTA00000339F.b.22.1 6867 7 3 0 0 0 0 0 0

1730 RTA00000411F.n.02.1 78049 1 0 0 0 0 0 0 0

1731 RTA00000419F.b. l7.1 63261 1 0 0 0 0 0 0 0

1733 RTAOOOOO 130A.e.20.1 79502 1 0 0 0 0 0 0 0

1735 RTA00000411F 13.1 66138 1 0 0 0 0 0 0 0

1736 RTA00000420F.e.20.1 64762 1 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib l lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 HI

ID clones clones clones clones clones clones clones cl

NO:

1737 RTAOOOOO 126A.p.23.2 80915 1 0 0 0 0 0 0 0

1739 RTA00000406F.g.08.1 37963 2 0 0 0 0 0 0 0

1740 RTA00000409F.a.08.1 74978 1 0 0 0 0 0 0 0

1741 RTA00000406F.d.24.1 37997 2 0 0 0 0 0 0 0

1744 RTA00000418F. 2.1 78971 1 0 0 0 0 0 0 0

1745 RTA00000121A.h.l9.1 80334 1 0 0 0 0 0 0 0

1746 RTA00000419F.b.l0.1 78566 1 0 0 0 0 0 0 0

1747 RTA00000406F.m.l0.1 38004 2 0 0 0 0 0 0 0

1748 RTA00000406F.O.05.1 37894 2 0 0 0 0 0 0 0

1749 RTA00000408F.b.04.2 39933 2 0 0 0 0 0 0 0

1750 RTA0000041 1F.k.04.1 65407 1 0 0 0 0 0 0 0

1752 RTA00000134A.1.9.1 81814 1 0 0 0 0 0 0 0

1754 RTA00000418F. 04.1 75864 1 0 0 0 0 0 0 0

1757 RTA00000419F.p.l8.1 63002 1 0 0 0 0 0 0 0

1759 RTA00000419F.a.24.1 79290 1 0 0 0 0 0 0 0

1761 RTAOOOOO 129A.e.14.1 80053 1 0 0 0 0 0 0 0

1762 RTA00000404F.a.01.1 19251 2 0 0 0 0 0 0 0

1765 RTA00000408F.n.l6.2 73720 1 0 0 0 0 0 0 0

1769 RTA00000412F.1.14.1 62792 1 0 0 0 0 0 0 0

1770 RTAOOOOO 129A.b.6.2 39111 2 0 0 0 0 0 0 0

1771 RTA00000406F.n.l2.1 37517 2 0 0 0 0 0 0 0

1772 RTA00000418F.e.03.1 73442 1 0 0 0 0 0 0 0

1774 RTA00000403F.g.03.1 23537 2 1 0 0 0 0 0 0

1775 RTA00000412F.p.06.1 65485 1 0 0 0 0 0 0 0

1776 RTA00000419F.b.21.1 65366 1 0 0 0 0 0 0 0

1779 RTA00000351R.J.16.1 64773 1 0 0 0 0 0 0 0

1781 RTA00000419F.f.l8.1 64047 1 0 0 0 0 0 0 0

1782 RTA00000423F.i.l6.1 38604 2 0 0 0 0 0 0 0

1784 RTA0000041 1F.f.04.1 64526 1 0 0 0 0 0 0 0

1785 RTAOOOOO 125A.C.17.1 80619 1 0 0 0 0 0 0 0

1786 RTA00000404F.g.08.1 38980 2 0 0 0 0 0 0 0

1787 RTA00000423F.C.13.1 39059 2 0 0 0 0 0 0 0

1790 RTA00000404F. 15.1 18225 2 0 0 0 0 0 0 0

1792 RTA00000339F.1.12.1 771 1 4 1 0 0 0 0 0 0

1793 RTA00000406F.b.01.1 39006 2 0 0 0 0 0 0 0

1794 RTA00000407F.C.08.1 37549 2 0 0 0 0 0 0 0

1796 RTA00000403F.b.05.1 74300 1 0 0 0 0 0 0 0

1800 RTA00000408F.J.05.2 73878 1 0 0 0 0 0 0 0

1802 RTA00000419F.C.14.1 65727 1 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib l lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 HI

ID clones clones clones clones clones clones clones cl

NO:

1806 RTA00000346F.h.24.1 4379 9 2 0 0 0 0 0 0

1807 RTA00000420F.b.02.1 64013 1 0 0 0 0 0 0 0

1808 RTA00000413F.b.24.1 651 17 1 0 0 0 0 0 0 0

1809 RTA00000412F.d.08.1 75328 1 0 0 0 0 0 0 0

181 1 RTA00000419F.m.l8.1 76014 1 0 0 0 0 0 0 0

1812 RTA00000419F.1.24.1 74628 1 0 0 0 0 0 0 0

1813 RTA00000408F.C.06.1 78619 1 0 0 0 0 0 0 0

1814 RTA00000405F.h.21.2 39072 2 0 0 0 0 0 0 0

1816 RTA00000405F.g.05.2 38987 2 0 0 0 0 0 0 0

1817 RTA00000411F.f.20.1 63501 1 0 0 0 0 0 0 0

1819 RTA00000420F.d. l9.1 43146 1 1 0 0 0 0 0 0

1820 RTAOOOOO 195R.a.06.1 35265 2 0 1 0 0 0 0 0

1821 RTAOOOOOl 23 A.f.2.1 80379 1 0 0 0 0 0 0 0

1822 RTA0000041 1FJ.11.1 66154 1 0 0 0 0 0 0 0

1827 RTA00000419F.J.03.1 77578 1 0 0 0 0 0 0 0

1829 RTA00000423F.h.l l .l 38977 2 0 0 0 0 0 0 0

1830 RTA00000413F.b.l7.1 21704 1 2 0 0 0 0 0 0

1833 RTA00000423FT.03.1 63852 1 0 0 0 0 0 0 0

1834 RTA00000419F.e.l0.1 63225 1 0 0 0 0 0 0 0

1836 RTA00000403F.d.02.1 39224 2 0 0 0 0 0 0 0

1838 RTA00000418FJ.20.1 77101 1 0 0 0 0 0 0 0

1846 RTA00000356R.h.05.1 35052 2 0 1 0 0 0 0 0

1848 RTA00000340F.Ϊ.15.1 26815 1 0 0 0 0 0 0 0

1850 RTA00000345F.C.12.1 23824 2 1 0 0 0 0 0 0

1852 RTA00000412F.O.03.1 65039 1 0 0 0 0 0 0 0

1853 RTA00000409F.d.l6.1 76090 1 0 0 0 0 0 0 0

1856 RTA00000408F.J.17.2 78935 1 0 0 0 0 0 0 0

1857 RTA00000126AJ.15.2 40425 2 0 0 0 0 0 0 0

1861 RTA00000410F.b.l7.1 77458 1 0 0 0 0 0 0 0

1862 RTA00000419F.1.22.1 78444 1 0 0 0 0 0 0 0

1864 RTA00000422F.f.22.1 38703 2 0 0 0 0 0 0 0

1867 RTA00000418F.C.05.1 76475 1 0 0 0 0 0 0 0

1868 RTA00000418F.p.21.1 78068 1 0 0 0 0 0 0 0

1870 RTA00000340F.i.08.1 12005 2 1 0 0 0 0 0 0

1871 RTA00000410F.O.04.1 79018 1 0 0 0 0 0 0 0

1872 RTA00000411F.1.16.1 16122 1 3 0 0 0 0 0 0

1873 RTA0000041 1FJ.03.1 66263 1 0 0 0 0 0 0 0

1874 RTAOOOOO 126A. 24.1 39428 2 0 0 0 0 0 0 0

1876 RTAOOOOO 120A.m.10.3 81376 1 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib l lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 HI ID clones clones clones clones clones clones clones cl

NO: 1877 RTA00000419F.f. l 6.1 64679 1 0 0 0 0 0 0 0

1878 RTA00000408F.C.23.1 42261 1 1 0 0 0 0 0 0

1881 RTAOOOOO 136A.h.6.1 81620 1 0 0 0 0 0 0 0

1886 RTA00000418F.e.20.1 73741 1 0 0 0 0 0 0 0

1888 RTA00000405F.1.03.1 38580 2 0 0 0 0 0 0 0

1889 RTA00000418F.m.02.1 74550 1 0 0 0 0 0 0 0

1891 RTA00000406F.C.05.1 22077 3 0 1 0 0 0 0 0

1893 RTA0000041 1F. 21.1 65349 1 0 0 0 0 0 0 0

1897 RTA00000418F.L06.1 75151 1 0 0 0 0 0 0 0

1898 RTA00000423F.a.03.1 26796 2 0 0 0 0 0 0 0

1900 RTA00O00423F.k.21.2 37499 2 0 0 0 0 0 0 0

1902 RTA00000404F.C.18.1 38982 2 0 0 0 0 0 0 0

1905 RTA00000411F.g.24.1 65233 1 0 0 0 0 0 0 0

1907 RTA00000405F.m.07.1 37733 2 0 0 0 0 0 0 0

1908 RTA0000041 1F.J.07.1 66963 1 0 0 0 0 0 0 0

1910 RTA00000353R.h.04.1 17123 4 0 0 0 0 0 0 0

191 1 RTA00000408F.f. l0.2 75309 1 0 0 0 0 0 0 0

1913 RTA00000405F.O.03.1 37575 2 0 0 0 0 0 0 0

1914 RTA00000413F.b. l 8.1 39873 2 0 0 0 0 0 0 0

1920 RTA00000408F.C.08.1 73473 1 0 0 0 0 0 0 0

1922 RTA00000410F.C.06.1 77784 1 0 0 0 1 0 0 0

1924 RTA00000405F.b.08.1 39182 2 0 0 0 0 0 0 0

1925 RTA00000409F.1.24.1 73174 1 0 0 0 0 0 0 0

1926 RTA00000406F.J.06.1 38952 2 0 0 0 0 0 0 0

1927 RTA00000423F.h.03.1 37903 2 0 0 0 0 0 0 0

1929 RTAOOOOOl 21 A.k.22.1 79523 1 0 0 0 0 0 0 0

1931 RTA0000041 1 F.m.06.1 24195 2 1 0 0 0 0 0 0

1932 RTAOOOOO 126A.b.9.1 81279 1 0 0 0 0 0 0 0

1935 RTA00000404F.1.05.1 38671 2 0 0 0 0 0 0 0

1941 RTA00000419F.p. l0.1 41448 1 1 0 0 0 0 0 0

1942 RTAOOOOO 120A.C.19.1 81016 1 0 0 0 0 0 0 0

1948 RTA0000041 1 F. 14.1 63987 1 0 0 0 0 0 0 0

1949 RTA00000420F.e.05.1 63908 1 0 0 0 0 0 0 0

1952 RTA00000128A.J.10.1 80085 1 0 0 0 0 0 0 0

1953 RTA00000412F.f. l 0.2 65405 1 0 0 0 0 0 0 0

1955 RTA00000422F. 17.1 38955 2 0 0 0 0 0 0 0

1957 RTA00000347F.h. l 0.1 22779 3 0 0 0 0 0 0 0

1959 RTA00000419F.1.02.1 75736 1 0 0 0 0 0 0 0

1961 RTA00000418F.b.20.1 73560 1 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib l lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 HI ID clones clones clones clones clones clones clones cl NO: 1964 RTA00000408F.n.05.2 77883 1 0 0 0 0 0 0 0

1965 RTA00000419F.O.09.1 66396 1 0 0 0 0 0 0 0

1970 RTA00000422F.O.08.2 26832 2 0 0 0 0 0 0 0

1973 RTA00000418F.m. l8.1 76479 1 0 0 0 0 0 0 0

1974 RTA00000347F.e.20.1 3991 1 2 0 0 0 0 0 0 0

1975 RTA00000419F.e.23.1 65772 1 0 0 0 0 0 0 0

1982 RTA00000411F.g.05.1 64664 1 0 0 0 0 0 0 0

1983 RTA00000404F.h.l0.1 37148 2 0 0 0 0 0 0 0

1984 RTA00000422F.n.l4.1 26787 2 0 0 0 0 0 0 0

1986 RTAOOOOO 120A.m.13.3 80608 1 0 0 0 0 0 0 0

1987 RTA00000412F.i.03.1 65617 1 0 0 0 0 0 0 0

1988 RTA00000418F.1.02.1 39316 2 0 0 0 0 0 0 0

1990 RTA0000041 1F.J.04.1 66219 1 0 0 0 0 0 0 0

1995 RTA00000404F.3.18.1 36267 2 0 0 0 0 0 0 0

1996 RTA00000408F.1.14.1 12001 2 3 0 0 0 0 0 0

1997 RTA00000405F.d.l0.1 39000 2 0 0 0 0 0 0 0

1999 RTA00000418F.h.23.1 75153 1 0 0 0 0 0 0 0

2001 RTA00000418F.J.1 1.1 73853 1 0 0 0 0 0 0 0

2002 RTA00000408F.O.13.1 74895 1 0 0 0 0 0 0 0

2003 RTA00000419F.O.07.1 14059 1 0 0 0 0 0 0 0

2004 RTA00000419F.n.l7.1 63186 1 0 0 0 0 0 0 0

2005 RTA00000403F.f.l5.1 22768 3 0 0 0 0 0 0 0

2006 RTA00000408F.d.03.1 22768 3 0 0 0 0 0 0 0

2008 RTA00000346F.f.02.1 62757 1 0 0 0 0 0 0 0

2010 RTA00000413F.i.21.1 64066 1 0 0 0 0 0 0 0

2012 RTA00000419F.h.21.1 64828 1 0 0 0 0 0 0 0

2021 RTA00000121A.3.2.1 81843 1 0 0 0 0 0 0 0

2022 RTA00000527F.g.l3.1 36035 2 0 0 0 0 0 0 0

2025 RTA00000426F.h.l l .l 75479 1 0 0 0 0 0 0 0

2030 RTA00000522F.b.22.1 75181 1 0 0 0 0 0 0 0

2033 RTA00000522F.3.23.1 38613 2 0 0 0 0 0 0 0

2035 RTA00000523F.b.02.1 65163 1 0 0 0 0 0 0 0

2036 RTA00000425F.J.14.1 73397 1 0 0 0 0 0 0 0

2039 RTA00000522F.e.l6.1 75283 1 0 0 0 0 0 0 0

2042 RTA00000523F.h.l7.1 65586 1 0 0 0 0 0 0 0

2044 RTA00000522F.p.07.1 76888 1 0 0 0 0 0 0 0

2045 RTA00000522F.n.08.1 76343 1 0 0 0 0 0 0 0

2046 RTA00000425F.C.06.1 78041 1 0 0 0 0 0 0 0

2047 RTA00000427F.b.23.1 64297 1 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib 1 lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 HI ID clones clones clones clones clones clones clones cl

2048 RTA00000527F.p.02.1 36844 2 0 0 0 0 0 0 0

2049 RTA00000427F.d.08.1 63967 1 0 0 0 0 0 0 0

2051 RTA00000426F.m.07.1 63504 1 0 0 0 0 0 0 0

2052 RTA00000427F.C.10.1 65478 1 0 0 0 0 0 0 0

2055 RTA00000424F.m.l5.1 73759 1 0 0 0 0 0 0 0

2056 RTA00000426F.f.l l .l 63102 1 0 0 0 0 0 0 0

2058 RTA00000426F.f.20.1 65134 1 0 0 0 0 0 0 0

2063 RTA00000527F.i.l9.2 38089 2 0 0 0 0 0 0 0

2068 RTA00000523F.e.l8.1 62898 1 0 0 0 0 0 0 0

2069 RTA00000527F.k.21.1 36051 2 0 0 0 0 0 0 0

2072 RTA00000522F.n.02.1 74959 1 0 0 0 0 0 0 0

2075 RTA00000425F.f.l9.1 32635 1 1 0 0 0 0 0 0

2076 RTA00000528F.e.23.1 19242 3 0 0 0 0 0 0 0

2077 RTA00000522F.n.l6.1 26769 1 0 0 0 0 0 0 0

2078 RTA00000427F.C.20.1 26527 1 0 0 0 0 0 0 0

2079 RTA00000527F.k.06.1 12469 3 1 0 0 0 0 0 0

2081 RTA00000523F.i.06.1 66341 1 0 0 0 0 0 0 0

2082 RTA00000427F.f.21.1 36853 2 0 0 0 0 0 0 0

2083 RTA00000427F.J.19.1 41395 1 1 0 0 0 0 0 0

2084 RTA00000522F.b.01.1 75691 1 0 0 0 0 0 0 0

2085 RTA00000424F.i.24.1 79101 1 0 0 0 0 0 0 0

2086 RTA00000523F.C.01.1 65710 1 0 0 0 0 0 0 0

2087 RTA00000427F.b.l5.1 66891 1 0 0 0 0 0 0 0

2090 RTA00000522F.J.15.2 76535 1 0 0 0 0 0 0 0

2093 RTA00000426F.f.l9.1 66701 1 0 1 0 0 0 0 0

2096 RTA00000523F.i.22.1 64688 1 0 0 0 0 0 0 0

2098 RTA00000425F.i.l7.1 43213 1 1 0 0 0 0 0 0

2101 RTA00000425F.p. l2.1 73219 1 0 0 0 0 0 0 0

2102 RTA00000427F.J.07.1 64819 1 0 0 0 0 0 0 0

2104 RTA00000527F.i.05.2 37481 2 0 0 0 0 0 0 0

2107 RTA00000523F.k.01.1 41437 1 1 0 0 0 0 0 0

2108 RTA00000425F.J.1 1.1 76667 1 0 0 0 0 0 0 0

2109 RTA00000424F.b.22.4 72971 1 0 0 0 0 0 0 0

211 1 RTA00000525F.3.03.1 36786 2 0 0 0 0 0 0 0

2112 RTA00000527F.i.21.2 37490 2 0 0 0 0 0 0 0

2113 RTA00000424F.3.24.4 73951 1 0 0 0 0 0 0 0

2114 RTA00000522F.k.l4.1 74280 1 0 0 0 0 0 0 0

2115 RTA00000522F.n.05.1 73260 1 0 0 0 0 0 0 0

2116 RTA00000523F.C.18.1 66179 1 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib l lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 lit

ID clones clones clones clones clones clones clones cl

NO:

21 17 RTA00000523F.b. l3.1 66330 1 0 0 0 0 0 0 0

21 19 RTA00000527F.p. l6.1 23798 2 1 0 0 0 0 0 0

2120 RTA00000425F.C.20.1 73581 1 0 0 0 0 0 0 0

2121 RTA00000424F.L21.1 73482 1 0 0 0 0 0 0 0

2122 RTA00000523F.J.19.1 65910 1 0 0 0 0 0 0 0

2124 RTA00000424F.b.22.1 72971 1 0 0 0 0 0 0 0

2125 RTA00000527F.b.l 8.1 37469 2 0 0 0 0 0 0 0

2129 RTA00000525F.e.l6.1 36837 2 0 0 0 0 0 0 0

2131 RTA00000522F.d.08.1 74284 1 0 0 0 0 0 0 0

2134 RTA00000527F.g.07.1 37488 2 0 0 0 0 0 0 0

2136 RTA00000525F.b.05.1 21 116 2 1 0 0 0 0 0 0

2137 RTA00000425F.n.05.1 73965 1 0 0 0 0 0 0 0

2138 RTA00000523F.d. l8.1 64072 1 0 0 0 0 0 0 0

2139 RTA00000525F.a.02.1 37454 2 0 0 0 0 0 0 0

2141 RTA00000426F.h.09.1 78797 1 0 0 0 0 0 0 0

2144 RTA00000427F.g.05.1 63138 1 0 0 0 0 0 0 0

2145 RTA00000424F.m.l2.1 77675 1 0 0 0 0 0 0 0

2151 RTA00000427F.h.l2.1 36894 2 0 0 0 0 0 0 0

2152 RTA00000523F.C.15.1 36935 2 0 0 0 0 0 0 0

2153 RTA00000427F. 17.1 64965 1 0 0 0 0 0 0 0

2155 RTA00000424F.C.14.3 76614 1 0 0 0 0 0 0 0

2156 RTA00000522F.k.l0.2 77619 1 0 0 0 0 0 0 0

2157 RTA00000424F.m.22.1 72943 1 0 0 0 0 0 0 0

2158 RTA00000527F.h. l7.1 37799 2 0 0 0 0 0 0 0

2159 RTA00000527F.C.22.1 37496 2 0 0 0 0 0 0 0

2160 RTA00000425F. 22.1 78123 1 0 0 0 0 0 0 0

2161 RTA00000424F.m. l4.1 77491 1 0 0 0 0 0 0 0

2162 RTA00000522F.k.l9.1 32625 1 1 0 0 0 0 0 0

2163 RTA00000523F.L18.1 64463 1 0 0 0 0 0 0 0

2164 RTA00000425F .22.1 73882 1 0 0 0 0 0 0 0

2165 RTA00000527F.g.23.1 37538 2 0 0 0 0 0 0 0

2166 RTA00000426F.m.24.1 63943 1 0 0 0 0 0 0 0

2168 RTA00000425F.d.21.1 78920 1 0 0 0 0 0 0 0

2170 RTA00000424F.d.04.3 76505 1 0 0 0 0 0 0 0

2171 RTA00000424F.d.04.1 76505 1 0 0 0 0 0 0 0

2172 RTA00000427F.C.12.1 66995 1 0 0 0 0 0 0 0

2174 RTA00000527F.il 3.1 36904 2 0 0 0 0 0 0 0

2175 RTA00000522F.h.l3.1 40823 1 1 0 0 0 0 0 0

2176 RTA00000424F.1.19.1 75454 1 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib l lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 HI ID clones clones clones clones clones clones clones cl

X JNTfUV.

2179 RTA00000427F.a.06.1 66550 1 0 0 0 0 0 0 0

2180 RTA00000525F.C.19.1 38159 2 0 0 0 0 0 0 0

2181 RTA00000523F.f.06.1 62871 1 0 0 0 0 0 0 0

2182 RTA00000424F.h. l0.1 72925 1 0 0 0 0 0 0 0

2183 RTA00000522F.a.l2.1 33515 1 1 0 0 0 0 0 0

2184 RTA00000522F.h.01.1 75010 1 0 0 0 0 0 0 0

2186 RTA00000425F.e.21.1 77203 1 0 0 0 0 0 0 0

2187 RTA00000523FT.07.1 62799 1 0 0 0 0 0 0 0

2189 RTA00000424F.J.12.1 73827 1 0 0 0 0 0 0 0

2191 RTA00000523F.d.l2.1 64888 1 0 0 0 0 0 0 0

2192 RTA00000523F.e. l0.1 62878 1 0 0 0 0 0 0 0

2193 RTA00000425F.f.l l .l 79275 1 0 0 0 0 0 0 0

2194 RTA00000426F.m. l 8.1 62974 1 0 0 0 0 0 0 0

2197 RTA00000522F.g.l5.1 76536 1 0 0 0 0 0 0 0

2198 RTA00000522F.n.l2.1 74117 1 0 0 0 0 0 0 0

2200 RTA00000424F.d.l0.3 731 10 1 0 0 0 0 0 0 0

2204 RTA00000527F.C.04.1 23090 3 0 0 0 0 0 0 0

2206 RTA00000527F.h.21.1 37630 2 0 0 0 0 0 0 0

2207 RTA00000425F.C.07.1 76042 1 0 0 0 0 0 0 0

2209 RTA00000525F.C.15.1 7692 2 0 0 0 0 0 0 0

2210 RTA00000424F.d.22.3 76189 1 0 0 0 0 0 0 0

221 1 RTA00000523F.h.l2.1 65745 1 0 0 0 0 0 0 0

2212 RTA00000522F.g.22.1 77504 1 0 0 0 0 0 0 0

2215 RTA00000522F.J.12.2 74341 1 0 0 0 0 0 0 0

2216 RTA00000523F.i.08.1 65099 1 0 0 0 0 0 0 0

2218 RTA00000425F .20.1 26760 1 0 0 0 0 0 0 0

2220 RTA00000427F.f.24.1 64572 1 0 0 0 0 0 0 0

2221 RTA00000527F.3.13.1 37740 2 0 0 0 0 0 0 0

2225 RTA00000424F.3.09.4 77833 1 0 0 0 0 0 0 0

2227 RTA00000525F.f.07.1 37500 2 0 0 0 0 0 0 0

2228 RTA00000424F.J.07.1 7921 1 1 0 0 0 0 0 0 0

2229 RTA00000424F.m.l0.1 34251 1 1 0 0 0 0 0 0

2231 RTA00000522F.g.06.1 78221 1 0 0 0 0 0 0 0

2232 RTA00000424F.h.03.1 74447 1 0 0 0 0 0 0 0

2233 RTA00000424F.n.06.1 74737 1 0 0 0 0 0 0 0

2234 RTA00000427F.C.22.1 63990 1 0 0 0 0 0 0 0

2235 RTA00000424F. 12.1 77666 1 0 0 0 0 0 0 0

2236 RTA00000425FT.02.1 76982 1 0 0 0 0 0 0 0

2237 RTA00000427F.h. l l .l 26494 1 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib l lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 lit

ID clones clones clones clones clones clones clones cl(

NO:

2238 RTA00000425FJ.16.1 75631 1 0 0 0 0 0 0 0

2240 RTA00000427F.f.l7.1 63803 1 0 0 0 0 0 0 0

2241 RTA00000522F.O.18.1 76366 1 0 0 0 0 0 0 0

2242 RTA00000427F .22.1 66367 1 0 0 0 0 0 0 0

2243 RTA00000426F.p.l0.1 65845 1 0 0 0 0 0 0 0

2244 RTA00000522F.m.02.1 76834 1 0 0 0 0 0 0 0

2247 RTA00000425F.e. l5.1 75921 1 0 0 0 0 0 0 0

2250 RTA00000424F.n.l3.1 74942 1 0 0 0 0 0 0 0

2251 RTA00000424F.g.l4.1 74879 1 0 0 0 0 0 0 0

2252 RTA00000426F.e.l7.1 64089 1 0 0 0 0 0 0 0

2256 RTA00000427F.g. l9.1 6461 1 1 0 0 0 0 0 0 0

2258 RTA00000522F.C.01.1 74938 1 0 0 0 0 0 0 0

2259 RTA00000522F.g.l7.1 76486 1 0 0 0 0 0 0 0

2260 RTA00000523F.J.17.1 63610 1 0 0 0 0 0 0 0

2261 RTA00000522F.n.l4.1 73410 1 0 0 0 0 0 1 0

2263 RTA00000523F.e.20.1 65164 1 0 0 0 0 0 0 0

2264 RTA00000424F.C.15.3 73533 1 0 0 0 0 0 0 0

2265 RTA00000426F.p.09.1 66665 1 0 0 0 0 0 0 0

2266 RTA00000522F.p.09.1 75204 1 0 0 0 0 0 0 0

2267 RTA00000426F.m.21.1 64915 1 0 0 0 0 0 0 0

2268 RTA00000425F.J.21.1 77373 1 0 0 0 0 0 0 0

2270 RTA00000523F.h.21.1 41440 1 1 0 0 0 0 0 0

2271 RTA00000427F.h.24.1 65193 1 0 0 0 0 0 0 0

2272 RTA00000425F.f.24.1 40841 1 1 0 0 0 0 0 0

2273 RTA00000425F.m.03.1 76045 1 0 0 0 0 0 0 0

2274 RTA00000426F.m.08.1 63781 1 0 0 0 0 0 0 0

2275 RTA00000523F.d.24.1 64799 1 0 0 0 0 0 0 0

2276 RTA00000523F.C.14.1 66015 1 0 0 0 0 0 0 0

2277 RTA00000523F.b.20.1 66492 1 0 0 0 0 0 0 0

2278 RTA00000522F.h.07.1 75149 1 0 0 0 0 0 0 0

2279 RTA00000527F.g.l0.1 37820 2 0 0 0 0 0 0 0

2282 RTA00000427F.i.22.1 63199 1 0 0 0 0 0 0 0

2284 RTA00000527F.n.07.1 15939 2 2 0 0 0 0 0 0

2285 RTA00000425F.e.09.1 75550 1 0 0 0 0 0 0 0

2286 RTA00000427F.h.02.1 63652 1 0 0 0 0 0 0 0

2287 RTA00000426F.f.16.1 65613 1 0 0 0 0 0 0 0

2288 RTA00000425F.i.21.1 75305 1 0 0 0 0 0 0 0

2289 RTA00000427F.k. l9.1 62851 1 0 0 0 0 0 0 0

2291 RTA00000426F.g. l6.1 41446 1 1 0 0 0 0 0 0 SEQ Sequence Name cluster lib l lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 li'

ID clones clones clones clones clones clones clones cl

NO:

2292 RTA00000527F.1.05.1 13016 4 0 0 1 1 0 0 0

2293 RTA00000426F.m.02.1 66237 1 0 0 0 0 0 0 0

2296 RTA00000522F.1.22.1 75801 1 0 0 0 0 0 0 0

2297 RTA00000427F.h. l9.1 63047 1 0 0 0 0 0 0 0

2299 RTA00000522F.g.21.1 77310 1 0 0 0 0 0 0 0

2301 RTA00000522F.g.20.1 77688 1 0 0 0 0 0 0 0

2304 RTA00000425F. 20.1 74048 1 0 0 0 0 0 0 0

2306 RTA00000522F.b.07.1 78634 1 0 0 0 0 0 0 0

2307 RTA00000426F.g.l9.1 63672 1 0 0 0 0 0 0 0

2308 RTA00000525F.d. l9.1 36860 2 0 0 0 0 0 0 0

2310 RTA00000427F.d.l0.1 40685 1 1 0 0 0 0 0 0

2313 RTA00000424F.3.05.4 77976 1 0 0 0 0 0 0 0

2315 RTA00000424F.3.05.1 77976 1 0 0 0 0 0 0 0

2316 RTA00000522F.1.15.1 74691 1 0 0 0 0 0 0 0

2317 RTA00000425F.e.02.1 76143 1 0 0 0 0 0 0 0

2318 RTA00000525F.C.1 1.1 37895 2 0 0 0 0 0 0 0

2320 RTA00000522F.C.14.1 75449 1 0 0 0 0 0 0 0

2321 RTA00000424F.m.08.1 19402 1 2 0 0 0 0 0 0

2322 RTA00000527F.f.l8.1 37577 2 0 0 0 0 0 0 0

2324 RTA00000522F.a.06.1 73662 1 0 0 0 0 0 0 0

2327 RTA00000522F.d.23.1 73868 1 0 0 0 0 0 0 0

2330 RTA00000523F .10.1 63384 1 0 0 0 0 0 0 0

2331 RTA00000527F.p.08.1 36013 2 0 0 0 0 0 0 0

2333 RTA00000426F.f.l7.1 66334 1 0 0 0 0 0 0 0

2334 RTA00000523FJ.21.1 36925 2 0 0 0 0 0 0 0

2339 RTA00000523F.3.01.1 74923 1 0 0 0 0 0 0 0

2341 RTA00000427FJ.06.1 63676 1 0 0 0 0 0 0 0

2342 RTA00000424F.m.04.1 79017 1 0 0 0 0 0 0 0

2343 RTA00000523F.U7.1 65779 1 0 0 0 0 0 0 0

2346 RTA00000525F.C.18.1 24208 2 1 0 0 0 0 0 0

2347 RTA00000527F.e.09.1 37521 2 0 0 0 0 0 0 0

2348 RTA00000424F .08.1 73972 1 0 0 0 0 0 0 0

2350 RTA00000527F.C.09.1 64859 1 0 0 0 0 0 0 0

2353 RTA00000523F.C.03.1 36913 2 0 0 0 0 0 0 0

2354 RTA00000427F.k.21.1 62880 1 0 0 0 0 0 0 0

2356 RTA00000427F.d.09.1 66486 1 0 0 0 0 0 0 0

2357 RTA00000426F.n. l7.1 66572 1 0 0 0 0 0 0 0

2360 RTA00000426F.m.03.1 66480 1 0 0 0 0 0 0 0

2361 RTA00000424F.h.06.1 77552 1 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib 1 lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 HI ID clones clones clones clones clones clones clones cl

X INI fU"V.

2362 RTA00000425F.d.06.1 77660 1 0 0 0 0 0 0 0

2363 RTA00000427F.e. l2.1 62813 1 0 0 0 0 0 0 0

2366 RTA00000426F.n.23.1 18176 1 0 0 0 0 0 0 0

2367 RTA00000522F.m. l9.1 41544 1 1 0 0 0 0 0 0

2368 RTA00000522F.a.05.1 32611 1 1 0 0 0 0 0 0

2369 RTA00000427F.L09.1 65916 1 0 0 0 0 0 0 0

2370 RTA00000424F .09.1 74387 1 0 0 0 0 0 0 0

2371 RTA00000424F.n.l l .l 73874 1 0 0 0 0 0 0 0

2373 RTA00000527F.e.l3.1 37588 2 0 0 0 0 0 0 0

2375 RTA00000425F.J.19.1 77925 1 0 0 0 0 0 0 0

2376 RTA00000522F.g. l2.1 78783 1 0 0 0 0 0 0 0

2377 RTA00000523F.a.07.1 75804 1 0 0 0 0 0 0 0

2378 RTA00000425F.e. l 9.1 73409 1 0 0 0 0 0 0 0

2379 RTA00000425F.n.l9.1 78324 1 0 0 0 0 0 0 0

2384 RTA00000427F. 07.1 63742 1 0 0 0 0 0 0 0

2387 RTA00000522F.a.l7.1 79032 1 0 0 0 0 0 0 0

2388 RTA00000527F.1.19.1 36856 2 0 0 0 0 0 0 0

2389 RTA00000424F.L1 1.1 41569 1 1 0 0 0 0 0 0

2391 RTA00000424F.d.l9.3 73180 1 0 0 0 0 0 0 0

2392 RTA00000522F.J.09.2 78522 1 0 0 0 0 0 0 0

2393 RTA00000424F.m.24.1 77045 1 0 0 0 0 0 0 0

2394 RTA00000522F.J.19.2 76224 1 0 0 0 0 0 0 0

2398 RTA00000527F.J.12.2 37503 2 0 0 0 0 0 0 0

2399 RTA00000522F.g. l l .l 75432 1 0 0 0 0 0 0 0

2400 RTA00000522F.k.02.2 77622 1 0 0 0 0 0 0 0

2401 RTA00000427F.e. l3.1 66080 1 0 0 0 0 0 0 0

2402 RTA00000426F.f.l8.1 63271 1 0 0 0 0 0 0 0

2403 RTA00000427F.a.l2.1 63377 1 0 0 0 0 0 0 0

2404 RTA00000424F.b.23.4 77322 1 0 0 0 0 0 0 0

2408 RTA00000427F.f.02.1 36822 2 0 0 0 0 0 0 0

2410 RTA00000424F.i. l5.1 78043 1 0 0 0 0 0 0 0

2412 RTA00000522F.m.03.1 79194 1 0 0 0 0 0 0 0

2413 RTA00000522F.a.20.1 74070 1 0 0 0 0 0 0 0

2414 RTA00000424F.b.l5.4 74958 1 0 0 0 0 0 0 0

2415 RTA00000527F.g.l4.1 37532 2 0 0 0 0 0 0 0

2416 RTA00000522F.d.06.1 74809 1 0 0 0 0 0 0 0

2418 RTA00000427F.e. l0.1 64599 1 0 0 0 0 0 0 0

2419 RTA00000527F.C.16.1 22908 3 0 0 0 0 0 0 0

2421 RTA00000523F.f.l7.1 63984 1 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib l lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 HI

ID clones clones clones clones clones clones clones cl

NO:

2423 RTA00000527F.p.24.1 36832 2 0 0 0 0 0 0 0

2424 RTA00000425F.n. l7.1 78304 1 0 0 0 0 0 0 0

2426 RTA00000425F.e.07.1 75992 1 0 0 0 0 0 0 0

2428 RTA00000523F.h.08.1 62893 1 0 0 0 0 0 0 0

2429 RTA00000522F.O.10.1 78798 1 0 0 0 0 0 0 0

2430 RTA00000425F.1.10.1 26893 1 0 0 0 0 0 0 0

2431 RTA00000427F.f.l6.1 64122 1 0 0 0 0 0 0 0

2434 RTA00000425F.i.l0.1 78736 1 0 0 0 0 0 0 0

2435 RTA00000426F.m.l2.1 63740 1 0 0 0 0 0 0 0

2436 RTA00000527F.g.l2.1 37746 2 0 0 0 0 0 0 0

2439 RTA00000425F.i.l8.1 42255 1 1 0 0 0 0 0 0

2441 RTA00000424FJ.13.1 74485 1 0 0 0 0 0 0 0

2445 RTA00000424F.k.l0.1 73232 1 0 0 0 0 0 0 0

2446 RTA00000522F.i.07.2 78377 1 0 0 0 0 0 0 0

2448 RTA00000522F.b.08.1 26915 1 0 0 0 0 0 0 0

2449 RTA00000522F.1.08.1 78781 1 0 0 0 0 0 0 0

2450 RTA00000525F.3.14.1 37566 2 0 0 0 0 0 0 0

2451 RTA00000424F.g.08.1 74928 1 0 0 0 0 0 0 0

2452 RTA00000425F.1.09.1 75251 1 0 0 0 0 0 0 0

2453 RTA00000522F.O.20.1 74853 1 0 0 0 0 0 0 0

2454 RTA00000527F.J.04.2 1 1809 3 1 0 0 0 0 0 0

2456 RTA00000523F.C.13.1 40668 1 1 0 0 0 0 0 0

2457 RTA00000427F.L21.1 65540 1 0 0 0 0 0 0 0

2459 RTA00000522F.h.02.1 74947 1 0 0 0 0 0 0 0

2460 RTA00000522F.g.l0.1 74294 1 0 0 0 0 0 0 0

2464 RTA00000425F.k.l6.1 75282 1 0 0 0 0 0 0 0

2465 RTA00000525F.b.09.1 23472 2 1 0 0 0 0 0 0

2466 RTA00000522F.J.08.2 76613 1 0 0 0 0 0 0 0

2468 RTA00000523FT.19.1 34169 1 1 0 0 0 0 0 0

2469 RTA00000425F.J.18.1 75561 1 0 0 0 0 1 0 0

2470 RTA00000426F.m.04.1 36865 2 0 0 0 0 0 0 0

2471 RTA00000527F.g.21.1 36028 2 0 0 0 0 0 0 0

2473 RTA00000525F.3.22.1 36848 2 0 0 0 0 0 0 0

2474 RTA00000522F.p.22.1 73322 1 0 0 0 0 0 0 0

2475 RTA00000424F.d.l2.2 74342 1 0 0 0 0 0 0 0

2476 RTA00000424F.g.24.1 79156 1 0 0 0 0 0 0 0

2477 RTA00000427F.a.l0.1 65370 1 0 0 0 0 0 0 0

2478 RTA00000426F.h.20.1 23187 3 0 0 0 0 0 0 0

2479 RTA00000424F.d.l2.3 74342 1 0 0 0 0 0 0 0 SEQ Sequence Name cluster lib l lib 2 lib 15 lib 16 lib 17 lib 18 lib 19 HI ID clones clones clones clones clones clones clones cl NO: 2480 RTA00000425F.C.03.1 74643 1 0 0 0 0 0 0 0

2481 RTA00000523F.f.l6.1 26522 1 0 0 0 0 0 0 0

2482 RTA00000427F.f.l5.1 66734 1 0 0 0 0 0 0 0

2485 RTA00000522F.p. l 8.1 76376 1 0 0 0 0 0 0 0

2493 RTA00000522F.g. l 8.1 73226 1 0 0 0 0 0 0 0

2495 RTA00000522F.h.05.1 73358 1 0 0 0 0 0 0 0

2497 RTA00000425F.n.l6.1 18265 1 0 0 0 0 0 0 0

2498 RTA00000527F.1.21.1 36439 2 0 0 0 0 0 0 0

2501 RTA00000424F.d.l7.3 73958 1 0 0 0 0 0 0 0

2502 RTA00000523FJ.02.1 62853 1 0 0 0 0 0 0 0

Table 21. Clones Deposited on January 22, 1999 cDN A Library Ref No. cDNA ES17 cDNA ESl δ CDNA ES19 ATCC Accession No. ATCC No. ATCC No. ATCC No.

Clone Names in M00001368A:D07 M00001594A:D06 M00003906A:F04 Library M00003917A:D02 M00001613D:H10 M00003908A:F12

M00001673A:A04 M00001596D:E10 M00003914A:G09

M00003868B:G1 1 M00001592C:G04 M00003915C:H04

M00003917C:D03 M00001599D:A09 M00003905D:B08

M00003791C:E09 M00001619B:A09 M00003908C:G09

M00003870A:C05 M00001593B:E1 1 M00003914B:A1 1

M00003922A:D02 M00001605A:E06 M00003916C:C05

M00003861C:H02 M00001608A:D03 M00003959A:A03

M00003931B:A1 1 M00001616C:A02 M00003905D:C08

M00001679D:B05 M00001617A:D06 M00003908D:D12

M00001679C:D05 M00001595C:E01 M00003901B:H04

M00001687A:G01 M00001616C:A1 1 M00004031A:E01

M00003945A:E09 M00001608C:E1 1 M00004029C:C12

M00003908A:H09 M00001610C:E06 M0000391 1A:F10

M00001649B:G12 M00001612B:D1 1 M00003914C:F09

M00003813D:H12 M00001618B:E05 M00003963D:B05

M00004087C:D03 M00001621C:C10 M00003986C:E09

M00004269B:C08 M00001647A:H08 M00004031A:F07

M00004348A:A02 M00001631D:B10 M00003907C:C02

M00001679C:D01 M00001608D:E09 M0000391 1B:F08

M00001490A:E1 1 M00001641B:C10 M00003914C:H05

M00001387A:E10 M00001641D:E02 M00003918C:C12

M00001397B:G03 M00001630D:H10 M00003914C:C02

M00001441D:E04 M00001585C:D10 M00003914A:E04

M00001352C:G09 M00001560A:H10 M00003903B:D03

M00001370D:A12 M00001573B:C06 M00003905A:F09

M00001387B:A06 M00001660C:D1 1 M00003867C:E1 1

M00001397C:A10 M00001641C:C05 M00003870B:B08

M00001536D:G02 M00001578B:B05 M00003879D:A08

M00003895C:A10 M00001587C:C10 M00003891D:B10

M00001464B:B03 M00001590B:C07 M00003901C:A08

M00004370A:G05 M00001554A:E04 M00003903C:C04

M00001490B:H1 1 M00001570C:G06 M00003905A:F10

M00001530B:D10 M00001576A:B09 M00003906C:D06

M00001579C:E09 M00001582A:H01 M00003907D:A12

M00001587A:H03 M00001582B:E12 M00003905C:G1 1

M00001457C:H12 M00001615B:F07 M00003914D:D10

M00001535C:E01 M00001571C:A04 M00003972A:G09

M00001561D:C05 M00001573D:D10 M00003975D:C06

M00001589A:C01 M00001576A:F1 1 M00003905C:B02

M00001664D:G07 M00001579C:G05 M00003907D:F1 1

M00001565A:H09 M00001582D:A02 M00003914A:G06

M00001381C:B08 M00001589B:E07 M00003914D:E03

M00001395C:F1 1 M00001575B:B02 M00003972C:F08

M00001429D:F1 1 M00001578C:G06 M00003976C:D06

M00001449A:F01 M00001591A:B08 M00003907C:C04

M00001391C:H02 M00001607A:F1 1 M00003905B:C06

M00001429D:H12 M00001579C:E06 M00004088C:A12

M00001450A:G1 1 M00001661C:F1 1 M00004103C:D04

M00001344B:F12 M00001650B:C10 M00004107A:D01 cDN A Library Ref No. cDNA ES17 cDNA ES18 CDNA ES19 ATCC Accession No. ATCC No. ATCC No. ATCC No.

M00001391D:C06 M00001654C:E04 M000041 10A:E04

M00003971A:A06 M00001656B:A08 M00004062A:H06

M00001346A:E04 M00001662C:B02 M00004075D:C10

M00001455C:G07 M00001656B:D05 M00004081D:H09

M00001402D:F02 M00001661C:F10 M00004089A:B08

M00001438D:C06 M00001663A:C1 1 M00004103D:F10

M00001349B:G05 M00001669A:C10 M00004107B:B04

M00001389C:A08 M00001651B:B12 M00004032C:B02

M00001439B:A10 M00001653B:E06 M00004078C:F04

M00001455B:A09 M00001659C:F02 M00004038B:H10

M00001441B:D1 1 M00001661B:F03 M00004089A:E02

M00001453A:B01 M00001663C:F10 M00004096B:F05

M00001456D:E08 M00001669A:G12 M00004104C:H12

M00001399A:C03 M00001674D:C10 M000041 10D:A10

M00004496C:H03 M00001651B:E06 M00004036D:F02

M00004135D:G02 M00001651C:C05 M00004088C:E04

M00004692A:E07 M00001657C:C07 M00004104D:A04

M00004374D:E10 M00001662A:C12 M00004107D:E12

M00004405D:C04 M00001663D:C06 M000041 15D:D08

M00004312B:H07 M00001590B:C05 M00003846A:D03

M00003976C:A10 M00001483C:G06 M00004072C:F08

M00004043A:D02 M00001653A:G07 M00004039B:G08

M00004081C:H06 M00001625B:C10 M00003986D:D02

M00004050D:A06 M00001626C:D12 M00003914A:B07

M00001361B:C07 M00001634D:D02 M00003914D:B02

M00004341B:G03 M00001641C:C06 M00003971 B:B07

M00001342B.Ε01 M00001642D:F02 M00003978C:A03

M00004064D:A1 1 M00001647B:E04 M00003983B:C08

M00004087A:G08 M00001632B:E05 M00004033D:D07

M00004344B:H04 M00001639A:C1 1 M00004072D:H12

M00004497A:H03 M00001642D:G10 M00004077B:H1 1

M00001338C:E10 M00001624A:G1 1 M00004080A:F01

M00001366D:E12 M00001626C:G08 M00004092C:B03

M00001390D:E03 M00001672D:D04 M00004037B:C04

M00001413B:H09 M00001639A:H06 M00004073C:D04

M00004271B:B06 M00001662C:A04 M00004081A:A08

M00004151D:E03 M00001641B:B01 M00004085B:B05

M00001660B:C04 M00001673C:A02 M00004090C:C07

M00003802D:B1 1 M00001650A:A12 M00004086D:B09

M00001579C:E08 M00001659D:D03 M00004088D:B03

M00001557D:C08 M00001661B:B05 M00004090C:C10

M00003779B:E12 M00001671D:E10 M00004102C:D09

M00001638A:D10 M00001652D:A06 M00004105C:E09

M00003794A:B03 M00001654C:D05 M00004035A:G10

M00001616C:F07 M00001656A:B07 M00003906A:H07

M00001679A:F01 M00001647B:C09 M00004083B:G03

M00001604C:E09 M00001635A:C06 M00001675B:E02

M00001653B:E09 M00001482D:A04 M00003793C:D09

M00001585A:F07 M00001485C:B10 M00003762B:H09

M0000381 1D:A12 M00001457D:A07 M00001694C:F12

M00001653C:F12 M00001461A:E05 M00001678D:C1 1

M00001679D:F06 M00001477A:G07 M00001677D:B07 cDNA Library Ref No. cDNA ES17 CDNA ES18 CDNA ES19 ATCC Accession No. ATCC No. ATCC No. ATCC No.

M00003751D:B02 M00001479D:H03 M00001677B:A02

M00003801A:B10 M00001482C:D02 M00001675B:H03

M00003844C:A08 M00001484D:G05 M00003808D:D04

M00001636C:C01 M00001459B:D03 M00003752B:C02

M00001669C:B01 M00001464B:C1 1 M00003819D:B1 1

M00003755A:A09 M0000151 1A:A05 M00001677D:B02

M00003798D:H08 M00001477B:C02 M00001694C:G04

M00001444C:D05 M00001471A:D04 M00003789C:F06

M00004040B.-F10 M00001485C:H10 M00001678C:C06

M00001355A:C12 M00001485D.-E05 M00001675B:D02

M00001401A:H07 M00001487C:G03 M00003750C:H05

M00001393B:B09 M00001514A:B04 M00001694A:B12

M00001409D:F1 1 M00001530C:G10 M00001677B:H06

M00001387B:H07 M00001534A:G06 M00001675C:G01

M00001394C:C1 1 M00001539A:C12 M00001675B:C01

M00001344A:H07 M00001547A:F11 M00003857B:F07

M00001490C:D07 M00001550D:A04 M00003812B:D07

M00001352C:F06 M00001460A:F07 M00001694B:B08

M00001476D:G03 M00001472C:A01 M00001677B:E06

M00001399C:D09 M00001481B:A07 M00004037A:E04

M00001347C:G08 M00001456D:F05 M00003870A:H01

M00001453D:G12 M00001456D:G1 1 M00003842C:D1 1

M00001382A:F04 M00001477D:F10 M00003828B:F09

M00001392D:H04 M00001481A:G06 M00003856C.H09

M00001429C:G12 M00001464A:B03 M00003851A:C10

M00001454A:C1 1 M00001469A:G1 1 M00003841C:E04

M00001517B:G08 M00001478B:D07 M00003837C:G08

M00001535A:D02 M00001473A:C1 1 M00003828B:E07

M00001352A:E12 M00001457A:G03 M00003772C:B12

M00001381B:F06 M00001669B:G02 M00001677D:F03

M000041 17A:D1 1 M00001479D:G06 M00001678B:B12

M00004217C:D03 M00001473D:B1 1 M00001678D:G03

M00004270A:F1 1 M00001475A:A12 M00001675C:F01

M00003996A:A06 M00001460A:G07 M00003809A:H04

M00004056B:D09 M00001464A:D03 M00003771D:G05

M00004142A:B12 M00001473D:G01 M00001678A:F05

M00001396D:B03 M00001476D:C05 M00001677B:B06

M00001370D:E12 M00001484A:A10 M00003794A:E12

M00001390C:C1 1 M00001457C:F02 M00003771B:E05

M00003989A:H1 1 M00001459B:A12 M00001678A:A1 1

M00001426A:A09 M00001464A.Ε07 M00003805B:C04

M00004498D:D05 M00001467A:B03 M00001680B:E10

M00001391B:G12 M00001514A:B08 M00001679B:H07

M00001391D:D10 M00001464A:B07 M00003904D:B12

M00001376B:A02 M00001579A:C03 M00003856C:B08

M00001405B:D07 M00001517A:G08 M00003858D:G06

M00001368A:A03 M00001530B:G09 M00003870B:F04

M00001392D:B1 1 M00001538A:F12 M00003871C-.B05

M00003900D:B10 M00001540C:B03 M00003875A:C04

M00001494B:C01 M00001547A:F06 M00003901B:A09

M00001352C:A05 M00001550A:F07 M00003901C.-D03

M00001408B:G06 M00001567B:G1 1 M00003904C:B06 cDNA Library Ref No. CDNA ES17 CDNA ES18 CDNA ES19 ATCC Accession No. ATCC No. ATCC No. ATCC No.

M00004252C:E03 M00001572A:A10 M00003901C:F09

M00003901C:A03 M00001575B:G01 M00003904D:B10

M00004071D:A10 M00001487D:C1 1 M00003850D:H1 1

M00001377B:H01 M00001577B:A03 M00003902B:D06

M00003939A:A02 M00001539D:E10 M00003879A:C01

M00004250D:D10 M00001587A:F05 M00003877D:G05

M00004290A:B03 M00001560A:F03 M00003881D:C12

M00003911D:B04 M00001569B:G11 M00003903A:H09

M00004128B:G01 M00001573A:A06 M00003905A:A06

M00004142A:D08 M00001575D:A10 M00003875D.-D09

M00003977A:E04 M00001583A:D01 M00003879B:A06

M00004236C:D10 M00001587A:F08 M00003823D:G05

M00004388B:A08 M00001590B:B02 M00003763A:C01

M00004409B:A1 1 M00001553A:E07 M00003903B:C02

M00003965A:B1 1 M00001560A:H06 M00003905A:E07

M00003988A:E10 M00001589C:A1 1 M00003867A:D12

M00004138A:H09 M00001538A:C08 M00003857C:C09

M00003933C:D06 M00001531A:H03 M00003829C:D10

M00004193C:G1 1 M00001548A:G01 M00003839D:E02

M00004039C:C01 M00001531A:H07 M00003841C:F03

M00003924B:D04 M00001542A:E04 M00003903D:C06

M00004375C:D01 M00001487A:F10 M00003852D:E08

M00001503C:G05 M00003845D:A09

M0000151 1A:G08 M00003824A:G10

M00001539A:H12 M00003841C.F06

M00001542A:F06 M00003848A:C09

M00001549A:F01 M00003857C:F11

M00001514A:A12 M00003816C:C01

M00001516A:D05 M00003843A:E08

M00001546C:C07 M00003850A:F06

M00001549A:H1 1 M00003813B:A1 1

M00001538A:D03 M00003855C:F10

M00001544A:C09 M00003850D:B05

M00001546B:F12 M00003841D:F06

M00001550A:D09 M00003858B:G05

M00001487B:F02 M00003854D:A12

M00001513A:G07 M00003857C:G01

M00001530A:F12 M00003816C:E09

M00001538A:D12 M00003813A:G04

M00001587A:G06 M00003850D:A05

M00001551A:D04

M00001485B:C03 Table 22. Clones Deposited on January 22, 1999 cDNA Ref No.; cDNA Ref ES20 cDNA Ref No. ES27 cDNA Ref ES28 ATCC Accession No. ATCC No. ATCC No. ATCC No. Clone Nsmes in M00004891D:A07 M00001623B:G07 M00001550D:H02 Library M000041 18B:C1 1 M00001619D:G05 M00001549C:D02

M00004105A:B10 M00001616C:C09 M00001549A:A09

M00004099A:F1 1 M00001615C:F03 M00001548A:B1 1

M00004037C:D07 M00001614D:D09 M00001546C:G10

M00004033D:C05 M00001608B:A03 M00001544C:C06

M00003983D:A09 M00001607D:F07 M00003820B:C05

M00004029B:H08 M00001623D:C10 M00001543A:H12

M00004927A:A02 M00001599B:E09 M00001540C:B10

M00003983C:F10 M00001632C:C09 M00001552B:G05

M00003980B:C06 M00001605C:D12 M00001543C:F01

M00004033D:B07 M00001625D:C07 M00001552D:G08

M00004034C:E08 M00001629B:E06 M00001554B:B07

M00005100B:H07 M00001594A:B12 M00001555A:B01

M00005136A:D10 M00001632C:A02 M00001557A:F01

M00005173D:H02 M00001567C:H12 M00001558A:E1 1

M00004891D:C1 1 M00001635C:A03 M00001561C:E1 1

M00004101A:F07 M00001636C:H09 M00001571D:B11

M00003982B:B06 M00001638A:E07 M00001563B:D1 1

M00004108C:E01 M00001639A:F10 M00001569C:B06

M00005136D:B07 M00001656C:G08 M00001539B:H06

M000041 18D:A11 M00001632A:F12 M00001571B:E03

M00005102C:C01 M00001557A:D02 M00001561D:C1 1

M00005177C:A01 M00001529B:C04 M00001487C:D06

M00004927C:H1 1 M00001534B:C12 M00001454B:D08

M00005174D:B02 M00001535D:C01 M00003772D:E10

M00004027A:D06 M00001536D:A12 M00001573C:D03

M00005217A:G10 M00001540B:C09 M00001454D:E05

M00003984A:B06 M00001540D:D02 M00001455D:F09

M00003851C:D07 M00001541C:B07 M00001457C:C1 1

M00003959C:G06 M00001546B:B02 M00001459B:C09

M00005100B:G1 1 M00001575B:C09 M00001460A:E01

M00005213C:G01 M00001554B:C07 M00001460C:H02

M00003982B:H07 M00001578D:C04 M00001456A:H02

M00004029C:B03 M00001557C:H07 M00001477B:F04

M00004033D:G06 M00001558B:D08 M00003845D:B04

M00004091B:H09 M00001560D:A03 M00001488A:E01

M00003959D:A04 M00001561C:F06 M00001492D:A1 1

M00004030D:B06 M00001564D:C09 M00001496C:G10

M00004034C:C06 M00003748B:F02 M00001499A:A05

M00004030C:D12 M00001570D:A03 M00001500A:B02

M00003982C:H10 M00001660C:B12 M00001500D:E10

M00003971C:F09 M00001577B:H02 M00001513D:A03

M00004031B:A06 M00001548A:A08 M00001528A:C1 1

M00003966B:D02 M00003868B:D12 M00001528C:H04

M00004028B:G08 M00001718D:F07 M00001531B:E09

M00004031C:H10 M00003829C:A1 1 M00001463A:F06

M00004076D:B09 M00003832B:E01 M00003755A:B03 cDNA Ref No.; cDNA Ref ES20 cDNA Ref No. ES27 cDNA Ref ES28 ATCC Accession No. ATCC No. ATCC No. ATCC No.

M00004092D:B 1 1 M00003842B:D09 M00001653B:G07

M00003981C:F05 M00003845A:H12 M00001654D:G11

M00004031 D:F05 M00003847B:G03 M00001656B:A07

M00004097B:D03 M00003847C:E09 M00001664B:D06

M00003986D:G07 M00003853D:G08 M00001664C:H10

M00004033B:C02 M00003828A:E04 M00001680B:C01

M00004037B:A04 M00003867C:H09 M00001681A:F03

M00004092C:B12 M00003822A:F02 M00001684B:G03

M00005140D:G09 M00003868C:H10 M00001771A:A07

M00004897D:G05 M00003871A:A05 M00003774C:D02

M00004960B:D12 M00003879C:G10 M00003754D:D02

M00005134C:G04 M00003880C:F10 M00001640B:F03

M00005139A:F01 M00003881D:D06 M00003763B:H01

M00005176A:C12 M00003884D:G07 M00003812C:A05

M00005178A:A07 M00003887A:A06 M00003803C:D09

M00005212A:A02 M00003889A:D10 M00003801B:B10

M00005229D:H07 M00003889D:B09 M00003798D:E03

M000041 15C:H04 M00003858D:F12 M00003773B:G01

M00004687A:C03 M00003774B:B08 M00003771A:G10

M00004900C:E11 M00001680D:D02 M00001452A:E07

M00004695B:E04 M00001528A:F09 M00004029B:F1 1

M00005134D:A06 M00003748A:B07 M00003751B:A05

M00004103B:B07 M00001655A:F06 M00001609B:A1 1

M00005177A:B06 M00003750A:D01 M00001573D:F10

M00005178A:A08 M00003761D:E02 M00001579C:B1 1

M00004104D:B05 M00003763D:E10 M00001579C:H10

M000041 17B:G01 M00003768A:E02 M00001579D:G07

M00004900D:B10 M00003829B:G03 M00001583B:E10

M00005134D:H03 M00003772A:D07 M00001586D:E02

M00005173C:A02 M00001661B:C08 M00001587D:A10

M00005177A:H09 M00003778A:D08 M00001589A:D12

M00005178B:H01 M00003799A:D09 M00001590C:H08

M00005216C:B09 M00003800A:C09 M00001651B:A1 1

M00003826B:E11 M00003804A:H04 M00001597A:E12

M00001596A:G06 M00003806D:G05 M00001649C:B10

M00005100B:D02 M00003808C:B05 M00001614A:E06

M00005137A:E01 M0000381 1A:E03 M00001615C:D02

M000041 19A:A06 M00003815D:H09 M00001621D:D03

M00004891 D:E07 M00003818B:G12 M00001623D:G03

M00004958B:D01 M00003769B:D03 M00001624A:F09

M00005102C:F09 M00001390A:A09 M00001624C:A06

M00005136D:C01 M00001432A:E06 M00001630B:A1 1

M00005174D:H02 M00001381A:D02 M00001634B:C10

M00005177C:B04 M00001383A:G04 M00001639D:B07

M00005218B:D09 M00001384C:E03 M00001573D:F04

M00004102C:F03 M00001384C:F12 M00001595B:A09

M000041 14B:D09 M00001384D:H07 M00004156B:A12

M000041 19D:A07 M00001385B:F10 M00004319D:G09

M00004895C:G05 M00001385C:H1 1 M00004096A:G02

M00004235A:A12 M00001386A:C02 M00004101C:G08 cDNA Ref No.; cDNA Ref ES20 cDNA Ref No. ES27 cDNA Ref ES28 ATCC Accession No. ATCC No. ATCC No. ATCC No.

M00005134B:E01 M00001372C:F07 M00004102A:H02

M000041 15C:G03 M00001389D:G1 1 M00004108A:A09

M00005175B:H04 M00001371D:G01 M000041 1 1D:D1 1

M00005214B:D11 M00001392C:D10 M00004115D:C08

M00004102D:B05 M00001392D:H06 M000041 18D:E08

M000041 15A:B12 M00001397B:B09 M00004121C:F06

M000041 19D:H06 M00001398A:G03 M00004131B:H09

M00004897D:F03 M00001400A:F06 M00004141D:A09

M00004960B:A09 M00001410B:G05 M00004090A:F09

M00005134C:E1 1 M00001413A:F02 M00004146A:C08

M00005138B:D12 M00001415B:E09 M00004078B:A1 1

M00005176A:A05 M00001425A:C1 1 M00004176B:E08

M00005214C:A09 M00001386A:D1 1 M00004188C:A09

M00004102C:D01 M00001354C:B06 M00004233C:H09

M00004960B:A08 M00001339D:G02 M00004241D:F1 1

M00001476D:A09 M00001660A:C 12 M00004246C:A09

M00001572A:B06 M00001528A:A01 M00004247C:C 12

M00005217D:F12 M00001343D:C04 M00004248B:E08

M00005233A:G08 M00001347B:E01 M00004257C:H06

M00005236B:F10 M00001348A:D04 M00004260D:C12

M00005259B:C01 M00001349C:C05 M00004295B:D02

M00005254D:B08 M00001350A:D06 M00004040D:F01

M00005259C:B05 M00001352D:C05 M00004142D:E10

M00001575A:D06 M00001380C:E05 M00003853D:D03

M00005259D:H08 M00001354B:B10 M00003860D:H07

M00003813C:D08 M00001380C:F02 M00003878C:E04

M00001530D:E06 M00001354C:C10 M00003879A:G05

M00004891 B:B12 M00001355B:G1 1 M00003880B:C08

M00001596B:C1 1 M00001356D:F06 M00003881A:D09

M00004300C:H09 M00001360D:E1 1 M00003881C:G09

M00001486D:D12 M00001361C:H1 1 M00003901B:A05

M00001585D:F03 M00001362C:A10 M00003904D:D10

M00001596B:D09 M00001363C:H02 M00003905C:G10

M00001570D:E06 M00001366D:G02 M00003906B:F12

M00001582C:E01 M00001369A:H12 M00003909A:H04

M00001586C:E06 M00001352D:D02 M00004091B:D1 1

M00001593B:D10 M00001485D:B10 M00003963A:E03

M00001595C:H1 1 M00001457B:E03 M00004353C:H07

M00001596B:H05 M00001457C:C12 M00003919A:A10

M00001576A:C11 M00001458C:E01 M00003938A:B04

M00001596C:F09 M00001462B:A10 M00003939C:F04

M00001567A:H05 M00001464D:F06 M00003946D:C1 1

M00001585D:D1 1 M00001467D:H05 M00003979A:F03

M00004688A:A02 M00001468B:H06 M00003985C:F01

M00004927A:E06 M00001505C:H01 M00003997B:G07

M00005229D:H09 M00001470A:H01 M00003860D:A01

M000041 17B:A12 M00001457A:B07 M00004035A:A04

M00004187D:G09 M00001479B:A01 M00004042D:H02

M00005173B:F01 M00001469D:D02 M00004073B:B01

M00005218A:G05 M00001487A:A05 M00003946A:H10 cDNA Ref No.: cDNA Ref ES20 cDNA Ref No. ES27 cDNA Ref ES28 ATCC Accession No. ATCC No. ATCC No. ATCC No.

M000041 18A:H08 M00001352C:H02 M00001423D:A09

M00005134A:D1 1 M00001488D:C 10 M00004314B:G07

M00005176C:C09 M00001490C:C12 M00001405D:D1 1

M00005230D:F06 M00001493B:D09 M00001408A:H04

M00005234D:B04 M00001504D:D1 1 M00001408D:D04

M00005101C:E09 M00001376B:C06 M0000141 1D:F05

M00004206A:E02 M00001506B:D09 M00001412A:E04

M00001570C:A05 M0000151 1 B:C06 M00001413A:F03

M00005231A:H04 M00001476B:F10 M00001417B:C04

M00005235A:A03 M00001450D:D04 M00001417D:A04

M000041 18B:B04 M00001433A:G07 M00001418B:F07

M00005136D:D06 M00001470C:B 10 M00001419D:C10

M00005231C:B01 M00001437D:C04 M00001402B:F12

M00004153B:B03 M00001447C:C01 M00001423A:G05

M00004897C:D06 M00001448B:F06 M00001401C:H03

M00005136D:G06 M00001449D:A06 M00001423D:D12

M00005212B:A02 M00001433B:H1 1 M00001424B:H04

M00005232A:C 10 M00001451D:C 10 M00001428B:A09

M00004692A:H10 M00001452A:C07 M00001430A:A02

M00005101C:B09 M00001453C:A1 1 M00001432D:F05

M00004144A:F04 M00001456B:C09 M00001438B:B09

M00003852B:D1 1 M00001454B:G03 M00001445B:E04

M00001660D:E05 M00001454B:G07 M00001445C:A08

M00003808A:F09 M00001454C:C08 M00001446C:D09

M00001656A:D10 M00001454C:F02 M00001448A:G09

M00001671A:H06 M00001454D:D06 M00001449C:H12

M00003809C:H07 M00001456B:F10 M00001422C:F12

M00003853C:C06 M00001455D:A09 M00001352C:H10

M00003860A:A08 M00001455D:A1 1 M00004375A:H01

M00003822B:D08 M00001448D:F09 M00004380B:A05

M00003845A:E12 M00004444B:D1 1

M00003854C:C02 M00001338B:E02

M00003860B:G09 M00001341A:F12

M00003822B:G01 M00001344A:G07

M00001670A:C1 1 M00001345A:G1 1

M00003852A:B03 M00001345B.Ε10

M00003829D:A1 1 M00001345C:B01

M00003854C:F01 M00001346B:B07

M00003856B:C04 M00001405B:E09

M00003905A:H1 1 M00001352B:F04

M00001530A:F1 1 M00001451C:E01

M00003840B:E07 M00001361A:H07

M00003905B:G03 M00001362B:H06

M00003840B:E08 M00001372C:G12

M00003855A:C12 M00001375B:G12

M00003905B:H05 M00001376A:C05

M00003826B:B04 M00001376B:A08

M00003851C:B06 M00001377C:E12

M00003853B:C08 M00001382B:F12 00003829A:F03 M00001385A:F12 cDNA Ref No.: cDNA Ref ES20 cDNA Ref No. ES27 cDNA Ref ES28 ATCC Accession No. ATCC No. ATCC No. ATCC No.

M00001638C:G01 M00001394A:E04

M00003845D:B02 M00001395A:C09

M00001653D:G07 M00001396A:H03

M00001578B:A02 M00001350B:G1 1

M00001590B:H10

M00001595C:A09

M00001596A:E07

M00001607A:B06

M00001607A:D10

M00001652C:B09

M00001671B:F02

M00001632C:D08

M00001638C:H07

M00001652D:B09

M00001614C:E1 1

M00001633B:B1 1

M00001651C:A04

M00001639D:G12

M00001671C:F1 1

M00001638A:B04

M00001637C:H12

M00001669B:H06

M00001639D:F02

M00001590A:C08

M00001636A:C02

M00001614A:A04

M00001639D:G06

Table 23. Library Deposited on January 22, 1999 cDNA Ref No.; cDNA Library Ref ES29 cDNA Library Ref ES30 ATCC Accession No. ATCC No. ATCC No. Clone Names in M00001449D:B01 M00001594D:B08 Library M00001476D:F03 M00001593A:B07

M00001456C:B12 M00001594A:C01

M00001469B:B01 M00001594A:D08

M00001471A:B04 M00001594A:G09

M00001472A:D08 M00001595C:B05

M00001473A:A07 M00001594B:F12

M00001473C:D09 M00001596D:E03

M00001475B:C04 M00001594D:C03

M00001475C:G1 1 M00001592C:F11

M00001476A:D1 1 M00001590D:G07

M00001476B:D10 M00001595D:A04

M00001468A:C05 M00001595D:G03

M00001476C:C1 1 M00001601A:A06

M00001467A:H07 M00001590C:F10

M00001477B:E02 M00001589B:B08

M00001478B:H08 M00001589C:E06

M00001479C:E01 M0000161 1B:A05

M00001480A:D03 M00001601A:E02

M00001480C:A05 M00001587A:D01

M00001481A:H08 M00001591B:B12

M00001481B:D09 M00001590B:G08

M00001482A:H05 M00001592C:E05

M00001482D:H1 1 M00001591B:B06

M00001483C:G09 M00001591D:C07

M00001485A:C05 M00001591D:F06

M00001476B:F08 M00001592A:E02

M00001460A:E1 1 M00001592A:H05

M00001456C:C 1 1 M00001592B:A04

M00001457A:C05 M00001587A:B10

M00001457A:G12 M00001609D:G10

M00001458A:A1 1 M00005231D:B09

M00001458C:D10 M00001614B:E08

M00001458D:A01 M00005217C:C01

M00001458D:A02 M00001587A:B01

M00001458D:C11 M00001613D:B03

M00001458D:D01 M00001613A:F03

M00001459B:C1 1 M0000161 1C:H1 1

M00001468A:H10 M0000161 1C:C12

M00001460A:C10 M0000161 1B:E06

M00001485B:F05 M0000161 1B:A09

M00001460A:H1 1 M00001610D:D05

M00001461A:F05 M00001610B:C07

M00001462A:D03 M00001610C:E07

M00001464A:B02 M00001610A.Ε09

M00001464A:E10 M00001601A:E12

M00001465A:B12 M00001609B:C09

M00001465A:C12 M00001608D:D1 1

M00001465A:E10 M00001608B:A09 cDNA Ref No.; cDNA Library Ref ES29 cDNA Library Ref ES30 ATCC Accession No. ATCC No. ATCC No.

M00001465A:G06 M00001607D:F06

M00001466A:F08 M00001607B:C05

M00001467A:C10 M00001606A:H09

M00001460A:B12 M00001605A:H03

M00001545A:B12 M00001605A:E09

M00001535A:D10 M00001605A:A06

M00001536A:F1 1 M00001604A:C1 1

M00001537A:H05 M00001604A:C07

M00001539A:E01 M00001604A:B08

M00001539A:H02 M00001604A:A09

M00001539B:G07 M00001610A:H05

M00001539D:B10 M00005214B.Α06

M00001540D:E02 M00005228A:A09

M00001541B:E05 M00001567A:B09

M00001542A:G12 M00001561A:D01

M00001485B:D09 M00001559A:C08

M00001545A:B10 M00001559A:A1 1

M00001533A:G05 M00001558A:G09

M00001545A:F02 M00001555A:B12

M00001545A:G05 M00001554A:A08

M00001546A:D08 M00001552A:H10

M00001548A.Η04 M00001552A:F06

M00001550A:E07 M00005231C:B07

M00001551A:A1 1 M00005218D:G10

M00001551A:D06 M00001570A:H01

M00001551A:H06 M00005214D:D10

M00001551D:H07 M00001570C:G03

M00001552A:E10 M00005213C:A01

M00001450A:B08 M00005212D:F08

M00001544A:F05 M00005212A:D10

M00001512A:G05 M0000521 1C:E09

M00001483B:D04 M0000521 1A:E09

M00001485B:H03 M00005210D:C09

M00001485C:C08 M00005179D:B03

M00001486B:D07 M00005179B:H02

M00001486B:E12 M00005177D:F09

M00001487B:A1 1 M00005177C:G04

M00001487B:E10 M00005177B.-H02

M00001507A:A1 1 M00001614D:B08

M00001507A:B02 M00001615A:D06

M00001507A:C05 M00005216B:D02

M00001507A:E04 M00001579C:A01

M00001534A:D03 M00001585B:C03

M0000151 1A:G01 M00001585B:A06

M00001533D:A08 M00001584D:H02

M00001513A:F05 M00001584A:G03

M00001514A:G03 M00001583D:B08

M00001516A:D02 M00001583B:F02

M00001516A:F06 M00001583A:F07

M00001517A:B1 1 M00001583A:A05 cDNA Ref No.; cDNA Library Ref ES29 cDNA Library Ref ES30 ATCC Accession No. ATCC No. ATCC No.

M00001529D:C05 M00001582D:F02

M00001530A:A09 M00001582D:B01

M00001530A:E10 M00001582A:A03

M00001532A:C01 M00001579D:H09

M00001532D:A06 M00001567D:B03

M00001485B:D10 M00001579C:H06

M0000151 1A:A02 M00001585B:F01

M00004249D:B08 M00001579B:F04

M00004185D:E04 M00001579A:E03

M00004188D:G08 M00001578C:F05

M00004197C:F03 M00001577D:H06

M00004198B:D02 M00001577B:F10

M00004204D:C03 M00001576C:G05

M00004208B:F05 M00001575D:D12

M00004208D:B10 M00001575D:B10

M00004210B:B05 M00001575D:A02

M00001362D:H01 M00001573B:G08

M00004216D:D03 M00001573A:E01

M00004167A:H03 M00001572A:B05

M00004275A:B03 M00001571D:F05

M00004285C:A08 M00001579D:F04

M00004316A:G09 M00001636A:F08

M00004465B:D04 M00001643B:E05

M00004493B:D09 M00001642C:G02

M00001347B:H04 M00001642A:F03

M00001351C:B06 M00001641D:C04

M00001360A:G10 M00001641C:H07

M00004216D:C03 M00001641C:F01

M00004076D:D04 M00001641C:D02

M00001484C:A04 M00001641B:F12

M00001456B:G01 M00001634A:B04

M00003972D:C09 M00001636B:G1 1

M00003974C:E04 M00001649C:D05

M00003979A:E11 M00001636A:C03

M00003983C:F03 M00001635D:D05

M00003989B:F1 1 M00001635D:C12

M00004031D:B05 M00001635B:H02

M00004177C:A01 M00001635B:H01

M00004076B:G03 M00001634D:G1 1

M00004167D:A07 M00001634D:D04

M00004078A:A06 M00001634A:H05

M00004085A:B02 M00001641A:A1 1

M00004107B:A06 M00001638B:E12

M0000411 1C:E1 1 M00001640A:H02

M00004130D:H01 M00001614C:E06

M00004157D:B03 M00001636D:F09

M00004159C:F09 M00001637A:A03

M00004162C:A07 M00001637A:A06

M00004135B:G01 M00001637A:E10

M00004040A:G12 M00001637A:F10 cDNA Ref No.; cDNA Library Ref ES29 cDNA Library Ref ES30 ATCC Accession No. ATCC No. ATCC No.

M00001453B:H12 M00001637C:C06

M00001448A:E11 M00001644A.H01

M00001448B:F09 M00001638B:E03

M00001448B:H05 M00001649A:E1 1

M00001448C:E11 M00001638B:F10

M00001448C:F10 M00001639A:C03

M00001448D:F12 M00001639A:G07

M00001449B:B03 M00001639B:H01

M00001449C:C05 M00001639B:H05

M00001449D:G10 M00001639C:A09

M00001448A:B12 M00001639C:C02

M00001453A:D08 M00001649C:E1 1

M00001451B:A04 M00001649C:H10

M00001454A:F11 M00001637C:E03

M00001454A:G03 M00001617A:A08

M00001455A:F04 M00001622A:H12

M00001455B:E07 M00001621C:H12

M00001455D:A06 M00001621B:G05

M00001364B:B06 M00001620D:H02

M00004117A:G01 M00001620D:G11

M00001455D:D1 1 M00001619D:D10

M00001456B:A06 M00001619C:C07

M00001451A:C10 M00001619A:E05

M00001395A:E03 M00001623A:F04

M00001366D:C06 M00001618A:A03

M00001365A:H10 M00001618B:D09

M00001366D:C12 M00001617A:A01

M00001373D:B03 M00001616D:C1 1

M00001453B:F08 M00001615C.-G05

M00001444D:C01 M00001615C:A1 1

M00001375B:C06 M00001615B:G07

M00001392C:D05 M00001633D:H06

M00001395A:A12 M00001639C:A10

M00001395A:H02 M00001615B:A09

M00001397D:G08 M00001615B:G01

M00001434A:B10 M00001618A:F10

M00001416A:D09 M00001632C:H07

M00001433C:F10 M00001633D:D12

M00001416A:H02 M00001633D.-D09

M00001428D:B10 M00001618A:F08

M00001428B:D01 M00001633D:G09

M00001426D:D12 M00001624A:A03

M00001400C:D02 M00001633C:F09

M00001427C:D01 M00001633C:H05

M00001633C:B09

M00001633A:E06

M00001633C:H1 1

M00001632C:B10

M00001625D:G10

M00001631 D:G05 cDNA RefNo.; cDNA Library Ref ES29 cDNA Library Ref ES30

ATCC Accession No. ATCC No. ATCC No.

M00001629C:E07 M00001629B:B08 M00001626C:E04 M00001626C:C11 M00001632A:B10 M00001624B:B10 M00001633C:A05 M00001625C:G05

Table 24. Clones Deposited on January 22, 1999 cDNA Ref No.; cDNA RefES31 cDNA Ref No. ES32 cDNA Ref ES33 ATCC Accession No. ATCC No. ATCC No. ATCC No. Clone Names in M00003843A:E04 M00003906A:F12 M00005254D:A10 Library M00003842C:G03 M00003906B:H06 M00005260B:E1 1

M00003842A:A03 M00003906C:C05 M00005260A:F04

M00003841D:A04 M00003907A:F01 M00005260A:A12

M00003841B:E06 M00003907B:C03 M00005259B:D12

M00003841C:H1 1 M00003907B:D05 M00005257D:H1 1

M00003844A:A1 1 M00003918A:D08 M00005257D:G07

M00003841C:F01 M00003918A:F09 M00005257D:A06

M00003841C:H08 M00003918C:H10 M00005257C:G01

M00003841C.-D07 M00003924A:D08 M00005257A:H1 1

M00003844D:A07 M00003958B:E1 1 M00005236B:H10

M00003845D:G08 M00003958B:H08 M00005236B:G03

M00003852C:B06 M00003960A:G07 M00005257C:E05

M00003854B:A07 M00003971B:A10 M00001608C:D02

M00003854B:D04 M00003972D:H02 M00001608C:G04

M00003859D:C05 M00003973C:C03 M00001608D:F1 1

M00003860B:F1 1 M00003974B:B1 1 M00001609C:A12

M00003867B:G07 M00003974D:F02 M00001609C:G05

M00003867B:G08 M00003974D:H04 M00001610C:B07

M00003841B:E03 M00003975C:F07 M00001612D:D12

M00003822D:B10 M00003977C:A06 M00001612D:F06

M00003867D:A06 M00003977C:B03 M00001613A:D02

M00003868B:G06 M00003977D:A03 M00001614A:B10

M00003867B:D10 M00003977D:A06 M00001614C:G07

M00003831C:G05 M00003977D:D04 M00001615C:E07

M00003901C:B01 M00003978D:G04 M00001625C:F10

M00003868C:C07 M00003980A:F04 M00001626D:A02

M00003820A:A08 M00003980B:C1 1 M00001629A:H09

M00003820B:D07 M00003981C:B04 M00001629D:B10

M00003820B:D10 M00003982A:B12 M00001629D:D10

M00003822D:C06 M00003982C:G04 M00001630C:F09

M00003823B:F07 M00003984D:B08 M00001631A:D03

M00003824C:D07 M00003985B:G04 M00001631A:F06

M00003825B:B10 M00003985D:E10 M00001631A:F12

M00003825B:B1 1 M00003986B:A08 M00001631B:H04

M00003828A:D05 M00003986C:D09 M00001633A:F1 1

M00003822D:D04 M00003986D:C08 M00001633A:G10

M00003830C:A03 M00003987B:E12 M00001633B:A12

M00003840D:H10 M00003987B:F08 M00001633B:E03

M00003832A:A09 M00003987C:G03 M00001633C:A08

M00003833B:B03 M00003988D:A08 M00001633C:E12

M00003833B:C12 M00003989C:D03 M00001635B:B02

M00003834B:G04 M00003989C:G05 M00001636A:H12

M00003835A:A09 M00003989D:F12 M00001638A:C08

M00003835B:H1 1 M00004029B:F01 M00001638B:C08

M00003835D:G06 M00004029C:C05 M00001639D:C12

M00003837C:E05 M00004029C:G 10 M00001640A:F05

M00003837C:F10 M00004030D:F1 1 M00001642D:G08 cDNA Ref No.; cDNA Ref ES31 cDNA Ref No. ES32 cDNA Ref ES33 ATCC Accession No. ATCC No. ATCC No. ATCC No.

M00003839A:D07 M00004034A:A01 M00001647D:G07

M00003839D:E1 1 M00004034C:G02 M00001649A:E10

M00003829C:H05 M00004034D:E09 M00001650D:D10

M00003901 B:C03 M00004035B:H09 M00001650D:F1 1

M00003878C:F06 M00004036D:B04 M00001651C:D1 1

M00003878C:G08 M00004036D:B09 M00001651C:G12

M00003879A:A02 M00004038A:F02 M00001652B:D06

M00003879A:B08 M00004038D:G06 M00001652D:G02

M00003879A:C1 1 M00004039A:C03 M00001652D:G06

M00003879A:D02 M00004039A:H1 1 M00001653A:A05

M00003879B:G02 M00004039B:A05 M00001653D:H07

M00003880B:D1 1 M00004039B:E12 M00001654A:E08

M00003880C:E1 1 M00004040C:A01 M00001654B:A01

M00003880C:H03 M00004051D:E01 M00001654C:D10

M00003901B:F10 M00004072D:F09 M00001654C:G07

M00003890B:C08 M00004073A:D10 M00001654C:G09

M00003877C:A1 1 M00004075B:G09 M00001655C:C07

M00003819D:B01 M00004076A:D12 M00001655D:E08

M00003901B:G1 1 M00004076D:H07 M00001655D:H1 1

M00001692A:G06 M00004078A:C1 1 M00001656A:H12

M00003903C:C05 M00004078A:E05 M00001656C:C04

M00003903C:E12 M00004078A:F07 M00001656D:C04

M00003903D:C12 M00004078B:C1 1 M00001657C:C11

M00003903D:D10 M00004078B:F12 M00001657D:A10

M00003903D:H1 1 M00004079D:G08 M00001659D:A09

M00003904A:C04 M00004081A:E02 M00001661D:D05

M00003904B:C03 M00004081A:G01 M00001664B:E08

M00003904C:A08 M00004081C:A10 M00001664B:F06

M00003881B:F10 M00004083A:E08 M00001669B:C12

M00003871D:G06 M00004083B:C01 M00001669C:B09

M00003868D:D09 M00004086D:G08 M00001670A:F09

M00003868D:D1 1 M00004087B:A12 M00001678C:F09

M00003870C:A01 M00004087C:A01 M00001693A:H06

M00003870C:A10 M00004088C:F01 M00003805D:E06

M00003870C:E10 M00004088D:A1 1 M00003806C:A06

M00003871A:A02 M00004088D:B05 M00003809B:A03

M00003871A.B09 M00004088D:B10 M00003810A:A02

M00003871A:C1 1 M00004090B:B04 M00003810B:B1 1

M00003871A:G09 M00004090B:H06 M00003810C:B06

M00003871C:E04 M00004092B:E05 M00003810D:H09

M00003871C:F12 M00004093C:C02 M0000381 1C:C02

M00003878C:D08 M00004096D:H03 M00003813B:F02

M00003871D:E1 1 M00004099D:F01 M00003813C:H08

M00003877C:G12 M00004100B:C07 M00003813D:B12

M00003875A:A07 M00004103B:E09 M00003813D:C02

M00003875A:B01 M00004105C:B05 M00003813D:G06

M00003875B:F12 M00004105C:C08 M00003814B:C01

M00003875C:A01 M00004107A:A12 M00003817C:A10

M00003875C:A09 M00004107B:D07 M00003817C:G06

M00003875C:G02 M00004108B:B02 M00003817D:D12 cDNA Ref No.; cDNA Ref ES31 cDNA Ref No. ES32 cDNA Ref ES33 ATCC Accession No. ATCC No. ATCC No. ATCC No.

M00003876B:C05 M00004108D:E07 M00003821A:H09

M00003876C:D02 M00004108D:G04 M00003822B:G12

M00003876C:F02 M000041 10A:A10 M00003822C:A07

M00003877B:H10 M000041 10B:A07 M00003823C:B01

M00003868D:B09 M000041 18B:A03 M00003823C:C04

M00003871D:A10 M000041 18B:F01 M00003824A:G1 1

M00001669D:D06 M000041 18D:B05 M00003824B:C09

M00001661A:B1 1 M00004119A:C09 M00003824C.Α10

M00001661B:F06 M00004136D:B02 M00003824D:D08

M00001662A:C07 M00004137A:D06 M00003825B:F10

M00001662A:G01 M00004139C:A12 M00003825D:F01

M00001662B:F06 M00004149C:B02 M00003826C:F05

M00001663C:F12 M00004159C:G12 M00003829A:B08

M00001664A:F08 M00004169D:B1 1 M00003829C:E08

M00001664D:F04 M00004187D:H06 M00003829D:D12

M00001661A:E06 M00004228C.Η03 M00003829D:F03

M00001669A:B02 M00004244C:G07 M00003830D:B1 1

M00001669B:B12 M00004358D:C02 M00003830D:H1 1

M00001669C:C08 M00004690A:G08 M00003833D:H08

M00001675A:G10 M00004891B:D01 M00003833D:H10

M00001669D:C03 M00004891C:D04 M00003840A:C10

M00001660B:E03 M00004895B:E12 M00003840B:F05

M00001669D:F05 M00004895B:G04 M00003840C:C02

M00001670B:G12 M00004895D:G07 M00003845C:D04

M00001671A:A10 M00004898C:F03 M00003845D:A04

M00001671B:G05 M00004899D:G06 M00003846B:C05

M00001671C:C1 1 M00004959D:H12 M00003846C:F08

M00001672D:E08 M00004960A:B08 M00003848B:E07

M00001673A:G08 M00004960C:E10 M00003848D:G02

M00001673B:B07 M00005100A:B02 M00003850C:G09

M00001673B:F07 M00005100A:C01 M00003851A:A06

M00001673D:D06 M00005101C:E12 M00003851B:D03

M00001673D:F10 M00005102C:D03 M00003851B:E01

M00001674A:G07 M00005134B:E08 M00003851C:F09

M00001692D:B01 M00005139A:H03 M00003851D:H1 1

M00001669C:D09 M00005140C:B10 M00003852B:G04

M00001655C:E01 M00005140D:C06 M00003852C:F07

M00001649D:A08 M00005178D:H04 M00003853B:C10

M00001650A:C1 1 M00005210A:E06 M00003854C:C09

M00001651A:H1 1 M00005212B:E01 M00003855A:A01

M00001652A:A01 M00005212C:C03 M00003855A:F01

M00001652B:G10 M00005212C:D02 M00003855B:B09

M00001652D:E05 M00005212C:H02 M00003856A:G04

M00001652D:E09 M00005212D:D09 M00003856B:A12

M00001653B:C06 M00005212D:H01 M00003857A:E12

M00001653B:G10 M00005216A:D09 M00003857A:H10

M00001653C:D10 M00005216A:H01 M00003857C:E05

M00001654D:A03 M00005217B:A06 M00003858B:G02

M00001654D:E12 M00005218A:F09 M00003860D:E06

M00001654D:F1 1 M00005228A:B03 M00003905C:F12 cDNA Ref No.; cDNA Ref ES31 cDNA Ref No. ES32 cDNA Ref ES33 ATCC Accession No. ATCC No. ATCC No. ATCC No.

M00001660C:B06 M00005228C:C05 M0000391 1A:D12

M00001658D:G12 M00005229B:G12 M00003966B:A04

M00001675C:A04 M00005229B:H04 M00003966C:A12

M00001660B:D03 M00005229B:H06 M00003966C:F03

M00001660B:A09 M00005229D:H03 M00003973D:F08

M00001659D:C09 M00005230B:H09 M00003974D:E01

M00001659D:B05 M00005232A:H12 M00003974D-.H07

M00001654D:F12 M00005233B:D04 M00003976B:E06

M00001659A:D12 M00005233D:H07 M00003976B:H07

M00001655A:B1 1 M00005235B:F10 M00003978A:E01

M00001658B:A07 M00005236A:E04 M00003978A:E09

M00001658A:G09 M00005236A:G10 M00003978C:A12

M00001657D:A04 M00005236B:A12 M00003980C:E12

M00001657B:B04 M00001448B:A07 M00003980C:F12

M00001656B:E01 M00001448B:G07 M00003981A:A07

M00001660B:E04 M00001448D:E1 1 M00003981B:B12

M00001659C:F10 M00001455A:D10 M00003982A:G03

M00003808C:A05 M00001455A:E1 1 M00003982B:C10

M00001694D:C 12 M00001476D:F12 M00003982B:H10

M00003746C:E02 M00001478A:F12 M00003983A:D02

M00003779D:E08 M00001482C:F09 M00003983A:F06

M00003792A:B10 M00001485C:D07 M00003983A:G02

M00003793D:A11 M00001485C:G06 M00003983D:E08

M00003794D:G03 M00001485D:A05 M00003983D:H02

M00003797A:C1 1 M00001487C:A1 1 M00003985A:C01

M00003797A:D06 M00001487C:G09 M00003986C:G1 1

M00003797A:G03 M00001530A:B02 M00003986D:H12

M00003800B:F03 M00001530A:H05 M00004027A:A08

M00003805A:F02 M00001530D:A1 1 M00004028A:B10

M00003806B:C09 M00001539B:B10 M00004028A:G03

M00001674A:G1 1 M00001567A:C04 M00004029B:A01

M00003806D:D1 1 M00001567A:C1 1 M00004029B:A06

M00001693D:E08 M00001567C:B08 M00004029B:G10

M00003808D:D08 M00001567C:E07 M00004029C:F02

M00003809A:C01 M00001570C:B02 M00004029C:F05

M00003809A:F01 M00001570D:E05 M00004030B:A12

M00003809B:B02 M00001570D:E07 M00004030B:D08

M00003809B:E10 M00001573B:A06 M00004030C:A08

M00003813A:B02 M00001573B:H12 M00004030C:C02

M00003813A:D08 M00001575A:D05 M00004034C:F05

M00003813B:E09 M00001575B:C01 M00004035B:F05

M00003814B:C12 M00001576C:H02 M00004036A:A1 1

M00003814B:F12 M00001577A:A03 M00004037C:D04

M00003815C:C06 M00001578B:A06 M00004038A:E05

M00003815C:D12 M00001579D:F02 M00004038B:D01

M00003817B:C04 M00001582C:C04 M00004039C:E02

M00003806B:G05 M00001582C:G02 M00004039D:B10

M00001679A:D10 M00001584A:A07 M00004040A:A07

M00001675C:C03 M00001584D:B06 M00004040A:B04

M00001675C:D12 M00001584D:C1 1 M00004040A:C08 cDNA Ref No.: cDNA Ref ES31 cDNA Ref No. ES32 cDNA Ref ES33 ATCC Accession No. ATCC No. ATCC No. ATCC No.

M00001675D:E10 M00001585D:B12 M00004040B:C05

M00001676B:B09 M00001586C:H07 M00004040B:F07

M00001676B:E01 M00001589D:A01 M00004069A:E12

M00001676C:A04 M00001590D:B04 M00004069C:C08

M00001676C:E07 M00001592B:B02 M00004077A:G12

M00001676D:A02 M00001592D:H02 M00004085B:G01

M00001676D:B02 M00001594C:E05 M00004087A:B05

M00001677A:G1 1 M00001594C:H03 M00004090D:F12

M00001677B:A12 M00001594D:G1 1 M00004092C:D08

M00001677B:B04 M00001595A:C07 M00004097C:E03

M00001677D:B01 M00001595A:D12 M00004097C:H08

M00001678D:B1 1 M00001595A:E07 M00004097D:B05

M00001681C:A08 M00001595B:G07

M00003819B:G01 M00001595B:G10

M00001693C:E09 M00001595B:H1 1

M00001693C:C12 M00001595C:A01

M00001692B:E01 M00001595C:A05

M00001692A:B06 M00001595C:B12

M00001678B:H01 M00001595C:E05

M00001681D:C12 M00001595C:E09

M00001694A:E03 M00001595D:C1 1

M00001680B:D02 M00001596A:A02

M00001680A:B02 M00001596A:D01

M00001679D:F02 M00001596C:G05

M00001679D:B02 M00001607A:A01

M00001679A:G06

Claims

We Claim:

1. A library of polynucleotides, the library comprising the sequence information of at least one of SEQ ID NOS: 1-3544, 3546-4510, 4512-4725, 4727-4748, and 4750-5252.

2. The library of claim 1, wherein the library is provided on a nucleic acid array.

3. The library of claim 1, wherein the library is provided in a computer-readable format.

4. The library of claim 1, wherein the library comprises a differentially expressed polynucleotide comprising a sequence selected from the group consisting of SEQ ID NOS:65, 174, 203, 252, 253, 387, 419, 420, 491, 552, 560, 581, 590, 648, 693, 726, 746, 990, 1095, 1124, 1205, 1354, 1387, 1780, 1899, 1915, 1979, 2007, 2024, 2245, and 2325.

5. The library of claim 1, wherein the library comprises a polynucleotide differentially expressed in a human breast cancer cell, where the polynucleotide comprises a sequence selected from the group consisting of SEQ ID NOS: 15, 36, 44, 45, 89, 146, 154, 159, 165, 174, 172, 183, 203, 261, 364, 366, 387, 419, 420, 496, 503, 510, 512, 529, 552, 560, 564, 570, 590, 606, 644, 646, 693, 707, 711, 726, 746, 754, 756, 875, 902, 921, 942, 990, 1095, 1104, 1122, 1131, 1142, 1170, 1184, 1205, 1286, 1289, 1354, 1387, 1435, 1535, 1751, 1764, 1777, 1795, 1860, 1869, 1882, 1890, 1915, 1933, 1934, 1979, 1980, 2007, 2023, 2040, 2059, 2223, 2245, 2300, 2325, 2409, 2462, 2486, 2488, and 2492.

6. The library of claim 1, wherein the library comprises a polynucleotide differentially expressed in a human colon cancer cell, where the polynucleotide comprises a sequence selected from the group consisting of SEQ ID NOS:33, 65, 228, 250, 252, 253, 280, 282, 355, 370, 387, 443, 460, 491, 545, 560, 581, 603, 680, 693, 703, 704, 716, 726, 746, 752, 753, 1095, 1104, 1205, 1241, 1264, 1354, 1387, 1401, 1442, 1514, 1734, 1742, 1780, 1851, 1899, 1915, 1954, 2024, 2066, 2262, and 2325.

7. The library of claim 1, wherein the library comprises a polynucleotide differentially expressed in a human lung cancer cell, where the polynucleotide comprises a sequence selected from the group consisting of SEQ ID NOS: 10, 54, 65, 171, 174, 203, 252, 253, 254, 285, 419, 420, 466, , 491, 525, 526, 552, 571, 574, 590, 693, 700, 726, 742, 746, 861, 990, 922, 1088, 1288, 1355, 1417, 1422, 1444, 1454, 1570, 1597, 1979, 2007, 2024, 2034, 2038, 2126, and 2245.

8. The library of claim 1, wherein the library comprises a polynucleotide differentially expressed in a human cancer cell, where the polynucleotide comprises a sequence selected from the group consisting of SEQ ID NOS:648 andl 899.

9. An isolated polynucleotide comprising a nucleotide sequence having at least 90% sequence identity to an identifying sequence of SEQ ID NOS: 1-3544, 3546-4510, 4512-4725, 4727-4748, and 4750-5252, or a degenerate variant or fragment thereof.

10. The polynucleotide ofclaim 9, wherein the polynucleotide comprises a sequence ofone of SEQ ID NOS:2503, 2504, 2550, 2555, 2578, 2656, 2667, 2712, 2723, 2728, 2738, 2734, 2754, 2758, 2760, 2832, 2835, 2842, 2843, 2849, 2893, 2933, 2956, 2971, 2981, 3009, 3018, 3019, 3046, 3084, 3190, 3129, 3173, 3226, 3227, 3274, 3290, 3356, 3365, 3377, 3381, 3390, 3391, 3404, 3407, 3408, 3409, 3418, 3419, 3451, 3597, 3600, 3618, 3632, 3635, 3646, 3648, 3657, 3665, 3669, 3670, 3671, 3656, 3680, 3686, 3695, 3696, 3700, 3710, 3736, 3762, 3763, 3774, 3775, 3791, 3804, 3806, 3836, 3895, 3905, 3919, 3920, 3927, 3936, 3951, 3974, 3998, 4036, 4038, 4044, 4056, 4072, 4117, 4119, 4152, 4153, 4154, 4172, 4175, 4159, 4175, 4205, 4216, 4223, 4228, 4238, 4241, 4243, 4251, 4253, 4261, 4263,4278, 4288, 4322, 4330, 4343, 4359, 4363, 4364, 4365, 4373, 4375, 4384, 4385, 4406, 4409, 4431, 4434, 4441, 4442, 4444, 4455, 4469, 4473, 4477, 4482, 4489, 4495, 4496, 4498, 4525, 4535, 4536, 4540, 4560, 4616, 4562, 4586, 4605, 4629, 4653, 4654, 4658, 4659, 4660, 4661, 4664, 4665, 4668, 4684, 4682, 4688, 4689, 4710, 4718, 4733, 4724, 4733, 4746, 4755, 4760, 4710, 4777, 4785, 4792, 4794, 4801, 4807, 4821, 4822, 4847, 4850, 4854, 4856, 4866, 4885, 4900, 4901, 4905, 4914, 4925, 4929, 4931, 4943, 4944, 4959, 5111, 5020, 5041, 5046, 5059, 5083, 5090, 5094, 5102, 5125, 5174, 5197, 5208, 5217, 5237, 5239, 5241, 5243, 5248, and 5252.

11. A recombinant host cell containing the polynucleotide of claim 9.

12. An isolated polypeptide encoded by the polynucleotide of claim 9.

13. An antibody that specifically binds a polypeptide of claim 12.

14. A vector comprising the polynucleotide of claim 9.

15. A polynucleotide comprising the nucleotide sequence of an insert contained in a clone deposited as ATCC accession number xx, xx, xx, xx, xx, xx, xx, xx, or xx.

16. A method of detecting differentially expressed genes correlated with a cancerous state of a mammalian cell, the method comprising the step of: detecting at least one differentially expressed gene product in a test sample derived from a cell suspected of being cancerous, where the gene product is encoded by a gene corresponding to a sequence ofat least one of SEQ ID NOS: 10, 15, 33, 36, 44, 45, 54, 65, 89, 146, 154, 159, 165, 171, 172, 174, 183, 203, 228, 250, 252, 253, 254, 261, 280, 282, 285, 355, 364, 366, 370, 387, 419, 420, 443, 460, 466, 491, 496, 503, 510, 512, 525, 526, 529, 545, 552, 560, 564, 570, 571, 574, 581, 590, 603, 606, 644, 646, 648, 680, 693, 700, 703, 704, 707, 711, 716, 726, 742, 746, 752, 753, 754, 756, 861, 875, 902, 921, 922, 942, 990, 1088, 1095, 1104, 1122, 1131, 1142, 1170, 1184, 1205, 1286, 1288, 1289, 1354, 1355, 1387, 1417, 1435, 1444, 1454, 1535, 1570, 1597, 1734, 1742, 1751, 1764, 1777, 1780, 1795, 1860, 1869, 1882, 1890, 1899, 1915, 1933, 1934, 1954, 1979, 1980, 2007, 2023, 2024, 2034, 2040, 2059, 2126, 2223, 2245, 2262, 2300, 2325, 2409, 2486, 2462, 2488, 2492, 1241, 1264, 1401, 1422, 1442, 1514, 1851, 1915, 2007, 2024, 2038, 2066, and 2245; wherein detection of the differentially expressed gene product is correlated with a cancerous state of the cell from which the test sample was derived.

17. The method of claim 16, wherein said detecting step is by hybridization of the test sample to a reference array, wherein the reference array comprises an identifying sequence of at least one of SEQ ID NOS: 65, 174, 203, 252, 253, 387, 419, 420, 491, 552, 560, 581, 590, 648, 693, 726, 746, 990, 1095, 1124, 1205, 1354, 1387, 1780, 1899, 1915, 1979, 2007, 2024, 2325, and 2245.

18. The method of claim 16, wherein the cell is a breast tissue derived cell, and the differentially expressed gene product is encoded by a gene corresponding to a sequence of at least one of SEQ ID NOS:36, 44, 45, 89, 146, 154, 159, 165, 172, 174, 183, 203, 261, 364, 366, 387, 419, 420, 496, 503, 510, 512, 529, 552, 560,564, 570, 590, 606, 644, 646, 693, 707, 711, 726, 746, 754, 756, 875, 902, 921, 942, 990, 1095, 1104, 1122, 1131, 1142, 1170, 1184, 1205, 1286, 1289, 1354, 1387, 1435, 1535, 1751, 1764, 1777, 1795, 1860, 1869, 1882, 1890, 1915, 1933, 1934, 1979, 1980, 2007, 2023, 2040, 2059, 2223, 2245, 2300, 2325, 2409, 2462, 2486, 2488, and 2492.

19. The method of claim 16, wherein the cell is a colon tissue derived cell, and the differentially expressed gene product is encoded by a gene corresponding to a sequence of at least one of SEQ ID NOS:33, 65, 228, 250, 252, 253, 280, 282, 355, 370, 387, 443, 460, 491, 545, 560, 581, 603, 680, 693, 703, 704, 716, 726, 746, 752, 753, 1095, 1104, 1205, 1241, 1264, 1354, 1387, 1401, 1442, 1514, 1734, 1742, 1780, 1851, 1899, 1915, 1954, 2024, 2066, 2262, and 2325.

20. The method of claim 16, wherein the cell is a lung tissue derived cell, and the differentially expressed gene product is encoded by a gene corresponding to a sequence of at least one of SEQ ID NOS: 10, 54, 65, 171, 174, 203, 252, 253, 254, 285, 419, 420, 466, 491, 525, 526, 552, 571, 574, 590, 693, 700, 726, 742, 746, 861, 922, 990, 1088, 1288, 1355, 1417, 1422, 1444, 1454, 1570, 1597, 1979, 2007, 2024, 2034, 2038, 2126, and 2245.

21. The method of claim 16, wherein the differentially expressed gene product is encoded by a gene corresponding to a sequence ofat least one of SEQ ID NOS:648 and 1899.